data_1apf_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1apf _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 24.6 t . . . . . 0 N--CA 1.497 1.876 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_endo -81.33 142.13 13.12 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 C-N-CA 123.293 2.662 . . . . 0.0 110.932 164.718 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -137.52 170.03 16.78 Favored 'General case' 0 N--CA 1.495 1.784 0 C-N-CA 119.455 -0.898 . . . . 0.0 111.659 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.483 HD22 ' N ' ' A' ' 6' ' ' CYS . 5.5 tt -85.62 148.05 26.1 Favored 'General case' 0 N--CA 1.495 1.792 0 N-CA-C 106.752 -1.573 . . . . 0.0 106.752 -179.823 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . 0.483 ' N ' HD22 ' A' ' 5' ' ' LEU . 2.4 m -127.73 -167.03 1.69 Allowed 'General case' 0 N--CA 1.488 1.443 0 N-CA-C 119.197 3.036 . . . . 0.0 119.197 -179.621 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 21.2 t70 . . . . . 0 N--CA 1.503 2.199 0 CA-C-N 112.932 -1.94 . . . . 0.0 112.353 -179.762 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 34.6 m . . . . . 0 N--CA 1.505 2.309 0 N-CA-C 113.099 0.777 . . . . 0.0 113.099 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -157.01 150.43 21.57 Favored Glycine 0 N--CA 1.493 2.46 0 N-CA-C 107.859 -2.096 . . . . 0.0 107.859 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.458 ' N ' ' O ' ' A' ' 47' ' ' CYS . 44.9 mm -113.48 152.99 15.1 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.282 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.501 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 4.2 pp -76.26 151.13 36.87 Favored 'General case' 0 N--CA 1.501 2.077 0 C-N-CA 117.908 -1.517 . . . . 0.0 108.714 179.569 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 30.0 m95 -132.68 130.3 39.92 Favored 'General case' 0 N--CA 1.485 1.288 0 N-CA-C 119.293 3.071 . . . . 0.0 119.293 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -88.28 53.06 2.61 Favored 'General case' 0 C--N 1.295 -1.804 0 CA-C-N 108.569 -3.923 . . . . 0.0 111.377 -179.495 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.462 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 2.3 m-85 -126.14 121.13 23.92 Favored Pre-proline 0 N--CA 1.495 1.784 0 CA-C-N 115.497 -0.774 . . . . 0.0 112.481 179.605 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -64.68 -19.58 64.73 Favored 'Trans proline' 0 C--N 1.307 -1.635 0 C-N-CA 123.941 3.094 . . . . 0.0 111.328 -177.281 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 6.1 p -94.81 11.37 31.78 Favored 'General case' 0 N--CA 1.489 1.507 0 CA-C-N 115.06 -0.973 . . . . 0.0 111.1 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 101.33 -121.83 7.37 Favored Glycine 0 N--CA 1.498 2.77 0 N-CA-C 106.198 -2.761 . . . . 0.0 106.198 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . 0.544 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 24.9 m -89.15 148.88 41.89 Favored Pre-proline 0 C--N 1.305 -1.348 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 179.72 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.684 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 19.5 Cg_endo -74.19 166.92 28.41 Favored 'Trans proline' 0 C--N 1.31 -1.466 0 C-N-CA 122.211 1.941 . . . . 0.0 114.143 172.895 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 9.4 t -53.89 114.52 1.6 Allowed 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 113.989 -1.46 . . . . 0.0 110.285 -179.755 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 113.6 -7.08 24.33 Favored Glycine 0 N--CA 1.5 2.948 0 CA-C-N 113.906 -1.497 . . . . 0.0 112.319 179.549 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' TRP . . . . . 0.684 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 53.7 m95 -110.29 166.24 11.13 Favored 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 106.745 -1.576 . . . . 0.0 106.745 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 51.9 t60 -146.04 29.82 1.07 Allowed 'General case' 0 N--CA 1.503 2.185 0 C-N-CA 117.911 -1.516 . . . . 0.0 113.95 -179.737 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . 0.544 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 23.3 t-20 64.1 152.03 0.04 OUTLIER 'General case' 0 N--CA 1.506 2.335 0 N-CA-C 115.164 1.542 . . . . 0.0 115.164 -179.818 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.659 ' SG ' ' HB3' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -130.16 -45.77 1.12 Allowed 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 113.32 -1.764 . . . . 0.0 107.543 -179.819 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . 0.533 ' C ' ' H ' ' A' ' 39' ' ' HIS . 82.7 tttt -118.57 103.11 9.41 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-O 122.858 1.313 . . . . 0.0 108.837 179.912 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.432 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -81.48 25.25 0.52 Allowed 'General case' 0 N--CA 1.494 1.761 0 N-CA-C 107.181 -1.414 . . . . 0.0 107.181 179.603 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . 0.533 ' H ' ' C ' ' A' ' 37' ' ' LYS . 5.5 m-70 -131.13 10.24 4.91 Favored 'General case' 0 N--CA 1.492 1.636 0 N-CA-C 108.628 -0.878 . . . . 0.0 108.628 -179.727 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 125.43 -142.62 13.91 Favored Glycine 0 N--CA 1.498 2.778 0 N-CA-C 110.168 -1.173 . . . . 0.0 110.168 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . 0.578 ' CD ' ' SG ' ' A' ' 46' ' ' CYS . 85.8 Cg_endo -66.12 -174.66 6.29 Favored 'Cis proline' 0 N--CA 1.5 1.856 0 CA-C-N 118.289 1.045 . . . . 0.0 110.251 -1.872 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.432 ' C ' ' H ' ' A' ' 44' ' ' GLY . 4.1 m-20 -91.7 -8.83 45.9 Favored 'General case' 0 CA--C 1.479 -1.786 0 N-CA-C 105.617 -1.994 . . . . 0.0 105.617 -179.147 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 37.4 mt -95.06 33.33 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.163 0 CA-C-O 123.624 1.678 . . . . 0.0 109.114 -179.495 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.432 ' H ' ' C ' ' A' ' 42' ' ' ASN . . . 114.06 135.54 6.11 Favored Glycine 0 N--CA 1.485 1.923 0 CA-C-N 111.275 -2.693 . . . . 0.0 107.41 -179.897 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . 0.462 ' NE1' ' O ' ' A' ' 25' ' ' TYR . 6.1 m95 -64.17 134.59 55.12 Favored 'General case' 0 N--CA 1.508 2.454 0 CA-C-O 116.796 -1.573 . . . . 0.0 106.787 -179.544 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' CYS . . . . . 0.659 ' HB3' ' SG ' ' A' ' 36' ' ' CYS . 35.4 m -89.45 124.15 34.23 Favored 'General case' 0 C--N 1.312 -1.063 0 N-CA-C 103.081 -2.933 . . . . 0.0 103.081 179.922 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.526 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 73.4 m -127.4 -169.74 2.1 Favored 'General case' 0 C--N 1.291 -1.972 0 CA-C-N 110.921 -2.854 . . . . 0.0 107.899 -179.533 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.411 ' N ' ' CD ' ' A' ' 48' ' ' LYS . 0.0 OUTLIER -151.67 173.2 14.96 Favored 'General case' 0 C--N 1.292 -1.924 0 N-CA-C 105.175 -2.157 . . . . 0.0 105.175 179.058 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 90.2 mttt . . . . . 0 C--N 1.289 -2.028 0 CA-C-O 114.691 -2.576 . . . . 0.0 106.392 179.524 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 22.4 t . . . . . 0 N--CA 1.495 1.777 0 N-CA-C 103.912 -2.625 . . . . 0.0 103.912 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -68.27 149.43 75.77 Favored 'Trans proline' 0 C--N 1.305 -1.75 0 C-N-CA 122.98 2.453 . . . . 0.0 108.038 170.78 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 1.2 p -141.72 175.02 10.03 Favored 'General case' 0 N--CA 1.495 1.811 0 N-CA-C 115.242 1.571 . . . . 0.0 115.242 -179.755 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 23.5 tp -104.16 150.03 24.72 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 103.682 -2.71 . . . . 0.0 103.682 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . 0.443 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 3.3 m -133.11 -162.51 1.25 Allowed 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 116.299 1.963 . . . . 0.0 116.299 -179.04 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 3.2 p-10 . . . . . 0 N--CA 1.499 1.989 0 O-C-N 126.751 2.532 . . . . 0.0 111.851 -179.967 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 25.0 m . . . . . 0 N--CA 1.502 2.138 0 N-CA-C 112.263 0.468 . . . . 0.0 112.263 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -164.74 179.59 39.34 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 108.945 -1.662 . . . . 0.0 108.945 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 34.3 mm -125.06 149.41 29.62 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.174 0 N-CA-C 108.42 -0.955 . . . . 0.0 108.42 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.549 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 4.5 pp -71.17 148.44 47.34 Favored 'General case' 0 N--CA 1.498 1.946 0 C-N-CA 118.513 -1.275 . . . . 0.0 110.875 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 38.2 m95 -131.4 131.47 43.66 Favored 'General case' 0 N--CA 1.486 1.36 0 N-CA-C 120.389 3.477 . . . . 0.0 120.389 -179.821 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -88.87 49.58 1.81 Allowed 'General case' 0 C--N 1.296 -1.734 1 CA-C-N 106.862 -4.699 . . . . 0.0 112.785 -179.389 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.4 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 2.2 m-85 -121.21 130.76 24.69 Favored Pre-proline 0 C--N 1.302 -1.468 0 CA-C-O 122.436 1.113 . . . . 0.0 111.3 179.525 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -69.79 -24.28 29.69 Favored 'Trans proline' 0 C--N 1.308 -1.595 0 C-N-CA 124.647 3.565 . . . . 0.0 110.662 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 6.1 p -93.63 15.12 16.97 Favored 'General case' 0 N--CA 1.492 1.642 0 CA-C-N 115.405 -0.816 . . . . 0.0 111.307 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 99.64 -126.01 8.77 Favored Glycine 0 N--CA 1.5 2.901 0 N-CA-C 105.674 -2.97 . . . . 0.0 105.674 -179.88 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . 0.541 ' SG ' ' CA ' ' A' ' 35' ' ' ASN . 35.7 m -86.66 152.24 54.02 Favored Pre-proline 0 C--N 1.304 -1.403 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 179.721 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.714 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 19.9 Cg_endo -73.04 165.83 31.71 Favored 'Trans proline' 0 C--N 1.305 -1.719 0 C-N-CA 122.525 2.15 . . . . 0.0 113.906 173.392 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 5.6 p -51.73 107.42 0.19 Allowed 'General case' 0 C--N 1.298 -1.632 0 CA-C-N 112.341 -2.209 . . . . 0.0 112.247 -179.741 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 115.34 -7.85 20.65 Favored Glycine 0 N--CA 1.498 2.826 0 O-C-N 124.514 1.134 . . . . 0.0 111.737 179.594 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' TRP . . . . . 0.714 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 45.7 m95 -105.76 166.87 10.16 Favored 'General case' 0 C--N 1.304 -1.389 0 N-CA-C 106.143 -1.799 . . . . 0.0 106.143 -179.874 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 54.0 t-80 -147.03 33.82 0.91 Allowed 'General case' 0 N--CA 1.497 1.894 0 C-N-CA 117.337 -1.745 . . . . 0.0 112.884 -179.648 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . 0.541 ' CA ' ' SG ' ' A' ' 29' ' ' CYS . 24.9 t-20 60.44 143.29 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.13 0 N-CA-C 115.187 1.551 . . . . 0.0 115.187 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.876 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 1.7 p -120.99 -41.16 2.56 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-N 114.28 -1.327 . . . . 0.0 108.448 -179.628 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 77.3 tttt -118.84 116.31 26.23 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 104.708 -2.33 . . . . 0.0 104.708 179.748 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -89.41 8.08 32.62 Favored 'General case' 0 N--CA 1.496 1.827 0 N-CA-C 107.475 -1.306 . . . . 0.0 107.475 179.79 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 16.2 m-70 -133.04 48.86 2.36 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-N 115.001 -0.999 . . . . 0.0 110.876 -179.708 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 113.41 -165.11 12.01 Favored Glycine 0 N--CA 1.497 2.705 0 O-C-N 124.293 0.995 . . . . 0.0 113.47 179.581 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 15.0 Cg_endo -73.75 -174.01 12.46 Favored 'Cis proline' 0 N--CA 1.497 1.703 0 O-C-N 123.085 1.045 . . . . 0.0 110.933 -5.182 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 6.7 m120 -92.08 -10.68 38.16 Favored 'General case' 0 CA--C 1.484 -1.587 0 N-CA-C 104.579 -2.378 . . . . 0.0 104.579 -179.676 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 33.0 pt -92.04 27.22 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.03 0 C-N-CA 118.204 -1.398 . . . . 0.0 113.689 -179.434 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 116.76 130.85 4.55 Favored Glycine 0 N--CA 1.489 2.215 0 CA-C-N 111.831 -2.44 . . . . 0.0 108.693 -179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . 0.4 ' NE1' ' O ' ' A' ' 25' ' ' TYR . 8.5 m95 -54.06 131.76 41.36 Favored 'General case' 0 N--CA 1.513 2.704 0 CA-C-O 116.248 -1.834 . . . . 0.0 107.56 -179.56 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' CYS . . . . . 0.876 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 53.3 t -89.44 131.85 35.3 Favored 'General case' 0 N--CA 1.479 0.983 1 N-CA-C 99.333 -4.321 . . . . 0.0 99.333 -179.882 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.453 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 86.2 m -133.74 -173.55 3.27 Favored 'General case' 0 C--N 1.292 -1.9 0 CA-C-N 111.056 -2.793 . . . . 0.0 109.876 -179.166 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.438 ' CD ' ' N ' ' A' ' 48' ' ' LYS . 0.0 OUTLIER -150.48 173.47 14.03 Favored 'General case' 0 C--N 1.297 -1.695 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 179.376 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 3.7 mmpt? . . . . . 0 N--CA 1.502 2.131 0 O-C-N 126.618 2.449 . . . . 0.0 110.874 179.929 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 21.8 t . . . . . 0 N--CA 1.5 2.051 0 N-CA-C 106.686 -1.598 . . . . 0.0 106.686 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -74.47 134.55 18.94 Favored 'Trans proline' 0 C--N 1.306 -1.681 0 C-N-CA 123.048 2.498 . . . . 0.0 117.73 163.819 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -128.82 173.66 10.16 Favored 'General case' 0 N--CA 1.493 1.679 0 N-CA-C 107.589 -1.263 . . . . 0.0 107.589 179.509 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.524 HD22 ' N ' ' A' ' 6' ' ' CYS . 5.4 tt -90.64 147.24 23.43 Favored 'General case' 0 N--CA 1.496 1.866 0 N-CA-C 103.665 -2.717 . . . . 0.0 103.665 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . 0.524 ' N ' HD22 ' A' ' 5' ' ' LEU . 4.4 m -128.34 -171.49 2.47 Favored 'General case' 0 C--N 1.307 -1.271 0 N-CA-C 116.005 1.854 . . . . 0.0 116.005 -179.851 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 34.1 t70 . . . . . 0 N--CA 1.489 1.481 0 CA-C-N 113.196 -1.82 . . . . 0.0 107.575 179.945 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 4.1 t . . . . . 0 N--CA 1.5 2.052 0 CA-C-O 121.505 0.669 . . . . 0.0 110.407 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.503 ' HA3' ' SG ' ' A' ' 6' ' ' CYS . . . -172.48 121.57 0.88 Allowed Glycine 0 N--CA 1.494 2.503 0 N-CA-C 107.065 -2.414 . . . . 0.0 107.065 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.457 ' N ' ' O ' ' A' ' 47' ' ' CYS . 36.3 mm -96.09 137.34 24.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 N-CA-C 104.691 -2.337 . . . . 0.0 104.691 179.736 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.568 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 4.3 pp -65.69 149.33 50.29 Favored 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 117.752 -1.579 . . . . 0.0 107.238 179.812 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.417 ' O ' ' CA ' ' A' ' 44' ' ' GLY . 20.2 m95 -132.17 135.78 46.6 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-O 124.542 2.115 . . . . 0.0 115.882 -179.727 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.1 m-85 -88.91 40.58 0.98 Allowed 'General case' 0 C--N 1.293 -1.849 0 CA-C-N 109.12 -3.673 . . . . 0.0 115.353 -179.383 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.444 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 1.2 m-30 -113.12 120.0 41.24 Favored Pre-proline 0 N--CA 1.487 1.396 0 N-CA-C 107.664 -1.236 . . . . 0.0 107.664 179.713 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -60.93 -21.28 70.53 Favored 'Trans proline' 0 C--N 1.298 -2.091 0 C-N-CA 122.511 2.14 . . . . 0.0 110.414 -170.207 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 4.3 p -97.45 3.67 50.77 Favored 'General case' 0 N--CA 1.491 1.6 0 CA-C-N 114.746 -1.115 . . . . 0.0 113.451 -179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 125.58 -121.86 4.35 Favored Glycine 0 N--CA 1.492 2.38 0 N-CA-C 108.601 -1.8 . . . . 0.0 108.601 179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . 0.49 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 3.9 m -95.2 158.6 34.51 Favored Pre-proline 0 C--N 1.304 -1.375 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.682 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.3 OUTLIER -79.11 -179.24 5.27 Favored 'Trans proline' 0 C--N 1.312 -1.343 0 C-N-CA 123.242 2.628 . . . . 0.0 114.896 171.033 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 18.4 p -58.41 104.62 0.22 Allowed 'General case' 0 C--N 1.299 -1.591 0 CA-C-N 112.922 -1.944 . . . . 0.0 112.941 -179.587 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 114.15 3.63 22.82 Favored Glycine 0 N--CA 1.501 2.969 0 O-C-N 124.759 1.287 . . . . 0.0 113.561 179.628 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' TRP . . . . . 0.682 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 39.7 m95 -117.75 153.07 34.03 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 107.369 -1.345 . . . . 0.0 107.369 -179.822 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . 0.408 ' O ' ' ND1' ' A' ' 34' ' ' HIS . 36.6 t-80 -137.4 41.5 2.4 Favored 'General case' 0 N--CA 1.5 2.044 0 CA-C-O 122.074 0.94 . . . . 0.0 109.847 -179.496 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . 0.49 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 24.6 t-20 59.59 156.73 0.03 OUTLIER 'General case' 0 N--CA 1.501 2.089 0 CA-C-O 123.9 1.81 . . . . 0.0 114.286 -179.765 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.778 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -125.66 -52.18 1.58 Allowed 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 104.354 -2.461 . . . . 0.0 104.354 179.725 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . 0.501 ' C ' ' H ' ' A' ' 39' ' ' HIS . 43.7 tttp -118.26 103.98 10.35 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 113.615 -1.63 . . . . 0.0 109.74 179.836 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.44 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -81.82 30.96 0.37 Allowed 'General case' 0 N--CA 1.497 1.902 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 179.573 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . 0.501 ' H ' ' C ' ' A' ' 37' ' ' LYS . 4.5 m-70 -130.49 8.32 4.99 Favored 'General case' 0 N--CA 1.492 1.636 0 CA-C-N 115.53 -0.759 . . . . 0.0 108.957 -179.73 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 128.51 -152.98 19.4 Favored Glycine 0 N--CA 1.496 2.7 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 179.902 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . 0.4 ' HG2' ' O ' ' A' ' 44' ' ' GLY . 26.8 Cg_endo -72.68 -174.61 12.62 Favored 'Cis proline' 0 N--CA 1.508 2.324 0 O-C-N 122.808 0.899 . . . . 0.0 112.586 -2.414 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.487 ' C ' ' H ' ' A' ' 44' ' ' GLY . 17.8 p-10 -91.88 -14.35 29.81 Favored 'General case' 0 CA--C 1.485 -1.533 0 N-CA-C 105.527 -2.027 . . . . 0.0 105.527 -179.654 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 11.0 mt -88.84 30.1 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.341 0 CA-C-N 113.809 -1.541 . . . . 0.0 109.617 -179.405 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.487 ' H ' ' C ' ' A' ' 42' ' ' ASN . . . 114.6 122.18 3.64 Favored Glycine 0 N--CA 1.491 2.347 0 CA-C-N 112.163 -2.289 . . . . 0.0 107.767 -179.853 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . 0.444 ' NE1' ' O ' ' A' ' 25' ' ' TYR . 3.9 m95 -54.68 138.79 40.85 Favored 'General case' 0 N--CA 1.514 2.735 0 CA-C-O 116.795 -1.574 . . . . 0.0 107.946 -179.378 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' CYS . . . . . 0.778 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 13.8 t -88.87 127.4 35.63 Favored 'General case' 0 C--N 1.309 -1.159 0 N-CA-C 102.587 -3.116 . . . . 0.0 102.587 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.489 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 98.0 m -128.9 176.51 7.8 Favored 'General case' 0 CA--C 1.478 -1.8 0 CA-C-N 112.009 -2.36 . . . . 0.0 113.656 -178.99 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.418 ' HD2' ' H ' ' A' ' 49' ' ' LYS . 41.1 tptt -150.83 153.08 34.73 Favored 'General case' 0 C--N 1.295 -1.804 0 C-N-CA 118.785 -1.166 . . . . 0.0 109.405 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . 0.448 ' HZ1' ' HB3' ' A' ' 49' ' ' LYS . 7.4 mtpm? . . . . . 0 N--CA 1.5 2.037 0 CA-C-N 111.703 -2.499 . . . . 0.0 110.886 179.775 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 6.3 t . . . . . 0 N--CA 1.5 2.053 0 N-CA-C 106.512 -1.662 . . . . 0.0 106.512 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -79.03 119.86 4.43 Favored 'Trans proline' 0 C--N 1.308 -1.568 0 C-N-CA 122.491 2.127 . . . . 0.0 113.337 160.019 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.448 ' SG ' ' HB3' ' A' ' 22' ' ' LEU . 0.5 OUTLIER -104.59 -171.63 1.96 Allowed 'General case' 0 N--CA 1.495 1.802 0 CA-C-N 114.956 -1.02 . . . . 0.0 110.893 -179.975 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 4.2 tp -98.38 152.29 19.64 Favored 'General case' 0 N--CA 1.497 1.907 0 N-CA-C 104.593 -2.373 . . . . 0.0 104.593 179.838 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 3.1 m -132.59 -170.63 2.48 Favored 'General case' 0 N--CA 1.485 1.321 0 N-CA-C 115.41 1.633 . . . . 0.0 115.41 -179.62 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 17.2 t70 . . . . . 0 C--N 1.3 -1.583 0 CA-C-N 112.971 -1.922 . . . . 0.0 109.752 -179.922 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 4.5 t . . . . . 0 N--CA 1.502 2.144 0 N-CA-C 113.507 0.929 . . . . 0.0 113.507 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 165.43 -176.3 41.04 Favored Glycine 0 N--CA 1.512 3.738 0 C-N-CA 118.742 -1.694 . . . . 0.0 114.94 179.573 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 19.3 mm -134.19 149.16 29.97 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.245 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 179.57 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.519 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.5 pp -69.19 146.71 52.19 Favored 'General case' 0 N--CA 1.495 1.794 0 C-N-CA 119.333 -0.947 . . . . 0.0 110.859 179.709 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 37.5 m95 -130.62 130.33 43.83 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 121.374 3.842 . . . . 0.0 121.374 -179.571 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 4.4 m-85 -89.0 49.81 1.85 Allowed 'General case' 0 C--N 1.295 -1.795 1 CA-C-N 108.093 -4.14 . . . . 0.0 112.209 -179.687 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.44 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 2.2 m-85 -122.56 124.56 26.7 Favored Pre-proline 0 N--CA 1.494 1.765 0 N-CA-C 114.144 1.164 . . . . 0.0 114.144 179.876 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -64.16 -20.82 67.63 Favored 'Trans proline' 0 C--N 1.307 -1.641 0 C-N-CA 124.065 3.177 . . . . 0.0 110.935 -177.02 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 5.1 p -94.06 6.9 47.07 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-N 114.576 -1.193 . . . . 0.0 111.207 179.829 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 104.17 -112.52 4.15 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 105.252 -3.139 . . . . 0.0 105.252 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . 0.537 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 13.5 m -96.55 147.96 33.73 Favored Pre-proline 0 C--N 1.305 -1.363 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 179.798 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.692 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 15.2 Cg_endo -74.23 174.67 12.08 Favored 'Trans proline' 0 C--N 1.308 -1.566 0 C-N-CA 122.628 2.219 . . . . 0.0 114.47 174.259 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 12.0 p -53.13 105.65 0.13 Allowed 'General case' 0 C--N 1.299 -1.63 0 CA-C-N 112.469 -2.151 . . . . 0.0 112.568 -179.694 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 111.92 -1.25 27.21 Favored Glycine 0 N--CA 1.503 3.139 0 O-C-N 124.156 0.91 . . . . 0.0 113.814 179.503 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' TRP . . . . . 0.692 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 52.1 m95 -110.45 166.79 10.71 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 108.053 -1.092 . . . . 0.0 108.053 -179.912 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 80.1 t60 -146.98 36.59 0.94 Allowed 'General case' 0 N--CA 1.5 2.03 0 C-N-CA 116.8 -1.96 . . . . 0.0 115.94 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . 0.537 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 0.4 OUTLIER 63.3 137.93 0.02 OUTLIER 'General case' 0 N--CA 1.506 2.326 0 N-CA-C 116.926 2.195 . . . . 0.0 116.926 179.714 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.626 ' SG ' ' HB3' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -118.06 -42.17 2.83 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 105.029 -2.211 . . . . 0.0 105.029 179.71 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 57.3 tttt -136.38 120.54 17.79 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 114.824 -1.08 . . . . 0.0 109.544 179.766 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.437 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -97.99 34.21 1.97 Allowed 'General case' 0 N--CA 1.496 1.829 0 N-CA-C 105.505 -2.035 . . . . 0.0 105.505 179.645 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . 0.437 ' ND1' ' C ' ' A' ' 38' ' ' ALA . 3.8 m-70 -133.5 47.92 2.42 Favored 'General case' 0 N--CA 1.495 1.792 0 N-CA-C 106.225 -1.769 . . . . 0.0 106.225 -179.67 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 85.21 -156.61 31.02 Favored Glycine 0 N--CA 1.498 2.779 0 N-CA-C 107.416 -2.274 . . . . 0.0 107.416 -179.749 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 17.6 Cg_endo -72.13 -172.76 9.41 Favored 'Cis proline' 0 N--CA 1.494 1.555 0 CA-C-N 118.612 1.206 . . . . 0.0 112.053 2.5 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 80.2 m-20 -92.32 -15.49 27.3 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 104.647 -2.353 . . . . 0.0 104.647 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 13.5 mt -90.87 29.5 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.21 0 CA-C-N 113.272 -1.786 . . . . 0.0 111.425 -179.255 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 109.07 119.11 4.2 Favored Glycine 0 N--CA 1.491 2.31 0 CA-C-N 112.178 -2.283 . . . . 0.0 111.601 179.853 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . 0.44 ' NE1' ' O ' ' A' ' 25' ' ' TYR . 2.2 m95 -49.44 134.74 18.74 Favored 'General case' 0 N--CA 1.516 2.856 0 CA-C-O 116.231 -1.843 . . . . 0.0 107.449 -179.743 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' CYS . . . . . 0.626 ' HB3' ' SG ' ' A' ' 36' ' ' CYS . 68.5 m -89.45 128.22 35.93 Favored 'General case' 0 N--CA 1.485 1.32 0 N-CA-C 103.689 -2.708 . . . . 0.0 103.689 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.515 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 86.7 m -131.12 -173.49 3.11 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-N 111.955 -2.384 . . . . 0.0 110.314 -179.165 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.09 173.7 14.05 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 118.574 -1.25 . . . . 0.0 109.106 179.357 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 95.0 mttt . . . . . 0 C--N 1.292 -1.909 0 O-C-N 126.402 2.314 . . . . 0.0 107.927 179.488 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 9.1 t . . . . . 0 N--CA 1.495 1.81 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_endo -77.2 131.64 11.99 Favored 'Trans proline' 0 N--CA 1.494 1.551 0 C-N-CA 124.067 3.178 . . . . 0.0 114.26 166.916 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -122.17 167.99 12.53 Favored 'General case' 0 N--CA 1.498 1.942 0 CA-C-O 122.602 1.191 . . . . 0.0 114.076 -179.702 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 12.7 tp -79.68 127.34 32.07 Favored 'General case' 0 N--CA 1.493 1.695 0 N-CA-C 106.907 -1.516 . . . . 0.0 106.907 -179.709 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 21.8 m -106.58 -174.11 2.46 Favored 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 118.844 -1.143 . . . . 0.0 112.883 179.65 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 16.3 t70 . . . . . 0 C--N 1.296 -1.727 0 CA-C-N 113.916 -1.493 . . . . 0.0 108.431 -179.778 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 3.2 p . . . . . 0 N--CA 1.488 1.47 0 CA-C-O 120.915 0.388 . . . . 0.0 111.901 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 159.33 178.98 33.84 Favored Glycine 0 N--CA 1.499 2.853 0 N-CA-C 108.016 -2.034 . . . . 0.0 108.016 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.438 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 48.6 mm -127.84 145.97 34.24 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.974 0 N-CA-C 106.141 -1.8 . . . . 0.0 106.141 179.736 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.483 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.8 pp -69.67 152.18 45.0 Favored 'General case' 0 N--CA 1.491 1.617 0 C-N-CA 118.257 -1.377 . . . . 0.0 110.115 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.414 ' O ' ' HA3' ' A' ' 44' ' ' GLY . 37.6 m95 -136.41 130.73 33.15 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 118.884 2.92 . . . . 0.0 118.884 179.763 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 6.0 m-85 -89.48 51.47 2.12 Favored 'General case' 0 C--N 1.296 -1.756 1 CA-C-N 107.467 -4.424 . . . . 0.0 111.613 -179.692 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.458 ' CE1' ' HB3' ' A' ' 30' ' ' PRO . 2.4 m-85 -125.07 137.03 28.93 Favored Pre-proline 0 C--N 1.303 -1.414 0 CA-C-O 121.482 0.658 . . . . 0.0 109.613 179.646 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 96.9 Cg_endo -66.95 -30.31 39.72 Favored 'Trans proline' 0 C--N 1.305 -1.75 0 C-N-CA 124.264 3.309 . . . . 0.0 108.636 177.56 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 11.8 p -86.65 31.9 0.67 Allowed 'General case' 0 C--N 1.299 -1.611 0 CA-C-N 113.989 -1.459 . . . . 0.0 109.239 179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.54 ' HA2' ' CD1' ' A' ' 45' ' ' TRP . . . 76.05 -92.76 0.94 Allowed Glycine 0 N--CA 1.482 1.764 0 N-CA-C 104.399 -3.48 . . . . 0.0 104.399 -179.499 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . 0.568 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 9.4 m -103.75 165.91 12.65 Favored Pre-proline 0 C--N 1.301 -1.515 0 CA-C-N 113.814 -1.193 . . . . 0.0 110.609 -179.849 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.651 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.1 OUTLIER -86.01 167.11 9.64 Favored 'Trans proline' 0 CA--C 1.553 1.472 0 C-N-CA 125.238 3.959 . . . . 0.0 118.336 157.924 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 3.8 m -49.64 109.57 0.29 Allowed 'General case' 0 C--N 1.299 -1.604 0 CA-C-N 111.769 -2.469 . . . . 0.0 112.283 179.845 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 113.46 -6.6 24.66 Favored Glycine 0 N--CA 1.5 2.948 0 CA-C-N 115.218 -0.901 . . . . 0.0 111.901 179.743 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' TRP . . . . . 0.651 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 48.1 m95 -111.51 162.57 14.97 Favored 'General case' 0 N--CA 1.486 1.341 0 N-CA-C 106.321 -1.733 . . . . 0.0 106.321 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . 0.419 ' O ' ' ND1' ' A' ' 34' ' ' HIS . 60.0 t-80 -143.62 34.18 1.29 Allowed 'General case' 0 N--CA 1.498 1.962 0 C-N-CA 118.138 -1.425 . . . . 0.0 113.406 -179.733 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . 0.568 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 3.2 t30 61.76 146.16 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.9 0 N-CA-C 114.375 1.25 . . . . 0.0 114.375 179.916 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.804 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -124.31 -45.74 1.95 Allowed 'General case' 0 N--CA 1.484 1.272 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.039 -179.715 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . 0.55 ' C ' ' H ' ' A' ' 39' ' ' HIS . 36.0 ttmt -122.01 100.35 6.93 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 105.44 -2.059 . . . . 0.0 105.44 179.431 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -77.55 19.9 0.34 Allowed 'General case' 0 N--CA 1.5 2.034 0 CA-C-N 114.431 -1.259 . . . . 0.0 107.742 179.649 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . 0.55 ' H ' ' C ' ' A' ' 37' ' ' LYS . 7.4 m-70 -132.75 16.82 4.29 Favored 'General case' 0 N--CA 1.487 1.378 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.476 -179.709 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 149.37 -177.8 27.32 Favored Glycine 0 N--CA 1.501 3.015 0 C-N-CA 119.412 -1.375 . . . . 0.0 111.432 179.695 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . 0.5 ' HD2' ' N ' ' A' ' 46' ' ' CYS . 35.5 Cg_endo -66.25 -171.89 4.45 Favored 'Cis proline' 0 N--CA 1.512 2.592 0 N-CA-C 116.167 1.564 . . . . 0.0 116.167 -4.604 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.406 ' C ' ' H ' ' A' ' 44' ' ' GLY . 16.1 p-10 -92.1 -12.76 32.11 Favored 'General case' 0 N--CA 1.486 1.336 0 N-CA-C 105.505 -2.035 . . . . 0.0 105.505 -179.715 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 12.1 pt -85.81 23.02 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.218 0 O-C-N 124.909 1.38 . . . . 0.0 113.814 -179.49 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.423 ' C ' ' CD1' ' A' ' 45' ' ' TRP . . . 134.63 -116.47 1.61 Allowed Glycine 0 C--N 1.291 -1.962 0 N-CA-C 104.404 -3.478 . . . . 0.0 104.404 -179.906 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . 0.54 ' CD1' ' HA2' ' A' ' 28' ' ' GLY . 1.8 m95 -157.03 151.28 25.09 Favored 'General case' 0 N--CA 1.509 2.501 0 N-CA-C 105.491 -2.04 . . . . 0.0 105.491 -179.891 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' CYS . . . . . 0.804 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 44.5 t -99.06 129.61 45.34 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 102.882 -3.006 . . . . 0.0 102.882 179.864 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.524 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 78.4 m -126.77 -170.7 2.25 Favored 'General case' 0 C--N 1.298 -1.641 0 CA-C-N 113.528 -1.669 . . . . 0.0 109.719 -179.409 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -150.58 172.72 15.06 Favored 'General case' 0 C--N 1.294 -1.822 0 N-CA-C 107.195 -1.409 . . . . 0.0 107.195 179.324 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 84.8 mttt . . . . . 0 N--CA 1.498 1.95 0 O-C-N 126.129 2.143 . . . . 0.0 109.131 179.456 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 11.4 t . . . . . 0 N--CA 1.494 1.766 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_endo -75.81 155.33 39.23 Favored 'Trans proline' 0 N--CA 1.496 1.65 0 C-N-CA 124.024 3.15 . . . . 0.0 112.963 166.717 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.408 ' SG ' ' SG ' ' A' ' 6' ' ' CYS . 9.4 p -132.39 170.78 14.61 Favored 'General case' 0 N--CA 1.499 1.982 0 C-N-CA 119.208 -0.997 . . . . 0.0 108.939 179.574 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 13.9 tp -86.64 81.21 8.32 Favored 'General case' 0 N--CA 1.491 1.624 0 N-CA-C 103.65 -2.722 . . . . 0.0 103.65 179.908 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . 0.408 ' SG ' ' SG ' ' A' ' 4' ' ' CYS . 6.6 m -69.18 170.96 9.1 Favored 'General case' 0 C--N 1.309 -1.188 0 CA-C-O 123.273 1.511 . . . . 0.0 112.375 -179.729 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 7.9 t70 . . . . . 0 N--CA 1.496 1.875 0 CA-C-N 111.07 -2.786 . . . . 0.0 111.301 -179.838 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 48.4 t . . . . . 0 N--CA 1.498 1.935 0 CA-C-O 119.071 -0.49 . . . . 0.0 110.304 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 174.05 -171.83 44.83 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 107.653 -2.179 . . . . 0.0 107.653 -179.882 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 1.2 mp -133.83 153.14 35.9 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.104 0 O-C-N 124.918 1.01 . . . . 0.0 108.553 -179.903 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.526 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.3 pp -71.33 146.34 48.9 Favored 'General case' 0 N--CA 1.499 1.998 0 C-N-CA 120.205 -0.598 . . . . 0.0 111.868 179.812 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.432 ' O ' ' CA ' ' A' ' 44' ' ' GLY . 39.0 m95 -129.08 130.28 46.32 Favored 'General case' 0 N--CA 1.491 1.603 0 N-CA-C 119.512 3.152 . . . . 0.0 119.512 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 3.5 m-85 -88.73 51.38 2.16 Favored 'General case' 0 C--N 1.294 -1.827 1 CA-C-N 107.886 -4.234 . . . . 0.0 113.154 -179.412 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 2.2 m-85 -120.79 142.33 34.21 Favored Pre-proline 0 C--N 1.3 -1.576 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 179.411 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -76.12 -33.16 3.71 Favored 'Trans proline' 0 C--N 1.3 -1.991 0 C-N-CA 125.063 3.842 . . . . 0.0 112.21 172.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 14.1 p -88.61 33.43 0.77 Allowed 'General case' 0 N--CA 1.494 1.735 0 CA-C-O 121.442 0.639 . . . . 0.0 111.083 -179.524 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 76.0 -158.82 50.09 Favored Glycine 0 N--CA 1.495 2.58 0 N-CA-C 105.912 -2.875 . . . . 0.0 105.912 -179.565 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . 0.586 ' SG ' ' CA ' ' A' ' 35' ' ' ASN . 14.0 m -53.06 150.76 9.95 Favored Pre-proline 0 C--N 1.303 -1.441 0 CA-C-N 117.599 0.699 . . . . 0.0 111.941 179.816 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.695 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 4.6 Cg_endo -76.41 159.74 36.01 Favored 'Trans proline' 0 C--N 1.308 -1.566 0 C-N-CA 122.956 2.437 . . . . 0.0 112.043 171.759 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 16.5 t -49.14 129.67 18.13 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-N 113.332 -1.758 . . . . 0.0 109.522 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 97.81 -5.14 61.71 Favored Glycine 0 N--CA 1.496 2.697 0 CA-C-N 112.664 -2.062 . . . . 0.0 111.687 179.762 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' TRP . . . . . 0.695 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 48.1 m95 -111.91 163.77 13.85 Favored 'General case' 0 C--N 1.305 -1.332 0 N-CA-C 106.29 -1.745 . . . . 0.0 106.29 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . 0.401 ' O ' ' ND1' ' A' ' 34' ' ' HIS . 45.5 t-80 -144.24 34.39 1.21 Allowed 'General case' 0 N--CA 1.498 1.974 0 C-N-CA 117.365 -1.734 . . . . 0.0 113.107 -179.818 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . 0.586 ' CA ' ' SG ' ' A' ' 29' ' ' CYS . 23.8 t-20 62.38 144.72 0.02 OUTLIER 'General case' 0 N--CA 1.506 2.333 0 N-CA-C 113.976 1.102 . . . . 0.0 113.976 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.851 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -124.74 -64.9 1.07 Allowed 'General case' 0 C--N 1.306 -1.3 0 N-CA-C 106.672 -1.603 . . . . 0.0 106.672 -179.751 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . 0.593 ' N ' ' SG ' ' A' ' 36' ' ' CYS . 33.1 ttmt -91.05 103.59 16.27 Favored 'General case' 0 C--N 1.302 -1.465 0 CA-C-O 123.567 1.651 . . . . 0.0 107.04 179.704 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.425 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -79.86 24.16 0.41 Allowed 'General case' 0 N--CA 1.495 1.781 0 CA-C-N 113.499 -1.682 . . . . 0.0 107.282 179.489 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . 0.548 ' H ' ' C ' ' A' ' 37' ' ' LYS . 3.3 m-70 -131.85 17.88 4.67 Favored 'General case' 0 N--CA 1.493 1.713 0 N-CA-C 106.966 -1.494 . . . . 0.0 106.966 -179.677 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 111.43 -132.0 10.63 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 25.9 Cg_endo -69.78 -164.06 2.43 Favored 'Cis proline' 0 N--CA 1.503 2.054 0 CA-C-N 117.843 0.821 . . . . 0.0 112.699 1.097 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.462 ' C ' ' H ' ' A' ' 44' ' ' GLY . 22.6 t-20 -92.13 -20.57 21.11 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 106.374 -1.713 . . . . 0.0 106.374 -179.757 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 39.7 pt -86.31 28.33 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 CA-C-N 112.367 -2.197 . . . . 0.0 113.349 -179.104 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.462 ' H ' ' C ' ' A' ' 42' ' ' ASN . . . 115.03 131.15 4.98 Favored Glycine 0 N--CA 1.484 1.859 0 CA-C-N 111.019 -2.81 . . . . 0.0 109.994 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 14.8 m95 -55.42 130.1 41.26 Favored 'General case' 0 N--CA 1.509 2.484 0 N-CA-C 106.311 -1.737 . . . . 0.0 106.311 -179.657 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' CYS . . . . . 0.851 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 42.7 t -89.15 129.42 35.75 Favored 'General case' 0 C--N 1.31 -1.139 1 N-CA-C 99.341 -4.318 . . . . 0.0 99.341 -179.89 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.522 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 77.8 m -133.93 -175.35 3.81 Favored 'General case' 0 C--N 1.293 -1.888 0 CA-C-N 110.671 -2.968 . . . . 0.0 110.881 -178.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.404 ' O ' ' HA ' ' A' ' 33' ' ' TRP . 0.0 OUTLIER -150.7 172.68 15.19 Favored 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 107.1 -1.445 . . . . 0.0 107.1 179.484 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 54.0 mtpt . . . . . 0 C--N 1.289 -2.032 0 O-C-N 127.248 2.843 . . . . 0.0 109.253 179.697 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 34.0 t . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -82.19 136.15 8.85 Favored 'Trans proline' 0 C--N 1.308 -1.594 0 C-N-CA 124.026 3.151 . . . . 0.0 113.516 162.76 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.403 ' SG ' ' N ' ' A' ' 5' ' ' LEU . 1.8 p -110.45 -156.87 0.6 Allowed 'General case' 0 N--CA 1.504 2.259 0 N-CA-C 107.601 -1.259 . . . . 0.0 107.601 179.778 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.403 ' N ' ' SG ' ' A' ' 4' ' ' CYS . 2.9 tt -118.85 99.97 7.09 Favored 'General case' 0 N--CA 1.503 2.212 0 N-CA-C 101.283 -3.599 . . . . 0.0 101.283 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 2.9 m -78.85 -176.11 4.81 Favored 'General case' 0 C--N 1.308 -1.214 0 N-CA-C 116.424 2.009 . . . . 0.0 116.424 -179.381 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 29.0 t70 . . . . . 0 C--N 1.298 -1.662 0 CA-C-N 112.319 -2.219 . . . . 0.0 109.843 -179.614 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 4.8 m . . . . . 0 N--CA 1.503 2.175 0 N-CA-C 115.385 1.624 . . . . 0.0 115.385 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 167.69 -179.36 41.13 Favored Glycine 0 N--CA 1.502 3.045 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 179.796 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 37.2 mm -132.71 143.94 38.18 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.399 0 O-C-N 124.555 0.797 . . . . 0.0 110.975 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.499 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.9 pp -63.56 154.75 31.63 Favored 'General case' 0 N--CA 1.504 2.244 0 N-CA-C 109.117 -0.697 . . . . 0.0 109.117 179.518 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.511 ' N ' ' O ' ' A' ' 45' ' ' TRP . 32.4 m95 -134.42 131.4 38.13 Favored 'General case' 0 C--N 1.308 -1.202 0 N-CA-C 118.91 2.93 . . . . 0.0 118.91 -179.694 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -87.57 53.48 2.8 Favored 'General case' 0 C--N 1.291 -1.973 0 CA-C-N 109.316 -3.584 . . . . 0.0 111.796 -179.245 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 2.7 m-85 -125.52 137.06 29.17 Favored Pre-proline 0 C--N 1.306 -1.302 0 CA-C-N 115.052 -0.976 . . . . 0.0 110.352 179.6 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_endo -73.81 -25.43 14.49 Favored 'Trans proline' 0 C--N 1.306 -1.696 1 C-N-CA 125.725 4.283 . . . . 0.0 112.817 177.746 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 5.9 p -95.03 20.66 8.68 Favored 'General case' 0 N--CA 1.493 1.706 0 CA-C-N 115.249 -0.887 . . . . 0.0 111.163 -179.875 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 89.91 -138.27 14.47 Favored Glycine 0 N--CA 1.496 2.687 0 N-CA-C 106.278 -2.729 . . . . 0.0 106.278 -179.817 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . 0.526 ' SG ' ' CA ' ' A' ' 35' ' ' ASN . 29.7 m -69.28 150.05 97.3 Favored Pre-proline 0 C--N 1.305 -1.355 0 CA-C-N 117.496 0.648 . . . . 0.0 109.971 179.889 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.679 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 1.9 Cg_endo -78.31 159.29 29.6 Favored 'Trans proline' 0 C--N 1.31 -1.469 0 C-N-CA 123.207 2.604 . . . . 0.0 112.403 171.198 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 24.1 t -47.96 128.86 14.13 Favored 'General case' 0 C--N 1.305 -1.326 0 CA-C-N 113.168 -1.833 . . . . 0.0 109.3 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 100.51 -8.07 58.3 Favored Glycine 0 N--CA 1.495 2.607 0 CA-C-N 112.628 -2.078 . . . . 0.0 111.421 179.77 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' TRP . . . . . 0.679 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 48.3 m95 -110.29 162.94 14.14 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 106.83 -1.544 . . . . 0.0 106.83 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 78.6 t60 -143.22 29.82 1.44 Allowed 'General case' 0 N--CA 1.499 1.997 0 C-N-CA 118.34 -1.344 . . . . 0.0 113.135 -179.843 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . 0.526 ' CA ' ' SG ' ' A' ' 29' ' ' CYS . 12.1 t-20 62.02 147.13 0.02 OUTLIER 'General case' 0 N--CA 1.505 2.301 0 CA-C-O 123.109 1.433 . . . . 0.0 114.097 -179.79 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.841 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -117.41 -46.91 2.67 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-N 113.341 -1.754 . . . . 0.0 108.003 -179.666 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . 0.405 ' C ' ' H ' ' A' ' 39' ' ' HIS . 19.4 ttpp -132.18 124.77 29.69 Favored 'General case' 0 N--CA 1.497 1.922 0 N-CA-C 107.814 -1.18 . . . . 0.0 107.814 179.43 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -87.13 22.07 2.18 Favored 'General case' 0 N--CA 1.493 1.688 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 179.788 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . 0.405 ' H ' ' C ' ' A' ' 37' ' ' LYS . 16.9 m-70 -131.33 76.72 1.73 Allowed 'General case' 0 N--CA 1.492 1.645 0 CA-C-O 122.243 1.02 . . . . 0.0 108.882 -179.773 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 68.83 -163.07 50.54 Favored Glycine 0 N--CA 1.492 2.418 0 CA-C-N 113.353 -1.749 . . . . 0.0 109.849 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . 0.412 ' HG2' ' O ' ' A' ' 44' ' ' GLY . 34.1 Cg_endo -71.86 175.14 43.78 Favored 'Cis proline' 0 N--CA 1.495 1.573 0 N-CA-C 107.635 -1.717 . . . . 0.0 107.635 -2.402 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.486 ' C ' ' H ' ' A' ' 44' ' ' GLY . 23.4 m120 -91.53 -10.12 41.86 Favored 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 105.299 -2.112 . . . . 0.0 105.299 -179.484 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 16.1 mt -88.79 28.75 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.225 0 CA-C-N 113.447 -1.706 . . . . 0.0 110.338 -179.438 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.486 ' H ' ' C ' ' A' ' 42' ' ' ASN . . . 115.98 135.29 5.65 Favored Glycine 0 N--CA 1.486 2.0 0 CA-C-N 111.827 -2.442 . . . . 0.0 112.687 179.789 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . 0.511 ' O ' ' N ' ' A' ' 23' ' ' TRP . 26.3 m95 -62.0 129.39 40.66 Favored 'General case' 0 N--CA 1.501 2.116 0 C-N-CA 120.19 -0.604 . . . . 0.0 111.388 -179.42 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' CYS . . . . . 0.841 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 46.4 t -88.52 114.72 25.43 Favored 'General case' 0 C--N 1.305 -1.359 1 N-CA-C 96.728 -5.286 . . . . 0.0 96.728 179.998 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.53 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 75.1 m -129.89 -176.18 3.84 Favored 'General case' 0 C--N 1.295 -1.768 1 CA-C-N 108.253 -4.067 . . . . 0.0 108.714 -179.407 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.437 ' O ' ' HA ' ' A' ' 33' ' ' TRP . 0.0 OUTLIER -149.97 169.74 20.48 Favored 'General case' 0 C--N 1.294 -1.836 0 C-N-CA 117.614 -1.634 . . . . 0.0 107.698 179.56 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 48.9 mtpt . . . . . 0 C--N 1.29 -2.02 0 O-C-N 127.577 3.048 . . . . 0.0 109.379 179.71 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 61.9 t . . . . . 0 N--CA 1.496 1.84 0 N-CA-C 108.026 -1.101 . . . . 0.0 108.026 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -76.22 158.93 37.27 Favored 'Trans proline' 0 C--N 1.309 -1.54 0 C-N-CA 124.509 3.473 . . . . 0.0 113.405 171.45 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -150.9 164.94 35.12 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 125.48 1.737 . . . . 0.0 108.036 179.614 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.408 HD21 ' N ' ' A' ' 6' ' ' CYS . 9.4 tt -79.38 168.18 19.85 Favored 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 103.404 -2.813 . . . . 0.0 103.404 179.759 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . 0.429 ' HB3' ' C ' ' A' ' 36' ' ' CYS . 3.5 m -140.93 -174.8 4.09 Favored 'General case' 0 C--N 1.302 -1.489 0 N-CA-C 116.662 2.097 . . . . 0.0 116.662 -179.257 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 30.7 t70 . . . . . 0 N--CA 1.492 1.654 0 CA-C-N 112.639 -2.073 . . . . 0.0 107.862 179.943 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 19.7 m . . . . . 0 N--CA 1.502 2.15 0 N-CA-C 112.681 0.623 . . . . 0.0 112.681 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -166.7 -162.46 18.32 Favored Glycine 0 N--CA 1.504 3.195 0 N-CA-C 110.904 -0.878 . . . . 0.0 110.904 -179.863 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 8.1 mm -135.75 146.48 29.59 Favored 'Isoleucine or valine' 0 N--CA 1.515 2.82 0 N-CA-C 113.992 1.108 . . . . 0.0 113.992 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.556 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.6 pp -64.25 151.15 44.41 Favored 'General case' 0 N--CA 1.505 2.317 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 179.17 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.448 ' N ' ' O ' ' A' ' 45' ' ' TRP . 22.3 m95 -133.45 137.41 45.7 Favored 'General case' 0 C--N 1.305 -1.347 0 N-CA-C 116.6 2.074 . . . . 0.0 116.6 -179.656 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -88.47 41.32 1.01 Allowed 'General case' 0 C--N 1.293 -1.87 0 CA-C-N 109.045 -3.707 . . . . 0.0 115.119 -179.408 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -114.67 129.28 25.11 Favored Pre-proline 0 N--CA 1.489 1.52 0 N-CA-C 115.45 1.648 . . . . 0.0 115.45 179.743 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -68.33 -21.53 41.07 Favored 'Trans proline' 0 C--N 1.307 -1.642 0 C-N-CA 123.402 2.734 . . . . 0.0 108.979 -175.106 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -91.32 1.29 57.22 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-N 112.864 -1.971 . . . . 0.0 110.797 179.752 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 107.72 -117.05 5.06 Favored Glycine 0 N--CA 1.498 2.828 0 N-CA-C 105.455 -3.058 . . . . 0.0 105.455 -179.831 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . 0.533 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 10.2 m -93.12 150.23 38.83 Favored Pre-proline 0 C--N 1.305 -1.361 0 N-CA-C 108.404 -0.962 . . . . 0.0 108.404 179.632 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.668 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.5 OUTLIER -76.49 175.53 11.23 Favored 'Trans proline' 0 C--N 1.311 -1.42 0 C-N-CA 123.241 2.627 . . . . 0.0 115.66 176.777 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 16.4 p -50.47 102.88 0.04 OUTLIER 'General case' 0 C--N 1.299 -1.605 0 CA-C-N 112.671 -2.059 . . . . 0.0 112.724 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 112.12 -0.24 26.89 Favored Glycine 0 N--CA 1.503 3.127 0 O-C-N 124.332 1.02 . . . . 0.0 113.61 179.435 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' TRP . . . . . 0.668 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 45.6 m95 -112.3 163.73 14.05 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 107.289 -1.375 . . . . 0.0 107.289 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 73.5 t60 -146.37 37.45 1.02 Allowed 'General case' 0 N--CA 1.501 2.098 0 C-N-CA 118.014 -1.475 . . . . 0.0 114.54 -179.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . 0.533 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 23.7 t-20 60.04 149.42 0.02 OUTLIER 'General case' 0 N--CA 1.506 2.338 0 N-CA-C 115.763 1.764 . . . . 0.0 115.763 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.623 ' SG ' ' HB3' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -125.21 -44.91 1.86 Allowed 'General case' 0 C--N 1.303 -1.451 0 CA-C-N 113.52 -1.673 . . . . 0.0 108.067 -179.913 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . 0.477 ' C ' ' H ' ' A' ' 39' ' ' HIS . 36.9 ttmt -124.66 111.13 15.24 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 105.101 -2.185 . . . . 0.0 105.101 179.61 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.436 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -85.01 31.84 0.54 Allowed 'General case' 0 N--CA 1.494 1.749 0 N-CA-C 106.132 -1.803 . . . . 0.0 106.132 179.587 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . 0.477 ' H ' ' C ' ' A' ' 37' ' ' LYS . 4.5 m-70 -132.21 22.28 4.45 Favored 'General case' 0 N--CA 1.497 1.88 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 -179.612 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 107.89 -145.88 16.26 Favored Glycine 0 N--CA 1.494 2.514 0 N-CA-C 109.292 -1.523 . . . . 0.0 109.292 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . 0.659 ' CD ' ' SG ' ' A' ' 46' ' ' CYS . 8.4 Cg_endo -74.97 -173.54 12.5 Favored 'Cis proline' 0 N--CA 1.502 2.011 0 C-N-CA 129.013 0.839 . . . . 0.0 111.36 0.87 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.505 ' C ' ' H ' ' A' ' 44' ' ' GLY . 0.2 OUTLIER -91.9 -8.61 45.9 Favored 'General case' 0 N--CA 1.487 1.385 0 N-CA-C 102.883 -3.006 . . . . 0.0 102.883 179.951 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.406 HD13 ' N ' ' A' ' 43' ' ' ILE . 4.0 mp -90.88 32.45 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 CA-C-O 123.159 1.457 . . . . 0.0 108.245 -179.419 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.505 ' H ' ' C ' ' A' ' 42' ' ' ASN . . . 102.89 127.74 6.19 Favored Glycine 0 N--CA 1.489 2.209 0 CA-C-N 111.88 -2.418 . . . . 0.0 107.094 -179.774 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . 0.448 ' O ' ' N ' ' A' ' 23' ' ' TRP . 6.7 m95 -54.8 135.67 47.32 Favored 'General case' 0 N--CA 1.509 2.485 0 CA-C-O 117.05 -1.452 . . . . 0.0 108.621 -179.519 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' CYS . . . . . 0.659 ' SG ' ' CD ' ' A' ' 41' ' ' PRO . 75.3 m -88.37 122.67 32.13 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 101.885 -3.376 . . . . 0.0 101.885 179.86 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.469 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 75.2 m -128.57 -174.71 3.31 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-N 110.43 -3.077 . . . . 0.0 108.739 -179.495 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.36 171.96 16.66 Favored 'General case' 0 C--N 1.299 -1.617 0 N-CA-C 106.684 -1.599 . . . . 0.0 106.684 179.176 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 92.3 mttt . . . . . 0 C--N 1.288 -2.076 0 O-C-N 125.675 1.859 . . . . 0.0 109.437 179.922 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 24.7 t . . . . . 0 N--CA 1.5 2.039 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 6.9 Cg_endo -79.18 129.65 8.86 Favored 'Trans proline' 0 N--CA 1.491 1.371 0 C-N-CA 123.836 3.024 . . . . 0.0 114.268 165.034 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -119.2 -163.0 0.94 Allowed 'General case' 0 N--CA 1.495 1.822 0 N-CA-C 113.549 0.944 . . . . 0.0 113.549 -179.729 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.43 HD22 ' N ' ' A' ' 6' ' ' CYS . 9.6 tt -111.71 151.68 28.63 Favored 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 104.456 -2.424 . . . . 0.0 104.456 179.848 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . 0.43 ' N ' HD22 ' A' ' 5' ' ' LEU . 5.1 m -140.95 -171.05 3.17 Favored 'General case' 0 N--CA 1.483 1.189 0 N-CA-C 116.224 1.935 . . . . 0.0 116.224 -179.378 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 39.0 t70 . . . . . 0 N--CA 1.49 1.558 0 CA-C-N 112.233 -2.258 . . . . 0.0 108.09 -179.958 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 41.4 t . . . . . 0 N--CA 1.5 2.041 0 CA-C-O 121.124 0.488 . . . . 0.0 110.468 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.433 ' HA2' ' HD3' ' A' ' 48' ' ' LYS . . . -170.99 119.23 0.79 Allowed Glycine 0 N--CA 1.499 2.843 0 CA-C-O 117.979 -1.456 . . . . 0.0 112.32 179.911 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.426 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 37.6 mm -102.71 131.13 51.56 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.312 0 N-CA-C 103.429 -2.804 . . . . 0.0 103.429 179.308 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.599 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 2.1 pp -64.45 158.75 23.05 Favored 'General case' 0 N--CA 1.496 1.85 0 C-N-CA 118.189 -1.404 . . . . 0.0 107.811 179.785 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.48 ' N ' ' O ' ' A' ' 45' ' ' TRP . 19.4 m95 -138.6 135.51 35.02 Favored 'General case' 0 C--N 1.306 -1.324 0 N-CA-C 115.919 1.822 . . . . 0.0 115.919 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -89.06 41.64 1.04 Allowed 'General case' 0 C--N 1.293 -1.878 0 CA-C-N 109.803 -3.362 . . . . 0.0 115.851 -179.611 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.444 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 1.0 OUTLIER -118.34 126.89 26.92 Favored Pre-proline 0 N--CA 1.487 1.379 0 CA-C-O 122.417 1.104 . . . . 0.0 110.225 179.646 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -64.82 -28.71 59.12 Favored 'Trans proline' 0 C--N 1.299 -2.039 0 C-N-CA 122.096 1.864 . . . . 0.0 108.781 -175.237 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 4.6 p -82.36 5.55 19.94 Favored 'General case' 0 N--CA 1.492 1.653 0 CA-C-N 114.661 -1.154 . . . . 0.0 112.52 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 105.79 -128.81 9.52 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 106.032 -2.827 . . . . 0.0 106.032 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . 0.505 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 4.3 m -83.9 145.55 47.04 Favored Pre-proline 0 C--N 1.302 -1.486 0 C-N-CA 120.595 -0.442 . . . . 0.0 110.301 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.659 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 7.0 Cg_endo -75.01 162.27 37.39 Favored 'Trans proline' 0 C--N 1.312 -1.343 0 C-N-CA 123.317 2.678 . . . . 0.0 113.958 176.769 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 18.8 t -45.66 111.94 0.4 Allowed 'General case' 0 N--CA 1.492 1.636 0 CA-C-N 114.362 -1.29 . . . . 0.0 110.205 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 114.14 -8.64 23.0 Favored Glycine 0 N--CA 1.5 2.963 0 CA-C-N 114.573 -1.194 . . . . 0.0 112.93 179.596 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' TRP . . . . . 0.659 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 50.9 m95 -110.76 161.2 16.01 Favored 'General case' 0 N--CA 1.489 1.498 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . 0.429 ' O ' ' ND1' ' A' ' 34' ' ' HIS . 56.5 t-80 -146.83 46.34 1.18 Allowed 'General case' 0 N--CA 1.499 1.978 0 C-N-CA 117.741 -1.584 . . . . 0.0 113.508 -179.812 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . 0.505 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 21.4 t-20 62.64 145.81 0.02 OUTLIER 'General case' 0 N--CA 1.511 2.6 0 N-CA-C 116.418 2.007 . . . . 0.0 116.418 179.846 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.791 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 0.7 OUTLIER -116.29 -43.0 2.98 Favored 'General case' 0 N--CA 1.485 1.28 0 N-CA-C 106.927 -1.509 . . . . 0.0 106.927 179.482 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . 0.42 ' C ' ' H ' ' A' ' 39' ' ' HIS . 8.8 ptpp? -124.31 127.24 47.33 Favored 'General case' 0 N--CA 1.498 1.94 0 N-CA-C 107.406 -1.331 . . . . 0.0 107.406 179.319 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.445 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -77.8 43.14 0.4 Allowed 'General case' 0 N--CA 1.497 1.909 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 179.869 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . 0.445 ' ND1' ' C ' ' A' ' 38' ' ' ALA . 3.5 m-70 -132.05 -81.35 0.51 Allowed 'General case' 0 N--CA 1.498 1.972 0 CA-C-O 119.084 -0.484 . . . . 0.0 110.748 -179.673 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -153.01 -130.38 1.51 Allowed Glycine 0 N--CA 1.509 3.524 0 N-CA-C 109.297 -1.521 . . . . 0.0 109.297 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 0.2 OUTLIER -81.07 -170.17 8.28 Favored 'Cis proline' 0 N--CA 1.5 1.903 0 CA-C-N 120.25 2.025 . . . . 0.0 111.319 -4.178 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.439 ' C ' ' H ' ' A' ' 44' ' ' GLY . 59.6 t30 -92.62 -13.97 28.84 Favored 'General case' 0 N--CA 1.486 1.365 0 N-CA-C 106.094 -1.817 . . . . 0.0 106.094 -179.798 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 37.3 pt -86.6 26.03 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 CA-C-N 113.591 -1.64 . . . . 0.0 113.382 -179.26 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.439 ' H ' ' C ' ' A' ' 42' ' ' ASN . . . 111.62 119.51 3.84 Favored Glycine 0 N--CA 1.486 2.007 0 CA-C-N 111.602 -2.545 . . . . 0.0 106.875 -179.836 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . 0.48 ' O ' ' N ' ' A' ' 23' ' ' TRP . 20.2 m95 -51.45 133.72 29.44 Favored 'General case' 0 N--CA 1.501 2.095 0 CA-C-N 113.253 -1.473 . . . . 0.0 111.111 -179.432 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' CYS . . . . . 0.791 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 22.8 t -89.26 118.69 29.12 Favored 'General case' 0 C--N 1.305 -1.359 1 N-CA-C 99.746 -4.168 . . . . 0.0 99.746 179.571 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.457 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 86.4 m -126.96 -176.27 3.66 Favored 'General case' 0 CA--C 1.487 -1.443 0 CA-C-N 111.172 -2.74 . . . . 0.0 112.604 -179.357 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.433 ' HD3' ' HA2' ' A' ' 20' ' ' GLY . 34.8 tptt -151.49 157.46 42.33 Favored 'General case' 0 C--N 1.297 -1.697 0 C-N-CA 118.297 -1.361 . . . . 0.0 109.999 -179.821 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 23.8 mttm . . . . . 0 N--CA 1.505 2.298 0 O-C-N 127.039 2.712 . . . . 0.0 110.666 179.646 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 38.9 t . . . . . 0 N--CA 1.494 1.774 0 N-CA-C 103.962 -2.607 . . . . 0.0 103.962 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -72.82 138.13 28.26 Favored 'Trans proline' 0 C--N 1.305 -1.761 0 C-N-CA 122.991 2.461 . . . . 0.0 117.568 163.662 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.556 ' SG ' ' SG ' ' A' ' 6' ' ' CYS . 12.5 p -124.56 159.1 31.4 Favored 'General case' 0 N--CA 1.494 1.766 0 CA-C-N 114.818 -1.083 . . . . 0.0 109.46 179.52 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 10.3 tp -79.7 84.03 5.58 Favored 'General case' 0 N--CA 1.491 1.62 1 N-CA-C 99.612 -4.218 . . . . 0.0 99.612 179.465 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . 0.678 ' SG ' ' HA3' ' A' ' 20' ' ' GLY . 34.7 m -68.41 175.07 3.57 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-O 123.391 1.567 . . . . 0.0 111.567 -179.716 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 12.7 t70 . . . . . 0 C--N 1.294 -1.809 0 CA-C-N 111.498 -2.592 . . . . 0.0 114.506 -179.202 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 12.4 t . . . . . 0 N--CA 1.504 2.274 0 CA-C-O 118.405 -0.807 . . . . 0.0 112.734 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.678 ' HA3' ' SG ' ' A' ' 6' ' ' CYS . . . -162.66 139.09 5.71 Favored Glycine 0 N--CA 1.493 2.467 0 CA-C-O 118.29 -1.283 . . . . 0.0 110.553 -179.785 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.438 ' N ' ' O ' ' A' ' 47' ' ' CYS . 32.7 mm -102.57 140.69 20.3 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.102 0 N-CA-C 104.268 -2.493 . . . . 0.0 104.268 179.571 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.487 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.6 pp -63.87 146.08 54.65 Favored 'General case' 0 N--CA 1.504 2.238 0 C-N-CA 117.407 -1.717 . . . . 0.0 112.154 179.727 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 40.6 m95 -130.82 131.88 44.9 Favored 'General case' 0 N--CA 1.486 1.327 0 N-CA-C 119.404 3.113 . . . . 0.0 119.404 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -89.39 51.32 2.09 Favored 'General case' 0 C--N 1.301 -1.512 1 CA-C-N 107.895 -4.229 . . . . 0.0 111.334 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.507 ' CE1' ' HB3' ' A' ' 30' ' ' PRO . 2.2 m-85 -125.99 126.37 24.81 Favored Pre-proline 0 N--CA 1.488 1.448 0 CA-C-O 121.588 0.708 . . . . 0.0 111.898 179.834 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -64.13 -19.99 66.79 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 C-N-CA 123.764 2.976 . . . . 0.0 110.286 -178.12 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 10.4 p -88.04 -6.69 57.82 Favored 'General case' 0 N--CA 1.491 1.587 0 CA-C-N 114.004 -1.453 . . . . 0.0 110.933 179.753 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.604 ' HA2' ' CD1' ' A' ' 45' ' ' TRP . . . 114.81 -95.3 0.71 Allowed Glycine 0 N--CA 1.483 1.776 1 N-CA-C 100.932 -4.867 . . . . 0.0 100.932 -179.531 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . 0.484 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 7.8 m -101.17 164.37 16.15 Favored Pre-proline 0 C--N 1.302 -1.459 0 CA-C-N 114.006 -1.097 . . . . 0.0 108.676 179.768 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.686 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.3 OUTLIER -83.83 167.1 13.05 Favored 'Trans proline' 0 C--N 1.311 -1.412 0 C-N-CA 124.917 3.745 . . . . 0.0 116.177 158.24 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 29.1 t -55.86 126.33 25.22 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-N 113.427 -1.715 . . . . 0.0 109.62 -179.843 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 104.58 -7.12 45.8 Favored Glycine 0 N--CA 1.495 2.628 0 CA-C-N 112.664 -2.062 . . . . 0.0 111.46 179.893 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' TRP . . . . . 0.686 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 49.7 m95 -113.4 152.96 29.36 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 106.335 -1.728 . . . . 0.0 106.335 -179.872 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 64.7 t60 -140.42 44.5 1.86 Allowed 'General case' 0 N--CA 1.493 1.717 0 C-N-CA 119.419 -0.913 . . . . 0.0 109.51 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . 0.579 ' HA ' ' SG ' ' A' ' 47' ' ' CYS . 23.2 t-20 54.74 147.86 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.171 0 CA-C-N 112.951 -1.932 . . . . 0.0 115.428 -179.985 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.676 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 0.8 OUTLIER -119.76 -36.27 3.34 Favored 'General case' 0 C--N 1.309 -1.184 0 N-CA-C 106.632 -1.618 . . . . 0.0 106.632 179.825 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 19.5 ttpt -139.02 122.4 17.16 Favored 'General case' 0 N--CA 1.486 1.336 0 CA-C-O 123.589 1.661 . . . . 0.0 109.98 179.668 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.43 ' O ' ' ND1' ' A' ' 39' ' ' HIS . . . -96.0 21.18 9.03 Favored 'General case' 0 C--N 1.303 -1.419 0 CA-C-N 112.273 -2.239 . . . . 0.0 105.541 179.72 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . 0.43 ' ND1' ' O ' ' A' ' 38' ' ' ALA . 10.7 m-70 -135.72 69.46 1.43 Allowed 'General case' 0 N--CA 1.497 1.895 0 N-CA-C 109.372 -0.603 . . . . 0.0 109.372 -179.719 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 84.08 176.47 51.17 Favored Glycine 0 N--CA 1.502 3.036 0 N-CA-C 106.165 -2.774 . . . . 0.0 106.165 -179.739 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_endo -60.96 169.8 19.37 Favored 'Cis proline' 0 N--CA 1.504 2.089 0 CA-C-N 119.771 1.786 . . . . 0.0 114.434 1.664 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 17.0 t-20 -92.45 -9.08 42.81 Favored 'General case' 0 N--CA 1.484 1.232 0 N-CA-C 104.773 -2.306 . . . . 0.0 104.773 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 17.6 mt -92.7 29.72 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.063 0 CA-C-O 123.059 1.409 . . . . 0.0 109.819 -179.29 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.465 ' C ' ' CD1' ' A' ' 45' ' ' TRP . . . 129.53 -116.58 2.17 Favored Glycine 0 N--CA 1.484 1.84 0 N-CA-C 103.744 -3.742 . . . . 0.0 103.744 -179.772 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . 0.604 ' CD1' ' HA2' ' A' ' 28' ' ' GLY . 3.0 m95 -155.26 -172.07 4.04 Favored 'General case' 0 N--CA 1.507 2.422 0 N-CA-C 104.254 -2.498 . . . . 0.0 104.254 179.853 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' CYS . . . . . 0.676 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 26.2 t -135.75 126.84 27.96 Favored 'General case' 0 N--CA 1.498 1.958 1 N-CA-C 98.985 -4.45 . . . . 0.0 98.985 179.493 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.579 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 70.9 m -131.47 -179.68 5.51 Favored 'General case' 0 CA--C 1.471 -2.061 0 N-CA-C 116.24 1.941 . . . . 0.0 116.24 -178.663 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.518 ' HD2' ' H ' ' A' ' 49' ' ' LYS . 44.1 tptt -151.04 149.21 29.28 Favored 'General case' 0 C--N 1.297 -1.693 0 C-N-CA 118.716 -1.194 . . . . 0.0 110.672 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . 0.518 ' H ' ' HD2' ' A' ' 48' ' ' LYS . 93.4 mttt . . . . . 0 N--CA 1.494 1.774 0 CA-C-N 112.133 -2.303 . . . . 0.0 108.59 179.317 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 21.4 t . . . . . 0 N--CA 1.497 1.919 0 N-CA-C 106.694 -1.595 . . . . 0.0 106.694 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.423 ' HA ' ' HA ' ' A' ' 21' ' ' ILE . 6.9 Cg_endo -77.84 149.76 26.49 Favored 'Trans proline' 0 C--N 1.309 -1.532 0 C-N-CA 122.536 2.157 . . . . 0.0 110.314 169.521 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -138.95 169.43 17.81 Favored 'General case' 0 C--N 1.3 -1.557 0 CA-C-O 121.862 0.839 . . . . 0.0 110.142 179.836 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 8.5 tt -91.88 150.52 21.0 Favored 'General case' 0 N--CA 1.492 1.655 0 N-CA-C 102.229 -3.248 . . . . 0.0 102.229 179.647 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . 0.443 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 3.1 m -139.78 -166.46 2.08 Favored 'General case' 0 N--CA 1.493 1.72 0 N-CA-C 113.973 1.101 . . . . 0.0 113.973 -179.519 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . 0.445 ' H ' ' HB3' ' A' ' 37' ' ' LYS . 30.1 t70 . . . . . 0 N--CA 1.496 1.86 0 CA-C-N 112.612 -2.085 . . . . 0.0 108.091 -179.754 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 64.0 p . . . . . 0 N--CA 1.499 1.984 0 N-CA-C 112.904 0.705 . . . . 0.0 112.904 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -135.45 156.49 22.72 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 108.791 -1.724 . . . . 0.0 108.791 -179.906 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.43 ' N ' ' O ' ' A' ' 47' ' ' CYS . 44.5 mm -115.56 144.93 22.03 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 N-CA-C 106.098 -1.816 . . . . 0.0 106.098 179.708 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.521 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 4.1 pp -72.69 151.0 42.45 Favored 'General case' 0 N--CA 1.488 1.464 0 C-N-CA 118.438 -1.305 . . . . 0.0 109.041 179.752 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 44.1 m95 -132.31 134.21 44.96 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 117.721 2.489 . . . . 0.0 117.721 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.3 m-85 -89.2 53.13 2.56 Favored 'General case' 0 C--N 1.296 -1.744 1 CA-C-N 107.623 -4.353 . . . . 0.0 109.43 -179.791 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.429 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 2.4 m-85 -126.58 139.2 34.13 Favored Pre-proline 0 C--N 1.306 -1.294 0 CA-C-O 121.671 0.748 . . . . 0.0 111.964 -179.962 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.68 -18.01 37.63 Favored 'Trans proline' 0 C--N 1.305 -1.734 1 C-N-CA 125.415 4.077 . . . . 0.0 110.6 177.161 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 10.7 p -100.26 22.65 11.19 Favored 'General case' 0 C--N 1.299 -1.613 0 CA-C-N 113.334 -1.757 . . . . 0.0 110.886 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.572 ' HA2' ' CD1' ' A' ' 45' ' ' TRP . . . 81.4 -89.98 1.41 Allowed Glycine 0 N--CA 1.484 1.838 1 N-CA-C 102.854 -4.098 . . . . 0.0 102.854 -179.674 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . 0.462 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 24.8 m -98.7 163.57 18.67 Favored Pre-proline 0 C--N 1.302 -1.457 0 CA-C-N 113.719 -1.24 . . . . 0.0 110.996 -179.887 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.66 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.1 OUTLIER -89.05 163.76 5.83 Favored 'Trans proline' 0 CA--C 1.554 1.496 1 C-N-CA 126.701 4.934 . . . . 0.0 117.122 155.785 . . . . . . . . 4 4 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 4.1 m -51.06 111.82 0.62 Allowed 'General case' 0 C--N 1.301 -1.526 0 CA-C-N 112.36 -2.2 . . . . 0.0 114.135 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 113.7 -6.54 24.22 Favored Glycine 0 N--CA 1.506 3.352 0 CA-C-N 115.046 -0.979 . . . . 0.0 112.638 179.68 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' TRP . . . . . 0.66 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 54.7 m95 -106.96 167.17 10.07 Favored 'General case' 0 C--N 1.299 -1.619 0 N-CA-C 106.517 -1.661 . . . . 0.0 106.517 -179.762 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 67.8 t60 -146.96 37.7 0.97 Allowed 'General case' 0 N--CA 1.493 1.69 0 C-N-CA 116.845 -1.942 . . . . 0.0 113.236 179.82 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . 0.518 ' HA ' ' SG ' ' A' ' 47' ' ' CYS . 13.9 t-20 55.88 143.04 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.113 0 N-CA-C 117.484 2.401 . . . . 0.0 117.484 179.556 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.842 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 2.7 p -120.3 -28.37 5.05 Favored 'General case' 0 N--CA 1.486 1.329 0 CA-C-N 115.652 -0.703 . . . . 0.0 111.345 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . 0.445 ' HB3' ' H ' ' A' ' 7' ' ' ASP . 9.5 ptpt -151.05 151.15 31.61 Favored 'General case' 0 N--CA 1.495 1.792 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 179.105 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.449 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -117.0 35.06 4.8 Favored 'General case' 0 N--CA 1.491 1.607 0 N-CA-C 102.388 -3.19 . . . . 0.0 102.388 179.661 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . 0.449 ' ND1' ' C ' ' A' ' 38' ' ' ALA . 4.5 m-70 -128.64 60.31 1.52 Allowed 'General case' 0 N--CA 1.497 1.881 0 N-CA-C 106.943 -1.503 . . . . 0.0 106.943 -179.534 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 74.19 -149.45 40.81 Favored Glycine 0 N--CA 1.496 2.646 0 N-CA-C 104.854 -3.298 . . . . 0.0 104.854 -179.702 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_endo -48.53 176.6 0.39 Allowed 'Cis proline' 0 N--CA 1.504 2.104 0 CA-C-N 119.765 1.783 . . . . 0.0 115.478 -5.499 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.5 m-20 -92.08 -7.77 47.72 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 104.34 -2.467 . . . . 0.0 104.34 -179.719 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 15.0 mt -99.53 22.29 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.85 0 CA-C-O 123.99 1.853 . . . . 0.0 113.006 -179.345 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 133.08 -119.87 2.48 Favored Glycine 0 C--N 1.288 -2.094 0 N-CA-C 104.195 -3.562 . . . . 0.0 104.195 -179.857 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . 0.572 ' CD1' ' HA2' ' A' ' 28' ' ' GLY . 3.9 m95 -152.56 -169.22 3.28 Favored 'General case' 0 N--CA 1.511 2.588 0 N-CA-C 106.923 -1.51 . . . . 0.0 106.923 -179.917 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' CYS . . . . . 0.842 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 43.8 t -139.17 129.4 25.39 Favored 'General case' 0 C--N 1.313 -0.982 0 N-CA-C 101.273 -3.603 . . . . 0.0 101.273 179.13 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.518 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 71.4 m -135.0 -172.13 2.97 Favored 'General case' 0 C--N 1.294 -1.805 0 CA-C-N 111.295 -2.684 . . . . 0.0 108.479 -179.435 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.406 ' N ' ' CD ' ' A' ' 48' ' ' LYS . 0.0 OUTLIER -150.55 173.5 14.03 Favored 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 107.125 -1.435 . . . . 0.0 107.125 179.352 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.499 1.993 0 O-C-N 125.803 1.939 . . . . 0.0 106.681 179.728 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 22.0 t . . . . . 0 N--CA 1.497 1.893 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -72.28 149.65 51.58 Favored 'Trans proline' 0 N--CA 1.494 1.506 0 C-N-CA 124.161 3.24 . . . . 0.0 112.716 167.625 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.577 ' SG ' ' HB3' ' A' ' 22' ' ' LEU . 0.1 OUTLIER -136.88 -176.89 4.51 Favored 'General case' 0 N--CA 1.496 1.844 0 CA-C-N 115.349 -0.842 . . . . 0.0 111.438 179.631 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 6.4 tt -91.15 110.93 22.21 Favored 'General case' 0 N--CA 1.491 1.587 0 C-N-CA 119.428 -0.909 . . . . 0.0 108.829 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . 0.441 ' SG ' ' HA3' ' A' ' 20' ' ' GLY . 7.7 m -88.13 178.42 6.64 Favored 'General case' 0 C--N 1.31 -1.123 0 CA-C-O 123.282 1.515 . . . . 0.0 113.827 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 9.4 t70 . . . . . 0 C--N 1.297 -1.712 0 CA-C-N 111.501 -2.59 . . . . 0.0 110.123 -179.84 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 8.9 t . . . . . 0 N--CA 1.501 2.112 0 CA-C-O 120.901 0.381 . . . . 0.0 111.077 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.441 ' HA3' ' SG ' ' A' ' 6' ' ' CYS . . . -154.4 141.33 8.13 Favored Glycine 0 N--CA 1.496 2.634 0 N-CA-C 110.349 -1.1 . . . . 0.0 110.349 179.987 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.405 ' N ' ' O ' ' A' ' 47' ' ' CYS . 40.8 mm -99.64 138.89 22.61 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.452 0 N-CA-C 107.122 -1.436 . . . . 0.0 107.122 179.767 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.577 ' HB3' ' SG ' ' A' ' 4' ' ' CYS . 1.3 pp -68.97 146.93 52.33 Favored 'General case' 0 N--CA 1.495 1.8 0 C-N-CA 118.925 -1.11 . . . . 0.0 109.155 179.889 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 29.9 m95 -129.06 135.03 48.37 Favored 'General case' 0 C--N 1.307 -1.246 0 N-CA-C 117.882 2.549 . . . . 0.0 117.882 -179.786 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -89.38 49.25 1.72 Allowed 'General case' 0 C--N 1.298 -1.635 1 CA-C-N 108.047 -4.16 . . . . 0.0 113.163 -179.791 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.403 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 2.0 m-85 -122.08 139.3 30.19 Favored Pre-proline 0 C--N 1.301 -1.542 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 179.573 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 13.9 Cg_endo -76.29 -26.3 9.07 Favored 'Trans proline' 0 C--N 1.303 -1.86 0 C-N-CA 125.255 3.97 . . . . 0.0 112.841 174.42 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -88.66 11.94 16.11 Favored 'General case' 0 N--CA 1.494 1.748 0 CA-C-N 114.876 -1.056 . . . . 0.0 113.224 -179.831 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 97.91 -127.2 9.14 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 103.755 -3.738 . . . . 0.0 103.755 -179.722 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . 0.54 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 8.3 m -85.38 147.04 46.04 Favored Pre-proline 0 C--N 1.303 -1.444 0 CA-C-N 117.716 0.758 . . . . 0.0 110.776 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.665 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 8.5 Cg_endo -75.19 168.28 25.05 Favored 'Trans proline' 0 C--N 1.308 -1.602 0 C-N-CA 123.037 2.491 . . . . 0.0 113.795 176.006 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 2.9 m -45.45 101.45 0.02 OUTLIER 'General case' 0 C--N 1.297 -1.68 0 CA-C-N 112.642 -2.072 . . . . 0.0 113.423 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 116.0 -2.11 21.12 Favored Glycine 0 N--CA 1.507 3.427 0 C-N-CA 120.945 -0.645 . . . . 0.0 114.057 179.63 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' TRP . . . . . 0.665 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 55.4 m95 -111.13 158.29 19.05 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 106.46 -1.682 . . . . 0.0 106.46 -179.851 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 2.0 t-80 -138.54 34.08 2.25 Favored 'General case' 0 N--CA 1.492 1.667 0 C-N-CA 117.615 -1.634 . . . . 0.0 112.507 -179.739 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . 0.54 ' HA ' ' SG ' ' A' ' 29' ' ' CYS . 0.3 OUTLIER 66.4 138.21 0.03 OUTLIER 'General case' 0 N--CA 1.509 2.498 0 N-CA-C 116.566 2.061 . . . . 0.0 116.566 179.734 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.683 ' SG ' ' CB ' ' A' ' 46' ' ' CYS . 0.8 OUTLIER -114.34 -33.37 5.65 Favored 'General case' 0 N--CA 1.484 1.243 0 N-CA-C 104.541 -2.392 . . . . 0.0 104.541 179.485 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 20.7 ptmt -146.4 139.95 25.97 Favored 'General case' 0 N--CA 1.494 1.764 0 CA-C-N 115.481 -0.781 . . . . 0.0 110.069 179.503 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.449 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -112.17 34.81 4.05 Favored 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 103.898 -2.63 . . . . 0.0 103.898 179.833 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . 0.449 ' ND1' ' C ' ' A' ' 38' ' ' ALA . 4.1 m-70 -129.12 57.28 1.65 Allowed 'General case' 0 N--CA 1.499 1.981 0 N-CA-C 107.611 -1.255 . . . . 0.0 107.611 -179.735 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 72.75 -142.04 31.56 Favored Glycine 0 N--CA 1.496 2.695 0 N-CA-C 106.739 -2.544 . . . . 0.0 106.739 -179.656 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . 0.443 ' HG2' ' O ' ' A' ' 44' ' ' GLY . 94.3 Cg_endo -62.34 -169.19 1.42 Allowed 'Cis proline' 0 N--CA 1.496 1.621 0 CA-C-N 118.804 1.302 . . . . 0.0 112.876 -5.065 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 54.2 t30 -93.66 1.53 56.58 Favored 'General case' 0 C--N 1.308 -1.217 0 N-CA-C 105.045 -2.206 . . . . 0.0 105.045 -179.334 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 1.1 mp -120.28 37.46 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 O-C-N 125.126 1.516 . . . . 0.0 114.843 -179.008 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.443 ' O ' ' HG2' ' A' ' 41' ' ' PRO . . . 119.59 149.99 8.56 Favored Glycine 0 N--CA 1.485 1.963 0 N-CA-C 106.85 -2.5 . . . . 0.0 106.85 179.932 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . 0.403 ' NE1' ' O ' ' A' ' 25' ' ' TYR . 5.1 m95 -89.38 136.42 33.04 Favored 'General case' 0 N--CA 1.506 2.326 0 CA-C-O 117.175 -1.393 . . . . 0.0 108.329 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' CYS . . . . . 0.683 ' CB ' ' SG ' ' A' ' 36' ' ' CYS . 59.1 m -88.77 127.34 35.6 Favored 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 101.957 -3.349 . . . . 0.0 101.957 179.527 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.554 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 79.7 m -129.81 -174.95 3.45 Favored 'General case' 0 C--N 1.299 -1.601 0 CA-C-N 110.959 -2.837 . . . . 0.0 113.817 -179.243 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.494 ' HD2' ' H ' ' A' ' 49' ' ' LYS . 25.7 tptp -151.6 150.68 30.57 Favored 'General case' 0 C--N 1.295 -1.781 0 C-N-CA 118.57 -1.252 . . . . 0.0 110.26 -179.907 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . 0.494 ' H ' ' HD2' ' A' ' 48' ' ' LYS . 6.0 mtpt . . . . . 0 N--CA 1.499 2.015 0 O-C-N 126.407 2.317 . . . . 0.0 108.422 179.448 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 40.0 t . . . . . 0 N--CA 1.496 1.861 0 N-CA-C 106.863 -1.532 . . . . 0.0 106.863 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -70.66 148.61 59.61 Favored 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 123.533 2.822 . . . . 0.0 111.718 172.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.511 ' SG ' ' HB3' ' A' ' 22' ' ' LEU . 0.8 OUTLIER -146.32 163.3 35.96 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 124.24 0.962 . . . . 0.0 109.724 179.779 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 8.9 tt -79.41 150.68 31.25 Favored 'General case' 0 N--CA 1.488 1.446 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . 0.417 ' HB3' ' HB3' ' A' ' 37' ' ' LYS . 2.5 m -137.83 -145.19 0.19 Allowed 'General case' 0 N--CA 1.491 1.607 0 N-CA-C 116.316 1.969 . . . . 0.0 116.316 -179.663 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 18.5 t70 . . . . . 0 N--CA 1.493 1.711 0 N-CA-C 105.941 -1.874 . . . . 0.0 105.941 179.891 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 7.3 t . . . . . 0 N--CA 1.498 1.953 0 N-CA-C 107.138 -1.43 . . . . 0.0 107.138 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 170.42 154.67 9.65 Favored Glycine 0 N--CA 1.493 2.448 0 CA-C-N 114.905 -1.043 . . . . 0.0 113.626 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.434 ' N ' ' O ' ' A' ' 47' ' ' CYS . 40.5 mm -116.82 144.77 23.74 Favored 'Isoleucine or valine' 0 N--CA 1.51 2.56 0 N-CA-C 107.639 -1.245 . . . . 0.0 107.639 179.736 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.57 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.8 pp -68.27 151.62 46.65 Favored 'General case' 0 N--CA 1.501 2.123 0 C-N-CA 117.543 -1.663 . . . . 0.0 107.528 179.447 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 22.1 m95 -131.2 140.33 49.87 Favored 'General case' 0 C--N 1.308 -1.198 0 CA-C-O 124.964 2.316 . . . . 0.0 116.985 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.5 m-30 -89.43 35.18 0.81 Allowed 'General case' 0 C--N 1.297 -1.696 1 CA-C-N 107.868 -4.242 . . . . 0.0 115.23 -179.636 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.438 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 1.2 m-30 -111.02 115.17 53.25 Favored Pre-proline 0 C--N 1.301 -1.506 0 N-CA-C 107.036 -1.468 . . . . 0.0 107.036 179.64 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo -61.27 -19.73 65.13 Favored 'Trans proline' 0 C--N 1.299 -2.031 0 C-N-CA 121.007 1.138 . . . . 0.0 109.524 -175.212 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 1.6 p -91.67 1.81 56.9 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 124.396 1.06 . . . . 0.0 112.574 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 121.03 -130.99 8.46 Favored Glycine 0 N--CA 1.497 2.739 0 N-CA-C 108.207 -1.957 . . . . 0.0 108.207 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . 0.617 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 8.4 m -93.36 150.28 38.73 Favored Pre-proline 0 C--N 1.303 -1.441 0 CA-C-N 117.382 0.591 . . . . 0.0 109.868 -179.938 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.678 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.7 OUTLIER -76.13 162.1 34.63 Favored 'Trans proline' 0 C--N 1.309 -1.545 0 C-N-CA 122.515 2.143 . . . . 0.0 113.206 176.079 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 26.4 t -46.14 110.44 0.27 Allowed 'General case' 0 N--CA 1.493 1.692 0 CA-C-N 113.12 -1.855 . . . . 0.0 111.013 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 113.95 -5.57 23.92 Favored Glycine 0 N--CA 1.5 2.936 0 CA-C-N 114.405 -1.27 . . . . 0.0 111.678 179.772 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' TRP . . . . . 0.678 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 35.4 m95 -117.5 152.59 34.74 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 106.992 -1.484 . . . . 0.0 106.992 -179.827 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 55.4 t60 -143.04 42.26 1.54 Allowed 'General case' 0 N--CA 1.496 1.872 0 C-N-CA 117.389 -1.725 . . . . 0.0 112.436 179.866 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . 0.617 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 27.5 t-20 60.63 149.98 0.02 OUTLIER 'General case' 0 N--CA 1.506 2.347 0 N-CA-C 117.947 2.573 . . . . 0.0 117.947 179.742 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.696 ' SG ' ' CB ' ' A' ' 46' ' ' CYS . 13.9 p -115.82 -16.41 11.19 Favored 'General case' 0 N--CA 1.485 1.3 0 CA-C-N 114.352 -1.295 . . . . 0.0 110.983 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . 0.488 ' C ' ' H ' ' A' ' 39' ' ' HIS . 15.3 ptmt -144.7 127.04 15.83 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.953 -0.467 . . . . 0.0 111.83 -179.967 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.451 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -80.98 44.29 0.75 Allowed 'General case' 0 N--CA 1.493 1.677 0 N-CA-C 106.606 -1.627 . . . . 0.0 106.606 179.618 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . 0.488 ' H ' ' C ' ' A' ' 37' ' ' LYS . 2.9 m-70 -131.24 -116.6 0.23 Allowed 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 101.53 -3.508 . . . . 0.0 101.53 -179.845 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -126.68 -113.11 1.82 Allowed Glycine 0 N--CA 1.506 3.311 0 N-CA-C 110.782 -0.927 . . . . 0.0 110.782 179.785 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 83.1 Cg_endo -65.7 -164.77 1.43 Allowed 'Cis proline' 0 N--CA 1.503 2.08 0 N-CA-C 116.316 1.622 . . . . 0.0 116.316 -4.057 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -93.03 -13.91 28.05 Favored 'General case' 0 N--CA 1.486 1.356 0 N-CA-C 106.233 -1.766 . . . . 0.0 106.233 -179.298 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 27.1 pt -103.52 28.76 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.148 0 O-C-N 125.913 2.008 . . . . 0.0 116.234 -179.135 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 129.05 168.36 12.35 Favored Glycine 0 C--N 1.292 -1.892 1 N-CA-C 102.149 -4.38 . . . . 0.0 102.149 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . 0.438 ' NE1' ' O ' ' A' ' 25' ' ' TYR . 26.2 m95 -102.9 137.3 41.28 Favored 'General case' 0 C--N 1.281 -2.396 0 N-CA-C 105.259 -2.126 . . . . 0.0 105.259 179.883 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' CYS . . . . . 0.696 ' CB ' ' SG ' ' A' ' 36' ' ' CYS . 98.9 m -90.11 130.12 36.32 Favored 'General case' 0 N--CA 1.478 0.966 1 N-CA-C 100.116 -4.031 . . . . 0.0 100.116 179.509 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.434 ' O ' ' N ' ' A' ' 21' ' ' ILE . 82.1 m -132.92 -170.88 2.54 Favored 'General case' 0 C--N 1.296 -1.754 0 CA-C-N 111.736 -2.483 . . . . 0.0 109.273 -179.305 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.46 ' CD ' ' N ' ' A' ' 48' ' ' LYS . 0.0 OUTLIER -150.55 174.35 13.05 Favored 'General case' 0 C--N 1.295 -1.769 0 O-C-N 124.55 1.156 . . . . 0.0 108.377 179.444 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 29.9 mtpt . . . . . 0 C--N 1.29 -2.006 0 CA-C-O 114.398 -2.715 . . . . 0.0 107.104 179.351 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 22.2 t . . . . . 0 N--CA 1.495 1.806 0 N-CA-C 107.149 -1.426 . . . . 0.0 107.149 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.427 ' HA ' ' HA ' ' A' ' 21' ' ' ILE . 37.5 Cg_endo -71.27 164.69 34.89 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 123.838 3.025 . . . . 0.0 112.439 166.603 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.488 ' SG ' ' HB3' ' A' ' 22' ' ' LEU . 0.1 OUTLIER -148.98 -171.0 3.77 Favored 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 107.205 -1.406 . . . . 0.0 107.205 179.508 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 5.2 tt -104.94 147.58 27.63 Favored 'General case' 0 N--CA 1.495 1.786 0 N-CA-C 103.056 -2.942 . . . . 0.0 103.056 179.792 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 3.9 m -122.73 -171.8 2.35 Favored 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 115.056 1.502 . . . . 0.0 115.056 -179.567 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 7.5 t70 . . . . . 0 N--CA 1.49 1.557 0 CA-C-N 112.873 -1.967 . . . . 0.0 108.177 -179.922 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 33.1 t . . . . . 0 N--CA 1.494 1.739 0 CA-C-O 119.058 -0.496 . . . . 0.0 112.102 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -176.14 -161.02 24.54 Favored Glycine 0 N--CA 1.498 2.767 0 C-N-CA 119.171 -1.49 . . . . 0.0 112.031 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.427 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 39.3 mm -132.22 148.58 32.03 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.924 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.507 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 2.9 pp -71.41 144.13 49.89 Favored 'General case' 0 N--CA 1.493 1.709 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 179.595 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 44.1 m95 -126.91 133.61 50.63 Favored 'General case' 0 C--N 1.308 -1.196 0 N-CA-C 118.773 2.879 . . . . 0.0 118.773 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -89.44 51.76 2.19 Favored 'General case' 0 C--N 1.299 -1.629 1 CA-C-N 107.138 -4.574 . . . . 0.0 110.612 -179.83 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.437 ' CE1' ' HB3' ' A' ' 30' ' ' PRO . 2.1 m-85 -124.51 142.54 40.71 Favored Pre-proline 0 C--N 1.304 -1.391 0 CA-C-O 122.468 1.128 . . . . 0.0 110.71 179.739 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 74.7 Cg_endo -68.53 -29.94 29.75 Favored 'Trans proline' 0 C--N 1.304 -1.777 0 C-N-CA 125.075 3.85 . . . . 0.0 108.186 177.936 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 5.1 p -90.36 24.4 2.59 Favored 'General case' 0 C--N 1.301 -1.542 0 CA-C-N 113.726 -1.579 . . . . 0.0 109.269 179.659 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.593 ' HA2' ' CD1' ' A' ' 45' ' ' TRP . . . 81.99 -84.56 1.48 Allowed Glycine 0 N--CA 1.482 1.759 0 N-CA-C 105.005 -3.238 . . . . 0.0 105.005 -179.748 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . 0.444 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 9.2 m -100.88 166.96 11.52 Favored Pre-proline 0 C--N 1.307 -1.275 0 CA-C-N 112.649 -1.775 . . . . 0.0 110.851 -179.971 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.682 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.1 OUTLIER -89.44 167.17 5.21 Favored 'Trans proline' 0 C--N 1.312 -1.355 1 C-N-CA 125.919 4.412 . . . . 0.0 113.763 155.523 . . . . . . . . 4 4 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 18.2 t -60.97 141.37 57.37 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-N 113.784 -1.553 . . . . 0.0 109.181 -179.766 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.06 -2.3 68.74 Favored Glycine 0 N--CA 1.495 2.6 0 CA-C-N 111.675 -2.511 . . . . 0.0 111.551 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' TRP . . . . . 0.682 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 58.7 m95 -111.04 166.52 10.99 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 106.143 -1.799 . . . . 0.0 106.143 -179.743 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . 0.514 ' O ' ' ND1' ' A' ' 34' ' ' HIS . 43.1 t-80 -140.02 31.9 1.98 Allowed 'General case' 0 N--CA 1.496 1.839 0 C-N-CA 118.497 -1.281 . . . . 0.0 112.878 -179.872 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . 0.52 ' HA ' ' SG ' ' A' ' 47' ' ' CYS . 16.7 t-20 59.03 139.66 0.01 OUTLIER 'General case' 0 N--CA 1.511 2.607 0 N-CA-C 114.458 1.281 . . . . 0.0 114.458 -179.934 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.642 ' SG ' ' CB ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -119.43 -41.06 2.73 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.445 -0.784 . . . . 0.0 110.129 -179.725 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 38.0 ttmt -131.14 138.59 49.54 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 104.696 -2.335 . . . . 0.0 104.696 179.423 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.438 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -117.97 35.63 4.65 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 103.004 -2.962 . . . . 0.0 103.004 179.723 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . 0.438 ' ND1' ' C ' ' A' ' 38' ' ' ALA . 2.7 m-70 -140.09 55.96 1.62 Allowed 'General case' 0 N--CA 1.494 1.769 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 -179.537 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 85.9 -160.55 33.97 Favored Glycine 0 N--CA 1.502 3.049 0 N-CA-C 108.773 -1.731 . . . . 0.0 108.773 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . 0.407 ' HG2' ' O ' ' A' ' 44' ' ' GLY . 68.6 Cg_endo -64.9 -171.0 3.02 Favored 'Cis proline' 0 N--CA 1.507 2.286 0 CA-C-N 118.305 1.053 . . . . 0.0 114.74 -1.551 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 20.9 m120 -92.96 -8.27 43.59 Favored 'General case' 0 N--CA 1.487 1.377 0 N-CA-C 104.616 -2.364 . . . . 0.0 104.616 -179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 9.9 mm -106.22 32.0 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.961 0 CA-C-O 123.545 1.64 . . . . 0.0 113.782 -178.76 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.407 ' O ' ' HG2' ' A' ' 41' ' ' PRO . . . 124.72 -179.29 16.2 Favored Glycine 0 C--N 1.292 -1.879 1 N-CA-C 102.693 -4.163 . . . . 0.0 102.693 -179.977 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . 0.593 ' CD1' ' HA2' ' A' ' 28' ' ' GLY . 1.2 m95 -119.86 140.65 50.5 Favored 'General case' 0 C--N 1.277 -2.55 0 N-CA-C 103.775 -2.676 . . . . 0.0 103.775 179.709 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' CYS . . . . . 0.642 ' CB ' ' SG ' ' A' ' 36' ' ' CYS . 99.4 m -88.74 133.92 34.08 Favored 'General case' 0 N--CA 1.485 1.298 0 CA-C-N 121.756 2.071 . . . . 0.0 107.34 -179.912 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.52 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 87.3 m -133.71 178.32 7.03 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-N 110.892 -2.867 . . . . 0.0 110.443 -179.233 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.401 ' N ' ' CD ' ' A' ' 48' ' ' LYS . 0.0 OUTLIER -149.27 172.96 14.02 Favored 'General case' 0 C--N 1.304 -1.41 0 C-N-CA 117.525 -1.67 . . . . 0.0 111.757 179.776 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 24.8 mmtm . . . . . 0 N--CA 1.496 1.84 0 O-C-N 127.11 2.756 . . . . 0.0 109.413 179.976 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 13.0 t . . . . . 0 N--CA 1.496 1.85 0 N-CA-C 107.988 -1.115 . . . . 0.0 107.988 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -79.32 135.19 11.83 Favored 'Trans proline' 0 C--N 1.308 -1.559 0 C-N-CA 124.352 3.368 . . . . 0.0 115.001 169.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.446 ' SG ' ' HB3' ' A' ' 22' ' ' LEU . 0.0 OUTLIER -119.46 -178.12 3.53 Favored 'General case' 0 N--CA 1.494 1.772 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.563 179.662 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 6.4 tt -98.5 113.65 25.74 Favored 'General case' 0 N--CA 1.497 1.908 0 N-CA-C 104.962 -2.236 . . . . 0.0 104.962 -179.836 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . 0.413 ' SG ' ' HA3' ' A' ' 20' ' ' GLY . 5.5 m -88.57 -169.01 2.38 Favored 'General case' 0 N--CA 1.487 1.387 0 N-CA-C 119.1 3.0 . . . . 0.0 119.1 -179.179 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 10.8 t0 . . . . . 0 N--CA 1.487 1.394 0 CA-C-N 111.876 -2.42 . . . . 0.0 112.562 -179.655 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 22.8 t . . . . . 0 N--CA 1.499 2.003 0 N-CA-C 112.725 0.639 . . . . 0.0 112.725 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.53 ' HA3' ' SG ' ' A' ' 36' ' ' CYS . . . 174.28 131.53 1.42 Allowed Glycine 0 N--CA 1.48 1.605 0 N-CA-C 108.341 -1.903 . . . . 0.0 108.341 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.457 ' N ' ' O ' ' A' ' 47' ' ' CYS . 49.7 mm -93.12 132.33 37.64 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.12 0 C-N-CA 116.593 -2.043 . . . . 0.0 105.565 179.851 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.547 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.9 pp -63.0 149.0 46.01 Favored 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 107.276 -1.379 . . . . 0.0 107.276 179.444 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.419 ' CE2' ' HG3' ' A' ' 30' ' ' PRO . 28.5 m95 -129.78 136.83 50.07 Favored 'General case' 0 C--N 1.3 -1.567 0 CA-C-O 124.008 1.861 . . . . 0.0 115.439 -179.812 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -89.11 47.67 1.52 Allowed 'General case' 0 C--N 1.294 -1.845 0 CA-C-N 108.914 -3.766 . . . . 0.0 112.499 -179.809 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 1.1 m-30 -117.33 143.46 32.0 Favored Pre-proline 0 C--N 1.306 -1.322 0 CA-C-O 122.537 1.161 . . . . 0.0 110.362 179.604 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 15.7 Cg_endo -77.19 -35.18 1.82 Allowed 'Trans proline' 0 C--N 1.301 -1.96 0 C-N-CA 123.622 2.881 . . . . 0.0 110.578 175.829 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 10.9 p -89.46 38.77 0.92 Allowed 'General case' 0 N--CA 1.49 1.536 0 CA-C-N 114.61 -1.177 . . . . 0.0 112.38 -179.626 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 73.17 -135.16 20.83 Favored Glycine 0 N--CA 1.5 2.955 0 N-CA-C 108.07 -2.012 . . . . 0.0 108.07 -179.864 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . 0.544 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 15.3 m -72.22 156.18 90.84 Favored Pre-proline 0 C--N 1.304 -1.406 0 CA-C-N 118.793 1.297 . . . . 0.0 111.471 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.689 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.4 OUTLIER -79.71 159.13 24.97 Favored 'Trans proline' 0 C--N 1.307 -1.617 0 C-N-CA 123.281 2.654 . . . . 0.0 111.831 166.597 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 42.0 t -50.07 134.27 22.1 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 113.334 -1.757 . . . . 0.0 109.299 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 95.4 -4.57 67.03 Favored Glycine 0 N--CA 1.498 2.773 0 CA-C-N 112.396 -2.184 . . . . 0.0 111.896 179.835 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' TRP . . . . . 0.689 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 56.4 m95 -112.95 157.2 21.78 Favored 'General case' 0 C--N 1.304 -1.391 0 N-CA-C 105.29 -2.115 . . . . 0.0 105.29 -179.855 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . 0.416 ' O ' ' ND1' ' A' ' 34' ' ' HIS . 65.1 t-80 -140.45 41.49 1.89 Allowed 'General case' 0 C--N 1.299 -1.593 0 C-N-CA 118.291 -1.363 . . . . 0.0 112.084 -179.914 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . 0.544 ' HA ' ' SG ' ' A' ' 29' ' ' CYS . 0.2 OUTLIER 63.17 138.37 0.02 OUTLIER 'General case' 0 N--CA 1.505 2.316 0 N-CA-C 115.74 1.755 . . . . 0.0 115.74 179.412 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.608 ' SG ' ' CB ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -114.9 -40.74 3.46 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 105.843 -1.91 . . . . 0.0 105.843 179.775 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 21.3 ptmt -138.41 149.32 45.4 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 106.864 -1.532 . . . . 0.0 106.864 179.64 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.452 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -120.0 35.43 4.86 Favored 'General case' 0 C--N 1.293 -1.85 0 N-CA-C 102.506 -3.146 . . . . 0.0 102.506 179.881 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . 0.452 ' ND1' ' C ' ' A' ' 38' ' ' ALA . 3.7 m-70 -127.57 54.9 1.65 Allowed 'General case' 0 N--CA 1.498 1.951 0 N-CA-C 108.404 -0.961 . . . . 0.0 108.404 -179.625 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 74.0 -148.86 40.24 Favored Glycine 0 N--CA 1.496 2.65 0 N-CA-C 105.604 -2.998 . . . . 0.0 105.604 -179.658 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . 0.423 ' HG2' ' O ' ' A' ' 44' ' ' GLY . 51.2 Cg_endo -65.64 -172.63 4.43 Favored 'Cis proline' 0 N--CA 1.501 1.915 0 CA-C-N 119.088 1.444 . . . . 0.0 111.713 -1.4 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 14.3 m120 -93.58 0.52 56.63 Favored 'General case' 0 C--N 1.307 -1.273 0 N-CA-C 104.144 -2.539 . . . . 0.0 104.144 -179.679 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 8.4 mt -116.64 35.02 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 N-CA-C 116.043 1.868 . . . . 0.0 116.043 -178.846 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.423 ' O ' ' HG2' ' A' ' 41' ' ' PRO . . . 119.81 139.76 5.98 Favored Glycine 0 N--CA 1.499 2.846 0 CA-C-N 114.004 -1.453 . . . . 0.0 110.642 179.721 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . 0.416 ' O ' ' N ' ' A' ' 23' ' ' TRP . 6.4 m95 -78.22 129.85 35.59 Favored 'General case' 0 N--CA 1.503 2.194 0 CA-C-O 117.783 -1.103 . . . . 0.0 111.096 -179.267 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' CYS . . . . . 0.608 ' CB ' ' SG ' ' A' ' 36' ' ' CYS . 66.2 m -87.71 122.67 31.66 Favored 'General case' 0 C--N 1.308 -1.204 1 N-CA-C 99.791 -4.152 . . . . 0.0 99.791 179.436 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.55 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 88.8 m -129.18 -178.84 4.81 Favored 'General case' 0 CA--C 1.476 -1.894 0 CA-C-N 109.895 -3.321 . . . . 0.0 111.205 -179.398 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.483 ' HD2' ' H ' ' A' ' 49' ' ' LYS . 24.2 tptp -150.52 152.01 33.53 Favored 'General case' 0 C--N 1.294 -1.846 0 C-N-CA 117.675 -1.61 . . . . 0.0 109.987 -179.84 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . 0.483 ' H ' ' HD2' ' A' ' 48' ' ' LYS . 51.2 mtpt . . . . . 0 N--CA 1.5 2.054 0 O-C-N 126.197 2.186 . . . . 0.0 111.899 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 33.0 t . . . . . 0 N--CA 1.497 1.885 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -77.27 127.77 9.32 Favored 'Trans proline' 0 N--CA 1.493 1.475 0 C-N-CA 124.523 3.482 . . . . 0.0 116.458 170.048 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.507 ' SG ' ' HB3' ' A' ' 22' ' ' LEU . 0.5 OUTLIER -121.08 179.46 4.38 Favored 'General case' 0 C--N 1.301 -1.508 0 CA-C-N 114.624 -1.171 . . . . 0.0 111.13 179.786 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 6.7 tp -91.68 145.98 24.15 Favored 'General case' 0 N--CA 1.491 1.594 0 N-CA-C 104.625 -2.361 . . . . 0.0 104.625 179.874 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . 0.405 ' HA ' ' HD2' ' A' ' 37' ' ' LYS . 6.9 m -119.42 -170.4 1.93 Allowed 'General case' 0 N--CA 1.491 1.583 0 N-CA-C 113.911 1.078 . . . . 0.0 113.911 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 19.8 t70 . . . . . 0 N--CA 1.497 1.887 0 CA-C-N 113.614 -1.63 . . . . 0.0 109.353 179.979 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.498 1.937 0 CA-C-O 122.597 1.189 . . . . 0.0 109.368 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.43 -165.61 18.19 Favored Glycine 0 N--CA 1.502 3.047 0 CA-C-N 114.382 -1.281 . . . . 0.0 111.21 179.804 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.409 ' N ' ' O ' ' A' ' 47' ' ' CYS . 28.8 mm -133.88 147.52 30.59 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.265 0 N-CA-C 112.744 0.646 . . . . 0.0 112.744 -179.94 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.572 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 2.8 pp -69.85 152.77 44.16 Favored 'General case' 0 N--CA 1.492 1.644 0 CA-C-N 114.919 -1.037 . . . . 0.0 108.819 179.499 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.643 ' HB2' ' SG ' ' A' ' 29' ' ' CYS . 28.3 m95 -131.93 135.32 46.52 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-O 125.045 2.355 . . . . 0.0 115.986 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.5 m-85 -88.84 54.34 2.98 Favored 'General case' 0 C--N 1.292 -1.892 1 CA-C-N 107.641 -4.345 . . . . 0.0 110.131 -179.669 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.531 ' CE1' ' HB3' ' A' ' 30' ' ' PRO . 2.2 m-85 -123.82 115.88 27.84 Favored Pre-proline 0 N--CA 1.491 1.618 0 CA-C-N 115.497 -0.774 . . . . 0.0 112.656 179.654 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -64.03 -11.85 29.35 Favored 'Trans proline' 0 C--N 1.308 -1.557 0 C-N-CA 123.389 2.726 . . . . 0.0 111.948 -175.412 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 6.6 p -108.93 3.93 22.8 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-N 115.37 -0.832 . . . . 0.0 111.025 179.753 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.4 ' O ' ' CD1' ' A' ' 45' ' ' TRP . . . 126.45 -113.21 1.75 Allowed Glycine 0 N--CA 1.502 3.058 0 N-CA-C 108.727 -1.749 . . . . 0.0 108.727 -179.913 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . 0.643 ' SG ' ' HB2' ' A' ' 23' ' ' TRP . 18.4 m -132.36 156.54 79.98 Favored Pre-proline 0 C--N 1.305 -1.357 0 CA-C-N 117.701 0.75 . . . . 0.0 110.687 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.707 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 9.0 Cg_endo -78.68 162.04 27.39 Favored 'Trans proline' 0 C--N 1.306 -1.68 0 C-N-CA 123.335 2.69 . . . . 0.0 113.323 -167.196 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 22.9 t -51.32 116.43 2.05 Favored 'General case' 0 C--N 1.302 -1.487 0 CA-C-N 113.292 -1.776 . . . . 0.0 110.473 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 115.5 -7.61 20.37 Favored Glycine 0 N--CA 1.499 2.87 0 CA-C-N 113.744 -1.571 . . . . 0.0 111.529 179.761 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' TRP . . . . . 0.707 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 49.9 m95 -109.22 158.94 17.35 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 104.77 -2.307 . . . . 0.0 104.77 -179.941 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 78.3 t60 -138.34 33.04 2.31 Favored 'General case' 0 C--N 1.298 -1.666 0 C-N-CA 118.05 -1.46 . . . . 0.0 114.074 -179.598 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . 0.793 ' HA ' ' SG ' ' A' ' 47' ' ' CYS . 5.1 m-20 57.34 137.35 0.0 OUTLIER 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 116.648 2.092 . . . . 0.0 116.648 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.585 ' SG ' ' HB3' ' A' ' 46' ' ' CYS . 0.6 OUTLIER -112.06 -40.13 4.3 Favored 'General case' 0 N--CA 1.489 1.489 0 CA-C-N 115.015 -0.993 . . . . 0.0 108.931 -179.644 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . 0.405 ' HD2' ' HA ' ' A' ' 6' ' ' CYS . 51.9 tttt -132.87 143.38 49.48 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 107.356 -1.349 . . . . 0.0 107.356 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.441 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -119.47 30.08 7.28 Favored 'General case' 0 N--CA 1.493 1.721 0 N-CA-C 104.772 -2.307 . . . . 0.0 104.772 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . 0.441 ' ND1' ' C ' ' A' ' 38' ' ' ALA . 4.5 m-70 -134.75 62.18 1.65 Allowed 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 107.023 -1.473 . . . . 0.0 107.023 -179.564 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 75.75 -155.94 47.22 Favored Glycine 0 N--CA 1.498 2.798 0 N-CA-C 106.213 -2.755 . . . . 0.0 106.213 -179.728 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_endo -74.09 -169.38 7.0 Favored 'Cis proline' 0 N--CA 1.496 1.669 0 CA-C-N 118.922 1.361 . . . . 0.0 113.923 -0.682 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 10.0 p30 -92.33 -14.66 28.43 Favored 'General case' 0 CA--C 1.486 -1.506 0 N-CA-C 105.992 -1.855 . . . . 0.0 105.992 -179.606 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 31.6 pt -90.28 24.17 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 O-C-N 125.277 1.61 . . . . 0.0 113.978 -179.431 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 114.37 137.79 6.6 Favored Glycine 0 N--CA 1.493 2.472 0 CA-C-N 113.246 -1.797 . . . . 0.0 109.696 -179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . 0.426 ' O ' ' N ' ' A' ' 23' ' ' TRP . 7.9 m95 -61.53 136.4 58.01 Favored 'General case' 0 N--CA 1.519 3.006 0 CA-C-O 117.317 -1.325 . . . . 0.0 108.421 -179.643 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' CYS . . . . . 0.585 ' HB3' ' SG ' ' A' ' 36' ' ' CYS . 93.0 m -89.9 127.08 35.94 Favored 'General case' 0 N--CA 1.482 1.141 0 CA-C-N 122.26 2.3 . . . . 0.0 105.127 -179.921 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.793 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 93.7 m -136.45 -171.82 3.0 Favored 'General case' 0 C--N 1.3 -1.563 0 CA-C-N 111.327 -2.67 . . . . 0.0 111.005 -179.409 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.452 ' CD ' ' N ' ' A' ' 48' ' ' LYS . 0.0 OUTLIER -151.31 172.29 16.12 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 179.574 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 47.4 mtpt . . . . . 0 C--N 1.291 -1.969 0 O-C-N 126.704 2.503 . . . . 0.0 110.347 179.828 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 29.6 t . . . . . 0 N--CA 1.496 1.852 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -67.27 135.57 37.36 Favored 'Trans proline' 0 N--CA 1.493 1.455 0 C-N-CA 122.333 2.022 . . . . 0.0 110.24 170.051 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -134.06 175.8 9.15 Favored 'General case' 0 N--CA 1.497 1.918 0 CA-C-O 121.563 0.697 . . . . 0.0 112.242 -179.724 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -101.55 141.89 33.74 Favored 'General case' 0 N--CA 1.494 1.732 0 N-CA-C 104.067 -2.568 . . . . 0.0 104.067 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 1.8 m -113.14 -138.8 0.38 Allowed 'General case' 0 N--CA 1.497 1.892 0 N-CA-C 120.395 3.48 . . . . 0.0 120.395 -178.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 . . . . . 0 N--CA 1.507 2.391 0 O-C-N 120.969 -1.082 . . . . 0.0 110.388 -179.828 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 7.1 m . . . . . 0 N--CA 1.5 2.064 0 N-CA-C 115.644 1.72 . . . . 0.0 115.644 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 148.69 -163.69 29.05 Favored Glycine 0 N--CA 1.497 2.743 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.473 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 35.5 mm -135.98 146.42 29.43 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.088 0 CA-C-O 122.487 1.137 . . . . 0.0 109.878 179.852 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.475 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 0.9 OUTLIER -69.69 134.79 49.06 Favored 'General case' 0 C--N 1.297 -1.693 0 CA-C-N 114.654 -1.157 . . . . 0.0 108.625 179.826 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 44.5 m95 -124.04 134.18 53.48 Favored 'General case' 0 N--CA 1.484 1.242 0 N-CA-C 118.96 2.948 . . . . 0.0 118.96 179.889 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.2 m-30 -88.93 39.58 0.94 Allowed 'General case' 0 C--N 1.296 -1.718 1 CA-C-N 107.366 -4.47 . . . . 0.0 113.064 -179.584 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.431 ' CD2' ' HA ' ' A' ' 30' ' ' PRO . 1.2 m-30 -113.07 125.13 30.25 Favored Pre-proline 0 C--N 1.304 -1.402 0 CA-C-O 122.697 1.237 . . . . 0.0 112.271 -179.935 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -66.21 -25.26 50.36 Favored 'Trans proline' 0 C--N 1.302 -1.872 0 C-N-CA 122.507 2.138 . . . . 0.0 108.341 -177.731 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 5.8 p -87.01 5.03 39.44 Favored 'General case' 0 N--CA 1.49 1.536 0 CA-C-N 114.375 -1.284 . . . . 0.0 112.468 179.926 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 110.65 -118.57 5.0 Favored Glycine 0 N--CA 1.498 2.806 0 N-CA-C 106.238 -2.745 . . . . 0.0 106.238 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . 0.504 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 37.4 m -96.65 153.79 38.65 Favored Pre-proline 0 C--N 1.303 -1.446 0 N-CA-C 106.726 -1.583 . . . . 0.0 106.726 179.735 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.694 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.8 OUTLIER -76.34 169.47 21.89 Favored 'Trans proline' 0 C--N 1.305 -1.726 0 C-N-CA 123.077 2.518 . . . . 0.0 113.829 174.588 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 5.7 m -46.17 103.83 0.04 OUTLIER 'General case' 0 C--N 1.298 -1.633 0 CA-C-N 112.01 -2.359 . . . . 0.0 113.99 -179.854 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 109.11 2.68 31.62 Favored Glycine 0 N--CA 1.501 2.996 0 C-N-CA 120.811 -0.709 . . . . 0.0 114.293 179.481 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' TRP . . . . . 0.694 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 44.7 m95 -110.82 164.81 12.39 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 106.999 -1.482 . . . . 0.0 106.999 -179.954 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 57.7 t-80 -144.76 37.23 1.18 Allowed 'General case' 0 N--CA 1.499 1.992 0 C-N-CA 117.757 -1.577 . . . . 0.0 113.072 -179.722 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . 0.504 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 24.0 t-20 58.43 146.48 0.01 OUTLIER 'General case' 0 N--CA 1.501 2.098 0 CA-C-N 113.248 -1.797 . . . . 0.0 114.673 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.64 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -121.09 -46.67 2.31 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 106.013 -1.847 . . . . 0.0 106.013 179.974 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . 0.425 ' C ' ' H ' ' A' ' 39' ' ' HIS . 13.1 ttmt -107.94 102.08 11.29 Favored 'General case' 0 C--N 1.301 -1.502 0 CA-C-N 113.315 -1.766 . . . . 0.0 108.618 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -83.36 12.28 5.66 Favored 'General case' 0 N--CA 1.496 1.869 0 CA-C-N 113.31 -1.768 . . . . 0.0 107.713 179.511 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . 0.425 ' H ' ' C ' ' A' ' 37' ' ' LYS . 7.4 m-70 -127.22 37.71 4.21 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-N 114.878 -1.055 . . . . 0.0 109.208 -179.667 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 96.23 -149.56 19.35 Favored Glycine 0 N--CA 1.498 2.768 0 CA-C-N 114.538 -1.21 . . . . 0.0 111.267 179.586 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 3.5 Cg_endo -75.5 -173.84 13.2 Favored 'Cis proline' 0 N--CA 1.5 1.861 0 N-CA-C 109.386 -1.044 . . . . 0.0 109.386 1.496 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.524 ' C ' ' H ' ' A' ' 44' ' ' GLY . 56.5 t30 -92.27 -11.97 33.81 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 105.463 -2.051 . . . . 0.0 105.463 -179.783 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 30.5 pt -85.66 28.92 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 CA-C-O 123.302 1.525 . . . . 0.0 112.741 -179.192 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.524 ' H ' ' C ' ' A' ' 42' ' ' ASN . . . 116.98 142.57 7.34 Favored Glycine 0 C--N 1.295 -1.71 0 CA-C-N 110.528 -3.033 . . . . 0.0 106.153 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . 0.42 ' NE1' ' O ' ' A' ' 25' ' ' TYR . 6.9 m95 -77.81 133.77 38.14 Favored 'General case' 0 C--N 1.293 -1.849 0 N-CA-C 104.674 -2.343 . . . . 0.0 104.674 -179.534 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' CYS . . . . . 0.64 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 46.0 t -89.22 129.14 35.84 Favored 'General case' 0 N--CA 1.485 1.318 1 N-CA-C 99.319 -4.326 . . . . 0.0 99.319 179.773 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.514 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 77.3 m -127.88 -170.53 2.25 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-N 113.096 -1.866 . . . . 0.0 110.254 -179.363 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.08 172.3 15.98 Favored 'General case' 0 C--N 1.298 -1.674 0 N-CA-C 107.599 -1.26 . . . . 0.0 107.599 179.311 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 65.3 mttt . . . . . 0 N--CA 1.498 1.961 0 O-C-N 126.267 2.229 . . . . 0.0 108.189 179.267 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 46.8 t . . . . . 0 N--CA 1.499 2.01 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 26.6 Cg_endo -73.11 116.03 4.56 Favored 'Trans proline' 0 C--N 1.308 -1.566 0 C-N-CA 122.877 2.384 . . . . 0.0 114.473 170.664 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.526 ' SG ' ' HB2' ' A' ' 22' ' ' LEU . 0.8 OUTLIER -122.15 163.94 18.65 Favored 'General case' 0 N--CA 1.494 1.774 0 CA-C-N 113.037 -1.892 . . . . 0.0 108.839 -179.799 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 12.2 tp -89.61 174.82 7.54 Favored 'General case' 0 N--CA 1.497 1.886 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 -179.895 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 1.8 m -135.26 -143.25 0.19 Allowed 'General case' 0 N--CA 1.501 2.097 1 N-CA-C 122.131 4.123 . . . . 0.0 122.131 -178.738 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.497 1.89 0 C-N-CA 118.405 -1.318 . . . . 0.0 108.813 -179.523 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 80.5 p . . . . . 0 N--CA 1.485 1.285 0 CA-C-O 120.987 0.422 . . . . 0.0 111.697 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 153.28 161.58 10.43 Favored Glycine 0 N--CA 1.5 2.926 0 C-N-CA 119.512 -1.328 . . . . 0.0 112.775 179.46 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.411 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 49.1 mm -124.07 137.83 55.75 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.176 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 179.57 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.532 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 34.7 tp -63.99 144.58 56.98 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 179.659 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 42.4 m95 -131.52 134.08 45.75 Favored 'General case' 0 C--N 1.308 -1.236 0 N-CA-C 119.428 3.122 . . . . 0.0 119.428 -179.568 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -88.87 54.45 3.02 Favored 'General case' 0 C--N 1.297 -1.675 1 CA-C-N 108.145 -4.116 . . . . 0.0 108.727 -179.962 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.442 ' CE1' ' HB3' ' A' ' 30' ' ' PRO . 2.4 m-85 -128.73 120.02 20.42 Favored Pre-proline 0 N--CA 1.486 1.368 0 CA-C-N 115.088 -0.96 . . . . 0.0 113.556 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -67.25 -13.48 39.66 Favored 'Trans proline' 0 C--N 1.309 -1.526 0 C-N-CA 123.793 2.996 . . . . 0.0 110.918 -178.121 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 12.8 p -93.51 -9.23 39.03 Favored 'General case' 0 N--CA 1.491 1.609 0 CA-C-N 114.565 -1.198 . . . . 0.0 110.43 179.81 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.407 ' HA2' ' CD2' ' A' ' 45' ' ' TRP . . . 116.3 -106.96 1.57 Allowed Glycine 0 N--CA 1.482 1.724 1 N-CA-C 102.512 -4.235 . . . . 0.0 102.512 -179.702 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . 0.602 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 16.7 m -99.36 151.66 37.5 Favored Pre-proline 0 C--N 1.301 -1.52 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.647 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.4 OUTLIER -79.46 164.57 23.73 Favored 'Trans proline' 0 C--N 1.306 -1.694 0 C-N-CA 123.005 2.47 . . . . 0.0 114.359 169.831 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 3.1 m -43.93 105.32 0.05 Allowed 'General case' 0 C--N 1.3 -1.581 0 CA-C-N 112.197 -2.274 . . . . 0.0 112.636 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 114.53 -4.12 23.22 Favored Glycine 0 N--CA 1.505 3.26 0 CA-C-N 115.665 -0.698 . . . . 0.0 113.495 179.581 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' TRP . . . . . 0.647 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 49.2 m95 -111.22 166.5 11.04 Favored 'General case' 0 N--CA 1.488 1.43 0 N-CA-C 107.061 -1.459 . . . . 0.0 107.061 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 55.0 t-80 -148.86 40.35 0.89 Allowed 'General case' 0 N--CA 1.505 2.312 0 C-N-CA 117.904 -1.518 . . . . 0.0 114.147 -179.856 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . 0.602 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 1.5 t30 52.36 146.66 0.0 OUTLIER 'General case' 0 N--CA 1.499 1.986 0 CA-C-N 113.001 -1.909 . . . . 0.0 116.073 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.505 ' SG ' ' O ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -119.08 -41.14 2.77 Favored 'General case' 0 C--N 1.306 -1.29 0 CA-C-N 114.582 -1.19 . . . . 0.0 111.336 -179.805 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . 0.553 ' C ' ' H ' ' A' ' 39' ' ' HIS . 44.3 tttm -106.04 106.36 16.83 Favored 'General case' 0 N--CA 1.502 2.136 0 C-N-CA 119.014 -1.074 . . . . 0.0 108.384 179.655 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -65.8 16.66 0.02 OUTLIER 'General case' 0 N--CA 1.505 2.299 0 N-CA-C 113.049 0.759 . . . . 0.0 113.049 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . 0.553 ' H ' ' C ' ' A' ' 37' ' ' LYS . 5.3 m-70 -128.38 -4.84 5.42 Favored 'General case' 0 N--CA 1.494 1.745 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.03 179.947 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 133.97 -119.86 2.36 Favored Glycine 0 N--CA 1.509 3.506 0 C-N-CA 120.685 -0.769 . . . . 0.0 113.086 179.872 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -68.1 -170.82 5.04 Favored 'Cis proline' 0 N--CA 1.504 2.138 0 CA-C-N 118.609 1.205 . . . . 0.0 111.824 -1.669 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 10.0 t-20 -93.72 -5.5 48.3 Favored 'General case' 0 CA--C 1.492 -1.253 0 N-CA-C 106.083 -1.821 . . . . 0.0 106.083 -179.709 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 28.4 mt -94.81 32.14 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.104 0 CA-C-O 123.897 1.808 . . . . 0.0 110.737 -179.005 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 115.96 153.99 10.27 Favored Glycine 0 C--N 1.295 -1.737 1 N-CA-C 101.137 -4.785 . . . . 0.0 101.137 -179.692 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . 0.407 ' CD2' ' HA2' ' A' ' 28' ' ' GLY . 56.4 m95 -86.56 135.37 33.46 Favored 'General case' 0 N--CA 1.505 2.298 0 CA-C-O 116.475 -1.726 . . . . 0.0 108.057 -179.769 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' CYS . . . . . 0.532 ' HA ' ' HA ' ' A' ' 22' ' ' LEU . 59.3 m -92.65 121.18 33.81 Favored 'General case' 0 C--N 1.308 -1.212 1 N-CA-C 96.884 -5.228 . . . . 0.0 96.884 179.763 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.518 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 96.1 m -127.57 -174.57 3.22 Favored 'General case' 0 C--N 1.297 -1.712 0 CA-C-N 112.419 -2.173 . . . . 0.0 108.366 -179.351 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.36 173.14 14.86 Favored 'General case' 0 C--N 1.297 -1.705 0 N-CA-C 106.923 -1.51 . . . . 0.0 106.923 179.32 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 86.8 mttt . . . . . 0 C--N 1.289 -2.049 0 O-C-N 126.255 2.222 . . . . 0.0 106.593 179.337 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 19.4 t . . . . . 0 N--CA 1.492 1.666 0 N-CA-C 106.939 -1.504 . . . . 0.0 106.939 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.447 ' HA ' ' O ' ' A' ' 20' ' ' GLY . 11.0 Cg_endo -77.09 132.95 13.12 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 123.246 2.63 . . . . 0.0 113.147 163.673 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -121.26 177.39 5.18 Favored 'General case' 0 N--CA 1.494 1.734 0 C-N-CA 119.966 -0.694 . . . . 0.0 112.038 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 9.4 tt -94.12 150.86 19.94 Favored 'General case' 0 N--CA 1.493 1.687 0 N-CA-C 105.036 -2.209 . . . . 0.0 105.036 179.768 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . 0.425 ' HB3' ' HB2' ' A' ' 37' ' ' LYS . 13.0 m -143.07 -174.85 4.3 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 124.683 1.239 . . . . 0.0 111.739 -179.337 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 9.6 t70 . . . . . 0 N--CA 1.493 1.707 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 179.881 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 5.5 t . . . . . 0 N--CA 1.5 2.074 0 CA-C-O 121.063 0.459 . . . . 0.0 110.079 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.447 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -173.83 -178.01 43.46 Favored Glycine 0 N--CA 1.5 2.904 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 28.8 mm -134.43 144.11 36.03 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.361 0 N-CA-C 107.072 -1.455 . . . . 0.0 107.072 -179.801 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.454 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.4 pp -66.78 156.62 35.01 Favored 'General case' 0 N--CA 1.491 1.621 0 C-N-CA 118.606 -1.238 . . . . 0.0 108.968 179.715 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.4 ' CE2' ' HG3' ' A' ' 30' ' ' PRO . 35.7 m95 -136.84 134.15 36.63 Favored 'General case' 0 C--N 1.304 -1.371 0 N-CA-C 117.948 2.573 . . . . 0.0 117.948 -179.789 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -89.92 42.49 1.1 Allowed 'General case' 0 C--N 1.296 -1.735 1 CA-C-N 107.784 -4.28 . . . . 0.0 112.411 -179.788 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.445 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 1.3 m-30 -116.3 136.96 23.16 Favored Pre-proline 0 C--N 1.303 -1.418 0 CA-C-O 121.985 0.897 . . . . 0.0 108.749 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -70.02 -17.43 36.39 Favored 'Trans proline' 0 C--N 1.298 -2.082 0 C-N-CA 122.717 2.278 . . . . 0.0 108.607 179.84 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 10.6 p -95.71 23.54 6.1 Favored 'General case' 0 N--CA 1.488 1.445 0 CA-C-N 113.776 -1.556 . . . . 0.0 109.513 179.765 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.587 ' HA2' ' CG ' ' A' ' 45' ' ' TRP . . . 83.13 -94.33 1.76 Allowed Glycine 0 N--CA 1.487 2.053 0 N-CA-C 104.209 -3.556 . . . . 0.0 104.209 -179.677 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . 0.579 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 25.2 m -98.47 165.27 15.47 Favored Pre-proline 0 C--N 1.301 -1.515 0 CA-C-N 113.777 -1.211 . . . . 0.0 110.604 -179.934 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.671 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.1 OUTLIER -88.59 161.48 6.51 Favored 'Trans proline' 0 C--N 1.312 -1.393 1 C-N-CA 125.881 4.387 . . . . 0.0 115.818 156.241 . . . . . . . . 4 4 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 14.0 p -51.55 113.55 1.0 Allowed 'General case' 0 C--N 1.301 -1.512 0 CA-C-N 112.132 -2.303 . . . . 0.0 113.16 -179.758 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 115.94 -6.76 19.7 Favored Glycine 0 N--CA 1.502 3.097 0 O-C-N 124.842 1.339 . . . . 0.0 111.12 179.692 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' TRP . . . . . 0.671 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 42.6 m95 -110.06 173.13 6.47 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 106.156 -1.794 . . . . 0.0 106.156 -179.849 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 77.5 t60 -149.91 29.29 0.74 Allowed 'General case' 0 N--CA 1.496 1.841 0 C-N-CA 117.935 -1.506 . . . . 0.0 112.668 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . 0.603 ' HA ' ' SG ' ' A' ' 47' ' ' CYS . 1.8 t30 62.07 153.35 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.753 0 CA-C-N 114.245 -1.343 . . . . 0.0 111.637 -179.751 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.532 ' SG ' ' HB3' ' A' ' 46' ' ' CYS . 13.9 p -117.68 -39.95 3.08 Favored 'General case' 0 N--CA 1.499 2.024 0 N-CA-C 114.924 1.453 . . . . 0.0 114.924 -179.499 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . 0.473 ' C ' ' H ' ' A' ' 39' ' ' HIS . 74.0 tttt -131.4 132.12 44.13 Favored 'General case' 0 N--CA 1.5 2.047 0 N-CA-C 103.532 -2.766 . . . . 0.0 103.532 179.59 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -78.8 22.4 0.37 Allowed 'General case' 0 N--CA 1.495 1.802 0 C-N-CA 117.553 -1.659 . . . . 0.0 107.985 179.716 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . 0.473 ' H ' ' C ' ' A' ' 37' ' ' LYS . 9.5 m-70 -138.79 107.43 5.89 Favored 'General case' 0 N--CA 1.496 1.829 0 N-CA-C 113.713 1.005 . . . . 0.0 113.713 -179.395 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 60.78 -161.93 22.4 Favored Glycine 0 N--CA 1.502 3.08 0 CA-C-N 114.311 -1.313 . . . . 0.0 113.901 179.547 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . 0.431 ' HD2' ' N ' ' A' ' 46' ' ' CYS . 73.0 Cg_endo -55.32 179.93 1.19 Allowed 'Cis proline' 0 N--CA 1.505 2.188 0 C-N-CA 129.362 0.984 . . . . 0.0 114.436 -5.499 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.2 m120 -92.98 -8.25 43.62 Favored 'General case' 0 C--N 1.306 -1.294 0 N-CA-C 104.496 -2.409 . . . . 0.0 104.496 -179.783 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 11.4 mm -100.96 28.86 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.02 0 CA-C-O 123.675 1.703 . . . . 0.0 113.86 -179.008 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 136.01 -131.65 5.81 Favored Glycine 0 N--CA 1.485 1.906 1 N-CA-C 101.762 -4.535 . . . . 0.0 101.762 179.888 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . 0.587 ' CG ' ' HA2' ' A' ' 28' ' ' GLY . 3.0 m95 -153.33 161.29 42.5 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 105.268 -2.123 . . . . 0.0 105.268 179.646 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' CYS . . . . . 0.532 ' HB3' ' SG ' ' A' ' 36' ' ' CYS . 19.3 m -111.54 133.97 53.45 Favored 'General case' 0 N--CA 1.498 1.943 0 CA-C-N 123.037 2.653 . . . . 0.0 104.278 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.603 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 79.0 m -135.12 -173.4 3.31 Favored 'General case' 0 C--N 1.293 -1.865 0 CA-C-N 111.287 -2.688 . . . . 0.0 108.143 -179.399 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -150.6 175.89 11.5 Favored 'General case' 0 C--N 1.294 -1.805 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 179.225 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . 0.456 ' HE3' ' CZ2' ' A' ' 33' ' ' TRP . 22.6 mmtp . . . . . 0 C--N 1.293 -1.861 0 CA-C-O 114.98 -2.438 . . . . 0.0 107.275 179.5 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 45.7 t . . . . . 0 N--CA 1.493 1.699 0 N-CA-C 104.916 -2.253 . . . . 0.0 104.916 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -70.61 135.19 27.85 Favored 'Trans proline' 0 C--N 1.306 -1.659 0 C-N-CA 123.481 2.787 . . . . 0.0 112.132 175.21 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.416 ' SG ' ' HB2' ' A' ' 22' ' ' LEU . 0.5 OUTLIER -139.64 174.66 10.28 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 123.968 0.792 . . . . 0.0 111.869 -179.995 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 13.6 tp -97.8 152.17 19.44 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 102.065 -3.309 . . . . 0.0 102.065 179.766 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . 0.417 ' HB3' ' C ' ' A' ' 36' ' ' CYS . 2.7 m -115.44 -138.08 0.37 Allowed 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 121.007 3.706 . . . . 0.0 121.007 -178.669 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 . . . . . 0 N--CA 1.502 2.163 0 C-N-CA 119.643 -0.823 . . . . 0.0 111.706 -179.699 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 27.3 t . . . . . 0 N--CA 1.5 2.04 0 CA-C-O 118.051 -0.976 . . . . 0.0 113.537 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.449 ' HA2' ' HD3' ' A' ' 48' ' ' LYS . . . -177.33 152.23 11.84 Favored Glycine 0 N--CA 1.501 2.985 0 C-N-CA 119.234 -1.46 . . . . 0.0 111.508 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.462 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 38.8 mm -101.31 137.49 28.79 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.206 0 C-N-CA 117.3 -1.76 . . . . 0.0 106.718 179.623 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' LEU . . . . . 0.514 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 30.8 tp -63.03 136.3 57.74 Favored 'General case' 0 C--N 1.295 -1.786 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 179.821 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 39.5 m95 -127.06 134.94 50.18 Favored 'General case' 0 C--N 1.31 -1.124 0 CA-C-O 125.397 2.522 . . . . 0.0 117.703 -179.848 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -88.73 40.65 0.98 Allowed 'General case' 0 C--N 1.295 -1.767 1 CA-C-N 107.669 -4.332 . . . . 0.0 113.98 -179.539 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.468 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 1.2 m-30 -115.17 122.22 33.68 Favored Pre-proline 0 N--CA 1.489 1.514 0 CA-C-O 122.86 1.314 . . . . 0.0 113.909 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo -63.66 -23.32 69.93 Favored 'Trans proline' 0 C--N 1.301 -1.938 0 C-N-CA 122.268 1.978 . . . . 0.0 108.924 -173.077 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 10.6 p -93.27 8.83 38.74 Favored 'General case' 0 N--CA 1.492 1.635 0 CA-C-N 114.502 -1.227 . . . . 0.0 112.651 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 112.04 -118.63 4.78 Favored Glycine 0 N--CA 1.495 2.62 0 N-CA-C 107.001 -2.439 . . . . 0.0 107.001 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . 0.471 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 14.8 m -96.21 159.54 31.86 Favored Pre-proline 0 C--N 1.303 -1.444 0 N-CA-C 107.504 -1.295 . . . . 0.0 107.504 179.8 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . 0.685 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 1.6 Cg_endo -78.35 159.56 29.38 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 C-N-CA 122.338 2.025 . . . . 0.0 112.126 169.588 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 27.9 t -49.61 121.97 5.79 Favored 'General case' 0 C--N 1.303 -1.438 0 CA-C-N 113.345 -1.752 . . . . 0.0 108.96 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 109.68 -6.3 31.36 Favored Glycine 0 N--CA 1.498 2.806 0 CA-C-N 113.279 -1.782 . . . . 0.0 111.655 179.673 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' TRP . . . . . 0.685 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 51.0 m95 -113.61 158.12 21.23 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 105.957 -1.868 . . . . 0.0 105.957 -179.938 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 50.6 t-80 -140.13 37.15 1.92 Allowed 'General case' 0 N--CA 1.493 1.7 0 C-N-CA 118.974 -1.09 . . . . 0.0 111.08 -179.774 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . 0.493 ' HA ' ' SG ' ' A' ' 47' ' ' CYS . 22.1 t-20 60.25 152.08 0.02 OUTLIER 'General case' 0 N--CA 1.504 2.225 0 CA-C-N 113.303 -1.772 . . . . 0.0 115.045 179.794 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . 0.548 ' SG ' ' CB ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -125.18 -48.55 1.72 Allowed 'General case' 0 N--CA 1.483 1.219 0 N-CA-C 105.869 -1.9 . . . . 0.0 105.869 -179.972 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 66.2 tttt -113.2 103.1 11.01 Favored 'General case' 0 C--N 1.305 -1.35 0 N-CA-C 105.709 -1.96 . . . . 0.0 105.709 179.719 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.426 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -88.96 18.56 4.76 Favored 'General case' 0 N--CA 1.497 1.885 0 CA-C-N 113.312 -1.767 . . . . 0.0 107.155 179.577 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' HIS . . . . . 0.426 ' ND1' ' C ' ' A' ' 38' ' ' ALA . 7.1 m-70 -129.29 37.37 4.04 Favored 'General case' 0 N--CA 1.489 1.509 0 CA-C-N 114.468 -1.242 . . . . 0.0 109.05 -179.733 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 96.9 -158.32 21.29 Favored Glycine 0 N--CA 1.501 3.009 0 N-CA-C 110.207 -1.157 . . . . 0.0 110.207 179.803 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . 0.421 ' HG2' ' O ' ' A' ' 44' ' ' GLY . 9.2 Cg_endo -74.44 -176.66 18.11 Favored 'Cis proline' 0 N--CA 1.505 2.159 0 CA-C-N 118.914 1.357 . . . . 0.0 110.91 1.448 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.465 ' C ' ' H ' ' A' ' 44' ' ' GLY . 19.4 p-10 -92.32 -11.3 35.49 Favored 'General case' 0 N--CA 1.491 1.578 0 N-CA-C 105.016 -2.216 . . . . 0.0 105.016 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 13.0 mm -88.4 29.05 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.31 0 CA-C-N 113.807 -1.542 . . . . 0.0 110.598 -179.427 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.465 ' H ' ' C ' ' A' ' 42' ' ' ASN . . . 115.37 130.64 4.81 Favored Glycine 0 N--CA 1.49 2.24 0 CA-C-N 112.414 -2.175 . . . . 0.0 107.853 -179.871 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' TRP . . . . . 0.468 ' NE1' ' O ' ' A' ' 25' ' ' TYR . 2.1 m95 -73.85 134.67 43.34 Favored 'General case' 0 N--CA 1.499 1.98 0 N-CA-C 105.882 -1.896 . . . . 0.0 105.882 -179.434 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' CYS . . . . . 0.548 ' CB ' ' SG ' ' A' ' 36' ' ' CYS . 96.0 m -87.9 128.78 35.36 Favored 'General case' 0 N--CA 1.491 1.62 0 N-CA-C 101.314 -3.587 . . . . 0.0 101.314 179.575 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.493 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 73.7 m -126.71 -176.28 3.65 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-N 113.28 -1.782 . . . . 0.0 113.755 -179.317 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' LYS . . . . . 0.51 ' HD2' ' H ' ' A' ' 49' ' ' LYS . 28.5 tptp -150.76 150.84 31.51 Favored 'General case' 0 C--N 1.292 -1.913 0 CA-C-N 114.931 -1.031 . . . . 0.0 109.817 -179.944 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . 0.51 ' H ' ' HD2' ' A' ' 48' ' ' LYS . 54.1 mtpt . . . . . 0 N--CA 1.501 2.085 0 O-C-N 126.16 2.162 . . . . 0.0 109.666 179.458 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.499 2.849 0 N-CA-C 109.94 -1.264 . . . . 0.0 109.94 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 24.6 t -123.31 142.11 37.78 Favored Pre-proline 0 N--CA 1.497 1.876 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_endo -81.33 142.13 13.12 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 C-N-CA 123.293 2.662 . . . . 0.0 110.932 164.718 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -137.52 170.03 16.78 Favored 'General case' 0 N--CA 1.495 1.784 0 C-N-CA 119.455 -0.898 . . . . 0.0 111.659 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.483 HD22 ' N ' ' A' ' 6' ' ' CYS . 5.5 tt -85.62 148.05 26.1 Favored 'General case' 0 N--CA 1.495 1.792 0 N-CA-C 106.752 -1.573 . . . . 0.0 106.752 -179.823 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.483 ' N ' HD22 ' A' ' 5' ' ' LEU . 2.4 m -127.73 -167.03 1.69 Allowed 'General case' 0 N--CA 1.488 1.443 0 N-CA-C 119.197 3.036 . . . . 0.0 119.197 -179.621 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . 0.424 ' C ' ' H ' ' A' ' 9' ' ' ASP . 21.2 t70 -74.86 -62.88 1.39 Allowed 'General case' 0 N--CA 1.503 2.199 0 CA-C-N 112.932 -1.94 . . . . 0.0 112.353 -179.762 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 31.9 p -86.48 17.08 4.02 Favored 'General case' 0 N--CA 1.498 1.936 0 C-N-CA 119.254 -0.979 . . . . 0.0 108.66 179.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.424 ' H ' ' C ' ' A' ' 7' ' ' ASP . 8.8 t70 -69.41 79.41 0.39 Allowed 'General case' 0 N--CA 1.491 1.623 0 CA-C-O 123.359 1.552 . . . . 0.0 106.985 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -152.01 -81.13 0.03 OUTLIER Glycine 0 N--CA 1.49 2.276 0 CA-C-N 112.294 -2.23 . . . . 0.0 107.863 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_endo -70.79 27.7 0.21 Allowed 'Trans proline' 0 N--CA 1.499 1.851 0 C-N-CA 124.257 3.305 . . . . 0.0 114.45 -176.407 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 75.3 mtt-85 -93.32 153.92 41.47 Favored Pre-proline 0 N--CA 1.497 1.918 0 C-N-CA 119.54 -0.864 . . . . 0.0 112.012 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 7.4 Cg_endo -73.05 -145.7 0.02 OUTLIER 'Trans proline' 0 N--CA 1.503 2.039 0 C-N-CA 125.228 3.952 . . . . 0.0 111.695 -178.397 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 2.7 mpt_? -42.39 136.3 2.4 Favored 'General case' 0 N--CA 1.498 1.928 0 CA-C-O 122.004 0.906 . . . . 0.0 110.439 179.817 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.521 ' O ' ' N ' ' A' ' 17' ' ' THR . . . 96.07 -37.92 3.27 Favored Glycine 0 N--CA 1.498 2.823 0 N-CA-C 109.188 -1.565 . . . . 0.0 109.188 -179.6 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 23.5 t-20 28.95 -64.38 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 117.259 2.318 . . . . 0.0 117.259 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.521 ' N ' ' O ' ' A' ' 15' ' ' GLY . 38.5 p -94.15 7.27 45.86 Favored 'General case' 0 N--CA 1.494 1.726 0 N-CA-C 114.157 1.169 . . . . 0.0 114.157 -179.663 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 31.9 mt -152.1 29.39 0.57 Allowed 'General case' 0 N--CA 1.502 2.139 0 CA-C-N 112.957 -1.929 . . . . 0.0 110.645 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 34.6 m -88.7 43.11 1.12 Allowed 'General case' 0 N--CA 1.505 2.309 0 C-N-CA 119.127 -1.029 . . . . 0.0 113.099 -179.581 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -157.01 150.43 21.57 Favored Glycine 0 N--CA 1.493 2.46 0 N-CA-C 107.859 -2.096 . . . . 0.0 107.859 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.458 ' N ' ' O ' ' A' ' 47' ' ' CYS . 44.9 mm -113.48 152.99 15.1 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.282 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.501 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 4.2 pp -76.26 151.13 36.87 Favored 'General case' 0 N--CA 1.501 2.077 0 C-N-CA 117.908 -1.517 . . . . 0.0 108.714 179.569 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 30.0 m95 -132.68 130.3 39.92 Favored 'General case' 0 N--CA 1.485 1.288 0 N-CA-C 119.293 3.071 . . . . 0.0 119.293 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -88.28 53.06 2.61 Favored 'General case' 0 C--N 1.295 -1.804 0 CA-C-N 108.569 -3.923 . . . . 0.0 111.377 -179.495 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.462 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 2.3 m-85 -126.14 121.13 23.92 Favored Pre-proline 0 N--CA 1.495 1.784 0 CA-C-N 115.497 -0.774 . . . . 0.0 112.481 179.605 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -64.68 -19.58 64.73 Favored 'Trans proline' 0 C--N 1.307 -1.635 0 C-N-CA 123.941 3.094 . . . . 0.0 111.328 -177.281 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 6.1 p -94.81 11.37 31.78 Favored 'General case' 0 N--CA 1.489 1.507 0 CA-C-N 115.06 -0.973 . . . . 0.0 111.1 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 101.33 -121.83 7.37 Favored Glycine 0 N--CA 1.498 2.77 0 N-CA-C 106.198 -2.761 . . . . 0.0 106.198 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . 0.544 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 24.9 m -89.15 148.88 41.89 Favored Pre-proline 0 C--N 1.305 -1.348 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 179.72 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.684 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 19.5 Cg_endo -74.19 166.92 28.41 Favored 'Trans proline' 0 C--N 1.31 -1.466 0 C-N-CA 122.211 1.941 . . . . 0.0 114.143 172.895 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 9.4 t -53.89 114.52 1.6 Allowed 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 113.989 -1.46 . . . . 0.0 110.285 -179.755 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 113.6 -7.08 24.33 Favored Glycine 0 N--CA 1.5 2.948 0 CA-C-N 113.906 -1.497 . . . . 0.0 112.319 179.549 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' TRP . . . . . 0.684 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 53.7 m95 -110.29 166.24 11.13 Favored 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 106.745 -1.576 . . . . 0.0 106.745 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 51.9 t60 -146.04 29.82 1.07 Allowed 'General case' 0 N--CA 1.503 2.185 0 C-N-CA 117.911 -1.516 . . . . 0.0 113.95 -179.737 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . 0.544 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 23.3 t-20 64.1 152.03 0.04 OUTLIER 'General case' 0 N--CA 1.506 2.335 0 N-CA-C 115.164 1.542 . . . . 0.0 115.164 -179.818 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.659 ' SG ' ' HB3' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -130.16 -45.77 1.12 Allowed 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 113.32 -1.764 . . . . 0.0 107.543 -179.819 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . 0.533 ' C ' ' H ' ' A' ' 39' ' ' HIS . 82.7 tttt -118.57 103.11 9.41 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-O 122.858 1.313 . . . . 0.0 108.837 179.912 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.432 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -81.48 25.25 0.52 Allowed 'General case' 0 N--CA 1.494 1.761 0 N-CA-C 107.181 -1.414 . . . . 0.0 107.181 179.603 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . 0.533 ' H ' ' C ' ' A' ' 37' ' ' LYS . 5.5 m-70 -131.13 10.24 4.91 Favored 'General case' 0 N--CA 1.492 1.636 0 N-CA-C 108.628 -0.878 . . . . 0.0 108.628 -179.727 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 125.43 -142.62 13.91 Favored Glycine 0 N--CA 1.498 2.778 0 N-CA-C 110.168 -1.173 . . . . 0.0 110.168 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . 0.578 ' CD ' ' SG ' ' A' ' 46' ' ' CYS . 85.8 Cg_endo -66.12 -174.66 6.29 Favored 'Cis proline' 0 N--CA 1.5 1.856 0 CA-C-N 118.289 1.045 . . . . 0.0 110.251 -1.872 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.432 ' C ' ' H ' ' A' ' 44' ' ' GLY . 4.1 m-20 -91.7 -8.83 45.9 Favored 'General case' 0 CA--C 1.479 -1.786 0 N-CA-C 105.617 -1.994 . . . . 0.0 105.617 -179.147 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 37.4 mt -95.06 33.33 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.163 0 CA-C-O 123.624 1.678 . . . . 0.0 109.114 -179.495 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.432 ' H ' ' C ' ' A' ' 42' ' ' ASN . . . 114.06 135.54 6.11 Favored Glycine 0 N--CA 1.485 1.923 0 CA-C-N 111.275 -2.693 . . . . 0.0 107.41 -179.897 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . 0.462 ' NE1' ' O ' ' A' ' 25' ' ' TYR . 6.1 m95 -64.17 134.59 55.12 Favored 'General case' 0 N--CA 1.508 2.454 0 CA-C-O 116.796 -1.573 . . . . 0.0 106.787 -179.544 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' CYS . . . . . 0.659 ' HB3' ' SG ' ' A' ' 36' ' ' CYS . 35.4 m -89.45 124.15 34.23 Favored 'General case' 0 C--N 1.312 -1.063 0 N-CA-C 103.081 -2.933 . . . . 0.0 103.081 179.922 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.526 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 73.4 m -127.4 -169.74 2.1 Favored 'General case' 0 C--N 1.291 -1.972 0 CA-C-N 110.921 -2.854 . . . . 0.0 107.899 -179.533 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.411 ' N ' ' CD ' ' A' ' 48' ' ' LYS . 0.0 OUTLIER -151.67 173.2 14.96 Favored 'General case' 0 C--N 1.292 -1.924 0 N-CA-C 105.175 -2.157 . . . . 0.0 105.175 179.058 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 90.2 mttt . . . . . 0 C--N 1.289 -2.028 0 CA-C-O 114.691 -2.576 . . . . 0.0 106.392 179.524 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 2.545 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 22.4 t -89.36 140.96 28.63 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 103.912 -2.625 . . . . 0.0 103.912 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -68.27 149.43 75.77 Favored 'Trans proline' 0 C--N 1.305 -1.75 0 C-N-CA 122.98 2.453 . . . . 0.0 108.038 170.78 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 1.2 p -141.72 175.02 10.03 Favored 'General case' 0 N--CA 1.495 1.811 0 N-CA-C 115.242 1.571 . . . . 0.0 115.242 -179.755 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 23.5 tp -104.16 150.03 24.72 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 103.682 -2.71 . . . . 0.0 103.682 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.443 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 3.3 m -133.11 -162.51 1.25 Allowed 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 116.299 1.963 . . . . 0.0 116.299 -179.04 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . 0.425 ' C ' ' H ' ' A' ' 9' ' ' ASP . 3.2 p-10 -25.39 -45.31 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.989 0 O-C-N 126.751 2.532 . . . . 0.0 111.851 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 32.6 t -83.28 48.91 1.46 Allowed 'General case' 0 N--CA 1.502 2.142 0 N-CA-C 106.946 -1.502 . . . . 0.0 106.946 179.775 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.425 ' H ' ' C ' ' A' ' 7' ' ' ASP . 0.1 OUTLIER -103.48 -71.82 0.72 Allowed 'General case' 0 N--CA 1.491 1.6 0 CA-C-N 113.834 -1.53 . . . . 0.0 108.863 -179.805 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.41 ' C ' ' H ' ' A' ' 12' ' ' ARG . . . 73.03 169.41 15.0 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 108.126 -1.99 . . . . 0.0 108.126 -179.725 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 14.8 Cg_endo -73.25 17.39 0.42 Allowed 'Trans proline' 0 N--CA 1.495 1.596 0 C-N-CA 124.1 3.2 . . . . 0.0 112.343 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . 0.41 ' H ' ' C ' ' A' ' 10' ' ' GLY . 34.6 ttt180 -130.07 57.63 32.37 Favored Pre-proline 0 N--CA 1.492 1.672 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.443 -179.827 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_endo -72.82 64.18 3.98 Favored 'Trans proline' 0 N--CA 1.499 1.84 0 C-N-CA 124.124 3.216 . . . . 0.0 111.179 -177.42 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . 0.414 ' C ' ' H ' ' A' ' 16' ' ' ASN . 16.5 ptt180 -67.86 146.61 53.49 Favored 'General case' 0 N--CA 1.499 2.004 0 CA-C-N 113.998 -1.455 . . . . 0.0 111.795 -179.713 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 55.69 -11.59 0.01 OUTLIER Glycine 0 N--CA 1.499 2.872 0 N-CA-C 117.13 1.612 . . . . 0.0 117.13 179.748 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . 0.414 ' H ' ' C ' ' A' ' 14' ' ' ARG . 50.1 t30 53.18 79.26 0.12 Allowed 'General case' 0 N--CA 1.508 2.433 0 CA-C-N 119.412 1.606 . . . . 0.0 110.09 -179.854 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 9.0 t -89.06 174.09 8.08 Favored 'General case' 0 N--CA 1.502 2.129 0 C-N-CA 118.493 -1.283 . . . . 0.0 110.437 -179.779 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 48.0 mt -130.36 104.47 7.29 Favored 'General case' 0 N--CA 1.492 1.626 0 CA-C-N 114.125 -1.398 . . . . 0.0 110.255 -179.281 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 25.0 m -114.51 -0.07 13.84 Favored 'General case' 0 N--CA 1.502 2.138 0 C-N-CA 119.766 -0.774 . . . . 0.0 112.263 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -164.74 179.59 39.34 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 108.945 -1.662 . . . . 0.0 108.945 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 34.3 mm -125.06 149.41 29.62 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.174 0 N-CA-C 108.42 -0.955 . . . . 0.0 108.42 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.549 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 4.5 pp -71.17 148.44 47.34 Favored 'General case' 0 N--CA 1.498 1.946 0 C-N-CA 118.513 -1.275 . . . . 0.0 110.875 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 38.2 m95 -131.4 131.47 43.66 Favored 'General case' 0 N--CA 1.486 1.36 0 N-CA-C 120.389 3.477 . . . . 0.0 120.389 -179.821 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -88.87 49.58 1.81 Allowed 'General case' 0 C--N 1.296 -1.734 1 CA-C-N 106.862 -4.699 . . . . 0.0 112.785 -179.389 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.4 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 2.2 m-85 -121.21 130.76 24.69 Favored Pre-proline 0 C--N 1.302 -1.468 0 CA-C-O 122.436 1.113 . . . . 0.0 111.3 179.525 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -69.79 -24.28 29.69 Favored 'Trans proline' 0 C--N 1.308 -1.595 0 C-N-CA 124.647 3.565 . . . . 0.0 110.662 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 6.1 p -93.63 15.12 16.97 Favored 'General case' 0 N--CA 1.492 1.642 0 CA-C-N 115.405 -0.816 . . . . 0.0 111.307 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 99.64 -126.01 8.77 Favored Glycine 0 N--CA 1.5 2.901 0 N-CA-C 105.674 -2.97 . . . . 0.0 105.674 -179.88 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . 0.541 ' SG ' ' CA ' ' A' ' 35' ' ' ASN . 35.7 m -86.66 152.24 54.02 Favored Pre-proline 0 C--N 1.304 -1.403 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 179.721 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.714 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 19.9 Cg_endo -73.04 165.83 31.71 Favored 'Trans proline' 0 C--N 1.305 -1.719 0 C-N-CA 122.525 2.15 . . . . 0.0 113.906 173.392 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 5.6 p -51.73 107.42 0.19 Allowed 'General case' 0 C--N 1.298 -1.632 0 CA-C-N 112.341 -2.209 . . . . 0.0 112.247 -179.741 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 115.34 -7.85 20.65 Favored Glycine 0 N--CA 1.498 2.826 0 O-C-N 124.514 1.134 . . . . 0.0 111.737 179.594 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' TRP . . . . . 0.714 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 45.7 m95 -105.76 166.87 10.16 Favored 'General case' 0 C--N 1.304 -1.389 0 N-CA-C 106.143 -1.799 . . . . 0.0 106.143 -179.874 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 54.0 t-80 -147.03 33.82 0.91 Allowed 'General case' 0 N--CA 1.497 1.894 0 C-N-CA 117.337 -1.745 . . . . 0.0 112.884 -179.648 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . 0.541 ' CA ' ' SG ' ' A' ' 29' ' ' CYS . 24.9 t-20 60.44 143.29 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.13 0 N-CA-C 115.187 1.551 . . . . 0.0 115.187 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.876 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 1.7 p -120.99 -41.16 2.56 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-N 114.28 -1.327 . . . . 0.0 108.448 -179.628 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 77.3 tttt -118.84 116.31 26.23 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 104.708 -2.33 . . . . 0.0 104.708 179.748 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -89.41 8.08 32.62 Favored 'General case' 0 N--CA 1.496 1.827 0 N-CA-C 107.475 -1.306 . . . . 0.0 107.475 179.79 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 16.2 m-70 -133.04 48.86 2.36 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-N 115.001 -0.999 . . . . 0.0 110.876 -179.708 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 113.41 -165.11 12.01 Favored Glycine 0 N--CA 1.497 2.705 0 O-C-N 124.293 0.995 . . . . 0.0 113.47 179.581 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 15.0 Cg_endo -73.75 -174.01 12.46 Favored 'Cis proline' 0 N--CA 1.497 1.703 0 O-C-N 123.085 1.045 . . . . 0.0 110.933 -5.182 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 6.7 m120 -92.08 -10.68 38.16 Favored 'General case' 0 CA--C 1.484 -1.587 0 N-CA-C 104.579 -2.378 . . . . 0.0 104.579 -179.676 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 33.0 pt -92.04 27.22 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.03 0 C-N-CA 118.204 -1.398 . . . . 0.0 113.689 -179.434 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 116.76 130.85 4.55 Favored Glycine 0 N--CA 1.489 2.215 0 CA-C-N 111.831 -2.44 . . . . 0.0 108.693 -179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . 0.4 ' NE1' ' O ' ' A' ' 25' ' ' TYR . 8.5 m95 -54.06 131.76 41.36 Favored 'General case' 0 N--CA 1.513 2.704 0 CA-C-O 116.248 -1.834 . . . . 0.0 107.56 -179.56 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' CYS . . . . . 0.876 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 53.3 t -89.44 131.85 35.3 Favored 'General case' 0 N--CA 1.479 0.983 1 N-CA-C 99.333 -4.321 . . . . 0.0 99.333 -179.882 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.453 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 86.2 m -133.74 -173.55 3.27 Favored 'General case' 0 C--N 1.292 -1.9 0 CA-C-N 111.056 -2.793 . . . . 0.0 109.876 -179.166 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.438 ' CD ' ' N ' ' A' ' 48' ' ' LYS . 0.0 OUTLIER -150.48 173.47 14.03 Favored 'General case' 0 C--N 1.297 -1.695 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 179.376 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 3.7 mmpt? . . . . . 0 N--CA 1.502 2.131 0 O-C-N 126.618 2.449 . . . . 0.0 110.874 179.929 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 2.74 0 N-CA-C 112.267 -0.333 . . . . 0.0 112.267 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 21.8 t -89.2 150.75 45.58 Favored Pre-proline 0 N--CA 1.5 2.051 0 N-CA-C 106.686 -1.598 . . . . 0.0 106.686 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.465 ' CB ' ' HG ' ' A' ' 18' ' ' LEU . 11.1 Cg_endo -74.47 134.55 18.94 Favored 'Trans proline' 0 C--N 1.306 -1.681 0 C-N-CA 123.048 2.498 . . . . 0.0 117.73 163.819 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -128.82 173.66 10.16 Favored 'General case' 0 N--CA 1.493 1.679 0 N-CA-C 107.589 -1.263 . . . . 0.0 107.589 179.509 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.524 HD22 ' N ' ' A' ' 6' ' ' CYS . 5.4 tt -90.64 147.24 23.43 Favored 'General case' 0 N--CA 1.496 1.866 0 N-CA-C 103.665 -2.717 . . . . 0.0 103.665 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.524 ' N ' HD22 ' A' ' 5' ' ' LEU . 4.4 m -128.34 -171.49 2.47 Favored 'General case' 0 C--N 1.307 -1.271 0 N-CA-C 116.005 1.854 . . . . 0.0 116.005 -179.851 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 34.1 t70 -82.44 -66.76 0.85 Allowed 'General case' 0 N--CA 1.489 1.481 0 CA-C-N 113.196 -1.82 . . . . 0.0 107.575 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 37.9 t -65.1 -7.25 11.43 Favored 'General case' 0 N--CA 1.501 2.095 0 C-N-CA 118.606 -1.238 . . . . 0.0 109.566 179.761 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.2 t0 -62.76 -23.7 67.34 Favored 'General case' 0 N--CA 1.499 1.979 0 O-C-N 124.358 1.036 . . . . 0.0 108.862 179.699 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 90.06 135.31 5.89 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 107.475 -2.25 . . . . 0.0 107.475 -179.805 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 0.5 OUTLIER -80.1 42.88 1.4 Allowed 'Trans proline' 0 N--CA 1.492 1.412 0 C-N-CA 124.839 3.693 . . . . 0.0 110.509 -171.822 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 1.1 mpt_? -89.97 131.52 38.99 Favored Pre-proline 0 N--CA 1.495 1.801 0 CA-C-N 115.399 -0.819 . . . . 0.0 112.845 -179.698 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -74.44 60.41 4.97 Favored 'Trans proline' 0 N--CA 1.499 1.831 0 C-N-CA 125.049 3.833 . . . . 0.0 112.394 -177.237 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 9.7 mmm180 -93.63 138.02 32.3 Favored 'General case' 0 N--CA 1.499 1.994 0 CA-C-N 113.745 -1.571 . . . . 0.0 109.447 -179.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -80.56 4.07 70.6 Favored Glycine 0 N--CA 1.501 3.009 0 C-N-CA 119.53 -1.319 . . . . 0.0 111.946 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 48.5 t30 -147.01 74.44 1.34 Allowed 'General case' 0 N--CA 1.497 1.893 0 N-CA-C 107.453 -1.314 . . . . 0.0 107.453 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 4.0 p -88.72 52.33 2.4 Favored 'General case' 0 C--N 1.298 -1.647 0 CA-C-N 115.158 -0.928 . . . . 0.0 110.693 -179.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.465 ' HG ' ' CB ' ' A' ' 3' ' ' PRO . 2.6 tt -73.1 75.7 1.24 Allowed 'General case' 0 N--CA 1.492 1.652 0 N-CA-C 106.133 -1.802 . . . . 0.0 106.133 179.895 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 4.1 t -136.81 23.5 3.09 Favored 'General case' 0 N--CA 1.5 2.052 0 CA-C-N 115.236 -0.893 . . . . 0.0 110.407 -179.704 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.503 ' HA3' ' SG ' ' A' ' 6' ' ' CYS . . . -172.48 121.57 0.88 Allowed Glycine 0 N--CA 1.494 2.503 0 N-CA-C 107.065 -2.414 . . . . 0.0 107.065 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.457 ' N ' ' O ' ' A' ' 47' ' ' CYS . 36.3 mm -96.09 137.34 24.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 N-CA-C 104.691 -2.337 . . . . 0.0 104.691 179.736 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.568 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 4.3 pp -65.69 149.33 50.29 Favored 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 117.752 -1.579 . . . . 0.0 107.238 179.812 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.417 ' O ' ' CA ' ' A' ' 44' ' ' GLY . 20.2 m95 -132.17 135.78 46.6 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-O 124.542 2.115 . . . . 0.0 115.882 -179.727 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.1 m-85 -88.91 40.58 0.98 Allowed 'General case' 0 C--N 1.293 -1.849 0 CA-C-N 109.12 -3.673 . . . . 0.0 115.353 -179.383 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.444 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 1.2 m-30 -113.12 120.0 41.24 Favored Pre-proline 0 N--CA 1.487 1.396 0 N-CA-C 107.664 -1.236 . . . . 0.0 107.664 179.713 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -60.93 -21.28 70.53 Favored 'Trans proline' 0 C--N 1.298 -2.091 0 C-N-CA 122.511 2.14 . . . . 0.0 110.414 -170.207 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 4.3 p -97.45 3.67 50.77 Favored 'General case' 0 N--CA 1.491 1.6 0 CA-C-N 114.746 -1.115 . . . . 0.0 113.451 -179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 125.58 -121.86 4.35 Favored Glycine 0 N--CA 1.492 2.38 0 N-CA-C 108.601 -1.8 . . . . 0.0 108.601 179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . 0.49 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 3.9 m -95.2 158.6 34.51 Favored Pre-proline 0 C--N 1.304 -1.375 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.682 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.3 OUTLIER -79.11 -179.24 5.27 Favored 'Trans proline' 0 C--N 1.312 -1.343 0 C-N-CA 123.242 2.628 . . . . 0.0 114.896 171.033 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 18.4 p -58.41 104.62 0.22 Allowed 'General case' 0 C--N 1.299 -1.591 0 CA-C-N 112.922 -1.944 . . . . 0.0 112.941 -179.587 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 114.15 3.63 22.82 Favored Glycine 0 N--CA 1.501 2.969 0 O-C-N 124.759 1.287 . . . . 0.0 113.561 179.628 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' TRP . . . . . 0.682 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 39.7 m95 -117.75 153.07 34.03 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 107.369 -1.345 . . . . 0.0 107.369 -179.822 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . 0.408 ' O ' ' ND1' ' A' ' 34' ' ' HIS . 36.6 t-80 -137.4 41.5 2.4 Favored 'General case' 0 N--CA 1.5 2.044 0 CA-C-O 122.074 0.94 . . . . 0.0 109.847 -179.496 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . 0.49 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 24.6 t-20 59.59 156.73 0.03 OUTLIER 'General case' 0 N--CA 1.501 2.089 0 CA-C-O 123.9 1.81 . . . . 0.0 114.286 -179.765 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.778 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -125.66 -52.18 1.58 Allowed 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 104.354 -2.461 . . . . 0.0 104.354 179.725 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . 0.501 ' C ' ' H ' ' A' ' 39' ' ' HIS . 43.7 tttp -118.26 103.98 10.35 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 113.615 -1.63 . . . . 0.0 109.74 179.836 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.44 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -81.82 30.96 0.37 Allowed 'General case' 0 N--CA 1.497 1.902 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 179.573 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . 0.501 ' H ' ' C ' ' A' ' 37' ' ' LYS . 4.5 m-70 -130.49 8.32 4.99 Favored 'General case' 0 N--CA 1.492 1.636 0 CA-C-N 115.53 -0.759 . . . . 0.0 108.957 -179.73 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 128.51 -152.98 19.4 Favored Glycine 0 N--CA 1.496 2.7 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 179.902 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . 0.4 ' HG2' ' O ' ' A' ' 44' ' ' GLY . 26.8 Cg_endo -72.68 -174.61 12.62 Favored 'Cis proline' 0 N--CA 1.508 2.324 0 O-C-N 122.808 0.899 . . . . 0.0 112.586 -2.414 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.487 ' C ' ' H ' ' A' ' 44' ' ' GLY . 17.8 p-10 -91.88 -14.35 29.81 Favored 'General case' 0 CA--C 1.485 -1.533 0 N-CA-C 105.527 -2.027 . . . . 0.0 105.527 -179.654 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 11.0 mt -88.84 30.1 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.341 0 CA-C-N 113.809 -1.541 . . . . 0.0 109.617 -179.405 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.487 ' H ' ' C ' ' A' ' 42' ' ' ASN . . . 114.6 122.18 3.64 Favored Glycine 0 N--CA 1.491 2.347 0 CA-C-N 112.163 -2.289 . . . . 0.0 107.767 -179.853 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . 0.444 ' NE1' ' O ' ' A' ' 25' ' ' TYR . 3.9 m95 -54.68 138.79 40.85 Favored 'General case' 0 N--CA 1.514 2.735 0 CA-C-O 116.795 -1.574 . . . . 0.0 107.946 -179.378 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' CYS . . . . . 0.778 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 13.8 t -88.87 127.4 35.63 Favored 'General case' 0 C--N 1.309 -1.159 0 N-CA-C 102.587 -3.116 . . . . 0.0 102.587 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.489 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 98.0 m -128.9 176.51 7.8 Favored 'General case' 0 CA--C 1.478 -1.8 0 CA-C-N 112.009 -2.36 . . . . 0.0 113.656 -178.99 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.418 ' HD2' ' H ' ' A' ' 49' ' ' LYS . 41.1 tptt -150.83 153.08 34.73 Favored 'General case' 0 C--N 1.295 -1.804 0 C-N-CA 118.785 -1.166 . . . . 0.0 109.405 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . 0.448 ' HZ1' ' HB3' ' A' ' 49' ' ' LYS . 7.4 mtpm? . . . . . 0 N--CA 1.5 2.037 0 CA-C-N 111.703 -2.499 . . . . 0.0 110.886 179.775 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 2.691 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 6.3 t -98.12 149.2 35.48 Favored Pre-proline 0 N--CA 1.5 2.053 0 N-CA-C 106.512 -1.662 . . . . 0.0 106.512 179.896 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -79.03 119.86 4.43 Favored 'Trans proline' 0 C--N 1.308 -1.568 0 C-N-CA 122.491 2.127 . . . . 0.0 113.337 160.019 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.448 ' SG ' ' HB3' ' A' ' 22' ' ' LEU . 0.5 OUTLIER -104.59 -171.63 1.96 Allowed 'General case' 0 N--CA 1.495 1.802 0 CA-C-N 114.956 -1.02 . . . . 0.0 110.893 -179.975 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 4.2 tp -98.38 152.29 19.64 Favored 'General case' 0 N--CA 1.497 1.907 0 N-CA-C 104.593 -2.373 . . . . 0.0 104.593 179.838 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.443 ' CB ' ' HB2' ' A' ' 9' ' ' ASP . 3.1 m -132.59 -170.63 2.48 Favored 'General case' 0 N--CA 1.485 1.321 0 N-CA-C 115.41 1.633 . . . . 0.0 115.41 -179.62 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -77.24 -63.93 1.25 Allowed 'General case' 0 C--N 1.3 -1.583 0 CA-C-N 112.971 -1.922 . . . . 0.0 109.752 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 2.4 p -97.46 32.47 2.25 Favored 'General case' 0 C--N 1.296 -1.723 0 CA-C-N 114.969 -1.014 . . . . 0.0 108.824 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.443 ' HB2' ' CB ' ' A' ' 6' ' ' CYS . 2.2 t70 -73.83 64.18 0.94 Allowed 'General case' 0 N--CA 1.496 1.834 0 CA-C-N 114.685 -1.143 . . . . 0.0 110.598 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 85.17 157.78 28.57 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 108.044 -2.022 . . . . 0.0 108.044 -179.875 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 8.7 Cg_endo -76.48 26.72 0.42 Allowed 'Trans proline' 0 N--CA 1.496 1.656 0 C-N-CA 124.101 3.201 . . . . 0.0 112.049 169.855 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 34.4 mtp85 -111.18 142.92 27.32 Favored Pre-proline 0 N--CA 1.497 1.884 0 N-CA-C 114.252 1.204 . . . . 0.0 114.252 -179.784 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -72.69 61.6 3.68 Favored 'Trans proline' 0 C--N 1.312 -1.351 0 C-N-CA 124.038 3.159 . . . . 0.0 111.748 170.703 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 14.4 mtm180 60.01 -140.35 0.62 Allowed 'General case' 0 N--CA 1.497 1.915 0 CA-C-N 113.643 -1.617 . . . . 0.0 114.315 179.666 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 85.25 -57.47 4.96 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 22.3 p-10 -156.98 54.38 0.52 Allowed 'General case' 0 N--CA 1.5 2.025 0 CA-C-O 122.369 1.081 . . . . 0.0 109.753 -179.835 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 39.1 p -115.65 90.67 3.39 Favored 'General case' 0 N--CA 1.491 1.587 0 CA-C-N 114.073 -1.422 . . . . 0.0 109.581 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 89.4 mt -118.49 74.08 0.94 Allowed 'General case' 0 N--CA 1.499 1.995 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 -179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 4.5 t -98.71 47.8 0.98 Allowed 'General case' 0 N--CA 1.502 2.144 0 N-CA-C 113.507 0.929 . . . . 0.0 113.507 -179.743 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 165.43 -176.3 41.04 Favored Glycine 0 N--CA 1.512 3.738 0 C-N-CA 118.742 -1.694 . . . . 0.0 114.94 179.573 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 19.3 mm -134.19 149.16 29.97 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.245 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 179.57 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.519 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.5 pp -69.19 146.71 52.19 Favored 'General case' 0 N--CA 1.495 1.794 0 C-N-CA 119.333 -0.947 . . . . 0.0 110.859 179.709 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 37.5 m95 -130.62 130.33 43.83 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 121.374 3.842 . . . . 0.0 121.374 -179.571 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 4.4 m-85 -89.0 49.81 1.85 Allowed 'General case' 0 C--N 1.295 -1.795 1 CA-C-N 108.093 -4.14 . . . . 0.0 112.209 -179.687 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.44 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 2.2 m-85 -122.56 124.56 26.7 Favored Pre-proline 0 N--CA 1.494 1.765 0 N-CA-C 114.144 1.164 . . . . 0.0 114.144 179.876 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -64.16 -20.82 67.63 Favored 'Trans proline' 0 C--N 1.307 -1.641 0 C-N-CA 124.065 3.177 . . . . 0.0 110.935 -177.02 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 5.1 p -94.06 6.9 47.07 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-N 114.576 -1.193 . . . . 0.0 111.207 179.829 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 104.17 -112.52 4.15 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 105.252 -3.139 . . . . 0.0 105.252 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . 0.537 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 13.5 m -96.55 147.96 33.73 Favored Pre-proline 0 C--N 1.305 -1.363 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 179.798 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.692 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 15.2 Cg_endo -74.23 174.67 12.08 Favored 'Trans proline' 0 C--N 1.308 -1.566 0 C-N-CA 122.628 2.219 . . . . 0.0 114.47 174.259 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 12.0 p -53.13 105.65 0.13 Allowed 'General case' 0 C--N 1.299 -1.63 0 CA-C-N 112.469 -2.151 . . . . 0.0 112.568 -179.694 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 111.92 -1.25 27.21 Favored Glycine 0 N--CA 1.503 3.139 0 O-C-N 124.156 0.91 . . . . 0.0 113.814 179.503 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' TRP . . . . . 0.692 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 52.1 m95 -110.45 166.79 10.71 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 108.053 -1.092 . . . . 0.0 108.053 -179.912 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 80.1 t60 -146.98 36.59 0.94 Allowed 'General case' 0 N--CA 1.5 2.03 0 C-N-CA 116.8 -1.96 . . . . 0.0 115.94 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . 0.537 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 0.4 OUTLIER 63.3 137.93 0.02 OUTLIER 'General case' 0 N--CA 1.506 2.326 0 N-CA-C 116.926 2.195 . . . . 0.0 116.926 179.714 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.626 ' SG ' ' HB3' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -118.06 -42.17 2.83 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 105.029 -2.211 . . . . 0.0 105.029 179.71 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 57.3 tttt -136.38 120.54 17.79 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 114.824 -1.08 . . . . 0.0 109.544 179.766 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.437 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -97.99 34.21 1.97 Allowed 'General case' 0 N--CA 1.496 1.829 0 N-CA-C 105.505 -2.035 . . . . 0.0 105.505 179.645 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . 0.437 ' ND1' ' C ' ' A' ' 38' ' ' ALA . 3.8 m-70 -133.5 47.92 2.42 Favored 'General case' 0 N--CA 1.495 1.792 0 N-CA-C 106.225 -1.769 . . . . 0.0 106.225 -179.67 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 85.21 -156.61 31.02 Favored Glycine 0 N--CA 1.498 2.779 0 N-CA-C 107.416 -2.274 . . . . 0.0 107.416 -179.749 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 17.6 Cg_endo -72.13 -172.76 9.41 Favored 'Cis proline' 0 N--CA 1.494 1.555 0 CA-C-N 118.612 1.206 . . . . 0.0 112.053 2.5 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 80.2 m-20 -92.32 -15.49 27.3 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 104.647 -2.353 . . . . 0.0 104.647 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 13.5 mt -90.87 29.5 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.21 0 CA-C-N 113.272 -1.786 . . . . 0.0 111.425 -179.255 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 109.07 119.11 4.2 Favored Glycine 0 N--CA 1.491 2.31 0 CA-C-N 112.178 -2.283 . . . . 0.0 111.601 179.853 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . 0.44 ' NE1' ' O ' ' A' ' 25' ' ' TYR . 2.2 m95 -49.44 134.74 18.74 Favored 'General case' 0 N--CA 1.516 2.856 0 CA-C-O 116.231 -1.843 . . . . 0.0 107.449 -179.743 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' CYS . . . . . 0.626 ' HB3' ' SG ' ' A' ' 36' ' ' CYS . 68.5 m -89.45 128.22 35.93 Favored 'General case' 0 N--CA 1.485 1.32 0 N-CA-C 103.689 -2.708 . . . . 0.0 103.689 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.515 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 86.7 m -131.12 -173.49 3.11 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-N 111.955 -2.384 . . . . 0.0 110.314 -179.165 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.09 173.7 14.05 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 118.574 -1.25 . . . . 0.0 109.106 179.357 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 95.0 mttt . . . . . 0 C--N 1.292 -1.909 0 O-C-N 126.402 2.314 . . . . 0.0 107.927 179.488 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 2.507 0 N-CA-C 110.613 -0.995 . . . . 0.0 110.613 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 9.1 t -97.82 142.25 24.27 Favored Pre-proline 0 N--CA 1.495 1.81 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_endo -77.2 131.64 11.99 Favored 'Trans proline' 0 N--CA 1.494 1.551 0 C-N-CA 124.067 3.178 . . . . 0.0 114.26 166.916 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -122.17 167.99 12.53 Favored 'General case' 0 N--CA 1.498 1.942 0 CA-C-O 122.602 1.191 . . . . 0.0 114.076 -179.702 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 12.7 tp -79.68 127.34 32.07 Favored 'General case' 0 N--CA 1.493 1.695 0 N-CA-C 106.907 -1.516 . . . . 0.0 106.907 -179.709 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.488 ' HB2' ' HB2' ' A' ' 9' ' ' ASP . 21.8 m -106.58 -174.11 2.46 Favored 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 118.844 -1.143 . . . . 0.0 112.883 179.65 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -80.47 -74.92 0.29 Allowed 'General case' 0 C--N 1.296 -1.727 0 CA-C-N 113.916 -1.493 . . . . 0.0 108.431 -179.778 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 1.1 m -46.08 -29.75 1.62 Allowed 'General case' 0 N--CA 1.501 2.076 0 CA-C-N 114.606 -1.179 . . . . 0.0 109.916 179.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.488 ' HB2' ' HB2' ' A' ' 6' ' ' CYS . 45.3 t0 -41.03 -51.48 3.3 Favored 'General case' 0 N--CA 1.494 1.756 0 CA-C-N 111.916 -2.402 . . . . 0.0 111.039 179.814 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 91.89 166.26 39.67 Favored Glycine 0 N--CA 1.501 2.976 0 C-N-CA 119.955 -1.117 . . . . 0.0 113.407 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 0.4 OUTLIER -79.81 40.09 0.92 Allowed 'Trans proline' 0 N--CA 1.502 1.999 1 C-N-CA 125.822 4.348 . . . . 0.0 113.453 -168.227 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.0 mpt_? -113.09 161.57 26.18 Favored Pre-proline 0 N--CA 1.496 1.838 0 CA-C-N 113.671 -1.604 . . . . 0.0 109.607 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 13.7 Cg_endo -75.49 145.32 29.7 Favored 'Trans proline' 0 N--CA 1.493 1.458 0 C-N-CA 124.198 3.265 . . . . 0.0 110.042 166.473 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . 0.402 ' C ' ' H ' ' A' ' 16' ' ' ASN . 75.8 mtt85 -67.82 33.67 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.127 0 N-CA-C 114.348 1.24 . . . . 0.0 114.348 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.97 23.44 0.09 OUTLIER Glycine 0 N--CA 1.496 2.69 0 N-CA-C 116.231 1.252 . . . . 0.0 116.231 -179.537 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . 0.402 ' H ' ' C ' ' A' ' 14' ' ' ARG . 9.3 m120 -119.58 -84.42 0.66 Allowed 'General case' 0 N--CA 1.493 1.713 0 N-CA-C 106.494 -1.669 . . . . 0.0 106.494 179.653 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 31.9 m -150.52 48.81 0.88 Allowed 'General case' 0 N--CA 1.496 1.859 0 N-CA-C 106.392 -1.707 . . . . 0.0 106.392 179.775 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 2.0 mm? 66.67 149.64 0.05 Allowed 'General case' 0 N--CA 1.5 2.028 0 O-C-N 125.152 1.532 . . . . 0.0 109.878 -179.733 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 3.2 p -89.6 -8.16 53.2 Favored 'General case' 0 C--N 1.298 -1.659 0 CA-C-N 115.65 -0.705 . . . . 0.0 111.901 179.806 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 159.33 178.98 33.84 Favored Glycine 0 N--CA 1.499 2.853 0 N-CA-C 108.016 -2.034 . . . . 0.0 108.016 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.438 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 48.6 mm -127.84 145.97 34.24 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.974 0 N-CA-C 106.141 -1.8 . . . . 0.0 106.141 179.736 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.483 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.8 pp -69.67 152.18 45.0 Favored 'General case' 0 N--CA 1.491 1.617 0 C-N-CA 118.257 -1.377 . . . . 0.0 110.115 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.414 ' O ' ' HA3' ' A' ' 44' ' ' GLY . 37.6 m95 -136.41 130.73 33.15 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 118.884 2.92 . . . . 0.0 118.884 179.763 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 6.0 m-85 -89.48 51.47 2.12 Favored 'General case' 0 C--N 1.296 -1.756 1 CA-C-N 107.467 -4.424 . . . . 0.0 111.613 -179.692 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.458 ' CE1' ' HB3' ' A' ' 30' ' ' PRO . 2.4 m-85 -125.07 137.03 28.93 Favored Pre-proline 0 C--N 1.303 -1.414 0 CA-C-O 121.482 0.658 . . . . 0.0 109.613 179.646 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 96.9 Cg_endo -66.95 -30.31 39.72 Favored 'Trans proline' 0 C--N 1.305 -1.75 0 C-N-CA 124.264 3.309 . . . . 0.0 108.636 177.56 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 11.8 p -86.65 31.9 0.67 Allowed 'General case' 0 C--N 1.299 -1.611 0 CA-C-N 113.989 -1.459 . . . . 0.0 109.239 179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.54 ' HA2' ' CD1' ' A' ' 45' ' ' TRP . . . 76.05 -92.76 0.94 Allowed Glycine 0 N--CA 1.482 1.764 0 N-CA-C 104.399 -3.48 . . . . 0.0 104.399 -179.499 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . 0.568 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 9.4 m -103.75 165.91 12.65 Favored Pre-proline 0 C--N 1.301 -1.515 0 CA-C-N 113.814 -1.193 . . . . 0.0 110.609 -179.849 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.651 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.1 OUTLIER -86.01 167.11 9.64 Favored 'Trans proline' 0 CA--C 1.553 1.472 0 C-N-CA 125.238 3.959 . . . . 0.0 118.336 157.924 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 3.8 m -49.64 109.57 0.29 Allowed 'General case' 0 C--N 1.299 -1.604 0 CA-C-N 111.769 -2.469 . . . . 0.0 112.283 179.845 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 113.46 -6.6 24.66 Favored Glycine 0 N--CA 1.5 2.948 0 CA-C-N 115.218 -0.901 . . . . 0.0 111.901 179.743 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' TRP . . . . . 0.651 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 48.1 m95 -111.51 162.57 14.97 Favored 'General case' 0 N--CA 1.486 1.341 0 N-CA-C 106.321 -1.733 . . . . 0.0 106.321 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . 0.419 ' O ' ' ND1' ' A' ' 34' ' ' HIS . 60.0 t-80 -143.62 34.18 1.29 Allowed 'General case' 0 N--CA 1.498 1.962 0 C-N-CA 118.138 -1.425 . . . . 0.0 113.406 -179.733 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . 0.568 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 3.2 t30 61.76 146.16 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.9 0 N-CA-C 114.375 1.25 . . . . 0.0 114.375 179.916 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.804 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -124.31 -45.74 1.95 Allowed 'General case' 0 N--CA 1.484 1.272 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.039 -179.715 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . 0.55 ' C ' ' H ' ' A' ' 39' ' ' HIS . 36.0 ttmt -122.01 100.35 6.93 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 105.44 -2.059 . . . . 0.0 105.44 179.431 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -77.55 19.9 0.34 Allowed 'General case' 0 N--CA 1.5 2.034 0 CA-C-N 114.431 -1.259 . . . . 0.0 107.742 179.649 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . 0.55 ' H ' ' C ' ' A' ' 37' ' ' LYS . 7.4 m-70 -132.75 16.82 4.29 Favored 'General case' 0 N--CA 1.487 1.378 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.476 -179.709 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 149.37 -177.8 27.32 Favored Glycine 0 N--CA 1.501 3.015 0 C-N-CA 119.412 -1.375 . . . . 0.0 111.432 179.695 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . 0.5 ' HD2' ' N ' ' A' ' 46' ' ' CYS . 35.5 Cg_endo -66.25 -171.89 4.45 Favored 'Cis proline' 0 N--CA 1.512 2.592 0 N-CA-C 116.167 1.564 . . . . 0.0 116.167 -4.604 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.406 ' C ' ' H ' ' A' ' 44' ' ' GLY . 16.1 p-10 -92.1 -12.76 32.11 Favored 'General case' 0 N--CA 1.486 1.336 0 N-CA-C 105.505 -2.035 . . . . 0.0 105.505 -179.715 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 12.1 pt -85.81 23.02 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.218 0 O-C-N 124.909 1.38 . . . . 0.0 113.814 -179.49 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.423 ' C ' ' CD1' ' A' ' 45' ' ' TRP . . . 134.63 -116.47 1.61 Allowed Glycine 0 C--N 1.291 -1.962 0 N-CA-C 104.404 -3.478 . . . . 0.0 104.404 -179.906 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . 0.54 ' CD1' ' HA2' ' A' ' 28' ' ' GLY . 1.8 m95 -157.03 151.28 25.09 Favored 'General case' 0 N--CA 1.509 2.501 0 N-CA-C 105.491 -2.04 . . . . 0.0 105.491 -179.891 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' CYS . . . . . 0.804 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 44.5 t -99.06 129.61 45.34 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 102.882 -3.006 . . . . 0.0 102.882 179.864 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.524 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 78.4 m -126.77 -170.7 2.25 Favored 'General case' 0 C--N 1.298 -1.641 0 CA-C-N 113.528 -1.669 . . . . 0.0 109.719 -179.409 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -150.58 172.72 15.06 Favored 'General case' 0 C--N 1.294 -1.822 0 N-CA-C 107.195 -1.409 . . . . 0.0 107.195 179.324 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 84.8 mttt . . . . . 0 N--CA 1.498 1.95 0 O-C-N 126.129 2.143 . . . . 0.0 109.131 179.456 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.418 0 N-CA-C 108.913 -1.675 . . . . 0.0 108.913 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 11.4 t -89.56 147.44 37.89 Favored Pre-proline 0 N--CA 1.494 1.766 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 -179.793 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_endo -75.81 155.33 39.23 Favored 'Trans proline' 0 N--CA 1.496 1.65 0 C-N-CA 124.024 3.15 . . . . 0.0 112.963 166.717 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.408 ' SG ' ' SG ' ' A' ' 6' ' ' CYS . 9.4 p -132.39 170.78 14.61 Favored 'General case' 0 N--CA 1.499 1.982 0 C-N-CA 119.208 -0.997 . . . . 0.0 108.939 179.574 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 13.9 tp -86.64 81.21 8.32 Favored 'General case' 0 N--CA 1.491 1.624 0 N-CA-C 103.65 -2.722 . . . . 0.0 103.65 179.908 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.408 ' SG ' ' SG ' ' A' ' 4' ' ' CYS . 6.6 m -69.18 170.96 9.1 Favored 'General case' 0 C--N 1.309 -1.188 0 CA-C-O 123.273 1.511 . . . . 0.0 112.375 -179.729 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 7.9 t70 -48.05 -46.55 33.52 Favored 'General case' 0 N--CA 1.496 1.875 0 CA-C-N 111.07 -2.786 . . . . 0.0 111.301 -179.838 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 3.9 p -91.14 -6.3 53.8 Favored 'General case' 0 C--N 1.301 -1.532 0 CA-C-N 114.521 -1.218 . . . . 0.0 110.95 179.796 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 10.7 t0 -72.83 80.25 1.15 Allowed 'General case' 0 N--CA 1.491 1.576 0 C-N-CA 118.635 -1.226 . . . . 0.0 110.452 -179.46 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 169.3 -81.65 0.09 OUTLIER Glycine 0 N--CA 1.491 2.359 0 CA-C-N 114.036 -1.438 . . . . 0.0 109.726 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 7.1 Cg_endo -76.37 -4.06 14.59 Favored 'Trans proline' 0 N--CA 1.501 1.956 0 C-N-CA 124.338 3.359 . . . . 0.0 115.099 -172.768 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -106.32 137.78 19.52 Favored Pre-proline 0 C--N 1.294 -1.826 0 CA-C-N 112.893 -1.958 . . . . 0.0 109.314 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -68.52 176.33 5.91 Favored 'Trans proline' 0 N--CA 1.492 1.419 0 C-N-CA 123.866 3.044 . . . . 0.0 110.175 -178.584 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 25.2 mtp85 51.11 19.08 0.64 Allowed 'General case' 0 N--CA 1.493 1.675 0 N-CA-C 113.891 1.071 . . . . 0.0 113.891 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -104.39 -0.89 43.89 Favored Glycine 0 N--CA 1.501 2.97 0 N-CA-C 108.805 -1.718 . . . . 0.0 108.805 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -68.53 -53.86 20.41 Favored 'General case' 0 N--CA 1.488 1.471 0 CA-C-O 122.482 1.134 . . . . 0.0 110.871 -179.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 7.2 m -88.84 59.28 4.99 Favored 'General case' 0 N--CA 1.495 1.778 0 CA-C-N 115.396 -0.82 . . . . 0.0 109.31 -179.342 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 8.9 mp 73.07 125.66 0.04 OUTLIER 'General case' 0 N--CA 1.497 1.909 0 O-C-N 126.246 2.216 . . . . 0.0 108.665 -179.748 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 48.4 t -91.78 -16.18 27.2 Favored 'General case' 0 N--CA 1.498 1.935 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.304 179.821 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 174.05 -171.83 44.83 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 107.653 -2.179 . . . . 0.0 107.653 -179.882 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 1.2 mp -133.83 153.14 35.9 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.104 0 O-C-N 124.918 1.01 . . . . 0.0 108.553 -179.903 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.526 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.3 pp -71.33 146.34 48.9 Favored 'General case' 0 N--CA 1.499 1.998 0 C-N-CA 120.205 -0.598 . . . . 0.0 111.868 179.812 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.432 ' O ' ' CA ' ' A' ' 44' ' ' GLY . 39.0 m95 -129.08 130.28 46.32 Favored 'General case' 0 N--CA 1.491 1.603 0 N-CA-C 119.512 3.152 . . . . 0.0 119.512 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 3.5 m-85 -88.73 51.38 2.16 Favored 'General case' 0 C--N 1.294 -1.827 1 CA-C-N 107.886 -4.234 . . . . 0.0 113.154 -179.412 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 2.2 m-85 -120.79 142.33 34.21 Favored Pre-proline 0 C--N 1.3 -1.576 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 179.411 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -76.12 -33.16 3.71 Favored 'Trans proline' 0 C--N 1.3 -1.991 0 C-N-CA 125.063 3.842 . . . . 0.0 112.21 172.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 14.1 p -88.61 33.43 0.77 Allowed 'General case' 0 N--CA 1.494 1.735 0 CA-C-O 121.442 0.639 . . . . 0.0 111.083 -179.524 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 76.0 -158.82 50.09 Favored Glycine 0 N--CA 1.495 2.58 0 N-CA-C 105.912 -2.875 . . . . 0.0 105.912 -179.565 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . 0.586 ' SG ' ' CA ' ' A' ' 35' ' ' ASN . 14.0 m -53.06 150.76 9.95 Favored Pre-proline 0 C--N 1.303 -1.441 0 CA-C-N 117.599 0.699 . . . . 0.0 111.941 179.816 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.695 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 4.6 Cg_endo -76.41 159.74 36.01 Favored 'Trans proline' 0 C--N 1.308 -1.566 0 C-N-CA 122.956 2.437 . . . . 0.0 112.043 171.759 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 16.5 t -49.14 129.67 18.13 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-N 113.332 -1.758 . . . . 0.0 109.522 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 97.81 -5.14 61.71 Favored Glycine 0 N--CA 1.496 2.697 0 CA-C-N 112.664 -2.062 . . . . 0.0 111.687 179.762 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' TRP . . . . . 0.695 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 48.1 m95 -111.91 163.77 13.85 Favored 'General case' 0 C--N 1.305 -1.332 0 N-CA-C 106.29 -1.745 . . . . 0.0 106.29 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . 0.401 ' O ' ' ND1' ' A' ' 34' ' ' HIS . 45.5 t-80 -144.24 34.39 1.21 Allowed 'General case' 0 N--CA 1.498 1.974 0 C-N-CA 117.365 -1.734 . . . . 0.0 113.107 -179.818 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . 0.586 ' CA ' ' SG ' ' A' ' 29' ' ' CYS . 23.8 t-20 62.38 144.72 0.02 OUTLIER 'General case' 0 N--CA 1.506 2.333 0 N-CA-C 113.976 1.102 . . . . 0.0 113.976 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.851 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -124.74 -64.9 1.07 Allowed 'General case' 0 C--N 1.306 -1.3 0 N-CA-C 106.672 -1.603 . . . . 0.0 106.672 -179.751 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . 0.593 ' N ' ' SG ' ' A' ' 36' ' ' CYS . 33.1 ttmt -91.05 103.59 16.27 Favored 'General case' 0 C--N 1.302 -1.465 0 CA-C-O 123.567 1.651 . . . . 0.0 107.04 179.704 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.425 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -79.86 24.16 0.41 Allowed 'General case' 0 N--CA 1.495 1.781 0 CA-C-N 113.499 -1.682 . . . . 0.0 107.282 179.489 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . 0.548 ' H ' ' C ' ' A' ' 37' ' ' LYS . 3.3 m-70 -131.85 17.88 4.67 Favored 'General case' 0 N--CA 1.493 1.713 0 N-CA-C 106.966 -1.494 . . . . 0.0 106.966 -179.677 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 111.43 -132.0 10.63 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 25.9 Cg_endo -69.78 -164.06 2.43 Favored 'Cis proline' 0 N--CA 1.503 2.054 0 CA-C-N 117.843 0.821 . . . . 0.0 112.699 1.097 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.462 ' C ' ' H ' ' A' ' 44' ' ' GLY . 22.6 t-20 -92.13 -20.57 21.11 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 106.374 -1.713 . . . . 0.0 106.374 -179.757 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 39.7 pt -86.31 28.33 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 CA-C-N 112.367 -2.197 . . . . 0.0 113.349 -179.104 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.462 ' H ' ' C ' ' A' ' 42' ' ' ASN . . . 115.03 131.15 4.98 Favored Glycine 0 N--CA 1.484 1.859 0 CA-C-N 111.019 -2.81 . . . . 0.0 109.994 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 14.8 m95 -55.42 130.1 41.26 Favored 'General case' 0 N--CA 1.509 2.484 0 N-CA-C 106.311 -1.737 . . . . 0.0 106.311 -179.657 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' CYS . . . . . 0.851 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 42.7 t -89.15 129.42 35.75 Favored 'General case' 0 C--N 1.31 -1.139 1 N-CA-C 99.341 -4.318 . . . . 0.0 99.341 -179.89 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.522 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 77.8 m -133.93 -175.35 3.81 Favored 'General case' 0 C--N 1.293 -1.888 0 CA-C-N 110.671 -2.968 . . . . 0.0 110.881 -178.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.404 ' O ' ' HA ' ' A' ' 33' ' ' TRP . 0.0 OUTLIER -150.7 172.68 15.19 Favored 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 107.1 -1.445 . . . . 0.0 107.1 179.484 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 54.0 mtpt . . . . . 0 C--N 1.289 -2.032 0 O-C-N 127.248 2.843 . . . . 0.0 109.253 179.697 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.495 2.616 0 N-CA-C 109.005 -1.638 . . . . 0.0 109.005 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 34.0 t -98.78 131.76 25.08 Favored Pre-proline 0 N--CA 1.49 1.565 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -82.19 136.15 8.85 Favored 'Trans proline' 0 C--N 1.308 -1.594 0 C-N-CA 124.026 3.151 . . . . 0.0 113.516 162.76 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.403 ' SG ' ' N ' ' A' ' 5' ' ' LEU . 1.8 p -110.45 -156.87 0.6 Allowed 'General case' 0 N--CA 1.504 2.259 0 N-CA-C 107.601 -1.259 . . . . 0.0 107.601 179.778 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.403 ' N ' ' SG ' ' A' ' 4' ' ' CYS . 2.9 tt -118.85 99.97 7.09 Favored 'General case' 0 N--CA 1.503 2.212 0 N-CA-C 101.283 -3.599 . . . . 0.0 101.283 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.462 ' CB ' ' HB2' ' A' ' 9' ' ' ASP . 2.9 m -78.85 -176.11 4.81 Favored 'General case' 0 C--N 1.308 -1.214 0 N-CA-C 116.424 2.009 . . . . 0.0 116.424 -179.381 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -74.04 -62.33 1.54 Allowed 'General case' 0 C--N 1.298 -1.662 0 CA-C-N 112.319 -2.219 . . . . 0.0 109.843 -179.614 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 1.7 p -89.42 20.23 4.0 Favored 'General case' 0 N--CA 1.493 1.718 0 CA-C-N 114.973 -1.012 . . . . 0.0 108.63 179.709 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.462 ' HB2' ' CB ' ' A' ' 6' ' ' CYS . 2.4 t0 -66.13 -32.58 74.12 Favored 'General case' 0 N--CA 1.494 1.755 0 N-CA-C 106.484 -1.673 . . . . 0.0 106.484 179.748 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 99.37 99.22 2.2 Favored Glycine 0 N--CA 1.486 1.999 0 N-CA-C 103.993 -3.643 . . . . 0.0 103.993 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_endo -78.41 49.18 2.96 Favored 'Trans proline' 0 N--CA 1.495 1.605 0 C-N-CA 124.162 3.241 . . . . 0.0 109.549 -176.351 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 64.7 mtt85 -108.61 163.25 17.4 Favored Pre-proline 0 N--CA 1.496 1.874 0 CA-C-N 113.775 -1.557 . . . . 0.0 111.484 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 13.7 Cg_endo -72.56 49.45 1.47 Allowed 'Trans proline' 0 N--CA 1.5 1.878 0 C-N-CA 124.812 3.675 . . . . 0.0 112.984 176.763 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . 0.514 ' C ' ' H ' ' A' ' 16' ' ' ASN . 0.0 OUTLIER -167.84 122.15 0.96 Allowed 'General case' 0 C--N 1.301 -1.538 0 CA-C-N 113.68 -1.6 . . . . 0.0 112.924 179.974 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.432 ' O ' ' N ' ' A' ' 17' ' ' THR . . . 74.64 -37.33 1.02 Allowed Glycine 0 N--CA 1.498 2.812 0 CA-C-N 114.669 -1.15 . . . . 0.0 112.552 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . 0.514 ' H ' ' C ' ' A' ' 14' ' ' ARG . 66.0 t30 2.74 -47.39 0.0 OUTLIER 'General case' 0 N--CA 1.507 2.417 0 N-CA-C 120.904 3.668 . . . . 0.0 120.904 -179.634 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.432 ' N ' ' O ' ' A' ' 15' ' ' GLY . 26.9 p -121.8 27.58 8.07 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-N 119.341 0.973 . . . . 0.0 112.31 -179.994 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -136.26 20.73 3.19 Favored 'General case' 0 N--CA 1.497 1.905 0 CA-C-N 114.56 -1.2 . . . . 0.0 110.438 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 4.8 m -89.07 14.51 10.55 Favored 'General case' 0 N--CA 1.503 2.175 0 N-CA-C 115.385 1.624 . . . . 0.0 115.385 -179.335 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 167.69 -179.36 41.13 Favored Glycine 0 N--CA 1.502 3.045 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 179.796 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 37.2 mm -132.71 143.94 38.18 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.399 0 O-C-N 124.555 0.797 . . . . 0.0 110.975 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.499 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.9 pp -63.56 154.75 31.63 Favored 'General case' 0 N--CA 1.504 2.244 0 N-CA-C 109.117 -0.697 . . . . 0.0 109.117 179.518 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.511 ' N ' ' O ' ' A' ' 45' ' ' TRP . 32.4 m95 -134.42 131.4 38.13 Favored 'General case' 0 C--N 1.308 -1.202 0 N-CA-C 118.91 2.93 . . . . 0.0 118.91 -179.694 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -87.57 53.48 2.8 Favored 'General case' 0 C--N 1.291 -1.973 0 CA-C-N 109.316 -3.584 . . . . 0.0 111.796 -179.245 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 2.7 m-85 -125.52 137.06 29.17 Favored Pre-proline 0 C--N 1.306 -1.302 0 CA-C-N 115.052 -0.976 . . . . 0.0 110.352 179.6 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_endo -73.81 -25.43 14.49 Favored 'Trans proline' 0 C--N 1.306 -1.696 1 C-N-CA 125.725 4.283 . . . . 0.0 112.817 177.746 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 5.9 p -95.03 20.66 8.68 Favored 'General case' 0 N--CA 1.493 1.706 0 CA-C-N 115.249 -0.887 . . . . 0.0 111.163 -179.875 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 89.91 -138.27 14.47 Favored Glycine 0 N--CA 1.496 2.687 0 N-CA-C 106.278 -2.729 . . . . 0.0 106.278 -179.817 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . 0.526 ' SG ' ' CA ' ' A' ' 35' ' ' ASN . 29.7 m -69.28 150.05 97.3 Favored Pre-proline 0 C--N 1.305 -1.355 0 CA-C-N 117.496 0.648 . . . . 0.0 109.971 179.889 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.679 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 1.9 Cg_endo -78.31 159.29 29.6 Favored 'Trans proline' 0 C--N 1.31 -1.469 0 C-N-CA 123.207 2.604 . . . . 0.0 112.403 171.198 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 24.1 t -47.96 128.86 14.13 Favored 'General case' 0 C--N 1.305 -1.326 0 CA-C-N 113.168 -1.833 . . . . 0.0 109.3 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 100.51 -8.07 58.3 Favored Glycine 0 N--CA 1.495 2.607 0 CA-C-N 112.628 -2.078 . . . . 0.0 111.421 179.77 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' TRP . . . . . 0.679 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 48.3 m95 -110.29 162.94 14.14 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 106.83 -1.544 . . . . 0.0 106.83 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 78.6 t60 -143.22 29.82 1.44 Allowed 'General case' 0 N--CA 1.499 1.997 0 C-N-CA 118.34 -1.344 . . . . 0.0 113.135 -179.843 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . 0.526 ' CA ' ' SG ' ' A' ' 29' ' ' CYS . 12.1 t-20 62.02 147.13 0.02 OUTLIER 'General case' 0 N--CA 1.505 2.301 0 CA-C-O 123.109 1.433 . . . . 0.0 114.097 -179.79 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.841 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -117.41 -46.91 2.67 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-N 113.341 -1.754 . . . . 0.0 108.003 -179.666 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . 0.405 ' C ' ' H ' ' A' ' 39' ' ' HIS . 19.4 ttpp -132.18 124.77 29.69 Favored 'General case' 0 N--CA 1.497 1.922 0 N-CA-C 107.814 -1.18 . . . . 0.0 107.814 179.43 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -87.13 22.07 2.18 Favored 'General case' 0 N--CA 1.493 1.688 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 179.788 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . 0.405 ' H ' ' C ' ' A' ' 37' ' ' LYS . 16.9 m-70 -131.33 76.72 1.73 Allowed 'General case' 0 N--CA 1.492 1.645 0 CA-C-O 122.243 1.02 . . . . 0.0 108.882 -179.773 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 68.83 -163.07 50.54 Favored Glycine 0 N--CA 1.492 2.418 0 CA-C-N 113.353 -1.749 . . . . 0.0 109.849 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . 0.412 ' HG2' ' O ' ' A' ' 44' ' ' GLY . 34.1 Cg_endo -71.86 175.14 43.78 Favored 'Cis proline' 0 N--CA 1.495 1.573 0 N-CA-C 107.635 -1.717 . . . . 0.0 107.635 -2.402 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.486 ' C ' ' H ' ' A' ' 44' ' ' GLY . 23.4 m120 -91.53 -10.12 41.86 Favored 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 105.299 -2.112 . . . . 0.0 105.299 -179.484 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 16.1 mt -88.79 28.75 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.225 0 CA-C-N 113.447 -1.706 . . . . 0.0 110.338 -179.438 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.486 ' H ' ' C ' ' A' ' 42' ' ' ASN . . . 115.98 135.29 5.65 Favored Glycine 0 N--CA 1.486 2.0 0 CA-C-N 111.827 -2.442 . . . . 0.0 112.687 179.789 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . 0.511 ' O ' ' N ' ' A' ' 23' ' ' TRP . 26.3 m95 -62.0 129.39 40.66 Favored 'General case' 0 N--CA 1.501 2.116 0 C-N-CA 120.19 -0.604 . . . . 0.0 111.388 -179.42 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' CYS . . . . . 0.841 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 46.4 t -88.52 114.72 25.43 Favored 'General case' 0 C--N 1.305 -1.359 1 N-CA-C 96.728 -5.286 . . . . 0.0 96.728 179.998 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.53 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 75.1 m -129.89 -176.18 3.84 Favored 'General case' 0 C--N 1.295 -1.768 1 CA-C-N 108.253 -4.067 . . . . 0.0 108.714 -179.407 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.437 ' O ' ' HA ' ' A' ' 33' ' ' TRP . 0.0 OUTLIER -149.97 169.74 20.48 Favored 'General case' 0 C--N 1.294 -1.836 0 C-N-CA 117.614 -1.634 . . . . 0.0 107.698 179.56 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 48.9 mtpt . . . . . 0 C--N 1.29 -2.02 0 O-C-N 127.577 3.048 . . . . 0.0 109.379 179.71 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.495 2.571 0 N-CA-C 109.053 -1.619 . . . . 0.0 109.053 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 61.9 t -99.73 142.46 24.65 Favored Pre-proline 0 N--CA 1.496 1.84 0 N-CA-C 108.026 -1.101 . . . . 0.0 108.026 -179.903 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -76.22 158.93 37.27 Favored 'Trans proline' 0 C--N 1.309 -1.54 0 C-N-CA 124.509 3.473 . . . . 0.0 113.405 171.45 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -150.9 164.94 35.12 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 125.48 1.737 . . . . 0.0 108.036 179.614 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.408 HD21 ' N ' ' A' ' 6' ' ' CYS . 9.4 tt -79.38 168.18 19.85 Favored 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 103.404 -2.813 . . . . 0.0 103.404 179.759 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.429 ' HB3' ' C ' ' A' ' 36' ' ' CYS . 3.5 m -140.93 -174.8 4.09 Favored 'General case' 0 C--N 1.302 -1.489 0 N-CA-C 116.662 2.097 . . . . 0.0 116.662 -179.257 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -76.74 -31.91 57.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 112.639 -2.073 . . . . 0.0 107.862 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 70.8 p -112.34 -14.77 13.26 Favored 'General case' 0 N--CA 1.496 1.848 0 CA-C-N 115.199 -0.91 . . . . 0.0 112.62 179.646 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.417 ' H ' ' HB2' ' A' ' 6' ' ' CYS . 0.7 OUTLIER -32.51 -39.81 0.04 OUTLIER 'General case' 0 N--CA 1.515 2.804 0 N-CA-C 113.9 1.074 . . . . 0.0 113.9 -179.737 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 140.65 137.52 3.46 Favored Glycine 0 N--CA 1.487 2.055 0 N-CA-C 105.027 -3.229 . . . . 0.0 105.027 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_endo -71.94 24.79 0.25 Allowed 'Trans proline' 0 N--CA 1.497 1.719 0 C-N-CA 124.358 3.372 . . . . 0.0 114.282 -166.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 76.2 mtt180 -109.85 100.36 42.59 Favored Pre-proline 0 N--CA 1.495 1.799 0 C-N-CA 119.849 -0.74 . . . . 0.0 109.546 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_endo -74.4 169.11 23.24 Favored 'Trans proline' 0 N--CA 1.494 1.503 0 C-N-CA 124.09 3.193 . . . . 0.0 111.166 176.39 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 74.8 mtp180 60.46 -169.05 0.16 Allowed 'General case' 0 N--CA 1.494 1.761 0 N-CA-C 108.539 -0.912 . . . . 0.0 108.539 -179.835 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.442 ' O ' ' CB ' ' A' ' 16' ' ' ASN . . . 74.34 -48.91 1.86 Allowed Glycine 0 N--CA 1.5 2.912 0 C-N-CA 119.909 -1.139 . . . . 0.0 113.337 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . 0.442 ' CB ' ' O ' ' A' ' 15' ' ' GLY . 17.1 t-20 98.98 91.53 0.01 OUTLIER 'General case' 0 N--CA 1.511 2.589 0 C-N-CA 126.059 1.744 . . . . 0.0 107.182 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 25.1 p -89.82 160.29 16.57 Favored 'General case' 0 N--CA 1.495 1.8 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.437 -179.843 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 2.0 tt -140.5 70.38 1.36 Allowed 'General case' 0 N--CA 1.501 2.092 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 19.7 m -91.45 -11.91 36.22 Favored 'General case' 0 N--CA 1.502 2.15 0 N-CA-C 112.681 0.623 . . . . 0.0 112.681 179.77 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -166.7 -162.46 18.32 Favored Glycine 0 N--CA 1.504 3.195 0 N-CA-C 110.904 -0.878 . . . . 0.0 110.904 -179.863 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 8.1 mm -135.75 146.48 29.59 Favored 'Isoleucine or valine' 0 N--CA 1.515 2.82 0 N-CA-C 113.992 1.108 . . . . 0.0 113.992 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.556 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.6 pp -64.25 151.15 44.41 Favored 'General case' 0 N--CA 1.505 2.317 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 179.17 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.448 ' N ' ' O ' ' A' ' 45' ' ' TRP . 22.3 m95 -133.45 137.41 45.7 Favored 'General case' 0 C--N 1.305 -1.347 0 N-CA-C 116.6 2.074 . . . . 0.0 116.6 -179.656 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -88.47 41.32 1.01 Allowed 'General case' 0 C--N 1.293 -1.87 0 CA-C-N 109.045 -3.707 . . . . 0.0 115.119 -179.408 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -114.67 129.28 25.11 Favored Pre-proline 0 N--CA 1.489 1.52 0 N-CA-C 115.45 1.648 . . . . 0.0 115.45 179.743 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -68.33 -21.53 41.07 Favored 'Trans proline' 0 C--N 1.307 -1.642 0 C-N-CA 123.402 2.734 . . . . 0.0 108.979 -175.106 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -91.32 1.29 57.22 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-N 112.864 -1.971 . . . . 0.0 110.797 179.752 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 107.72 -117.05 5.06 Favored Glycine 0 N--CA 1.498 2.828 0 N-CA-C 105.455 -3.058 . . . . 0.0 105.455 -179.831 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . 0.533 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 10.2 m -93.12 150.23 38.83 Favored Pre-proline 0 C--N 1.305 -1.361 0 N-CA-C 108.404 -0.962 . . . . 0.0 108.404 179.632 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.668 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.5 OUTLIER -76.49 175.53 11.23 Favored 'Trans proline' 0 C--N 1.311 -1.42 0 C-N-CA 123.241 2.627 . . . . 0.0 115.66 176.777 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 16.4 p -50.47 102.88 0.04 OUTLIER 'General case' 0 C--N 1.299 -1.605 0 CA-C-N 112.671 -2.059 . . . . 0.0 112.724 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 112.12 -0.24 26.89 Favored Glycine 0 N--CA 1.503 3.127 0 O-C-N 124.332 1.02 . . . . 0.0 113.61 179.435 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' TRP . . . . . 0.668 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 45.6 m95 -112.3 163.73 14.05 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 107.289 -1.375 . . . . 0.0 107.289 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 73.5 t60 -146.37 37.45 1.02 Allowed 'General case' 0 N--CA 1.501 2.098 0 C-N-CA 118.014 -1.475 . . . . 0.0 114.54 -179.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . 0.533 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 23.7 t-20 60.04 149.42 0.02 OUTLIER 'General case' 0 N--CA 1.506 2.338 0 N-CA-C 115.763 1.764 . . . . 0.0 115.763 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.623 ' SG ' ' HB3' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -125.21 -44.91 1.86 Allowed 'General case' 0 C--N 1.303 -1.451 0 CA-C-N 113.52 -1.673 . . . . 0.0 108.067 -179.913 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . 0.477 ' C ' ' H ' ' A' ' 39' ' ' HIS . 36.9 ttmt -124.66 111.13 15.24 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 105.101 -2.185 . . . . 0.0 105.101 179.61 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.436 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -85.01 31.84 0.54 Allowed 'General case' 0 N--CA 1.494 1.749 0 N-CA-C 106.132 -1.803 . . . . 0.0 106.132 179.587 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . 0.477 ' H ' ' C ' ' A' ' 37' ' ' LYS . 4.5 m-70 -132.21 22.28 4.45 Favored 'General case' 0 N--CA 1.497 1.88 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 -179.612 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 107.89 -145.88 16.26 Favored Glycine 0 N--CA 1.494 2.514 0 N-CA-C 109.292 -1.523 . . . . 0.0 109.292 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . 0.659 ' CD ' ' SG ' ' A' ' 46' ' ' CYS . 8.4 Cg_endo -74.97 -173.54 12.5 Favored 'Cis proline' 0 N--CA 1.502 2.011 0 C-N-CA 129.013 0.839 . . . . 0.0 111.36 0.87 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.505 ' C ' ' H ' ' A' ' 44' ' ' GLY . 0.2 OUTLIER -91.9 -8.61 45.9 Favored 'General case' 0 N--CA 1.487 1.385 0 N-CA-C 102.883 -3.006 . . . . 0.0 102.883 179.951 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.406 HD13 ' N ' ' A' ' 43' ' ' ILE . 4.0 mp -90.88 32.45 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 CA-C-O 123.159 1.457 . . . . 0.0 108.245 -179.419 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.505 ' H ' ' C ' ' A' ' 42' ' ' ASN . . . 102.89 127.74 6.19 Favored Glycine 0 N--CA 1.489 2.209 0 CA-C-N 111.88 -2.418 . . . . 0.0 107.094 -179.774 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . 0.448 ' O ' ' N ' ' A' ' 23' ' ' TRP . 6.7 m95 -54.8 135.67 47.32 Favored 'General case' 0 N--CA 1.509 2.485 0 CA-C-O 117.05 -1.452 . . . . 0.0 108.621 -179.519 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' CYS . . . . . 0.659 ' SG ' ' CD ' ' A' ' 41' ' ' PRO . 75.3 m -88.37 122.67 32.13 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 101.885 -3.376 . . . . 0.0 101.885 179.86 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.469 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 75.2 m -128.57 -174.71 3.31 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-N 110.43 -3.077 . . . . 0.0 108.739 -179.495 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.36 171.96 16.66 Favored 'General case' 0 C--N 1.299 -1.617 0 N-CA-C 106.684 -1.599 . . . . 0.0 106.684 179.176 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 92.3 mttt . . . . . 0 C--N 1.288 -2.076 0 O-C-N 125.675 1.859 . . . . 0.0 109.437 179.922 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.5 2.902 0 N-CA-C 110.01 -1.236 . . . . 0.0 110.01 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 24.7 t -96.22 135.61 22.51 Favored Pre-proline 0 N--CA 1.5 2.039 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 179.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 6.9 Cg_endo -79.18 129.65 8.86 Favored 'Trans proline' 0 N--CA 1.491 1.371 0 C-N-CA 123.836 3.024 . . . . 0.0 114.268 165.034 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -119.2 -163.0 0.94 Allowed 'General case' 0 N--CA 1.495 1.822 0 N-CA-C 113.549 0.944 . . . . 0.0 113.549 -179.729 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.43 HD22 ' N ' ' A' ' 6' ' ' CYS . 9.6 tt -111.71 151.68 28.63 Favored 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 104.456 -2.424 . . . . 0.0 104.456 179.848 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.43 ' N ' HD22 ' A' ' 5' ' ' LEU . 5.1 m -140.95 -171.05 3.17 Favored 'General case' 0 N--CA 1.483 1.189 0 N-CA-C 116.224 1.935 . . . . 0.0 116.224 -179.378 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 39.0 t70 -83.26 -56.67 3.64 Favored 'General case' 0 N--CA 1.49 1.558 0 CA-C-N 112.233 -2.258 . . . . 0.0 108.09 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 34.1 m -76.22 -12.08 60.03 Favored 'General case' 0 N--CA 1.493 1.724 0 C-N-CA 119.425 -0.91 . . . . 0.0 109.592 179.625 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -52.18 -31.75 33.03 Favored 'General case' 0 N--CA 1.502 2.14 0 CA-C-N 114.622 -1.172 . . . . 0.0 112.115 179.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 118.72 141.18 6.53 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 107.669 -2.172 . . . . 0.0 107.669 -179.73 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_endo -76.58 37.78 0.58 Allowed 'Trans proline' 0 N--CA 1.498 1.763 1 C-N-CA 125.762 4.308 . . . . 0.0 112.124 -171.136 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 7.4 mtp180 -111.9 81.72 3.69 Favored Pre-proline 0 N--CA 1.491 1.579 0 CA-C-N 115.018 -0.992 . . . . 0.0 110.356 -179.718 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -68.07 154.2 73.14 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.438 2.759 . . . . 0.0 109.187 179.589 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 80.7 mtt180 48.09 15.05 0.06 Allowed 'General case' 0 N--CA 1.501 2.092 0 N-CA-C 114.488 1.292 . . . . 0.0 114.488 -179.744 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -91.59 32.54 5.24 Favored Glycine 0 N--CA 1.498 2.8 0 CA-C-N 114.812 -1.085 . . . . 0.0 111.634 -179.823 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 9.9 t-20 41.55 33.3 0.29 Allowed 'General case' 0 N--CA 1.509 2.485 0 N-CA-C 112.75 0.648 . . . . 0.0 112.75 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 9.1 t -89.71 157.02 18.16 Favored 'General case' 0 N--CA 1.498 1.954 0 C-N-CA 119.36 -0.936 . . . . 0.0 108.955 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 85.5 mt -144.91 49.3 1.29 Allowed 'General case' 0 N--CA 1.501 2.116 0 CA-C-O 122.008 0.908 . . . . 0.0 112.512 -179.503 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 41.4 t -88.69 56.6 3.82 Favored 'General case' 0 N--CA 1.5 2.041 0 C-N-CA 118.106 -1.438 . . . . 0.0 110.468 -179.503 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.433 ' HA2' ' HD3' ' A' ' 48' ' ' LYS . . . -170.99 119.23 0.79 Allowed Glycine 0 N--CA 1.499 2.843 0 CA-C-O 117.979 -1.456 . . . . 0.0 112.32 179.911 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.426 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 37.6 mm -102.71 131.13 51.56 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.312 0 N-CA-C 103.429 -2.804 . . . . 0.0 103.429 179.308 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.599 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 2.1 pp -64.45 158.75 23.05 Favored 'General case' 0 N--CA 1.496 1.85 0 C-N-CA 118.189 -1.404 . . . . 0.0 107.811 179.785 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.48 ' N ' ' O ' ' A' ' 45' ' ' TRP . 19.4 m95 -138.6 135.51 35.02 Favored 'General case' 0 C--N 1.306 -1.324 0 N-CA-C 115.919 1.822 . . . . 0.0 115.919 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -89.06 41.64 1.04 Allowed 'General case' 0 C--N 1.293 -1.878 0 CA-C-N 109.803 -3.362 . . . . 0.0 115.851 -179.611 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.444 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 1.0 OUTLIER -118.34 126.89 26.92 Favored Pre-proline 0 N--CA 1.487 1.379 0 CA-C-O 122.417 1.104 . . . . 0.0 110.225 179.646 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -64.82 -28.71 59.12 Favored 'Trans proline' 0 C--N 1.299 -2.039 0 C-N-CA 122.096 1.864 . . . . 0.0 108.781 -175.237 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 4.6 p -82.36 5.55 19.94 Favored 'General case' 0 N--CA 1.492 1.653 0 CA-C-N 114.661 -1.154 . . . . 0.0 112.52 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 105.79 -128.81 9.52 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 106.032 -2.827 . . . . 0.0 106.032 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . 0.505 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 4.3 m -83.9 145.55 47.04 Favored Pre-proline 0 C--N 1.302 -1.486 0 C-N-CA 120.595 -0.442 . . . . 0.0 110.301 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.659 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 7.0 Cg_endo -75.01 162.27 37.39 Favored 'Trans proline' 0 C--N 1.312 -1.343 0 C-N-CA 123.317 2.678 . . . . 0.0 113.958 176.769 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 18.8 t -45.66 111.94 0.4 Allowed 'General case' 0 N--CA 1.492 1.636 0 CA-C-N 114.362 -1.29 . . . . 0.0 110.205 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 114.14 -8.64 23.0 Favored Glycine 0 N--CA 1.5 2.963 0 CA-C-N 114.573 -1.194 . . . . 0.0 112.93 179.596 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' TRP . . . . . 0.659 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 50.9 m95 -110.76 161.2 16.01 Favored 'General case' 0 N--CA 1.489 1.498 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . 0.429 ' O ' ' ND1' ' A' ' 34' ' ' HIS . 56.5 t-80 -146.83 46.34 1.18 Allowed 'General case' 0 N--CA 1.499 1.978 0 C-N-CA 117.741 -1.584 . . . . 0.0 113.508 -179.812 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . 0.505 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 21.4 t-20 62.64 145.81 0.02 OUTLIER 'General case' 0 N--CA 1.511 2.6 0 N-CA-C 116.418 2.007 . . . . 0.0 116.418 179.846 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.791 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 0.7 OUTLIER -116.29 -43.0 2.98 Favored 'General case' 0 N--CA 1.485 1.28 0 N-CA-C 106.927 -1.509 . . . . 0.0 106.927 179.482 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . 0.42 ' C ' ' H ' ' A' ' 39' ' ' HIS . 8.8 ptpp? -124.31 127.24 47.33 Favored 'General case' 0 N--CA 1.498 1.94 0 N-CA-C 107.406 -1.331 . . . . 0.0 107.406 179.319 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.445 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -77.8 43.14 0.4 Allowed 'General case' 0 N--CA 1.497 1.909 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 179.869 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . 0.445 ' ND1' ' C ' ' A' ' 38' ' ' ALA . 3.5 m-70 -132.05 -81.35 0.51 Allowed 'General case' 0 N--CA 1.498 1.972 0 CA-C-O 119.084 -0.484 . . . . 0.0 110.748 -179.673 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -153.01 -130.38 1.51 Allowed Glycine 0 N--CA 1.509 3.524 0 N-CA-C 109.297 -1.521 . . . . 0.0 109.297 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 0.2 OUTLIER -81.07 -170.17 8.28 Favored 'Cis proline' 0 N--CA 1.5 1.903 0 CA-C-N 120.25 2.025 . . . . 0.0 111.319 -4.178 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.439 ' C ' ' H ' ' A' ' 44' ' ' GLY . 59.6 t30 -92.62 -13.97 28.84 Favored 'General case' 0 N--CA 1.486 1.365 0 N-CA-C 106.094 -1.817 . . . . 0.0 106.094 -179.798 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 37.3 pt -86.6 26.03 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 CA-C-N 113.591 -1.64 . . . . 0.0 113.382 -179.26 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.439 ' H ' ' C ' ' A' ' 42' ' ' ASN . . . 111.62 119.51 3.84 Favored Glycine 0 N--CA 1.486 2.007 0 CA-C-N 111.602 -2.545 . . . . 0.0 106.875 -179.836 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . 0.48 ' O ' ' N ' ' A' ' 23' ' ' TRP . 20.2 m95 -51.45 133.72 29.44 Favored 'General case' 0 N--CA 1.501 2.095 0 CA-C-N 113.253 -1.473 . . . . 0.0 111.111 -179.432 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' CYS . . . . . 0.791 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 22.8 t -89.26 118.69 29.12 Favored 'General case' 0 C--N 1.305 -1.359 1 N-CA-C 99.746 -4.168 . . . . 0.0 99.746 179.571 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.457 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 86.4 m -126.96 -176.27 3.66 Favored 'General case' 0 CA--C 1.487 -1.443 0 CA-C-N 111.172 -2.74 . . . . 0.0 112.604 -179.357 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.433 ' HD3' ' HA2' ' A' ' 20' ' ' GLY . 34.8 tptt -151.49 157.46 42.33 Favored 'General case' 0 C--N 1.297 -1.697 0 C-N-CA 118.297 -1.361 . . . . 0.0 109.999 -179.821 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 23.8 mttm . . . . . 0 N--CA 1.505 2.298 0 O-C-N 127.039 2.712 . . . . 0.0 110.666 179.646 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.466 0 N-CA-C 108.761 -1.736 . . . . 0.0 108.761 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 38.9 t -131.36 153.66 81.7 Favored Pre-proline 0 N--CA 1.494 1.774 0 N-CA-C 103.962 -2.607 . . . . 0.0 103.962 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.436 ' CB ' ' HA ' ' A' ' 18' ' ' LEU . 18.6 Cg_endo -72.82 138.13 28.26 Favored 'Trans proline' 0 C--N 1.305 -1.761 0 C-N-CA 122.991 2.461 . . . . 0.0 117.568 163.662 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.556 ' SG ' ' SG ' ' A' ' 6' ' ' CYS . 12.5 p -124.56 159.1 31.4 Favored 'General case' 0 N--CA 1.494 1.766 0 CA-C-N 114.818 -1.083 . . . . 0.0 109.46 179.52 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 10.3 tp -79.7 84.03 5.58 Favored 'General case' 0 N--CA 1.491 1.62 1 N-CA-C 99.612 -4.218 . . . . 0.0 99.612 179.465 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.678 ' SG ' ' HA3' ' A' ' 20' ' ' GLY . 34.7 m -68.41 175.07 3.57 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-O 123.391 1.567 . . . . 0.0 111.567 -179.716 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 12.7 t70 -49.16 -55.16 13.28 Favored 'General case' 0 C--N 1.294 -1.809 0 CA-C-N 111.498 -2.592 . . . . 0.0 114.506 -179.202 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 27.2 p -90.25 9.2 29.55 Favored 'General case' 0 N--CA 1.499 2.012 0 C-N-CA 118.23 -1.388 . . . . 0.0 108.541 179.784 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 41.2 t0 -84.81 56.8 4.05 Favored 'General case' 0 N--CA 1.488 1.435 0 N-CA-C 105.791 -1.929 . . . . 0.0 105.791 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -95.62 -146.89 21.74 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 104.967 -3.253 . . . . 0.0 104.967 179.836 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 7.2 Cg_endo -77.47 44.85 1.6 Allowed 'Trans proline' 0 C--N 1.311 -1.409 0 C-N-CA 124.586 3.524 . . . . 0.0 109.711 -178.171 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 46.3 mtp180 -89.76 150.23 43.58 Favored Pre-proline 0 C--N 1.297 -1.713 0 CA-C-N 115.311 -0.859 . . . . 0.0 111.147 179.724 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 80.5 Cg_endo -65.09 109.85 1.4 Allowed 'Trans proline' 0 N--CA 1.492 1.401 0 C-N-CA 123.656 2.904 . . . . 0.0 109.747 -178.944 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 9.1 mtp-105 71.99 134.11 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.481 0 O-C-N 125.532 1.77 . . . . 0.0 107.731 -179.81 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 114.59 -24.67 10.96 Favored Glycine 0 N--CA 1.502 3.075 0 C-N-CA 120.267 -0.968 . . . . 0.0 110.853 -179.827 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 29.3 m-80 -40.18 -31.5 0.13 Allowed 'General case' 0 N--CA 1.516 2.874 0 N-CA-C 113.851 1.056 . . . . 0.0 113.851 179.805 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -131.34 27.63 4.75 Favored 'General case' 0 N--CA 1.495 1.791 0 CA-C-N 115.166 -0.925 . . . . 0.0 109.678 -179.796 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.436 ' HA ' ' CB ' ' A' ' 3' ' ' PRO . 0.6 OUTLIER -178.7 39.94 0.0 OUTLIER 'General case' 0 N--CA 1.508 2.466 0 N-CA-C 114.517 1.302 . . . . 0.0 114.517 -179.643 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 12.4 t -89.26 -1.7 58.18 Favored 'General case' 0 N--CA 1.504 2.274 0 C-N-CA 118.956 -1.098 . . . . 0.0 112.734 -179.895 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.678 ' HA3' ' SG ' ' A' ' 6' ' ' CYS . . . -162.66 139.09 5.71 Favored Glycine 0 N--CA 1.493 2.467 0 CA-C-O 118.29 -1.283 . . . . 0.0 110.553 -179.785 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.438 ' N ' ' O ' ' A' ' 47' ' ' CYS . 32.7 mm -102.57 140.69 20.3 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.102 0 N-CA-C 104.268 -2.493 . . . . 0.0 104.268 179.571 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.487 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.6 pp -63.87 146.08 54.65 Favored 'General case' 0 N--CA 1.504 2.238 0 C-N-CA 117.407 -1.717 . . . . 0.0 112.154 179.727 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 40.6 m95 -130.82 131.88 44.9 Favored 'General case' 0 N--CA 1.486 1.327 0 N-CA-C 119.404 3.113 . . . . 0.0 119.404 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -89.39 51.32 2.09 Favored 'General case' 0 C--N 1.301 -1.512 1 CA-C-N 107.895 -4.229 . . . . 0.0 111.334 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.507 ' CE1' ' HB3' ' A' ' 30' ' ' PRO . 2.2 m-85 -125.99 126.37 24.81 Favored Pre-proline 0 N--CA 1.488 1.448 0 CA-C-O 121.588 0.708 . . . . 0.0 111.898 179.834 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -64.13 -19.99 66.79 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 C-N-CA 123.764 2.976 . . . . 0.0 110.286 -178.12 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 10.4 p -88.04 -6.69 57.82 Favored 'General case' 0 N--CA 1.491 1.587 0 CA-C-N 114.004 -1.453 . . . . 0.0 110.933 179.753 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.604 ' HA2' ' CD1' ' A' ' 45' ' ' TRP . . . 114.81 -95.3 0.71 Allowed Glycine 0 N--CA 1.483 1.776 1 N-CA-C 100.932 -4.867 . . . . 0.0 100.932 -179.531 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . 0.484 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 7.8 m -101.17 164.37 16.15 Favored Pre-proline 0 C--N 1.302 -1.459 0 CA-C-N 114.006 -1.097 . . . . 0.0 108.676 179.768 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.686 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.3 OUTLIER -83.83 167.1 13.05 Favored 'Trans proline' 0 C--N 1.311 -1.412 0 C-N-CA 124.917 3.745 . . . . 0.0 116.177 158.24 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 29.1 t -55.86 126.33 25.22 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-N 113.427 -1.715 . . . . 0.0 109.62 -179.843 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 104.58 -7.12 45.8 Favored Glycine 0 N--CA 1.495 2.628 0 CA-C-N 112.664 -2.062 . . . . 0.0 111.46 179.893 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' TRP . . . . . 0.686 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 49.7 m95 -113.4 152.96 29.36 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 106.335 -1.728 . . . . 0.0 106.335 -179.872 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 64.7 t60 -140.42 44.5 1.86 Allowed 'General case' 0 N--CA 1.493 1.717 0 C-N-CA 119.419 -0.913 . . . . 0.0 109.51 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . 0.579 ' HA ' ' SG ' ' A' ' 47' ' ' CYS . 23.2 t-20 54.74 147.86 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.171 0 CA-C-N 112.951 -1.932 . . . . 0.0 115.428 -179.985 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.676 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 0.8 OUTLIER -119.76 -36.27 3.34 Favored 'General case' 0 C--N 1.309 -1.184 0 N-CA-C 106.632 -1.618 . . . . 0.0 106.632 179.825 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 19.5 ttpt -139.02 122.4 17.16 Favored 'General case' 0 N--CA 1.486 1.336 0 CA-C-O 123.589 1.661 . . . . 0.0 109.98 179.668 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.43 ' O ' ' ND1' ' A' ' 39' ' ' HIS . . . -96.0 21.18 9.03 Favored 'General case' 0 C--N 1.303 -1.419 0 CA-C-N 112.273 -2.239 . . . . 0.0 105.541 179.72 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . 0.43 ' ND1' ' O ' ' A' ' 38' ' ' ALA . 10.7 m-70 -135.72 69.46 1.43 Allowed 'General case' 0 N--CA 1.497 1.895 0 N-CA-C 109.372 -0.603 . . . . 0.0 109.372 -179.719 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 84.08 176.47 51.17 Favored Glycine 0 N--CA 1.502 3.036 0 N-CA-C 106.165 -2.774 . . . . 0.0 106.165 -179.739 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_endo -60.96 169.8 19.37 Favored 'Cis proline' 0 N--CA 1.504 2.089 0 CA-C-N 119.771 1.786 . . . . 0.0 114.434 1.664 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 17.0 t-20 -92.45 -9.08 42.81 Favored 'General case' 0 N--CA 1.484 1.232 0 N-CA-C 104.773 -2.306 . . . . 0.0 104.773 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 17.6 mt -92.7 29.72 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.063 0 CA-C-O 123.059 1.409 . . . . 0.0 109.819 -179.29 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.465 ' C ' ' CD1' ' A' ' 45' ' ' TRP . . . 129.53 -116.58 2.17 Favored Glycine 0 N--CA 1.484 1.84 0 N-CA-C 103.744 -3.742 . . . . 0.0 103.744 -179.772 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . 0.604 ' CD1' ' HA2' ' A' ' 28' ' ' GLY . 3.0 m95 -155.26 -172.07 4.04 Favored 'General case' 0 N--CA 1.507 2.422 0 N-CA-C 104.254 -2.498 . . . . 0.0 104.254 179.853 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' CYS . . . . . 0.676 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 26.2 t -135.75 126.84 27.96 Favored 'General case' 0 N--CA 1.498 1.958 1 N-CA-C 98.985 -4.45 . . . . 0.0 98.985 179.493 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.579 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 70.9 m -131.47 -179.68 5.51 Favored 'General case' 0 CA--C 1.471 -2.061 0 N-CA-C 116.24 1.941 . . . . 0.0 116.24 -178.663 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.518 ' HD2' ' H ' ' A' ' 49' ' ' LYS . 44.1 tptt -151.04 149.21 29.28 Favored 'General case' 0 C--N 1.297 -1.693 0 C-N-CA 118.716 -1.194 . . . . 0.0 110.672 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . 0.518 ' H ' ' HD2' ' A' ' 48' ' ' LYS . 93.4 mttt . . . . . 0 N--CA 1.494 1.774 0 CA-C-N 112.133 -2.303 . . . . 0.0 108.59 179.317 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.495 2.576 0 N-CA-C 109.093 -1.603 . . . . 0.0 109.093 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 21.4 t -97.22 147.28 32.72 Favored Pre-proline 0 N--CA 1.497 1.919 0 N-CA-C 106.694 -1.595 . . . . 0.0 106.694 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.423 ' HA ' ' HA ' ' A' ' 21' ' ' ILE . 6.9 Cg_endo -77.84 149.76 26.49 Favored 'Trans proline' 0 C--N 1.309 -1.532 0 C-N-CA 122.536 2.157 . . . . 0.0 110.314 169.521 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -138.95 169.43 17.81 Favored 'General case' 0 C--N 1.3 -1.557 0 CA-C-O 121.862 0.839 . . . . 0.0 110.142 179.836 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 8.5 tt -91.88 150.52 21.0 Favored 'General case' 0 N--CA 1.492 1.655 0 N-CA-C 102.229 -3.248 . . . . 0.0 102.229 179.647 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.443 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 3.1 m -139.78 -166.46 2.08 Favored 'General case' 0 N--CA 1.493 1.72 0 N-CA-C 113.973 1.101 . . . . 0.0 113.973 -179.519 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . 0.445 ' H ' ' HB3' ' A' ' 37' ' ' LYS . 30.1 t70 -81.19 -59.8 2.52 Favored 'General case' 0 N--CA 1.496 1.86 0 CA-C-N 112.612 -2.085 . . . . 0.0 108.091 -179.754 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 15.2 m -76.51 -13.26 60.1 Favored 'General case' 0 N--CA 1.499 2.002 0 CA-C-N 114.56 -1.2 . . . . 0.0 109.605 179.636 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.437 ' HB2' ' CB ' ' A' ' 6' ' ' CYS . 28.7 t70 -65.42 -15.5 62.67 Favored 'General case' 0 N--CA 1.492 1.63 0 CA-C-N 113.655 -1.611 . . . . 0.0 115.18 -179.743 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.457 ' C ' ' H ' ' A' ' 12' ' ' ARG . . . -163.29 70.79 0.21 Allowed Glycine 0 N--CA 1.5 2.957 0 C-N-CA 118.87 -1.633 . . . . 0.0 113.559 -179.659 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_endo -72.43 27.52 0.27 Allowed 'Trans proline' 0 N--CA 1.498 1.784 0 C-N-CA 123.791 2.994 . . . . 0.0 112.276 173.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . 0.457 ' H ' ' C ' ' A' ' 10' ' ' GLY . 19.8 mtp180 -145.36 135.07 11.56 Favored Pre-proline 0 N--CA 1.494 1.77 0 N-CA-C 107.658 -1.238 . . . . 0.0 107.658 -179.841 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 23.2 Cg_endo -73.28 145.04 38.01 Favored 'Trans proline' 0 N--CA 1.49 1.317 0 C-N-CA 123.811 3.007 . . . . 0.0 110.075 -178.773 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 72.8 mtp180 54.11 20.39 2.5 Favored 'General case' 0 N--CA 1.498 1.95 0 CA-C-O 121.994 0.902 . . . . 0.0 111.274 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -70.5 -24.21 76.98 Favored Glycine 0 N--CA 1.493 2.498 0 CA-C-N 114.085 -1.416 . . . . 0.0 112.425 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 38.9 m-80 50.41 41.33 24.73 Favored 'General case' 0 N--CA 1.505 2.283 0 CA-C-O 122.15 0.976 . . . . 0.0 111.072 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.3 p -88.97 148.21 23.9 Favored 'General case' 0 C--N 1.301 -1.535 0 CA-C-N 115.47 -0.786 . . . . 0.0 108.987 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 2.0 tt -161.51 91.95 0.86 Allowed 'General case' 0 N--CA 1.499 1.999 0 N-CA-C 106.741 -1.577 . . . . 0.0 106.741 -179.564 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 64.0 p -128.26 31.55 5.02 Favored 'General case' 0 N--CA 1.499 1.984 0 N-CA-C 112.904 0.705 . . . . 0.0 112.904 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -135.45 156.49 22.72 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 108.791 -1.724 . . . . 0.0 108.791 -179.906 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.43 ' N ' ' O ' ' A' ' 47' ' ' CYS . 44.5 mm -115.56 144.93 22.03 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 N-CA-C 106.098 -1.816 . . . . 0.0 106.098 179.708 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.521 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 4.1 pp -72.69 151.0 42.45 Favored 'General case' 0 N--CA 1.488 1.464 0 C-N-CA 118.438 -1.305 . . . . 0.0 109.041 179.752 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 44.1 m95 -132.31 134.21 44.96 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 117.721 2.489 . . . . 0.0 117.721 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.3 m-85 -89.2 53.13 2.56 Favored 'General case' 0 C--N 1.296 -1.744 1 CA-C-N 107.623 -4.353 . . . . 0.0 109.43 -179.791 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.429 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 2.4 m-85 -126.58 139.2 34.13 Favored Pre-proline 0 C--N 1.306 -1.294 0 CA-C-O 121.671 0.748 . . . . 0.0 111.964 -179.962 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.68 -18.01 37.63 Favored 'Trans proline' 0 C--N 1.305 -1.734 1 C-N-CA 125.415 4.077 . . . . 0.0 110.6 177.161 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 10.7 p -100.26 22.65 11.19 Favored 'General case' 0 C--N 1.299 -1.613 0 CA-C-N 113.334 -1.757 . . . . 0.0 110.886 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.572 ' HA2' ' CD1' ' A' ' 45' ' ' TRP . . . 81.4 -89.98 1.41 Allowed Glycine 0 N--CA 1.484 1.838 1 N-CA-C 102.854 -4.098 . . . . 0.0 102.854 -179.674 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . 0.462 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 24.8 m -98.7 163.57 18.67 Favored Pre-proline 0 C--N 1.302 -1.457 0 CA-C-N 113.719 -1.24 . . . . 0.0 110.996 -179.887 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.66 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.1 OUTLIER -89.05 163.76 5.83 Favored 'Trans proline' 0 CA--C 1.554 1.496 1 C-N-CA 126.701 4.934 . . . . 0.0 117.122 155.785 . . . . . . . . 4 4 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 4.1 m -51.06 111.82 0.62 Allowed 'General case' 0 C--N 1.301 -1.526 0 CA-C-N 112.36 -2.2 . . . . 0.0 114.135 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 113.7 -6.54 24.22 Favored Glycine 0 N--CA 1.506 3.352 0 CA-C-N 115.046 -0.979 . . . . 0.0 112.638 179.68 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' TRP . . . . . 0.66 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 54.7 m95 -106.96 167.17 10.07 Favored 'General case' 0 C--N 1.299 -1.619 0 N-CA-C 106.517 -1.661 . . . . 0.0 106.517 -179.762 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 67.8 t60 -146.96 37.7 0.97 Allowed 'General case' 0 N--CA 1.493 1.69 0 C-N-CA 116.845 -1.942 . . . . 0.0 113.236 179.82 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . 0.518 ' HA ' ' SG ' ' A' ' 47' ' ' CYS . 13.9 t-20 55.88 143.04 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.113 0 N-CA-C 117.484 2.401 . . . . 0.0 117.484 179.556 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.842 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 2.7 p -120.3 -28.37 5.05 Favored 'General case' 0 N--CA 1.486 1.329 0 CA-C-N 115.652 -0.703 . . . . 0.0 111.345 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . 0.445 ' HB3' ' H ' ' A' ' 7' ' ' ASP . 9.5 ptpt -151.05 151.15 31.61 Favored 'General case' 0 N--CA 1.495 1.792 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 179.105 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.449 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -117.0 35.06 4.8 Favored 'General case' 0 N--CA 1.491 1.607 0 N-CA-C 102.388 -3.19 . . . . 0.0 102.388 179.661 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . 0.449 ' ND1' ' C ' ' A' ' 38' ' ' ALA . 4.5 m-70 -128.64 60.31 1.52 Allowed 'General case' 0 N--CA 1.497 1.881 0 N-CA-C 106.943 -1.503 . . . . 0.0 106.943 -179.534 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 74.19 -149.45 40.81 Favored Glycine 0 N--CA 1.496 2.646 0 N-CA-C 104.854 -3.298 . . . . 0.0 104.854 -179.702 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_endo -48.53 176.6 0.39 Allowed 'Cis proline' 0 N--CA 1.504 2.104 0 CA-C-N 119.765 1.783 . . . . 0.0 115.478 -5.499 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.5 m-20 -92.08 -7.77 47.72 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 104.34 -2.467 . . . . 0.0 104.34 -179.719 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 15.0 mt -99.53 22.29 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.85 0 CA-C-O 123.99 1.853 . . . . 0.0 113.006 -179.345 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 133.08 -119.87 2.48 Favored Glycine 0 C--N 1.288 -2.094 0 N-CA-C 104.195 -3.562 . . . . 0.0 104.195 -179.857 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . 0.572 ' CD1' ' HA2' ' A' ' 28' ' ' GLY . 3.9 m95 -152.56 -169.22 3.28 Favored 'General case' 0 N--CA 1.511 2.588 0 N-CA-C 106.923 -1.51 . . . . 0.0 106.923 -179.917 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' CYS . . . . . 0.842 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 43.8 t -139.17 129.4 25.39 Favored 'General case' 0 C--N 1.313 -0.982 0 N-CA-C 101.273 -3.603 . . . . 0.0 101.273 179.13 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.518 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 71.4 m -135.0 -172.13 2.97 Favored 'General case' 0 C--N 1.294 -1.805 0 CA-C-N 111.295 -2.684 . . . . 0.0 108.479 -179.435 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.406 ' N ' ' CD ' ' A' ' 48' ' ' LYS . 0.0 OUTLIER -150.55 173.5 14.03 Favored 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 107.125 -1.435 . . . . 0.0 107.125 179.352 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.499 1.993 0 O-C-N 125.803 1.939 . . . . 0.0 106.681 179.728 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 2.725 0 N-CA-C 108.914 -1.674 . . . . 0.0 108.914 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 22.0 t -94.74 146.13 30.85 Favored Pre-proline 0 N--CA 1.497 1.893 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -72.28 149.65 51.58 Favored 'Trans proline' 0 N--CA 1.494 1.506 0 C-N-CA 124.161 3.24 . . . . 0.0 112.716 167.625 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.577 ' SG ' ' HB3' ' A' ' 22' ' ' LEU . 0.1 OUTLIER -136.88 -176.89 4.51 Favored 'General case' 0 N--CA 1.496 1.844 0 CA-C-N 115.349 -0.842 . . . . 0.0 111.438 179.631 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 6.4 tt -91.15 110.93 22.21 Favored 'General case' 0 N--CA 1.491 1.587 0 C-N-CA 119.428 -0.909 . . . . 0.0 108.829 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.441 ' SG ' ' HA3' ' A' ' 20' ' ' GLY . 7.7 m -88.13 178.42 6.64 Favored 'General case' 0 C--N 1.31 -1.123 0 CA-C-O 123.282 1.515 . . . . 0.0 113.827 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . 0.401 ' C ' ' H ' ' A' ' 9' ' ' ASP . 9.4 t70 -55.36 -65.73 0.54 Allowed 'General case' 0 C--N 1.297 -1.712 0 CA-C-N 111.501 -2.59 . . . . 0.0 110.123 -179.84 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 65.1 m -80.69 26.55 0.4 Allowed 'General case' 0 N--CA 1.498 1.947 0 C-N-CA 118.971 -1.092 . . . . 0.0 109.381 179.804 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.401 ' H ' ' C ' ' A' ' 7' ' ' ASP . 38.8 t70 -94.79 -3.0 49.84 Favored 'General case' 0 N--CA 1.495 1.819 0 C-N-CA 119.341 -0.943 . . . . 0.0 113.536 -179.554 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -39.52 -55.41 2.61 Favored Glycine 0 N--CA 1.506 3.336 0 N-CA-C 115.049 0.78 . . . . 0.0 115.049 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_endo -75.34 11.0 1.64 Allowed 'Trans proline' 0 N--CA 1.5 1.872 0 C-N-CA 123.501 2.801 . . . . 0.0 113.903 179.721 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 51.9 mtt85 -135.93 70.68 63.82 Favored Pre-proline 0 N--CA 1.492 1.67 0 CA-C-N 114.635 -1.166 . . . . 0.0 112.133 -179.768 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_endo -74.78 -147.78 0.03 OUTLIER 'Trans proline' 0 N--CA 1.493 1.471 0 C-N-CA 124.785 3.656 . . . . 0.0 111.495 178.915 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 6.3 ptp180 -62.66 -161.1 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.044 0 CA-C-N 115.7 -0.682 . . . . 0.0 112.016 -179.886 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 86.16 31.52 19.71 Favored Glycine 0 N--CA 1.5 2.943 0 C-N-CA 120.0 -1.095 . . . . 0.0 111.213 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 1.7 t30 61.89 52.23 3.49 Favored 'General case' 0 N--CA 1.506 2.348 0 CA-C-O 122.788 1.28 . . . . 0.0 109.663 179.913 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 23.3 m -98.86 121.75 41.22 Favored 'General case' 0 N--CA 1.495 1.811 0 CA-C-N 114.074 -1.421 . . . . 0.0 110.528 -179.897 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 7.4 mp -117.95 85.87 2.42 Favored 'General case' 0 N--CA 1.504 2.244 0 CA-C-O 122.36 1.076 . . . . 0.0 111.191 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 8.9 t -90.11 -29.12 18.52 Favored 'General case' 0 N--CA 1.501 2.112 0 CA-C-N 113.374 -1.739 . . . . 0.0 111.077 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.441 ' HA3' ' SG ' ' A' ' 6' ' ' CYS . . . -154.4 141.33 8.13 Favored Glycine 0 N--CA 1.496 2.634 0 N-CA-C 110.349 -1.1 . . . . 0.0 110.349 179.987 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.405 ' N ' ' O ' ' A' ' 47' ' ' CYS . 40.8 mm -99.64 138.89 22.61 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.452 0 N-CA-C 107.122 -1.436 . . . . 0.0 107.122 179.767 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.577 ' HB3' ' SG ' ' A' ' 4' ' ' CYS . 1.3 pp -68.97 146.93 52.33 Favored 'General case' 0 N--CA 1.495 1.8 0 C-N-CA 118.925 -1.11 . . . . 0.0 109.155 179.889 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 29.9 m95 -129.06 135.03 48.37 Favored 'General case' 0 C--N 1.307 -1.246 0 N-CA-C 117.882 2.549 . . . . 0.0 117.882 -179.786 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -89.38 49.25 1.72 Allowed 'General case' 0 C--N 1.298 -1.635 1 CA-C-N 108.047 -4.16 . . . . 0.0 113.163 -179.791 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.403 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 2.0 m-85 -122.08 139.3 30.19 Favored Pre-proline 0 C--N 1.301 -1.542 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 179.573 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 13.9 Cg_endo -76.29 -26.3 9.07 Favored 'Trans proline' 0 C--N 1.303 -1.86 0 C-N-CA 125.255 3.97 . . . . 0.0 112.841 174.42 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -88.66 11.94 16.11 Favored 'General case' 0 N--CA 1.494 1.748 0 CA-C-N 114.876 -1.056 . . . . 0.0 113.224 -179.831 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 97.91 -127.2 9.14 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 103.755 -3.738 . . . . 0.0 103.755 -179.722 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . 0.54 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 8.3 m -85.38 147.04 46.04 Favored Pre-proline 0 C--N 1.303 -1.444 0 CA-C-N 117.716 0.758 . . . . 0.0 110.776 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.665 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 8.5 Cg_endo -75.19 168.28 25.05 Favored 'Trans proline' 0 C--N 1.308 -1.602 0 C-N-CA 123.037 2.491 . . . . 0.0 113.795 176.006 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 2.9 m -45.45 101.45 0.02 OUTLIER 'General case' 0 C--N 1.297 -1.68 0 CA-C-N 112.642 -2.072 . . . . 0.0 113.423 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 116.0 -2.11 21.12 Favored Glycine 0 N--CA 1.507 3.427 0 C-N-CA 120.945 -0.645 . . . . 0.0 114.057 179.63 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' TRP . . . . . 0.665 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 55.4 m95 -111.13 158.29 19.05 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 106.46 -1.682 . . . . 0.0 106.46 -179.851 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 2.0 t-80 -138.54 34.08 2.25 Favored 'General case' 0 N--CA 1.492 1.667 0 C-N-CA 117.615 -1.634 . . . . 0.0 112.507 -179.739 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . 0.54 ' HA ' ' SG ' ' A' ' 29' ' ' CYS . 0.3 OUTLIER 66.4 138.21 0.03 OUTLIER 'General case' 0 N--CA 1.509 2.498 0 N-CA-C 116.566 2.061 . . . . 0.0 116.566 179.734 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.683 ' SG ' ' CB ' ' A' ' 46' ' ' CYS . 0.8 OUTLIER -114.34 -33.37 5.65 Favored 'General case' 0 N--CA 1.484 1.243 0 N-CA-C 104.541 -2.392 . . . . 0.0 104.541 179.485 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 20.7 ptmt -146.4 139.95 25.97 Favored 'General case' 0 N--CA 1.494 1.764 0 CA-C-N 115.481 -0.781 . . . . 0.0 110.069 179.503 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.449 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -112.17 34.81 4.05 Favored 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 103.898 -2.63 . . . . 0.0 103.898 179.833 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . 0.449 ' ND1' ' C ' ' A' ' 38' ' ' ALA . 4.1 m-70 -129.12 57.28 1.65 Allowed 'General case' 0 N--CA 1.499 1.981 0 N-CA-C 107.611 -1.255 . . . . 0.0 107.611 -179.735 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 72.75 -142.04 31.56 Favored Glycine 0 N--CA 1.496 2.695 0 N-CA-C 106.739 -2.544 . . . . 0.0 106.739 -179.656 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . 0.443 ' HG2' ' O ' ' A' ' 44' ' ' GLY . 94.3 Cg_endo -62.34 -169.19 1.42 Allowed 'Cis proline' 0 N--CA 1.496 1.621 0 CA-C-N 118.804 1.302 . . . . 0.0 112.876 -5.065 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 54.2 t30 -93.66 1.53 56.58 Favored 'General case' 0 C--N 1.308 -1.217 0 N-CA-C 105.045 -2.206 . . . . 0.0 105.045 -179.334 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 1.1 mp -120.28 37.46 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 O-C-N 125.126 1.516 . . . . 0.0 114.843 -179.008 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.443 ' O ' ' HG2' ' A' ' 41' ' ' PRO . . . 119.59 149.99 8.56 Favored Glycine 0 N--CA 1.485 1.963 0 N-CA-C 106.85 -2.5 . . . . 0.0 106.85 179.932 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . 0.403 ' NE1' ' O ' ' A' ' 25' ' ' TYR . 5.1 m95 -89.38 136.42 33.04 Favored 'General case' 0 N--CA 1.506 2.326 0 CA-C-O 117.175 -1.393 . . . . 0.0 108.329 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' CYS . . . . . 0.683 ' CB ' ' SG ' ' A' ' 36' ' ' CYS . 59.1 m -88.77 127.34 35.6 Favored 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 101.957 -3.349 . . . . 0.0 101.957 179.527 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.554 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 79.7 m -129.81 -174.95 3.45 Favored 'General case' 0 C--N 1.299 -1.601 0 CA-C-N 110.959 -2.837 . . . . 0.0 113.817 -179.243 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.494 ' HD2' ' H ' ' A' ' 49' ' ' LYS . 25.7 tptp -151.6 150.68 30.57 Favored 'General case' 0 C--N 1.295 -1.781 0 C-N-CA 118.57 -1.252 . . . . 0.0 110.26 -179.907 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . 0.494 ' H ' ' HD2' ' A' ' 48' ' ' LYS . 6.0 mtpt . . . . . 0 N--CA 1.499 2.015 0 O-C-N 126.407 2.317 . . . . 0.0 108.422 179.448 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 2.673 0 N-CA-C 108.968 -1.653 . . . . 0.0 108.968 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 40.0 t -98.23 140.86 22.15 Favored Pre-proline 0 N--CA 1.496 1.861 0 N-CA-C 106.863 -1.532 . . . . 0.0 106.863 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -70.66 148.61 59.61 Favored 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 123.533 2.822 . . . . 0.0 111.718 172.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.511 ' SG ' ' HB3' ' A' ' 22' ' ' LEU . 0.8 OUTLIER -146.32 163.3 35.96 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 124.24 0.962 . . . . 0.0 109.724 179.779 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 8.9 tt -79.41 150.68 31.25 Favored 'General case' 0 N--CA 1.488 1.446 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.548 ' SG ' ' HB2' ' A' ' 9' ' ' ASP . 2.5 m -137.83 -145.19 0.19 Allowed 'General case' 0 N--CA 1.491 1.607 0 N-CA-C 116.316 1.969 . . . . 0.0 116.316 -179.663 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -106.15 -59.02 1.84 Allowed 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 105.941 -1.874 . . . . 0.0 105.941 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 2.7 m -90.97 12.57 19.22 Favored 'General case' 0 N--CA 1.497 1.917 0 CA-C-N 114.164 -1.38 . . . . 0.0 108.508 179.668 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.548 ' HB2' ' SG ' ' A' ' 6' ' ' CYS . 5.0 t0 -66.21 72.24 0.07 Allowed 'General case' 0 N--CA 1.487 1.39 0 CA-C-N 115.013 -0.994 . . . . 0.0 111.49 -179.91 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 120.88 80.9 0.61 Allowed Glycine 0 N--CA 1.495 2.589 0 C-N-CA 120.242 -0.98 . . . . 0.0 112.979 179.827 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 7.4 Cg_endo -74.99 35.99 0.43 Allowed 'Trans proline' 0 N--CA 1.503 2.031 1 C-N-CA 125.336 4.024 . . . . 0.0 112.528 177.999 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 76.3 mtt85 -144.11 168.32 12.88 Favored Pre-proline 0 N--CA 1.49 1.567 0 N-CA-C 107.525 -1.287 . . . . 0.0 107.525 -179.87 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 16.4 Cg_endo -72.58 -170.53 0.6 Allowed 'Trans proline' 0 N--CA 1.493 1.456 0 C-N-CA 123.666 2.911 . . . . 0.0 113.188 169.633 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 16.0 ptt85 -16.62 109.99 0.02 OUTLIER 'General case' 0 N--CA 1.502 2.125 0 N-CA-C 117.433 2.383 . . . . 0.0 117.433 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 119.81 -21.6 8.95 Favored Glycine 0 N--CA 1.505 3.24 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 15.9 p-10 -61.34 72.46 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.466 0 CA-C-O 122.996 1.379 . . . . 0.0 111.408 -179.922 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 7.5 p -138.76 169.69 17.33 Favored 'General case' 0 C--N 1.295 -1.774 0 N-CA-C 106.02 -1.844 . . . . 0.0 106.02 179.605 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 20.2 tp 49.45 56.82 7.25 Favored 'General case' 0 N--CA 1.509 2.495 0 CA-C-O 123.142 1.449 . . . . 0.0 110.224 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 7.3 t -121.25 43.43 2.81 Favored 'General case' 0 N--CA 1.498 1.953 0 CA-C-N 113.993 -1.458 . . . . 0.0 107.138 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 170.42 154.67 9.65 Favored Glycine 0 N--CA 1.493 2.448 0 CA-C-N 114.905 -1.043 . . . . 0.0 113.626 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.434 ' N ' ' O ' ' A' ' 47' ' ' CYS . 40.5 mm -116.82 144.77 23.74 Favored 'Isoleucine or valine' 0 N--CA 1.51 2.56 0 N-CA-C 107.639 -1.245 . . . . 0.0 107.639 179.736 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.57 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.8 pp -68.27 151.62 46.65 Favored 'General case' 0 N--CA 1.501 2.123 0 C-N-CA 117.543 -1.663 . . . . 0.0 107.528 179.447 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 22.1 m95 -131.2 140.33 49.87 Favored 'General case' 0 C--N 1.308 -1.198 0 CA-C-O 124.964 2.316 . . . . 0.0 116.985 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.5 m-30 -89.43 35.18 0.81 Allowed 'General case' 0 C--N 1.297 -1.696 1 CA-C-N 107.868 -4.242 . . . . 0.0 115.23 -179.636 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.438 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 1.2 m-30 -111.02 115.17 53.25 Favored Pre-proline 0 C--N 1.301 -1.506 0 N-CA-C 107.036 -1.468 . . . . 0.0 107.036 179.64 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo -61.27 -19.73 65.13 Favored 'Trans proline' 0 C--N 1.299 -2.031 0 C-N-CA 121.007 1.138 . . . . 0.0 109.524 -175.212 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 1.6 p -91.67 1.81 56.9 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 124.396 1.06 . . . . 0.0 112.574 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 121.03 -130.99 8.46 Favored Glycine 0 N--CA 1.497 2.739 0 N-CA-C 108.207 -1.957 . . . . 0.0 108.207 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . 0.617 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 8.4 m -93.36 150.28 38.73 Favored Pre-proline 0 C--N 1.303 -1.441 0 CA-C-N 117.382 0.591 . . . . 0.0 109.868 -179.938 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.678 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.7 OUTLIER -76.13 162.1 34.63 Favored 'Trans proline' 0 C--N 1.309 -1.545 0 C-N-CA 122.515 2.143 . . . . 0.0 113.206 176.079 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 26.4 t -46.14 110.44 0.27 Allowed 'General case' 0 N--CA 1.493 1.692 0 CA-C-N 113.12 -1.855 . . . . 0.0 111.013 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 113.95 -5.57 23.92 Favored Glycine 0 N--CA 1.5 2.936 0 CA-C-N 114.405 -1.27 . . . . 0.0 111.678 179.772 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' TRP . . . . . 0.678 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 35.4 m95 -117.5 152.59 34.74 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 106.992 -1.484 . . . . 0.0 106.992 -179.827 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 55.4 t60 -143.04 42.26 1.54 Allowed 'General case' 0 N--CA 1.496 1.872 0 C-N-CA 117.389 -1.725 . . . . 0.0 112.436 179.866 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . 0.617 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 27.5 t-20 60.63 149.98 0.02 OUTLIER 'General case' 0 N--CA 1.506 2.347 0 N-CA-C 117.947 2.573 . . . . 0.0 117.947 179.742 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.696 ' SG ' ' CB ' ' A' ' 46' ' ' CYS . 13.9 p -115.82 -16.41 11.19 Favored 'General case' 0 N--CA 1.485 1.3 0 CA-C-N 114.352 -1.295 . . . . 0.0 110.983 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . 0.488 ' C ' ' H ' ' A' ' 39' ' ' HIS . 15.3 ptmt -144.7 127.04 15.83 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.953 -0.467 . . . . 0.0 111.83 -179.967 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.451 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -80.98 44.29 0.75 Allowed 'General case' 0 N--CA 1.493 1.677 0 N-CA-C 106.606 -1.627 . . . . 0.0 106.606 179.618 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . 0.488 ' H ' ' C ' ' A' ' 37' ' ' LYS . 2.9 m-70 -131.24 -116.6 0.23 Allowed 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 101.53 -3.508 . . . . 0.0 101.53 -179.845 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -126.68 -113.11 1.82 Allowed Glycine 0 N--CA 1.506 3.311 0 N-CA-C 110.782 -0.927 . . . . 0.0 110.782 179.785 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 83.1 Cg_endo -65.7 -164.77 1.43 Allowed 'Cis proline' 0 N--CA 1.503 2.08 0 N-CA-C 116.316 1.622 . . . . 0.0 116.316 -4.057 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -93.03 -13.91 28.05 Favored 'General case' 0 N--CA 1.486 1.356 0 N-CA-C 106.233 -1.766 . . . . 0.0 106.233 -179.298 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 27.1 pt -103.52 28.76 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.148 0 O-C-N 125.913 2.008 . . . . 0.0 116.234 -179.135 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 129.05 168.36 12.35 Favored Glycine 0 C--N 1.292 -1.892 1 N-CA-C 102.149 -4.38 . . . . 0.0 102.149 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . 0.438 ' NE1' ' O ' ' A' ' 25' ' ' TYR . 26.2 m95 -102.9 137.3 41.28 Favored 'General case' 0 C--N 1.281 -2.396 0 N-CA-C 105.259 -2.126 . . . . 0.0 105.259 179.883 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' CYS . . . . . 0.696 ' CB ' ' SG ' ' A' ' 36' ' ' CYS . 98.9 m -90.11 130.12 36.32 Favored 'General case' 0 N--CA 1.478 0.966 1 N-CA-C 100.116 -4.031 . . . . 0.0 100.116 179.509 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.434 ' O ' ' N ' ' A' ' 21' ' ' ILE . 82.1 m -132.92 -170.88 2.54 Favored 'General case' 0 C--N 1.296 -1.754 0 CA-C-N 111.736 -2.483 . . . . 0.0 109.273 -179.305 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.46 ' N ' ' CD ' ' A' ' 48' ' ' LYS . 0.0 OUTLIER -150.55 174.35 13.05 Favored 'General case' 0 C--N 1.295 -1.769 0 O-C-N 124.55 1.156 . . . . 0.0 108.377 179.444 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 29.9 mtpt . . . . . 0 C--N 1.29 -2.006 0 CA-C-O 114.398 -2.715 . . . . 0.0 107.104 179.351 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 2.721 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 22.2 t -99.99 140.44 21.52 Favored Pre-proline 0 N--CA 1.495 1.806 0 N-CA-C 107.149 -1.426 . . . . 0.0 107.149 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.427 ' HA ' ' HA ' ' A' ' 21' ' ' ILE . 37.5 Cg_endo -71.27 164.69 34.89 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 123.838 3.025 . . . . 0.0 112.439 166.603 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.488 ' SG ' ' HB3' ' A' ' 22' ' ' LEU . 0.1 OUTLIER -148.98 -171.0 3.77 Favored 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 107.205 -1.406 . . . . 0.0 107.205 179.508 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 5.2 tt -104.94 147.58 27.63 Favored 'General case' 0 N--CA 1.495 1.786 0 N-CA-C 103.056 -2.942 . . . . 0.0 103.056 179.792 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 3.9 m -122.73 -171.8 2.35 Favored 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 115.056 1.502 . . . . 0.0 115.056 -179.567 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 7.5 t70 -67.45 -76.26 0.09 Allowed 'General case' 0 N--CA 1.49 1.557 0 CA-C-N 112.873 -1.967 . . . . 0.0 108.177 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 50.3 m -85.25 50.34 1.93 Allowed 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 107.648 -1.241 . . . . 0.0 107.648 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 14.9 t0 -102.18 126.0 49.03 Favored 'General case' 0 N--CA 1.489 1.479 0 CA-C-N 114.851 -1.068 . . . . 0.0 112.886 -179.658 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.473 ' H ' ' HD2' ' A' ' 11' ' ' PRO . . . -111.75 -51.28 0.57 Allowed Glycine 0 N--CA 1.503 3.135 0 CA-C-N 112.915 -1.948 . . . . 0.0 112.665 179.655 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.473 ' HD2' ' H ' ' A' ' 10' ' ' GLY . 10.0 Cg_endo -82.54 70.34 6.96 Favored 'Trans proline' 0 N--CA 1.488 1.179 0 C-N-CA 125.289 3.993 . . . . 0.0 103.303 174.537 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 13.1 mtt85 -87.62 156.13 53.31 Favored Pre-proline 0 C--N 1.293 -1.878 0 CA-C-N 110.297 -3.138 . . . . 0.0 111.623 -179.694 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 85.1 Cg_endo -62.47 135.62 54.43 Favored 'Trans proline' 0 N--CA 1.489 1.261 0 C-N-CA 123.744 2.963 . . . . 0.0 109.551 175.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 80.5 mtm180 87.45 109.85 0.04 OUTLIER 'General case' 0 N--CA 1.485 1.297 0 O-C-N 126.123 2.139 . . . . 0.0 106.771 -179.632 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 94.42 -16.87 60.15 Favored Glycine 0 N--CA 1.496 2.684 0 C-N-CA 120.083 -1.056 . . . . 0.0 111.382 -179.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 18.8 t-20 -149.43 -117.97 0.05 Allowed 'General case' 0 N--CA 1.498 1.934 0 C-N-CA 118.749 -1.18 . . . . 0.0 113.114 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.1 m -126.97 -144.73 0.3 Allowed 'General case' 0 N--CA 1.495 1.813 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 -179.362 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -131.23 137.99 49.15 Favored 'General case' 0 N--CA 1.494 1.729 0 N-CA-C 106.715 -1.587 . . . . 0.0 106.715 179.631 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 33.1 t -89.66 -13.66 36.53 Favored 'General case' 0 N--CA 1.494 1.739 0 CA-C-N 115.196 -0.911 . . . . 0.0 112.102 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -176.14 -161.02 24.54 Favored Glycine 0 N--CA 1.498 2.767 0 C-N-CA 119.171 -1.49 . . . . 0.0 112.031 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.427 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 39.3 mm -132.22 148.58 32.03 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.924 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.507 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 2.9 pp -71.41 144.13 49.89 Favored 'General case' 0 N--CA 1.493 1.709 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 179.595 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 44.1 m95 -126.91 133.61 50.63 Favored 'General case' 0 C--N 1.308 -1.196 0 N-CA-C 118.773 2.879 . . . . 0.0 118.773 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -89.44 51.76 2.19 Favored 'General case' 0 C--N 1.299 -1.629 1 CA-C-N 107.138 -4.574 . . . . 0.0 110.612 -179.83 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.437 ' CE1' ' HB3' ' A' ' 30' ' ' PRO . 2.1 m-85 -124.51 142.54 40.71 Favored Pre-proline 0 C--N 1.304 -1.391 0 CA-C-O 122.468 1.128 . . . . 0.0 110.71 179.739 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 74.7 Cg_endo -68.53 -29.94 29.75 Favored 'Trans proline' 0 C--N 1.304 -1.777 0 C-N-CA 125.075 3.85 . . . . 0.0 108.186 177.936 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 5.1 p -90.36 24.4 2.59 Favored 'General case' 0 C--N 1.301 -1.542 0 CA-C-N 113.726 -1.579 . . . . 0.0 109.269 179.659 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.593 ' HA2' ' CD1' ' A' ' 45' ' ' TRP . . . 81.99 -84.56 1.48 Allowed Glycine 0 N--CA 1.482 1.759 0 N-CA-C 105.005 -3.238 . . . . 0.0 105.005 -179.748 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . 0.444 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 9.2 m -100.88 166.96 11.52 Favored Pre-proline 0 C--N 1.307 -1.275 0 CA-C-N 112.649 -1.775 . . . . 0.0 110.851 -179.971 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.682 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.1 OUTLIER -89.44 167.17 5.21 Favored 'Trans proline' 0 C--N 1.312 -1.355 1 C-N-CA 125.919 4.412 . . . . 0.0 113.763 155.523 . . . . . . . . 4 4 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 18.2 t -60.97 141.37 57.37 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-N 113.784 -1.553 . . . . 0.0 109.181 -179.766 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.06 -2.3 68.74 Favored Glycine 0 N--CA 1.495 2.6 0 CA-C-N 111.675 -2.511 . . . . 0.0 111.551 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' TRP . . . . . 0.682 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 58.7 m95 -111.04 166.52 10.99 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 106.143 -1.799 . . . . 0.0 106.143 -179.743 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . 0.514 ' O ' ' ND1' ' A' ' 34' ' ' HIS . 43.1 t-80 -140.02 31.9 1.98 Allowed 'General case' 0 N--CA 1.496 1.839 0 C-N-CA 118.497 -1.281 . . . . 0.0 112.878 -179.872 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . 0.52 ' HA ' ' SG ' ' A' ' 47' ' ' CYS . 16.7 t-20 59.03 139.66 0.01 OUTLIER 'General case' 0 N--CA 1.511 2.607 0 N-CA-C 114.458 1.281 . . . . 0.0 114.458 -179.934 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.642 ' SG ' ' CB ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -119.43 -41.06 2.73 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.445 -0.784 . . . . 0.0 110.129 -179.725 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 38.0 ttmt -131.14 138.59 49.54 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 104.696 -2.335 . . . . 0.0 104.696 179.423 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.438 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -117.97 35.63 4.65 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 103.004 -2.962 . . . . 0.0 103.004 179.723 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . 0.438 ' ND1' ' C ' ' A' ' 38' ' ' ALA . 2.7 m-70 -140.09 55.96 1.62 Allowed 'General case' 0 N--CA 1.494 1.769 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 -179.537 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 85.9 -160.55 33.97 Favored Glycine 0 N--CA 1.502 3.049 0 N-CA-C 108.773 -1.731 . . . . 0.0 108.773 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . 0.407 ' HG2' ' O ' ' A' ' 44' ' ' GLY . 68.6 Cg_endo -64.9 -171.0 3.02 Favored 'Cis proline' 0 N--CA 1.507 2.286 0 CA-C-N 118.305 1.053 . . . . 0.0 114.74 -1.551 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 20.9 m120 -92.96 -8.27 43.59 Favored 'General case' 0 N--CA 1.487 1.377 0 N-CA-C 104.616 -2.364 . . . . 0.0 104.616 -179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 9.9 mm -106.22 32.0 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.961 0 CA-C-O 123.545 1.64 . . . . 0.0 113.782 -178.76 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.407 ' O ' ' HG2' ' A' ' 41' ' ' PRO . . . 124.72 -179.29 16.2 Favored Glycine 0 C--N 1.292 -1.879 1 N-CA-C 102.693 -4.163 . . . . 0.0 102.693 -179.977 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . 0.593 ' CD1' ' HA2' ' A' ' 28' ' ' GLY . 1.2 m95 -119.86 140.65 50.5 Favored 'General case' 0 C--N 1.277 -2.55 0 N-CA-C 103.775 -2.676 . . . . 0.0 103.775 179.709 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' CYS . . . . . 0.642 ' CB ' ' SG ' ' A' ' 36' ' ' CYS . 99.4 m -88.74 133.92 34.08 Favored 'General case' 0 N--CA 1.485 1.298 0 CA-C-N 121.756 2.071 . . . . 0.0 107.34 -179.912 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.52 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 87.3 m -133.71 178.32 7.03 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-N 110.892 -2.867 . . . . 0.0 110.443 -179.233 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.401 ' N ' ' CD ' ' A' ' 48' ' ' LYS . 0.0 OUTLIER -149.27 172.96 14.02 Favored 'General case' 0 C--N 1.304 -1.41 0 C-N-CA 117.525 -1.67 . . . . 0.0 111.757 179.776 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 24.8 mmtm . . . . . 0 N--CA 1.496 1.84 0 O-C-N 127.11 2.756 . . . . 0.0 109.413 179.976 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 2.693 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 13.0 t -96.11 141.88 23.77 Favored Pre-proline 0 N--CA 1.496 1.85 0 N-CA-C 107.988 -1.115 . . . . 0.0 107.988 -179.867 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -79.32 135.19 11.83 Favored 'Trans proline' 0 C--N 1.308 -1.559 0 C-N-CA 124.352 3.368 . . . . 0.0 115.001 169.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.446 ' SG ' ' HB3' ' A' ' 22' ' ' LEU . 0.0 OUTLIER -119.46 -178.12 3.53 Favored 'General case' 0 N--CA 1.494 1.772 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.563 179.662 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 6.4 tt -98.5 113.65 25.74 Favored 'General case' 0 N--CA 1.497 1.908 0 N-CA-C 104.962 -2.236 . . . . 0.0 104.962 -179.836 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.413 ' SG ' ' HA3' ' A' ' 20' ' ' GLY . 5.5 m -88.57 -169.01 2.38 Favored 'General case' 0 N--CA 1.487 1.387 0 N-CA-C 119.1 3.0 . . . . 0.0 119.1 -179.179 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 10.8 t0 -66.0 -83.66 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.394 0 CA-C-N 111.876 -2.42 . . . . 0.0 112.562 -179.655 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 1.4 m -55.33 -20.95 13.07 Favored 'General case' 0 N--CA 1.498 1.97 0 CA-C-O 121.53 0.681 . . . . 0.0 110.928 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 45.2 t0 -46.69 -62.04 1.56 Allowed 'General case' 0 C--N 1.303 -1.443 0 CA-C-N 112.571 -2.104 . . . . 0.0 114.681 -179.912 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 52.76 -144.62 21.71 Favored Glycine 0 N--CA 1.498 2.793 0 N-CA-C 108.139 -1.984 . . . . 0.0 108.139 -179.514 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER -83.75 19.14 1.4 Allowed 'Trans proline' 0 N--CA 1.494 1.514 0 C-N-CA 123.984 3.123 . . . . 0.0 113.092 170.8 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 93.6 mtt-85 -132.28 80.28 63.95 Favored Pre-proline 0 N--CA 1.502 2.175 0 N-CA-C 114.52 1.304 . . . . 0.0 114.52 -179.692 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -68.06 143.59 60.43 Favored 'Trans proline' 0 N--CA 1.5 1.863 0 C-N-CA 124.667 3.578 . . . . 0.0 110.575 171.027 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 74.6 mtm180 -101.26 105.23 16.3 Favored 'General case' 0 N--CA 1.499 2.005 0 CA-C-O 122.163 0.983 . . . . 0.0 112.255 -179.848 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 129.17 37.0 0.4 Allowed Glycine 0 N--CA 1.499 2.891 0 N-CA-C 109.31 -1.516 . . . . 0.0 109.31 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 35.9 m-80 77.02 -48.42 0.53 Allowed 'General case' 0 N--CA 1.509 2.499 0 C-N-CA 124.393 1.077 . . . . 0.0 108.954 -179.842 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 7.8 t -150.33 -176.28 5.41 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 106.643 -1.614 . . . . 0.0 106.643 179.786 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 4.7 mp 63.53 136.54 0.02 OUTLIER 'General case' 0 N--CA 1.507 2.4 0 O-C-N 125.114 1.509 . . . . 0.0 111.087 -179.546 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 22.8 t -129.91 -10.48 4.35 Favored 'General case' 0 N--CA 1.499 2.003 0 C-N-CA 118.436 -1.305 . . . . 0.0 112.725 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.53 ' HA3' ' SG ' ' A' ' 36' ' ' CYS . . . 174.28 131.53 1.42 Allowed Glycine 0 N--CA 1.48 1.605 0 N-CA-C 108.341 -1.903 . . . . 0.0 108.341 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.457 ' N ' ' O ' ' A' ' 47' ' ' CYS . 49.7 mm -93.12 132.33 37.64 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.12 0 C-N-CA 116.593 -2.043 . . . . 0.0 105.565 179.851 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.547 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.9 pp -63.0 149.0 46.01 Favored 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 107.276 -1.379 . . . . 0.0 107.276 179.444 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.419 ' CE2' ' HG3' ' A' ' 30' ' ' PRO . 28.5 m95 -129.78 136.83 50.07 Favored 'General case' 0 C--N 1.3 -1.567 0 CA-C-O 124.008 1.861 . . . . 0.0 115.439 -179.812 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -89.11 47.67 1.52 Allowed 'General case' 0 C--N 1.294 -1.845 0 CA-C-N 108.914 -3.766 . . . . 0.0 112.499 -179.809 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 1.1 m-30 -117.33 143.46 32.0 Favored Pre-proline 0 C--N 1.306 -1.322 0 CA-C-O 122.537 1.161 . . . . 0.0 110.362 179.604 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 15.7 Cg_endo -77.19 -35.18 1.82 Allowed 'Trans proline' 0 C--N 1.301 -1.96 0 C-N-CA 123.622 2.881 . . . . 0.0 110.578 175.829 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 10.9 p -89.46 38.77 0.92 Allowed 'General case' 0 N--CA 1.49 1.536 0 CA-C-N 114.61 -1.177 . . . . 0.0 112.38 -179.626 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 73.17 -135.16 20.83 Favored Glycine 0 N--CA 1.5 2.955 0 N-CA-C 108.07 -2.012 . . . . 0.0 108.07 -179.864 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . 0.544 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 15.3 m -72.22 156.18 90.84 Favored Pre-proline 0 C--N 1.304 -1.406 0 CA-C-N 118.793 1.297 . . . . 0.0 111.471 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.689 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.4 OUTLIER -79.71 159.13 24.97 Favored 'Trans proline' 0 C--N 1.307 -1.617 0 C-N-CA 123.281 2.654 . . . . 0.0 111.831 166.597 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 42.0 t -50.07 134.27 22.1 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 113.334 -1.757 . . . . 0.0 109.299 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 95.4 -4.57 67.03 Favored Glycine 0 N--CA 1.498 2.773 0 CA-C-N 112.396 -2.184 . . . . 0.0 111.896 179.835 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' TRP . . . . . 0.689 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 56.4 m95 -112.95 157.2 21.78 Favored 'General case' 0 C--N 1.304 -1.391 0 N-CA-C 105.29 -2.115 . . . . 0.0 105.29 -179.855 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . 0.416 ' O ' ' ND1' ' A' ' 34' ' ' HIS . 65.1 t-80 -140.45 41.49 1.89 Allowed 'General case' 0 C--N 1.299 -1.593 0 C-N-CA 118.291 -1.363 . . . . 0.0 112.084 -179.914 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . 0.544 ' HA ' ' SG ' ' A' ' 29' ' ' CYS . 0.2 OUTLIER 63.17 138.37 0.02 OUTLIER 'General case' 0 N--CA 1.505 2.316 0 N-CA-C 115.74 1.755 . . . . 0.0 115.74 179.412 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.608 ' SG ' ' CB ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -114.9 -40.74 3.46 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 105.843 -1.91 . . . . 0.0 105.843 179.775 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 21.3 ptmt -138.41 149.32 45.4 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 106.864 -1.532 . . . . 0.0 106.864 179.64 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.452 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -120.0 35.43 4.86 Favored 'General case' 0 C--N 1.293 -1.85 0 N-CA-C 102.506 -3.146 . . . . 0.0 102.506 179.881 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . 0.452 ' ND1' ' C ' ' A' ' 38' ' ' ALA . 3.7 m-70 -127.57 54.9 1.65 Allowed 'General case' 0 N--CA 1.498 1.951 0 N-CA-C 108.404 -0.961 . . . . 0.0 108.404 -179.625 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 74.0 -148.86 40.24 Favored Glycine 0 N--CA 1.496 2.65 0 N-CA-C 105.604 -2.998 . . . . 0.0 105.604 -179.658 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . 0.423 ' HG2' ' O ' ' A' ' 44' ' ' GLY . 51.2 Cg_endo -65.64 -172.63 4.43 Favored 'Cis proline' 0 N--CA 1.501 1.915 0 CA-C-N 119.088 1.444 . . . . 0.0 111.713 -1.4 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 14.3 m120 -93.58 0.52 56.63 Favored 'General case' 0 C--N 1.307 -1.273 0 N-CA-C 104.144 -2.539 . . . . 0.0 104.144 -179.679 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 8.4 mt -116.64 35.02 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 N-CA-C 116.043 1.868 . . . . 0.0 116.043 -178.846 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.423 ' O ' ' HG2' ' A' ' 41' ' ' PRO . . . 119.81 139.76 5.98 Favored Glycine 0 N--CA 1.499 2.846 0 CA-C-N 114.004 -1.453 . . . . 0.0 110.642 179.721 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . 0.416 ' O ' ' N ' ' A' ' 23' ' ' TRP . 6.4 m95 -78.22 129.85 35.59 Favored 'General case' 0 N--CA 1.503 2.194 0 CA-C-O 117.783 -1.103 . . . . 0.0 111.096 -179.267 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' CYS . . . . . 0.608 ' CB ' ' SG ' ' A' ' 36' ' ' CYS . 66.2 m -87.71 122.67 31.66 Favored 'General case' 0 C--N 1.308 -1.204 1 N-CA-C 99.791 -4.152 . . . . 0.0 99.791 179.436 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.55 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 88.8 m -129.18 -178.84 4.81 Favored 'General case' 0 CA--C 1.476 -1.894 0 CA-C-N 109.895 -3.321 . . . . 0.0 111.205 -179.398 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.483 ' HD2' ' H ' ' A' ' 49' ' ' LYS . 24.2 tptp -150.52 152.01 33.53 Favored 'General case' 0 C--N 1.294 -1.846 0 C-N-CA 117.675 -1.61 . . . . 0.0 109.987 -179.84 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . 0.483 ' H ' ' HD2' ' A' ' 48' ' ' LYS . 51.2 mtpt . . . . . 0 N--CA 1.5 2.054 0 O-C-N 126.197 2.186 . . . . 0.0 111.899 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.495 2.585 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 33.0 t -97.25 135.59 21.8 Favored Pre-proline 0 N--CA 1.497 1.885 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.44 ' CB ' ' HG ' ' A' ' 18' ' ' LEU . 3.0 Cg_endo -77.27 127.77 9.32 Favored 'Trans proline' 0 N--CA 1.493 1.475 0 C-N-CA 124.523 3.482 . . . . 0.0 116.458 170.048 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.507 ' SG ' ' HB3' ' A' ' 22' ' ' LEU . 0.5 OUTLIER -121.08 179.46 4.38 Favored 'General case' 0 C--N 1.301 -1.508 0 CA-C-N 114.624 -1.171 . . . . 0.0 111.13 179.786 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 6.7 tp -91.68 145.98 24.15 Favored 'General case' 0 N--CA 1.491 1.594 0 N-CA-C 104.625 -2.361 . . . . 0.0 104.625 179.874 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.436 ' HB2' ' HB2' ' A' ' 9' ' ' ASP . 6.9 m -119.42 -170.4 1.93 Allowed 'General case' 0 N--CA 1.491 1.583 0 N-CA-C 113.911 1.078 . . . . 0.0 113.911 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -86.74 -50.46 6.74 Favored 'General case' 0 N--CA 1.497 1.887 0 CA-C-N 113.614 -1.63 . . . . 0.0 109.353 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -67.21 -32.23 73.14 Favored 'General case' 0 N--CA 1.492 1.664 0 CA-C-N 111.881 -2.418 . . . . 0.0 107.157 179.668 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.436 ' HB2' ' HB2' ' A' ' 6' ' ' CYS . 63.1 t0 -49.43 -69.71 0.11 Allowed 'General case' 0 N--CA 1.497 1.878 0 CA-C-N 112.052 -2.34 . . . . 0.0 109.326 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 63.53 165.7 0.75 Allowed Glycine 0 N--CA 1.488 2.137 0 CA-C-N 113.261 -1.79 . . . . 0.0 111.572 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_endo -79.23 39.04 0.77 Allowed 'Trans proline' 0 C--N 1.308 -1.603 0 C-N-CA 123.882 3.055 . . . . 0.0 110.149 175.559 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.0 mpt_? -89.51 158.97 45.0 Favored Pre-proline 0 N--CA 1.493 1.717 0 CA-C-N 115.462 -0.79 . . . . 0.0 112.578 -179.607 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -72.67 58.93 3.3 Favored 'Trans proline' 0 N--CA 1.495 1.562 0 C-N-CA 124.424 3.416 . . . . 0.0 112.132 174.537 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -173.77 116.9 0.25 Allowed 'General case' 0 N--CA 1.493 1.721 0 CA-C-N 113.683 -1.599 . . . . 0.0 110.424 179.873 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 54.7 32.19 54.09 Favored Glycine 0 N--CA 1.504 3.202 0 N-CA-C 110.187 -1.165 . . . . 0.0 110.187 -179.909 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 -60.59 -44.53 96.13 Favored 'General case' 0 N--CA 1.503 2.188 0 CA-C-O 121.982 0.896 . . . . 0.0 109.819 -179.793 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.0 t -104.19 155.47 18.69 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 104.487 -2.412 . . . . 0.0 104.487 179.807 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.44 ' HG ' ' CB ' ' A' ' 3' ' ' PRO . 2.3 tt 38.51 66.6 0.49 Allowed 'General case' 0 N--CA 1.499 2.012 0 O-C-N 125.11 1.506 . . . . 0.0 108.911 -179.52 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -88.66 52.98 2.57 Favored 'General case' 0 N--CA 1.498 1.937 0 CA-C-N 113.781 -1.554 . . . . 0.0 109.368 -179.339 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.43 -165.61 18.19 Favored Glycine 0 N--CA 1.502 3.047 0 CA-C-N 114.382 -1.281 . . . . 0.0 111.21 179.804 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.409 ' N ' ' O ' ' A' ' 47' ' ' CYS . 28.8 mm -133.88 147.52 30.59 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.265 0 N-CA-C 112.744 0.646 . . . . 0.0 112.744 -179.94 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.572 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 2.8 pp -69.85 152.77 44.16 Favored 'General case' 0 N--CA 1.492 1.644 0 CA-C-N 114.919 -1.037 . . . . 0.0 108.819 179.499 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.643 ' HB2' ' SG ' ' A' ' 29' ' ' CYS . 28.3 m95 -131.93 135.32 46.52 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-O 125.045 2.355 . . . . 0.0 115.986 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.5 m-85 -88.84 54.34 2.98 Favored 'General case' 0 C--N 1.292 -1.892 1 CA-C-N 107.641 -4.345 . . . . 0.0 110.131 -179.669 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.531 ' CE1' ' HB3' ' A' ' 30' ' ' PRO . 2.2 m-85 -123.82 115.88 27.84 Favored Pre-proline 0 N--CA 1.491 1.618 0 CA-C-N 115.497 -0.774 . . . . 0.0 112.656 179.654 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -64.03 -11.85 29.35 Favored 'Trans proline' 0 C--N 1.308 -1.557 0 C-N-CA 123.389 2.726 . . . . 0.0 111.948 -175.412 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 6.6 p -108.93 3.93 22.8 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-N 115.37 -0.832 . . . . 0.0 111.025 179.753 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.4 ' O ' ' CD1' ' A' ' 45' ' ' TRP . . . 126.45 -113.21 1.75 Allowed Glycine 0 N--CA 1.502 3.058 0 N-CA-C 108.727 -1.749 . . . . 0.0 108.727 -179.913 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . 0.643 ' SG ' ' HB2' ' A' ' 23' ' ' TRP . 18.4 m -132.36 156.54 79.98 Favored Pre-proline 0 C--N 1.305 -1.357 0 CA-C-N 117.701 0.75 . . . . 0.0 110.687 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.707 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 9.0 Cg_endo -78.68 162.04 27.39 Favored 'Trans proline' 0 C--N 1.306 -1.68 0 C-N-CA 123.335 2.69 . . . . 0.0 113.323 -167.196 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 22.9 t -51.32 116.43 2.05 Favored 'General case' 0 C--N 1.302 -1.487 0 CA-C-N 113.292 -1.776 . . . . 0.0 110.473 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 115.5 -7.61 20.37 Favored Glycine 0 N--CA 1.499 2.87 0 CA-C-N 113.744 -1.571 . . . . 0.0 111.529 179.761 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' TRP . . . . . 0.707 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 49.9 m95 -109.22 158.94 17.35 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 104.77 -2.307 . . . . 0.0 104.77 -179.941 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 78.3 t60 -138.34 33.04 2.31 Favored 'General case' 0 C--N 1.298 -1.666 0 C-N-CA 118.05 -1.46 . . . . 0.0 114.074 -179.598 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . 0.793 ' HA ' ' SG ' ' A' ' 47' ' ' CYS . 5.1 m-20 57.34 137.35 0.0 OUTLIER 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 116.648 2.092 . . . . 0.0 116.648 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.585 ' SG ' ' HB3' ' A' ' 46' ' ' CYS . 0.6 OUTLIER -112.06 -40.13 4.3 Favored 'General case' 0 N--CA 1.489 1.489 0 CA-C-N 115.015 -0.993 . . . . 0.0 108.931 -179.644 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . 0.405 ' HD2' ' HA ' ' A' ' 6' ' ' CYS . 51.9 tttt -132.87 143.38 49.48 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 107.356 -1.349 . . . . 0.0 107.356 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.441 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -119.47 30.08 7.28 Favored 'General case' 0 N--CA 1.493 1.721 0 N-CA-C 104.772 -2.307 . . . . 0.0 104.772 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . 0.441 ' ND1' ' C ' ' A' ' 38' ' ' ALA . 4.5 m-70 -134.75 62.18 1.65 Allowed 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 107.023 -1.473 . . . . 0.0 107.023 -179.564 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 75.75 -155.94 47.22 Favored Glycine 0 N--CA 1.498 2.798 0 N-CA-C 106.213 -2.755 . . . . 0.0 106.213 -179.728 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_endo -74.09 -169.38 7.0 Favored 'Cis proline' 0 N--CA 1.496 1.669 0 CA-C-N 118.922 1.361 . . . . 0.0 113.923 -0.682 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 10.0 p30 -92.33 -14.66 28.43 Favored 'General case' 0 CA--C 1.486 -1.506 0 N-CA-C 105.992 -1.855 . . . . 0.0 105.992 -179.606 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 31.6 pt -90.28 24.17 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 O-C-N 125.277 1.61 . . . . 0.0 113.978 -179.431 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 114.37 137.79 6.6 Favored Glycine 0 N--CA 1.493 2.472 0 CA-C-N 113.246 -1.797 . . . . 0.0 109.696 -179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . 0.426 ' O ' ' N ' ' A' ' 23' ' ' TRP . 7.9 m95 -61.53 136.4 58.01 Favored 'General case' 0 N--CA 1.519 3.006 0 CA-C-O 117.317 -1.325 . . . . 0.0 108.421 -179.643 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' CYS . . . . . 0.585 ' HB3' ' SG ' ' A' ' 36' ' ' CYS . 93.0 m -89.9 127.08 35.94 Favored 'General case' 0 N--CA 1.482 1.141 0 CA-C-N 122.26 2.3 . . . . 0.0 105.127 -179.921 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.793 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 93.7 m -136.45 -171.82 3.0 Favored 'General case' 0 C--N 1.3 -1.563 0 CA-C-N 111.327 -2.67 . . . . 0.0 111.005 -179.409 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.452 ' N ' ' CD ' ' A' ' 48' ' ' LYS . 0.0 OUTLIER -151.31 172.29 16.12 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 179.574 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 47.4 mtpt . . . . . 0 C--N 1.291 -1.969 0 O-C-N 126.704 2.503 . . . . 0.0 110.347 179.828 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 2.656 0 N-CA-C 109.314 -1.514 . . . . 0.0 109.314 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 29.6 t -89.57 137.34 28.84 Favored Pre-proline 0 N--CA 1.496 1.852 0 C-N-CA 118.779 -1.168 . . . . 0.0 109.407 -179.78 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -67.27 135.57 37.36 Favored 'Trans proline' 0 N--CA 1.493 1.455 0 C-N-CA 122.333 2.022 . . . . 0.0 110.24 170.051 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -134.06 175.8 9.15 Favored 'General case' 0 N--CA 1.497 1.918 0 CA-C-O 121.563 0.697 . . . . 0.0 112.242 -179.724 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -101.55 141.89 33.74 Favored 'General case' 0 N--CA 1.494 1.732 0 N-CA-C 104.067 -2.568 . . . . 0.0 104.067 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.402 ' O ' ' CB ' ' A' ' 9' ' ' ASP . 1.8 m -113.14 -138.8 0.38 Allowed 'General case' 0 N--CA 1.497 1.892 0 N-CA-C 120.395 3.48 . . . . 0.0 120.395 -178.95 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -60.39 -15.79 29.47 Favored 'General case' 0 N--CA 1.507 2.391 0 O-C-N 120.969 -1.082 . . . . 0.0 110.388 -179.828 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 31.7 t -92.81 9.28 35.9 Favored 'General case' 0 N--CA 1.503 2.194 0 N-CA-C 107.383 -1.34 . . . . 0.0 107.383 179.347 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.402 ' CB ' ' O ' ' A' ' 6' ' ' CYS . 19.1 t70 -81.02 79.2 7.74 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 106.802 -1.555 . . . . 0.0 106.802 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.415 ' C ' ' H ' ' A' ' 12' ' ' ARG . . . -73.27 -157.25 4.15 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 106.755 -2.538 . . . . 0.0 106.755 179.62 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 17.6 Cg_endo -75.36 41.35 0.77 Allowed 'Trans proline' 0 N--CA 1.497 1.697 0 C-N-CA 124.502 3.468 . . . . 0.0 110.448 179.332 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . 0.415 ' H ' ' C ' ' A' ' 10' ' ' GLY . 7.9 ttt85 -122.09 135.53 25.48 Favored Pre-proline 0 C--N 1.304 -1.375 0 N-CA-C 106.953 -1.499 . . . . 0.0 106.953 -179.854 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -62.25 154.94 59.78 Favored 'Trans proline' 0 C--N 1.311 -1.418 0 C-N-CA 123.323 2.682 . . . . 0.0 115.113 -177.104 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 35.1 ptt180 -70.26 149.33 47.55 Favored 'General case' 0 N--CA 1.489 1.51 0 CA-C-N 111.648 -2.524 . . . . 0.0 108.595 179.849 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 102.88 -30.62 10.04 Favored Glycine 0 N--CA 1.498 2.806 0 N-CA-C 109.619 -1.392 . . . . 0.0 109.619 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 15.4 m-20 -45.26 -41.91 9.04 Favored 'General case' 0 N--CA 1.502 2.152 0 CA-C-O 121.611 0.72 . . . . 0.0 112.378 179.835 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 6.9 t -150.29 153.89 36.94 Favored 'General case' 0 N--CA 1.49 1.563 0 N-CA-C 107.268 -1.382 . . . . 0.0 107.268 179.814 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 34.7 mt -106.98 91.08 3.51 Favored 'General case' 0 N--CA 1.496 1.867 0 N-CA-C 105.075 -2.195 . . . . 0.0 105.075 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 7.1 m -90.16 21.95 3.52 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 115.644 1.72 . . . . 0.0 115.644 -179.571 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 148.69 -163.69 29.05 Favored Glycine 0 N--CA 1.497 2.743 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.473 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 35.5 mm -135.98 146.42 29.43 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.088 0 CA-C-O 122.487 1.137 . . . . 0.0 109.878 179.852 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.475 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 0.9 OUTLIER -69.69 134.79 49.06 Favored 'General case' 0 C--N 1.297 -1.693 0 CA-C-N 114.654 -1.157 . . . . 0.0 108.625 179.826 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 44.5 m95 -124.04 134.18 53.48 Favored 'General case' 0 N--CA 1.484 1.242 0 N-CA-C 118.96 2.948 . . . . 0.0 118.96 179.889 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.2 m-30 -88.93 39.58 0.94 Allowed 'General case' 0 C--N 1.296 -1.718 1 CA-C-N 107.366 -4.47 . . . . 0.0 113.064 -179.584 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.431 ' CD2' ' HA ' ' A' ' 30' ' ' PRO . 1.2 m-30 -113.07 125.13 30.25 Favored Pre-proline 0 C--N 1.304 -1.402 0 CA-C-O 122.697 1.237 . . . . 0.0 112.271 -179.935 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -66.21 -25.26 50.36 Favored 'Trans proline' 0 C--N 1.302 -1.872 0 C-N-CA 122.507 2.138 . . . . 0.0 108.341 -177.731 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 5.8 p -87.01 5.03 39.44 Favored 'General case' 0 N--CA 1.49 1.536 0 CA-C-N 114.375 -1.284 . . . . 0.0 112.468 179.926 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 110.65 -118.57 5.0 Favored Glycine 0 N--CA 1.498 2.806 0 N-CA-C 106.238 -2.745 . . . . 0.0 106.238 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . 0.504 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 37.4 m -96.65 153.79 38.65 Favored Pre-proline 0 C--N 1.303 -1.446 0 N-CA-C 106.726 -1.583 . . . . 0.0 106.726 179.735 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.694 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.8 OUTLIER -76.34 169.47 21.89 Favored 'Trans proline' 0 C--N 1.305 -1.726 0 C-N-CA 123.077 2.518 . . . . 0.0 113.829 174.588 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 5.7 m -46.17 103.83 0.04 OUTLIER 'General case' 0 C--N 1.298 -1.633 0 CA-C-N 112.01 -2.359 . . . . 0.0 113.99 -179.854 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 109.11 2.68 31.62 Favored Glycine 0 N--CA 1.501 2.996 0 C-N-CA 120.811 -0.709 . . . . 0.0 114.293 179.481 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' TRP . . . . . 0.694 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 44.7 m95 -110.82 164.81 12.39 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 106.999 -1.482 . . . . 0.0 106.999 -179.954 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 57.7 t-80 -144.76 37.23 1.18 Allowed 'General case' 0 N--CA 1.499 1.992 0 C-N-CA 117.757 -1.577 . . . . 0.0 113.072 -179.722 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . 0.504 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 24.0 t-20 58.43 146.48 0.01 OUTLIER 'General case' 0 N--CA 1.501 2.098 0 CA-C-N 113.248 -1.797 . . . . 0.0 114.673 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.64 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -121.09 -46.67 2.31 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 106.013 -1.847 . . . . 0.0 106.013 179.974 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . 0.425 ' C ' ' H ' ' A' ' 39' ' ' HIS . 13.1 ttmt -107.94 102.08 11.29 Favored 'General case' 0 C--N 1.301 -1.502 0 CA-C-N 113.315 -1.766 . . . . 0.0 108.618 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -83.36 12.28 5.66 Favored 'General case' 0 N--CA 1.496 1.869 0 CA-C-N 113.31 -1.768 . . . . 0.0 107.713 179.511 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . 0.425 ' H ' ' C ' ' A' ' 37' ' ' LYS . 7.4 m-70 -127.22 37.71 4.21 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-N 114.878 -1.055 . . . . 0.0 109.208 -179.667 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 96.23 -149.56 19.35 Favored Glycine 0 N--CA 1.498 2.768 0 CA-C-N 114.538 -1.21 . . . . 0.0 111.267 179.586 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 3.5 Cg_endo -75.5 -173.84 13.2 Favored 'Cis proline' 0 N--CA 1.5 1.861 0 N-CA-C 109.386 -1.044 . . . . 0.0 109.386 1.496 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.524 ' C ' ' H ' ' A' ' 44' ' ' GLY . 56.5 t30 -92.27 -11.97 33.81 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 105.463 -2.051 . . . . 0.0 105.463 -179.783 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 30.5 pt -85.66 28.92 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 CA-C-O 123.302 1.525 . . . . 0.0 112.741 -179.192 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.524 ' H ' ' C ' ' A' ' 42' ' ' ASN . . . 116.98 142.57 7.34 Favored Glycine 0 C--N 1.295 -1.71 0 CA-C-N 110.528 -3.033 . . . . 0.0 106.153 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . 0.42 ' NE1' ' O ' ' A' ' 25' ' ' TYR . 6.9 m95 -77.81 133.77 38.14 Favored 'General case' 0 C--N 1.293 -1.849 0 N-CA-C 104.674 -2.343 . . . . 0.0 104.674 -179.534 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' CYS . . . . . 0.64 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 46.0 t -89.22 129.14 35.84 Favored 'General case' 0 N--CA 1.485 1.318 1 N-CA-C 99.319 -4.326 . . . . 0.0 99.319 179.773 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.514 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 77.3 m -127.88 -170.53 2.25 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-N 113.096 -1.866 . . . . 0.0 110.254 -179.363 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.08 172.3 15.98 Favored 'General case' 0 C--N 1.298 -1.674 0 N-CA-C 107.599 -1.26 . . . . 0.0 107.599 179.311 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 65.3 mttt . . . . . 0 N--CA 1.498 1.961 0 O-C-N 126.267 2.229 . . . . 0.0 108.189 179.267 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.498 2.831 0 N-CA-C 109.993 -1.243 . . . . 0.0 109.993 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 46.8 t -112.98 134.94 21.69 Favored Pre-proline 0 N--CA 1.499 2.01 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 26.6 Cg_endo -73.11 116.03 4.56 Favored 'Trans proline' 0 C--N 1.308 -1.566 0 C-N-CA 122.877 2.384 . . . . 0.0 114.473 170.664 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.526 ' SG ' ' HB2' ' A' ' 22' ' ' LEU . 0.8 OUTLIER -122.15 163.94 18.65 Favored 'General case' 0 N--CA 1.494 1.774 0 CA-C-N 113.037 -1.892 . . . . 0.0 108.839 -179.799 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 12.2 tp -89.61 174.82 7.54 Favored 'General case' 0 N--CA 1.497 1.886 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 -179.895 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.433 ' O ' ' HB3' ' A' ' 9' ' ' ASP . 1.8 m -135.26 -143.25 0.19 Allowed 'General case' 0 N--CA 1.501 2.097 1 N-CA-C 122.131 4.123 . . . . 0.0 122.131 -178.738 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -56.55 -31.63 64.36 Favored 'General case' 0 N--CA 1.497 1.89 0 C-N-CA 118.405 -1.318 . . . . 0.0 108.813 -179.523 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 24.9 m -80.42 13.93 2.23 Favored 'General case' 0 N--CA 1.497 1.888 0 C-N-CA 119.469 -0.892 . . . . 0.0 110.246 179.689 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.433 ' HB3' ' O ' ' A' ' 6' ' ' CYS . 5.6 t0 -75.06 63.85 1.3 Allowed 'General case' 0 N--CA 1.502 2.166 0 CA-C-O 121.928 0.87 . . . . 0.0 109.13 179.845 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -148.43 -169.82 15.7 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 107.401 -2.28 . . . . 0.0 107.401 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_endo -76.24 34.23 0.43 Allowed 'Trans proline' 0 N--CA 1.499 1.834 1 C-N-CA 125.434 4.089 . . . . 0.0 114.789 -162.779 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 29.7 mtp180 -119.3 122.94 29.07 Favored Pre-proline 0 N--CA 1.498 1.942 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.068 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 17.4 Cg_endo -72.08 60.22 3.07 Favored 'Trans proline' 0 N--CA 1.501 1.919 0 C-N-CA 123.742 2.961 . . . . 0.0 114.472 -174.859 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . 0.448 ' C ' ' H ' ' A' ' 16' ' ' ASN . 86.5 mtt-85 -147.13 136.87 23.03 Favored 'General case' 0 N--CA 1.489 1.498 0 CA-C-N 113.882 -1.508 . . . . 0.0 107.951 179.991 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.405 ' O ' ' N ' ' A' ' 17' ' ' THR . . . 76.35 -39.38 1.45 Allowed Glycine 0 N--CA 1.499 2.842 0 C-N-CA 120.789 -0.72 . . . . 0.0 111.945 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . 0.566 HD21 ' N ' ' A' ' 17' ' ' THR . 0.5 OUTLIER -22.53 -41.2 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.333 0 N-CA-C 117.696 2.48 . . . . 0.0 117.696 -179.807 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.566 ' N ' HD21 ' A' ' 16' ' ' ASN . 0.7 OUTLIER -96.14 99.97 11.66 Favored 'General case' 0 C--N 1.297 -1.687 0 N-CA-C 114.286 1.217 . . . . 0.0 114.286 -179.463 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 25.8 mt 31.77 55.26 0.3 Allowed 'General case' 0 N--CA 1.502 2.146 0 N-CA-C 116.014 1.857 . . . . 0.0 116.014 179.399 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 80.5 p -89.06 57.63 4.19 Favored 'General case' 0 C--N 1.3 -1.544 0 C-N-CA 119.896 -0.722 . . . . 0.0 111.697 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 153.28 161.58 10.43 Favored Glycine 0 N--CA 1.5 2.926 0 C-N-CA 119.512 -1.328 . . . . 0.0 112.775 179.46 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.411 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 49.1 mm -124.07 137.83 55.75 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.176 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 179.57 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.532 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 34.7 tp -63.99 144.58 56.98 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 179.659 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 42.4 m95 -131.52 134.08 45.75 Favored 'General case' 0 C--N 1.308 -1.236 0 N-CA-C 119.428 3.122 . . . . 0.0 119.428 -179.568 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -88.87 54.45 3.02 Favored 'General case' 0 C--N 1.297 -1.675 1 CA-C-N 108.145 -4.116 . . . . 0.0 108.727 -179.962 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.442 ' CE1' ' HB3' ' A' ' 30' ' ' PRO . 2.4 m-85 -128.73 120.02 20.42 Favored Pre-proline 0 N--CA 1.486 1.368 0 CA-C-N 115.088 -0.96 . . . . 0.0 113.556 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -67.25 -13.48 39.66 Favored 'Trans proline' 0 C--N 1.309 -1.526 0 C-N-CA 123.793 2.996 . . . . 0.0 110.918 -178.121 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 12.8 p -93.51 -9.23 39.03 Favored 'General case' 0 N--CA 1.491 1.609 0 CA-C-N 114.565 -1.198 . . . . 0.0 110.43 179.81 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.407 ' HA2' ' CD2' ' A' ' 45' ' ' TRP . . . 116.3 -106.96 1.57 Allowed Glycine 0 N--CA 1.482 1.724 1 N-CA-C 102.512 -4.235 . . . . 0.0 102.512 -179.702 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . 0.602 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 16.7 m -99.36 151.66 37.5 Favored Pre-proline 0 C--N 1.301 -1.52 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.647 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.4 OUTLIER -79.46 164.57 23.73 Favored 'Trans proline' 0 C--N 1.306 -1.694 0 C-N-CA 123.005 2.47 . . . . 0.0 114.359 169.831 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 3.1 m -43.93 105.32 0.05 Allowed 'General case' 0 C--N 1.3 -1.581 0 CA-C-N 112.197 -2.274 . . . . 0.0 112.636 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 114.53 -4.12 23.22 Favored Glycine 0 N--CA 1.505 3.26 0 CA-C-N 115.665 -0.698 . . . . 0.0 113.495 179.581 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' TRP . . . . . 0.647 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 49.2 m95 -111.22 166.5 11.04 Favored 'General case' 0 N--CA 1.488 1.43 0 N-CA-C 107.061 -1.459 . . . . 0.0 107.061 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 55.0 t-80 -148.86 40.35 0.89 Allowed 'General case' 0 N--CA 1.505 2.312 0 C-N-CA 117.904 -1.518 . . . . 0.0 114.147 -179.856 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . 0.602 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 1.5 t30 52.36 146.66 0.0 OUTLIER 'General case' 0 N--CA 1.499 1.986 0 CA-C-N 113.001 -1.909 . . . . 0.0 116.073 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.505 ' SG ' ' O ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -119.08 -41.14 2.77 Favored 'General case' 0 C--N 1.306 -1.29 0 CA-C-N 114.582 -1.19 . . . . 0.0 111.336 -179.805 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . 0.553 ' C ' ' H ' ' A' ' 39' ' ' HIS . 44.3 tttm -106.04 106.36 16.83 Favored 'General case' 0 N--CA 1.502 2.136 0 C-N-CA 119.014 -1.074 . . . . 0.0 108.384 179.655 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -65.8 16.66 0.02 OUTLIER 'General case' 0 N--CA 1.505 2.299 0 N-CA-C 113.049 0.759 . . . . 0.0 113.049 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . 0.553 ' H ' ' C ' ' A' ' 37' ' ' LYS . 5.3 m-70 -128.38 -4.84 5.42 Favored 'General case' 0 N--CA 1.494 1.745 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.03 179.947 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 133.97 -119.86 2.36 Favored Glycine 0 N--CA 1.509 3.506 0 C-N-CA 120.685 -0.769 . . . . 0.0 113.086 179.872 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -68.1 -170.82 5.04 Favored 'Cis proline' 0 N--CA 1.504 2.138 0 CA-C-N 118.609 1.205 . . . . 0.0 111.824 -1.669 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 10.0 t-20 -93.72 -5.5 48.3 Favored 'General case' 0 CA--C 1.492 -1.253 0 N-CA-C 106.083 -1.821 . . . . 0.0 106.083 -179.709 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 28.4 mt -94.81 32.14 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.104 0 CA-C-O 123.897 1.808 . . . . 0.0 110.737 -179.005 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 115.96 153.99 10.27 Favored Glycine 0 C--N 1.295 -1.737 1 N-CA-C 101.137 -4.785 . . . . 0.0 101.137 -179.692 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . 0.407 ' CD2' ' HA2' ' A' ' 28' ' ' GLY . 56.4 m95 -86.56 135.37 33.46 Favored 'General case' 0 N--CA 1.505 2.298 0 CA-C-O 116.475 -1.726 . . . . 0.0 108.057 -179.769 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' CYS . . . . . 0.532 ' HA ' ' HA ' ' A' ' 22' ' ' LEU . 59.3 m -92.65 121.18 33.81 Favored 'General case' 0 C--N 1.308 -1.212 1 N-CA-C 96.884 -5.228 . . . . 0.0 96.884 179.763 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.518 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 96.1 m -127.57 -174.57 3.22 Favored 'General case' 0 C--N 1.297 -1.712 0 CA-C-N 112.419 -2.173 . . . . 0.0 108.366 -179.351 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.36 173.14 14.86 Favored 'General case' 0 C--N 1.297 -1.705 0 N-CA-C 106.923 -1.51 . . . . 0.0 106.923 179.32 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 86.8 mttt . . . . . 0 C--N 1.289 -2.049 0 O-C-N 126.255 2.222 . . . . 0.0 106.593 179.337 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.495 2.576 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 19.4 t -89.92 141.11 27.88 Favored Pre-proline 0 N--CA 1.492 1.666 0 N-CA-C 106.939 -1.504 . . . . 0.0 106.939 -179.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.447 ' HA ' ' O ' ' A' ' 20' ' ' GLY . 11.0 Cg_endo -77.09 132.95 13.12 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 123.246 2.63 . . . . 0.0 113.147 163.673 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -121.26 177.39 5.18 Favored 'General case' 0 N--CA 1.494 1.734 0 C-N-CA 119.966 -0.694 . . . . 0.0 112.038 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 9.4 tt -94.12 150.86 19.94 Favored 'General case' 0 N--CA 1.493 1.687 0 N-CA-C 105.036 -2.209 . . . . 0.0 105.036 179.768 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.425 ' HB3' ' HB2' ' A' ' 37' ' ' LYS . 13.0 m -143.07 -174.85 4.3 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 124.683 1.239 . . . . 0.0 111.739 -179.337 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -78.24 -45.01 24.02 Favored 'General case' 0 N--CA 1.493 1.707 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 179.881 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 63.6 m -109.39 33.55 4.26 Favored 'General case' 0 N--CA 1.494 1.733 0 N-CA-C 106.72 -1.585 . . . . 0.0 106.72 179.705 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -69.98 78.89 0.48 Allowed 'General case' 0 N--CA 1.501 2.107 0 CA-C-O 121.747 0.784 . . . . 0.0 112.109 -179.94 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 58.18 63.38 5.3 Favored Glycine 0 N--CA 1.504 3.205 0 CA-C-N 114.246 -1.343 . . . . 0.0 112.929 179.653 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 14.5 Cg_endo -71.19 25.86 0.22 Allowed 'Trans proline' 0 N--CA 1.503 2.037 1 C-N-CA 125.493 4.129 . . . . 0.0 115.224 -166.581 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 13.8 mtt-85 -140.76 162.07 50.79 Favored Pre-proline 0 N--CA 1.49 1.554 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 179.819 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_endo -67.86 64.01 0.93 Allowed 'Trans proline' 0 N--CA 1.497 1.729 0 C-N-CA 124.001 3.134 . . . . 0.0 113.765 -179.523 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . 0.496 ' C ' ' H ' ' A' ' 16' ' ' ASN . 47.7 mtm180 -137.47 136.19 37.51 Favored 'General case' 0 N--CA 1.493 1.702 0 N-CA-C 103.3 -2.852 . . . . 0.0 103.3 179.736 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 77.58 -34.14 1.6 Allowed Glycine 0 N--CA 1.508 3.459 0 C-N-CA 120.155 -1.021 . . . . 0.0 110.874 -179.817 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . 0.496 ' H ' ' C ' ' A' ' 14' ' ' ARG . 1.2 m-80 81.46 -56.6 0.27 Allowed 'General case' 0 N--CA 1.505 2.298 0 C-N-CA 125.929 1.692 . . . . 0.0 106.626 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 86.6 m -151.0 155.92 40.07 Favored 'General case' 0 N--CA 1.497 1.918 0 N-CA-C 105.593 -2.002 . . . . 0.0 105.593 179.593 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 47.1 mt 71.68 111.79 0.06 Allowed 'General case' 0 N--CA 1.511 2.613 0 O-C-N 124.596 1.185 . . . . 0.0 110.593 179.874 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 5.5 t -144.64 32.27 1.17 Allowed 'General case' 0 N--CA 1.5 2.074 0 C-N-CA 120.019 -0.672 . . . . 0.0 110.079 -179.902 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.447 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -173.83 -178.01 43.46 Favored Glycine 0 N--CA 1.5 2.904 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 28.8 mm -134.43 144.11 36.03 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.361 0 N-CA-C 107.072 -1.455 . . . . 0.0 107.072 -179.801 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.454 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.4 pp -66.78 156.62 35.01 Favored 'General case' 0 N--CA 1.491 1.621 0 C-N-CA 118.606 -1.238 . . . . 0.0 108.968 179.715 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.4 ' CE2' ' HG3' ' A' ' 30' ' ' PRO . 35.7 m95 -136.84 134.15 36.63 Favored 'General case' 0 C--N 1.304 -1.371 0 N-CA-C 117.948 2.573 . . . . 0.0 117.948 -179.789 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -89.92 42.49 1.1 Allowed 'General case' 0 C--N 1.296 -1.735 1 CA-C-N 107.784 -4.28 . . . . 0.0 112.411 -179.788 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.445 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 1.3 m-30 -116.3 136.96 23.16 Favored Pre-proline 0 C--N 1.303 -1.418 0 CA-C-O 121.985 0.897 . . . . 0.0 108.749 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -70.02 -17.43 36.39 Favored 'Trans proline' 0 C--N 1.298 -2.082 0 C-N-CA 122.717 2.278 . . . . 0.0 108.607 179.84 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 10.6 p -95.71 23.54 6.1 Favored 'General case' 0 N--CA 1.488 1.445 0 CA-C-N 113.776 -1.556 . . . . 0.0 109.513 179.765 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.587 ' HA2' ' CG ' ' A' ' 45' ' ' TRP . . . 83.13 -94.33 1.76 Allowed Glycine 0 N--CA 1.487 2.053 0 N-CA-C 104.209 -3.556 . . . . 0.0 104.209 -179.677 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . 0.579 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 25.2 m -98.47 165.27 15.47 Favored Pre-proline 0 C--N 1.301 -1.515 0 CA-C-N 113.777 -1.211 . . . . 0.0 110.604 -179.934 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.671 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.1 OUTLIER -88.59 161.48 6.51 Favored 'Trans proline' 0 C--N 1.312 -1.393 1 C-N-CA 125.881 4.387 . . . . 0.0 115.818 156.241 . . . . . . . . 4 4 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 14.0 p -51.55 113.55 1.0 Allowed 'General case' 0 C--N 1.301 -1.512 0 CA-C-N 112.132 -2.303 . . . . 0.0 113.16 -179.758 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 115.94 -6.76 19.7 Favored Glycine 0 N--CA 1.502 3.097 0 O-C-N 124.842 1.339 . . . . 0.0 111.12 179.692 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' TRP . . . . . 0.671 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 42.6 m95 -110.06 173.13 6.47 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 106.156 -1.794 . . . . 0.0 106.156 -179.849 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 77.5 t60 -149.91 29.29 0.74 Allowed 'General case' 0 N--CA 1.496 1.841 0 C-N-CA 117.935 -1.506 . . . . 0.0 112.668 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . 0.603 ' HA ' ' SG ' ' A' ' 47' ' ' CYS . 1.8 t30 62.07 153.35 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.753 0 CA-C-N 114.245 -1.343 . . . . 0.0 111.637 -179.751 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.532 ' SG ' ' HB3' ' A' ' 46' ' ' CYS . 13.9 p -117.68 -39.95 3.08 Favored 'General case' 0 N--CA 1.499 2.024 0 N-CA-C 114.924 1.453 . . . . 0.0 114.924 -179.499 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . 0.473 ' C ' ' H ' ' A' ' 39' ' ' HIS . 74.0 tttt -131.4 132.12 44.13 Favored 'General case' 0 N--CA 1.5 2.047 0 N-CA-C 103.532 -2.766 . . . . 0.0 103.532 179.59 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -78.8 22.4 0.37 Allowed 'General case' 0 N--CA 1.495 1.802 0 C-N-CA 117.553 -1.659 . . . . 0.0 107.985 179.716 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . 0.473 ' H ' ' C ' ' A' ' 37' ' ' LYS . 9.5 m-70 -138.79 107.43 5.89 Favored 'General case' 0 N--CA 1.496 1.829 0 N-CA-C 113.713 1.005 . . . . 0.0 113.713 -179.395 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 60.78 -161.93 22.4 Favored Glycine 0 N--CA 1.502 3.08 0 CA-C-N 114.311 -1.313 . . . . 0.0 113.901 179.547 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . 0.431 ' HD2' ' N ' ' A' ' 46' ' ' CYS . 73.0 Cg_endo -55.32 179.93 1.19 Allowed 'Cis proline' 0 N--CA 1.505 2.188 0 C-N-CA 129.362 0.984 . . . . 0.0 114.436 -5.499 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.2 m120 -92.98 -8.25 43.62 Favored 'General case' 0 C--N 1.306 -1.294 0 N-CA-C 104.496 -2.409 . . . . 0.0 104.496 -179.783 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 11.4 mm -100.96 28.86 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.02 0 CA-C-O 123.675 1.703 . . . . 0.0 113.86 -179.008 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 136.01 -131.65 5.81 Favored Glycine 0 N--CA 1.485 1.906 1 N-CA-C 101.762 -4.535 . . . . 0.0 101.762 179.888 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . 0.587 ' CG ' ' HA2' ' A' ' 28' ' ' GLY . 3.0 m95 -153.33 161.29 42.5 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 105.268 -2.123 . . . . 0.0 105.268 179.646 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' CYS . . . . . 0.532 ' HB3' ' SG ' ' A' ' 36' ' ' CYS . 19.3 m -111.54 133.97 53.45 Favored 'General case' 0 N--CA 1.498 1.943 0 CA-C-N 123.037 2.653 . . . . 0.0 104.278 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.603 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 79.0 m -135.12 -173.4 3.31 Favored 'General case' 0 C--N 1.293 -1.865 0 CA-C-N 111.287 -2.688 . . . . 0.0 108.143 -179.399 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -150.6 175.89 11.5 Favored 'General case' 0 C--N 1.294 -1.805 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 179.225 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . 0.456 ' HE3' ' CZ2' ' A' ' 33' ' ' TRP . 22.6 mmtp . . . . . 0 C--N 1.293 -1.861 0 CA-C-O 114.98 -2.438 . . . . 0.0 107.275 179.5 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 2.733 0 N-CA-C 110.46 -1.056 . . . . 0.0 110.46 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 45.7 t -112.58 135.61 21.52 Favored Pre-proline 0 N--CA 1.493 1.699 0 N-CA-C 104.916 -2.253 . . . . 0.0 104.916 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -70.61 135.19 27.85 Favored 'Trans proline' 0 C--N 1.306 -1.659 0 C-N-CA 123.481 2.787 . . . . 0.0 112.132 175.21 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.416 ' SG ' ' HB2' ' A' ' 22' ' ' LEU . 0.5 OUTLIER -139.64 174.66 10.28 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 123.968 0.792 . . . . 0.0 111.869 -179.995 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 13.6 tp -97.8 152.17 19.44 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 102.065 -3.309 . . . . 0.0 102.065 179.766 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.417 ' HB3' ' C ' ' A' ' 36' ' ' CYS . 2.7 m -115.44 -138.08 0.37 Allowed 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 121.007 3.706 . . . . 0.0 121.007 -178.669 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -52.34 -25.08 8.77 Favored 'General case' 0 N--CA 1.502 2.163 0 C-N-CA 119.643 -0.823 . . . . 0.0 111.706 -179.699 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 12.6 t -94.75 19.62 9.79 Favored 'General case' 0 N--CA 1.499 2.015 0 CA-C-O 121.752 0.786 . . . . 0.0 109.336 179.762 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -75.8 75.16 2.75 Favored 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 107.591 -1.263 . . . . 0.0 107.591 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -157.83 -84.52 0.05 OUTLIER Glycine 0 N--CA 1.489 2.22 0 CA-C-N 112.716 -2.038 . . . . 0.0 108.955 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_endo -76.17 37.85 0.56 Allowed 'Trans proline' 0 N--CA 1.5 1.911 1 C-N-CA 125.748 4.298 . . . . 0.0 112.512 -167.562 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 1.4 tpt180 -121.85 132.54 24.22 Favored Pre-proline 0 N--CA 1.495 1.799 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 -179.711 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -77.48 -166.87 0.42 Allowed 'Trans proline' 0 C--N 1.314 -1.243 0 C-N-CA 123.735 2.957 . . . . 0.0 111.499 176.888 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 54.7 mtt180 -74.57 158.09 34.32 Favored 'General case' 0 N--CA 1.494 1.77 0 N-CA-C 107.927 -1.138 . . . . 0.0 107.927 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 148.63 -44.17 0.77 Allowed Glycine 0 N--CA 1.498 2.804 0 N-CA-C 108.76 -1.736 . . . . 0.0 108.76 179.861 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 8.3 t-20 75.13 85.29 0.1 Allowed 'General case' 0 N--CA 1.501 2.098 0 CA-C-N 113.686 -1.257 . . . . 0.0 109.343 179.917 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.3 m -94.08 120.77 34.8 Favored 'General case' 0 N--CA 1.494 1.761 0 CA-C-N 113.76 -1.564 . . . . 0.0 109.195 -179.845 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 2.4 mp -66.26 88.34 0.12 Allowed 'General case' 0 N--CA 1.499 1.986 0 CA-C-O 121.391 0.615 . . . . 0.0 110.944 179.793 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 27.3 t -90.25 -16.82 28.6 Favored 'General case' 0 N--CA 1.5 2.04 0 CA-C-O 118.051 -0.976 . . . . 0.0 113.537 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.449 ' HA2' ' HD3' ' A' ' 48' ' ' LYS . . . -177.33 152.23 11.84 Favored Glycine 0 N--CA 1.501 2.985 0 C-N-CA 119.234 -1.46 . . . . 0.0 111.508 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.462 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 38.8 mm -101.31 137.49 28.79 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.206 0 C-N-CA 117.3 -1.76 . . . . 0.0 106.718 179.623 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . 0.514 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 30.8 tp -63.03 136.3 57.74 Favored 'General case' 0 C--N 1.295 -1.786 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 179.821 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 39.5 m95 -127.06 134.94 50.18 Favored 'General case' 0 C--N 1.31 -1.124 0 CA-C-O 125.397 2.522 . . . . 0.0 117.703 -179.848 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -88.73 40.65 0.98 Allowed 'General case' 0 C--N 1.295 -1.767 1 CA-C-N 107.669 -4.332 . . . . 0.0 113.98 -179.539 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.468 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 1.2 m-30 -115.17 122.22 33.68 Favored Pre-proline 0 N--CA 1.489 1.514 0 CA-C-O 122.86 1.314 . . . . 0.0 113.909 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo -63.66 -23.32 69.93 Favored 'Trans proline' 0 C--N 1.301 -1.938 0 C-N-CA 122.268 1.978 . . . . 0.0 108.924 -173.077 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 10.6 p -93.27 8.83 38.74 Favored 'General case' 0 N--CA 1.492 1.635 0 CA-C-N 114.502 -1.227 . . . . 0.0 112.651 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 112.04 -118.63 4.78 Favored Glycine 0 N--CA 1.495 2.62 0 N-CA-C 107.001 -2.439 . . . . 0.0 107.001 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . 0.471 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 14.8 m -96.21 159.54 31.86 Favored Pre-proline 0 C--N 1.303 -1.444 0 N-CA-C 107.504 -1.295 . . . . 0.0 107.504 179.8 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . 0.685 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 1.6 Cg_endo -78.35 159.56 29.38 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 C-N-CA 122.338 2.025 . . . . 0.0 112.126 169.588 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 27.9 t -49.61 121.97 5.79 Favored 'General case' 0 C--N 1.303 -1.438 0 CA-C-N 113.345 -1.752 . . . . 0.0 108.96 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 109.68 -6.3 31.36 Favored Glycine 0 N--CA 1.498 2.806 0 CA-C-N 113.279 -1.782 . . . . 0.0 111.655 179.673 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' TRP . . . . . 0.685 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 51.0 m95 -113.61 158.12 21.23 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 105.957 -1.868 . . . . 0.0 105.957 -179.938 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 50.6 t-80 -140.13 37.15 1.92 Allowed 'General case' 0 N--CA 1.493 1.7 0 C-N-CA 118.974 -1.09 . . . . 0.0 111.08 -179.774 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . 0.493 ' HA ' ' SG ' ' A' ' 47' ' ' CYS . 22.1 t-20 60.25 152.08 0.02 OUTLIER 'General case' 0 N--CA 1.504 2.225 0 CA-C-N 113.303 -1.772 . . . . 0.0 115.045 179.794 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . 0.548 ' SG ' ' CB ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -125.18 -48.55 1.72 Allowed 'General case' 0 N--CA 1.483 1.219 0 N-CA-C 105.869 -1.9 . . . . 0.0 105.869 -179.972 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 66.2 tttt -113.2 103.1 11.01 Favored 'General case' 0 C--N 1.305 -1.35 0 N-CA-C 105.709 -1.96 . . . . 0.0 105.709 179.719 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.426 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -88.96 18.56 4.76 Favored 'General case' 0 N--CA 1.497 1.885 0 CA-C-N 113.312 -1.767 . . . . 0.0 107.155 179.577 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' HIS . . . . . 0.426 ' ND1' ' C ' ' A' ' 38' ' ' ALA . 7.1 m-70 -129.29 37.37 4.04 Favored 'General case' 0 N--CA 1.489 1.509 0 CA-C-N 114.468 -1.242 . . . . 0.0 109.05 -179.733 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 96.9 -158.32 21.29 Favored Glycine 0 N--CA 1.501 3.009 0 N-CA-C 110.207 -1.157 . . . . 0.0 110.207 179.803 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . 0.421 ' HG2' ' O ' ' A' ' 44' ' ' GLY . 9.2 Cg_endo -74.44 -176.66 18.11 Favored 'Cis proline' 0 N--CA 1.505 2.159 0 CA-C-N 118.914 1.357 . . . . 0.0 110.91 1.448 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.465 ' C ' ' H ' ' A' ' 44' ' ' GLY . 19.4 p-10 -92.32 -11.3 35.49 Favored 'General case' 0 N--CA 1.491 1.578 0 N-CA-C 105.016 -2.216 . . . . 0.0 105.016 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 13.0 mm -88.4 29.05 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.31 0 CA-C-N 113.807 -1.542 . . . . 0.0 110.598 -179.427 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.465 ' H ' ' C ' ' A' ' 42' ' ' ASN . . . 115.37 130.64 4.81 Favored Glycine 0 N--CA 1.49 2.24 0 CA-C-N 112.414 -2.175 . . . . 0.0 107.853 -179.871 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' TRP . . . . . 0.468 ' NE1' ' O ' ' A' ' 25' ' ' TYR . 2.1 m95 -73.85 134.67 43.34 Favored 'General case' 0 N--CA 1.499 1.98 0 N-CA-C 105.882 -1.896 . . . . 0.0 105.882 -179.434 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' CYS . . . . . 0.548 ' CB ' ' SG ' ' A' ' 36' ' ' CYS . 96.0 m -87.9 128.78 35.36 Favored 'General case' 0 N--CA 1.491 1.62 0 N-CA-C 101.314 -3.587 . . . . 0.0 101.314 179.575 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.493 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 73.7 m -126.71 -176.28 3.65 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-N 113.28 -1.782 . . . . 0.0 113.755 -179.317 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' LYS . . . . . 0.51 ' HD2' ' H ' ' A' ' 49' ' ' LYS . 28.5 tptp -150.76 150.84 31.51 Favored 'General case' 0 C--N 1.292 -1.913 0 CA-C-N 114.931 -1.031 . . . . 0.0 109.817 -179.944 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . 0.51 ' H ' ' HD2' ' A' ' 48' ' ' LYS . 54.1 mtpt . . . . . 0 N--CA 1.501 2.085 0 O-C-N 126.16 2.162 . . . . 0.0 109.666 179.458 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 24.6 t . . . . . 0 N--CA 1.497 1.876 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.412 ' HA ' ' O ' ' A' ' 20' ' ' GLY . 4.9 Cg_endo -81.33 142.13 13.12 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 C-N-CA 123.293 2.662 . . . . 0.0 110.932 164.718 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -137.52 170.03 16.78 Favored 'General case' 0 N--CA 1.495 1.784 0 C-N-CA 119.455 -0.898 . . . . 0.0 111.659 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.534 HD23 ' N ' ' A' ' 6' ' ' CYS . 5.5 tt -85.62 148.05 26.1 Favored 'General case' 0 N--CA 1.495 1.792 0 N-CA-C 106.752 -1.573 . . . . 0.0 106.752 -179.823 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 6' ' ' CYS . . . . . 0.546 ' HB3' ' C ' ' A' ' 36' ' ' CYS . 2.4 m -127.73 -167.03 1.69 Allowed 'General case' 0 N--CA 1.488 1.443 0 N-CA-C 119.197 3.036 . . . . 0.0 119.197 -179.621 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 21.2 t70 . . . . . 0 N--CA 1.503 2.199 0 CA-C-N 112.932 -1.94 . . . . 0.0 112.353 -179.762 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 34.6 m . . . . . 0 N--CA 1.505 2.309 0 N-CA-C 113.099 0.777 . . . . 0.0 113.099 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.412 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -157.01 150.43 21.57 Favored Glycine 0 N--CA 1.493 2.46 0 N-CA-C 107.859 -2.096 . . . . 0.0 107.859 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.458 ' N ' ' O ' ' A' ' 47' ' ' CYS . 44.9 mm -113.48 152.99 15.1 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.282 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.528 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 4.2 pp -76.26 151.13 36.87 Favored 'General case' 0 N--CA 1.501 2.077 0 C-N-CA 117.908 -1.517 . . . . 0.0 108.714 179.569 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 30.0 m95 -132.68 130.3 39.92 Favored 'General case' 0 N--CA 1.485 1.288 0 N-CA-C 119.293 3.071 . . . . 0.0 119.293 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -88.28 53.06 2.61 Favored 'General case' 0 C--N 1.295 -1.804 0 CA-C-N 108.569 -3.923 . . . . 0.0 111.377 -179.495 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.462 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 2.3 m-85 -126.14 121.13 23.92 Favored Pre-proline 0 N--CA 1.495 1.784 0 CA-C-N 115.497 -0.774 . . . . 0.0 112.481 179.605 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -64.68 -19.58 64.73 Favored 'Trans proline' 0 C--N 1.307 -1.635 0 C-N-CA 123.941 3.094 . . . . 0.0 111.328 -177.281 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 6.1 p -94.81 11.37 31.78 Favored 'General case' 0 N--CA 1.489 1.507 0 CA-C-N 115.06 -0.973 . . . . 0.0 111.1 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 101.33 -121.83 7.37 Favored Glycine 0 N--CA 1.498 2.77 0 N-CA-C 106.198 -2.761 . . . . 0.0 106.198 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.544 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 24.9 m -89.15 148.88 41.89 Favored Pre-proline 0 C--N 1.305 -1.348 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 179.72 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.723 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 19.5 Cg_endo -74.19 166.92 28.41 Favored 'Trans proline' 0 C--N 1.31 -1.466 0 C-N-CA 122.211 1.941 . . . . 0.0 114.143 172.895 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 9.4 t -53.89 114.52 1.6 Allowed 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 113.989 -1.46 . . . . 0.0 110.285 -179.755 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 113.6 -7.08 24.33 Favored Glycine 0 N--CA 1.5 2.948 0 CA-C-N 113.906 -1.497 . . . . 0.0 112.319 179.549 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' TRP . . . . . 0.723 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 53.7 m95 -110.29 166.24 11.13 Favored 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 106.745 -1.576 . . . . 0.0 106.745 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 57.3 t-80 -146.04 29.82 1.07 Allowed 'General case' 0 N--CA 1.503 2.185 0 C-N-CA 117.911 -1.516 . . . . 0.0 113.95 -179.737 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' ASN . . . . . 0.544 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 23.3 t-20 64.1 152.03 0.04 OUTLIER 'General case' 0 N--CA 1.506 2.335 0 N-CA-C 115.164 1.542 . . . . 0.0 115.164 -179.818 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.717 ' SG ' ' HB3' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -130.16 -45.77 1.12 Allowed 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 113.32 -1.764 . . . . 0.0 107.543 -179.819 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 37' ' ' LYS . . . . . 0.497 ' C ' ' H ' ' A' ' 39' ' ' HIS . 82.7 tttt -118.57 103.11 9.41 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-O 122.858 1.313 . . . . 0.0 108.837 179.912 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.432 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -81.48 25.25 0.52 Allowed 'General case' 0 N--CA 1.494 1.761 0 N-CA-C 107.181 -1.414 . . . . 0.0 107.181 179.603 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' HIS . . . . . 0.497 ' H ' ' C ' ' A' ' 37' ' ' LYS . 5.5 m-70 -131.13 10.24 4.91 Favored 'General case' 0 N--CA 1.492 1.636 0 N-CA-C 108.628 -0.878 . . . . 0.0 108.628 -179.727 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 125.43 -142.62 13.91 Favored Glycine 0 N--CA 1.498 2.778 0 N-CA-C 110.168 -1.173 . . . . 0.0 110.168 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' PRO . . . . . 0.578 ' CD ' ' SG ' ' A' ' 46' ' ' CYS . 85.8 Cg_endo -66.12 -174.66 6.29 Favored 'Cis proline' 0 N--CA 1.5 1.856 0 CA-C-N 118.289 1.045 . . . . 0.0 110.251 -1.872 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 4.1 m-20 -91.7 -8.83 45.9 Favored 'General case' 0 CA--C 1.479 -1.786 0 N-CA-C 105.617 -1.994 . . . . 0.0 105.617 -179.147 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 37.4 mt -95.06 33.33 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.163 0 CA-C-O 123.624 1.678 . . . . 0.0 109.114 -179.495 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.405 ' O ' ' HG2' ' A' ' 41' ' ' PRO . . . 114.06 135.54 6.11 Favored Glycine 0 N--CA 1.485 1.923 0 CA-C-N 111.275 -2.693 . . . . 0.0 107.41 -179.897 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' TRP . . . . . 0.462 ' NE1' ' O ' ' A' ' 25' ' ' TYR . 6.1 m95 -64.17 134.59 55.12 Favored 'General case' 0 N--CA 1.508 2.454 0 CA-C-O 116.796 -1.573 . . . . 0.0 106.787 -179.544 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 46' ' ' CYS . . . . . 0.717 ' HB3' ' SG ' ' A' ' 36' ' ' CYS . 35.4 m -89.45 124.15 34.23 Favored 'General case' 0 C--N 1.312 -1.063 0 N-CA-C 103.081 -2.933 . . . . 0.0 103.081 179.922 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.538 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 73.4 m -127.4 -169.74 2.1 Favored 'General case' 0 C--N 1.291 -1.972 0 CA-C-N 110.921 -2.854 . . . . 0.0 107.899 -179.533 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.411 ' N ' ' CD ' ' A' ' 48' ' ' LYS . 0.0 OUTLIER -151.67 173.2 14.96 Favored 'General case' 0 C--N 1.292 -1.924 0 N-CA-C 105.175 -2.157 . . . . 0.0 105.175 179.058 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 90.2 mttt . . . . . 0 C--N 1.289 -2.028 0 CA-C-O 114.691 -2.576 . . . . 0.0 106.392 179.524 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 22.4 t . . . . . 0 N--CA 1.495 1.777 0 N-CA-C 103.912 -2.625 . . . . 0.0 103.912 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -68.27 149.43 75.77 Favored 'Trans proline' 0 C--N 1.305 -1.75 0 C-N-CA 122.98 2.453 . . . . 0.0 108.038 170.78 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 1.2 p -141.72 175.02 10.03 Favored 'General case' 0 N--CA 1.495 1.811 0 N-CA-C 115.242 1.571 . . . . 0.0 115.242 -179.755 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.417 HD12 ' HA ' ' A' ' 5' ' ' LEU . 23.5 tp -104.16 150.03 24.72 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 103.682 -2.71 . . . . 0.0 103.682 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 6' ' ' CYS . . . . . 0.443 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 3.3 m -133.11 -162.51 1.25 Allowed 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 116.299 1.963 . . . . 0.0 116.299 -179.04 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 3.2 p-10 . . . . . 0 N--CA 1.499 1.989 0 O-C-N 126.751 2.532 . . . . 0.0 111.851 -179.967 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 25.0 m . . . . . 0 N--CA 1.502 2.138 0 N-CA-C 112.263 0.468 . . . . 0.0 112.263 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -164.74 179.59 39.34 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 108.945 -1.662 . . . . 0.0 108.945 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 34.3 mm -125.06 149.41 29.62 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.174 0 N-CA-C 108.42 -0.955 . . . . 0.0 108.42 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.664 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 4.5 pp -71.17 148.44 47.34 Favored 'General case' 0 N--CA 1.498 1.946 0 C-N-CA 118.513 -1.275 . . . . 0.0 110.875 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 38.2 m95 -131.4 131.47 43.66 Favored 'General case' 0 N--CA 1.486 1.36 0 N-CA-C 120.389 3.477 . . . . 0.0 120.389 -179.821 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -88.87 49.58 1.81 Allowed 'General case' 0 C--N 1.296 -1.734 1 CA-C-N 106.862 -4.699 . . . . 0.0 112.785 -179.389 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.407 ' CE1' ' HB3' ' A' ' 30' ' ' PRO . 2.2 m-85 -121.21 130.76 24.69 Favored Pre-proline 0 C--N 1.302 -1.468 0 CA-C-O 122.436 1.113 . . . . 0.0 111.3 179.525 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -69.79 -24.28 29.69 Favored 'Trans proline' 0 C--N 1.308 -1.595 0 C-N-CA 124.647 3.565 . . . . 0.0 110.662 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 6.1 p -93.63 15.12 16.97 Favored 'General case' 0 N--CA 1.492 1.642 0 CA-C-N 115.405 -0.816 . . . . 0.0 111.307 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 99.64 -126.01 8.77 Favored Glycine 0 N--CA 1.5 2.901 0 N-CA-C 105.674 -2.97 . . . . 0.0 105.674 -179.88 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.541 ' SG ' ' CA ' ' A' ' 35' ' ' ASN . 35.7 m -86.66 152.24 54.02 Favored Pre-proline 0 C--N 1.304 -1.403 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 179.721 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.758 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 19.9 Cg_endo -73.04 165.83 31.71 Favored 'Trans proline' 0 C--N 1.305 -1.719 0 C-N-CA 122.525 2.15 . . . . 0.0 113.906 173.392 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 5.6 p -51.73 107.42 0.19 Allowed 'General case' 0 C--N 1.298 -1.632 0 CA-C-N 112.341 -2.209 . . . . 0.0 112.247 -179.741 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 115.34 -7.85 20.65 Favored Glycine 0 N--CA 1.498 2.826 0 O-C-N 124.514 1.134 . . . . 0.0 111.737 179.594 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' TRP . . . . . 0.758 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 45.7 m95 -105.76 166.87 10.16 Favored 'General case' 0 C--N 1.304 -1.389 0 N-CA-C 106.143 -1.799 . . . . 0.0 106.143 -179.874 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 54.0 t-80 -147.03 33.82 0.91 Allowed 'General case' 0 N--CA 1.497 1.894 0 C-N-CA 117.337 -1.745 . . . . 0.0 112.884 -179.648 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' ASN . . . . . 0.541 ' CA ' ' SG ' ' A' ' 29' ' ' CYS . 24.9 t-20 60.44 143.29 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.13 0 N-CA-C 115.187 1.551 . . . . 0.0 115.187 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.876 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 1.7 p -120.99 -41.16 2.56 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-N 114.28 -1.327 . . . . 0.0 108.448 -179.628 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' LYS . . . . . 0.403 ' HG2' ' H ' ' A' ' 39' ' ' HIS . 77.3 tttt -118.84 116.31 26.23 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 104.708 -2.33 . . . . 0.0 104.708 179.748 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -89.41 8.08 32.62 Favored 'General case' 0 N--CA 1.496 1.827 0 N-CA-C 107.475 -1.306 . . . . 0.0 107.475 179.79 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' HIS . . . . . 0.403 ' H ' ' HG2' ' A' ' 37' ' ' LYS . 16.2 m-70 -133.04 48.86 2.36 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-N 115.001 -0.999 . . . . 0.0 110.876 -179.708 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 113.41 -165.11 12.01 Favored Glycine 0 N--CA 1.497 2.705 0 O-C-N 124.293 0.995 . . . . 0.0 113.47 179.581 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 15.0 Cg_endo -73.75 -174.01 12.46 Favored 'Cis proline' 0 N--CA 1.497 1.703 0 O-C-N 123.085 1.045 . . . . 0.0 110.933 -5.182 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 6.7 m120 -92.08 -10.68 38.16 Favored 'General case' 0 CA--C 1.484 -1.587 0 N-CA-C 104.579 -2.378 . . . . 0.0 104.579 -179.676 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 33.0 pt -92.04 27.22 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.03 0 C-N-CA 118.204 -1.398 . . . . 0.0 113.689 -179.434 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 116.76 130.85 4.55 Favored Glycine 0 N--CA 1.489 2.215 0 CA-C-N 111.831 -2.44 . . . . 0.0 108.693 -179.911 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' TRP . . . . . 0.4 ' NE1' ' O ' ' A' ' 25' ' ' TYR . 8.5 m95 -54.06 131.76 41.36 Favored 'General case' 0 N--CA 1.513 2.704 0 CA-C-O 116.248 -1.834 . . . . 0.0 107.56 -179.56 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 46' ' ' CYS . . . . . 0.876 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 53.3 t -89.44 131.85 35.3 Favored 'General case' 0 N--CA 1.479 0.983 1 N-CA-C 99.333 -4.321 . . . . 0.0 99.333 -179.882 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.459 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 86.2 m -133.74 -173.55 3.27 Favored 'General case' 0 C--N 1.292 -1.9 0 CA-C-N 111.056 -2.793 . . . . 0.0 109.876 -179.166 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.449 ' O ' ' HA ' ' A' ' 33' ' ' TRP . 0.0 OUTLIER -150.48 173.47 14.03 Favored 'General case' 0 C--N 1.297 -1.695 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 179.376 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 3.7 mmpt? . . . . . 0 N--CA 1.502 2.131 0 O-C-N 126.618 2.449 . . . . 0.0 110.874 179.929 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 21.8 t . . . . . 0 N--CA 1.5 2.051 0 N-CA-C 106.686 -1.598 . . . . 0.0 106.686 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -74.47 134.55 18.94 Favored 'Trans proline' 0 C--N 1.306 -1.681 0 C-N-CA 123.048 2.498 . . . . 0.0 117.73 163.819 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -128.82 173.66 10.16 Favored 'General case' 0 N--CA 1.493 1.679 0 N-CA-C 107.589 -1.263 . . . . 0.0 107.589 179.509 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.594 HD23 ' N ' ' A' ' 6' ' ' CYS . 5.4 tt -90.64 147.24 23.43 Favored 'General case' 0 N--CA 1.496 1.866 0 N-CA-C 103.665 -2.717 . . . . 0.0 103.665 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 6' ' ' CYS . . . . . 0.594 ' N ' HD23 ' A' ' 5' ' ' LEU . 4.4 m -128.34 -171.49 2.47 Favored 'General case' 0 C--N 1.307 -1.271 0 N-CA-C 116.005 1.854 . . . . 0.0 116.005 -179.851 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 34.1 t70 . . . . . 0 N--CA 1.489 1.481 0 CA-C-N 113.196 -1.82 . . . . 0.0 107.575 179.945 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 4.1 t . . . . . 0 N--CA 1.5 2.052 0 CA-C-O 121.505 0.669 . . . . 0.0 110.407 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.516 ' HA3' ' SG ' ' A' ' 6' ' ' CYS . . . -172.48 121.57 0.88 Allowed Glycine 0 N--CA 1.494 2.503 0 N-CA-C 107.065 -2.414 . . . . 0.0 107.065 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.457 ' N ' ' O ' ' A' ' 47' ' ' CYS . 36.3 mm -96.09 137.34 24.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 N-CA-C 104.691 -2.337 . . . . 0.0 104.691 179.736 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.562 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 4.3 pp -65.69 149.33 50.29 Favored 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 117.752 -1.579 . . . . 0.0 107.238 179.812 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.417 ' O ' ' CA ' ' A' ' 44' ' ' GLY . 20.2 m95 -132.17 135.78 46.6 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-O 124.542 2.115 . . . . 0.0 115.882 -179.727 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.1 m-85 -88.91 40.58 0.98 Allowed 'General case' 0 C--N 1.293 -1.849 0 CA-C-N 109.12 -3.673 . . . . 0.0 115.353 -179.383 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.444 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 1.2 m-30 -113.12 120.0 41.24 Favored Pre-proline 0 N--CA 1.487 1.396 0 N-CA-C 107.664 -1.236 . . . . 0.0 107.664 179.713 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -60.93 -21.28 70.53 Favored 'Trans proline' 0 C--N 1.298 -2.091 0 C-N-CA 122.511 2.14 . . . . 0.0 110.414 -170.207 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 4.3 p -97.45 3.67 50.77 Favored 'General case' 0 N--CA 1.491 1.6 0 CA-C-N 114.746 -1.115 . . . . 0.0 113.451 -179.923 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 125.58 -121.86 4.35 Favored Glycine 0 N--CA 1.492 2.38 0 N-CA-C 108.601 -1.8 . . . . 0.0 108.601 179.911 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.55 ' HB3' ' HB2' ' A' ' 33' ' ' TRP . 3.9 m -95.2 158.6 34.51 Favored Pre-proline 0 C--N 1.304 -1.375 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.727 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.3 OUTLIER -79.11 -179.24 5.27 Favored 'Trans proline' 0 C--N 1.312 -1.343 0 C-N-CA 123.242 2.628 . . . . 0.0 114.896 171.033 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 18.4 p -58.41 104.62 0.22 Allowed 'General case' 0 C--N 1.299 -1.591 0 CA-C-N 112.922 -1.944 . . . . 0.0 112.941 -179.587 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 114.15 3.63 22.82 Favored Glycine 0 N--CA 1.501 2.969 0 O-C-N 124.759 1.287 . . . . 0.0 113.561 179.628 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' TRP . . . . . 0.727 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 39.7 m95 -117.75 153.07 34.03 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 107.369 -1.345 . . . . 0.0 107.369 -179.822 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' HIS . . . . . 0.408 ' O ' ' ND1' ' A' ' 34' ' ' HIS . 36.6 t-80 -137.4 41.5 2.4 Favored 'General case' 0 N--CA 1.5 2.044 0 CA-C-O 122.074 0.94 . . . . 0.0 109.847 -179.496 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' ASN . . . . . 0.496 ' HA ' ' SG ' ' A' ' 47' ' ' CYS . 24.6 t-20 59.59 156.73 0.03 OUTLIER 'General case' 0 N--CA 1.501 2.089 0 CA-C-O 123.9 1.81 . . . . 0.0 114.286 -179.765 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.778 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -125.66 -52.18 1.58 Allowed 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 104.354 -2.461 . . . . 0.0 104.354 179.725 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 37' ' ' LYS . . . . . 0.464 ' C ' ' H ' ' A' ' 39' ' ' HIS . 43.7 tttp -118.26 103.98 10.35 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 113.615 -1.63 . . . . 0.0 109.74 179.836 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.44 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -81.82 30.96 0.37 Allowed 'General case' 0 N--CA 1.497 1.902 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 179.573 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' HIS . . . . . 0.464 ' H ' ' C ' ' A' ' 37' ' ' LYS . 4.5 m-70 -130.49 8.32 4.99 Favored 'General case' 0 N--CA 1.492 1.636 0 CA-C-N 115.53 -0.759 . . . . 0.0 108.957 -179.73 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 128.51 -152.98 19.4 Favored Glycine 0 N--CA 1.496 2.7 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 179.902 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' PRO . . . . . 0.43 ' HG2' ' O ' ' A' ' 44' ' ' GLY . 26.8 Cg_endo -72.68 -174.61 12.62 Favored 'Cis proline' 0 N--CA 1.508 2.324 0 O-C-N 122.808 0.899 . . . . 0.0 112.586 -2.414 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' ASN . . . . . 0.446 ' C ' ' H ' ' A' ' 44' ' ' GLY . 17.8 p-10 -91.88 -14.35 29.81 Favored 'General case' 0 CA--C 1.485 -1.533 0 N-CA-C 105.527 -2.027 . . . . 0.0 105.527 -179.654 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 11.0 mt -88.84 30.1 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.341 0 CA-C-N 113.809 -1.541 . . . . 0.0 109.617 -179.405 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.446 ' H ' ' C ' ' A' ' 42' ' ' ASN . . . 114.6 122.18 3.64 Favored Glycine 0 N--CA 1.491 2.347 0 CA-C-N 112.163 -2.289 . . . . 0.0 107.767 -179.853 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' TRP . . . . . 0.444 ' NE1' ' O ' ' A' ' 25' ' ' TYR . 3.9 m95 -54.68 138.79 40.85 Favored 'General case' 0 N--CA 1.514 2.735 0 CA-C-O 116.795 -1.574 . . . . 0.0 107.946 -179.378 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 46' ' ' CYS . . . . . 0.778 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 13.8 t -88.87 127.4 35.63 Favored 'General case' 0 C--N 1.309 -1.159 0 N-CA-C 102.587 -3.116 . . . . 0.0 102.587 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.496 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 98.0 m -128.9 176.51 7.8 Favored 'General case' 0 CA--C 1.478 -1.8 0 CA-C-N 112.009 -2.36 . . . . 0.0 113.656 -178.99 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.461 ' HD2' ' HA ' ' A' ' 48' ' ' LYS . 41.1 tptt -150.83 153.08 34.73 Favored 'General case' 0 C--N 1.295 -1.804 0 C-N-CA 118.785 -1.166 . . . . 0.0 109.405 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 7.4 mtpm? . . . . . 0 N--CA 1.5 2.037 0 CA-C-N 111.703 -2.499 . . . . 0.0 110.886 179.775 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 6.3 t . . . . . 0 N--CA 1.5 2.053 0 N-CA-C 106.512 -1.662 . . . . 0.0 106.512 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -79.03 119.86 4.43 Favored 'Trans proline' 0 C--N 1.308 -1.568 0 C-N-CA 122.491 2.127 . . . . 0.0 113.337 160.019 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.453 ' SG ' ' HB3' ' A' ' 22' ' ' LEU . 0.5 OUTLIER -104.59 -171.63 1.96 Allowed 'General case' 0 N--CA 1.495 1.802 0 CA-C-N 114.956 -1.02 . . . . 0.0 110.893 -179.975 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 4.2 tp -98.38 152.29 19.64 Favored 'General case' 0 N--CA 1.497 1.907 0 N-CA-C 104.593 -2.373 . . . . 0.0 104.593 179.838 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' CYS . . . . . 0.452 ' HB3' ' O ' ' A' ' 36' ' ' CYS . 3.1 m -132.59 -170.63 2.48 Favored 'General case' 0 N--CA 1.485 1.321 0 N-CA-C 115.41 1.633 . . . . 0.0 115.41 -179.62 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 17.2 t70 . . . . . 0 C--N 1.3 -1.583 0 CA-C-N 112.971 -1.922 . . . . 0.0 109.752 -179.922 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 4.5 t . . . . . 0 N--CA 1.502 2.144 0 N-CA-C 113.507 0.929 . . . . 0.0 113.507 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 165.43 -176.3 41.04 Favored Glycine 0 N--CA 1.512 3.738 0 C-N-CA 118.742 -1.694 . . . . 0.0 114.94 179.573 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.405 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 19.3 mm -134.19 149.16 29.97 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.245 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 179.57 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.587 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.5 pp -69.19 146.71 52.19 Favored 'General case' 0 N--CA 1.495 1.794 0 C-N-CA 119.333 -0.947 . . . . 0.0 110.859 179.709 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 37.5 m95 -130.62 130.33 43.83 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 121.374 3.842 . . . . 0.0 121.374 -179.571 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 4.4 m-85 -89.0 49.81 1.85 Allowed 'General case' 0 C--N 1.295 -1.795 1 CA-C-N 108.093 -4.14 . . . . 0.0 112.209 -179.687 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.44 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 2.2 m-85 -122.56 124.56 26.7 Favored Pre-proline 0 N--CA 1.494 1.765 0 N-CA-C 114.144 1.164 . . . . 0.0 114.144 179.876 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -64.16 -20.82 67.63 Favored 'Trans proline' 0 C--N 1.307 -1.641 0 C-N-CA 124.065 3.177 . . . . 0.0 110.935 -177.02 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 5.1 p -94.06 6.9 47.07 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-N 114.576 -1.193 . . . . 0.0 111.207 179.829 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 104.17 -112.52 4.15 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 105.252 -3.139 . . . . 0.0 105.252 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.537 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 13.5 m -96.55 147.96 33.73 Favored Pre-proline 0 C--N 1.305 -1.363 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 179.798 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.73 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 15.2 Cg_endo -74.23 174.67 12.08 Favored 'Trans proline' 0 C--N 1.308 -1.566 0 C-N-CA 122.628 2.219 . . . . 0.0 114.47 174.259 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 12.0 p -53.13 105.65 0.13 Allowed 'General case' 0 C--N 1.299 -1.63 0 CA-C-N 112.469 -2.151 . . . . 0.0 112.568 -179.694 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 111.92 -1.25 27.21 Favored Glycine 0 N--CA 1.503 3.139 0 O-C-N 124.156 0.91 . . . . 0.0 113.814 179.503 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' TRP . . . . . 0.73 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 52.1 m95 -110.45 166.79 10.71 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 108.053 -1.092 . . . . 0.0 108.053 -179.912 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 80.1 t60 -146.98 36.59 0.94 Allowed 'General case' 0 N--CA 1.5 2.03 0 C-N-CA 116.8 -1.96 . . . . 0.0 115.94 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' ASN . . . . . 0.537 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 0.4 OUTLIER 63.3 137.93 0.02 OUTLIER 'General case' 0 N--CA 1.506 2.326 0 N-CA-C 116.926 2.195 . . . . 0.0 116.926 179.714 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.688 ' SG ' ' HB3' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -118.06 -42.17 2.83 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 105.029 -2.211 . . . . 0.0 105.029 179.71 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 37' ' ' LYS . . . . . 0.442 ' HD2' ' HA ' ' A' ' 6' ' ' CYS . 57.3 tttt -136.38 120.54 17.79 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 114.824 -1.08 . . . . 0.0 109.544 179.766 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.437 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -97.99 34.21 1.97 Allowed 'General case' 0 N--CA 1.496 1.829 0 N-CA-C 105.505 -2.035 . . . . 0.0 105.505 179.645 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' HIS . . . . . 0.437 ' ND1' ' C ' ' A' ' 38' ' ' ALA . 3.8 m-70 -133.5 47.92 2.42 Favored 'General case' 0 N--CA 1.495 1.792 0 N-CA-C 106.225 -1.769 . . . . 0.0 106.225 -179.67 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 85.21 -156.61 31.02 Favored Glycine 0 N--CA 1.498 2.779 0 N-CA-C 107.416 -2.274 . . . . 0.0 107.416 -179.749 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 17.6 Cg_endo -72.13 -172.76 9.41 Favored 'Cis proline' 0 N--CA 1.494 1.555 0 CA-C-N 118.612 1.206 . . . . 0.0 112.053 2.5 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 80.2 m-20 -92.32 -15.49 27.3 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 104.647 -2.353 . . . . 0.0 104.647 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 13.5 mt -90.87 29.5 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.21 0 CA-C-N 113.272 -1.786 . . . . 0.0 111.425 -179.255 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 109.07 119.11 4.2 Favored Glycine 0 N--CA 1.491 2.31 0 CA-C-N 112.178 -2.283 . . . . 0.0 111.601 179.853 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' TRP . . . . . 0.44 ' NE1' ' O ' ' A' ' 25' ' ' TYR . 2.2 m95 -49.44 134.74 18.74 Favored 'General case' 0 N--CA 1.516 2.856 0 CA-C-O 116.231 -1.843 . . . . 0.0 107.449 -179.743 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 46' ' ' CYS . . . . . 0.688 ' HB3' ' SG ' ' A' ' 36' ' ' CYS . 68.5 m -89.45 128.22 35.93 Favored 'General case' 0 N--CA 1.485 1.32 0 N-CA-C 103.689 -2.708 . . . . 0.0 103.689 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.522 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 86.7 m -131.12 -173.49 3.11 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-N 111.955 -2.384 . . . . 0.0 110.314 -179.165 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.417 ' O ' ' HA ' ' A' ' 33' ' ' TRP . 0.0 OUTLIER -151.09 173.7 14.05 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 118.574 -1.25 . . . . 0.0 109.106 179.357 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 95.0 mttt . . . . . 0 C--N 1.292 -1.909 0 O-C-N 126.402 2.314 . . . . 0.0 107.927 179.488 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 9.1 t . . . . . 0 N--CA 1.495 1.81 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.443 ' HA ' ' O ' ' A' ' 20' ' ' GLY . 4.3 Cg_endo -77.2 131.64 11.99 Favored 'Trans proline' 0 N--CA 1.494 1.551 0 C-N-CA 124.067 3.178 . . . . 0.0 114.26 166.916 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -122.17 167.99 12.53 Favored 'General case' 0 N--CA 1.498 1.942 0 CA-C-O 122.602 1.191 . . . . 0.0 114.076 -179.702 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 12.7 tp -79.68 127.34 32.07 Favored 'General case' 0 N--CA 1.493 1.695 0 N-CA-C 106.907 -1.516 . . . . 0.0 106.907 -179.709 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 21.8 m -106.58 -174.11 2.46 Favored 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 118.844 -1.143 . . . . 0.0 112.883 179.65 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 16.3 t70 . . . . . 0 C--N 1.296 -1.727 0 CA-C-N 113.916 -1.493 . . . . 0.0 108.431 -179.778 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 3.2 p . . . . . 0 N--CA 1.488 1.47 0 CA-C-O 120.915 0.388 . . . . 0.0 111.901 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.443 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . 159.33 178.98 33.84 Favored Glycine 0 N--CA 1.499 2.853 0 N-CA-C 108.016 -2.034 . . . . 0.0 108.016 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.474 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 48.6 mm -127.84 145.97 34.24 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.974 0 N-CA-C 106.141 -1.8 . . . . 0.0 106.141 179.736 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.561 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.8 pp -69.67 152.18 45.0 Favored 'General case' 0 N--CA 1.491 1.617 0 C-N-CA 118.257 -1.377 . . . . 0.0 110.115 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.444 ' O ' ' HA3' ' A' ' 44' ' ' GLY . 37.6 m95 -136.41 130.73 33.15 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 118.884 2.92 . . . . 0.0 118.884 179.763 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 6.0 m-85 -89.48 51.47 2.12 Favored 'General case' 0 C--N 1.296 -1.756 1 CA-C-N 107.467 -4.424 . . . . 0.0 111.613 -179.692 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.484 ' CE1' ' HB3' ' A' ' 30' ' ' PRO . 2.4 m-85 -125.07 137.03 28.93 Favored Pre-proline 0 C--N 1.303 -1.414 0 CA-C-O 121.482 0.658 . . . . 0.0 109.613 179.646 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 96.9 Cg_endo -66.95 -30.31 39.72 Favored 'Trans proline' 0 C--N 1.305 -1.75 0 C-N-CA 124.264 3.309 . . . . 0.0 108.636 177.56 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 11.8 p -86.65 31.9 0.67 Allowed 'General case' 0 C--N 1.299 -1.611 0 CA-C-N 113.989 -1.459 . . . . 0.0 109.239 179.915 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.547 ' HA2' ' CD1' ' A' ' 45' ' ' TRP . . . 76.05 -92.76 0.94 Allowed Glycine 0 N--CA 1.482 1.764 0 N-CA-C 104.399 -3.48 . . . . 0.0 104.399 -179.499 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.568 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 9.4 m -103.75 165.91 12.65 Favored Pre-proline 0 C--N 1.301 -1.515 0 CA-C-N 113.814 -1.193 . . . . 0.0 110.609 -179.849 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.686 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.1 OUTLIER -86.01 167.11 9.64 Favored 'Trans proline' 0 CA--C 1.553 1.472 0 C-N-CA 125.238 3.959 . . . . 0.0 118.336 157.924 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 3.8 m -49.64 109.57 0.29 Allowed 'General case' 0 C--N 1.299 -1.604 0 CA-C-N 111.769 -2.469 . . . . 0.0 112.283 179.845 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 113.46 -6.6 24.66 Favored Glycine 0 N--CA 1.5 2.948 0 CA-C-N 115.218 -0.901 . . . . 0.0 111.901 179.743 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' TRP . . . . . 0.686 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 48.1 m95 -111.51 162.57 14.97 Favored 'General case' 0 N--CA 1.486 1.341 0 N-CA-C 106.321 -1.733 . . . . 0.0 106.321 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' HIS . . . . . 0.419 ' ND1' ' O ' ' A' ' 34' ' ' HIS . 60.0 t-80 -143.62 34.18 1.29 Allowed 'General case' 0 N--CA 1.498 1.962 0 C-N-CA 118.138 -1.425 . . . . 0.0 113.406 -179.733 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 35' ' ' ASN . . . . . 0.568 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 24.2 t-20 61.76 146.16 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.9 0 N-CA-C 114.375 1.25 . . . . 0.0 114.375 179.916 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.804 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -124.31 -45.74 1.95 Allowed 'General case' 0 N--CA 1.484 1.272 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.039 -179.715 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 37' ' ' LYS . . . . . 0.53 ' HG2' ' H ' ' A' ' 39' ' ' HIS . 36.0 ttmt -122.01 100.35 6.93 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 105.44 -2.059 . . . . 0.0 105.44 179.431 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -77.55 19.9 0.34 Allowed 'General case' 0 N--CA 1.5 2.034 0 CA-C-N 114.431 -1.259 . . . . 0.0 107.742 179.649 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' HIS . . . . . 0.53 ' H ' ' HG2' ' A' ' 37' ' ' LYS . 7.4 m-70 -132.75 16.82 4.29 Favored 'General case' 0 N--CA 1.487 1.378 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.476 -179.709 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 149.37 -177.8 27.32 Favored Glycine 0 N--CA 1.501 3.015 0 C-N-CA 119.412 -1.375 . . . . 0.0 111.432 179.695 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' PRO . . . . . 0.524 ' HD2' ' N ' ' A' ' 46' ' ' CYS . 35.5 Cg_endo -66.25 -171.89 4.45 Favored 'Cis proline' 0 N--CA 1.512 2.592 0 N-CA-C 116.167 1.564 . . . . 0.0 116.167 -4.604 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 16.1 p-10 -92.1 -12.76 32.11 Favored 'General case' 0 N--CA 1.486 1.336 0 N-CA-C 105.505 -2.035 . . . . 0.0 105.505 -179.715 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.43 HG12 ' HB2' ' A' ' 41' ' ' PRO . 12.1 pt -85.81 23.02 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.218 0 O-C-N 124.909 1.38 . . . . 0.0 113.814 -179.49 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.444 ' HA3' ' O ' ' A' ' 23' ' ' TRP . . . 134.63 -116.47 1.61 Allowed Glycine 0 C--N 1.291 -1.962 0 N-CA-C 104.404 -3.478 . . . . 0.0 104.404 -179.906 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' TRP . . . . . 0.547 ' CD1' ' HA2' ' A' ' 28' ' ' GLY . 1.8 m95 -157.03 151.28 25.09 Favored 'General case' 0 N--CA 1.509 2.501 0 N-CA-C 105.491 -2.04 . . . . 0.0 105.491 -179.891 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 46' ' ' CYS . . . . . 0.804 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 44.5 t -99.06 129.61 45.34 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 102.882 -3.006 . . . . 0.0 102.882 179.864 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.524 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 78.4 m -126.77 -170.7 2.25 Favored 'General case' 0 C--N 1.298 -1.641 0 CA-C-N 113.528 -1.669 . . . . 0.0 109.719 -179.409 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.412 ' HD3' ' H ' ' A' ' 48' ' ' LYS . 0.0 OUTLIER -150.58 172.72 15.06 Favored 'General case' 0 C--N 1.294 -1.822 0 N-CA-C 107.195 -1.409 . . . . 0.0 107.195 179.324 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 84.8 mttt . . . . . 0 N--CA 1.498 1.95 0 O-C-N 126.129 2.143 . . . . 0.0 109.131 179.456 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.408 ' HB ' HD23 ' A' ' 22' ' ' LEU . 11.4 t . . . . . 0 N--CA 1.494 1.766 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_endo -75.81 155.33 39.23 Favored 'Trans proline' 0 N--CA 1.496 1.65 0 C-N-CA 124.024 3.15 . . . . 0.0 112.963 166.717 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.408 ' SG ' ' SG ' ' A' ' 6' ' ' CYS . 9.4 p -132.39 170.78 14.61 Favored 'General case' 0 N--CA 1.499 1.982 0 C-N-CA 119.208 -0.997 . . . . 0.0 108.939 179.574 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 13.9 tp -86.64 81.21 8.32 Favored 'General case' 0 N--CA 1.491 1.624 0 N-CA-C 103.65 -2.722 . . . . 0.0 103.65 179.908 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' CYS . . . . . 0.408 ' SG ' ' SG ' ' A' ' 4' ' ' CYS . 6.6 m -69.18 170.96 9.1 Favored 'General case' 0 C--N 1.309 -1.188 0 CA-C-O 123.273 1.511 . . . . 0.0 112.375 -179.729 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 7.9 t70 . . . . . 0 N--CA 1.496 1.875 0 CA-C-N 111.07 -2.786 . . . . 0.0 111.301 -179.838 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 48.4 t . . . . . 0 N--CA 1.498 1.935 0 CA-C-O 119.071 -0.49 . . . . 0.0 110.304 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 174.05 -171.83 44.83 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 107.653 -2.179 . . . . 0.0 107.653 -179.882 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 1.2 mp -133.83 153.14 35.9 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.104 0 O-C-N 124.918 1.01 . . . . 0.0 108.553 -179.903 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.621 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.3 pp -71.33 146.34 48.9 Favored 'General case' 0 N--CA 1.499 1.998 0 C-N-CA 120.205 -0.598 . . . . 0.0 111.868 179.812 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.432 ' O ' ' CA ' ' A' ' 44' ' ' GLY . 39.0 m95 -129.08 130.28 46.32 Favored 'General case' 0 N--CA 1.491 1.603 0 N-CA-C 119.512 3.152 . . . . 0.0 119.512 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 3.5 m-85 -88.73 51.38 2.16 Favored 'General case' 0 C--N 1.294 -1.827 1 CA-C-N 107.886 -4.234 . . . . 0.0 113.154 -179.412 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 2.2 m-85 -120.79 142.33 34.21 Favored Pre-proline 0 C--N 1.3 -1.576 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 179.411 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -76.12 -33.16 3.71 Favored 'Trans proline' 0 C--N 1.3 -1.991 0 C-N-CA 125.063 3.842 . . . . 0.0 112.21 172.983 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 14.1 p -88.61 33.43 0.77 Allowed 'General case' 0 N--CA 1.494 1.735 0 CA-C-O 121.442 0.639 . . . . 0.0 111.083 -179.524 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 76.0 -158.82 50.09 Favored Glycine 0 N--CA 1.495 2.58 0 N-CA-C 105.912 -2.875 . . . . 0.0 105.912 -179.565 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.586 ' SG ' ' CA ' ' A' ' 35' ' ' ASN . 14.0 m -53.06 150.76 9.95 Favored Pre-proline 0 C--N 1.303 -1.441 0 CA-C-N 117.599 0.699 . . . . 0.0 111.941 179.816 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.739 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 4.6 Cg_endo -76.41 159.74 36.01 Favored 'Trans proline' 0 C--N 1.308 -1.566 0 C-N-CA 122.956 2.437 . . . . 0.0 112.043 171.759 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 16.5 t -49.14 129.67 18.13 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-N 113.332 -1.758 . . . . 0.0 109.522 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 97.81 -5.14 61.71 Favored Glycine 0 N--CA 1.496 2.697 0 CA-C-N 112.664 -2.062 . . . . 0.0 111.687 179.762 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' TRP . . . . . 0.739 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 48.1 m95 -111.91 163.77 13.85 Favored 'General case' 0 C--N 1.305 -1.332 0 N-CA-C 106.29 -1.745 . . . . 0.0 106.29 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' HIS . . . . . 0.401 ' O ' ' ND1' ' A' ' 34' ' ' HIS . 45.5 t-80 -144.24 34.39 1.21 Allowed 'General case' 0 N--CA 1.498 1.974 0 C-N-CA 117.365 -1.734 . . . . 0.0 113.107 -179.818 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 35' ' ' ASN . . . . . 0.586 ' CA ' ' SG ' ' A' ' 29' ' ' CYS . 23.8 t-20 62.38 144.72 0.02 OUTLIER 'General case' 0 N--CA 1.506 2.333 0 N-CA-C 113.976 1.102 . . . . 0.0 113.976 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.851 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -124.74 -64.9 1.07 Allowed 'General case' 0 C--N 1.306 -1.3 0 N-CA-C 106.672 -1.603 . . . . 0.0 106.672 -179.751 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 37' ' ' LYS . . . . . 0.593 ' N ' ' SG ' ' A' ' 36' ' ' CYS . 33.1 ttmt -91.05 103.59 16.27 Favored 'General case' 0 C--N 1.302 -1.465 0 CA-C-O 123.567 1.651 . . . . 0.0 107.04 179.704 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.425 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -79.86 24.16 0.41 Allowed 'General case' 0 N--CA 1.495 1.781 0 CA-C-N 113.499 -1.682 . . . . 0.0 107.282 179.489 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' HIS . . . . . 0.519 ' H ' ' C ' ' A' ' 37' ' ' LYS . 3.3 m-70 -131.85 17.88 4.67 Favored 'General case' 0 N--CA 1.493 1.713 0 N-CA-C 106.966 -1.494 . . . . 0.0 106.966 -179.677 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 111.43 -132.0 10.63 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 25.9 Cg_endo -69.78 -164.06 2.43 Favored 'Cis proline' 0 N--CA 1.503 2.054 0 CA-C-N 117.843 0.821 . . . . 0.0 112.699 1.097 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' ASN . . . . . 0.409 ' C ' ' H ' ' A' ' 44' ' ' GLY . 22.6 t-20 -92.13 -20.57 21.11 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 106.374 -1.713 . . . . 0.0 106.374 -179.757 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 39.7 pt -86.31 28.33 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 CA-C-N 112.367 -2.197 . . . . 0.0 113.349 -179.104 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.432 ' CA ' ' O ' ' A' ' 23' ' ' TRP . . . 115.03 131.15 4.98 Favored Glycine 0 N--CA 1.484 1.859 0 CA-C-N 111.019 -2.81 . . . . 0.0 109.994 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 14.8 m95 -55.42 130.1 41.26 Favored 'General case' 0 N--CA 1.509 2.484 0 N-CA-C 106.311 -1.737 . . . . 0.0 106.311 -179.657 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' CYS . . . . . 0.851 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 42.7 t -89.15 129.42 35.75 Favored 'General case' 0 C--N 1.31 -1.139 1 N-CA-C 99.341 -4.318 . . . . 0.0 99.341 -179.89 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.539 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 77.8 m -133.93 -175.35 3.81 Favored 'General case' 0 C--N 1.293 -1.888 0 CA-C-N 110.671 -2.968 . . . . 0.0 110.881 -178.997 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.467 ' O ' ' HA ' ' A' ' 33' ' ' TRP . 0.0 OUTLIER -150.7 172.68 15.19 Favored 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 107.1 -1.445 . . . . 0.0 107.1 179.484 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 54.0 mtpt . . . . . 0 C--N 1.289 -2.032 0 O-C-N 127.248 2.843 . . . . 0.0 109.253 179.697 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 34.0 t . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -82.19 136.15 8.85 Favored 'Trans proline' 0 C--N 1.308 -1.594 0 C-N-CA 124.026 3.151 . . . . 0.0 113.516 162.76 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.403 ' SG ' ' N ' ' A' ' 5' ' ' LEU . 1.8 p -110.45 -156.87 0.6 Allowed 'General case' 0 N--CA 1.504 2.259 0 N-CA-C 107.601 -1.259 . . . . 0.0 107.601 179.778 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.403 ' N ' ' SG ' ' A' ' 4' ' ' CYS . 2.9 tt -118.85 99.97 7.09 Favored 'General case' 0 N--CA 1.503 2.212 0 N-CA-C 101.283 -3.599 . . . . 0.0 101.283 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 2.9 m -78.85 -176.11 4.81 Favored 'General case' 0 C--N 1.308 -1.214 0 N-CA-C 116.424 2.009 . . . . 0.0 116.424 -179.381 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 29.0 t70 . . . . . 0 C--N 1.298 -1.662 0 CA-C-N 112.319 -2.219 . . . . 0.0 109.843 -179.614 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 4.8 m . . . . . 0 N--CA 1.503 2.175 0 N-CA-C 115.385 1.624 . . . . 0.0 115.385 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 167.69 -179.36 41.13 Favored Glycine 0 N--CA 1.502 3.045 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 179.796 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 37.2 mm -132.71 143.94 38.18 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.399 0 O-C-N 124.555 0.797 . . . . 0.0 110.975 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.433 ' O ' HD12 ' A' ' 22' ' ' LEU . 3.9 pp -63.56 154.75 31.63 Favored 'General case' 0 N--CA 1.504 2.244 0 N-CA-C 109.117 -0.697 . . . . 0.0 109.117 179.518 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.552 ' O ' ' HA2' ' A' ' 44' ' ' GLY . 32.4 m95 -134.42 131.4 38.13 Favored 'General case' 0 C--N 1.308 -1.202 0 N-CA-C 118.91 2.93 . . . . 0.0 118.91 -179.694 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -87.57 53.48 2.8 Favored 'General case' 0 C--N 1.291 -1.973 0 CA-C-N 109.316 -3.584 . . . . 0.0 111.796 -179.245 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 2.7 m-85 -125.52 137.06 29.17 Favored Pre-proline 0 C--N 1.306 -1.302 0 CA-C-N 115.052 -0.976 . . . . 0.0 110.352 179.6 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_endo -73.81 -25.43 14.49 Favored 'Trans proline' 0 C--N 1.306 -1.696 1 C-N-CA 125.725 4.283 . . . . 0.0 112.817 177.746 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 5.9 p -95.03 20.66 8.68 Favored 'General case' 0 N--CA 1.493 1.706 0 CA-C-N 115.249 -0.887 . . . . 0.0 111.163 -179.875 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 89.91 -138.27 14.47 Favored Glycine 0 N--CA 1.496 2.687 0 N-CA-C 106.278 -2.729 . . . . 0.0 106.278 -179.817 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.526 ' SG ' ' CA ' ' A' ' 35' ' ' ASN . 29.7 m -69.28 150.05 97.3 Favored Pre-proline 0 C--N 1.305 -1.355 0 CA-C-N 117.496 0.648 . . . . 0.0 109.971 179.889 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.717 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 1.9 Cg_endo -78.31 159.29 29.6 Favored 'Trans proline' 0 C--N 1.31 -1.469 0 C-N-CA 123.207 2.604 . . . . 0.0 112.403 171.198 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 24.1 t -47.96 128.86 14.13 Favored 'General case' 0 C--N 1.305 -1.326 0 CA-C-N 113.168 -1.833 . . . . 0.0 109.3 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 100.51 -8.07 58.3 Favored Glycine 0 N--CA 1.495 2.607 0 CA-C-N 112.628 -2.078 . . . . 0.0 111.421 179.77 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' TRP . . . . . 0.717 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 48.3 m95 -110.29 162.94 14.14 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 106.83 -1.544 . . . . 0.0 106.83 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 78.6 t60 -143.22 29.82 1.44 Allowed 'General case' 0 N--CA 1.499 1.997 0 C-N-CA 118.34 -1.344 . . . . 0.0 113.135 -179.843 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' ASN . . . . . 0.526 ' CA ' ' SG ' ' A' ' 29' ' ' CYS . 12.1 t-20 62.02 147.13 0.02 OUTLIER 'General case' 0 N--CA 1.505 2.301 0 CA-C-O 123.109 1.433 . . . . 0.0 114.097 -179.79 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.841 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -117.41 -46.91 2.67 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-N 113.341 -1.754 . . . . 0.0 108.003 -179.666 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 19.4 ttpp -132.18 124.77 29.69 Favored 'General case' 0 N--CA 1.497 1.922 0 N-CA-C 107.814 -1.18 . . . . 0.0 107.814 179.43 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -87.13 22.07 2.18 Favored 'General case' 0 N--CA 1.493 1.688 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 179.788 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 16.9 m-70 -131.33 76.72 1.73 Allowed 'General case' 0 N--CA 1.492 1.645 0 CA-C-O 122.243 1.02 . . . . 0.0 108.882 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 68.83 -163.07 50.54 Favored Glycine 0 N--CA 1.492 2.418 0 CA-C-N 113.353 -1.749 . . . . 0.0 109.849 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' PRO . . . . . 0.446 ' HG2' ' O ' ' A' ' 44' ' ' GLY . 34.1 Cg_endo -71.86 175.14 43.78 Favored 'Cis proline' 0 N--CA 1.495 1.573 0 N-CA-C 107.635 -1.717 . . . . 0.0 107.635 -2.402 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' ASN . . . . . 0.442 ' C ' ' H ' ' A' ' 44' ' ' GLY . 23.4 m120 -91.53 -10.12 41.86 Favored 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 105.299 -2.112 . . . . 0.0 105.299 -179.484 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 16.1 mt -88.79 28.75 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.225 0 CA-C-N 113.447 -1.706 . . . . 0.0 110.338 -179.438 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.552 ' HA2' ' O ' ' A' ' 23' ' ' TRP . . . 115.98 135.29 5.65 Favored Glycine 0 N--CA 1.486 2.0 0 CA-C-N 111.827 -2.442 . . . . 0.0 112.687 179.789 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' TRP . . . . . 0.511 ' O ' ' N ' ' A' ' 23' ' ' TRP . 26.3 m95 -62.0 129.39 40.66 Favored 'General case' 0 N--CA 1.501 2.116 0 C-N-CA 120.19 -0.604 . . . . 0.0 111.388 -179.42 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' CYS . . . . . 0.841 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 46.4 t -88.52 114.72 25.43 Favored 'General case' 0 C--N 1.305 -1.359 1 N-CA-C 96.728 -5.286 . . . . 0.0 96.728 179.998 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.532 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 75.1 m -129.89 -176.18 3.84 Favored 'General case' 0 C--N 1.295 -1.768 1 CA-C-N 108.253 -4.067 . . . . 0.0 108.714 -179.407 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.507 ' O ' ' HA ' ' A' ' 33' ' ' TRP . 0.0 OUTLIER -149.97 169.74 20.48 Favored 'General case' 0 C--N 1.294 -1.836 0 C-N-CA 117.614 -1.634 . . . . 0.0 107.698 179.56 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 48.9 mtpt . . . . . 0 C--N 1.29 -2.02 0 O-C-N 127.577 3.048 . . . . 0.0 109.379 179.71 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 61.9 t . . . . . 0 N--CA 1.496 1.84 0 N-CA-C 108.026 -1.101 . . . . 0.0 108.026 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -76.22 158.93 37.27 Favored 'Trans proline' 0 C--N 1.309 -1.54 0 C-N-CA 124.509 3.473 . . . . 0.0 113.405 171.45 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -150.9 164.94 35.12 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 125.48 1.737 . . . . 0.0 108.036 179.614 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.484 HD23 ' N ' ' A' ' 6' ' ' CYS . 9.4 tt -79.38 168.18 19.85 Favored 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 103.404 -2.813 . . . . 0.0 103.404 179.759 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 6' ' ' CYS . . . . . 0.49 ' HB3' ' C ' ' A' ' 36' ' ' CYS . 3.5 m -140.93 -174.8 4.09 Favored 'General case' 0 C--N 1.302 -1.489 0 N-CA-C 116.662 2.097 . . . . 0.0 116.662 -179.257 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 30.7 t70 . . . . . 0 N--CA 1.492 1.654 0 CA-C-N 112.639 -2.073 . . . . 0.0 107.862 179.943 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 19.7 m . . . . . 0 N--CA 1.502 2.15 0 N-CA-C 112.681 0.623 . . . . 0.0 112.681 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -166.7 -162.46 18.32 Favored Glycine 0 N--CA 1.504 3.195 0 N-CA-C 110.904 -0.878 . . . . 0.0 110.904 -179.863 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 8.1 mm -135.75 146.48 29.59 Favored 'Isoleucine or valine' 0 N--CA 1.515 2.82 0 N-CA-C 113.992 1.108 . . . . 0.0 113.992 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.56 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.6 pp -64.25 151.15 44.41 Favored 'General case' 0 N--CA 1.505 2.317 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 179.17 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.448 ' N ' ' O ' ' A' ' 45' ' ' TRP . 22.3 m95 -133.45 137.41 45.7 Favored 'General case' 0 C--N 1.305 -1.347 0 N-CA-C 116.6 2.074 . . . . 0.0 116.6 -179.656 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -88.47 41.32 1.01 Allowed 'General case' 0 C--N 1.293 -1.87 0 CA-C-N 109.045 -3.707 . . . . 0.0 115.119 -179.408 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -114.67 129.28 25.11 Favored Pre-proline 0 N--CA 1.489 1.52 0 N-CA-C 115.45 1.648 . . . . 0.0 115.45 179.743 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -68.33 -21.53 41.07 Favored 'Trans proline' 0 C--N 1.307 -1.642 0 C-N-CA 123.402 2.734 . . . . 0.0 108.979 -175.106 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -91.32 1.29 57.22 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-N 112.864 -1.971 . . . . 0.0 110.797 179.752 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 107.72 -117.05 5.06 Favored Glycine 0 N--CA 1.498 2.828 0 N-CA-C 105.455 -3.058 . . . . 0.0 105.455 -179.831 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.533 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 10.2 m -93.12 150.23 38.83 Favored Pre-proline 0 C--N 1.305 -1.361 0 N-CA-C 108.404 -0.962 . . . . 0.0 108.404 179.632 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.712 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.5 OUTLIER -76.49 175.53 11.23 Favored 'Trans proline' 0 C--N 1.311 -1.42 0 C-N-CA 123.241 2.627 . . . . 0.0 115.66 176.777 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 16.4 p -50.47 102.88 0.04 OUTLIER 'General case' 0 C--N 1.299 -1.605 0 CA-C-N 112.671 -2.059 . . . . 0.0 112.724 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 112.12 -0.24 26.89 Favored Glycine 0 N--CA 1.503 3.127 0 O-C-N 124.332 1.02 . . . . 0.0 113.61 179.435 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' TRP . . . . . 0.712 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 45.6 m95 -112.3 163.73 14.05 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 107.289 -1.375 . . . . 0.0 107.289 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 73.5 t60 -146.37 37.45 1.02 Allowed 'General case' 0 N--CA 1.501 2.098 0 C-N-CA 118.014 -1.475 . . . . 0.0 114.54 -179.866 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' ASN . . . . . 0.533 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 23.7 t-20 60.04 149.42 0.02 OUTLIER 'General case' 0 N--CA 1.506 2.338 0 N-CA-C 115.763 1.764 . . . . 0.0 115.763 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.66 ' SG ' ' HB3' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -125.21 -44.91 1.86 Allowed 'General case' 0 C--N 1.303 -1.451 0 CA-C-N 113.52 -1.673 . . . . 0.0 108.067 -179.913 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 37' ' ' LYS . . . . . 0.46 ' C ' ' H ' ' A' ' 39' ' ' HIS . 36.9 ttmt -124.66 111.13 15.24 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 105.101 -2.185 . . . . 0.0 105.101 179.61 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.436 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -85.01 31.84 0.54 Allowed 'General case' 0 N--CA 1.494 1.749 0 N-CA-C 106.132 -1.803 . . . . 0.0 106.132 179.587 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' HIS . . . . . 0.46 ' H ' ' C ' ' A' ' 37' ' ' LYS . 4.5 m-70 -132.21 22.28 4.45 Favored 'General case' 0 N--CA 1.497 1.88 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 -179.612 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 107.89 -145.88 16.26 Favored Glycine 0 N--CA 1.494 2.514 0 N-CA-C 109.292 -1.523 . . . . 0.0 109.292 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' PRO . . . . . 0.659 ' CD ' ' SG ' ' A' ' 46' ' ' CYS . 8.4 Cg_endo -74.97 -173.54 12.5 Favored 'Cis proline' 0 N--CA 1.502 2.011 0 C-N-CA 129.013 0.839 . . . . 0.0 111.36 0.87 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 42' ' ' ASN . . . . . 0.466 ' C ' ' H ' ' A' ' 44' ' ' GLY . 0.2 OUTLIER -91.9 -8.61 45.9 Favored 'General case' 0 N--CA 1.487 1.385 0 N-CA-C 102.883 -3.006 . . . . 0.0 102.883 179.951 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.488 HD12 ' N ' ' A' ' 43' ' ' ILE . 4.0 mp -90.88 32.45 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 CA-C-O 123.159 1.457 . . . . 0.0 108.245 -179.419 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.466 ' H ' ' C ' ' A' ' 42' ' ' ASN . . . 102.89 127.74 6.19 Favored Glycine 0 N--CA 1.489 2.209 0 CA-C-N 111.88 -2.418 . . . . 0.0 107.094 -179.774 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' TRP . . . . . 0.448 ' O ' ' N ' ' A' ' 23' ' ' TRP . 6.7 m95 -54.8 135.67 47.32 Favored 'General case' 0 N--CA 1.509 2.485 0 CA-C-O 117.05 -1.452 . . . . 0.0 108.621 -179.519 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' CYS . . . . . 0.66 ' HB3' ' SG ' ' A' ' 36' ' ' CYS . 75.3 m -88.37 122.67 32.13 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 101.885 -3.376 . . . . 0.0 101.885 179.86 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.479 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 75.2 m -128.57 -174.71 3.31 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-N 110.43 -3.077 . . . . 0.0 108.739 -179.495 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.408 ' O ' ' HA ' ' A' ' 33' ' ' TRP . 0.0 OUTLIER -151.36 171.96 16.66 Favored 'General case' 0 C--N 1.299 -1.617 0 N-CA-C 106.684 -1.599 . . . . 0.0 106.684 179.176 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 92.3 mttt . . . . . 0 C--N 1.288 -2.076 0 O-C-N 125.675 1.859 . . . . 0.0 109.437 179.922 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 24.7 t . . . . . 0 N--CA 1.5 2.039 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.405 ' HA ' ' O ' ' A' ' 20' ' ' GLY . 6.9 Cg_endo -79.18 129.65 8.86 Favored 'Trans proline' 0 N--CA 1.491 1.371 0 C-N-CA 123.836 3.024 . . . . 0.0 114.268 165.034 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -119.2 -163.0 0.94 Allowed 'General case' 0 N--CA 1.495 1.822 0 N-CA-C 113.549 0.944 . . . . 0.0 113.549 -179.729 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.473 HD23 ' N ' ' A' ' 6' ' ' CYS . 9.6 tt -111.71 151.68 28.63 Favored 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 104.456 -2.424 . . . . 0.0 104.456 179.848 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 6' ' ' CYS . . . . . 0.473 ' N ' HD23 ' A' ' 5' ' ' LEU . 5.1 m -140.95 -171.05 3.17 Favored 'General case' 0 N--CA 1.483 1.189 0 N-CA-C 116.224 1.935 . . . . 0.0 116.224 -179.378 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 39.0 t70 . . . . . 0 N--CA 1.49 1.558 0 CA-C-N 112.233 -2.258 . . . . 0.0 108.09 -179.958 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 41.4 t . . . . . 0 N--CA 1.5 2.041 0 CA-C-O 121.124 0.488 . . . . 0.0 110.468 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.517 ' HA2' ' HD3' ' A' ' 48' ' ' LYS . . . -170.99 119.23 0.79 Allowed Glycine 0 N--CA 1.499 2.843 0 CA-C-O 117.979 -1.456 . . . . 0.0 112.32 179.911 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.461 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 37.6 mm -102.71 131.13 51.56 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.312 0 N-CA-C 103.429 -2.804 . . . . 0.0 103.429 179.308 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.595 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 2.1 pp -64.45 158.75 23.05 Favored 'General case' 0 N--CA 1.496 1.85 0 C-N-CA 118.189 -1.404 . . . . 0.0 107.811 179.785 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.48 ' N ' ' O ' ' A' ' 45' ' ' TRP . 19.4 m95 -138.6 135.51 35.02 Favored 'General case' 0 C--N 1.306 -1.324 0 N-CA-C 115.919 1.822 . . . . 0.0 115.919 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -89.06 41.64 1.04 Allowed 'General case' 0 C--N 1.293 -1.878 0 CA-C-N 109.803 -3.362 . . . . 0.0 115.851 -179.611 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.444 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 1.0 OUTLIER -118.34 126.89 26.92 Favored Pre-proline 0 N--CA 1.487 1.379 0 CA-C-O 122.417 1.104 . . . . 0.0 110.225 179.646 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -64.82 -28.71 59.12 Favored 'Trans proline' 0 C--N 1.299 -2.039 0 C-N-CA 122.096 1.864 . . . . 0.0 108.781 -175.237 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 4.6 p -82.36 5.55 19.94 Favored 'General case' 0 N--CA 1.492 1.653 0 CA-C-N 114.661 -1.154 . . . . 0.0 112.52 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 105.79 -128.81 9.52 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 106.032 -2.827 . . . . 0.0 106.032 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.505 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 4.3 m -83.9 145.55 47.04 Favored Pre-proline 0 C--N 1.302 -1.486 0 C-N-CA 120.595 -0.442 . . . . 0.0 110.301 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.693 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 7.0 Cg_endo -75.01 162.27 37.39 Favored 'Trans proline' 0 C--N 1.312 -1.343 0 C-N-CA 123.317 2.678 . . . . 0.0 113.958 176.769 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 18.8 t -45.66 111.94 0.4 Allowed 'General case' 0 N--CA 1.492 1.636 0 CA-C-N 114.362 -1.29 . . . . 0.0 110.205 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 114.14 -8.64 23.0 Favored Glycine 0 N--CA 1.5 2.963 0 CA-C-N 114.573 -1.194 . . . . 0.0 112.93 179.596 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' TRP . . . . . 0.693 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 50.9 m95 -110.76 161.2 16.01 Favored 'General case' 0 N--CA 1.489 1.498 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' HIS . . . . . 0.429 ' ND1' ' O ' ' A' ' 34' ' ' HIS . 56.5 t-80 -146.83 46.34 1.18 Allowed 'General case' 0 N--CA 1.499 1.978 0 C-N-CA 117.741 -1.584 . . . . 0.0 113.508 -179.812 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 35' ' ' ASN . . . . . 0.505 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 21.4 t-20 62.64 145.81 0.02 OUTLIER 'General case' 0 N--CA 1.511 2.6 0 N-CA-C 116.418 2.007 . . . . 0.0 116.418 179.846 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.791 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 0.7 OUTLIER -116.29 -43.0 2.98 Favored 'General case' 0 N--CA 1.485 1.28 0 N-CA-C 106.927 -1.509 . . . . 0.0 106.927 179.482 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 8.8 ptpp? -124.31 127.24 47.33 Favored 'General case' 0 N--CA 1.498 1.94 0 N-CA-C 107.406 -1.331 . . . . 0.0 107.406 179.319 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.445 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -77.8 43.14 0.4 Allowed 'General case' 0 N--CA 1.497 1.909 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 179.869 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' HIS . . . . . 0.445 ' ND1' ' C ' ' A' ' 38' ' ' ALA . 3.5 m-70 -132.05 -81.35 0.51 Allowed 'General case' 0 N--CA 1.498 1.972 0 CA-C-O 119.084 -0.484 . . . . 0.0 110.748 -179.673 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -153.01 -130.38 1.51 Allowed Glycine 0 N--CA 1.509 3.524 0 N-CA-C 109.297 -1.521 . . . . 0.0 109.297 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 0.2 OUTLIER -81.07 -170.17 8.28 Favored 'Cis proline' 0 N--CA 1.5 1.903 0 CA-C-N 120.25 2.025 . . . . 0.0 111.319 -4.178 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 59.6 t30 -92.62 -13.97 28.84 Favored 'General case' 0 N--CA 1.486 1.365 0 N-CA-C 106.094 -1.817 . . . . 0.0 106.094 -179.798 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 37.3 pt -86.6 26.03 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 CA-C-N 113.591 -1.64 . . . . 0.0 113.382 -179.26 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.444 ' HA2' ' O ' ' A' ' 23' ' ' TRP . . . 111.62 119.51 3.84 Favored Glycine 0 N--CA 1.486 2.007 0 CA-C-N 111.602 -2.545 . . . . 0.0 106.875 -179.836 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' TRP . . . . . 0.48 ' O ' ' N ' ' A' ' 23' ' ' TRP . 20.2 m95 -51.45 133.72 29.44 Favored 'General case' 0 N--CA 1.501 2.095 0 CA-C-N 113.253 -1.473 . . . . 0.0 111.111 -179.432 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 46' ' ' CYS . . . . . 0.791 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 22.8 t -89.26 118.69 29.12 Favored 'General case' 0 C--N 1.305 -1.359 1 N-CA-C 99.746 -4.168 . . . . 0.0 99.746 179.571 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.467 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 86.4 m -126.96 -176.27 3.66 Favored 'General case' 0 CA--C 1.487 -1.443 0 CA-C-N 111.172 -2.74 . . . . 0.0 112.604 -179.357 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.517 ' HD3' ' HA2' ' A' ' 20' ' ' GLY . 34.8 tptt -151.49 157.46 42.33 Favored 'General case' 0 C--N 1.297 -1.697 0 C-N-CA 118.297 -1.361 . . . . 0.0 109.999 -179.821 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 23.8 mttm . . . . . 0 N--CA 1.505 2.298 0 O-C-N 127.039 2.712 . . . . 0.0 110.666 179.646 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 38.9 t . . . . . 0 N--CA 1.494 1.774 0 N-CA-C 103.962 -2.607 . . . . 0.0 103.962 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.429 ' HA ' ' O ' ' A' ' 20' ' ' GLY . 18.6 Cg_endo -72.82 138.13 28.26 Favored 'Trans proline' 0 C--N 1.305 -1.761 0 C-N-CA 122.991 2.461 . . . . 0.0 117.568 163.662 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.556 ' SG ' ' SG ' ' A' ' 6' ' ' CYS . 12.5 p -124.56 159.1 31.4 Favored 'General case' 0 N--CA 1.494 1.766 0 CA-C-N 114.818 -1.083 . . . . 0.0 109.46 179.52 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 10.3 tp -79.7 84.03 5.58 Favored 'General case' 0 N--CA 1.491 1.62 1 N-CA-C 99.612 -4.218 . . . . 0.0 99.612 179.465 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 6' ' ' CYS . . . . . 0.657 ' SG ' ' HA3' ' A' ' 20' ' ' GLY . 34.7 m -68.41 175.07 3.57 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-O 123.391 1.567 . . . . 0.0 111.567 -179.716 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 12.7 t70 . . . . . 0 C--N 1.294 -1.809 0 CA-C-N 111.498 -2.592 . . . . 0.0 114.506 -179.202 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 12.4 t . . . . . 0 N--CA 1.504 2.274 0 CA-C-O 118.405 -0.807 . . . . 0.0 112.734 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.657 ' HA3' ' SG ' ' A' ' 6' ' ' CYS . . . -162.66 139.09 5.71 Favored Glycine 0 N--CA 1.493 2.467 0 CA-C-O 118.29 -1.283 . . . . 0.0 110.553 -179.785 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.466 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 32.7 mm -102.57 140.69 20.3 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.102 0 N-CA-C 104.268 -2.493 . . . . 0.0 104.268 179.571 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.595 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.6 pp -63.87 146.08 54.65 Favored 'General case' 0 N--CA 1.504 2.238 0 C-N-CA 117.407 -1.717 . . . . 0.0 112.154 179.727 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 40.6 m95 -130.82 131.88 44.9 Favored 'General case' 0 N--CA 1.486 1.327 0 N-CA-C 119.404 3.113 . . . . 0.0 119.404 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -89.39 51.32 2.09 Favored 'General case' 0 C--N 1.301 -1.512 1 CA-C-N 107.895 -4.229 . . . . 0.0 111.334 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.53 ' CE1' ' HB3' ' A' ' 30' ' ' PRO . 2.2 m-85 -125.99 126.37 24.81 Favored Pre-proline 0 N--CA 1.488 1.448 0 CA-C-O 121.588 0.708 . . . . 0.0 111.898 179.834 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -64.13 -19.99 66.79 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 C-N-CA 123.764 2.976 . . . . 0.0 110.286 -178.12 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 10.4 p -88.04 -6.69 57.82 Favored 'General case' 0 N--CA 1.491 1.587 0 CA-C-N 114.004 -1.453 . . . . 0.0 110.933 179.753 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.592 ' HA2' ' CD1' ' A' ' 45' ' ' TRP . . . 114.81 -95.3 0.71 Allowed Glycine 0 N--CA 1.483 1.776 1 N-CA-C 100.932 -4.867 . . . . 0.0 100.932 -179.531 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.541 ' HB3' ' HB2' ' A' ' 33' ' ' TRP . 7.8 m -101.17 164.37 16.15 Favored Pre-proline 0 C--N 1.302 -1.459 0 CA-C-N 114.006 -1.097 . . . . 0.0 108.676 179.768 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.722 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.3 OUTLIER -83.83 167.1 13.05 Favored 'Trans proline' 0 C--N 1.311 -1.412 0 C-N-CA 124.917 3.745 . . . . 0.0 116.177 158.24 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 29.1 t -55.86 126.33 25.22 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-N 113.427 -1.715 . . . . 0.0 109.62 -179.843 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 104.58 -7.12 45.8 Favored Glycine 0 N--CA 1.495 2.628 0 CA-C-N 112.664 -2.062 . . . . 0.0 111.46 179.893 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' TRP . . . . . 0.722 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 49.7 m95 -113.4 152.96 29.36 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 106.335 -1.728 . . . . 0.0 106.335 -179.872 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 56.4 t-80 -140.42 44.5 1.86 Allowed 'General case' 0 N--CA 1.493 1.717 0 C-N-CA 119.419 -0.913 . . . . 0.0 109.51 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' ASN . . . . . 0.571 ' HA ' ' SG ' ' A' ' 47' ' ' CYS . 23.2 t-20 54.74 147.86 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.171 0 CA-C-N 112.951 -1.932 . . . . 0.0 115.428 -179.985 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.676 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 0.8 OUTLIER -119.76 -36.27 3.34 Favored 'General case' 0 C--N 1.309 -1.184 0 N-CA-C 106.632 -1.618 . . . . 0.0 106.632 179.825 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 19.5 ttpt -139.02 122.4 17.16 Favored 'General case' 0 N--CA 1.486 1.336 0 CA-C-O 123.589 1.661 . . . . 0.0 109.98 179.668 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.43 ' O ' ' ND1' ' A' ' 39' ' ' HIS . . . -96.0 21.18 9.03 Favored 'General case' 0 C--N 1.303 -1.419 0 CA-C-N 112.273 -2.239 . . . . 0.0 105.541 179.72 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' HIS . . . . . 0.43 ' ND1' ' O ' ' A' ' 38' ' ' ALA . 10.7 m-70 -135.72 69.46 1.43 Allowed 'General case' 0 N--CA 1.497 1.895 0 N-CA-C 109.372 -0.603 . . . . 0.0 109.372 -179.719 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 84.08 176.47 51.17 Favored Glycine 0 N--CA 1.502 3.036 0 N-CA-C 106.165 -2.774 . . . . 0.0 106.165 -179.739 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_endo -60.96 169.8 19.37 Favored 'Cis proline' 0 N--CA 1.504 2.089 0 CA-C-N 119.771 1.786 . . . . 0.0 114.434 1.664 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 17.0 t-20 -92.45 -9.08 42.81 Favored 'General case' 0 N--CA 1.484 1.232 0 N-CA-C 104.773 -2.306 . . . . 0.0 104.773 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 17.6 mt -92.7 29.72 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.063 0 CA-C-O 123.059 1.409 . . . . 0.0 109.819 -179.29 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.465 ' C ' ' CD1' ' A' ' 45' ' ' TRP . . . 129.53 -116.58 2.17 Favored Glycine 0 N--CA 1.484 1.84 0 N-CA-C 103.744 -3.742 . . . . 0.0 103.744 -179.772 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' TRP . . . . . 0.592 ' CD1' ' HA2' ' A' ' 28' ' ' GLY . 3.0 m95 -155.26 -172.07 4.04 Favored 'General case' 0 N--CA 1.507 2.422 0 N-CA-C 104.254 -2.498 . . . . 0.0 104.254 179.853 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 46' ' ' CYS . . . . . 0.676 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 26.2 t -135.75 126.84 27.96 Favored 'General case' 0 N--CA 1.498 1.958 1 N-CA-C 98.985 -4.45 . . . . 0.0 98.985 179.493 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.573 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 70.9 m -131.47 -179.68 5.51 Favored 'General case' 0 CA--C 1.471 -2.061 0 N-CA-C 116.24 1.941 . . . . 0.0 116.24 -178.663 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.567 ' HD3' ' HA2' ' A' ' 20' ' ' GLY . 44.1 tptt -151.04 149.21 29.28 Favored 'General case' 0 C--N 1.297 -1.693 0 C-N-CA 118.716 -1.194 . . . . 0.0 110.672 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 49' ' ' LYS . . . . . 0.479 ' H ' ' HD2' ' A' ' 48' ' ' LYS . 93.4 mttt . . . . . 0 N--CA 1.494 1.774 0 CA-C-N 112.133 -2.303 . . . . 0.0 108.59 179.317 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 21.4 t . . . . . 0 N--CA 1.497 1.919 0 N-CA-C 106.694 -1.595 . . . . 0.0 106.694 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.419 ' HA ' ' O ' ' A' ' 20' ' ' GLY . 6.9 Cg_endo -77.84 149.76 26.49 Favored 'Trans proline' 0 C--N 1.309 -1.532 0 C-N-CA 122.536 2.157 . . . . 0.0 110.314 169.521 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -138.95 169.43 17.81 Favored 'General case' 0 C--N 1.3 -1.557 0 CA-C-O 121.862 0.839 . . . . 0.0 110.142 179.836 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.413 HD23 ' N ' ' A' ' 6' ' ' CYS . 8.5 tt -91.88 150.52 21.0 Favored 'General case' 0 N--CA 1.492 1.655 0 N-CA-C 102.229 -3.248 . . . . 0.0 102.229 179.647 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 6' ' ' CYS . . . . . 0.443 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 3.1 m -139.78 -166.46 2.08 Favored 'General case' 0 N--CA 1.493 1.72 0 N-CA-C 113.973 1.101 . . . . 0.0 113.973 -179.519 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 7' ' ' ASP . . . . . 0.472 ' H ' ' HB3' ' A' ' 37' ' ' LYS . 30.1 t70 . . . . . 0 N--CA 1.496 1.86 0 CA-C-N 112.612 -2.085 . . . . 0.0 108.091 -179.754 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 64.0 p . . . . . 0 N--CA 1.499 1.984 0 N-CA-C 112.904 0.705 . . . . 0.0 112.904 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.419 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -135.45 156.49 22.72 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 108.791 -1.724 . . . . 0.0 108.791 -179.906 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.448 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 44.5 mm -115.56 144.93 22.03 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 N-CA-C 106.098 -1.816 . . . . 0.0 106.098 179.708 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.609 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 4.1 pp -72.69 151.0 42.45 Favored 'General case' 0 N--CA 1.488 1.464 0 C-N-CA 118.438 -1.305 . . . . 0.0 109.041 179.752 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 44.1 m95 -132.31 134.21 44.96 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 117.721 2.489 . . . . 0.0 117.721 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.3 m-85 -89.2 53.13 2.56 Favored 'General case' 0 C--N 1.296 -1.744 1 CA-C-N 107.623 -4.353 . . . . 0.0 109.43 -179.791 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.429 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 2.4 m-85 -126.58 139.2 34.13 Favored Pre-proline 0 C--N 1.306 -1.294 0 CA-C-O 121.671 0.748 . . . . 0.0 111.964 -179.962 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.68 -18.01 37.63 Favored 'Trans proline' 0 C--N 1.305 -1.734 1 C-N-CA 125.415 4.077 . . . . 0.0 110.6 177.161 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 10.7 p -100.26 22.65 11.19 Favored 'General case' 0 C--N 1.299 -1.613 0 CA-C-N 113.334 -1.757 . . . . 0.0 110.886 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.577 ' HA2' ' CD1' ' A' ' 45' ' ' TRP . . . 81.4 -89.98 1.41 Allowed Glycine 0 N--CA 1.484 1.838 1 N-CA-C 102.854 -4.098 . . . . 0.0 102.854 -179.674 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.462 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 24.8 m -98.7 163.57 18.67 Favored Pre-proline 0 C--N 1.302 -1.457 0 CA-C-N 113.719 -1.24 . . . . 0.0 110.996 -179.887 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.696 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.1 OUTLIER -89.05 163.76 5.83 Favored 'Trans proline' 0 CA--C 1.554 1.496 1 C-N-CA 126.701 4.934 . . . . 0.0 117.122 155.785 . . . . . . . . 4 4 . 1 . 011 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 4.1 m -51.06 111.82 0.62 Allowed 'General case' 0 C--N 1.301 -1.526 0 CA-C-N 112.36 -2.2 . . . . 0.0 114.135 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 113.7 -6.54 24.22 Favored Glycine 0 N--CA 1.506 3.352 0 CA-C-N 115.046 -0.979 . . . . 0.0 112.638 179.68 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' TRP . . . . . 0.696 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 54.7 m95 -106.96 167.17 10.07 Favored 'General case' 0 C--N 1.299 -1.619 0 N-CA-C 106.517 -1.661 . . . . 0.0 106.517 -179.762 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 51.1 t-80 -146.96 37.7 0.97 Allowed 'General case' 0 N--CA 1.493 1.69 0 C-N-CA 116.845 -1.942 . . . . 0.0 113.236 179.82 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' ASN . . . . . 0.499 ' HA ' ' SG ' ' A' ' 47' ' ' CYS . 13.9 t-20 55.88 143.04 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.113 0 N-CA-C 117.484 2.401 . . . . 0.0 117.484 179.556 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.842 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 2.7 p -120.3 -28.37 5.05 Favored 'General case' 0 N--CA 1.486 1.329 0 CA-C-N 115.652 -0.703 . . . . 0.0 111.345 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 37' ' ' LYS . . . . . 0.472 ' HB3' ' H ' ' A' ' 7' ' ' ASP . 9.5 ptpt -151.05 151.15 31.61 Favored 'General case' 0 N--CA 1.495 1.792 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 179.105 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.449 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -117.0 35.06 4.8 Favored 'General case' 0 N--CA 1.491 1.607 0 N-CA-C 102.388 -3.19 . . . . 0.0 102.388 179.661 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 39' ' ' HIS . . . . . 0.449 ' ND1' ' C ' ' A' ' 38' ' ' ALA . 4.5 m-70 -128.64 60.31 1.52 Allowed 'General case' 0 N--CA 1.497 1.881 0 N-CA-C 106.943 -1.503 . . . . 0.0 106.943 -179.534 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 74.19 -149.45 40.81 Favored Glycine 0 N--CA 1.496 2.646 0 N-CA-C 104.854 -3.298 . . . . 0.0 104.854 -179.702 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' PRO . . . . . 0.412 ' HD2' ' C ' ' A' ' 45' ' ' TRP . 42.1 Cg_endo -48.53 176.6 0.39 Allowed 'Cis proline' 0 N--CA 1.504 2.104 0 CA-C-N 119.765 1.783 . . . . 0.0 115.478 -5.499 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.5 m-20 -92.08 -7.77 47.72 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 104.34 -2.467 . . . . 0.0 104.34 -179.719 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 15.0 mt -99.53 22.29 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.85 0 CA-C-O 123.99 1.853 . . . . 0.0 113.006 -179.345 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 133.08 -119.87 2.48 Favored Glycine 0 C--N 1.288 -2.094 0 N-CA-C 104.195 -3.562 . . . . 0.0 104.195 -179.857 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 45' ' ' TRP . . . . . 0.577 ' CD1' ' HA2' ' A' ' 28' ' ' GLY . 3.9 m95 -152.56 -169.22 3.28 Favored 'General case' 0 N--CA 1.511 2.588 0 N-CA-C 106.923 -1.51 . . . . 0.0 106.923 -179.917 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 46' ' ' CYS . . . . . 0.842 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 43.8 t -139.17 129.4 25.39 Favored 'General case' 0 C--N 1.313 -0.982 0 N-CA-C 101.273 -3.603 . . . . 0.0 101.273 179.13 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.499 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 71.4 m -135.0 -172.13 2.97 Favored 'General case' 0 C--N 1.294 -1.805 0 CA-C-N 111.295 -2.684 . . . . 0.0 108.479 -179.435 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.406 ' N ' ' CD ' ' A' ' 48' ' ' LYS . 0.0 OUTLIER -150.55 173.5 14.03 Favored 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 107.125 -1.435 . . . . 0.0 107.125 179.352 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.499 1.993 0 O-C-N 125.803 1.939 . . . . 0.0 106.681 179.728 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.415 ' HB ' HD23 ' A' ' 22' ' ' LEU . 22.0 t . . . . . 0 N--CA 1.497 1.893 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -72.28 149.65 51.58 Favored 'Trans proline' 0 N--CA 1.494 1.506 0 C-N-CA 124.161 3.24 . . . . 0.0 112.716 167.625 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.595 ' SG ' ' HB3' ' A' ' 22' ' ' LEU . 0.1 OUTLIER -136.88 -176.89 4.51 Favored 'General case' 0 N--CA 1.496 1.844 0 CA-C-N 115.349 -0.842 . . . . 0.0 111.438 179.631 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 6.4 tt -91.15 110.93 22.21 Favored 'General case' 0 N--CA 1.491 1.587 0 C-N-CA 119.428 -0.909 . . . . 0.0 108.829 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' CYS . . . . . 0.423 ' SG ' ' HA3' ' A' ' 20' ' ' GLY . 7.7 m -88.13 178.42 6.64 Favored 'General case' 0 C--N 1.31 -1.123 0 CA-C-O 123.282 1.515 . . . . 0.0 113.827 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 9.4 t70 . . . . . 0 C--N 1.297 -1.712 0 CA-C-N 111.501 -2.59 . . . . 0.0 110.123 -179.84 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 8.9 t . . . . . 0 N--CA 1.501 2.112 0 CA-C-O 120.901 0.381 . . . . 0.0 111.077 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.423 ' HA3' ' SG ' ' A' ' 6' ' ' CYS . . . -154.4 141.33 8.13 Favored Glycine 0 N--CA 1.496 2.634 0 N-CA-C 110.349 -1.1 . . . . 0.0 110.349 179.987 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.432 ' N ' ' O ' ' A' ' 47' ' ' CYS . 40.8 mm -99.64 138.89 22.61 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.452 0 N-CA-C 107.122 -1.436 . . . . 0.0 107.122 179.767 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.595 ' HB3' ' SG ' ' A' ' 4' ' ' CYS . 1.3 pp -68.97 146.93 52.33 Favored 'General case' 0 N--CA 1.495 1.8 0 C-N-CA 118.925 -1.11 . . . . 0.0 109.155 179.889 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 29.9 m95 -129.06 135.03 48.37 Favored 'General case' 0 C--N 1.307 -1.246 0 N-CA-C 117.882 2.549 . . . . 0.0 117.882 -179.786 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -89.38 49.25 1.72 Allowed 'General case' 0 C--N 1.298 -1.635 1 CA-C-N 108.047 -4.16 . . . . 0.0 113.163 -179.791 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.403 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 2.0 m-85 -122.08 139.3 30.19 Favored Pre-proline 0 C--N 1.301 -1.542 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 179.573 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 13.9 Cg_endo -76.29 -26.3 9.07 Favored 'Trans proline' 0 C--N 1.303 -1.86 0 C-N-CA 125.255 3.97 . . . . 0.0 112.841 174.42 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -88.66 11.94 16.11 Favored 'General case' 0 N--CA 1.494 1.748 0 CA-C-N 114.876 -1.056 . . . . 0.0 113.224 -179.831 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 97.91 -127.2 9.14 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 103.755 -3.738 . . . . 0.0 103.755 -179.722 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.527 ' HB3' ' HB2' ' A' ' 33' ' ' TRP . 8.3 m -85.38 147.04 46.04 Favored Pre-proline 0 C--N 1.303 -1.444 0 CA-C-N 117.716 0.758 . . . . 0.0 110.776 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.698 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 8.5 Cg_endo -75.19 168.28 25.05 Favored 'Trans proline' 0 C--N 1.308 -1.602 0 C-N-CA 123.037 2.491 . . . . 0.0 113.795 176.006 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 2.9 m -45.45 101.45 0.02 OUTLIER 'General case' 0 C--N 1.297 -1.68 0 CA-C-N 112.642 -2.072 . . . . 0.0 113.423 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 116.0 -2.11 21.12 Favored Glycine 0 N--CA 1.507 3.427 0 C-N-CA 120.945 -0.645 . . . . 0.0 114.057 179.63 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' TRP . . . . . 0.698 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 55.4 m95 -111.13 158.29 19.05 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 106.46 -1.682 . . . . 0.0 106.46 -179.851 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 2.0 t-80 -138.54 34.08 2.25 Favored 'General case' 0 N--CA 1.492 1.667 0 C-N-CA 117.615 -1.634 . . . . 0.0 112.507 -179.739 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' ASN . . . . . 0.507 ' HA ' ' SG ' ' A' ' 29' ' ' CYS . 0.3 OUTLIER 66.4 138.21 0.03 OUTLIER 'General case' 0 N--CA 1.509 2.498 0 N-CA-C 116.566 2.061 . . . . 0.0 116.566 179.734 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.683 ' SG ' ' CB ' ' A' ' 46' ' ' CYS . 0.8 OUTLIER -114.34 -33.37 5.65 Favored 'General case' 0 N--CA 1.484 1.243 0 N-CA-C 104.541 -2.392 . . . . 0.0 104.541 179.485 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 20.7 ptmt -146.4 139.95 25.97 Favored 'General case' 0 N--CA 1.494 1.764 0 CA-C-N 115.481 -0.781 . . . . 0.0 110.069 179.503 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.449 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -112.17 34.81 4.05 Favored 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 103.898 -2.63 . . . . 0.0 103.898 179.833 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 39' ' ' HIS . . . . . 0.449 ' ND1' ' C ' ' A' ' 38' ' ' ALA . 4.1 m-70 -129.12 57.28 1.65 Allowed 'General case' 0 N--CA 1.499 1.981 0 N-CA-C 107.611 -1.255 . . . . 0.0 107.611 -179.735 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 72.75 -142.04 31.56 Favored Glycine 0 N--CA 1.496 2.695 0 N-CA-C 106.739 -2.544 . . . . 0.0 106.739 -179.656 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' PRO . . . . . 0.46 ' HG2' ' O ' ' A' ' 44' ' ' GLY . 94.3 Cg_endo -62.34 -169.19 1.42 Allowed 'Cis proline' 0 N--CA 1.496 1.621 0 CA-C-N 118.804 1.302 . . . . 0.0 112.876 -5.065 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 54.2 t30 -93.66 1.53 56.58 Favored 'General case' 0 C--N 1.308 -1.217 0 N-CA-C 105.045 -2.206 . . . . 0.0 105.045 -179.334 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.443 HD12 ' N ' ' A' ' 43' ' ' ILE . 1.1 mp -120.28 37.46 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 O-C-N 125.126 1.516 . . . . 0.0 114.843 -179.008 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.46 ' O ' ' HG2' ' A' ' 41' ' ' PRO . . . 119.59 149.99 8.56 Favored Glycine 0 N--CA 1.485 1.963 0 N-CA-C 106.85 -2.5 . . . . 0.0 106.85 179.932 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' TRP . . . . . 0.403 ' NE1' ' O ' ' A' ' 25' ' ' TYR . 5.1 m95 -89.38 136.42 33.04 Favored 'General case' 0 N--CA 1.506 2.326 0 CA-C-O 117.175 -1.393 . . . . 0.0 108.329 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 46' ' ' CYS . . . . . 0.683 ' CB ' ' SG ' ' A' ' 36' ' ' CYS . 59.1 m -88.77 127.34 35.6 Favored 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 101.957 -3.349 . . . . 0.0 101.957 179.527 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.569 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 79.7 m -129.81 -174.95 3.45 Favored 'General case' 0 C--N 1.299 -1.601 0 CA-C-N 110.959 -2.837 . . . . 0.0 113.817 -179.243 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.433 ' HD2' ' H ' ' A' ' 49' ' ' LYS . 25.7 tptp -151.6 150.68 30.57 Favored 'General case' 0 C--N 1.295 -1.781 0 C-N-CA 118.57 -1.252 . . . . 0.0 110.26 -179.907 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 49' ' ' LYS . . . . . 0.433 ' H ' ' HD2' ' A' ' 48' ' ' LYS . 6.0 mtpt . . . . . 0 N--CA 1.499 2.015 0 O-C-N 126.407 2.317 . . . . 0.0 108.422 179.448 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 40.0 t . . . . . 0 N--CA 1.496 1.861 0 N-CA-C 106.863 -1.532 . . . . 0.0 106.863 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -70.66 148.61 59.61 Favored 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 123.533 2.822 . . . . 0.0 111.718 172.965 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.522 ' SG ' ' HB3' ' A' ' 22' ' ' LEU . 0.8 OUTLIER -146.32 163.3 35.96 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 124.24 0.962 . . . . 0.0 109.724 179.779 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.43 HD23 ' N ' ' A' ' 6' ' ' CYS . 8.9 tt -79.41 150.68 31.25 Favored 'General case' 0 N--CA 1.488 1.446 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 -179.833 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 6' ' ' CYS . . . . . 0.501 ' HB3' ' HB3' ' A' ' 37' ' ' LYS . 2.5 m -137.83 -145.19 0.19 Allowed 'General case' 0 N--CA 1.491 1.607 0 N-CA-C 116.316 1.969 . . . . 0.0 116.316 -179.663 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 7' ' ' ASP . . . . . 0.401 ' HB3' ' HA ' ' A' ' 37' ' ' LYS . 18.5 t70 . . . . . 0 N--CA 1.493 1.711 0 N-CA-C 105.941 -1.874 . . . . 0.0 105.941 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 7.3 t . . . . . 0 N--CA 1.498 1.953 0 N-CA-C 107.138 -1.43 . . . . 0.0 107.138 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 170.42 154.67 9.65 Favored Glycine 0 N--CA 1.493 2.448 0 CA-C-N 114.905 -1.043 . . . . 0.0 113.626 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.434 ' N ' ' O ' ' A' ' 47' ' ' CYS . 40.5 mm -116.82 144.77 23.74 Favored 'Isoleucine or valine' 0 N--CA 1.51 2.56 0 N-CA-C 107.639 -1.245 . . . . 0.0 107.639 179.736 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.623 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.8 pp -68.27 151.62 46.65 Favored 'General case' 0 N--CA 1.501 2.123 0 C-N-CA 117.543 -1.663 . . . . 0.0 107.528 179.447 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 22.1 m95 -131.2 140.33 49.87 Favored 'General case' 0 C--N 1.308 -1.198 0 CA-C-O 124.964 2.316 . . . . 0.0 116.985 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.5 m-30 -89.43 35.18 0.81 Allowed 'General case' 0 C--N 1.297 -1.696 1 CA-C-N 107.868 -4.242 . . . . 0.0 115.23 -179.636 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.438 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 1.2 m-30 -111.02 115.17 53.25 Favored Pre-proline 0 C--N 1.301 -1.506 0 N-CA-C 107.036 -1.468 . . . . 0.0 107.036 179.64 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo -61.27 -19.73 65.13 Favored 'Trans proline' 0 C--N 1.299 -2.031 0 C-N-CA 121.007 1.138 . . . . 0.0 109.524 -175.212 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 1.6 p -91.67 1.81 56.9 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 124.396 1.06 . . . . 0.0 112.574 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 121.03 -130.99 8.46 Favored Glycine 0 N--CA 1.497 2.739 0 N-CA-C 108.207 -1.957 . . . . 0.0 108.207 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.617 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 8.4 m -93.36 150.28 38.73 Favored Pre-proline 0 C--N 1.303 -1.441 0 CA-C-N 117.382 0.591 . . . . 0.0 109.868 -179.938 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.72 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.7 OUTLIER -76.13 162.1 34.63 Favored 'Trans proline' 0 C--N 1.309 -1.545 0 C-N-CA 122.515 2.143 . . . . 0.0 113.206 176.079 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 26.4 t -46.14 110.44 0.27 Allowed 'General case' 0 N--CA 1.493 1.692 0 CA-C-N 113.12 -1.855 . . . . 0.0 111.013 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 113.95 -5.57 23.92 Favored Glycine 0 N--CA 1.5 2.936 0 CA-C-N 114.405 -1.27 . . . . 0.0 111.678 179.772 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' TRP . . . . . 0.72 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 35.4 m95 -117.5 152.59 34.74 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 106.992 -1.484 . . . . 0.0 106.992 -179.827 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 55.4 t60 -143.04 42.26 1.54 Allowed 'General case' 0 N--CA 1.496 1.872 0 C-N-CA 117.389 -1.725 . . . . 0.0 112.436 179.866 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' ASN . . . . . 0.617 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 27.5 t-20 60.63 149.98 0.02 OUTLIER 'General case' 0 N--CA 1.506 2.347 0 N-CA-C 117.947 2.573 . . . . 0.0 117.947 179.742 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.696 ' SG ' ' CB ' ' A' ' 46' ' ' CYS . 13.9 p -115.82 -16.41 11.19 Favored 'General case' 0 N--CA 1.485 1.3 0 CA-C-N 114.352 -1.295 . . . . 0.0 110.983 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 37' ' ' LYS . . . . . 0.501 ' HB3' ' HB3' ' A' ' 6' ' ' CYS . 15.3 ptmt -144.7 127.04 15.83 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.953 -0.467 . . . . 0.0 111.83 -179.967 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.451 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -80.98 44.29 0.75 Allowed 'General case' 0 N--CA 1.493 1.677 0 N-CA-C 106.606 -1.627 . . . . 0.0 106.606 179.618 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 39' ' ' HIS . . . . . 0.467 ' H ' ' C ' ' A' ' 37' ' ' LYS . 2.9 m-70 -131.24 -116.6 0.23 Allowed 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 101.53 -3.508 . . . . 0.0 101.53 -179.845 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -126.68 -113.11 1.82 Allowed Glycine 0 N--CA 1.506 3.311 0 N-CA-C 110.782 -0.927 . . . . 0.0 110.782 179.785 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' PRO . . . . . 0.423 ' HG2' ' O ' ' A' ' 44' ' ' GLY . 83.1 Cg_endo -65.7 -164.77 1.43 Allowed 'Cis proline' 0 N--CA 1.503 2.08 0 N-CA-C 116.316 1.622 . . . . 0.0 116.316 -4.057 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -93.03 -13.91 28.05 Favored 'General case' 0 N--CA 1.486 1.356 0 N-CA-C 106.233 -1.766 . . . . 0.0 106.233 -179.298 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 27.1 pt -103.52 28.76 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.148 0 O-C-N 125.913 2.008 . . . . 0.0 116.234 -179.135 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.423 ' O ' ' HG2' ' A' ' 41' ' ' PRO . . . 129.05 168.36 12.35 Favored Glycine 0 C--N 1.292 -1.892 1 N-CA-C 102.149 -4.38 . . . . 0.0 102.149 -179.973 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 45' ' ' TRP . . . . . 0.438 ' NE1' ' O ' ' A' ' 25' ' ' TYR . 26.2 m95 -102.9 137.3 41.28 Favored 'General case' 0 C--N 1.281 -2.396 0 N-CA-C 105.259 -2.126 . . . . 0.0 105.259 179.883 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 46' ' ' CYS . . . . . 0.696 ' CB ' ' SG ' ' A' ' 36' ' ' CYS . 98.9 m -90.11 130.12 36.32 Favored 'General case' 0 N--CA 1.478 0.966 1 N-CA-C 100.116 -4.031 . . . . 0.0 100.116 179.509 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.434 ' O ' ' N ' ' A' ' 21' ' ' ILE . 82.1 m -132.92 -170.88 2.54 Favored 'General case' 0 C--N 1.296 -1.754 0 CA-C-N 111.736 -2.483 . . . . 0.0 109.273 -179.305 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.568 ' HD3' ' H ' ' A' ' 48' ' ' LYS . 0.0 OUTLIER -150.55 174.35 13.05 Favored 'General case' 0 C--N 1.295 -1.769 0 O-C-N 124.55 1.156 . . . . 0.0 108.377 179.444 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 29.9 mtpt . . . . . 0 C--N 1.29 -2.006 0 CA-C-O 114.398 -2.715 . . . . 0.0 107.104 179.351 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.403 ' HB ' HD23 ' A' ' 22' ' ' LEU . 22.2 t . . . . . 0 N--CA 1.495 1.806 0 N-CA-C 107.149 -1.426 . . . . 0.0 107.149 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.418 ' HA ' ' HA ' ' A' ' 21' ' ' ILE . 37.5 Cg_endo -71.27 164.69 34.89 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 123.838 3.025 . . . . 0.0 112.439 166.603 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.508 ' SG ' ' HB3' ' A' ' 22' ' ' LEU . 0.1 OUTLIER -148.98 -171.0 3.77 Favored 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 107.205 -1.406 . . . . 0.0 107.205 179.508 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 5.2 tt -104.94 147.58 27.63 Favored 'General case' 0 N--CA 1.495 1.786 0 N-CA-C 103.056 -2.942 . . . . 0.0 103.056 179.792 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' CYS . . . . . 0.412 ' HA ' ' HE3' ' A' ' 37' ' ' LYS . 3.9 m -122.73 -171.8 2.35 Favored 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 115.056 1.502 . . . . 0.0 115.056 -179.567 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 7.5 t70 . . . . . 0 N--CA 1.49 1.557 0 CA-C-N 112.873 -1.967 . . . . 0.0 108.177 -179.922 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 33.1 t . . . . . 0 N--CA 1.494 1.739 0 CA-C-O 119.058 -0.496 . . . . 0.0 112.102 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -176.14 -161.02 24.54 Favored Glycine 0 N--CA 1.498 2.767 0 C-N-CA 119.171 -1.49 . . . . 0.0 112.031 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.418 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 39.3 mm -132.22 148.58 32.03 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.924 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.52 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 2.9 pp -71.41 144.13 49.89 Favored 'General case' 0 N--CA 1.493 1.709 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 179.595 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 44.1 m95 -126.91 133.61 50.63 Favored 'General case' 0 C--N 1.308 -1.196 0 N-CA-C 118.773 2.879 . . . . 0.0 118.773 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -89.44 51.76 2.19 Favored 'General case' 0 C--N 1.299 -1.629 1 CA-C-N 107.138 -4.574 . . . . 0.0 110.612 -179.83 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.46 ' CE1' ' HB3' ' A' ' 30' ' ' PRO . 2.1 m-85 -124.51 142.54 40.71 Favored Pre-proline 0 C--N 1.304 -1.391 0 CA-C-O 122.468 1.128 . . . . 0.0 110.71 179.739 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 74.7 Cg_endo -68.53 -29.94 29.75 Favored 'Trans proline' 0 C--N 1.304 -1.777 0 C-N-CA 125.075 3.85 . . . . 0.0 108.186 177.936 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 5.1 p -90.36 24.4 2.59 Favored 'General case' 0 C--N 1.301 -1.542 0 CA-C-N 113.726 -1.579 . . . . 0.0 109.269 179.659 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.602 ' HA2' ' CD1' ' A' ' 45' ' ' TRP . . . 81.99 -84.56 1.48 Allowed Glycine 0 N--CA 1.482 1.759 0 N-CA-C 105.005 -3.238 . . . . 0.0 105.005 -179.748 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 9.2 m -100.88 166.96 11.52 Favored Pre-proline 0 C--N 1.307 -1.275 0 CA-C-N 112.649 -1.775 . . . . 0.0 110.851 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.717 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.1 OUTLIER -89.44 167.17 5.21 Favored 'Trans proline' 0 C--N 1.312 -1.355 1 C-N-CA 125.919 4.412 . . . . 0.0 113.763 155.523 . . . . . . . . 4 4 . 1 . 014 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 18.2 t -60.97 141.37 57.37 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-N 113.784 -1.553 . . . . 0.0 109.181 -179.766 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.06 -2.3 68.74 Favored Glycine 0 N--CA 1.495 2.6 0 CA-C-N 111.675 -2.511 . . . . 0.0 111.551 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' TRP . . . . . 0.717 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 58.7 m95 -111.04 166.52 10.99 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 106.143 -1.799 . . . . 0.0 106.143 -179.743 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' HIS . . . . . 0.514 ' ND1' ' O ' ' A' ' 34' ' ' HIS . 43.1 t-80 -140.02 31.9 1.98 Allowed 'General case' 0 N--CA 1.496 1.839 0 C-N-CA 118.497 -1.281 . . . . 0.0 112.878 -179.872 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 35' ' ' ASN . . . . . 0.51 ' HA ' ' SG ' ' A' ' 47' ' ' CYS . 16.7 t-20 59.03 139.66 0.01 OUTLIER 'General case' 0 N--CA 1.511 2.607 0 N-CA-C 114.458 1.281 . . . . 0.0 114.458 -179.934 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.642 ' SG ' ' CB ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -119.43 -41.06 2.73 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.445 -0.784 . . . . 0.0 110.129 -179.725 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 37' ' ' LYS . . . . . 0.464 ' HG2' ' H ' ' A' ' 39' ' ' HIS . 38.0 ttmt -131.14 138.59 49.54 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 104.696 -2.335 . . . . 0.0 104.696 179.423 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.438 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -117.97 35.63 4.65 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 103.004 -2.962 . . . . 0.0 103.004 179.723 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 39' ' ' HIS . . . . . 0.464 ' H ' ' HG2' ' A' ' 37' ' ' LYS . 2.7 m-70 -140.09 55.96 1.62 Allowed 'General case' 0 N--CA 1.494 1.769 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 -179.537 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 85.9 -160.55 33.97 Favored Glycine 0 N--CA 1.502 3.049 0 N-CA-C 108.773 -1.731 . . . . 0.0 108.773 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' PRO . . . . . 0.414 ' HG2' ' O ' ' A' ' 44' ' ' GLY . 68.6 Cg_endo -64.9 -171.0 3.02 Favored 'Cis proline' 0 N--CA 1.507 2.286 0 CA-C-N 118.305 1.053 . . . . 0.0 114.74 -1.551 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 20.9 m120 -92.96 -8.27 43.59 Favored 'General case' 0 N--CA 1.487 1.377 0 N-CA-C 104.616 -2.364 . . . . 0.0 104.616 -179.921 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 9.9 mm -106.22 32.0 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.961 0 CA-C-O 123.545 1.64 . . . . 0.0 113.782 -178.76 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.414 ' O ' ' HG2' ' A' ' 41' ' ' PRO . . . 124.72 -179.29 16.2 Favored Glycine 0 C--N 1.292 -1.879 1 N-CA-C 102.693 -4.163 . . . . 0.0 102.693 -179.977 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 45' ' ' TRP . . . . . 0.602 ' CD1' ' HA2' ' A' ' 28' ' ' GLY . 1.2 m95 -119.86 140.65 50.5 Favored 'General case' 0 C--N 1.277 -2.55 0 N-CA-C 103.775 -2.676 . . . . 0.0 103.775 179.709 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 46' ' ' CYS . . . . . 0.642 ' CB ' ' SG ' ' A' ' 36' ' ' CYS . 99.4 m -88.74 133.92 34.08 Favored 'General case' 0 N--CA 1.485 1.298 0 CA-C-N 121.756 2.071 . . . . 0.0 107.34 -179.912 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.516 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 87.3 m -133.71 178.32 7.03 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-N 110.892 -2.867 . . . . 0.0 110.443 -179.233 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.468 ' O ' ' HA ' ' A' ' 33' ' ' TRP . 0.0 OUTLIER -149.27 172.96 14.02 Favored 'General case' 0 C--N 1.304 -1.41 0 C-N-CA 117.525 -1.67 . . . . 0.0 111.757 179.776 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 24.8 mmtm . . . . . 0 N--CA 1.496 1.84 0 O-C-N 127.11 2.756 . . . . 0.0 109.413 179.976 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 13.0 t . . . . . 0 N--CA 1.496 1.85 0 N-CA-C 107.988 -1.115 . . . . 0.0 107.988 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -79.32 135.19 11.83 Favored 'Trans proline' 0 C--N 1.308 -1.559 0 C-N-CA 124.352 3.368 . . . . 0.0 115.001 169.994 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.44 ' SG ' ' HB3' ' A' ' 22' ' ' LEU . 0.0 OUTLIER -119.46 -178.12 3.53 Favored 'General case' 0 N--CA 1.494 1.772 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.563 179.662 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 6.4 tt -98.5 113.65 25.74 Favored 'General case' 0 N--CA 1.497 1.908 0 N-CA-C 104.962 -2.236 . . . . 0.0 104.962 -179.836 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' CYS . . . . . 0.403 ' SG ' ' HA3' ' A' ' 20' ' ' GLY . 5.5 m -88.57 -169.01 2.38 Favored 'General case' 0 N--CA 1.487 1.387 0 N-CA-C 119.1 3.0 . . . . 0.0 119.1 -179.179 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 10.8 t0 . . . . . 0 N--CA 1.487 1.394 0 CA-C-N 111.876 -2.42 . . . . 0.0 112.562 -179.655 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 22.8 t . . . . . 0 N--CA 1.499 2.003 0 N-CA-C 112.725 0.639 . . . . 0.0 112.725 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.546 ' HA3' ' SG ' ' A' ' 36' ' ' CYS . . . 174.28 131.53 1.42 Allowed Glycine 0 N--CA 1.48 1.605 0 N-CA-C 108.341 -1.903 . . . . 0.0 108.341 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.493 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 49.7 mm -93.12 132.33 37.64 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.12 0 C-N-CA 116.593 -2.043 . . . . 0.0 105.565 179.851 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.581 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.9 pp -63.0 149.0 46.01 Favored 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 107.276 -1.379 . . . . 0.0 107.276 179.444 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.441 ' CE2' ' HG3' ' A' ' 30' ' ' PRO . 28.5 m95 -129.78 136.83 50.07 Favored 'General case' 0 C--N 1.3 -1.567 0 CA-C-O 124.008 1.861 . . . . 0.0 115.439 -179.812 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -89.11 47.67 1.52 Allowed 'General case' 0 C--N 1.294 -1.845 0 CA-C-N 108.914 -3.766 . . . . 0.0 112.499 -179.809 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 1.1 m-30 -117.33 143.46 32.0 Favored Pre-proline 0 C--N 1.306 -1.322 0 CA-C-O 122.537 1.161 . . . . 0.0 110.362 179.604 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 15.7 Cg_endo -77.19 -35.18 1.82 Allowed 'Trans proline' 0 C--N 1.301 -1.96 0 C-N-CA 123.622 2.881 . . . . 0.0 110.578 175.829 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 10.9 p -89.46 38.77 0.92 Allowed 'General case' 0 N--CA 1.49 1.536 0 CA-C-N 114.61 -1.177 . . . . 0.0 112.38 -179.626 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 73.17 -135.16 20.83 Favored Glycine 0 N--CA 1.5 2.955 0 N-CA-C 108.07 -2.012 . . . . 0.0 108.07 -179.864 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.478 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 15.3 m -72.22 156.18 90.84 Favored Pre-proline 0 C--N 1.304 -1.406 0 CA-C-N 118.793 1.297 . . . . 0.0 111.471 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.726 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.4 OUTLIER -79.71 159.13 24.97 Favored 'Trans proline' 0 C--N 1.307 -1.617 0 C-N-CA 123.281 2.654 . . . . 0.0 111.831 166.597 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 42.0 t -50.07 134.27 22.1 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 113.334 -1.757 . . . . 0.0 109.299 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 95.4 -4.57 67.03 Favored Glycine 0 N--CA 1.498 2.773 0 CA-C-N 112.396 -2.184 . . . . 0.0 111.896 179.835 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' TRP . . . . . 0.726 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 56.4 m95 -112.95 157.2 21.78 Favored 'General case' 0 C--N 1.304 -1.391 0 N-CA-C 105.29 -2.115 . . . . 0.0 105.29 -179.855 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' HIS . . . . . 0.419 ' ND1' ' O ' ' A' ' 34' ' ' HIS . 65.1 t-80 -140.45 41.49 1.89 Allowed 'General case' 0 C--N 1.299 -1.593 0 C-N-CA 118.291 -1.363 . . . . 0.0 112.084 -179.914 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 35' ' ' ASN . . . . . 0.478 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 14.4 t-20 63.17 138.37 0.02 OUTLIER 'General case' 0 N--CA 1.505 2.316 0 N-CA-C 115.74 1.755 . . . . 0.0 115.74 179.412 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.608 ' SG ' ' CB ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -114.9 -40.74 3.46 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 105.843 -1.91 . . . . 0.0 105.843 179.775 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 21.3 ptmt -138.41 149.32 45.4 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 106.864 -1.532 . . . . 0.0 106.864 179.64 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.452 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -120.0 35.43 4.86 Favored 'General case' 0 C--N 1.293 -1.85 0 N-CA-C 102.506 -3.146 . . . . 0.0 102.506 179.881 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 39' ' ' HIS . . . . . 0.452 ' ND1' ' C ' ' A' ' 38' ' ' ALA . 3.7 m-70 -127.57 54.9 1.65 Allowed 'General case' 0 N--CA 1.498 1.951 0 N-CA-C 108.404 -0.961 . . . . 0.0 108.404 -179.625 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 74.0 -148.86 40.24 Favored Glycine 0 N--CA 1.496 2.65 0 N-CA-C 105.604 -2.998 . . . . 0.0 105.604 -179.658 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' PRO . . . . . 0.439 ' HG2' ' O ' ' A' ' 44' ' ' GLY . 51.2 Cg_endo -65.64 -172.63 4.43 Favored 'Cis proline' 0 N--CA 1.501 1.915 0 CA-C-N 119.088 1.444 . . . . 0.0 111.713 -1.4 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 14.3 m120 -93.58 0.52 56.63 Favored 'General case' 0 C--N 1.307 -1.273 0 N-CA-C 104.144 -2.539 . . . . 0.0 104.144 -179.679 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 8.4 mt -116.64 35.02 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 N-CA-C 116.043 1.868 . . . . 0.0 116.043 -178.846 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.439 ' O ' ' HG2' ' A' ' 41' ' ' PRO . . . 119.81 139.76 5.98 Favored Glycine 0 N--CA 1.499 2.846 0 CA-C-N 114.004 -1.453 . . . . 0.0 110.642 179.721 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 45' ' ' TRP . . . . . 0.416 ' O ' ' N ' ' A' ' 23' ' ' TRP . 6.4 m95 -78.22 129.85 35.59 Favored 'General case' 0 N--CA 1.503 2.194 0 CA-C-O 117.783 -1.103 . . . . 0.0 111.096 -179.267 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 46' ' ' CYS . . . . . 0.608 ' CB ' ' SG ' ' A' ' 36' ' ' CYS . 66.2 m -87.71 122.67 31.66 Favored 'General case' 0 C--N 1.308 -1.204 1 N-CA-C 99.791 -4.152 . . . . 0.0 99.791 179.436 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.56 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 88.8 m -129.18 -178.84 4.81 Favored 'General case' 0 CA--C 1.476 -1.894 0 CA-C-N 109.895 -3.321 . . . . 0.0 111.205 -179.398 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.425 ' HD2' ' H ' ' A' ' 49' ' ' LYS . 24.2 tptp -150.52 152.01 33.53 Favored 'General case' 0 C--N 1.294 -1.846 0 C-N-CA 117.675 -1.61 . . . . 0.0 109.987 -179.84 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 49' ' ' LYS . . . . . 0.425 ' H ' ' HD2' ' A' ' 48' ' ' LYS . 51.2 mtpt . . . . . 0 N--CA 1.5 2.054 0 O-C-N 126.197 2.186 . . . . 0.0 111.899 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 33.0 t . . . . . 0 N--CA 1.497 1.885 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -77.27 127.77 9.32 Favored 'Trans proline' 0 N--CA 1.493 1.475 0 C-N-CA 124.523 3.482 . . . . 0.0 116.458 170.048 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.526 ' SG ' ' HB3' ' A' ' 22' ' ' LEU . 0.5 OUTLIER -121.08 179.46 4.38 Favored 'General case' 0 C--N 1.301 -1.508 0 CA-C-N 114.624 -1.171 . . . . 0.0 111.13 179.786 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 6.7 tp -91.68 145.98 24.15 Favored 'General case' 0 N--CA 1.491 1.594 0 N-CA-C 104.625 -2.361 . . . . 0.0 104.625 179.874 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' CYS . . . . . 0.548 ' HA ' ' HD2' ' A' ' 37' ' ' LYS . 6.9 m -119.42 -170.4 1.93 Allowed 'General case' 0 N--CA 1.491 1.583 0 N-CA-C 113.911 1.078 . . . . 0.0 113.911 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 19.8 t70 . . . . . 0 N--CA 1.497 1.887 0 CA-C-N 113.614 -1.63 . . . . 0.0 109.353 179.979 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.498 1.937 0 CA-C-O 122.597 1.189 . . . . 0.0 109.368 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.43 -165.61 18.19 Favored Glycine 0 N--CA 1.502 3.047 0 CA-C-N 114.382 -1.281 . . . . 0.0 111.21 179.804 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.437 HG22 ' O ' ' A' ' 22' ' ' LEU . 28.8 mm -133.88 147.52 30.59 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.265 0 N-CA-C 112.744 0.646 . . . . 0.0 112.744 -179.94 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.588 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 2.8 pp -69.85 152.77 44.16 Favored 'General case' 0 N--CA 1.492 1.644 0 CA-C-N 114.919 -1.037 . . . . 0.0 108.819 179.499 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.678 ' HB2' ' SG ' ' A' ' 29' ' ' CYS . 28.3 m95 -131.93 135.32 46.52 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-O 125.045 2.355 . . . . 0.0 115.986 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.5 m-85 -88.84 54.34 2.98 Favored 'General case' 0 C--N 1.292 -1.892 1 CA-C-N 107.641 -4.345 . . . . 0.0 110.131 -179.669 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.551 ' CE1' ' HB3' ' A' ' 30' ' ' PRO . 2.2 m-85 -123.82 115.88 27.84 Favored Pre-proline 0 N--CA 1.491 1.618 0 CA-C-N 115.497 -0.774 . . . . 0.0 112.656 179.654 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -64.03 -11.85 29.35 Favored 'Trans proline' 0 C--N 1.308 -1.557 0 C-N-CA 123.389 2.726 . . . . 0.0 111.948 -175.412 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 6.6 p -108.93 3.93 22.8 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-N 115.37 -0.832 . . . . 0.0 111.025 179.753 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.4 ' O ' ' CD1' ' A' ' 45' ' ' TRP . . . 126.45 -113.21 1.75 Allowed Glycine 0 N--CA 1.502 3.058 0 N-CA-C 108.727 -1.749 . . . . 0.0 108.727 -179.913 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.678 ' SG ' ' HB2' ' A' ' 23' ' ' TRP . 18.4 m -132.36 156.54 79.98 Favored Pre-proline 0 C--N 1.305 -1.357 0 CA-C-N 117.701 0.75 . . . . 0.0 110.687 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.737 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 9.0 Cg_endo -78.68 162.04 27.39 Favored 'Trans proline' 0 C--N 1.306 -1.68 0 C-N-CA 123.335 2.69 . . . . 0.0 113.323 -167.196 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 22.9 t -51.32 116.43 2.05 Favored 'General case' 0 C--N 1.302 -1.487 0 CA-C-N 113.292 -1.776 . . . . 0.0 110.473 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 115.5 -7.61 20.37 Favored Glycine 0 N--CA 1.499 2.87 0 CA-C-N 113.744 -1.571 . . . . 0.0 111.529 179.761 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' TRP . . . . . 0.737 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 49.9 m95 -109.22 158.94 17.35 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 104.77 -2.307 . . . . 0.0 104.77 -179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 78.3 t60 -138.34 33.04 2.31 Favored 'General case' 0 C--N 1.298 -1.666 0 C-N-CA 118.05 -1.46 . . . . 0.0 114.074 -179.598 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' ASN . . . . . 0.774 ' HA ' ' SG ' ' A' ' 47' ' ' CYS . 5.1 m-20 57.34 137.35 0.0 OUTLIER 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 116.648 2.092 . . . . 0.0 116.648 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.587 ' SG ' ' HB3' ' A' ' 46' ' ' CYS . 0.6 OUTLIER -112.06 -40.13 4.3 Favored 'General case' 0 N--CA 1.489 1.489 0 CA-C-N 115.015 -0.993 . . . . 0.0 108.931 -179.644 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 37' ' ' LYS . . . . . 0.548 ' HD2' ' HA ' ' A' ' 6' ' ' CYS . 51.9 tttt -132.87 143.38 49.48 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 107.356 -1.349 . . . . 0.0 107.356 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.441 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -119.47 30.08 7.28 Favored 'General case' 0 N--CA 1.493 1.721 0 N-CA-C 104.772 -2.307 . . . . 0.0 104.772 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 39' ' ' HIS . . . . . 0.482 ' H ' ' HG2' ' A' ' 37' ' ' LYS . 4.5 m-70 -134.75 62.18 1.65 Allowed 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 107.023 -1.473 . . . . 0.0 107.023 -179.564 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 75.75 -155.94 47.22 Favored Glycine 0 N--CA 1.498 2.798 0 N-CA-C 106.213 -2.755 . . . . 0.0 106.213 -179.728 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_endo -74.09 -169.38 7.0 Favored 'Cis proline' 0 N--CA 1.496 1.669 0 CA-C-N 118.922 1.361 . . . . 0.0 113.923 -0.682 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 10.0 p30 -92.33 -14.66 28.43 Favored 'General case' 0 CA--C 1.486 -1.506 0 N-CA-C 105.992 -1.855 . . . . 0.0 105.992 -179.606 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 31.6 pt -90.28 24.17 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 O-C-N 125.277 1.61 . . . . 0.0 113.978 -179.431 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 114.37 137.79 6.6 Favored Glycine 0 N--CA 1.493 2.472 0 CA-C-N 113.246 -1.797 . . . . 0.0 109.696 -179.945 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 45' ' ' TRP . . . . . 0.426 ' O ' ' N ' ' A' ' 23' ' ' TRP . 7.9 m95 -61.53 136.4 58.01 Favored 'General case' 0 N--CA 1.519 3.006 0 CA-C-O 117.317 -1.325 . . . . 0.0 108.421 -179.643 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 46' ' ' CYS . . . . . 0.588 ' HA ' ' HA ' ' A' ' 22' ' ' LEU . 93.0 m -89.9 127.08 35.94 Favored 'General case' 0 N--CA 1.482 1.141 0 CA-C-N 122.26 2.3 . . . . 0.0 105.127 -179.921 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.774 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 93.7 m -136.45 -171.82 3.0 Favored 'General case' 0 C--N 1.3 -1.563 0 CA-C-N 111.327 -2.67 . . . . 0.0 111.005 -179.409 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.538 ' O ' ' HA ' ' A' ' 33' ' ' TRP . 0.0 OUTLIER -151.31 172.29 16.12 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 179.574 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 47.4 mtpt . . . . . 0 C--N 1.291 -1.969 0 O-C-N 126.704 2.503 . . . . 0.0 110.347 179.828 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 29.6 t . . . . . 0 N--CA 1.496 1.852 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -67.27 135.57 37.36 Favored 'Trans proline' 0 N--CA 1.493 1.455 0 C-N-CA 122.333 2.022 . . . . 0.0 110.24 170.051 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -134.06 175.8 9.15 Favored 'General case' 0 N--CA 1.497 1.918 0 CA-C-O 121.563 0.697 . . . . 0.0 112.242 -179.724 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -101.55 141.89 33.74 Favored 'General case' 0 N--CA 1.494 1.732 0 N-CA-C 104.067 -2.568 . . . . 0.0 104.067 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 6' ' ' CYS . . . . . 0.437 ' HB3' ' C ' ' A' ' 36' ' ' CYS . 1.8 m -113.14 -138.8 0.38 Allowed 'General case' 0 N--CA 1.497 1.892 0 N-CA-C 120.395 3.48 . . . . 0.0 120.395 -178.95 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 . . . . . 0 N--CA 1.507 2.391 0 O-C-N 120.969 -1.082 . . . . 0.0 110.388 -179.828 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 7.1 m . . . . . 0 N--CA 1.5 2.064 0 N-CA-C 115.644 1.72 . . . . 0.0 115.644 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 148.69 -163.69 29.05 Favored Glycine 0 N--CA 1.497 2.743 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.517 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 35.5 mm -135.98 146.42 29.43 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.088 0 CA-C-O 122.487 1.137 . . . . 0.0 109.878 179.852 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.546 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 0.9 OUTLIER -69.69 134.79 49.06 Favored 'General case' 0 C--N 1.297 -1.693 0 CA-C-N 114.654 -1.157 . . . . 0.0 108.625 179.826 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.421 ' CE2' ' HG3' ' A' ' 30' ' ' PRO . 44.5 m95 -124.04 134.18 53.48 Favored 'General case' 0 N--CA 1.484 1.242 0 N-CA-C 118.96 2.948 . . . . 0.0 118.96 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.2 m-30 -88.93 39.58 0.94 Allowed 'General case' 0 C--N 1.296 -1.718 1 CA-C-N 107.366 -4.47 . . . . 0.0 113.064 -179.584 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.42 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 1.2 m-30 -113.07 125.13 30.25 Favored Pre-proline 0 C--N 1.304 -1.402 0 CA-C-O 122.697 1.237 . . . . 0.0 112.271 -179.935 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -66.21 -25.26 50.36 Favored 'Trans proline' 0 C--N 1.302 -1.872 0 C-N-CA 122.507 2.138 . . . . 0.0 108.341 -177.731 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 5.8 p -87.01 5.03 39.44 Favored 'General case' 0 N--CA 1.49 1.536 0 CA-C-N 114.375 -1.284 . . . . 0.0 112.468 179.926 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 110.65 -118.57 5.0 Favored Glycine 0 N--CA 1.498 2.806 0 N-CA-C 106.238 -2.745 . . . . 0.0 106.238 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.51 ' HB3' ' HB2' ' A' ' 33' ' ' TRP . 37.4 m -96.65 153.79 38.65 Favored Pre-proline 0 C--N 1.303 -1.446 0 N-CA-C 106.726 -1.583 . . . . 0.0 106.726 179.735 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.748 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.8 OUTLIER -76.34 169.47 21.89 Favored 'Trans proline' 0 C--N 1.305 -1.726 0 C-N-CA 123.077 2.518 . . . . 0.0 113.829 174.588 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 5.7 m -46.17 103.83 0.04 OUTLIER 'General case' 0 C--N 1.298 -1.633 0 CA-C-N 112.01 -2.359 . . . . 0.0 113.99 -179.854 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 109.11 2.68 31.62 Favored Glycine 0 N--CA 1.501 2.996 0 C-N-CA 120.811 -0.709 . . . . 0.0 114.293 179.481 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' TRP . . . . . 0.748 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 44.7 m95 -110.82 164.81 12.39 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 106.999 -1.482 . . . . 0.0 106.999 -179.954 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 57.7 t-80 -144.76 37.23 1.18 Allowed 'General case' 0 N--CA 1.499 1.992 0 C-N-CA 117.757 -1.577 . . . . 0.0 113.072 -179.722 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' ASN . . . . . 0.504 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 24.0 t-20 58.43 146.48 0.01 OUTLIER 'General case' 0 N--CA 1.501 2.098 0 CA-C-N 113.248 -1.797 . . . . 0.0 114.673 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.64 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -121.09 -46.67 2.31 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 106.013 -1.847 . . . . 0.0 106.013 179.974 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 13.1 ttmt -107.94 102.08 11.29 Favored 'General case' 0 C--N 1.301 -1.502 0 CA-C-N 113.315 -1.766 . . . . 0.0 108.618 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -83.36 12.28 5.66 Favored 'General case' 0 N--CA 1.496 1.869 0 CA-C-N 113.31 -1.768 . . . . 0.0 107.713 179.511 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 7.4 m-70 -127.22 37.71 4.21 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-N 114.878 -1.055 . . . . 0.0 109.208 -179.667 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 96.23 -149.56 19.35 Favored Glycine 0 N--CA 1.498 2.768 0 CA-C-N 114.538 -1.21 . . . . 0.0 111.267 179.586 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' PRO . . . . . 0.45 ' HB2' HG12 ' A' ' 43' ' ' ILE . 3.5 Cg_endo -75.5 -173.84 13.2 Favored 'Cis proline' 0 N--CA 1.5 1.861 0 N-CA-C 109.386 -1.044 . . . . 0.0 109.386 1.496 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 42' ' ' ASN . . . . . 0.476 ' C ' ' H ' ' A' ' 44' ' ' GLY . 56.5 t30 -92.27 -11.97 33.81 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 105.463 -2.051 . . . . 0.0 105.463 -179.783 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.45 HG12 ' HB2' ' A' ' 41' ' ' PRO . 30.5 pt -85.66 28.92 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 CA-C-O 123.302 1.525 . . . . 0.0 112.741 -179.192 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.476 ' H ' ' C ' ' A' ' 42' ' ' ASN . . . 116.98 142.57 7.34 Favored Glycine 0 C--N 1.295 -1.71 0 CA-C-N 110.528 -3.033 . . . . 0.0 106.153 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 45' ' ' TRP . . . . . 0.42 ' NE1' ' O ' ' A' ' 25' ' ' TYR . 6.9 m95 -77.81 133.77 38.14 Favored 'General case' 0 C--N 1.293 -1.849 0 N-CA-C 104.674 -2.343 . . . . 0.0 104.674 -179.534 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 46' ' ' CYS . . . . . 0.64 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 46.0 t -89.22 129.14 35.84 Favored 'General case' 0 N--CA 1.485 1.318 1 N-CA-C 99.319 -4.326 . . . . 0.0 99.319 179.773 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.524 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 77.3 m -127.88 -170.53 2.25 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-N 113.096 -1.866 . . . . 0.0 110.254 -179.363 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.08 172.3 15.98 Favored 'General case' 0 C--N 1.298 -1.674 0 N-CA-C 107.599 -1.26 . . . . 0.0 107.599 179.311 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 65.3 mttt . . . . . 0 N--CA 1.498 1.961 0 O-C-N 126.267 2.229 . . . . 0.0 108.189 179.267 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 46.8 t . . . . . 0 N--CA 1.499 2.01 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 26.6 Cg_endo -73.11 116.03 4.56 Favored 'Trans proline' 0 C--N 1.308 -1.566 0 C-N-CA 122.877 2.384 . . . . 0.0 114.473 170.664 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.533 ' SG ' ' HB2' ' A' ' 22' ' ' LEU . 0.8 OUTLIER -122.15 163.94 18.65 Favored 'General case' 0 N--CA 1.494 1.774 0 CA-C-N 113.037 -1.892 . . . . 0.0 108.839 -179.799 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.432 HD12 ' HA ' ' A' ' 5' ' ' LEU . 12.2 tp -89.61 174.82 7.54 Favored 'General case' 0 N--CA 1.497 1.886 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 -179.895 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 6' ' ' CYS . . . . . 0.455 ' HB3' ' C ' ' A' ' 36' ' ' CYS . 1.8 m -135.26 -143.25 0.19 Allowed 'General case' 0 N--CA 1.501 2.097 1 N-CA-C 122.131 4.123 . . . . 0.0 122.131 -178.738 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.497 1.89 0 C-N-CA 118.405 -1.318 . . . . 0.0 108.813 -179.523 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 80.5 p . . . . . 0 N--CA 1.485 1.285 0 CA-C-O 120.987 0.422 . . . . 0.0 111.697 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 153.28 161.58 10.43 Favored Glycine 0 N--CA 1.5 2.926 0 C-N-CA 119.512 -1.328 . . . . 0.0 112.775 179.46 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.458 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 49.1 mm -124.07 137.83 55.75 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.176 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 179.57 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.533 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 34.7 tp -63.99 144.58 56.98 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 179.659 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 42.4 m95 -131.52 134.08 45.75 Favored 'General case' 0 C--N 1.308 -1.236 0 N-CA-C 119.428 3.122 . . . . 0.0 119.428 -179.568 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -88.87 54.45 3.02 Favored 'General case' 0 C--N 1.297 -1.675 1 CA-C-N 108.145 -4.116 . . . . 0.0 108.727 -179.962 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.48 ' CE1' ' HB3' ' A' ' 30' ' ' PRO . 2.4 m-85 -128.73 120.02 20.42 Favored Pre-proline 0 N--CA 1.486 1.368 0 CA-C-N 115.088 -0.96 . . . . 0.0 113.556 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.402 ' HD2' ' HA ' ' A' ' 25' ' ' TYR . 57.3 Cg_endo -67.25 -13.48 39.66 Favored 'Trans proline' 0 C--N 1.309 -1.526 0 C-N-CA 123.793 2.996 . . . . 0.0 110.918 -178.121 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 12.8 p -93.51 -9.23 39.03 Favored 'General case' 0 N--CA 1.491 1.609 0 CA-C-N 114.565 -1.198 . . . . 0.0 110.43 179.81 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.43 ' HA2' ' CD2' ' A' ' 45' ' ' TRP . . . 116.3 -106.96 1.57 Allowed Glycine 0 N--CA 1.482 1.724 1 N-CA-C 102.512 -4.235 . . . . 0.0 102.512 -179.702 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.602 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 16.7 m -99.36 151.66 37.5 Favored Pre-proline 0 C--N 1.301 -1.52 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.678 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.4 OUTLIER -79.46 164.57 23.73 Favored 'Trans proline' 0 C--N 1.306 -1.694 0 C-N-CA 123.005 2.47 . . . . 0.0 114.359 169.831 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 3.1 m -43.93 105.32 0.05 Allowed 'General case' 0 C--N 1.3 -1.581 0 CA-C-N 112.197 -2.274 . . . . 0.0 112.636 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 114.53 -4.12 23.22 Favored Glycine 0 N--CA 1.505 3.26 0 CA-C-N 115.665 -0.698 . . . . 0.0 113.495 179.581 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' TRP . . . . . 0.678 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 49.2 m95 -111.22 166.5 11.04 Favored 'General case' 0 N--CA 1.488 1.43 0 N-CA-C 107.061 -1.459 . . . . 0.0 107.061 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 55.0 t-80 -148.86 40.35 0.89 Allowed 'General case' 0 N--CA 1.505 2.312 0 C-N-CA 117.904 -1.518 . . . . 0.0 114.147 -179.856 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' ASN . . . . . 0.602 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 11.4 t-20 52.36 146.66 0.0 OUTLIER 'General case' 0 N--CA 1.499 1.986 0 CA-C-N 113.001 -1.909 . . . . 0.0 116.073 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.505 ' SG ' ' O ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -119.08 -41.14 2.77 Favored 'General case' 0 C--N 1.306 -1.29 0 CA-C-N 114.582 -1.19 . . . . 0.0 111.336 -179.805 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 37' ' ' LYS . . . . . 0.514 ' C ' ' H ' ' A' ' 39' ' ' HIS . 44.3 tttm -106.04 106.36 16.83 Favored 'General case' 0 N--CA 1.502 2.136 0 C-N-CA 119.014 -1.074 . . . . 0.0 108.384 179.655 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -65.8 16.66 0.02 OUTLIER 'General case' 0 N--CA 1.505 2.299 0 N-CA-C 113.049 0.759 . . . . 0.0 113.049 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' HIS . . . . . 0.514 ' H ' ' C ' ' A' ' 37' ' ' LYS . 5.3 m-70 -128.38 -4.84 5.42 Favored 'General case' 0 N--CA 1.494 1.745 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.03 179.947 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 133.97 -119.86 2.36 Favored Glycine 0 N--CA 1.509 3.506 0 C-N-CA 120.685 -0.769 . . . . 0.0 113.086 179.872 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -68.1 -170.82 5.04 Favored 'Cis proline' 0 N--CA 1.504 2.138 0 CA-C-N 118.609 1.205 . . . . 0.0 111.824 -1.669 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 59.4 t30 -93.72 -5.5 48.3 Favored 'General case' 0 CA--C 1.492 -1.253 0 N-CA-C 106.083 -1.821 . . . . 0.0 106.083 -179.709 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 28.4 mt -94.81 32.14 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.104 0 CA-C-O 123.897 1.808 . . . . 0.0 110.737 -179.005 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 115.96 153.99 10.27 Favored Glycine 0 C--N 1.295 -1.737 1 N-CA-C 101.137 -4.785 . . . . 0.0 101.137 -179.692 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 45' ' ' TRP . . . . . 0.43 ' CD2' ' HA2' ' A' ' 28' ' ' GLY . 56.4 m95 -86.56 135.37 33.46 Favored 'General case' 0 N--CA 1.505 2.298 0 CA-C-O 116.475 -1.726 . . . . 0.0 108.057 -179.769 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 46' ' ' CYS . . . . . 0.509 ' HA ' ' HA ' ' A' ' 22' ' ' LEU . 59.3 m -92.65 121.18 33.81 Favored 'General case' 0 C--N 1.308 -1.212 1 N-CA-C 96.884 -5.228 . . . . 0.0 96.884 179.763 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.501 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 96.1 m -127.57 -174.57 3.22 Favored 'General case' 0 C--N 1.297 -1.712 0 CA-C-N 112.419 -2.173 . . . . 0.0 108.366 -179.351 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.36 173.14 14.86 Favored 'General case' 0 C--N 1.297 -1.705 0 N-CA-C 106.923 -1.51 . . . . 0.0 106.923 179.32 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 86.8 mttt . . . . . 0 C--N 1.289 -2.049 0 O-C-N 126.255 2.222 . . . . 0.0 106.593 179.337 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 19.4 t . . . . . 0 N--CA 1.492 1.666 0 N-CA-C 106.939 -1.504 . . . . 0.0 106.939 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.47 ' HA ' ' O ' ' A' ' 20' ' ' GLY . 11.0 Cg_endo -77.09 132.95 13.12 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 123.246 2.63 . . . . 0.0 113.147 163.673 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -121.26 177.39 5.18 Favored 'General case' 0 N--CA 1.494 1.734 0 C-N-CA 119.966 -0.694 . . . . 0.0 112.038 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.448 HD23 ' N ' ' A' ' 6' ' ' CYS . 9.4 tt -94.12 150.86 19.94 Favored 'General case' 0 N--CA 1.493 1.687 0 N-CA-C 105.036 -2.209 . . . . 0.0 105.036 179.768 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 6' ' ' CYS . . . . . 0.481 ' HB3' ' HB2' ' A' ' 37' ' ' LYS . 13.0 m -143.07 -174.85 4.3 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 124.683 1.239 . . . . 0.0 111.739 -179.337 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 9.6 t70 . . . . . 0 N--CA 1.493 1.707 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 179.881 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 5.5 t . . . . . 0 N--CA 1.5 2.074 0 CA-C-O 121.063 0.459 . . . . 0.0 110.079 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.47 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -173.83 -178.01 43.46 Favored Glycine 0 N--CA 1.5 2.904 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.433 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 28.8 mm -134.43 144.11 36.03 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.361 0 N-CA-C 107.072 -1.455 . . . . 0.0 107.072 -179.801 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.504 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.4 pp -66.78 156.62 35.01 Favored 'General case' 0 N--CA 1.491 1.621 0 C-N-CA 118.606 -1.238 . . . . 0.0 108.968 179.715 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.424 ' CE2' ' HG3' ' A' ' 30' ' ' PRO . 35.7 m95 -136.84 134.15 36.63 Favored 'General case' 0 C--N 1.304 -1.371 0 N-CA-C 117.948 2.573 . . . . 0.0 117.948 -179.789 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -89.92 42.49 1.1 Allowed 'General case' 0 C--N 1.296 -1.735 1 CA-C-N 107.784 -4.28 . . . . 0.0 112.411 -179.788 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.445 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 1.3 m-30 -116.3 136.96 23.16 Favored Pre-proline 0 C--N 1.303 -1.418 0 CA-C-O 121.985 0.897 . . . . 0.0 108.749 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -70.02 -17.43 36.39 Favored 'Trans proline' 0 C--N 1.298 -2.082 0 C-N-CA 122.717 2.278 . . . . 0.0 108.607 179.84 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 10.6 p -95.71 23.54 6.1 Favored 'General case' 0 N--CA 1.488 1.445 0 CA-C-N 113.776 -1.556 . . . . 0.0 109.513 179.765 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.611 ' HA2' ' CG ' ' A' ' 45' ' ' TRP . . . 83.13 -94.33 1.76 Allowed Glycine 0 N--CA 1.487 2.053 0 N-CA-C 104.209 -3.556 . . . . 0.0 104.209 -179.677 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.579 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 25.2 m -98.47 165.27 15.47 Favored Pre-proline 0 C--N 1.301 -1.515 0 CA-C-N 113.777 -1.211 . . . . 0.0 110.604 -179.934 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.711 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.1 OUTLIER -88.59 161.48 6.51 Favored 'Trans proline' 0 C--N 1.312 -1.393 1 C-N-CA 125.881 4.387 . . . . 0.0 115.818 156.241 . . . . . . . . 4 4 . 1 . 019 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 14.0 p -51.55 113.55 1.0 Allowed 'General case' 0 C--N 1.301 -1.512 0 CA-C-N 112.132 -2.303 . . . . 0.0 113.16 -179.758 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 115.94 -6.76 19.7 Favored Glycine 0 N--CA 1.502 3.097 0 O-C-N 124.842 1.339 . . . . 0.0 111.12 179.692 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' TRP . . . . . 0.711 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 42.6 m95 -110.06 173.13 6.47 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 106.156 -1.794 . . . . 0.0 106.156 -179.849 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 77.5 t60 -149.91 29.29 0.74 Allowed 'General case' 0 N--CA 1.496 1.841 0 C-N-CA 117.935 -1.506 . . . . 0.0 112.668 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' ASN . . . . . 0.588 ' HA ' ' SG ' ' A' ' 47' ' ' CYS . 19.9 t-20 62.07 153.35 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.753 0 CA-C-N 114.245 -1.343 . . . . 0.0 111.637 -179.751 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.55 ' SG ' ' HB3' ' A' ' 46' ' ' CYS . 13.9 p -117.68 -39.95 3.08 Favored 'General case' 0 N--CA 1.499 2.024 0 N-CA-C 114.924 1.453 . . . . 0.0 114.924 -179.499 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 37' ' ' LYS . . . . . 0.481 ' HB2' ' HB3' ' A' ' 6' ' ' CYS . 74.0 tttt -131.4 132.12 44.13 Favored 'General case' 0 N--CA 1.5 2.047 0 N-CA-C 103.532 -2.766 . . . . 0.0 103.532 179.59 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -78.8 22.4 0.37 Allowed 'General case' 0 N--CA 1.495 1.802 0 C-N-CA 117.553 -1.659 . . . . 0.0 107.985 179.716 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' HIS . . . . . 0.429 ' H ' ' C ' ' A' ' 37' ' ' LYS . 9.5 m-70 -138.79 107.43 5.89 Favored 'General case' 0 N--CA 1.496 1.829 0 N-CA-C 113.713 1.005 . . . . 0.0 113.713 -179.395 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 60.78 -161.93 22.4 Favored Glycine 0 N--CA 1.502 3.08 0 CA-C-N 114.311 -1.313 . . . . 0.0 113.901 179.547 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' PRO . . . . . 0.45 ' HD2' ' N ' ' A' ' 46' ' ' CYS . 73.0 Cg_endo -55.32 179.93 1.19 Allowed 'Cis proline' 0 N--CA 1.505 2.188 0 C-N-CA 129.362 0.984 . . . . 0.0 114.436 -5.499 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 21.9 m-20 -92.98 -8.25 43.62 Favored 'General case' 0 C--N 1.306 -1.294 0 N-CA-C 104.496 -2.409 . . . . 0.0 104.496 -179.783 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 11.4 mm -100.96 28.86 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.02 0 CA-C-O 123.675 1.703 . . . . 0.0 113.86 -179.008 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 136.01 -131.65 5.81 Favored Glycine 0 N--CA 1.485 1.906 1 N-CA-C 101.762 -4.535 . . . . 0.0 101.762 179.888 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 45' ' ' TRP . . . . . 0.611 ' CG ' ' HA2' ' A' ' 28' ' ' GLY . 3.0 m95 -153.33 161.29 42.5 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 105.268 -2.123 . . . . 0.0 105.268 179.646 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 46' ' ' CYS . . . . . 0.55 ' HB3' ' SG ' ' A' ' 36' ' ' CYS . 19.3 m -111.54 133.97 53.45 Favored 'General case' 0 N--CA 1.498 1.943 0 CA-C-N 123.037 2.653 . . . . 0.0 104.278 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.588 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 79.0 m -135.12 -173.4 3.31 Favored 'General case' 0 C--N 1.293 -1.865 0 CA-C-N 111.287 -2.688 . . . . 0.0 108.143 -179.399 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -150.6 175.89 11.5 Favored 'General case' 0 C--N 1.294 -1.805 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 179.225 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 49' ' ' LYS . . . . . 0.473 ' HE3' ' CZ2' ' A' ' 33' ' ' TRP . 22.6 mmtp . . . . . 0 C--N 1.293 -1.861 0 CA-C-O 114.98 -2.438 . . . . 0.0 107.275 179.5 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 45.7 t . . . . . 0 N--CA 1.493 1.699 0 N-CA-C 104.916 -2.253 . . . . 0.0 104.916 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -70.61 135.19 27.85 Favored 'Trans proline' 0 C--N 1.306 -1.659 0 C-N-CA 123.481 2.787 . . . . 0.0 112.132 175.21 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -139.64 174.66 10.28 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 123.968 0.792 . . . . 0.0 111.869 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.523 HD12 ' HA ' ' A' ' 5' ' ' LEU . 13.6 tp -97.8 152.17 19.44 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 102.065 -3.309 . . . . 0.0 102.065 179.766 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 6' ' ' CYS . . . . . 0.497 ' HB3' ' C ' ' A' ' 36' ' ' CYS . 2.7 m -115.44 -138.08 0.37 Allowed 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 121.007 3.706 . . . . 0.0 121.007 -178.669 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 . . . . . 0 N--CA 1.502 2.163 0 C-N-CA 119.643 -0.823 . . . . 0.0 111.706 -179.699 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 27.3 t . . . . . 0 N--CA 1.5 2.04 0 CA-C-O 118.051 -0.976 . . . . 0.0 113.537 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.457 ' HA2' ' HD3' ' A' ' 48' ' ' LYS . . . -177.33 152.23 11.84 Favored Glycine 0 N--CA 1.501 2.985 0 C-N-CA 119.234 -1.46 . . . . 0.0 111.508 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.502 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 38.8 mm -101.31 137.49 28.79 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.206 0 C-N-CA 117.3 -1.76 . . . . 0.0 106.718 179.623 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' LEU . . . . . 0.53 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 30.8 tp -63.03 136.3 57.74 Favored 'General case' 0 C--N 1.295 -1.786 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 179.821 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 39.5 m95 -127.06 134.94 50.18 Favored 'General case' 0 C--N 1.31 -1.124 0 CA-C-O 125.397 2.522 . . . . 0.0 117.703 -179.848 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -88.73 40.65 0.98 Allowed 'General case' 0 C--N 1.295 -1.767 1 CA-C-N 107.669 -4.332 . . . . 0.0 113.98 -179.539 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.468 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 1.2 m-30 -115.17 122.22 33.68 Favored Pre-proline 0 N--CA 1.489 1.514 0 CA-C-O 122.86 1.314 . . . . 0.0 113.909 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo -63.66 -23.32 69.93 Favored 'Trans proline' 0 C--N 1.301 -1.938 0 C-N-CA 122.268 1.978 . . . . 0.0 108.924 -173.077 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 10.6 p -93.27 8.83 38.74 Favored 'General case' 0 N--CA 1.492 1.635 0 CA-C-N 114.502 -1.227 . . . . 0.0 112.651 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 112.04 -118.63 4.78 Favored Glycine 0 N--CA 1.495 2.62 0 N-CA-C 107.001 -2.439 . . . . 0.0 107.001 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' CYS . . . . . 0.526 ' HB3' ' HB2' ' A' ' 33' ' ' TRP . 14.8 m -96.21 159.54 31.86 Favored Pre-proline 0 C--N 1.303 -1.444 0 N-CA-C 107.504 -1.295 . . . . 0.0 107.504 179.8 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.723 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 1.6 Cg_endo -78.35 159.56 29.38 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 C-N-CA 122.338 2.025 . . . . 0.0 112.126 169.588 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 27.9 t -49.61 121.97 5.79 Favored 'General case' 0 C--N 1.303 -1.438 0 CA-C-N 113.345 -1.752 . . . . 0.0 108.96 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 109.68 -6.3 31.36 Favored Glycine 0 N--CA 1.498 2.806 0 CA-C-N 113.279 -1.782 . . . . 0.0 111.655 179.673 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' TRP . . . . . 0.723 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 51.0 m95 -113.61 158.12 21.23 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 105.957 -1.868 . . . . 0.0 105.957 -179.938 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 50.6 t-80 -140.13 37.15 1.92 Allowed 'General case' 0 N--CA 1.493 1.7 0 C-N-CA 118.974 -1.09 . . . . 0.0 111.08 -179.774 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' ASN . . . . . 0.489 ' HA ' ' SG ' ' A' ' 47' ' ' CYS . 22.1 t-20 60.25 152.08 0.02 OUTLIER 'General case' 0 N--CA 1.504 2.225 0 CA-C-N 113.303 -1.772 . . . . 0.0 115.045 179.794 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 36' ' ' CYS . . . . . 0.548 ' SG ' ' HB3' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -125.18 -48.55 1.72 Allowed 'General case' 0 N--CA 1.483 1.219 0 N-CA-C 105.869 -1.9 . . . . 0.0 105.869 -179.972 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 66.2 tttt -113.2 103.1 11.01 Favored 'General case' 0 C--N 1.305 -1.35 0 N-CA-C 105.709 -1.96 . . . . 0.0 105.709 179.719 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.426 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -88.96 18.56 4.76 Favored 'General case' 0 N--CA 1.497 1.885 0 CA-C-N 113.312 -1.767 . . . . 0.0 107.155 179.577 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 39' ' ' HIS . . . . . 0.426 ' ND1' ' C ' ' A' ' 38' ' ' ALA . 7.1 m-70 -129.29 37.37 4.04 Favored 'General case' 0 N--CA 1.489 1.509 0 CA-C-N 114.468 -1.242 . . . . 0.0 109.05 -179.733 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 96.9 -158.32 21.29 Favored Glycine 0 N--CA 1.501 3.009 0 N-CA-C 110.207 -1.157 . . . . 0.0 110.207 179.803 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' PRO . . . . . 0.461 ' HG2' ' O ' ' A' ' 44' ' ' GLY . 9.2 Cg_endo -74.44 -176.66 18.11 Favored 'Cis proline' 0 N--CA 1.505 2.159 0 CA-C-N 118.914 1.357 . . . . 0.0 110.91 1.448 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 19.4 p-10 -92.32 -11.3 35.49 Favored 'General case' 0 N--CA 1.491 1.578 0 N-CA-C 105.016 -2.216 . . . . 0.0 105.016 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 13.0 mm -88.4 29.05 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.31 0 CA-C-N 113.807 -1.542 . . . . 0.0 110.598 -179.427 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.461 ' O ' ' HG2' ' A' ' 41' ' ' PRO . . . 115.37 130.64 4.81 Favored Glycine 0 N--CA 1.49 2.24 0 CA-C-N 112.414 -2.175 . . . . 0.0 107.853 -179.871 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 45' ' ' TRP . . . . . 0.468 ' NE1' ' O ' ' A' ' 25' ' ' TYR . 2.1 m95 -73.85 134.67 43.34 Favored 'General case' 0 N--CA 1.499 1.98 0 N-CA-C 105.882 -1.896 . . . . 0.0 105.882 -179.434 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 46' ' ' CYS . . . . . 0.548 ' HB3' ' SG ' ' A' ' 36' ' ' CYS . 96.0 m -87.9 128.78 35.36 Favored 'General case' 0 N--CA 1.491 1.62 0 N-CA-C 101.314 -3.587 . . . . 0.0 101.314 179.575 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.503 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 73.7 m -126.71 -176.28 3.65 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-N 113.28 -1.782 . . . . 0.0 113.755 -179.317 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 48' ' ' LYS . . . . . 0.468 ' HD2' ' H ' ' A' ' 49' ' ' LYS . 28.5 tptp -150.76 150.84 31.51 Favored 'General case' 0 C--N 1.292 -1.913 0 CA-C-N 114.931 -1.031 . . . . 0.0 109.817 -179.944 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 49' ' ' LYS . . . . . 0.468 ' H ' ' HD2' ' A' ' 48' ' ' LYS . 54.1 mtpt . . . . . 0 N--CA 1.501 2.085 0 O-C-N 126.16 2.162 . . . . 0.0 109.666 179.458 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.499 2.849 0 N-CA-C 109.94 -1.264 . . . . 0.0 109.94 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 24.6 t -123.31 142.11 37.78 Favored Pre-proline 0 N--CA 1.497 1.876 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.412 ' HA ' ' O ' ' A' ' 20' ' ' GLY . 4.9 Cg_endo -81.33 142.13 13.12 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 C-N-CA 123.293 2.662 . . . . 0.0 110.932 164.718 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -137.52 170.03 16.78 Favored 'General case' 0 N--CA 1.495 1.784 0 C-N-CA 119.455 -0.898 . . . . 0.0 111.659 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.534 HD23 ' N ' ' A' ' 6' ' ' CYS . 5.5 tt -85.62 148.05 26.1 Favored 'General case' 0 N--CA 1.495 1.792 0 N-CA-C 106.752 -1.573 . . . . 0.0 106.752 -179.823 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.546 ' HB3' ' C ' ' A' ' 36' ' ' CYS . 2.4 m -127.73 -167.03 1.69 Allowed 'General case' 0 N--CA 1.488 1.443 0 N-CA-C 119.197 3.036 . . . . 0.0 119.197 -179.621 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -74.86 -62.88 1.39 Allowed 'General case' 0 N--CA 1.503 2.199 0 CA-C-N 112.932 -1.94 . . . . 0.0 112.353 -179.762 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 31.9 p -86.48 17.08 4.02 Favored 'General case' 0 N--CA 1.498 1.936 0 C-N-CA 119.254 -0.979 . . . . 0.0 108.66 179.859 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.48 ' HB2' ' HB2' ' A' ' 6' ' ' CYS . 8.8 t70 -69.41 79.41 0.39 Allowed 'General case' 0 N--CA 1.491 1.623 0 CA-C-O 123.359 1.552 . . . . 0.0 106.985 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -152.01 -81.13 0.03 OUTLIER Glycine 0 N--CA 1.49 2.276 0 CA-C-N 112.294 -2.23 . . . . 0.0 107.863 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_endo -70.79 27.7 0.21 Allowed 'Trans proline' 0 N--CA 1.499 1.851 0 C-N-CA 124.257 3.305 . . . . 0.0 114.45 -176.407 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 75.3 mtt-85 -93.32 153.92 41.47 Favored Pre-proline 0 N--CA 1.497 1.918 0 C-N-CA 119.54 -0.864 . . . . 0.0 112.012 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 7.4 Cg_endo -73.05 -145.7 0.02 OUTLIER 'Trans proline' 0 N--CA 1.503 2.039 0 C-N-CA 125.228 3.952 . . . . 0.0 111.695 -178.397 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 2.7 mpt_? -42.39 136.3 2.4 Favored 'General case' 0 N--CA 1.498 1.928 0 CA-C-O 122.004 0.906 . . . . 0.0 110.439 179.817 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.521 ' O ' ' N ' ' A' ' 17' ' ' THR . . . 96.07 -37.92 3.27 Favored Glycine 0 N--CA 1.498 2.823 0 N-CA-C 109.188 -1.565 . . . . 0.0 109.188 -179.6 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 23.5 t-20 28.95 -64.38 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 117.259 2.318 . . . . 0.0 117.259 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.521 ' N ' ' O ' ' A' ' 15' ' ' GLY . 38.5 p -94.15 7.27 45.86 Favored 'General case' 0 N--CA 1.494 1.726 0 N-CA-C 114.157 1.169 . . . . 0.0 114.157 -179.663 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 31.9 mt -152.1 29.39 0.57 Allowed 'General case' 0 N--CA 1.502 2.139 0 CA-C-N 112.957 -1.929 . . . . 0.0 110.645 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 34.6 m -88.7 43.11 1.12 Allowed 'General case' 0 N--CA 1.505 2.309 0 C-N-CA 119.127 -1.029 . . . . 0.0 113.099 -179.581 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.412 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -157.01 150.43 21.57 Favored Glycine 0 N--CA 1.493 2.46 0 N-CA-C 107.859 -2.096 . . . . 0.0 107.859 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.458 ' N ' ' O ' ' A' ' 47' ' ' CYS . 44.9 mm -113.48 152.99 15.1 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.282 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.528 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 4.2 pp -76.26 151.13 36.87 Favored 'General case' 0 N--CA 1.501 2.077 0 C-N-CA 117.908 -1.517 . . . . 0.0 108.714 179.569 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 30.0 m95 -132.68 130.3 39.92 Favored 'General case' 0 N--CA 1.485 1.288 0 N-CA-C 119.293 3.071 . . . . 0.0 119.293 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -88.28 53.06 2.61 Favored 'General case' 0 C--N 1.295 -1.804 0 CA-C-N 108.569 -3.923 . . . . 0.0 111.377 -179.495 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.462 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 2.3 m-85 -126.14 121.13 23.92 Favored Pre-proline 0 N--CA 1.495 1.784 0 CA-C-N 115.497 -0.774 . . . . 0.0 112.481 179.605 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -64.68 -19.58 64.73 Favored 'Trans proline' 0 C--N 1.307 -1.635 0 C-N-CA 123.941 3.094 . . . . 0.0 111.328 -177.281 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 6.1 p -94.81 11.37 31.78 Favored 'General case' 0 N--CA 1.489 1.507 0 CA-C-N 115.06 -0.973 . . . . 0.0 111.1 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 101.33 -121.83 7.37 Favored Glycine 0 N--CA 1.498 2.77 0 N-CA-C 106.198 -2.761 . . . . 0.0 106.198 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.544 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 24.9 m -89.15 148.88 41.89 Favored Pre-proline 0 C--N 1.305 -1.348 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 179.72 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.723 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 19.5 Cg_endo -74.19 166.92 28.41 Favored 'Trans proline' 0 C--N 1.31 -1.466 0 C-N-CA 122.211 1.941 . . . . 0.0 114.143 172.895 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 9.4 t -53.89 114.52 1.6 Allowed 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 113.989 -1.46 . . . . 0.0 110.285 -179.755 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 113.6 -7.08 24.33 Favored Glycine 0 N--CA 1.5 2.948 0 CA-C-N 113.906 -1.497 . . . . 0.0 112.319 179.549 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' TRP . . . . . 0.723 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 53.7 m95 -110.29 166.24 11.13 Favored 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 106.745 -1.576 . . . . 0.0 106.745 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 57.3 t-80 -146.04 29.82 1.07 Allowed 'General case' 0 N--CA 1.503 2.185 0 C-N-CA 117.911 -1.516 . . . . 0.0 113.95 -179.737 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' ASN . . . . . 0.544 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 23.3 t-20 64.1 152.03 0.04 OUTLIER 'General case' 0 N--CA 1.506 2.335 0 N-CA-C 115.164 1.542 . . . . 0.0 115.164 -179.818 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.717 ' SG ' ' HB3' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -130.16 -45.77 1.12 Allowed 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 113.32 -1.764 . . . . 0.0 107.543 -179.819 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 37' ' ' LYS . . . . . 0.497 ' C ' ' H ' ' A' ' 39' ' ' HIS . 82.7 tttt -118.57 103.11 9.41 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-O 122.858 1.313 . . . . 0.0 108.837 179.912 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.432 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -81.48 25.25 0.52 Allowed 'General case' 0 N--CA 1.494 1.761 0 N-CA-C 107.181 -1.414 . . . . 0.0 107.181 179.603 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' HIS . . . . . 0.497 ' H ' ' C ' ' A' ' 37' ' ' LYS . 5.5 m-70 -131.13 10.24 4.91 Favored 'General case' 0 N--CA 1.492 1.636 0 N-CA-C 108.628 -0.878 . . . . 0.0 108.628 -179.727 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 125.43 -142.62 13.91 Favored Glycine 0 N--CA 1.498 2.778 0 N-CA-C 110.168 -1.173 . . . . 0.0 110.168 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.578 ' CD ' ' SG ' ' A' ' 46' ' ' CYS . 85.8 Cg_endo -66.12 -174.66 6.29 Favored 'Cis proline' 0 N--CA 1.5 1.856 0 CA-C-N 118.289 1.045 . . . . 0.0 110.251 -1.872 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 4.1 m-20 -91.7 -8.83 45.9 Favored 'General case' 0 CA--C 1.479 -1.786 0 N-CA-C 105.617 -1.994 . . . . 0.0 105.617 -179.147 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 37.4 mt -95.06 33.33 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.163 0 CA-C-O 123.624 1.678 . . . . 0.0 109.114 -179.495 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.405 ' O ' ' HG2' ' A' ' 41' ' ' PRO . . . 114.06 135.54 6.11 Favored Glycine 0 N--CA 1.485 1.923 0 CA-C-N 111.275 -2.693 . . . . 0.0 107.41 -179.897 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' TRP . . . . . 0.462 ' NE1' ' O ' ' A' ' 25' ' ' TYR . 6.1 m95 -64.17 134.59 55.12 Favored 'General case' 0 N--CA 1.508 2.454 0 CA-C-O 116.796 -1.573 . . . . 0.0 106.787 -179.544 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' CYS . . . . . 0.717 ' HB3' ' SG ' ' A' ' 36' ' ' CYS . 35.4 m -89.45 124.15 34.23 Favored 'General case' 0 C--N 1.312 -1.063 0 N-CA-C 103.081 -2.933 . . . . 0.0 103.081 179.922 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.538 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 73.4 m -127.4 -169.74 2.1 Favored 'General case' 0 C--N 1.291 -1.972 0 CA-C-N 110.921 -2.854 . . . . 0.0 107.899 -179.533 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.411 ' N ' ' CD ' ' A' ' 48' ' ' LYS . 0.0 OUTLIER -151.67 173.2 14.96 Favored 'General case' 0 C--N 1.292 -1.924 0 N-CA-C 105.175 -2.157 . . . . 0.0 105.175 179.058 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 90.2 mttt . . . . . 0 C--N 1.289 -2.028 0 CA-C-O 114.691 -2.576 . . . . 0.0 106.392 179.524 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 2.545 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 22.4 t -89.36 140.96 28.63 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 103.912 -2.625 . . . . 0.0 103.912 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -68.27 149.43 75.77 Favored 'Trans proline' 0 C--N 1.305 -1.75 0 C-N-CA 122.98 2.453 . . . . 0.0 108.038 170.78 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 1.2 p -141.72 175.02 10.03 Favored 'General case' 0 N--CA 1.495 1.811 0 N-CA-C 115.242 1.571 . . . . 0.0 115.242 -179.755 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.417 HD12 ' HA ' ' A' ' 5' ' ' LEU . 23.5 tp -104.16 150.03 24.72 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 103.682 -2.71 . . . . 0.0 103.682 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.443 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 3.3 m -133.11 -162.51 1.25 Allowed 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 116.299 1.963 . . . . 0.0 116.299 -179.04 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 3.2 p-10 -25.39 -45.31 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.989 0 O-C-N 126.751 2.532 . . . . 0.0 111.851 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 32.6 t -83.28 48.91 1.46 Allowed 'General case' 0 N--CA 1.502 2.142 0 N-CA-C 106.946 -1.502 . . . . 0.0 106.946 179.775 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -103.48 -71.82 0.72 Allowed 'General case' 0 N--CA 1.491 1.6 0 CA-C-N 113.834 -1.53 . . . . 0.0 108.863 -179.805 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 73.03 169.41 15.0 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 108.126 -1.99 . . . . 0.0 108.126 -179.725 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 14.8 Cg_endo -73.25 17.39 0.42 Allowed 'Trans proline' 0 N--CA 1.495 1.596 0 C-N-CA 124.1 3.2 . . . . 0.0 112.343 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 34.6 ttt180 -130.07 57.63 32.37 Favored Pre-proline 0 N--CA 1.492 1.672 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.443 -179.827 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_endo -72.82 64.18 3.98 Favored 'Trans proline' 0 N--CA 1.499 1.84 0 C-N-CA 124.124 3.216 . . . . 0.0 111.179 -177.42 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 16.5 ptt180 -67.86 146.61 53.49 Favored 'General case' 0 N--CA 1.499 2.004 0 CA-C-N 113.998 -1.455 . . . . 0.0 111.795 -179.713 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 55.69 -11.59 0.01 OUTLIER Glycine 0 N--CA 1.499 2.872 0 N-CA-C 117.13 1.612 . . . . 0.0 117.13 179.748 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 50.1 t30 53.18 79.26 0.12 Allowed 'General case' 0 N--CA 1.508 2.433 0 CA-C-N 119.412 1.606 . . . . 0.0 110.09 -179.854 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 9.0 t -89.06 174.09 8.08 Favored 'General case' 0 N--CA 1.502 2.129 0 C-N-CA 118.493 -1.283 . . . . 0.0 110.437 -179.779 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 48.0 mt -130.36 104.47 7.29 Favored 'General case' 0 N--CA 1.492 1.626 0 CA-C-N 114.125 -1.398 . . . . 0.0 110.255 -179.281 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 25.0 m -114.51 -0.07 13.84 Favored 'General case' 0 N--CA 1.502 2.138 0 C-N-CA 119.766 -0.774 . . . . 0.0 112.263 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -164.74 179.59 39.34 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 108.945 -1.662 . . . . 0.0 108.945 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 34.3 mm -125.06 149.41 29.62 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.174 0 N-CA-C 108.42 -0.955 . . . . 0.0 108.42 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.664 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 4.5 pp -71.17 148.44 47.34 Favored 'General case' 0 N--CA 1.498 1.946 0 C-N-CA 118.513 -1.275 . . . . 0.0 110.875 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 38.2 m95 -131.4 131.47 43.66 Favored 'General case' 0 N--CA 1.486 1.36 0 N-CA-C 120.389 3.477 . . . . 0.0 120.389 -179.821 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -88.87 49.58 1.81 Allowed 'General case' 0 C--N 1.296 -1.734 1 CA-C-N 106.862 -4.699 . . . . 0.0 112.785 -179.389 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.407 ' CE1' ' HB3' ' A' ' 30' ' ' PRO . 2.2 m-85 -121.21 130.76 24.69 Favored Pre-proline 0 C--N 1.302 -1.468 0 CA-C-O 122.436 1.113 . . . . 0.0 111.3 179.525 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -69.79 -24.28 29.69 Favored 'Trans proline' 0 C--N 1.308 -1.595 0 C-N-CA 124.647 3.565 . . . . 0.0 110.662 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 6.1 p -93.63 15.12 16.97 Favored 'General case' 0 N--CA 1.492 1.642 0 CA-C-N 115.405 -0.816 . . . . 0.0 111.307 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 99.64 -126.01 8.77 Favored Glycine 0 N--CA 1.5 2.901 0 N-CA-C 105.674 -2.97 . . . . 0.0 105.674 -179.88 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.541 ' SG ' ' CA ' ' A' ' 35' ' ' ASN . 35.7 m -86.66 152.24 54.02 Favored Pre-proline 0 C--N 1.304 -1.403 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 179.721 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.758 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 19.9 Cg_endo -73.04 165.83 31.71 Favored 'Trans proline' 0 C--N 1.305 -1.719 0 C-N-CA 122.525 2.15 . . . . 0.0 113.906 173.392 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 5.6 p -51.73 107.42 0.19 Allowed 'General case' 0 C--N 1.298 -1.632 0 CA-C-N 112.341 -2.209 . . . . 0.0 112.247 -179.741 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 115.34 -7.85 20.65 Favored Glycine 0 N--CA 1.498 2.826 0 O-C-N 124.514 1.134 . . . . 0.0 111.737 179.594 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' TRP . . . . . 0.758 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 45.7 m95 -105.76 166.87 10.16 Favored 'General case' 0 C--N 1.304 -1.389 0 N-CA-C 106.143 -1.799 . . . . 0.0 106.143 -179.874 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 54.0 t-80 -147.03 33.82 0.91 Allowed 'General case' 0 N--CA 1.497 1.894 0 C-N-CA 117.337 -1.745 . . . . 0.0 112.884 -179.648 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' ASN . . . . . 0.541 ' CA ' ' SG ' ' A' ' 29' ' ' CYS . 24.9 t-20 60.44 143.29 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.13 0 N-CA-C 115.187 1.551 . . . . 0.0 115.187 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.876 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 1.7 p -120.99 -41.16 2.56 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-N 114.28 -1.327 . . . . 0.0 108.448 -179.628 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' LYS . . . . . 0.403 ' HG2' ' H ' ' A' ' 39' ' ' HIS . 77.3 tttt -118.84 116.31 26.23 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 104.708 -2.33 . . . . 0.0 104.708 179.748 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -89.41 8.08 32.62 Favored 'General case' 0 N--CA 1.496 1.827 0 N-CA-C 107.475 -1.306 . . . . 0.0 107.475 179.79 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' HIS . . . . . 0.403 ' H ' ' HG2' ' A' ' 37' ' ' LYS . 16.2 m-70 -133.04 48.86 2.36 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-N 115.001 -0.999 . . . . 0.0 110.876 -179.708 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 113.41 -165.11 12.01 Favored Glycine 0 N--CA 1.497 2.705 0 O-C-N 124.293 0.995 . . . . 0.0 113.47 179.581 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 15.0 Cg_endo -73.75 -174.01 12.46 Favored 'Cis proline' 0 N--CA 1.497 1.703 0 O-C-N 123.085 1.045 . . . . 0.0 110.933 -5.182 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 6.7 m120 -92.08 -10.68 38.16 Favored 'General case' 0 CA--C 1.484 -1.587 0 N-CA-C 104.579 -2.378 . . . . 0.0 104.579 -179.676 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 33.0 pt -92.04 27.22 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.03 0 C-N-CA 118.204 -1.398 . . . . 0.0 113.689 -179.434 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 116.76 130.85 4.55 Favored Glycine 0 N--CA 1.489 2.215 0 CA-C-N 111.831 -2.44 . . . . 0.0 108.693 -179.911 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' TRP . . . . . 0.4 ' NE1' ' O ' ' A' ' 25' ' ' TYR . 8.5 m95 -54.06 131.76 41.36 Favored 'General case' 0 N--CA 1.513 2.704 0 CA-C-O 116.248 -1.834 . . . . 0.0 107.56 -179.56 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 46' ' ' CYS . . . . . 0.876 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 53.3 t -89.44 131.85 35.3 Favored 'General case' 0 N--CA 1.479 0.983 1 N-CA-C 99.333 -4.321 . . . . 0.0 99.333 -179.882 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.459 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 86.2 m -133.74 -173.55 3.27 Favored 'General case' 0 C--N 1.292 -1.9 0 CA-C-N 111.056 -2.793 . . . . 0.0 109.876 -179.166 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.449 ' O ' ' HA ' ' A' ' 33' ' ' TRP . 0.0 OUTLIER -150.48 173.47 14.03 Favored 'General case' 0 C--N 1.297 -1.695 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 179.376 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 3.7 mmpt? . . . . . 0 N--CA 1.502 2.131 0 O-C-N 126.618 2.449 . . . . 0.0 110.874 179.929 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 2.74 0 N-CA-C 112.267 -0.333 . . . . 0.0 112.267 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 21.8 t -89.2 150.75 45.58 Favored Pre-proline 0 N--CA 1.5 2.051 0 N-CA-C 106.686 -1.598 . . . . 0.0 106.686 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.534 ' CB ' ' HG ' ' A' ' 18' ' ' LEU . 11.1 Cg_endo -74.47 134.55 18.94 Favored 'Trans proline' 0 C--N 1.306 -1.681 0 C-N-CA 123.048 2.498 . . . . 0.0 117.73 163.819 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -128.82 173.66 10.16 Favored 'General case' 0 N--CA 1.493 1.679 0 N-CA-C 107.589 -1.263 . . . . 0.0 107.589 179.509 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.594 HD23 ' N ' ' A' ' 6' ' ' CYS . 5.4 tt -90.64 147.24 23.43 Favored 'General case' 0 N--CA 1.496 1.866 0 N-CA-C 103.665 -2.717 . . . . 0.0 103.665 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.594 ' N ' HD23 ' A' ' 5' ' ' LEU . 4.4 m -128.34 -171.49 2.47 Favored 'General case' 0 C--N 1.307 -1.271 0 N-CA-C 116.005 1.854 . . . . 0.0 116.005 -179.851 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 34.1 t70 -82.44 -66.76 0.85 Allowed 'General case' 0 N--CA 1.489 1.481 0 CA-C-N 113.196 -1.82 . . . . 0.0 107.575 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 37.9 t -65.1 -7.25 11.43 Favored 'General case' 0 N--CA 1.501 2.095 0 C-N-CA 118.606 -1.238 . . . . 0.0 109.566 179.761 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.561 ' HB2' ' HB2' ' A' ' 6' ' ' CYS . 16.2 t0 -62.76 -23.7 67.34 Favored 'General case' 0 N--CA 1.499 1.979 0 O-C-N 124.358 1.036 . . . . 0.0 108.862 179.699 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 90.06 135.31 5.89 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 107.475 -2.25 . . . . 0.0 107.475 -179.805 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 0.5 OUTLIER -80.1 42.88 1.4 Allowed 'Trans proline' 0 N--CA 1.492 1.412 0 C-N-CA 124.839 3.693 . . . . 0.0 110.509 -171.822 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 1.1 mpt_? -89.97 131.52 38.99 Favored Pre-proline 0 N--CA 1.495 1.801 0 CA-C-N 115.399 -0.819 . . . . 0.0 112.845 -179.698 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -74.44 60.41 4.97 Favored 'Trans proline' 0 N--CA 1.499 1.831 0 C-N-CA 125.049 3.833 . . . . 0.0 112.394 -177.237 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 9.7 mmm180 -93.63 138.02 32.3 Favored 'General case' 0 N--CA 1.499 1.994 0 CA-C-N 113.745 -1.571 . . . . 0.0 109.447 -179.893 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -80.56 4.07 70.6 Favored Glycine 0 N--CA 1.501 3.009 0 C-N-CA 119.53 -1.319 . . . . 0.0 111.946 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 48.5 t30 -147.01 74.44 1.34 Allowed 'General case' 0 N--CA 1.497 1.893 0 N-CA-C 107.453 -1.314 . . . . 0.0 107.453 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 4.0 p -88.72 52.33 2.4 Favored 'General case' 0 C--N 1.298 -1.647 0 CA-C-N 115.158 -0.928 . . . . 0.0 110.693 -179.842 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.534 ' HG ' ' CB ' ' A' ' 3' ' ' PRO . 2.6 tt -73.1 75.7 1.24 Allowed 'General case' 0 N--CA 1.492 1.652 0 N-CA-C 106.133 -1.802 . . . . 0.0 106.133 179.895 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 4.1 t -136.81 23.5 3.09 Favored 'General case' 0 N--CA 1.5 2.052 0 CA-C-N 115.236 -0.893 . . . . 0.0 110.407 -179.704 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.516 ' HA3' ' SG ' ' A' ' 6' ' ' CYS . . . -172.48 121.57 0.88 Allowed Glycine 0 N--CA 1.494 2.503 0 N-CA-C 107.065 -2.414 . . . . 0.0 107.065 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.457 ' N ' ' O ' ' A' ' 47' ' ' CYS . 36.3 mm -96.09 137.34 24.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 N-CA-C 104.691 -2.337 . . . . 0.0 104.691 179.736 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.562 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 4.3 pp -65.69 149.33 50.29 Favored 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 117.752 -1.579 . . . . 0.0 107.238 179.812 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.417 ' O ' ' CA ' ' A' ' 44' ' ' GLY . 20.2 m95 -132.17 135.78 46.6 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-O 124.542 2.115 . . . . 0.0 115.882 -179.727 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.1 m-85 -88.91 40.58 0.98 Allowed 'General case' 0 C--N 1.293 -1.849 0 CA-C-N 109.12 -3.673 . . . . 0.0 115.353 -179.383 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.444 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 1.2 m-30 -113.12 120.0 41.24 Favored Pre-proline 0 N--CA 1.487 1.396 0 N-CA-C 107.664 -1.236 . . . . 0.0 107.664 179.713 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -60.93 -21.28 70.53 Favored 'Trans proline' 0 C--N 1.298 -2.091 0 C-N-CA 122.511 2.14 . . . . 0.0 110.414 -170.207 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 4.3 p -97.45 3.67 50.77 Favored 'General case' 0 N--CA 1.491 1.6 0 CA-C-N 114.746 -1.115 . . . . 0.0 113.451 -179.923 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 125.58 -121.86 4.35 Favored Glycine 0 N--CA 1.492 2.38 0 N-CA-C 108.601 -1.8 . . . . 0.0 108.601 179.911 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.55 ' HB3' ' HB2' ' A' ' 33' ' ' TRP . 3.9 m -95.2 158.6 34.51 Favored Pre-proline 0 C--N 1.304 -1.375 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.727 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.3 OUTLIER -79.11 -179.24 5.27 Favored 'Trans proline' 0 C--N 1.312 -1.343 0 C-N-CA 123.242 2.628 . . . . 0.0 114.896 171.033 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 18.4 p -58.41 104.62 0.22 Allowed 'General case' 0 C--N 1.299 -1.591 0 CA-C-N 112.922 -1.944 . . . . 0.0 112.941 -179.587 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 114.15 3.63 22.82 Favored Glycine 0 N--CA 1.501 2.969 0 O-C-N 124.759 1.287 . . . . 0.0 113.561 179.628 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' TRP . . . . . 0.727 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 39.7 m95 -117.75 153.07 34.03 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 107.369 -1.345 . . . . 0.0 107.369 -179.822 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' HIS . . . . . 0.408 ' O ' ' ND1' ' A' ' 34' ' ' HIS . 36.6 t-80 -137.4 41.5 2.4 Favored 'General case' 0 N--CA 1.5 2.044 0 CA-C-O 122.074 0.94 . . . . 0.0 109.847 -179.496 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' ASN . . . . . 0.496 ' HA ' ' SG ' ' A' ' 47' ' ' CYS . 24.6 t-20 59.59 156.73 0.03 OUTLIER 'General case' 0 N--CA 1.501 2.089 0 CA-C-O 123.9 1.81 . . . . 0.0 114.286 -179.765 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.778 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -125.66 -52.18 1.58 Allowed 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 104.354 -2.461 . . . . 0.0 104.354 179.725 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 37' ' ' LYS . . . . . 0.464 ' C ' ' H ' ' A' ' 39' ' ' HIS . 43.7 tttp -118.26 103.98 10.35 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 113.615 -1.63 . . . . 0.0 109.74 179.836 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.44 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -81.82 30.96 0.37 Allowed 'General case' 0 N--CA 1.497 1.902 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 179.573 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' HIS . . . . . 0.464 ' H ' ' C ' ' A' ' 37' ' ' LYS . 4.5 m-70 -130.49 8.32 4.99 Favored 'General case' 0 N--CA 1.492 1.636 0 CA-C-N 115.53 -0.759 . . . . 0.0 108.957 -179.73 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 128.51 -152.98 19.4 Favored Glycine 0 N--CA 1.496 2.7 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 179.902 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.43 ' HG2' ' O ' ' A' ' 44' ' ' GLY . 26.8 Cg_endo -72.68 -174.61 12.62 Favored 'Cis proline' 0 N--CA 1.508 2.324 0 O-C-N 122.808 0.899 . . . . 0.0 112.586 -2.414 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' ASN . . . . . 0.446 ' C ' ' H ' ' A' ' 44' ' ' GLY . 17.8 p-10 -91.88 -14.35 29.81 Favored 'General case' 0 CA--C 1.485 -1.533 0 N-CA-C 105.527 -2.027 . . . . 0.0 105.527 -179.654 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 11.0 mt -88.84 30.1 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.341 0 CA-C-N 113.809 -1.541 . . . . 0.0 109.617 -179.405 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.446 ' H ' ' C ' ' A' ' 42' ' ' ASN . . . 114.6 122.18 3.64 Favored Glycine 0 N--CA 1.491 2.347 0 CA-C-N 112.163 -2.289 . . . . 0.0 107.767 -179.853 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' TRP . . . . . 0.444 ' NE1' ' O ' ' A' ' 25' ' ' TYR . 3.9 m95 -54.68 138.79 40.85 Favored 'General case' 0 N--CA 1.514 2.735 0 CA-C-O 116.795 -1.574 . . . . 0.0 107.946 -179.378 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' CYS . . . . . 0.778 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 13.8 t -88.87 127.4 35.63 Favored 'General case' 0 C--N 1.309 -1.159 0 N-CA-C 102.587 -3.116 . . . . 0.0 102.587 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.496 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 98.0 m -128.9 176.51 7.8 Favored 'General case' 0 CA--C 1.478 -1.8 0 CA-C-N 112.009 -2.36 . . . . 0.0 113.656 -178.99 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.461 ' HD2' ' HA ' ' A' ' 48' ' ' LYS . 41.1 tptt -150.83 153.08 34.73 Favored 'General case' 0 C--N 1.295 -1.804 0 C-N-CA 118.785 -1.166 . . . . 0.0 109.405 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 7.4 mtpm? . . . . . 0 N--CA 1.5 2.037 0 CA-C-N 111.703 -2.499 . . . . 0.0 110.886 179.775 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 2.691 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 6.3 t -98.12 149.2 35.48 Favored Pre-proline 0 N--CA 1.5 2.053 0 N-CA-C 106.512 -1.662 . . . . 0.0 106.512 179.896 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -79.03 119.86 4.43 Favored 'Trans proline' 0 C--N 1.308 -1.568 0 C-N-CA 122.491 2.127 . . . . 0.0 113.337 160.019 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.453 ' SG ' ' HB3' ' A' ' 22' ' ' LEU . 0.5 OUTLIER -104.59 -171.63 1.96 Allowed 'General case' 0 N--CA 1.495 1.802 0 CA-C-N 114.956 -1.02 . . . . 0.0 110.893 -179.975 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 4.2 tp -98.38 152.29 19.64 Favored 'General case' 0 N--CA 1.497 1.907 0 N-CA-C 104.593 -2.373 . . . . 0.0 104.593 179.838 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.681 ' HB2' ' HB2' ' A' ' 9' ' ' ASP . 3.1 m -132.59 -170.63 2.48 Favored 'General case' 0 N--CA 1.485 1.321 0 N-CA-C 115.41 1.633 . . . . 0.0 115.41 -179.62 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -77.24 -63.93 1.25 Allowed 'General case' 0 C--N 1.3 -1.583 0 CA-C-N 112.971 -1.922 . . . . 0.0 109.752 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 2.4 p -97.46 32.47 2.25 Favored 'General case' 0 C--N 1.296 -1.723 0 CA-C-N 114.969 -1.014 . . . . 0.0 108.824 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.681 ' HB2' ' HB2' ' A' ' 6' ' ' CYS . 2.2 t70 -73.83 64.18 0.94 Allowed 'General case' 0 N--CA 1.496 1.834 0 CA-C-N 114.685 -1.143 . . . . 0.0 110.598 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 85.17 157.78 28.57 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 108.044 -2.022 . . . . 0.0 108.044 -179.875 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 8.7 Cg_endo -76.48 26.72 0.42 Allowed 'Trans proline' 0 N--CA 1.496 1.656 0 C-N-CA 124.101 3.201 . . . . 0.0 112.049 169.855 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 34.4 mtp85 -111.18 142.92 27.32 Favored Pre-proline 0 N--CA 1.497 1.884 0 N-CA-C 114.252 1.204 . . . . 0.0 114.252 -179.784 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -72.69 61.6 3.68 Favored 'Trans proline' 0 C--N 1.312 -1.351 0 C-N-CA 124.038 3.159 . . . . 0.0 111.748 170.703 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 14.4 mtm180 60.01 -140.35 0.62 Allowed 'General case' 0 N--CA 1.497 1.915 0 CA-C-N 113.643 -1.617 . . . . 0.0 114.315 179.666 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 85.25 -57.47 4.96 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 22.3 p-10 -156.98 54.38 0.52 Allowed 'General case' 0 N--CA 1.5 2.025 0 CA-C-O 122.369 1.081 . . . . 0.0 109.753 -179.835 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 39.1 p -115.65 90.67 3.39 Favored 'General case' 0 N--CA 1.491 1.587 0 CA-C-N 114.073 -1.422 . . . . 0.0 109.581 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 89.4 mt -118.49 74.08 0.94 Allowed 'General case' 0 N--CA 1.499 1.995 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 -179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 4.5 t -98.71 47.8 0.98 Allowed 'General case' 0 N--CA 1.502 2.144 0 N-CA-C 113.507 0.929 . . . . 0.0 113.507 -179.743 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 165.43 -176.3 41.04 Favored Glycine 0 N--CA 1.512 3.738 0 C-N-CA 118.742 -1.694 . . . . 0.0 114.94 179.573 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.405 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 19.3 mm -134.19 149.16 29.97 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.245 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 179.57 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.587 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.5 pp -69.19 146.71 52.19 Favored 'General case' 0 N--CA 1.495 1.794 0 C-N-CA 119.333 -0.947 . . . . 0.0 110.859 179.709 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 37.5 m95 -130.62 130.33 43.83 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 121.374 3.842 . . . . 0.0 121.374 -179.571 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 4.4 m-85 -89.0 49.81 1.85 Allowed 'General case' 0 C--N 1.295 -1.795 1 CA-C-N 108.093 -4.14 . . . . 0.0 112.209 -179.687 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.44 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 2.2 m-85 -122.56 124.56 26.7 Favored Pre-proline 0 N--CA 1.494 1.765 0 N-CA-C 114.144 1.164 . . . . 0.0 114.144 179.876 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -64.16 -20.82 67.63 Favored 'Trans proline' 0 C--N 1.307 -1.641 0 C-N-CA 124.065 3.177 . . . . 0.0 110.935 -177.02 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 5.1 p -94.06 6.9 47.07 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-N 114.576 -1.193 . . . . 0.0 111.207 179.829 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 104.17 -112.52 4.15 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 105.252 -3.139 . . . . 0.0 105.252 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.537 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 13.5 m -96.55 147.96 33.73 Favored Pre-proline 0 C--N 1.305 -1.363 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 179.798 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.73 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 15.2 Cg_endo -74.23 174.67 12.08 Favored 'Trans proline' 0 C--N 1.308 -1.566 0 C-N-CA 122.628 2.219 . . . . 0.0 114.47 174.259 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 12.0 p -53.13 105.65 0.13 Allowed 'General case' 0 C--N 1.299 -1.63 0 CA-C-N 112.469 -2.151 . . . . 0.0 112.568 -179.694 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 111.92 -1.25 27.21 Favored Glycine 0 N--CA 1.503 3.139 0 O-C-N 124.156 0.91 . . . . 0.0 113.814 179.503 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' TRP . . . . . 0.73 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 52.1 m95 -110.45 166.79 10.71 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 108.053 -1.092 . . . . 0.0 108.053 -179.912 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 80.1 t60 -146.98 36.59 0.94 Allowed 'General case' 0 N--CA 1.5 2.03 0 C-N-CA 116.8 -1.96 . . . . 0.0 115.94 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' ASN . . . . . 0.537 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 0.4 OUTLIER 63.3 137.93 0.02 OUTLIER 'General case' 0 N--CA 1.506 2.326 0 N-CA-C 116.926 2.195 . . . . 0.0 116.926 179.714 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.688 ' SG ' ' HB3' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -118.06 -42.17 2.83 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 105.029 -2.211 . . . . 0.0 105.029 179.71 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 37' ' ' LYS . . . . . 0.442 ' HD2' ' HA ' ' A' ' 6' ' ' CYS . 57.3 tttt -136.38 120.54 17.79 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 114.824 -1.08 . . . . 0.0 109.544 179.766 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.437 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -97.99 34.21 1.97 Allowed 'General case' 0 N--CA 1.496 1.829 0 N-CA-C 105.505 -2.035 . . . . 0.0 105.505 179.645 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' HIS . . . . . 0.437 ' ND1' ' C ' ' A' ' 38' ' ' ALA . 3.8 m-70 -133.5 47.92 2.42 Favored 'General case' 0 N--CA 1.495 1.792 0 N-CA-C 106.225 -1.769 . . . . 0.0 106.225 -179.67 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 85.21 -156.61 31.02 Favored Glycine 0 N--CA 1.498 2.779 0 N-CA-C 107.416 -2.274 . . . . 0.0 107.416 -179.749 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 17.6 Cg_endo -72.13 -172.76 9.41 Favored 'Cis proline' 0 N--CA 1.494 1.555 0 CA-C-N 118.612 1.206 . . . . 0.0 112.053 2.5 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 80.2 m-20 -92.32 -15.49 27.3 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 104.647 -2.353 . . . . 0.0 104.647 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 13.5 mt -90.87 29.5 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.21 0 CA-C-N 113.272 -1.786 . . . . 0.0 111.425 -179.255 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 109.07 119.11 4.2 Favored Glycine 0 N--CA 1.491 2.31 0 CA-C-N 112.178 -2.283 . . . . 0.0 111.601 179.853 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' TRP . . . . . 0.44 ' NE1' ' O ' ' A' ' 25' ' ' TYR . 2.2 m95 -49.44 134.74 18.74 Favored 'General case' 0 N--CA 1.516 2.856 0 CA-C-O 116.231 -1.843 . . . . 0.0 107.449 -179.743 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' CYS . . . . . 0.688 ' HB3' ' SG ' ' A' ' 36' ' ' CYS . 68.5 m -89.45 128.22 35.93 Favored 'General case' 0 N--CA 1.485 1.32 0 N-CA-C 103.689 -2.708 . . . . 0.0 103.689 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.522 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 86.7 m -131.12 -173.49 3.11 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-N 111.955 -2.384 . . . . 0.0 110.314 -179.165 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.417 ' O ' ' HA ' ' A' ' 33' ' ' TRP . 0.0 OUTLIER -151.09 173.7 14.05 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 118.574 -1.25 . . . . 0.0 109.106 179.357 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 95.0 mttt . . . . . 0 C--N 1.292 -1.909 0 O-C-N 126.402 2.314 . . . . 0.0 107.927 179.488 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 2.507 0 N-CA-C 110.613 -0.995 . . . . 0.0 110.613 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 9.1 t -97.82 142.25 24.27 Favored Pre-proline 0 N--CA 1.495 1.81 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.513 ' HB3' ' HG ' ' A' ' 18' ' ' LEU . 4.3 Cg_endo -77.2 131.64 11.99 Favored 'Trans proline' 0 N--CA 1.494 1.551 0 C-N-CA 124.067 3.178 . . . . 0.0 114.26 166.916 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -122.17 167.99 12.53 Favored 'General case' 0 N--CA 1.498 1.942 0 CA-C-O 122.602 1.191 . . . . 0.0 114.076 -179.702 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 12.7 tp -79.68 127.34 32.07 Favored 'General case' 0 N--CA 1.493 1.695 0 N-CA-C 106.907 -1.516 . . . . 0.0 106.907 -179.709 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.671 ' HB2' ' HB2' ' A' ' 9' ' ' ASP . 21.8 m -106.58 -174.11 2.46 Favored 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 118.844 -1.143 . . . . 0.0 112.883 179.65 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -80.47 -74.92 0.29 Allowed 'General case' 0 C--N 1.296 -1.727 0 CA-C-N 113.916 -1.493 . . . . 0.0 108.431 -179.778 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 1.1 m -46.08 -29.75 1.62 Allowed 'General case' 0 N--CA 1.501 2.076 0 CA-C-N 114.606 -1.179 . . . . 0.0 109.916 179.934 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.671 ' HB2' ' HB2' ' A' ' 6' ' ' CYS . 45.3 t0 -41.03 -51.48 3.3 Favored 'General case' 0 N--CA 1.494 1.756 0 CA-C-N 111.916 -2.402 . . . . 0.0 111.039 179.814 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 91.89 166.26 39.67 Favored Glycine 0 N--CA 1.501 2.976 0 C-N-CA 119.955 -1.117 . . . . 0.0 113.407 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 0.4 OUTLIER -79.81 40.09 0.92 Allowed 'Trans proline' 0 N--CA 1.502 1.999 1 C-N-CA 125.822 4.348 . . . . 0.0 113.453 -168.227 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.0 mpt_? -113.09 161.57 26.18 Favored Pre-proline 0 N--CA 1.496 1.838 0 CA-C-N 113.671 -1.604 . . . . 0.0 109.607 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 13.7 Cg_endo -75.49 145.32 29.7 Favored 'Trans proline' 0 N--CA 1.493 1.458 0 C-N-CA 124.198 3.265 . . . . 0.0 110.042 166.473 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' ARG . . . . . 0.472 ' HB3' ' HA ' ' A' ' 18' ' ' LEU . 75.8 mtt85 -67.82 33.67 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.127 0 N-CA-C 114.348 1.24 . . . . 0.0 114.348 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.97 23.44 0.09 OUTLIER Glycine 0 N--CA 1.496 2.69 0 N-CA-C 116.231 1.252 . . . . 0.0 116.231 -179.537 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 64.3 m-20 -119.58 -84.42 0.66 Allowed 'General case' 0 N--CA 1.493 1.713 0 N-CA-C 106.494 -1.669 . . . . 0.0 106.494 179.653 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 31.9 m -150.52 48.81 0.88 Allowed 'General case' 0 N--CA 1.496 1.859 0 N-CA-C 106.392 -1.707 . . . . 0.0 106.392 179.775 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.513 ' HG ' ' HB3' ' A' ' 3' ' ' PRO . 2.0 mm? 66.67 149.64 0.05 Allowed 'General case' 0 N--CA 1.5 2.028 0 O-C-N 125.152 1.532 . . . . 0.0 109.878 -179.733 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 3.2 p -89.6 -8.16 53.2 Favored 'General case' 0 C--N 1.298 -1.659 0 CA-C-N 115.65 -0.705 . . . . 0.0 111.901 179.806 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.443 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . 159.33 178.98 33.84 Favored Glycine 0 N--CA 1.499 2.853 0 N-CA-C 108.016 -2.034 . . . . 0.0 108.016 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.474 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 48.6 mm -127.84 145.97 34.24 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.974 0 N-CA-C 106.141 -1.8 . . . . 0.0 106.141 179.736 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.561 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.8 pp -69.67 152.18 45.0 Favored 'General case' 0 N--CA 1.491 1.617 0 C-N-CA 118.257 -1.377 . . . . 0.0 110.115 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.444 ' O ' ' HA3' ' A' ' 44' ' ' GLY . 37.6 m95 -136.41 130.73 33.15 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 118.884 2.92 . . . . 0.0 118.884 179.763 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 6.0 m-85 -89.48 51.47 2.12 Favored 'General case' 0 C--N 1.296 -1.756 1 CA-C-N 107.467 -4.424 . . . . 0.0 111.613 -179.692 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.484 ' CE1' ' HB3' ' A' ' 30' ' ' PRO . 2.4 m-85 -125.07 137.03 28.93 Favored Pre-proline 0 C--N 1.303 -1.414 0 CA-C-O 121.482 0.658 . . . . 0.0 109.613 179.646 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 96.9 Cg_endo -66.95 -30.31 39.72 Favored 'Trans proline' 0 C--N 1.305 -1.75 0 C-N-CA 124.264 3.309 . . . . 0.0 108.636 177.56 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 11.8 p -86.65 31.9 0.67 Allowed 'General case' 0 C--N 1.299 -1.611 0 CA-C-N 113.989 -1.459 . . . . 0.0 109.239 179.915 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.547 ' HA2' ' CD1' ' A' ' 45' ' ' TRP . . . 76.05 -92.76 0.94 Allowed Glycine 0 N--CA 1.482 1.764 0 N-CA-C 104.399 -3.48 . . . . 0.0 104.399 -179.499 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.568 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 9.4 m -103.75 165.91 12.65 Favored Pre-proline 0 C--N 1.301 -1.515 0 CA-C-N 113.814 -1.193 . . . . 0.0 110.609 -179.849 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.686 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.1 OUTLIER -86.01 167.11 9.64 Favored 'Trans proline' 0 CA--C 1.553 1.472 0 C-N-CA 125.238 3.959 . . . . 0.0 118.336 157.924 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 3.8 m -49.64 109.57 0.29 Allowed 'General case' 0 C--N 1.299 -1.604 0 CA-C-N 111.769 -2.469 . . . . 0.0 112.283 179.845 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 113.46 -6.6 24.66 Favored Glycine 0 N--CA 1.5 2.948 0 CA-C-N 115.218 -0.901 . . . . 0.0 111.901 179.743 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' TRP . . . . . 0.686 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 48.1 m95 -111.51 162.57 14.97 Favored 'General case' 0 N--CA 1.486 1.341 0 N-CA-C 106.321 -1.733 . . . . 0.0 106.321 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' HIS . . . . . 0.419 ' ND1' ' O ' ' A' ' 34' ' ' HIS . 60.0 t-80 -143.62 34.18 1.29 Allowed 'General case' 0 N--CA 1.498 1.962 0 C-N-CA 118.138 -1.425 . . . . 0.0 113.406 -179.733 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' ASN . . . . . 0.568 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 24.2 t-20 61.76 146.16 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.9 0 N-CA-C 114.375 1.25 . . . . 0.0 114.375 179.916 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.804 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -124.31 -45.74 1.95 Allowed 'General case' 0 N--CA 1.484 1.272 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.039 -179.715 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 37' ' ' LYS . . . . . 0.53 ' HG2' ' H ' ' A' ' 39' ' ' HIS . 36.0 ttmt -122.01 100.35 6.93 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 105.44 -2.059 . . . . 0.0 105.44 179.431 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -77.55 19.9 0.34 Allowed 'General case' 0 N--CA 1.5 2.034 0 CA-C-N 114.431 -1.259 . . . . 0.0 107.742 179.649 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' HIS . . . . . 0.53 ' H ' ' HG2' ' A' ' 37' ' ' LYS . 7.4 m-70 -132.75 16.82 4.29 Favored 'General case' 0 N--CA 1.487 1.378 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.476 -179.709 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 149.37 -177.8 27.32 Favored Glycine 0 N--CA 1.501 3.015 0 C-N-CA 119.412 -1.375 . . . . 0.0 111.432 179.695 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.524 ' HD2' ' N ' ' A' ' 46' ' ' CYS . 35.5 Cg_endo -66.25 -171.89 4.45 Favored 'Cis proline' 0 N--CA 1.512 2.592 0 N-CA-C 116.167 1.564 . . . . 0.0 116.167 -4.604 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 16.1 p-10 -92.1 -12.76 32.11 Favored 'General case' 0 N--CA 1.486 1.336 0 N-CA-C 105.505 -2.035 . . . . 0.0 105.505 -179.715 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.43 HG12 ' HB2' ' A' ' 41' ' ' PRO . 12.1 pt -85.81 23.02 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.218 0 O-C-N 124.909 1.38 . . . . 0.0 113.814 -179.49 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.444 ' HA3' ' O ' ' A' ' 23' ' ' TRP . . . 134.63 -116.47 1.61 Allowed Glycine 0 C--N 1.291 -1.962 0 N-CA-C 104.404 -3.478 . . . . 0.0 104.404 -179.906 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' TRP . . . . . 0.547 ' CD1' ' HA2' ' A' ' 28' ' ' GLY . 1.8 m95 -157.03 151.28 25.09 Favored 'General case' 0 N--CA 1.509 2.501 0 N-CA-C 105.491 -2.04 . . . . 0.0 105.491 -179.891 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' CYS . . . . . 0.804 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 44.5 t -99.06 129.61 45.34 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 102.882 -3.006 . . . . 0.0 102.882 179.864 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.524 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 78.4 m -126.77 -170.7 2.25 Favored 'General case' 0 C--N 1.298 -1.641 0 CA-C-N 113.528 -1.669 . . . . 0.0 109.719 -179.409 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.412 ' HD3' ' H ' ' A' ' 48' ' ' LYS . 0.0 OUTLIER -150.58 172.72 15.06 Favored 'General case' 0 C--N 1.294 -1.822 0 N-CA-C 107.195 -1.409 . . . . 0.0 107.195 179.324 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 84.8 mttt . . . . . 0 N--CA 1.498 1.95 0 O-C-N 126.129 2.143 . . . . 0.0 109.131 179.456 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.418 0 N-CA-C 108.913 -1.675 . . . . 0.0 108.913 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.408 ' HB ' HD23 ' A' ' 22' ' ' LEU . 11.4 t -89.56 147.44 37.89 Favored Pre-proline 0 N--CA 1.494 1.766 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 -179.793 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.421 ' HG3' ' HG ' ' A' ' 18' ' ' LEU . 3.9 Cg_endo -75.81 155.33 39.23 Favored 'Trans proline' 0 N--CA 1.496 1.65 0 C-N-CA 124.024 3.15 . . . . 0.0 112.963 166.717 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.408 ' SG ' ' SG ' ' A' ' 6' ' ' CYS . 9.4 p -132.39 170.78 14.61 Favored 'General case' 0 N--CA 1.499 1.982 0 C-N-CA 119.208 -0.997 . . . . 0.0 108.939 179.574 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 13.9 tp -86.64 81.21 8.32 Favored 'General case' 0 N--CA 1.491 1.624 0 N-CA-C 103.65 -2.722 . . . . 0.0 103.65 179.908 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.408 ' SG ' ' SG ' ' A' ' 4' ' ' CYS . 6.6 m -69.18 170.96 9.1 Favored 'General case' 0 C--N 1.309 -1.188 0 CA-C-O 123.273 1.511 . . . . 0.0 112.375 -179.729 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 7.9 t70 -48.05 -46.55 33.52 Favored 'General case' 0 N--CA 1.496 1.875 0 CA-C-N 111.07 -2.786 . . . . 0.0 111.301 -179.838 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 3.9 p -91.14 -6.3 53.8 Favored 'General case' 0 C--N 1.301 -1.532 0 CA-C-N 114.521 -1.218 . . . . 0.0 110.95 179.796 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 10.7 t0 -72.83 80.25 1.15 Allowed 'General case' 0 N--CA 1.491 1.576 0 C-N-CA 118.635 -1.226 . . . . 0.0 110.452 -179.46 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 169.3 -81.65 0.09 OUTLIER Glycine 0 N--CA 1.491 2.359 0 CA-C-N 114.036 -1.438 . . . . 0.0 109.726 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 7.1 Cg_endo -76.37 -4.06 14.59 Favored 'Trans proline' 0 N--CA 1.501 1.956 0 C-N-CA 124.338 3.359 . . . . 0.0 115.099 -172.768 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -106.32 137.78 19.52 Favored Pre-proline 0 C--N 1.294 -1.826 0 CA-C-N 112.893 -1.958 . . . . 0.0 109.314 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -68.52 176.33 5.91 Favored 'Trans proline' 0 N--CA 1.492 1.419 0 C-N-CA 123.866 3.044 . . . . 0.0 110.175 -178.584 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 25.2 mtp85 51.11 19.08 0.64 Allowed 'General case' 0 N--CA 1.493 1.675 0 N-CA-C 113.891 1.071 . . . . 0.0 113.891 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -104.39 -0.89 43.89 Favored Glycine 0 N--CA 1.501 2.97 0 N-CA-C 108.805 -1.718 . . . . 0.0 108.805 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -68.53 -53.86 20.41 Favored 'General case' 0 N--CA 1.488 1.471 0 CA-C-O 122.482 1.134 . . . . 0.0 110.871 -179.927 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.409 ' O ' ' HB2' ' A' ' 18' ' ' LEU . 7.2 m -88.84 59.28 4.99 Favored 'General case' 0 N--CA 1.495 1.778 0 CA-C-N 115.396 -0.82 . . . . 0.0 109.31 -179.342 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.421 ' HG ' ' HG3' ' A' ' 3' ' ' PRO . 8.9 mp 73.07 125.66 0.04 OUTLIER 'General case' 0 N--CA 1.497 1.909 0 O-C-N 126.246 2.216 . . . . 0.0 108.665 -179.748 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 48.4 t -91.78 -16.18 27.2 Favored 'General case' 0 N--CA 1.498 1.935 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.304 179.821 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 174.05 -171.83 44.83 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 107.653 -2.179 . . . . 0.0 107.653 -179.882 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 1.2 mp -133.83 153.14 35.9 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.104 0 O-C-N 124.918 1.01 . . . . 0.0 108.553 -179.903 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.621 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.3 pp -71.33 146.34 48.9 Favored 'General case' 0 N--CA 1.499 1.998 0 C-N-CA 120.205 -0.598 . . . . 0.0 111.868 179.812 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.432 ' O ' ' CA ' ' A' ' 44' ' ' GLY . 39.0 m95 -129.08 130.28 46.32 Favored 'General case' 0 N--CA 1.491 1.603 0 N-CA-C 119.512 3.152 . . . . 0.0 119.512 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 3.5 m-85 -88.73 51.38 2.16 Favored 'General case' 0 C--N 1.294 -1.827 1 CA-C-N 107.886 -4.234 . . . . 0.0 113.154 -179.412 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 2.2 m-85 -120.79 142.33 34.21 Favored Pre-proline 0 C--N 1.3 -1.576 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 179.411 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -76.12 -33.16 3.71 Favored 'Trans proline' 0 C--N 1.3 -1.991 0 C-N-CA 125.063 3.842 . . . . 0.0 112.21 172.983 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 14.1 p -88.61 33.43 0.77 Allowed 'General case' 0 N--CA 1.494 1.735 0 CA-C-O 121.442 0.639 . . . . 0.0 111.083 -179.524 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 76.0 -158.82 50.09 Favored Glycine 0 N--CA 1.495 2.58 0 N-CA-C 105.912 -2.875 . . . . 0.0 105.912 -179.565 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.586 ' SG ' ' CA ' ' A' ' 35' ' ' ASN . 14.0 m -53.06 150.76 9.95 Favored Pre-proline 0 C--N 1.303 -1.441 0 CA-C-N 117.599 0.699 . . . . 0.0 111.941 179.816 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.739 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 4.6 Cg_endo -76.41 159.74 36.01 Favored 'Trans proline' 0 C--N 1.308 -1.566 0 C-N-CA 122.956 2.437 . . . . 0.0 112.043 171.759 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 16.5 t -49.14 129.67 18.13 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-N 113.332 -1.758 . . . . 0.0 109.522 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 97.81 -5.14 61.71 Favored Glycine 0 N--CA 1.496 2.697 0 CA-C-N 112.664 -2.062 . . . . 0.0 111.687 179.762 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' TRP . . . . . 0.739 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 48.1 m95 -111.91 163.77 13.85 Favored 'General case' 0 C--N 1.305 -1.332 0 N-CA-C 106.29 -1.745 . . . . 0.0 106.29 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' HIS . . . . . 0.401 ' O ' ' ND1' ' A' ' 34' ' ' HIS . 45.5 t-80 -144.24 34.39 1.21 Allowed 'General case' 0 N--CA 1.498 1.974 0 C-N-CA 117.365 -1.734 . . . . 0.0 113.107 -179.818 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' ASN . . . . . 0.586 ' CA ' ' SG ' ' A' ' 29' ' ' CYS . 23.8 t-20 62.38 144.72 0.02 OUTLIER 'General case' 0 N--CA 1.506 2.333 0 N-CA-C 113.976 1.102 . . . . 0.0 113.976 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.851 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -124.74 -64.9 1.07 Allowed 'General case' 0 C--N 1.306 -1.3 0 N-CA-C 106.672 -1.603 . . . . 0.0 106.672 -179.751 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 37' ' ' LYS . . . . . 0.593 ' N ' ' SG ' ' A' ' 36' ' ' CYS . 33.1 ttmt -91.05 103.59 16.27 Favored 'General case' 0 C--N 1.302 -1.465 0 CA-C-O 123.567 1.651 . . . . 0.0 107.04 179.704 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.425 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -79.86 24.16 0.41 Allowed 'General case' 0 N--CA 1.495 1.781 0 CA-C-N 113.499 -1.682 . . . . 0.0 107.282 179.489 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' HIS . . . . . 0.519 ' H ' ' C ' ' A' ' 37' ' ' LYS . 3.3 m-70 -131.85 17.88 4.67 Favored 'General case' 0 N--CA 1.493 1.713 0 N-CA-C 106.966 -1.494 . . . . 0.0 106.966 -179.677 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 111.43 -132.0 10.63 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 25.9 Cg_endo -69.78 -164.06 2.43 Favored 'Cis proline' 0 N--CA 1.503 2.054 0 CA-C-N 117.843 0.821 . . . . 0.0 112.699 1.097 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' ASN . . . . . 0.409 ' C ' ' H ' ' A' ' 44' ' ' GLY . 22.6 t-20 -92.13 -20.57 21.11 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 106.374 -1.713 . . . . 0.0 106.374 -179.757 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 39.7 pt -86.31 28.33 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 CA-C-N 112.367 -2.197 . . . . 0.0 113.349 -179.104 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.432 ' CA ' ' O ' ' A' ' 23' ' ' TRP . . . 115.03 131.15 4.98 Favored Glycine 0 N--CA 1.484 1.859 0 CA-C-N 111.019 -2.81 . . . . 0.0 109.994 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 14.8 m95 -55.42 130.1 41.26 Favored 'General case' 0 N--CA 1.509 2.484 0 N-CA-C 106.311 -1.737 . . . . 0.0 106.311 -179.657 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' CYS . . . . . 0.851 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 42.7 t -89.15 129.42 35.75 Favored 'General case' 0 C--N 1.31 -1.139 1 N-CA-C 99.341 -4.318 . . . . 0.0 99.341 -179.89 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.539 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 77.8 m -133.93 -175.35 3.81 Favored 'General case' 0 C--N 1.293 -1.888 0 CA-C-N 110.671 -2.968 . . . . 0.0 110.881 -178.997 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.467 ' O ' ' HA ' ' A' ' 33' ' ' TRP . 0.0 OUTLIER -150.7 172.68 15.19 Favored 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 107.1 -1.445 . . . . 0.0 107.1 179.484 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 54.0 mtpt . . . . . 0 C--N 1.289 -2.032 0 O-C-N 127.248 2.843 . . . . 0.0 109.253 179.697 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.495 2.616 0 N-CA-C 109.005 -1.638 . . . . 0.0 109.005 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 34.0 t -98.78 131.76 25.08 Favored Pre-proline 0 N--CA 1.49 1.565 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -82.19 136.15 8.85 Favored 'Trans proline' 0 C--N 1.308 -1.594 0 C-N-CA 124.026 3.151 . . . . 0.0 113.516 162.76 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.403 ' SG ' ' N ' ' A' ' 5' ' ' LEU . 1.8 p -110.45 -156.87 0.6 Allowed 'General case' 0 N--CA 1.504 2.259 0 N-CA-C 107.601 -1.259 . . . . 0.0 107.601 179.778 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.403 ' N ' ' SG ' ' A' ' 4' ' ' CYS . 2.9 tt -118.85 99.97 7.09 Favored 'General case' 0 N--CA 1.503 2.212 0 N-CA-C 101.283 -3.599 . . . . 0.0 101.283 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.703 ' HB2' ' HB2' ' A' ' 9' ' ' ASP . 2.9 m -78.85 -176.11 4.81 Favored 'General case' 0 C--N 1.308 -1.214 0 N-CA-C 116.424 2.009 . . . . 0.0 116.424 -179.381 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -74.04 -62.33 1.54 Allowed 'General case' 0 C--N 1.298 -1.662 0 CA-C-N 112.319 -2.219 . . . . 0.0 109.843 -179.614 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 1.7 p -89.42 20.23 4.0 Favored 'General case' 0 N--CA 1.493 1.718 0 CA-C-N 114.973 -1.012 . . . . 0.0 108.63 179.709 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.703 ' HB2' ' HB2' ' A' ' 6' ' ' CYS . 2.4 t0 -66.13 -32.58 74.12 Favored 'General case' 0 N--CA 1.494 1.755 0 N-CA-C 106.484 -1.673 . . . . 0.0 106.484 179.748 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 99.37 99.22 2.2 Favored Glycine 0 N--CA 1.486 1.999 0 N-CA-C 103.993 -3.643 . . . . 0.0 103.993 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_endo -78.41 49.18 2.96 Favored 'Trans proline' 0 N--CA 1.495 1.605 0 C-N-CA 124.162 3.241 . . . . 0.0 109.549 -176.351 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 64.7 mtt85 -108.61 163.25 17.4 Favored Pre-proline 0 N--CA 1.496 1.874 0 CA-C-N 113.775 -1.557 . . . . 0.0 111.484 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 13.7 Cg_endo -72.56 49.45 1.47 Allowed 'Trans proline' 0 N--CA 1.5 1.878 0 C-N-CA 124.812 3.675 . . . . 0.0 112.984 176.763 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' ARG . . . . . 0.472 ' C ' ' H ' ' A' ' 16' ' ' ASN . 0.0 OUTLIER -167.84 122.15 0.96 Allowed 'General case' 0 C--N 1.301 -1.538 0 CA-C-N 113.68 -1.6 . . . . 0.0 112.924 179.974 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.432 ' O ' ' N ' ' A' ' 17' ' ' THR . . . 74.64 -37.33 1.02 Allowed Glycine 0 N--CA 1.498 2.812 0 CA-C-N 114.669 -1.15 . . . . 0.0 112.552 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' ASN . . . . . 0.472 ' H ' ' C ' ' A' ' 14' ' ' ARG . 66.0 t30 2.74 -47.39 0.0 OUTLIER 'General case' 0 N--CA 1.507 2.417 0 N-CA-C 120.904 3.668 . . . . 0.0 120.904 -179.634 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.432 ' N ' ' O ' ' A' ' 15' ' ' GLY . 26.9 p -121.8 27.58 8.07 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-N 119.341 0.973 . . . . 0.0 112.31 -179.994 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -136.26 20.73 3.19 Favored 'General case' 0 N--CA 1.497 1.905 0 CA-C-N 114.56 -1.2 . . . . 0.0 110.438 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 4.8 m -89.07 14.51 10.55 Favored 'General case' 0 N--CA 1.503 2.175 0 N-CA-C 115.385 1.624 . . . . 0.0 115.385 -179.335 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 167.69 -179.36 41.13 Favored Glycine 0 N--CA 1.502 3.045 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 179.796 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 37.2 mm -132.71 143.94 38.18 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.399 0 O-C-N 124.555 0.797 . . . . 0.0 110.975 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.433 ' O ' HD12 ' A' ' 22' ' ' LEU . 3.9 pp -63.56 154.75 31.63 Favored 'General case' 0 N--CA 1.504 2.244 0 N-CA-C 109.117 -0.697 . . . . 0.0 109.117 179.518 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.552 ' O ' ' HA2' ' A' ' 44' ' ' GLY . 32.4 m95 -134.42 131.4 38.13 Favored 'General case' 0 C--N 1.308 -1.202 0 N-CA-C 118.91 2.93 . . . . 0.0 118.91 -179.694 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -87.57 53.48 2.8 Favored 'General case' 0 C--N 1.291 -1.973 0 CA-C-N 109.316 -3.584 . . . . 0.0 111.796 -179.245 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 2.7 m-85 -125.52 137.06 29.17 Favored Pre-proline 0 C--N 1.306 -1.302 0 CA-C-N 115.052 -0.976 . . . . 0.0 110.352 179.6 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_endo -73.81 -25.43 14.49 Favored 'Trans proline' 0 C--N 1.306 -1.696 1 C-N-CA 125.725 4.283 . . . . 0.0 112.817 177.746 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 5.9 p -95.03 20.66 8.68 Favored 'General case' 0 N--CA 1.493 1.706 0 CA-C-N 115.249 -0.887 . . . . 0.0 111.163 -179.875 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 89.91 -138.27 14.47 Favored Glycine 0 N--CA 1.496 2.687 0 N-CA-C 106.278 -2.729 . . . . 0.0 106.278 -179.817 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.526 ' SG ' ' CA ' ' A' ' 35' ' ' ASN . 29.7 m -69.28 150.05 97.3 Favored Pre-proline 0 C--N 1.305 -1.355 0 CA-C-N 117.496 0.648 . . . . 0.0 109.971 179.889 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.717 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 1.9 Cg_endo -78.31 159.29 29.6 Favored 'Trans proline' 0 C--N 1.31 -1.469 0 C-N-CA 123.207 2.604 . . . . 0.0 112.403 171.198 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 24.1 t -47.96 128.86 14.13 Favored 'General case' 0 C--N 1.305 -1.326 0 CA-C-N 113.168 -1.833 . . . . 0.0 109.3 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 100.51 -8.07 58.3 Favored Glycine 0 N--CA 1.495 2.607 0 CA-C-N 112.628 -2.078 . . . . 0.0 111.421 179.77 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' TRP . . . . . 0.717 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 48.3 m95 -110.29 162.94 14.14 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 106.83 -1.544 . . . . 0.0 106.83 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 78.6 t60 -143.22 29.82 1.44 Allowed 'General case' 0 N--CA 1.499 1.997 0 C-N-CA 118.34 -1.344 . . . . 0.0 113.135 -179.843 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' ASN . . . . . 0.526 ' CA ' ' SG ' ' A' ' 29' ' ' CYS . 12.1 t-20 62.02 147.13 0.02 OUTLIER 'General case' 0 N--CA 1.505 2.301 0 CA-C-O 123.109 1.433 . . . . 0.0 114.097 -179.79 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.841 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -117.41 -46.91 2.67 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-N 113.341 -1.754 . . . . 0.0 108.003 -179.666 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 19.4 ttpp -132.18 124.77 29.69 Favored 'General case' 0 N--CA 1.497 1.922 0 N-CA-C 107.814 -1.18 . . . . 0.0 107.814 179.43 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -87.13 22.07 2.18 Favored 'General case' 0 N--CA 1.493 1.688 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 179.788 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 16.9 m-70 -131.33 76.72 1.73 Allowed 'General case' 0 N--CA 1.492 1.645 0 CA-C-O 122.243 1.02 . . . . 0.0 108.882 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 68.83 -163.07 50.54 Favored Glycine 0 N--CA 1.492 2.418 0 CA-C-N 113.353 -1.749 . . . . 0.0 109.849 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.446 ' HG2' ' O ' ' A' ' 44' ' ' GLY . 34.1 Cg_endo -71.86 175.14 43.78 Favored 'Cis proline' 0 N--CA 1.495 1.573 0 N-CA-C 107.635 -1.717 . . . . 0.0 107.635 -2.402 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' ASN . . . . . 0.442 ' C ' ' H ' ' A' ' 44' ' ' GLY . 23.4 m120 -91.53 -10.12 41.86 Favored 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 105.299 -2.112 . . . . 0.0 105.299 -179.484 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 16.1 mt -88.79 28.75 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.225 0 CA-C-N 113.447 -1.706 . . . . 0.0 110.338 -179.438 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.552 ' HA2' ' O ' ' A' ' 23' ' ' TRP . . . 115.98 135.29 5.65 Favored Glycine 0 N--CA 1.486 2.0 0 CA-C-N 111.827 -2.442 . . . . 0.0 112.687 179.789 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' TRP . . . . . 0.511 ' O ' ' N ' ' A' ' 23' ' ' TRP . 26.3 m95 -62.0 129.39 40.66 Favored 'General case' 0 N--CA 1.501 2.116 0 C-N-CA 120.19 -0.604 . . . . 0.0 111.388 -179.42 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' CYS . . . . . 0.841 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 46.4 t -88.52 114.72 25.43 Favored 'General case' 0 C--N 1.305 -1.359 1 N-CA-C 96.728 -5.286 . . . . 0.0 96.728 179.998 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.532 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 75.1 m -129.89 -176.18 3.84 Favored 'General case' 0 C--N 1.295 -1.768 1 CA-C-N 108.253 -4.067 . . . . 0.0 108.714 -179.407 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.507 ' O ' ' HA ' ' A' ' 33' ' ' TRP . 0.0 OUTLIER -149.97 169.74 20.48 Favored 'General case' 0 C--N 1.294 -1.836 0 C-N-CA 117.614 -1.634 . . . . 0.0 107.698 179.56 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 48.9 mtpt . . . . . 0 C--N 1.29 -2.02 0 O-C-N 127.577 3.048 . . . . 0.0 109.379 179.71 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.495 2.571 0 N-CA-C 109.053 -1.619 . . . . 0.0 109.053 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 61.9 t -99.73 142.46 24.65 Favored Pre-proline 0 N--CA 1.496 1.84 0 N-CA-C 108.026 -1.101 . . . . 0.0 108.026 -179.903 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -76.22 158.93 37.27 Favored 'Trans proline' 0 C--N 1.309 -1.54 0 C-N-CA 124.509 3.473 . . . . 0.0 113.405 171.45 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -150.9 164.94 35.12 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 125.48 1.737 . . . . 0.0 108.036 179.614 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.484 HD23 ' N ' ' A' ' 6' ' ' CYS . 9.4 tt -79.38 168.18 19.85 Favored 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 103.404 -2.813 . . . . 0.0 103.404 179.759 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.566 ' HB2' ' H ' ' A' ' 9' ' ' ASP . 3.5 m -140.93 -174.8 4.09 Favored 'General case' 0 C--N 1.302 -1.489 0 N-CA-C 116.662 2.097 . . . . 0.0 116.662 -179.257 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -76.74 -31.91 57.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 112.639 -2.073 . . . . 0.0 107.862 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 70.8 p -112.34 -14.77 13.26 Favored 'General case' 0 N--CA 1.496 1.848 0 CA-C-N 115.199 -0.91 . . . . 0.0 112.62 179.646 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.566 ' H ' ' HB2' ' A' ' 6' ' ' CYS . 0.7 OUTLIER -32.51 -39.81 0.04 OUTLIER 'General case' 0 N--CA 1.515 2.804 0 N-CA-C 113.9 1.074 . . . . 0.0 113.9 -179.737 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 140.65 137.52 3.46 Favored Glycine 0 N--CA 1.487 2.055 0 N-CA-C 105.027 -3.229 . . . . 0.0 105.027 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_endo -71.94 24.79 0.25 Allowed 'Trans proline' 0 N--CA 1.497 1.719 0 C-N-CA 124.358 3.372 . . . . 0.0 114.282 -166.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 76.2 mtt180 -109.85 100.36 42.59 Favored Pre-proline 0 N--CA 1.495 1.799 0 C-N-CA 119.849 -0.74 . . . . 0.0 109.546 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_endo -74.4 169.11 23.24 Favored 'Trans proline' 0 N--CA 1.494 1.503 0 C-N-CA 124.09 3.193 . . . . 0.0 111.166 176.39 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 74.8 mtp180 60.46 -169.05 0.16 Allowed 'General case' 0 N--CA 1.494 1.761 0 N-CA-C 108.539 -0.912 . . . . 0.0 108.539 -179.835 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.442 ' O ' ' CB ' ' A' ' 16' ' ' ASN . . . 74.34 -48.91 1.86 Allowed Glycine 0 N--CA 1.5 2.912 0 C-N-CA 119.909 -1.139 . . . . 0.0 113.337 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' ASN . . . . . 0.442 ' CB ' ' O ' ' A' ' 15' ' ' GLY . 17.1 t-20 98.98 91.53 0.01 OUTLIER 'General case' 0 N--CA 1.511 2.589 0 C-N-CA 126.059 1.744 . . . . 0.0 107.182 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 25.1 p -89.82 160.29 16.57 Favored 'General case' 0 N--CA 1.495 1.8 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.437 -179.843 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 2.0 tt -140.5 70.38 1.36 Allowed 'General case' 0 N--CA 1.501 2.092 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 19.7 m -91.45 -11.91 36.22 Favored 'General case' 0 N--CA 1.502 2.15 0 N-CA-C 112.681 0.623 . . . . 0.0 112.681 179.77 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -166.7 -162.46 18.32 Favored Glycine 0 N--CA 1.504 3.195 0 N-CA-C 110.904 -0.878 . . . . 0.0 110.904 -179.863 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 8.1 mm -135.75 146.48 29.59 Favored 'Isoleucine or valine' 0 N--CA 1.515 2.82 0 N-CA-C 113.992 1.108 . . . . 0.0 113.992 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.56 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.6 pp -64.25 151.15 44.41 Favored 'General case' 0 N--CA 1.505 2.317 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 179.17 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.448 ' N ' ' O ' ' A' ' 45' ' ' TRP . 22.3 m95 -133.45 137.41 45.7 Favored 'General case' 0 C--N 1.305 -1.347 0 N-CA-C 116.6 2.074 . . . . 0.0 116.6 -179.656 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -88.47 41.32 1.01 Allowed 'General case' 0 C--N 1.293 -1.87 0 CA-C-N 109.045 -3.707 . . . . 0.0 115.119 -179.408 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -114.67 129.28 25.11 Favored Pre-proline 0 N--CA 1.489 1.52 0 N-CA-C 115.45 1.648 . . . . 0.0 115.45 179.743 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -68.33 -21.53 41.07 Favored 'Trans proline' 0 C--N 1.307 -1.642 0 C-N-CA 123.402 2.734 . . . . 0.0 108.979 -175.106 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -91.32 1.29 57.22 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-N 112.864 -1.971 . . . . 0.0 110.797 179.752 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 107.72 -117.05 5.06 Favored Glycine 0 N--CA 1.498 2.828 0 N-CA-C 105.455 -3.058 . . . . 0.0 105.455 -179.831 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.533 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 10.2 m -93.12 150.23 38.83 Favored Pre-proline 0 C--N 1.305 -1.361 0 N-CA-C 108.404 -0.962 . . . . 0.0 108.404 179.632 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.712 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.5 OUTLIER -76.49 175.53 11.23 Favored 'Trans proline' 0 C--N 1.311 -1.42 0 C-N-CA 123.241 2.627 . . . . 0.0 115.66 176.777 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 16.4 p -50.47 102.88 0.04 OUTLIER 'General case' 0 C--N 1.299 -1.605 0 CA-C-N 112.671 -2.059 . . . . 0.0 112.724 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 112.12 -0.24 26.89 Favored Glycine 0 N--CA 1.503 3.127 0 O-C-N 124.332 1.02 . . . . 0.0 113.61 179.435 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' TRP . . . . . 0.712 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 45.6 m95 -112.3 163.73 14.05 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 107.289 -1.375 . . . . 0.0 107.289 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 73.5 t60 -146.37 37.45 1.02 Allowed 'General case' 0 N--CA 1.501 2.098 0 C-N-CA 118.014 -1.475 . . . . 0.0 114.54 -179.866 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' ASN . . . . . 0.533 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 23.7 t-20 60.04 149.42 0.02 OUTLIER 'General case' 0 N--CA 1.506 2.338 0 N-CA-C 115.763 1.764 . . . . 0.0 115.763 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.66 ' SG ' ' HB3' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -125.21 -44.91 1.86 Allowed 'General case' 0 C--N 1.303 -1.451 0 CA-C-N 113.52 -1.673 . . . . 0.0 108.067 -179.913 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 37' ' ' LYS . . . . . 0.46 ' C ' ' H ' ' A' ' 39' ' ' HIS . 36.9 ttmt -124.66 111.13 15.24 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 105.101 -2.185 . . . . 0.0 105.101 179.61 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.436 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -85.01 31.84 0.54 Allowed 'General case' 0 N--CA 1.494 1.749 0 N-CA-C 106.132 -1.803 . . . . 0.0 106.132 179.587 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' HIS . . . . . 0.46 ' H ' ' C ' ' A' ' 37' ' ' LYS . 4.5 m-70 -132.21 22.28 4.45 Favored 'General case' 0 N--CA 1.497 1.88 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 -179.612 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 107.89 -145.88 16.26 Favored Glycine 0 N--CA 1.494 2.514 0 N-CA-C 109.292 -1.523 . . . . 0.0 109.292 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.659 ' CD ' ' SG ' ' A' ' 46' ' ' CYS . 8.4 Cg_endo -74.97 -173.54 12.5 Favored 'Cis proline' 0 N--CA 1.502 2.011 0 C-N-CA 129.013 0.839 . . . . 0.0 111.36 0.87 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' ASN . . . . . 0.466 ' C ' ' H ' ' A' ' 44' ' ' GLY . 0.2 OUTLIER -91.9 -8.61 45.9 Favored 'General case' 0 N--CA 1.487 1.385 0 N-CA-C 102.883 -3.006 . . . . 0.0 102.883 179.951 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.488 HD12 ' N ' ' A' ' 43' ' ' ILE . 4.0 mp -90.88 32.45 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 CA-C-O 123.159 1.457 . . . . 0.0 108.245 -179.419 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.466 ' H ' ' C ' ' A' ' 42' ' ' ASN . . . 102.89 127.74 6.19 Favored Glycine 0 N--CA 1.489 2.209 0 CA-C-N 111.88 -2.418 . . . . 0.0 107.094 -179.774 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' TRP . . . . . 0.448 ' O ' ' N ' ' A' ' 23' ' ' TRP . 6.7 m95 -54.8 135.67 47.32 Favored 'General case' 0 N--CA 1.509 2.485 0 CA-C-O 117.05 -1.452 . . . . 0.0 108.621 -179.519 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' CYS . . . . . 0.66 ' HB3' ' SG ' ' A' ' 36' ' ' CYS . 75.3 m -88.37 122.67 32.13 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 101.885 -3.376 . . . . 0.0 101.885 179.86 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.479 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 75.2 m -128.57 -174.71 3.31 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-N 110.43 -3.077 . . . . 0.0 108.739 -179.495 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.408 ' O ' ' HA ' ' A' ' 33' ' ' TRP . 0.0 OUTLIER -151.36 171.96 16.66 Favored 'General case' 0 C--N 1.299 -1.617 0 N-CA-C 106.684 -1.599 . . . . 0.0 106.684 179.176 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 92.3 mttt . . . . . 0 C--N 1.288 -2.076 0 O-C-N 125.675 1.859 . . . . 0.0 109.437 179.922 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.5 2.902 0 N-CA-C 110.01 -1.236 . . . . 0.0 110.01 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 24.7 t -96.22 135.61 22.51 Favored Pre-proline 0 N--CA 1.5 2.039 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 179.901 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.434 ' HB2' ' HB3' ' A' ' 18' ' ' LEU . 6.9 Cg_endo -79.18 129.65 8.86 Favored 'Trans proline' 0 N--CA 1.491 1.371 0 C-N-CA 123.836 3.024 . . . . 0.0 114.268 165.034 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -119.2 -163.0 0.94 Allowed 'General case' 0 N--CA 1.495 1.822 0 N-CA-C 113.549 0.944 . . . . 0.0 113.549 -179.729 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.473 HD23 ' N ' ' A' ' 6' ' ' CYS . 9.6 tt -111.71 151.68 28.63 Favored 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 104.456 -2.424 . . . . 0.0 104.456 179.848 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.535 ' HB2' ' HB2' ' A' ' 9' ' ' ASP . 5.1 m -140.95 -171.05 3.17 Favored 'General case' 0 N--CA 1.483 1.189 0 N-CA-C 116.224 1.935 . . . . 0.0 116.224 -179.378 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 39.0 t70 -83.26 -56.67 3.64 Favored 'General case' 0 N--CA 1.49 1.558 0 CA-C-N 112.233 -2.258 . . . . 0.0 108.09 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 34.1 m -76.22 -12.08 60.03 Favored 'General case' 0 N--CA 1.493 1.724 0 C-N-CA 119.425 -0.91 . . . . 0.0 109.592 179.625 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.535 ' HB2' ' HB2' ' A' ' 6' ' ' CYS . 2.5 t70 -52.18 -31.75 33.03 Favored 'General case' 0 N--CA 1.502 2.14 0 CA-C-N 114.622 -1.172 . . . . 0.0 112.115 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 118.72 141.18 6.53 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 107.669 -2.172 . . . . 0.0 107.669 -179.73 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_endo -76.58 37.78 0.58 Allowed 'Trans proline' 0 N--CA 1.498 1.763 1 C-N-CA 125.762 4.308 . . . . 0.0 112.124 -171.136 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 7.4 mtp180 -111.9 81.72 3.69 Favored Pre-proline 0 N--CA 1.491 1.579 0 CA-C-N 115.018 -0.992 . . . . 0.0 110.356 -179.718 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -68.07 154.2 73.14 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.438 2.759 . . . . 0.0 109.187 179.589 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 80.7 mtt180 48.09 15.05 0.06 Allowed 'General case' 0 N--CA 1.501 2.092 0 N-CA-C 114.488 1.292 . . . . 0.0 114.488 -179.744 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -91.59 32.54 5.24 Favored Glycine 0 N--CA 1.498 2.8 0 CA-C-N 114.812 -1.085 . . . . 0.0 111.634 -179.823 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 9.9 t-20 41.55 33.3 0.29 Allowed 'General case' 0 N--CA 1.509 2.485 0 N-CA-C 112.75 0.648 . . . . 0.0 112.75 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 9.1 t -89.71 157.02 18.16 Favored 'General case' 0 N--CA 1.498 1.954 0 C-N-CA 119.36 -0.936 . . . . 0.0 108.955 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.434 ' HB3' ' HB2' ' A' ' 3' ' ' PRO . 85.5 mt -144.91 49.3 1.29 Allowed 'General case' 0 N--CA 1.501 2.116 0 CA-C-O 122.008 0.908 . . . . 0.0 112.512 -179.503 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 41.4 t -88.69 56.6 3.82 Favored 'General case' 0 N--CA 1.5 2.041 0 C-N-CA 118.106 -1.438 . . . . 0.0 110.468 -179.503 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.517 ' HA2' ' HD3' ' A' ' 48' ' ' LYS . . . -170.99 119.23 0.79 Allowed Glycine 0 N--CA 1.499 2.843 0 CA-C-O 117.979 -1.456 . . . . 0.0 112.32 179.911 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.461 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 37.6 mm -102.71 131.13 51.56 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.312 0 N-CA-C 103.429 -2.804 . . . . 0.0 103.429 179.308 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.595 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 2.1 pp -64.45 158.75 23.05 Favored 'General case' 0 N--CA 1.496 1.85 0 C-N-CA 118.189 -1.404 . . . . 0.0 107.811 179.785 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.48 ' N ' ' O ' ' A' ' 45' ' ' TRP . 19.4 m95 -138.6 135.51 35.02 Favored 'General case' 0 C--N 1.306 -1.324 0 N-CA-C 115.919 1.822 . . . . 0.0 115.919 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -89.06 41.64 1.04 Allowed 'General case' 0 C--N 1.293 -1.878 0 CA-C-N 109.803 -3.362 . . . . 0.0 115.851 -179.611 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.444 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 1.0 OUTLIER -118.34 126.89 26.92 Favored Pre-proline 0 N--CA 1.487 1.379 0 CA-C-O 122.417 1.104 . . . . 0.0 110.225 179.646 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -64.82 -28.71 59.12 Favored 'Trans proline' 0 C--N 1.299 -2.039 0 C-N-CA 122.096 1.864 . . . . 0.0 108.781 -175.237 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 4.6 p -82.36 5.55 19.94 Favored 'General case' 0 N--CA 1.492 1.653 0 CA-C-N 114.661 -1.154 . . . . 0.0 112.52 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 105.79 -128.81 9.52 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 106.032 -2.827 . . . . 0.0 106.032 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.505 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 4.3 m -83.9 145.55 47.04 Favored Pre-proline 0 C--N 1.302 -1.486 0 C-N-CA 120.595 -0.442 . . . . 0.0 110.301 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.693 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 7.0 Cg_endo -75.01 162.27 37.39 Favored 'Trans proline' 0 C--N 1.312 -1.343 0 C-N-CA 123.317 2.678 . . . . 0.0 113.958 176.769 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 18.8 t -45.66 111.94 0.4 Allowed 'General case' 0 N--CA 1.492 1.636 0 CA-C-N 114.362 -1.29 . . . . 0.0 110.205 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 114.14 -8.64 23.0 Favored Glycine 0 N--CA 1.5 2.963 0 CA-C-N 114.573 -1.194 . . . . 0.0 112.93 179.596 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' TRP . . . . . 0.693 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 50.9 m95 -110.76 161.2 16.01 Favored 'General case' 0 N--CA 1.489 1.498 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' HIS . . . . . 0.429 ' ND1' ' O ' ' A' ' 34' ' ' HIS . 56.5 t-80 -146.83 46.34 1.18 Allowed 'General case' 0 N--CA 1.499 1.978 0 C-N-CA 117.741 -1.584 . . . . 0.0 113.508 -179.812 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' ASN . . . . . 0.505 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 21.4 t-20 62.64 145.81 0.02 OUTLIER 'General case' 0 N--CA 1.511 2.6 0 N-CA-C 116.418 2.007 . . . . 0.0 116.418 179.846 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.791 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 0.7 OUTLIER -116.29 -43.0 2.98 Favored 'General case' 0 N--CA 1.485 1.28 0 N-CA-C 106.927 -1.509 . . . . 0.0 106.927 179.482 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 8.8 ptpp? -124.31 127.24 47.33 Favored 'General case' 0 N--CA 1.498 1.94 0 N-CA-C 107.406 -1.331 . . . . 0.0 107.406 179.319 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.445 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -77.8 43.14 0.4 Allowed 'General case' 0 N--CA 1.497 1.909 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 179.869 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' HIS . . . . . 0.445 ' ND1' ' C ' ' A' ' 38' ' ' ALA . 3.5 m-70 -132.05 -81.35 0.51 Allowed 'General case' 0 N--CA 1.498 1.972 0 CA-C-O 119.084 -0.484 . . . . 0.0 110.748 -179.673 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -153.01 -130.38 1.51 Allowed Glycine 0 N--CA 1.509 3.524 0 N-CA-C 109.297 -1.521 . . . . 0.0 109.297 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 0.2 OUTLIER -81.07 -170.17 8.28 Favored 'Cis proline' 0 N--CA 1.5 1.903 0 CA-C-N 120.25 2.025 . . . . 0.0 111.319 -4.178 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 59.6 t30 -92.62 -13.97 28.84 Favored 'General case' 0 N--CA 1.486 1.365 0 N-CA-C 106.094 -1.817 . . . . 0.0 106.094 -179.798 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 37.3 pt -86.6 26.03 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 CA-C-N 113.591 -1.64 . . . . 0.0 113.382 -179.26 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.444 ' HA2' ' O ' ' A' ' 23' ' ' TRP . . . 111.62 119.51 3.84 Favored Glycine 0 N--CA 1.486 2.007 0 CA-C-N 111.602 -2.545 . . . . 0.0 106.875 -179.836 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' TRP . . . . . 0.48 ' O ' ' N ' ' A' ' 23' ' ' TRP . 20.2 m95 -51.45 133.72 29.44 Favored 'General case' 0 N--CA 1.501 2.095 0 CA-C-N 113.253 -1.473 . . . . 0.0 111.111 -179.432 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 46' ' ' CYS . . . . . 0.791 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 22.8 t -89.26 118.69 29.12 Favored 'General case' 0 C--N 1.305 -1.359 1 N-CA-C 99.746 -4.168 . . . . 0.0 99.746 179.571 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.467 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 86.4 m -126.96 -176.27 3.66 Favored 'General case' 0 CA--C 1.487 -1.443 0 CA-C-N 111.172 -2.74 . . . . 0.0 112.604 -179.357 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.517 ' HD3' ' HA2' ' A' ' 20' ' ' GLY . 34.8 tptt -151.49 157.46 42.33 Favored 'General case' 0 C--N 1.297 -1.697 0 C-N-CA 118.297 -1.361 . . . . 0.0 109.999 -179.821 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 23.8 mttm . . . . . 0 N--CA 1.505 2.298 0 O-C-N 127.039 2.712 . . . . 0.0 110.666 179.646 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.466 0 N-CA-C 108.761 -1.736 . . . . 0.0 108.761 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 38.9 t -131.36 153.66 81.7 Favored Pre-proline 0 N--CA 1.494 1.774 0 N-CA-C 103.962 -2.607 . . . . 0.0 103.962 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.446 ' CB ' ' HA ' ' A' ' 18' ' ' LEU . 18.6 Cg_endo -72.82 138.13 28.26 Favored 'Trans proline' 0 C--N 1.305 -1.761 0 C-N-CA 122.991 2.461 . . . . 0.0 117.568 163.662 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.556 ' SG ' ' SG ' ' A' ' 6' ' ' CYS . 12.5 p -124.56 159.1 31.4 Favored 'General case' 0 N--CA 1.494 1.766 0 CA-C-N 114.818 -1.083 . . . . 0.0 109.46 179.52 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 10.3 tp -79.7 84.03 5.58 Favored 'General case' 0 N--CA 1.491 1.62 1 N-CA-C 99.612 -4.218 . . . . 0.0 99.612 179.465 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.657 ' SG ' ' HA3' ' A' ' 20' ' ' GLY . 34.7 m -68.41 175.07 3.57 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-O 123.391 1.567 . . . . 0.0 111.567 -179.716 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 12.7 t70 -49.16 -55.16 13.28 Favored 'General case' 0 C--N 1.294 -1.809 0 CA-C-N 111.498 -2.592 . . . . 0.0 114.506 -179.202 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 27.2 p -90.25 9.2 29.55 Favored 'General case' 0 N--CA 1.499 2.012 0 C-N-CA 118.23 -1.388 . . . . 0.0 108.541 179.784 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.422 ' HB3' ' N ' ' A' ' 6' ' ' CYS . 41.2 t0 -84.81 56.8 4.05 Favored 'General case' 0 N--CA 1.488 1.435 0 N-CA-C 105.791 -1.929 . . . . 0.0 105.791 -179.858 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -95.62 -146.89 21.74 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 104.967 -3.253 . . . . 0.0 104.967 179.836 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 7.2 Cg_endo -77.47 44.85 1.6 Allowed 'Trans proline' 0 C--N 1.311 -1.409 0 C-N-CA 124.586 3.524 . . . . 0.0 109.711 -178.171 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 46.3 mtp180 -89.76 150.23 43.58 Favored Pre-proline 0 C--N 1.297 -1.713 0 CA-C-N 115.311 -0.859 . . . . 0.0 111.147 179.724 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 80.5 Cg_endo -65.09 109.85 1.4 Allowed 'Trans proline' 0 N--CA 1.492 1.401 0 C-N-CA 123.656 2.904 . . . . 0.0 109.747 -178.944 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 9.1 mtp-105 71.99 134.11 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.481 0 O-C-N 125.532 1.77 . . . . 0.0 107.731 -179.81 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 114.59 -24.67 10.96 Favored Glycine 0 N--CA 1.502 3.075 0 C-N-CA 120.267 -0.968 . . . . 0.0 110.853 -179.827 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 29.3 m-80 -40.18 -31.5 0.13 Allowed 'General case' 0 N--CA 1.516 2.874 0 N-CA-C 113.851 1.056 . . . . 0.0 113.851 179.805 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -131.34 27.63 4.75 Favored 'General case' 0 N--CA 1.495 1.791 0 CA-C-N 115.166 -0.925 . . . . 0.0 109.678 -179.796 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.446 ' HA ' ' CB ' ' A' ' 3' ' ' PRO . 0.6 OUTLIER -178.7 39.94 0.0 OUTLIER 'General case' 0 N--CA 1.508 2.466 0 N-CA-C 114.517 1.302 . . . . 0.0 114.517 -179.643 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 12.4 t -89.26 -1.7 58.18 Favored 'General case' 0 N--CA 1.504 2.274 0 C-N-CA 118.956 -1.098 . . . . 0.0 112.734 -179.895 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.657 ' HA3' ' SG ' ' A' ' 6' ' ' CYS . . . -162.66 139.09 5.71 Favored Glycine 0 N--CA 1.493 2.467 0 CA-C-O 118.29 -1.283 . . . . 0.0 110.553 -179.785 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.466 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 32.7 mm -102.57 140.69 20.3 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.102 0 N-CA-C 104.268 -2.493 . . . . 0.0 104.268 179.571 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.595 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.6 pp -63.87 146.08 54.65 Favored 'General case' 0 N--CA 1.504 2.238 0 C-N-CA 117.407 -1.717 . . . . 0.0 112.154 179.727 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 40.6 m95 -130.82 131.88 44.9 Favored 'General case' 0 N--CA 1.486 1.327 0 N-CA-C 119.404 3.113 . . . . 0.0 119.404 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -89.39 51.32 2.09 Favored 'General case' 0 C--N 1.301 -1.512 1 CA-C-N 107.895 -4.229 . . . . 0.0 111.334 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.53 ' CE1' ' HB3' ' A' ' 30' ' ' PRO . 2.2 m-85 -125.99 126.37 24.81 Favored Pre-proline 0 N--CA 1.488 1.448 0 CA-C-O 121.588 0.708 . . . . 0.0 111.898 179.834 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -64.13 -19.99 66.79 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 C-N-CA 123.764 2.976 . . . . 0.0 110.286 -178.12 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 10.4 p -88.04 -6.69 57.82 Favored 'General case' 0 N--CA 1.491 1.587 0 CA-C-N 114.004 -1.453 . . . . 0.0 110.933 179.753 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.592 ' HA2' ' CD1' ' A' ' 45' ' ' TRP . . . 114.81 -95.3 0.71 Allowed Glycine 0 N--CA 1.483 1.776 1 N-CA-C 100.932 -4.867 . . . . 0.0 100.932 -179.531 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.541 ' HB3' ' HB2' ' A' ' 33' ' ' TRP . 7.8 m -101.17 164.37 16.15 Favored Pre-proline 0 C--N 1.302 -1.459 0 CA-C-N 114.006 -1.097 . . . . 0.0 108.676 179.768 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.722 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.3 OUTLIER -83.83 167.1 13.05 Favored 'Trans proline' 0 C--N 1.311 -1.412 0 C-N-CA 124.917 3.745 . . . . 0.0 116.177 158.24 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 29.1 t -55.86 126.33 25.22 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-N 113.427 -1.715 . . . . 0.0 109.62 -179.843 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 104.58 -7.12 45.8 Favored Glycine 0 N--CA 1.495 2.628 0 CA-C-N 112.664 -2.062 . . . . 0.0 111.46 179.893 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' TRP . . . . . 0.722 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 49.7 m95 -113.4 152.96 29.36 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 106.335 -1.728 . . . . 0.0 106.335 -179.872 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 56.4 t-80 -140.42 44.5 1.86 Allowed 'General case' 0 N--CA 1.493 1.717 0 C-N-CA 119.419 -0.913 . . . . 0.0 109.51 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' ASN . . . . . 0.571 ' HA ' ' SG ' ' A' ' 47' ' ' CYS . 23.2 t-20 54.74 147.86 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.171 0 CA-C-N 112.951 -1.932 . . . . 0.0 115.428 -179.985 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.676 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 0.8 OUTLIER -119.76 -36.27 3.34 Favored 'General case' 0 C--N 1.309 -1.184 0 N-CA-C 106.632 -1.618 . . . . 0.0 106.632 179.825 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 19.5 ttpt -139.02 122.4 17.16 Favored 'General case' 0 N--CA 1.486 1.336 0 CA-C-O 123.589 1.661 . . . . 0.0 109.98 179.668 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.43 ' O ' ' ND1' ' A' ' 39' ' ' HIS . . . -96.0 21.18 9.03 Favored 'General case' 0 C--N 1.303 -1.419 0 CA-C-N 112.273 -2.239 . . . . 0.0 105.541 179.72 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' HIS . . . . . 0.43 ' ND1' ' O ' ' A' ' 38' ' ' ALA . 10.7 m-70 -135.72 69.46 1.43 Allowed 'General case' 0 N--CA 1.497 1.895 0 N-CA-C 109.372 -0.603 . . . . 0.0 109.372 -179.719 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 84.08 176.47 51.17 Favored Glycine 0 N--CA 1.502 3.036 0 N-CA-C 106.165 -2.774 . . . . 0.0 106.165 -179.739 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_endo -60.96 169.8 19.37 Favored 'Cis proline' 0 N--CA 1.504 2.089 0 CA-C-N 119.771 1.786 . . . . 0.0 114.434 1.664 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 17.0 t-20 -92.45 -9.08 42.81 Favored 'General case' 0 N--CA 1.484 1.232 0 N-CA-C 104.773 -2.306 . . . . 0.0 104.773 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 17.6 mt -92.7 29.72 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.063 0 CA-C-O 123.059 1.409 . . . . 0.0 109.819 -179.29 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.465 ' C ' ' CD1' ' A' ' 45' ' ' TRP . . . 129.53 -116.58 2.17 Favored Glycine 0 N--CA 1.484 1.84 0 N-CA-C 103.744 -3.742 . . . . 0.0 103.744 -179.772 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' TRP . . . . . 0.592 ' CD1' ' HA2' ' A' ' 28' ' ' GLY . 3.0 m95 -155.26 -172.07 4.04 Favored 'General case' 0 N--CA 1.507 2.422 0 N-CA-C 104.254 -2.498 . . . . 0.0 104.254 179.853 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' CYS . . . . . 0.676 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 26.2 t -135.75 126.84 27.96 Favored 'General case' 0 N--CA 1.498 1.958 1 N-CA-C 98.985 -4.45 . . . . 0.0 98.985 179.493 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.573 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 70.9 m -131.47 -179.68 5.51 Favored 'General case' 0 CA--C 1.471 -2.061 0 N-CA-C 116.24 1.941 . . . . 0.0 116.24 -178.663 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.567 ' HD3' ' HA2' ' A' ' 20' ' ' GLY . 44.1 tptt -151.04 149.21 29.28 Favored 'General case' 0 C--N 1.297 -1.693 0 C-N-CA 118.716 -1.194 . . . . 0.0 110.672 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' LYS . . . . . 0.479 ' H ' ' HD2' ' A' ' 48' ' ' LYS . 93.4 mttt . . . . . 0 N--CA 1.494 1.774 0 CA-C-N 112.133 -2.303 . . . . 0.0 108.59 179.317 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.495 2.576 0 N-CA-C 109.093 -1.603 . . . . 0.0 109.093 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 21.4 t -97.22 147.28 32.72 Favored Pre-proline 0 N--CA 1.497 1.919 0 N-CA-C 106.694 -1.595 . . . . 0.0 106.694 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.419 ' HA ' ' O ' ' A' ' 20' ' ' GLY . 6.9 Cg_endo -77.84 149.76 26.49 Favored 'Trans proline' 0 C--N 1.309 -1.532 0 C-N-CA 122.536 2.157 . . . . 0.0 110.314 169.521 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -138.95 169.43 17.81 Favored 'General case' 0 C--N 1.3 -1.557 0 CA-C-O 121.862 0.839 . . . . 0.0 110.142 179.836 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.413 HD23 ' N ' ' A' ' 6' ' ' CYS . 8.5 tt -91.88 150.52 21.0 Favored 'General case' 0 N--CA 1.492 1.655 0 N-CA-C 102.229 -3.248 . . . . 0.0 102.229 179.647 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.542 ' H ' ' HB3' ' A' ' 9' ' ' ASP . 3.1 m -139.78 -166.46 2.08 Favored 'General case' 0 N--CA 1.493 1.72 0 N-CA-C 113.973 1.101 . . . . 0.0 113.973 -179.519 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' ASP . . . . . 0.472 ' H ' ' HB3' ' A' ' 37' ' ' LYS . 30.1 t70 -81.19 -59.8 2.52 Favored 'General case' 0 N--CA 1.496 1.86 0 CA-C-N 112.612 -2.085 . . . . 0.0 108.091 -179.754 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 15.2 m -76.51 -13.26 60.1 Favored 'General case' 0 N--CA 1.499 2.002 0 CA-C-N 114.56 -1.2 . . . . 0.0 109.605 179.636 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.542 ' HB3' ' H ' ' A' ' 6' ' ' CYS . 28.7 t70 -65.42 -15.5 62.67 Favored 'General case' 0 N--CA 1.492 1.63 0 CA-C-N 113.655 -1.611 . . . . 0.0 115.18 -179.743 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.447 ' C ' ' H ' ' A' ' 12' ' ' ARG . . . -163.29 70.79 0.21 Allowed Glycine 0 N--CA 1.5 2.957 0 C-N-CA 118.87 -1.633 . . . . 0.0 113.559 -179.659 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_endo -72.43 27.52 0.27 Allowed 'Trans proline' 0 N--CA 1.498 1.784 0 C-N-CA 123.791 2.994 . . . . 0.0 112.276 173.946 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.447 ' H ' ' C ' ' A' ' 10' ' ' GLY . 19.8 mtp180 -145.36 135.07 11.56 Favored Pre-proline 0 N--CA 1.494 1.77 0 N-CA-C 107.658 -1.238 . . . . 0.0 107.658 -179.841 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 23.2 Cg_endo -73.28 145.04 38.01 Favored 'Trans proline' 0 N--CA 1.49 1.317 0 C-N-CA 123.811 3.007 . . . . 0.0 110.075 -178.773 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 72.8 mtp180 54.11 20.39 2.5 Favored 'General case' 0 N--CA 1.498 1.95 0 CA-C-O 121.994 0.902 . . . . 0.0 111.274 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -70.5 -24.21 76.98 Favored Glycine 0 N--CA 1.493 2.498 0 CA-C-N 114.085 -1.416 . . . . 0.0 112.425 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 38.9 m-80 50.41 41.33 24.73 Favored 'General case' 0 N--CA 1.505 2.283 0 CA-C-O 122.15 0.976 . . . . 0.0 111.072 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.3 p -88.97 148.21 23.9 Favored 'General case' 0 C--N 1.301 -1.535 0 CA-C-N 115.47 -0.786 . . . . 0.0 108.987 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 2.0 tt -161.51 91.95 0.86 Allowed 'General case' 0 N--CA 1.499 1.999 0 N-CA-C 106.741 -1.577 . . . . 0.0 106.741 -179.564 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 64.0 p -128.26 31.55 5.02 Favored 'General case' 0 N--CA 1.499 1.984 0 N-CA-C 112.904 0.705 . . . . 0.0 112.904 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.419 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -135.45 156.49 22.72 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 108.791 -1.724 . . . . 0.0 108.791 -179.906 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.448 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 44.5 mm -115.56 144.93 22.03 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 N-CA-C 106.098 -1.816 . . . . 0.0 106.098 179.708 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.609 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 4.1 pp -72.69 151.0 42.45 Favored 'General case' 0 N--CA 1.488 1.464 0 C-N-CA 118.438 -1.305 . . . . 0.0 109.041 179.752 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 44.1 m95 -132.31 134.21 44.96 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 117.721 2.489 . . . . 0.0 117.721 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.3 m-85 -89.2 53.13 2.56 Favored 'General case' 0 C--N 1.296 -1.744 1 CA-C-N 107.623 -4.353 . . . . 0.0 109.43 -179.791 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.429 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 2.4 m-85 -126.58 139.2 34.13 Favored Pre-proline 0 C--N 1.306 -1.294 0 CA-C-O 121.671 0.748 . . . . 0.0 111.964 -179.962 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.68 -18.01 37.63 Favored 'Trans proline' 0 C--N 1.305 -1.734 1 C-N-CA 125.415 4.077 . . . . 0.0 110.6 177.161 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 10.7 p -100.26 22.65 11.19 Favored 'General case' 0 C--N 1.299 -1.613 0 CA-C-N 113.334 -1.757 . . . . 0.0 110.886 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.577 ' HA2' ' CD1' ' A' ' 45' ' ' TRP . . . 81.4 -89.98 1.41 Allowed Glycine 0 N--CA 1.484 1.838 1 N-CA-C 102.854 -4.098 . . . . 0.0 102.854 -179.674 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.462 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 24.8 m -98.7 163.57 18.67 Favored Pre-proline 0 C--N 1.302 -1.457 0 CA-C-N 113.719 -1.24 . . . . 0.0 110.996 -179.887 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.696 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.1 OUTLIER -89.05 163.76 5.83 Favored 'Trans proline' 0 CA--C 1.554 1.496 1 C-N-CA 126.701 4.934 . . . . 0.0 117.122 155.785 . . . . . . . . 4 4 . 1 . 011 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 4.1 m -51.06 111.82 0.62 Allowed 'General case' 0 C--N 1.301 -1.526 0 CA-C-N 112.36 -2.2 . . . . 0.0 114.135 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 113.7 -6.54 24.22 Favored Glycine 0 N--CA 1.506 3.352 0 CA-C-N 115.046 -0.979 . . . . 0.0 112.638 179.68 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' TRP . . . . . 0.696 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 54.7 m95 -106.96 167.17 10.07 Favored 'General case' 0 C--N 1.299 -1.619 0 N-CA-C 106.517 -1.661 . . . . 0.0 106.517 -179.762 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 51.1 t-80 -146.96 37.7 0.97 Allowed 'General case' 0 N--CA 1.493 1.69 0 C-N-CA 116.845 -1.942 . . . . 0.0 113.236 179.82 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' ASN . . . . . 0.499 ' HA ' ' SG ' ' A' ' 47' ' ' CYS . 13.9 t-20 55.88 143.04 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.113 0 N-CA-C 117.484 2.401 . . . . 0.0 117.484 179.556 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.842 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 2.7 p -120.3 -28.37 5.05 Favored 'General case' 0 N--CA 1.486 1.329 0 CA-C-N 115.652 -0.703 . . . . 0.0 111.345 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' LYS . . . . . 0.472 ' HB3' ' H ' ' A' ' 7' ' ' ASP . 9.5 ptpt -151.05 151.15 31.61 Favored 'General case' 0 N--CA 1.495 1.792 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 179.105 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.449 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -117.0 35.06 4.8 Favored 'General case' 0 N--CA 1.491 1.607 0 N-CA-C 102.388 -3.19 . . . . 0.0 102.388 179.661 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 39' ' ' HIS . . . . . 0.449 ' ND1' ' C ' ' A' ' 38' ' ' ALA . 4.5 m-70 -128.64 60.31 1.52 Allowed 'General case' 0 N--CA 1.497 1.881 0 N-CA-C 106.943 -1.503 . . . . 0.0 106.943 -179.534 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 74.19 -149.45 40.81 Favored Glycine 0 N--CA 1.496 2.646 0 N-CA-C 104.854 -3.298 . . . . 0.0 104.854 -179.702 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.412 ' HD2' ' C ' ' A' ' 45' ' ' TRP . 42.1 Cg_endo -48.53 176.6 0.39 Allowed 'Cis proline' 0 N--CA 1.504 2.104 0 CA-C-N 119.765 1.783 . . . . 0.0 115.478 -5.499 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.5 m-20 -92.08 -7.77 47.72 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 104.34 -2.467 . . . . 0.0 104.34 -179.719 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 15.0 mt -99.53 22.29 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.85 0 CA-C-O 123.99 1.853 . . . . 0.0 113.006 -179.345 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 133.08 -119.87 2.48 Favored Glycine 0 C--N 1.288 -2.094 0 N-CA-C 104.195 -3.562 . . . . 0.0 104.195 -179.857 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' TRP . . . . . 0.577 ' CD1' ' HA2' ' A' ' 28' ' ' GLY . 3.9 m95 -152.56 -169.22 3.28 Favored 'General case' 0 N--CA 1.511 2.588 0 N-CA-C 106.923 -1.51 . . . . 0.0 106.923 -179.917 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' CYS . . . . . 0.842 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 43.8 t -139.17 129.4 25.39 Favored 'General case' 0 C--N 1.313 -0.982 0 N-CA-C 101.273 -3.603 . . . . 0.0 101.273 179.13 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.499 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 71.4 m -135.0 -172.13 2.97 Favored 'General case' 0 C--N 1.294 -1.805 0 CA-C-N 111.295 -2.684 . . . . 0.0 108.479 -179.435 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.406 ' N ' ' CD ' ' A' ' 48' ' ' LYS . 0.0 OUTLIER -150.55 173.5 14.03 Favored 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 107.125 -1.435 . . . . 0.0 107.125 179.352 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.499 1.993 0 O-C-N 125.803 1.939 . . . . 0.0 106.681 179.728 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 2.725 0 N-CA-C 108.914 -1.674 . . . . 0.0 108.914 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.415 ' HB ' HD23 ' A' ' 22' ' ' LEU . 22.0 t -94.74 146.13 30.85 Favored Pre-proline 0 N--CA 1.497 1.893 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 -179.926 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -72.28 149.65 51.58 Favored 'Trans proline' 0 N--CA 1.494 1.506 0 C-N-CA 124.161 3.24 . . . . 0.0 112.716 167.625 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.595 ' SG ' ' HB3' ' A' ' 22' ' ' LEU . 0.1 OUTLIER -136.88 -176.89 4.51 Favored 'General case' 0 N--CA 1.496 1.844 0 CA-C-N 115.349 -0.842 . . . . 0.0 111.438 179.631 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 6.4 tt -91.15 110.93 22.21 Favored 'General case' 0 N--CA 1.491 1.587 0 C-N-CA 119.428 -0.909 . . . . 0.0 108.829 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.423 ' SG ' ' HA3' ' A' ' 20' ' ' GLY . 7.7 m -88.13 178.42 6.64 Favored 'General case' 0 C--N 1.31 -1.123 0 CA-C-O 123.282 1.515 . . . . 0.0 113.827 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -55.36 -65.73 0.54 Allowed 'General case' 0 C--N 1.297 -1.712 0 CA-C-N 111.501 -2.59 . . . . 0.0 110.123 -179.84 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 65.1 m -80.69 26.55 0.4 Allowed 'General case' 0 N--CA 1.498 1.947 0 C-N-CA 118.971 -1.092 . . . . 0.0 109.381 179.804 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -94.79 -3.0 49.84 Favored 'General case' 0 N--CA 1.495 1.819 0 C-N-CA 119.341 -0.943 . . . . 0.0 113.536 -179.554 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -39.52 -55.41 2.61 Favored Glycine 0 N--CA 1.506 3.336 0 N-CA-C 115.049 0.78 . . . . 0.0 115.049 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_endo -75.34 11.0 1.64 Allowed 'Trans proline' 0 N--CA 1.5 1.872 0 C-N-CA 123.501 2.801 . . . . 0.0 113.903 179.721 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.433 ' HB3' HG21 ' A' ' 17' ' ' THR . 51.9 mtt85 -135.93 70.68 63.82 Favored Pre-proline 0 N--CA 1.492 1.67 0 CA-C-N 114.635 -1.166 . . . . 0.0 112.133 -179.768 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_endo -74.78 -147.78 0.03 OUTLIER 'Trans proline' 0 N--CA 1.493 1.471 0 C-N-CA 124.785 3.656 . . . . 0.0 111.495 178.915 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 6.3 ptp180 -62.66 -161.1 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.044 0 CA-C-N 115.7 -0.682 . . . . 0.0 112.016 -179.886 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 86.16 31.52 19.71 Favored Glycine 0 N--CA 1.5 2.943 0 C-N-CA 120.0 -1.095 . . . . 0.0 111.213 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 1.7 t30 61.89 52.23 3.49 Favored 'General case' 0 N--CA 1.506 2.348 0 CA-C-O 122.788 1.28 . . . . 0.0 109.663 179.913 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.433 HG21 ' HB3' ' A' ' 12' ' ' ARG . 23.3 m -98.86 121.75 41.22 Favored 'General case' 0 N--CA 1.495 1.811 0 CA-C-N 114.074 -1.421 . . . . 0.0 110.528 -179.897 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 7.4 mp -117.95 85.87 2.42 Favored 'General case' 0 N--CA 1.504 2.244 0 CA-C-O 122.36 1.076 . . . . 0.0 111.191 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 8.9 t -90.11 -29.12 18.52 Favored 'General case' 0 N--CA 1.501 2.112 0 CA-C-N 113.374 -1.739 . . . . 0.0 111.077 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.423 ' HA3' ' SG ' ' A' ' 6' ' ' CYS . . . -154.4 141.33 8.13 Favored Glycine 0 N--CA 1.496 2.634 0 N-CA-C 110.349 -1.1 . . . . 0.0 110.349 179.987 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.432 ' N ' ' O ' ' A' ' 47' ' ' CYS . 40.8 mm -99.64 138.89 22.61 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.452 0 N-CA-C 107.122 -1.436 . . . . 0.0 107.122 179.767 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.595 ' HB3' ' SG ' ' A' ' 4' ' ' CYS . 1.3 pp -68.97 146.93 52.33 Favored 'General case' 0 N--CA 1.495 1.8 0 C-N-CA 118.925 -1.11 . . . . 0.0 109.155 179.889 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 29.9 m95 -129.06 135.03 48.37 Favored 'General case' 0 C--N 1.307 -1.246 0 N-CA-C 117.882 2.549 . . . . 0.0 117.882 -179.786 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -89.38 49.25 1.72 Allowed 'General case' 0 C--N 1.298 -1.635 1 CA-C-N 108.047 -4.16 . . . . 0.0 113.163 -179.791 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.403 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 2.0 m-85 -122.08 139.3 30.19 Favored Pre-proline 0 C--N 1.301 -1.542 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 179.573 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 13.9 Cg_endo -76.29 -26.3 9.07 Favored 'Trans proline' 0 C--N 1.303 -1.86 0 C-N-CA 125.255 3.97 . . . . 0.0 112.841 174.42 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -88.66 11.94 16.11 Favored 'General case' 0 N--CA 1.494 1.748 0 CA-C-N 114.876 -1.056 . . . . 0.0 113.224 -179.831 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 97.91 -127.2 9.14 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 103.755 -3.738 . . . . 0.0 103.755 -179.722 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.527 ' HB3' ' HB2' ' A' ' 33' ' ' TRP . 8.3 m -85.38 147.04 46.04 Favored Pre-proline 0 C--N 1.303 -1.444 0 CA-C-N 117.716 0.758 . . . . 0.0 110.776 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.698 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 8.5 Cg_endo -75.19 168.28 25.05 Favored 'Trans proline' 0 C--N 1.308 -1.602 0 C-N-CA 123.037 2.491 . . . . 0.0 113.795 176.006 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 2.9 m -45.45 101.45 0.02 OUTLIER 'General case' 0 C--N 1.297 -1.68 0 CA-C-N 112.642 -2.072 . . . . 0.0 113.423 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 116.0 -2.11 21.12 Favored Glycine 0 N--CA 1.507 3.427 0 C-N-CA 120.945 -0.645 . . . . 0.0 114.057 179.63 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' TRP . . . . . 0.698 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 55.4 m95 -111.13 158.29 19.05 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 106.46 -1.682 . . . . 0.0 106.46 -179.851 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 2.0 t-80 -138.54 34.08 2.25 Favored 'General case' 0 N--CA 1.492 1.667 0 C-N-CA 117.615 -1.634 . . . . 0.0 112.507 -179.739 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' ASN . . . . . 0.507 ' HA ' ' SG ' ' A' ' 29' ' ' CYS . 0.3 OUTLIER 66.4 138.21 0.03 OUTLIER 'General case' 0 N--CA 1.509 2.498 0 N-CA-C 116.566 2.061 . . . . 0.0 116.566 179.734 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.683 ' SG ' ' CB ' ' A' ' 46' ' ' CYS . 0.8 OUTLIER -114.34 -33.37 5.65 Favored 'General case' 0 N--CA 1.484 1.243 0 N-CA-C 104.541 -2.392 . . . . 0.0 104.541 179.485 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 20.7 ptmt -146.4 139.95 25.97 Favored 'General case' 0 N--CA 1.494 1.764 0 CA-C-N 115.481 -0.781 . . . . 0.0 110.069 179.503 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.449 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -112.17 34.81 4.05 Favored 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 103.898 -2.63 . . . . 0.0 103.898 179.833 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 39' ' ' HIS . . . . . 0.449 ' ND1' ' C ' ' A' ' 38' ' ' ALA . 4.1 m-70 -129.12 57.28 1.65 Allowed 'General case' 0 N--CA 1.499 1.981 0 N-CA-C 107.611 -1.255 . . . . 0.0 107.611 -179.735 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 72.75 -142.04 31.56 Favored Glycine 0 N--CA 1.496 2.695 0 N-CA-C 106.739 -2.544 . . . . 0.0 106.739 -179.656 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.46 ' HG2' ' O ' ' A' ' 44' ' ' GLY . 94.3 Cg_endo -62.34 -169.19 1.42 Allowed 'Cis proline' 0 N--CA 1.496 1.621 0 CA-C-N 118.804 1.302 . . . . 0.0 112.876 -5.065 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 54.2 t30 -93.66 1.53 56.58 Favored 'General case' 0 C--N 1.308 -1.217 0 N-CA-C 105.045 -2.206 . . . . 0.0 105.045 -179.334 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.443 HD12 ' N ' ' A' ' 43' ' ' ILE . 1.1 mp -120.28 37.46 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 O-C-N 125.126 1.516 . . . . 0.0 114.843 -179.008 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.46 ' O ' ' HG2' ' A' ' 41' ' ' PRO . . . 119.59 149.99 8.56 Favored Glycine 0 N--CA 1.485 1.963 0 N-CA-C 106.85 -2.5 . . . . 0.0 106.85 179.932 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' TRP . . . . . 0.403 ' NE1' ' O ' ' A' ' 25' ' ' TYR . 5.1 m95 -89.38 136.42 33.04 Favored 'General case' 0 N--CA 1.506 2.326 0 CA-C-O 117.175 -1.393 . . . . 0.0 108.329 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 46' ' ' CYS . . . . . 0.683 ' CB ' ' SG ' ' A' ' 36' ' ' CYS . 59.1 m -88.77 127.34 35.6 Favored 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 101.957 -3.349 . . . . 0.0 101.957 179.527 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.569 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 79.7 m -129.81 -174.95 3.45 Favored 'General case' 0 C--N 1.299 -1.601 0 CA-C-N 110.959 -2.837 . . . . 0.0 113.817 -179.243 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.433 ' HD2' ' H ' ' A' ' 49' ' ' LYS . 25.7 tptp -151.6 150.68 30.57 Favored 'General case' 0 C--N 1.295 -1.781 0 C-N-CA 118.57 -1.252 . . . . 0.0 110.26 -179.907 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 49' ' ' LYS . . . . . 0.433 ' H ' ' HD2' ' A' ' 48' ' ' LYS . 6.0 mtpt . . . . . 0 N--CA 1.499 2.015 0 O-C-N 126.407 2.317 . . . . 0.0 108.422 179.448 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 2.673 0 N-CA-C 108.968 -1.653 . . . . 0.0 108.968 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 40.0 t -98.23 140.86 22.15 Favored Pre-proline 0 N--CA 1.496 1.861 0 N-CA-C 106.863 -1.532 . . . . 0.0 106.863 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -70.66 148.61 59.61 Favored 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 123.533 2.822 . . . . 0.0 111.718 172.965 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.522 ' SG ' ' HB3' ' A' ' 22' ' ' LEU . 0.8 OUTLIER -146.32 163.3 35.96 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 124.24 0.962 . . . . 0.0 109.724 179.779 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.43 HD23 ' N ' ' A' ' 6' ' ' CYS . 8.9 tt -79.41 150.68 31.25 Favored 'General case' 0 N--CA 1.488 1.446 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 -179.833 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.573 ' SG ' ' HB2' ' A' ' 9' ' ' ASP . 2.5 m -137.83 -145.19 0.19 Allowed 'General case' 0 N--CA 1.491 1.607 0 N-CA-C 116.316 1.969 . . . . 0.0 116.316 -179.663 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' ASP . . . . . 0.401 ' HB3' ' HA ' ' A' ' 37' ' ' LYS . 18.5 t70 -106.15 -59.02 1.84 Allowed 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 105.941 -1.874 . . . . 0.0 105.941 179.891 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 2.7 m -90.97 12.57 19.22 Favored 'General case' 0 N--CA 1.497 1.917 0 CA-C-N 114.164 -1.38 . . . . 0.0 108.508 179.668 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.573 ' HB2' ' SG ' ' A' ' 6' ' ' CYS . 5.0 t0 -66.21 72.24 0.07 Allowed 'General case' 0 N--CA 1.487 1.39 0 CA-C-N 115.013 -0.994 . . . . 0.0 111.49 -179.91 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.42 ' HA3' ' HB2' ' A' ' 16' ' ' ASN . . . 120.88 80.9 0.61 Allowed Glycine 0 N--CA 1.495 2.589 0 C-N-CA 120.242 -0.98 . . . . 0.0 112.979 179.827 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 7.4 Cg_endo -74.99 35.99 0.43 Allowed 'Trans proline' 0 N--CA 1.503 2.031 1 C-N-CA 125.336 4.024 . . . . 0.0 112.528 177.999 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 76.3 mtt85 -144.11 168.32 12.88 Favored Pre-proline 0 N--CA 1.49 1.567 0 N-CA-C 107.525 -1.287 . . . . 0.0 107.525 -179.87 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 16.4 Cg_endo -72.58 -170.53 0.6 Allowed 'Trans proline' 0 N--CA 1.493 1.456 0 C-N-CA 123.666 2.911 . . . . 0.0 113.188 169.633 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 16.0 ptt85 -16.62 109.99 0.02 OUTLIER 'General case' 0 N--CA 1.502 2.125 0 N-CA-C 117.433 2.383 . . . . 0.0 117.433 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 119.81 -21.6 8.95 Favored Glycine 0 N--CA 1.505 3.24 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' ASN . . . . . 0.42 ' HB2' ' HA3' ' A' ' 10' ' ' GLY . 15.9 p-10 -61.34 72.46 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.466 0 CA-C-O 122.996 1.379 . . . . 0.0 111.408 -179.922 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 7.5 p -138.76 169.69 17.33 Favored 'General case' 0 C--N 1.295 -1.774 0 N-CA-C 106.02 -1.844 . . . . 0.0 106.02 179.605 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 20.2 tp 49.45 56.82 7.25 Favored 'General case' 0 N--CA 1.509 2.495 0 CA-C-O 123.142 1.449 . . . . 0.0 110.224 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 7.3 t -121.25 43.43 2.81 Favored 'General case' 0 N--CA 1.498 1.953 0 CA-C-N 113.993 -1.458 . . . . 0.0 107.138 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 170.42 154.67 9.65 Favored Glycine 0 N--CA 1.493 2.448 0 CA-C-N 114.905 -1.043 . . . . 0.0 113.626 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.434 ' N ' ' O ' ' A' ' 47' ' ' CYS . 40.5 mm -116.82 144.77 23.74 Favored 'Isoleucine or valine' 0 N--CA 1.51 2.56 0 N-CA-C 107.639 -1.245 . . . . 0.0 107.639 179.736 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.623 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.8 pp -68.27 151.62 46.65 Favored 'General case' 0 N--CA 1.501 2.123 0 C-N-CA 117.543 -1.663 . . . . 0.0 107.528 179.447 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 22.1 m95 -131.2 140.33 49.87 Favored 'General case' 0 C--N 1.308 -1.198 0 CA-C-O 124.964 2.316 . . . . 0.0 116.985 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.5 m-30 -89.43 35.18 0.81 Allowed 'General case' 0 C--N 1.297 -1.696 1 CA-C-N 107.868 -4.242 . . . . 0.0 115.23 -179.636 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.438 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 1.2 m-30 -111.02 115.17 53.25 Favored Pre-proline 0 C--N 1.301 -1.506 0 N-CA-C 107.036 -1.468 . . . . 0.0 107.036 179.64 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo -61.27 -19.73 65.13 Favored 'Trans proline' 0 C--N 1.299 -2.031 0 C-N-CA 121.007 1.138 . . . . 0.0 109.524 -175.212 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 1.6 p -91.67 1.81 56.9 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 124.396 1.06 . . . . 0.0 112.574 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 121.03 -130.99 8.46 Favored Glycine 0 N--CA 1.497 2.739 0 N-CA-C 108.207 -1.957 . . . . 0.0 108.207 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.617 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 8.4 m -93.36 150.28 38.73 Favored Pre-proline 0 C--N 1.303 -1.441 0 CA-C-N 117.382 0.591 . . . . 0.0 109.868 -179.938 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.72 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.7 OUTLIER -76.13 162.1 34.63 Favored 'Trans proline' 0 C--N 1.309 -1.545 0 C-N-CA 122.515 2.143 . . . . 0.0 113.206 176.079 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 26.4 t -46.14 110.44 0.27 Allowed 'General case' 0 N--CA 1.493 1.692 0 CA-C-N 113.12 -1.855 . . . . 0.0 111.013 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 113.95 -5.57 23.92 Favored Glycine 0 N--CA 1.5 2.936 0 CA-C-N 114.405 -1.27 . . . . 0.0 111.678 179.772 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' TRP . . . . . 0.72 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 35.4 m95 -117.5 152.59 34.74 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 106.992 -1.484 . . . . 0.0 106.992 -179.827 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 55.4 t60 -143.04 42.26 1.54 Allowed 'General case' 0 N--CA 1.496 1.872 0 C-N-CA 117.389 -1.725 . . . . 0.0 112.436 179.866 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' ASN . . . . . 0.617 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 27.5 t-20 60.63 149.98 0.02 OUTLIER 'General case' 0 N--CA 1.506 2.347 0 N-CA-C 117.947 2.573 . . . . 0.0 117.947 179.742 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.696 ' SG ' ' CB ' ' A' ' 46' ' ' CYS . 13.9 p -115.82 -16.41 11.19 Favored 'General case' 0 N--CA 1.485 1.3 0 CA-C-N 114.352 -1.295 . . . . 0.0 110.983 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 37' ' ' LYS . . . . . 0.501 ' HB3' ' HB3' ' A' ' 6' ' ' CYS . 15.3 ptmt -144.7 127.04 15.83 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.953 -0.467 . . . . 0.0 111.83 -179.967 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.451 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -80.98 44.29 0.75 Allowed 'General case' 0 N--CA 1.493 1.677 0 N-CA-C 106.606 -1.627 . . . . 0.0 106.606 179.618 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 39' ' ' HIS . . . . . 0.467 ' H ' ' C ' ' A' ' 37' ' ' LYS . 2.9 m-70 -131.24 -116.6 0.23 Allowed 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 101.53 -3.508 . . . . 0.0 101.53 -179.845 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -126.68 -113.11 1.82 Allowed Glycine 0 N--CA 1.506 3.311 0 N-CA-C 110.782 -0.927 . . . . 0.0 110.782 179.785 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.423 ' HG2' ' O ' ' A' ' 44' ' ' GLY . 83.1 Cg_endo -65.7 -164.77 1.43 Allowed 'Cis proline' 0 N--CA 1.503 2.08 0 N-CA-C 116.316 1.622 . . . . 0.0 116.316 -4.057 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -93.03 -13.91 28.05 Favored 'General case' 0 N--CA 1.486 1.356 0 N-CA-C 106.233 -1.766 . . . . 0.0 106.233 -179.298 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 27.1 pt -103.52 28.76 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.148 0 O-C-N 125.913 2.008 . . . . 0.0 116.234 -179.135 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.423 ' O ' ' HG2' ' A' ' 41' ' ' PRO . . . 129.05 168.36 12.35 Favored Glycine 0 C--N 1.292 -1.892 1 N-CA-C 102.149 -4.38 . . . . 0.0 102.149 -179.973 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 45' ' ' TRP . . . . . 0.438 ' NE1' ' O ' ' A' ' 25' ' ' TYR . 26.2 m95 -102.9 137.3 41.28 Favored 'General case' 0 C--N 1.281 -2.396 0 N-CA-C 105.259 -2.126 . . . . 0.0 105.259 179.883 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' CYS . . . . . 0.696 ' CB ' ' SG ' ' A' ' 36' ' ' CYS . 98.9 m -90.11 130.12 36.32 Favored 'General case' 0 N--CA 1.478 0.966 1 N-CA-C 100.116 -4.031 . . . . 0.0 100.116 179.509 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.434 ' O ' ' N ' ' A' ' 21' ' ' ILE . 82.1 m -132.92 -170.88 2.54 Favored 'General case' 0 C--N 1.296 -1.754 0 CA-C-N 111.736 -2.483 . . . . 0.0 109.273 -179.305 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.568 ' HD3' ' H ' ' A' ' 48' ' ' LYS . 0.0 OUTLIER -150.55 174.35 13.05 Favored 'General case' 0 C--N 1.295 -1.769 0 O-C-N 124.55 1.156 . . . . 0.0 108.377 179.444 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 29.9 mtpt . . . . . 0 C--N 1.29 -2.006 0 CA-C-O 114.398 -2.715 . . . . 0.0 107.104 179.351 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 2.721 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.403 ' HB ' HD23 ' A' ' 22' ' ' LEU . 22.2 t -99.99 140.44 21.52 Favored Pre-proline 0 N--CA 1.495 1.806 0 N-CA-C 107.149 -1.426 . . . . 0.0 107.149 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.418 ' HA ' ' HA ' ' A' ' 21' ' ' ILE . 37.5 Cg_endo -71.27 164.69 34.89 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 123.838 3.025 . . . . 0.0 112.439 166.603 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.508 ' SG ' ' HB3' ' A' ' 22' ' ' LEU . 0.1 OUTLIER -148.98 -171.0 3.77 Favored 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 107.205 -1.406 . . . . 0.0 107.205 179.508 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 5.2 tt -104.94 147.58 27.63 Favored 'General case' 0 N--CA 1.495 1.786 0 N-CA-C 103.056 -2.942 . . . . 0.0 103.056 179.792 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.584 ' HB2' ' HB2' ' A' ' 9' ' ' ASP . 3.9 m -122.73 -171.8 2.35 Favored 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 115.056 1.502 . . . . 0.0 115.056 -179.567 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 7.5 t70 -67.45 -76.26 0.09 Allowed 'General case' 0 N--CA 1.49 1.557 0 CA-C-N 112.873 -1.967 . . . . 0.0 108.177 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 50.3 m -85.25 50.34 1.93 Allowed 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 107.648 -1.241 . . . . 0.0 107.648 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.584 ' HB2' ' HB2' ' A' ' 6' ' ' CYS . 14.9 t0 -102.18 126.0 49.03 Favored 'General case' 0 N--CA 1.489 1.479 0 CA-C-N 114.851 -1.068 . . . . 0.0 112.886 -179.658 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.613 ' H ' ' HD2' ' A' ' 11' ' ' PRO . . . -111.75 -51.28 0.57 Allowed Glycine 0 N--CA 1.503 3.135 0 CA-C-N 112.915 -1.948 . . . . 0.0 112.665 179.655 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.613 ' HD2' ' H ' ' A' ' 10' ' ' GLY . 10.0 Cg_endo -82.54 70.34 6.96 Favored 'Trans proline' 0 N--CA 1.488 1.179 0 C-N-CA 125.289 3.993 . . . . 0.0 103.303 174.537 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 13.1 mtt85 -87.62 156.13 53.31 Favored Pre-proline 0 C--N 1.293 -1.878 0 CA-C-N 110.297 -3.138 . . . . 0.0 111.623 -179.694 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 85.1 Cg_endo -62.47 135.62 54.43 Favored 'Trans proline' 0 N--CA 1.489 1.261 0 C-N-CA 123.744 2.963 . . . . 0.0 109.551 175.985 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 80.5 mtm180 87.45 109.85 0.04 OUTLIER 'General case' 0 N--CA 1.485 1.297 0 O-C-N 126.123 2.139 . . . . 0.0 106.771 -179.632 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 94.42 -16.87 60.15 Favored Glycine 0 N--CA 1.496 2.684 0 C-N-CA 120.083 -1.056 . . . . 0.0 111.382 -179.956 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 18.8 t-20 -149.43 -117.97 0.05 Allowed 'General case' 0 N--CA 1.498 1.934 0 C-N-CA 118.749 -1.18 . . . . 0.0 113.114 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.1 m -126.97 -144.73 0.3 Allowed 'General case' 0 N--CA 1.495 1.813 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 -179.362 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -131.23 137.99 49.15 Favored 'General case' 0 N--CA 1.494 1.729 0 N-CA-C 106.715 -1.587 . . . . 0.0 106.715 179.631 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 33.1 t -89.66 -13.66 36.53 Favored 'General case' 0 N--CA 1.494 1.739 0 CA-C-N 115.196 -0.911 . . . . 0.0 112.102 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -176.14 -161.02 24.54 Favored Glycine 0 N--CA 1.498 2.767 0 C-N-CA 119.171 -1.49 . . . . 0.0 112.031 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.418 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 39.3 mm -132.22 148.58 32.03 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.924 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.52 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 2.9 pp -71.41 144.13 49.89 Favored 'General case' 0 N--CA 1.493 1.709 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 179.595 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 44.1 m95 -126.91 133.61 50.63 Favored 'General case' 0 C--N 1.308 -1.196 0 N-CA-C 118.773 2.879 . . . . 0.0 118.773 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -89.44 51.76 2.19 Favored 'General case' 0 C--N 1.299 -1.629 1 CA-C-N 107.138 -4.574 . . . . 0.0 110.612 -179.83 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.46 ' CE1' ' HB3' ' A' ' 30' ' ' PRO . 2.1 m-85 -124.51 142.54 40.71 Favored Pre-proline 0 C--N 1.304 -1.391 0 CA-C-O 122.468 1.128 . . . . 0.0 110.71 179.739 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 74.7 Cg_endo -68.53 -29.94 29.75 Favored 'Trans proline' 0 C--N 1.304 -1.777 0 C-N-CA 125.075 3.85 . . . . 0.0 108.186 177.936 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 5.1 p -90.36 24.4 2.59 Favored 'General case' 0 C--N 1.301 -1.542 0 CA-C-N 113.726 -1.579 . . . . 0.0 109.269 179.659 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.602 ' HA2' ' CD1' ' A' ' 45' ' ' TRP . . . 81.99 -84.56 1.48 Allowed Glycine 0 N--CA 1.482 1.759 0 N-CA-C 105.005 -3.238 . . . . 0.0 105.005 -179.748 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 9.2 m -100.88 166.96 11.52 Favored Pre-proline 0 C--N 1.307 -1.275 0 CA-C-N 112.649 -1.775 . . . . 0.0 110.851 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.717 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.1 OUTLIER -89.44 167.17 5.21 Favored 'Trans proline' 0 C--N 1.312 -1.355 1 C-N-CA 125.919 4.412 . . . . 0.0 113.763 155.523 . . . . . . . . 4 4 . 1 . 014 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 18.2 t -60.97 141.37 57.37 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-N 113.784 -1.553 . . . . 0.0 109.181 -179.766 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.06 -2.3 68.74 Favored Glycine 0 N--CA 1.495 2.6 0 CA-C-N 111.675 -2.511 . . . . 0.0 111.551 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' TRP . . . . . 0.717 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 58.7 m95 -111.04 166.52 10.99 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 106.143 -1.799 . . . . 0.0 106.143 -179.743 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' HIS . . . . . 0.514 ' ND1' ' O ' ' A' ' 34' ' ' HIS . 43.1 t-80 -140.02 31.9 1.98 Allowed 'General case' 0 N--CA 1.496 1.839 0 C-N-CA 118.497 -1.281 . . . . 0.0 112.878 -179.872 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' ASN . . . . . 0.51 ' HA ' ' SG ' ' A' ' 47' ' ' CYS . 16.7 t-20 59.03 139.66 0.01 OUTLIER 'General case' 0 N--CA 1.511 2.607 0 N-CA-C 114.458 1.281 . . . . 0.0 114.458 -179.934 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.642 ' SG ' ' CB ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -119.43 -41.06 2.73 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.445 -0.784 . . . . 0.0 110.129 -179.725 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 37' ' ' LYS . . . . . 0.464 ' HG2' ' H ' ' A' ' 39' ' ' HIS . 38.0 ttmt -131.14 138.59 49.54 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 104.696 -2.335 . . . . 0.0 104.696 179.423 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.438 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -117.97 35.63 4.65 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 103.004 -2.962 . . . . 0.0 103.004 179.723 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' HIS . . . . . 0.464 ' H ' ' HG2' ' A' ' 37' ' ' LYS . 2.7 m-70 -140.09 55.96 1.62 Allowed 'General case' 0 N--CA 1.494 1.769 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 -179.537 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 85.9 -160.55 33.97 Favored Glycine 0 N--CA 1.502 3.049 0 N-CA-C 108.773 -1.731 . . . . 0.0 108.773 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.414 ' HG2' ' O ' ' A' ' 44' ' ' GLY . 68.6 Cg_endo -64.9 -171.0 3.02 Favored 'Cis proline' 0 N--CA 1.507 2.286 0 CA-C-N 118.305 1.053 . . . . 0.0 114.74 -1.551 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 20.9 m120 -92.96 -8.27 43.59 Favored 'General case' 0 N--CA 1.487 1.377 0 N-CA-C 104.616 -2.364 . . . . 0.0 104.616 -179.921 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 9.9 mm -106.22 32.0 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.961 0 CA-C-O 123.545 1.64 . . . . 0.0 113.782 -178.76 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.414 ' O ' ' HG2' ' A' ' 41' ' ' PRO . . . 124.72 -179.29 16.2 Favored Glycine 0 C--N 1.292 -1.879 1 N-CA-C 102.693 -4.163 . . . . 0.0 102.693 -179.977 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 45' ' ' TRP . . . . . 0.602 ' CD1' ' HA2' ' A' ' 28' ' ' GLY . 1.2 m95 -119.86 140.65 50.5 Favored 'General case' 0 C--N 1.277 -2.55 0 N-CA-C 103.775 -2.676 . . . . 0.0 103.775 179.709 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 46' ' ' CYS . . . . . 0.642 ' CB ' ' SG ' ' A' ' 36' ' ' CYS . 99.4 m -88.74 133.92 34.08 Favored 'General case' 0 N--CA 1.485 1.298 0 CA-C-N 121.756 2.071 . . . . 0.0 107.34 -179.912 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.516 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 87.3 m -133.71 178.32 7.03 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-N 110.892 -2.867 . . . . 0.0 110.443 -179.233 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.468 ' O ' ' HA ' ' A' ' 33' ' ' TRP . 0.0 OUTLIER -149.27 172.96 14.02 Favored 'General case' 0 C--N 1.304 -1.41 0 C-N-CA 117.525 -1.67 . . . . 0.0 111.757 179.776 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 24.8 mmtm . . . . . 0 N--CA 1.496 1.84 0 O-C-N 127.11 2.756 . . . . 0.0 109.413 179.976 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 2.693 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 13.0 t -96.11 141.88 23.77 Favored Pre-proline 0 N--CA 1.496 1.85 0 N-CA-C 107.988 -1.115 . . . . 0.0 107.988 -179.867 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.401 ' CB ' ' HG ' ' A' ' 18' ' ' LEU . 1.7 Cg_endo -79.32 135.19 11.83 Favored 'Trans proline' 0 C--N 1.308 -1.559 0 C-N-CA 124.352 3.368 . . . . 0.0 115.001 169.994 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.44 ' SG ' ' HB3' ' A' ' 22' ' ' LEU . 0.0 OUTLIER -119.46 -178.12 3.53 Favored 'General case' 0 N--CA 1.494 1.772 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.563 179.662 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 6.4 tt -98.5 113.65 25.74 Favored 'General case' 0 N--CA 1.497 1.908 0 N-CA-C 104.962 -2.236 . . . . 0.0 104.962 -179.836 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.44 ' HB2' ' HB2' ' A' ' 9' ' ' ASP . 5.5 m -88.57 -169.01 2.38 Favored 'General case' 0 N--CA 1.487 1.387 0 N-CA-C 119.1 3.0 . . . . 0.0 119.1 -179.179 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 10.8 t0 -66.0 -83.66 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.394 0 CA-C-N 111.876 -2.42 . . . . 0.0 112.562 -179.655 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 1.4 m -55.33 -20.95 13.07 Favored 'General case' 0 N--CA 1.498 1.97 0 CA-C-O 121.53 0.681 . . . . 0.0 110.928 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.44 ' HB2' ' HB2' ' A' ' 6' ' ' CYS . 45.2 t0 -46.69 -62.04 1.56 Allowed 'General case' 0 C--N 1.303 -1.443 0 CA-C-N 112.571 -2.104 . . . . 0.0 114.681 -179.912 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 52.76 -144.62 21.71 Favored Glycine 0 N--CA 1.498 2.793 0 N-CA-C 108.139 -1.984 . . . . 0.0 108.139 -179.514 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER -83.75 19.14 1.4 Allowed 'Trans proline' 0 N--CA 1.494 1.514 0 C-N-CA 123.984 3.123 . . . . 0.0 113.092 170.8 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 93.6 mtt-85 -132.28 80.28 63.95 Favored Pre-proline 0 N--CA 1.502 2.175 0 N-CA-C 114.52 1.304 . . . . 0.0 114.52 -179.692 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -68.06 143.59 60.43 Favored 'Trans proline' 0 N--CA 1.5 1.863 0 C-N-CA 124.667 3.578 . . . . 0.0 110.575 171.027 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 74.6 mtm180 -101.26 105.23 16.3 Favored 'General case' 0 N--CA 1.499 2.005 0 CA-C-O 122.163 0.983 . . . . 0.0 112.255 -179.848 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 129.17 37.0 0.4 Allowed Glycine 0 N--CA 1.499 2.891 0 N-CA-C 109.31 -1.516 . . . . 0.0 109.31 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 35.9 m-80 77.02 -48.42 0.53 Allowed 'General case' 0 N--CA 1.509 2.499 0 C-N-CA 124.393 1.077 . . . . 0.0 108.954 -179.842 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 7.8 t -150.33 -176.28 5.41 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 106.643 -1.614 . . . . 0.0 106.643 179.786 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.401 ' HG ' ' CB ' ' A' ' 3' ' ' PRO . 4.7 mp 63.53 136.54 0.02 OUTLIER 'General case' 0 N--CA 1.507 2.4 0 O-C-N 125.114 1.509 . . . . 0.0 111.087 -179.546 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 22.8 t -129.91 -10.48 4.35 Favored 'General case' 0 N--CA 1.499 2.003 0 C-N-CA 118.436 -1.305 . . . . 0.0 112.725 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.546 ' HA3' ' SG ' ' A' ' 36' ' ' CYS . . . 174.28 131.53 1.42 Allowed Glycine 0 N--CA 1.48 1.605 0 N-CA-C 108.341 -1.903 . . . . 0.0 108.341 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.493 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 49.7 mm -93.12 132.33 37.64 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.12 0 C-N-CA 116.593 -2.043 . . . . 0.0 105.565 179.851 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.581 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.9 pp -63.0 149.0 46.01 Favored 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 107.276 -1.379 . . . . 0.0 107.276 179.444 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.441 ' CE2' ' HG3' ' A' ' 30' ' ' PRO . 28.5 m95 -129.78 136.83 50.07 Favored 'General case' 0 C--N 1.3 -1.567 0 CA-C-O 124.008 1.861 . . . . 0.0 115.439 -179.812 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -89.11 47.67 1.52 Allowed 'General case' 0 C--N 1.294 -1.845 0 CA-C-N 108.914 -3.766 . . . . 0.0 112.499 -179.809 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 1.1 m-30 -117.33 143.46 32.0 Favored Pre-proline 0 C--N 1.306 -1.322 0 CA-C-O 122.537 1.161 . . . . 0.0 110.362 179.604 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 15.7 Cg_endo -77.19 -35.18 1.82 Allowed 'Trans proline' 0 C--N 1.301 -1.96 0 C-N-CA 123.622 2.881 . . . . 0.0 110.578 175.829 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 10.9 p -89.46 38.77 0.92 Allowed 'General case' 0 N--CA 1.49 1.536 0 CA-C-N 114.61 -1.177 . . . . 0.0 112.38 -179.626 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 73.17 -135.16 20.83 Favored Glycine 0 N--CA 1.5 2.955 0 N-CA-C 108.07 -2.012 . . . . 0.0 108.07 -179.864 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.478 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 15.3 m -72.22 156.18 90.84 Favored Pre-proline 0 C--N 1.304 -1.406 0 CA-C-N 118.793 1.297 . . . . 0.0 111.471 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.726 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.4 OUTLIER -79.71 159.13 24.97 Favored 'Trans proline' 0 C--N 1.307 -1.617 0 C-N-CA 123.281 2.654 . . . . 0.0 111.831 166.597 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 42.0 t -50.07 134.27 22.1 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 113.334 -1.757 . . . . 0.0 109.299 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 95.4 -4.57 67.03 Favored Glycine 0 N--CA 1.498 2.773 0 CA-C-N 112.396 -2.184 . . . . 0.0 111.896 179.835 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' TRP . . . . . 0.726 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 56.4 m95 -112.95 157.2 21.78 Favored 'General case' 0 C--N 1.304 -1.391 0 N-CA-C 105.29 -2.115 . . . . 0.0 105.29 -179.855 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' HIS . . . . . 0.419 ' ND1' ' O ' ' A' ' 34' ' ' HIS . 65.1 t-80 -140.45 41.49 1.89 Allowed 'General case' 0 C--N 1.299 -1.593 0 C-N-CA 118.291 -1.363 . . . . 0.0 112.084 -179.914 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 35' ' ' ASN . . . . . 0.478 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 14.4 t-20 63.17 138.37 0.02 OUTLIER 'General case' 0 N--CA 1.505 2.316 0 N-CA-C 115.74 1.755 . . . . 0.0 115.74 179.412 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.608 ' SG ' ' CB ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -114.9 -40.74 3.46 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 105.843 -1.91 . . . . 0.0 105.843 179.775 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 21.3 ptmt -138.41 149.32 45.4 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 106.864 -1.532 . . . . 0.0 106.864 179.64 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.452 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -120.0 35.43 4.86 Favored 'General case' 0 C--N 1.293 -1.85 0 N-CA-C 102.506 -3.146 . . . . 0.0 102.506 179.881 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' HIS . . . . . 0.452 ' ND1' ' C ' ' A' ' 38' ' ' ALA . 3.7 m-70 -127.57 54.9 1.65 Allowed 'General case' 0 N--CA 1.498 1.951 0 N-CA-C 108.404 -0.961 . . . . 0.0 108.404 -179.625 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 74.0 -148.86 40.24 Favored Glycine 0 N--CA 1.496 2.65 0 N-CA-C 105.604 -2.998 . . . . 0.0 105.604 -179.658 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.439 ' HG2' ' O ' ' A' ' 44' ' ' GLY . 51.2 Cg_endo -65.64 -172.63 4.43 Favored 'Cis proline' 0 N--CA 1.501 1.915 0 CA-C-N 119.088 1.444 . . . . 0.0 111.713 -1.4 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 14.3 m120 -93.58 0.52 56.63 Favored 'General case' 0 C--N 1.307 -1.273 0 N-CA-C 104.144 -2.539 . . . . 0.0 104.144 -179.679 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 8.4 mt -116.64 35.02 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 N-CA-C 116.043 1.868 . . . . 0.0 116.043 -178.846 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.439 ' O ' ' HG2' ' A' ' 41' ' ' PRO . . . 119.81 139.76 5.98 Favored Glycine 0 N--CA 1.499 2.846 0 CA-C-N 114.004 -1.453 . . . . 0.0 110.642 179.721 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' TRP . . . . . 0.416 ' O ' ' N ' ' A' ' 23' ' ' TRP . 6.4 m95 -78.22 129.85 35.59 Favored 'General case' 0 N--CA 1.503 2.194 0 CA-C-O 117.783 -1.103 . . . . 0.0 111.096 -179.267 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 46' ' ' CYS . . . . . 0.608 ' CB ' ' SG ' ' A' ' 36' ' ' CYS . 66.2 m -87.71 122.67 31.66 Favored 'General case' 0 C--N 1.308 -1.204 1 N-CA-C 99.791 -4.152 . . . . 0.0 99.791 179.436 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.56 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 88.8 m -129.18 -178.84 4.81 Favored 'General case' 0 CA--C 1.476 -1.894 0 CA-C-N 109.895 -3.321 . . . . 0.0 111.205 -179.398 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.425 ' HD2' ' H ' ' A' ' 49' ' ' LYS . 24.2 tptp -150.52 152.01 33.53 Favored 'General case' 0 C--N 1.294 -1.846 0 C-N-CA 117.675 -1.61 . . . . 0.0 109.987 -179.84 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 49' ' ' LYS . . . . . 0.425 ' H ' ' HD2' ' A' ' 48' ' ' LYS . 51.2 mtpt . . . . . 0 N--CA 1.5 2.054 0 O-C-N 126.197 2.186 . . . . 0.0 111.899 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.495 2.585 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 33.0 t -97.25 135.59 21.8 Favored Pre-proline 0 N--CA 1.497 1.885 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.5 ' HB2' ' HA ' ' A' ' 18' ' ' LEU . 3.0 Cg_endo -77.27 127.77 9.32 Favored 'Trans proline' 0 N--CA 1.493 1.475 0 C-N-CA 124.523 3.482 . . . . 0.0 116.458 170.048 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.526 ' SG ' ' HB3' ' A' ' 22' ' ' LEU . 0.5 OUTLIER -121.08 179.46 4.38 Favored 'General case' 0 C--N 1.301 -1.508 0 CA-C-N 114.624 -1.171 . . . . 0.0 111.13 179.786 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 6.7 tp -91.68 145.98 24.15 Favored 'General case' 0 N--CA 1.491 1.594 0 N-CA-C 104.625 -2.361 . . . . 0.0 104.625 179.874 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.613 ' HB2' ' HB2' ' A' ' 9' ' ' ASP . 6.9 m -119.42 -170.4 1.93 Allowed 'General case' 0 N--CA 1.491 1.583 0 N-CA-C 113.911 1.078 . . . . 0.0 113.911 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -86.74 -50.46 6.74 Favored 'General case' 0 N--CA 1.497 1.887 0 CA-C-N 113.614 -1.63 . . . . 0.0 109.353 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -67.21 -32.23 73.14 Favored 'General case' 0 N--CA 1.492 1.664 0 CA-C-N 111.881 -2.418 . . . . 0.0 107.157 179.668 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.613 ' HB2' ' HB2' ' A' ' 6' ' ' CYS . 63.1 t0 -49.43 -69.71 0.11 Allowed 'General case' 0 N--CA 1.497 1.878 0 CA-C-N 112.052 -2.34 . . . . 0.0 109.326 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 63.53 165.7 0.75 Allowed Glycine 0 N--CA 1.488 2.137 0 CA-C-N 113.261 -1.79 . . . . 0.0 111.572 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_endo -79.23 39.04 0.77 Allowed 'Trans proline' 0 C--N 1.308 -1.603 0 C-N-CA 123.882 3.055 . . . . 0.0 110.149 175.559 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.0 mpt_? -89.51 158.97 45.0 Favored Pre-proline 0 N--CA 1.493 1.717 0 CA-C-N 115.462 -0.79 . . . . 0.0 112.578 -179.607 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -72.67 58.93 3.3 Favored 'Trans proline' 0 N--CA 1.495 1.562 0 C-N-CA 124.424 3.416 . . . . 0.0 112.132 174.537 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -173.77 116.9 0.25 Allowed 'General case' 0 N--CA 1.493 1.721 0 CA-C-N 113.683 -1.599 . . . . 0.0 110.424 179.873 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 54.7 32.19 54.09 Favored Glycine 0 N--CA 1.504 3.202 0 N-CA-C 110.187 -1.165 . . . . 0.0 110.187 -179.909 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 -60.59 -44.53 96.13 Favored 'General case' 0 N--CA 1.503 2.188 0 CA-C-O 121.982 0.896 . . . . 0.0 109.819 -179.793 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.0 t -104.19 155.47 18.69 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 104.487 -2.412 . . . . 0.0 104.487 179.807 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.5 ' HA ' ' HB2' ' A' ' 3' ' ' PRO . 2.3 tt 38.51 66.6 0.49 Allowed 'General case' 0 N--CA 1.499 2.012 0 O-C-N 125.11 1.506 . . . . 0.0 108.911 -179.52 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -88.66 52.98 2.57 Favored 'General case' 0 N--CA 1.498 1.937 0 CA-C-N 113.781 -1.554 . . . . 0.0 109.368 -179.339 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.43 -165.61 18.19 Favored Glycine 0 N--CA 1.502 3.047 0 CA-C-N 114.382 -1.281 . . . . 0.0 111.21 179.804 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.437 HG22 ' O ' ' A' ' 22' ' ' LEU . 28.8 mm -133.88 147.52 30.59 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.265 0 N-CA-C 112.744 0.646 . . . . 0.0 112.744 -179.94 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.588 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 2.8 pp -69.85 152.77 44.16 Favored 'General case' 0 N--CA 1.492 1.644 0 CA-C-N 114.919 -1.037 . . . . 0.0 108.819 179.499 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.678 ' HB2' ' SG ' ' A' ' 29' ' ' CYS . 28.3 m95 -131.93 135.32 46.52 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-O 125.045 2.355 . . . . 0.0 115.986 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.5 m-85 -88.84 54.34 2.98 Favored 'General case' 0 C--N 1.292 -1.892 1 CA-C-N 107.641 -4.345 . . . . 0.0 110.131 -179.669 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.551 ' CE1' ' HB3' ' A' ' 30' ' ' PRO . 2.2 m-85 -123.82 115.88 27.84 Favored Pre-proline 0 N--CA 1.491 1.618 0 CA-C-N 115.497 -0.774 . . . . 0.0 112.656 179.654 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -64.03 -11.85 29.35 Favored 'Trans proline' 0 C--N 1.308 -1.557 0 C-N-CA 123.389 2.726 . . . . 0.0 111.948 -175.412 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 6.6 p -108.93 3.93 22.8 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-N 115.37 -0.832 . . . . 0.0 111.025 179.753 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.4 ' O ' ' CD1' ' A' ' 45' ' ' TRP . . . 126.45 -113.21 1.75 Allowed Glycine 0 N--CA 1.502 3.058 0 N-CA-C 108.727 -1.749 . . . . 0.0 108.727 -179.913 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.678 ' SG ' ' HB2' ' A' ' 23' ' ' TRP . 18.4 m -132.36 156.54 79.98 Favored Pre-proline 0 C--N 1.305 -1.357 0 CA-C-N 117.701 0.75 . . . . 0.0 110.687 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.737 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 9.0 Cg_endo -78.68 162.04 27.39 Favored 'Trans proline' 0 C--N 1.306 -1.68 0 C-N-CA 123.335 2.69 . . . . 0.0 113.323 -167.196 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 22.9 t -51.32 116.43 2.05 Favored 'General case' 0 C--N 1.302 -1.487 0 CA-C-N 113.292 -1.776 . . . . 0.0 110.473 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 115.5 -7.61 20.37 Favored Glycine 0 N--CA 1.499 2.87 0 CA-C-N 113.744 -1.571 . . . . 0.0 111.529 179.761 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' TRP . . . . . 0.737 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 49.9 m95 -109.22 158.94 17.35 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 104.77 -2.307 . . . . 0.0 104.77 -179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 78.3 t60 -138.34 33.04 2.31 Favored 'General case' 0 C--N 1.298 -1.666 0 C-N-CA 118.05 -1.46 . . . . 0.0 114.074 -179.598 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' ASN . . . . . 0.774 ' HA ' ' SG ' ' A' ' 47' ' ' CYS . 5.1 m-20 57.34 137.35 0.0 OUTLIER 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 116.648 2.092 . . . . 0.0 116.648 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.587 ' SG ' ' HB3' ' A' ' 46' ' ' CYS . 0.6 OUTLIER -112.06 -40.13 4.3 Favored 'General case' 0 N--CA 1.489 1.489 0 CA-C-N 115.015 -0.993 . . . . 0.0 108.931 -179.644 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 37' ' ' LYS . . . . . 0.548 ' HD2' ' HA ' ' A' ' 6' ' ' CYS . 51.9 tttt -132.87 143.38 49.48 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 107.356 -1.349 . . . . 0.0 107.356 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.441 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -119.47 30.08 7.28 Favored 'General case' 0 N--CA 1.493 1.721 0 N-CA-C 104.772 -2.307 . . . . 0.0 104.772 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' HIS . . . . . 0.482 ' H ' ' HG2' ' A' ' 37' ' ' LYS . 4.5 m-70 -134.75 62.18 1.65 Allowed 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 107.023 -1.473 . . . . 0.0 107.023 -179.564 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 75.75 -155.94 47.22 Favored Glycine 0 N--CA 1.498 2.798 0 N-CA-C 106.213 -2.755 . . . . 0.0 106.213 -179.728 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_endo -74.09 -169.38 7.0 Favored 'Cis proline' 0 N--CA 1.496 1.669 0 CA-C-N 118.922 1.361 . . . . 0.0 113.923 -0.682 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 10.0 p30 -92.33 -14.66 28.43 Favored 'General case' 0 CA--C 1.486 -1.506 0 N-CA-C 105.992 -1.855 . . . . 0.0 105.992 -179.606 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 31.6 pt -90.28 24.17 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 O-C-N 125.277 1.61 . . . . 0.0 113.978 -179.431 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 114.37 137.79 6.6 Favored Glycine 0 N--CA 1.493 2.472 0 CA-C-N 113.246 -1.797 . . . . 0.0 109.696 -179.945 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' TRP . . . . . 0.426 ' O ' ' N ' ' A' ' 23' ' ' TRP . 7.9 m95 -61.53 136.4 58.01 Favored 'General case' 0 N--CA 1.519 3.006 0 CA-C-O 117.317 -1.325 . . . . 0.0 108.421 -179.643 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' CYS . . . . . 0.588 ' HA ' ' HA ' ' A' ' 22' ' ' LEU . 93.0 m -89.9 127.08 35.94 Favored 'General case' 0 N--CA 1.482 1.141 0 CA-C-N 122.26 2.3 . . . . 0.0 105.127 -179.921 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.774 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 93.7 m -136.45 -171.82 3.0 Favored 'General case' 0 C--N 1.3 -1.563 0 CA-C-N 111.327 -2.67 . . . . 0.0 111.005 -179.409 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.538 ' O ' ' HA ' ' A' ' 33' ' ' TRP . 0.0 OUTLIER -151.31 172.29 16.12 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 179.574 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 47.4 mtpt . . . . . 0 C--N 1.291 -1.969 0 O-C-N 126.704 2.503 . . . . 0.0 110.347 179.828 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 2.656 0 N-CA-C 109.314 -1.514 . . . . 0.0 109.314 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 29.6 t -89.57 137.34 28.84 Favored Pre-proline 0 N--CA 1.496 1.852 0 C-N-CA 118.779 -1.168 . . . . 0.0 109.407 -179.78 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -67.27 135.57 37.36 Favored 'Trans proline' 0 N--CA 1.493 1.455 0 C-N-CA 122.333 2.022 . . . . 0.0 110.24 170.051 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -134.06 175.8 9.15 Favored 'General case' 0 N--CA 1.497 1.918 0 CA-C-O 121.563 0.697 . . . . 0.0 112.242 -179.724 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -101.55 141.89 33.74 Favored 'General case' 0 N--CA 1.494 1.732 0 N-CA-C 104.067 -2.568 . . . . 0.0 104.067 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.437 ' HB3' ' C ' ' A' ' 36' ' ' CYS . 1.8 m -113.14 -138.8 0.38 Allowed 'General case' 0 N--CA 1.497 1.892 0 N-CA-C 120.395 3.48 . . . . 0.0 120.395 -178.95 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -60.39 -15.79 29.47 Favored 'General case' 0 N--CA 1.507 2.391 0 O-C-N 120.969 -1.082 . . . . 0.0 110.388 -179.828 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 31.7 t -92.81 9.28 35.9 Favored 'General case' 0 N--CA 1.503 2.194 0 N-CA-C 107.383 -1.34 . . . . 0.0 107.383 179.347 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.402 ' CB ' ' O ' ' A' ' 6' ' ' CYS . 19.1 t70 -81.02 79.2 7.74 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 106.802 -1.555 . . . . 0.0 106.802 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.4 ' C ' ' H ' ' A' ' 12' ' ' ARG . . . -73.27 -157.25 4.15 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 106.755 -2.538 . . . . 0.0 106.755 179.62 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 17.6 Cg_endo -75.36 41.35 0.77 Allowed 'Trans proline' 0 N--CA 1.497 1.697 0 C-N-CA 124.502 3.468 . . . . 0.0 110.448 179.332 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.4 ' H ' ' C ' ' A' ' 10' ' ' GLY . 7.9 ttt85 -122.09 135.53 25.48 Favored Pre-proline 0 C--N 1.304 -1.375 0 N-CA-C 106.953 -1.499 . . . . 0.0 106.953 -179.854 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -62.25 154.94 59.78 Favored 'Trans proline' 0 C--N 1.311 -1.418 0 C-N-CA 123.323 2.682 . . . . 0.0 115.113 -177.104 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 35.1 ptt180 -70.26 149.33 47.55 Favored 'General case' 0 N--CA 1.489 1.51 0 CA-C-N 111.648 -2.524 . . . . 0.0 108.595 179.849 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 102.88 -30.62 10.04 Favored Glycine 0 N--CA 1.498 2.806 0 N-CA-C 109.619 -1.392 . . . . 0.0 109.619 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 15.4 m-20 -45.26 -41.91 9.04 Favored 'General case' 0 N--CA 1.502 2.152 0 CA-C-O 121.611 0.72 . . . . 0.0 112.378 179.835 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 6.9 t -150.29 153.89 36.94 Favored 'General case' 0 N--CA 1.49 1.563 0 N-CA-C 107.268 -1.382 . . . . 0.0 107.268 179.814 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 34.7 mt -106.98 91.08 3.51 Favored 'General case' 0 N--CA 1.496 1.867 0 N-CA-C 105.075 -2.195 . . . . 0.0 105.075 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 7.1 m -90.16 21.95 3.52 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 115.644 1.72 . . . . 0.0 115.644 -179.571 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 148.69 -163.69 29.05 Favored Glycine 0 N--CA 1.497 2.743 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.517 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 35.5 mm -135.98 146.42 29.43 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.088 0 CA-C-O 122.487 1.137 . . . . 0.0 109.878 179.852 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.546 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 0.9 OUTLIER -69.69 134.79 49.06 Favored 'General case' 0 C--N 1.297 -1.693 0 CA-C-N 114.654 -1.157 . . . . 0.0 108.625 179.826 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.421 ' CE2' ' HG3' ' A' ' 30' ' ' PRO . 44.5 m95 -124.04 134.18 53.48 Favored 'General case' 0 N--CA 1.484 1.242 0 N-CA-C 118.96 2.948 . . . . 0.0 118.96 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.2 m-30 -88.93 39.58 0.94 Allowed 'General case' 0 C--N 1.296 -1.718 1 CA-C-N 107.366 -4.47 . . . . 0.0 113.064 -179.584 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.42 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 1.2 m-30 -113.07 125.13 30.25 Favored Pre-proline 0 C--N 1.304 -1.402 0 CA-C-O 122.697 1.237 . . . . 0.0 112.271 -179.935 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -66.21 -25.26 50.36 Favored 'Trans proline' 0 C--N 1.302 -1.872 0 C-N-CA 122.507 2.138 . . . . 0.0 108.341 -177.731 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 5.8 p -87.01 5.03 39.44 Favored 'General case' 0 N--CA 1.49 1.536 0 CA-C-N 114.375 -1.284 . . . . 0.0 112.468 179.926 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 110.65 -118.57 5.0 Favored Glycine 0 N--CA 1.498 2.806 0 N-CA-C 106.238 -2.745 . . . . 0.0 106.238 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.51 ' HB3' ' HB2' ' A' ' 33' ' ' TRP . 37.4 m -96.65 153.79 38.65 Favored Pre-proline 0 C--N 1.303 -1.446 0 N-CA-C 106.726 -1.583 . . . . 0.0 106.726 179.735 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.748 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.8 OUTLIER -76.34 169.47 21.89 Favored 'Trans proline' 0 C--N 1.305 -1.726 0 C-N-CA 123.077 2.518 . . . . 0.0 113.829 174.588 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 5.7 m -46.17 103.83 0.04 OUTLIER 'General case' 0 C--N 1.298 -1.633 0 CA-C-N 112.01 -2.359 . . . . 0.0 113.99 -179.854 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 109.11 2.68 31.62 Favored Glycine 0 N--CA 1.501 2.996 0 C-N-CA 120.811 -0.709 . . . . 0.0 114.293 179.481 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' TRP . . . . . 0.748 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 44.7 m95 -110.82 164.81 12.39 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 106.999 -1.482 . . . . 0.0 106.999 -179.954 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 57.7 t-80 -144.76 37.23 1.18 Allowed 'General case' 0 N--CA 1.499 1.992 0 C-N-CA 117.757 -1.577 . . . . 0.0 113.072 -179.722 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' ASN . . . . . 0.504 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 24.0 t-20 58.43 146.48 0.01 OUTLIER 'General case' 0 N--CA 1.501 2.098 0 CA-C-N 113.248 -1.797 . . . . 0.0 114.673 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.64 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -121.09 -46.67 2.31 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 106.013 -1.847 . . . . 0.0 106.013 179.974 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 13.1 ttmt -107.94 102.08 11.29 Favored 'General case' 0 C--N 1.301 -1.502 0 CA-C-N 113.315 -1.766 . . . . 0.0 108.618 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -83.36 12.28 5.66 Favored 'General case' 0 N--CA 1.496 1.869 0 CA-C-N 113.31 -1.768 . . . . 0.0 107.713 179.511 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 7.4 m-70 -127.22 37.71 4.21 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-N 114.878 -1.055 . . . . 0.0 109.208 -179.667 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 96.23 -149.56 19.35 Favored Glycine 0 N--CA 1.498 2.768 0 CA-C-N 114.538 -1.21 . . . . 0.0 111.267 179.586 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.45 ' HB2' HG12 ' A' ' 43' ' ' ILE . 3.5 Cg_endo -75.5 -173.84 13.2 Favored 'Cis proline' 0 N--CA 1.5 1.861 0 N-CA-C 109.386 -1.044 . . . . 0.0 109.386 1.496 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' ASN . . . . . 0.476 ' C ' ' H ' ' A' ' 44' ' ' GLY . 56.5 t30 -92.27 -11.97 33.81 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 105.463 -2.051 . . . . 0.0 105.463 -179.783 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.45 HG12 ' HB2' ' A' ' 41' ' ' PRO . 30.5 pt -85.66 28.92 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 CA-C-O 123.302 1.525 . . . . 0.0 112.741 -179.192 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.476 ' H ' ' C ' ' A' ' 42' ' ' ASN . . . 116.98 142.57 7.34 Favored Glycine 0 C--N 1.295 -1.71 0 CA-C-N 110.528 -3.033 . . . . 0.0 106.153 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 45' ' ' TRP . . . . . 0.42 ' NE1' ' O ' ' A' ' 25' ' ' TYR . 6.9 m95 -77.81 133.77 38.14 Favored 'General case' 0 C--N 1.293 -1.849 0 N-CA-C 104.674 -2.343 . . . . 0.0 104.674 -179.534 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 46' ' ' CYS . . . . . 0.64 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 46.0 t -89.22 129.14 35.84 Favored 'General case' 0 N--CA 1.485 1.318 1 N-CA-C 99.319 -4.326 . . . . 0.0 99.319 179.773 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.524 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 77.3 m -127.88 -170.53 2.25 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-N 113.096 -1.866 . . . . 0.0 110.254 -179.363 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.08 172.3 15.98 Favored 'General case' 0 C--N 1.298 -1.674 0 N-CA-C 107.599 -1.26 . . . . 0.0 107.599 179.311 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 65.3 mttt . . . . . 0 N--CA 1.498 1.961 0 O-C-N 126.267 2.229 . . . . 0.0 108.189 179.267 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.498 2.831 0 N-CA-C 109.993 -1.243 . . . . 0.0 109.993 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 46.8 t -112.98 134.94 21.69 Favored Pre-proline 0 N--CA 1.499 2.01 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.401 ' HB2' ' HB3' ' A' ' 18' ' ' LEU . 26.6 Cg_endo -73.11 116.03 4.56 Favored 'Trans proline' 0 C--N 1.308 -1.566 0 C-N-CA 122.877 2.384 . . . . 0.0 114.473 170.664 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.533 ' SG ' ' HB2' ' A' ' 22' ' ' LEU . 0.8 OUTLIER -122.15 163.94 18.65 Favored 'General case' 0 N--CA 1.494 1.774 0 CA-C-N 113.037 -1.892 . . . . 0.0 108.839 -179.799 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.432 HD12 ' HA ' ' A' ' 5' ' ' LEU . 12.2 tp -89.61 174.82 7.54 Favored 'General case' 0 N--CA 1.497 1.886 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 -179.895 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.455 ' HB3' ' C ' ' A' ' 36' ' ' CYS . 1.8 m -135.26 -143.25 0.19 Allowed 'General case' 0 N--CA 1.501 2.097 1 N-CA-C 122.131 4.123 . . . . 0.0 122.131 -178.738 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -56.55 -31.63 64.36 Favored 'General case' 0 N--CA 1.497 1.89 0 C-N-CA 118.405 -1.318 . . . . 0.0 108.813 -179.523 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 24.9 m -80.42 13.93 2.23 Favored 'General case' 0 N--CA 1.497 1.888 0 C-N-CA 119.469 -0.892 . . . . 0.0 110.246 179.689 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.416 ' HB3' ' O ' ' A' ' 6' ' ' CYS . 5.6 t0 -75.06 63.85 1.3 Allowed 'General case' 0 N--CA 1.502 2.166 0 CA-C-O 121.928 0.87 . . . . 0.0 109.13 179.845 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -148.43 -169.82 15.7 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 107.401 -2.28 . . . . 0.0 107.401 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_endo -76.24 34.23 0.43 Allowed 'Trans proline' 0 N--CA 1.499 1.834 1 C-N-CA 125.434 4.089 . . . . 0.0 114.789 -162.779 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 29.7 mtp180 -119.3 122.94 29.07 Favored Pre-proline 0 N--CA 1.498 1.942 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.068 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.427 ' HA ' HD21 ' A' ' 16' ' ' ASN . 17.4 Cg_endo -72.08 60.22 3.07 Favored 'Trans proline' 0 N--CA 1.501 1.919 0 C-N-CA 123.742 2.961 . . . . 0.0 114.472 -174.859 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' ARG . . . . . 0.4 ' C ' ' H ' ' A' ' 16' ' ' ASN . 86.5 mtt-85 -147.13 136.87 23.03 Favored 'General case' 0 N--CA 1.489 1.498 0 CA-C-N 113.882 -1.508 . . . . 0.0 107.951 179.991 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.405 ' O ' ' N ' ' A' ' 17' ' ' THR . . . 76.35 -39.38 1.45 Allowed Glycine 0 N--CA 1.499 2.842 0 C-N-CA 120.789 -0.72 . . . . 0.0 111.945 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' ASN . . . . . 0.427 HD21 ' HA ' ' A' ' 13' ' ' PRO . 9.6 p30 -22.53 -41.2 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.333 0 N-CA-C 117.696 2.48 . . . . 0.0 117.696 -179.807 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.405 ' N ' ' O ' ' A' ' 15' ' ' GLY . 0.7 OUTLIER -96.14 99.97 11.66 Favored 'General case' 0 C--N 1.297 -1.687 0 N-CA-C 114.286 1.217 . . . . 0.0 114.286 -179.463 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.401 ' HB3' ' HB2' ' A' ' 3' ' ' PRO . 25.8 mt 31.77 55.26 0.3 Allowed 'General case' 0 N--CA 1.502 2.146 0 N-CA-C 116.014 1.857 . . . . 0.0 116.014 179.399 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 80.5 p -89.06 57.63 4.19 Favored 'General case' 0 C--N 1.3 -1.544 0 C-N-CA 119.896 -0.722 . . . . 0.0 111.697 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 153.28 161.58 10.43 Favored Glycine 0 N--CA 1.5 2.926 0 C-N-CA 119.512 -1.328 . . . . 0.0 112.775 179.46 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.458 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 49.1 mm -124.07 137.83 55.75 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.176 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 179.57 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.533 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 34.7 tp -63.99 144.58 56.98 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 179.659 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 42.4 m95 -131.52 134.08 45.75 Favored 'General case' 0 C--N 1.308 -1.236 0 N-CA-C 119.428 3.122 . . . . 0.0 119.428 -179.568 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -88.87 54.45 3.02 Favored 'General case' 0 C--N 1.297 -1.675 1 CA-C-N 108.145 -4.116 . . . . 0.0 108.727 -179.962 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.48 ' CE1' ' HB3' ' A' ' 30' ' ' PRO . 2.4 m-85 -128.73 120.02 20.42 Favored Pre-proline 0 N--CA 1.486 1.368 0 CA-C-N 115.088 -0.96 . . . . 0.0 113.556 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.402 ' HD2' ' HA ' ' A' ' 25' ' ' TYR . 57.3 Cg_endo -67.25 -13.48 39.66 Favored 'Trans proline' 0 C--N 1.309 -1.526 0 C-N-CA 123.793 2.996 . . . . 0.0 110.918 -178.121 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 12.8 p -93.51 -9.23 39.03 Favored 'General case' 0 N--CA 1.491 1.609 0 CA-C-N 114.565 -1.198 . . . . 0.0 110.43 179.81 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.43 ' HA2' ' CD2' ' A' ' 45' ' ' TRP . . . 116.3 -106.96 1.57 Allowed Glycine 0 N--CA 1.482 1.724 1 N-CA-C 102.512 -4.235 . . . . 0.0 102.512 -179.702 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.602 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 16.7 m -99.36 151.66 37.5 Favored Pre-proline 0 C--N 1.301 -1.52 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.678 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.4 OUTLIER -79.46 164.57 23.73 Favored 'Trans proline' 0 C--N 1.306 -1.694 0 C-N-CA 123.005 2.47 . . . . 0.0 114.359 169.831 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 3.1 m -43.93 105.32 0.05 Allowed 'General case' 0 C--N 1.3 -1.581 0 CA-C-N 112.197 -2.274 . . . . 0.0 112.636 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 114.53 -4.12 23.22 Favored Glycine 0 N--CA 1.505 3.26 0 CA-C-N 115.665 -0.698 . . . . 0.0 113.495 179.581 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' TRP . . . . . 0.678 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 49.2 m95 -111.22 166.5 11.04 Favored 'General case' 0 N--CA 1.488 1.43 0 N-CA-C 107.061 -1.459 . . . . 0.0 107.061 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 55.0 t-80 -148.86 40.35 0.89 Allowed 'General case' 0 N--CA 1.505 2.312 0 C-N-CA 117.904 -1.518 . . . . 0.0 114.147 -179.856 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' ASN . . . . . 0.602 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 11.4 t-20 52.36 146.66 0.0 OUTLIER 'General case' 0 N--CA 1.499 1.986 0 CA-C-N 113.001 -1.909 . . . . 0.0 116.073 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.505 ' SG ' ' O ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -119.08 -41.14 2.77 Favored 'General case' 0 C--N 1.306 -1.29 0 CA-C-N 114.582 -1.19 . . . . 0.0 111.336 -179.805 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 37' ' ' LYS . . . . . 0.514 ' C ' ' H ' ' A' ' 39' ' ' HIS . 44.3 tttm -106.04 106.36 16.83 Favored 'General case' 0 N--CA 1.502 2.136 0 C-N-CA 119.014 -1.074 . . . . 0.0 108.384 179.655 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -65.8 16.66 0.02 OUTLIER 'General case' 0 N--CA 1.505 2.299 0 N-CA-C 113.049 0.759 . . . . 0.0 113.049 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' HIS . . . . . 0.514 ' H ' ' C ' ' A' ' 37' ' ' LYS . 5.3 m-70 -128.38 -4.84 5.42 Favored 'General case' 0 N--CA 1.494 1.745 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.03 179.947 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 133.97 -119.86 2.36 Favored Glycine 0 N--CA 1.509 3.506 0 C-N-CA 120.685 -0.769 . . . . 0.0 113.086 179.872 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -68.1 -170.82 5.04 Favored 'Cis proline' 0 N--CA 1.504 2.138 0 CA-C-N 118.609 1.205 . . . . 0.0 111.824 -1.669 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 59.4 t30 -93.72 -5.5 48.3 Favored 'General case' 0 CA--C 1.492 -1.253 0 N-CA-C 106.083 -1.821 . . . . 0.0 106.083 -179.709 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 28.4 mt -94.81 32.14 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.104 0 CA-C-O 123.897 1.808 . . . . 0.0 110.737 -179.005 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 115.96 153.99 10.27 Favored Glycine 0 C--N 1.295 -1.737 1 N-CA-C 101.137 -4.785 . . . . 0.0 101.137 -179.692 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' TRP . . . . . 0.43 ' CD2' ' HA2' ' A' ' 28' ' ' GLY . 56.4 m95 -86.56 135.37 33.46 Favored 'General case' 0 N--CA 1.505 2.298 0 CA-C-O 116.475 -1.726 . . . . 0.0 108.057 -179.769 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 46' ' ' CYS . . . . . 0.509 ' HA ' ' HA ' ' A' ' 22' ' ' LEU . 59.3 m -92.65 121.18 33.81 Favored 'General case' 0 C--N 1.308 -1.212 1 N-CA-C 96.884 -5.228 . . . . 0.0 96.884 179.763 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.501 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 96.1 m -127.57 -174.57 3.22 Favored 'General case' 0 C--N 1.297 -1.712 0 CA-C-N 112.419 -2.173 . . . . 0.0 108.366 -179.351 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.36 173.14 14.86 Favored 'General case' 0 C--N 1.297 -1.705 0 N-CA-C 106.923 -1.51 . . . . 0.0 106.923 179.32 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 86.8 mttt . . . . . 0 C--N 1.289 -2.049 0 O-C-N 126.255 2.222 . . . . 0.0 106.593 179.337 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.495 2.576 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 19.4 t -89.92 141.11 27.88 Favored Pre-proline 0 N--CA 1.492 1.666 0 N-CA-C 106.939 -1.504 . . . . 0.0 106.939 -179.931 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.47 ' HA ' ' O ' ' A' ' 20' ' ' GLY . 11.0 Cg_endo -77.09 132.95 13.12 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 123.246 2.63 . . . . 0.0 113.147 163.673 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -121.26 177.39 5.18 Favored 'General case' 0 N--CA 1.494 1.734 0 C-N-CA 119.966 -0.694 . . . . 0.0 112.038 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.448 HD23 ' N ' ' A' ' 6' ' ' CYS . 9.4 tt -94.12 150.86 19.94 Favored 'General case' 0 N--CA 1.493 1.687 0 N-CA-C 105.036 -2.209 . . . . 0.0 105.036 179.768 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.5 ' HB2' ' HB2' ' A' ' 9' ' ' ASP . 13.0 m -143.07 -174.85 4.3 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 124.683 1.239 . . . . 0.0 111.739 -179.337 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -78.24 -45.01 24.02 Favored 'General case' 0 N--CA 1.493 1.707 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 179.881 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 63.6 m -109.39 33.55 4.26 Favored 'General case' 0 N--CA 1.494 1.733 0 N-CA-C 106.72 -1.585 . . . . 0.0 106.72 179.705 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.5 ' HB2' ' HB2' ' A' ' 6' ' ' CYS . 0.8 OUTLIER -69.98 78.89 0.48 Allowed 'General case' 0 N--CA 1.501 2.107 0 CA-C-O 121.747 0.784 . . . . 0.0 112.109 -179.94 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 58.18 63.38 5.3 Favored Glycine 0 N--CA 1.504 3.205 0 CA-C-N 114.246 -1.343 . . . . 0.0 112.929 179.653 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 14.5 Cg_endo -71.19 25.86 0.22 Allowed 'Trans proline' 0 N--CA 1.503 2.037 1 C-N-CA 125.493 4.129 . . . . 0.0 115.224 -166.581 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.423 ' HD2' ' NH1' ' A' ' 14' ' ' ARG . 13.8 mtt-85 -140.76 162.07 50.79 Favored Pre-proline 0 N--CA 1.49 1.554 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 179.819 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_endo -67.86 64.01 0.93 Allowed 'Trans proline' 0 N--CA 1.497 1.729 0 C-N-CA 124.001 3.134 . . . . 0.0 113.765 -179.523 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' ARG . . . . . 0.48 ' C ' ' H ' ' A' ' 16' ' ' ASN . 47.7 mtm180 -137.47 136.19 37.51 Favored 'General case' 0 N--CA 1.493 1.702 0 N-CA-C 103.3 -2.852 . . . . 0.0 103.3 179.736 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.422 ' O ' ' HB2' ' A' ' 16' ' ' ASN . . . 77.58 -34.14 1.6 Allowed Glycine 0 N--CA 1.508 3.459 0 C-N-CA 120.155 -1.021 . . . . 0.0 110.874 -179.817 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' ASN . . . . . 0.48 ' H ' ' C ' ' A' ' 14' ' ' ARG . 2.8 m120 81.46 -56.6 0.27 Allowed 'General case' 0 N--CA 1.505 2.298 0 C-N-CA 125.929 1.692 . . . . 0.0 106.626 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 86.6 m -151.0 155.92 40.07 Favored 'General case' 0 N--CA 1.497 1.918 0 N-CA-C 105.593 -2.002 . . . . 0.0 105.593 179.593 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 47.1 mt 71.68 111.79 0.06 Allowed 'General case' 0 N--CA 1.511 2.613 0 O-C-N 124.596 1.185 . . . . 0.0 110.593 179.874 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 5.5 t -144.64 32.27 1.17 Allowed 'General case' 0 N--CA 1.5 2.074 0 C-N-CA 120.019 -0.672 . . . . 0.0 110.079 -179.902 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.47 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -173.83 -178.01 43.46 Favored Glycine 0 N--CA 1.5 2.904 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.433 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 28.8 mm -134.43 144.11 36.03 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.361 0 N-CA-C 107.072 -1.455 . . . . 0.0 107.072 -179.801 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.504 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.4 pp -66.78 156.62 35.01 Favored 'General case' 0 N--CA 1.491 1.621 0 C-N-CA 118.606 -1.238 . . . . 0.0 108.968 179.715 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.424 ' CE2' ' HG3' ' A' ' 30' ' ' PRO . 35.7 m95 -136.84 134.15 36.63 Favored 'General case' 0 C--N 1.304 -1.371 0 N-CA-C 117.948 2.573 . . . . 0.0 117.948 -179.789 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -89.92 42.49 1.1 Allowed 'General case' 0 C--N 1.296 -1.735 1 CA-C-N 107.784 -4.28 . . . . 0.0 112.411 -179.788 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.445 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 1.3 m-30 -116.3 136.96 23.16 Favored Pre-proline 0 C--N 1.303 -1.418 0 CA-C-O 121.985 0.897 . . . . 0.0 108.749 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -70.02 -17.43 36.39 Favored 'Trans proline' 0 C--N 1.298 -2.082 0 C-N-CA 122.717 2.278 . . . . 0.0 108.607 179.84 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 10.6 p -95.71 23.54 6.1 Favored 'General case' 0 N--CA 1.488 1.445 0 CA-C-N 113.776 -1.556 . . . . 0.0 109.513 179.765 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.611 ' HA2' ' CG ' ' A' ' 45' ' ' TRP . . . 83.13 -94.33 1.76 Allowed Glycine 0 N--CA 1.487 2.053 0 N-CA-C 104.209 -3.556 . . . . 0.0 104.209 -179.677 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.579 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 25.2 m -98.47 165.27 15.47 Favored Pre-proline 0 C--N 1.301 -1.515 0 CA-C-N 113.777 -1.211 . . . . 0.0 110.604 -179.934 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.711 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.1 OUTLIER -88.59 161.48 6.51 Favored 'Trans proline' 0 C--N 1.312 -1.393 1 C-N-CA 125.881 4.387 . . . . 0.0 115.818 156.241 . . . . . . . . 4 4 . 1 . 019 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 14.0 p -51.55 113.55 1.0 Allowed 'General case' 0 C--N 1.301 -1.512 0 CA-C-N 112.132 -2.303 . . . . 0.0 113.16 -179.758 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 115.94 -6.76 19.7 Favored Glycine 0 N--CA 1.502 3.097 0 O-C-N 124.842 1.339 . . . . 0.0 111.12 179.692 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' TRP . . . . . 0.711 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 42.6 m95 -110.06 173.13 6.47 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 106.156 -1.794 . . . . 0.0 106.156 -179.849 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 77.5 t60 -149.91 29.29 0.74 Allowed 'General case' 0 N--CA 1.496 1.841 0 C-N-CA 117.935 -1.506 . . . . 0.0 112.668 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' ASN . . . . . 0.588 ' HA ' ' SG ' ' A' ' 47' ' ' CYS . 19.9 t-20 62.07 153.35 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.753 0 CA-C-N 114.245 -1.343 . . . . 0.0 111.637 -179.751 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.55 ' SG ' ' HB3' ' A' ' 46' ' ' CYS . 13.9 p -117.68 -39.95 3.08 Favored 'General case' 0 N--CA 1.499 2.024 0 N-CA-C 114.924 1.453 . . . . 0.0 114.924 -179.499 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 37' ' ' LYS . . . . . 0.481 ' HB2' ' HB3' ' A' ' 6' ' ' CYS . 74.0 tttt -131.4 132.12 44.13 Favored 'General case' 0 N--CA 1.5 2.047 0 N-CA-C 103.532 -2.766 . . . . 0.0 103.532 179.59 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -78.8 22.4 0.37 Allowed 'General case' 0 N--CA 1.495 1.802 0 C-N-CA 117.553 -1.659 . . . . 0.0 107.985 179.716 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' HIS . . . . . 0.429 ' H ' ' C ' ' A' ' 37' ' ' LYS . 9.5 m-70 -138.79 107.43 5.89 Favored 'General case' 0 N--CA 1.496 1.829 0 N-CA-C 113.713 1.005 . . . . 0.0 113.713 -179.395 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 60.78 -161.93 22.4 Favored Glycine 0 N--CA 1.502 3.08 0 CA-C-N 114.311 -1.313 . . . . 0.0 113.901 179.547 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.45 ' HD2' ' N ' ' A' ' 46' ' ' CYS . 73.0 Cg_endo -55.32 179.93 1.19 Allowed 'Cis proline' 0 N--CA 1.505 2.188 0 C-N-CA 129.362 0.984 . . . . 0.0 114.436 -5.499 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 21.9 m-20 -92.98 -8.25 43.62 Favored 'General case' 0 C--N 1.306 -1.294 0 N-CA-C 104.496 -2.409 . . . . 0.0 104.496 -179.783 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 11.4 mm -100.96 28.86 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.02 0 CA-C-O 123.675 1.703 . . . . 0.0 113.86 -179.008 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 136.01 -131.65 5.81 Favored Glycine 0 N--CA 1.485 1.906 1 N-CA-C 101.762 -4.535 . . . . 0.0 101.762 179.888 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 45' ' ' TRP . . . . . 0.611 ' CG ' ' HA2' ' A' ' 28' ' ' GLY . 3.0 m95 -153.33 161.29 42.5 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 105.268 -2.123 . . . . 0.0 105.268 179.646 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 46' ' ' CYS . . . . . 0.55 ' HB3' ' SG ' ' A' ' 36' ' ' CYS . 19.3 m -111.54 133.97 53.45 Favored 'General case' 0 N--CA 1.498 1.943 0 CA-C-N 123.037 2.653 . . . . 0.0 104.278 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.588 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 79.0 m -135.12 -173.4 3.31 Favored 'General case' 0 C--N 1.293 -1.865 0 CA-C-N 111.287 -2.688 . . . . 0.0 108.143 -179.399 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -150.6 175.89 11.5 Favored 'General case' 0 C--N 1.294 -1.805 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 179.225 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 49' ' ' LYS . . . . . 0.473 ' HE3' ' CZ2' ' A' ' 33' ' ' TRP . 22.6 mmtp . . . . . 0 C--N 1.293 -1.861 0 CA-C-O 114.98 -2.438 . . . . 0.0 107.275 179.5 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 2.733 0 N-CA-C 110.46 -1.056 . . . . 0.0 110.46 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 45.7 t -112.58 135.61 21.52 Favored Pre-proline 0 N--CA 1.493 1.699 0 N-CA-C 104.916 -2.253 . . . . 0.0 104.916 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -70.61 135.19 27.85 Favored 'Trans proline' 0 C--N 1.306 -1.659 0 C-N-CA 123.481 2.787 . . . . 0.0 112.132 175.21 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -139.64 174.66 10.28 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 123.968 0.792 . . . . 0.0 111.869 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.523 HD12 ' HA ' ' A' ' 5' ' ' LEU . 13.6 tp -97.8 152.17 19.44 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 102.065 -3.309 . . . . 0.0 102.065 179.766 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.497 ' HB3' ' C ' ' A' ' 36' ' ' CYS . 2.7 m -115.44 -138.08 0.37 Allowed 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 121.007 3.706 . . . . 0.0 121.007 -178.669 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -52.34 -25.08 8.77 Favored 'General case' 0 N--CA 1.502 2.163 0 C-N-CA 119.643 -0.823 . . . . 0.0 111.706 -179.699 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 12.6 t -94.75 19.62 9.79 Favored 'General case' 0 N--CA 1.499 2.015 0 CA-C-O 121.752 0.786 . . . . 0.0 109.336 179.762 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -75.8 75.16 2.75 Favored 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 107.591 -1.263 . . . . 0.0 107.591 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -157.83 -84.52 0.05 OUTLIER Glycine 0 N--CA 1.489 2.22 0 CA-C-N 112.716 -2.038 . . . . 0.0 108.955 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_endo -76.17 37.85 0.56 Allowed 'Trans proline' 0 N--CA 1.5 1.911 1 C-N-CA 125.748 4.298 . . . . 0.0 112.512 -167.562 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 1.4 tpt180 -121.85 132.54 24.22 Favored Pre-proline 0 N--CA 1.495 1.799 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 -179.711 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -77.48 -166.87 0.42 Allowed 'Trans proline' 0 C--N 1.314 -1.243 0 C-N-CA 123.735 2.957 . . . . 0.0 111.499 176.888 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 54.7 mtt180 -74.57 158.09 34.32 Favored 'General case' 0 N--CA 1.494 1.77 0 N-CA-C 107.927 -1.138 . . . . 0.0 107.927 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 148.63 -44.17 0.77 Allowed Glycine 0 N--CA 1.498 2.804 0 N-CA-C 108.76 -1.736 . . . . 0.0 108.76 179.861 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 8.3 t-20 75.13 85.29 0.1 Allowed 'General case' 0 N--CA 1.501 2.098 0 CA-C-N 113.686 -1.257 . . . . 0.0 109.343 179.917 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.3 m -94.08 120.77 34.8 Favored 'General case' 0 N--CA 1.494 1.761 0 CA-C-N 113.76 -1.564 . . . . 0.0 109.195 -179.845 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 2.4 mp -66.26 88.34 0.12 Allowed 'General case' 0 N--CA 1.499 1.986 0 CA-C-O 121.391 0.615 . . . . 0.0 110.944 179.793 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 27.3 t -90.25 -16.82 28.6 Favored 'General case' 0 N--CA 1.5 2.04 0 CA-C-O 118.051 -0.976 . . . . 0.0 113.537 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.457 ' HA2' ' HD3' ' A' ' 48' ' ' LYS . . . -177.33 152.23 11.84 Favored Glycine 0 N--CA 1.501 2.985 0 C-N-CA 119.234 -1.46 . . . . 0.0 111.508 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.502 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 38.8 mm -101.31 137.49 28.79 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.206 0 C-N-CA 117.3 -1.76 . . . . 0.0 106.718 179.623 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.53 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 30.8 tp -63.03 136.3 57.74 Favored 'General case' 0 C--N 1.295 -1.786 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 179.821 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 39.5 m95 -127.06 134.94 50.18 Favored 'General case' 0 C--N 1.31 -1.124 0 CA-C-O 125.397 2.522 . . . . 0.0 117.703 -179.848 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -88.73 40.65 0.98 Allowed 'General case' 0 C--N 1.295 -1.767 1 CA-C-N 107.669 -4.332 . . . . 0.0 113.98 -179.539 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.468 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 1.2 m-30 -115.17 122.22 33.68 Favored Pre-proline 0 N--CA 1.489 1.514 0 CA-C-O 122.86 1.314 . . . . 0.0 113.909 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo -63.66 -23.32 69.93 Favored 'Trans proline' 0 C--N 1.301 -1.938 0 C-N-CA 122.268 1.978 . . . . 0.0 108.924 -173.077 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 10.6 p -93.27 8.83 38.74 Favored 'General case' 0 N--CA 1.492 1.635 0 CA-C-N 114.502 -1.227 . . . . 0.0 112.651 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 112.04 -118.63 4.78 Favored Glycine 0 N--CA 1.495 2.62 0 N-CA-C 107.001 -2.439 . . . . 0.0 107.001 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' CYS . . . . . 0.526 ' HB3' ' HB2' ' A' ' 33' ' ' TRP . 14.8 m -96.21 159.54 31.86 Favored Pre-proline 0 C--N 1.303 -1.444 0 N-CA-C 107.504 -1.295 . . . . 0.0 107.504 179.8 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.723 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 1.6 Cg_endo -78.35 159.56 29.38 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 C-N-CA 122.338 2.025 . . . . 0.0 112.126 169.588 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 27.9 t -49.61 121.97 5.79 Favored 'General case' 0 C--N 1.303 -1.438 0 CA-C-N 113.345 -1.752 . . . . 0.0 108.96 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 109.68 -6.3 31.36 Favored Glycine 0 N--CA 1.498 2.806 0 CA-C-N 113.279 -1.782 . . . . 0.0 111.655 179.673 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' TRP . . . . . 0.723 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 51.0 m95 -113.61 158.12 21.23 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 105.957 -1.868 . . . . 0.0 105.957 -179.938 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 50.6 t-80 -140.13 37.15 1.92 Allowed 'General case' 0 N--CA 1.493 1.7 0 C-N-CA 118.974 -1.09 . . . . 0.0 111.08 -179.774 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' ASN . . . . . 0.489 ' HA ' ' SG ' ' A' ' 47' ' ' CYS . 22.1 t-20 60.25 152.08 0.02 OUTLIER 'General case' 0 N--CA 1.504 2.225 0 CA-C-N 113.303 -1.772 . . . . 0.0 115.045 179.794 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 36' ' ' CYS . . . . . 0.548 ' SG ' ' HB3' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -125.18 -48.55 1.72 Allowed 'General case' 0 N--CA 1.483 1.219 0 N-CA-C 105.869 -1.9 . . . . 0.0 105.869 -179.972 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 66.2 tttt -113.2 103.1 11.01 Favored 'General case' 0 C--N 1.305 -1.35 0 N-CA-C 105.709 -1.96 . . . . 0.0 105.709 179.719 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.426 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -88.96 18.56 4.76 Favored 'General case' 0 N--CA 1.497 1.885 0 CA-C-N 113.312 -1.767 . . . . 0.0 107.155 179.577 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 39' ' ' HIS . . . . . 0.426 ' ND1' ' C ' ' A' ' 38' ' ' ALA . 7.1 m-70 -129.29 37.37 4.04 Favored 'General case' 0 N--CA 1.489 1.509 0 CA-C-N 114.468 -1.242 . . . . 0.0 109.05 -179.733 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 96.9 -158.32 21.29 Favored Glycine 0 N--CA 1.501 3.009 0 N-CA-C 110.207 -1.157 . . . . 0.0 110.207 179.803 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.461 ' HG2' ' O ' ' A' ' 44' ' ' GLY . 9.2 Cg_endo -74.44 -176.66 18.11 Favored 'Cis proline' 0 N--CA 1.505 2.159 0 CA-C-N 118.914 1.357 . . . . 0.0 110.91 1.448 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 19.4 p-10 -92.32 -11.3 35.49 Favored 'General case' 0 N--CA 1.491 1.578 0 N-CA-C 105.016 -2.216 . . . . 0.0 105.016 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 13.0 mm -88.4 29.05 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.31 0 CA-C-N 113.807 -1.542 . . . . 0.0 110.598 -179.427 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.461 ' O ' ' HG2' ' A' ' 41' ' ' PRO . . . 115.37 130.64 4.81 Favored Glycine 0 N--CA 1.49 2.24 0 CA-C-N 112.414 -2.175 . . . . 0.0 107.853 -179.871 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' TRP . . . . . 0.468 ' NE1' ' O ' ' A' ' 25' ' ' TYR . 2.1 m95 -73.85 134.67 43.34 Favored 'General case' 0 N--CA 1.499 1.98 0 N-CA-C 105.882 -1.896 . . . . 0.0 105.882 -179.434 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 46' ' ' CYS . . . . . 0.548 ' HB3' ' SG ' ' A' ' 36' ' ' CYS . 96.0 m -87.9 128.78 35.36 Favored 'General case' 0 N--CA 1.491 1.62 0 N-CA-C 101.314 -3.587 . . . . 0.0 101.314 179.575 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.503 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 73.7 m -126.71 -176.28 3.65 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-N 113.28 -1.782 . . . . 0.0 113.755 -179.317 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 48' ' ' LYS . . . . . 0.468 ' HD2' ' H ' ' A' ' 49' ' ' LYS . 28.5 tptp -150.76 150.84 31.51 Favored 'General case' 0 C--N 1.292 -1.913 0 CA-C-N 114.931 -1.031 . . . . 0.0 109.817 -179.944 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 49' ' ' LYS . . . . . 0.468 ' H ' ' HD2' ' A' ' 48' ' ' LYS . 54.1 mtpt . . . . . 0 N--CA 1.501 2.085 0 O-C-N 126.16 2.162 . . . . 0.0 109.666 179.458 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 24.6 t . . . . . 0 N--CA 1.497 1.876 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.412 ' HA ' ' O ' ' A' ' 20' ' ' GLY . 4.9 Cg_endo -81.33 142.13 13.12 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 C-N-CA 123.293 2.662 . . . . 0.0 110.932 164.718 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -137.52 170.03 16.78 Favored 'General case' 0 N--CA 1.495 1.784 0 C-N-CA 119.455 -0.898 . . . . 0.0 111.659 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.534 HD23 ' N ' ' A' ' 6' ' ' CYS . 5.5 tt -85.62 148.05 26.1 Favored 'General case' 0 N--CA 1.495 1.792 0 N-CA-C 106.752 -1.573 . . . . 0.0 106.752 -179.823 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . 0.546 ' HB3' ' C ' ' A' ' 36' ' ' CYS . 2.4 m -127.73 -167.03 1.69 Allowed 'General case' 0 N--CA 1.488 1.443 0 N-CA-C 119.197 3.036 . . . . 0.0 119.197 -179.621 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 21.2 t70 . . . . . 0 N--CA 1.503 2.199 0 CA-C-N 112.932 -1.94 . . . . 0.0 112.353 -179.762 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 34.6 m . . . . . 0 N--CA 1.505 2.309 0 N-CA-C 113.099 0.777 . . . . 0.0 113.099 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.412 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -157.01 150.43 21.57 Favored Glycine 0 N--CA 1.493 2.46 0 N-CA-C 107.859 -2.096 . . . . 0.0 107.859 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.458 ' N ' ' O ' ' A' ' 47' ' ' CYS . 44.9 mm -113.48 152.99 15.1 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.282 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.528 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 4.2 pp -76.26 151.13 36.87 Favored 'General case' 0 N--CA 1.501 2.077 0 C-N-CA 117.908 -1.517 . . . . 0.0 108.714 179.569 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 30.0 m95 -132.68 130.3 39.92 Favored 'General case' 0 N--CA 1.485 1.288 0 N-CA-C 119.293 3.071 . . . . 0.0 119.293 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -88.28 53.06 2.61 Favored 'General case' 0 C--N 1.295 -1.804 0 CA-C-N 108.569 -3.923 . . . . 0.0 111.377 -179.495 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.462 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 2.3 m-85 -126.14 121.13 23.92 Favored Pre-proline 0 N--CA 1.495 1.784 0 CA-C-N 115.497 -0.774 . . . . 0.0 112.481 179.605 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -64.68 -19.58 64.73 Favored 'Trans proline' 0 C--N 1.307 -1.635 0 C-N-CA 123.941 3.094 . . . . 0.0 111.328 -177.281 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 6.1 p -94.81 11.37 31.78 Favored 'General case' 0 N--CA 1.489 1.507 0 CA-C-N 115.06 -0.973 . . . . 0.0 111.1 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 101.33 -121.83 7.37 Favored Glycine 0 N--CA 1.498 2.77 0 N-CA-C 106.198 -2.761 . . . . 0.0 106.198 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.544 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 24.9 m -89.15 148.88 41.89 Favored Pre-proline 0 C--N 1.305 -1.348 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 179.72 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.723 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 19.5 Cg_endo -74.19 166.92 28.41 Favored 'Trans proline' 0 C--N 1.31 -1.466 0 C-N-CA 122.211 1.941 . . . . 0.0 114.143 172.895 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 9.4 t -53.89 114.52 1.6 Allowed 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 113.989 -1.46 . . . . 0.0 110.285 -179.755 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 113.6 -7.08 24.33 Favored Glycine 0 N--CA 1.5 2.948 0 CA-C-N 113.906 -1.497 . . . . 0.0 112.319 179.549 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' TRP . . . . . 0.723 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 53.7 m95 -110.29 166.24 11.13 Favored 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 106.745 -1.576 . . . . 0.0 106.745 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 51.9 t60 -146.04 29.82 1.07 Allowed 'General case' 0 N--CA 1.503 2.185 0 C-N-CA 117.911 -1.516 . . . . 0.0 113.95 -179.737 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . 0.544 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 23.3 t-20 64.1 152.03 0.04 OUTLIER 'General case' 0 N--CA 1.506 2.335 0 N-CA-C 115.164 1.542 . . . . 0.0 115.164 -179.818 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.717 ' SG ' ' HB3' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -130.16 -45.77 1.12 Allowed 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 113.32 -1.764 . . . . 0.0 107.543 -179.819 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . 0.497 ' C ' ' H ' ' A' ' 39' ' ' HIS . 82.7 tttt -118.57 103.11 9.41 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-O 122.858 1.313 . . . . 0.0 108.837 179.912 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.432 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -81.48 25.25 0.52 Allowed 'General case' 0 N--CA 1.494 1.761 0 N-CA-C 107.181 -1.414 . . . . 0.0 107.181 179.603 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . 0.497 ' H ' ' C ' ' A' ' 37' ' ' LYS . 5.5 m-70 -131.13 10.24 4.91 Favored 'General case' 0 N--CA 1.492 1.636 0 N-CA-C 108.628 -0.878 . . . . 0.0 108.628 -179.727 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 125.43 -142.62 13.91 Favored Glycine 0 N--CA 1.498 2.778 0 N-CA-C 110.168 -1.173 . . . . 0.0 110.168 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . 0.578 ' CD ' ' SG ' ' A' ' 46' ' ' CYS . 85.8 Cg_endo -66.12 -174.66 6.29 Favored 'Cis proline' 0 N--CA 1.5 1.856 0 CA-C-N 118.289 1.045 . . . . 0.0 110.251 -1.872 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 4.1 m-20 -91.7 -8.83 45.9 Favored 'General case' 0 CA--C 1.479 -1.786 0 N-CA-C 105.617 -1.994 . . . . 0.0 105.617 -179.147 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 37.4 mt -95.06 33.33 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.163 0 CA-C-O 123.624 1.678 . . . . 0.0 109.114 -179.495 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.405 ' O ' ' HG2' ' A' ' 41' ' ' PRO . . . 114.06 135.54 6.11 Favored Glycine 0 N--CA 1.485 1.923 0 CA-C-N 111.275 -2.693 . . . . 0.0 107.41 -179.897 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . 0.462 ' NE1' ' O ' ' A' ' 25' ' ' TYR . 6.1 m95 -64.17 134.59 55.12 Favored 'General case' 0 N--CA 1.508 2.454 0 CA-C-O 116.796 -1.573 . . . . 0.0 106.787 -179.544 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' CYS . . . . . 0.717 ' HB3' ' SG ' ' A' ' 36' ' ' CYS . 35.4 m -89.45 124.15 34.23 Favored 'General case' 0 C--N 1.312 -1.063 0 N-CA-C 103.081 -2.933 . . . . 0.0 103.081 179.922 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.538 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 73.4 m -127.4 -169.74 2.1 Favored 'General case' 0 C--N 1.291 -1.972 0 CA-C-N 110.921 -2.854 . . . . 0.0 107.899 -179.533 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.411 ' N ' ' CD ' ' A' ' 48' ' ' LYS . 0.0 OUTLIER -151.67 173.2 14.96 Favored 'General case' 0 C--N 1.292 -1.924 0 N-CA-C 105.175 -2.157 . . . . 0.0 105.175 179.058 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 90.2 mttt . . . . . 0 C--N 1.289 -2.028 0 CA-C-O 114.691 -2.576 . . . . 0.0 106.392 179.524 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 22.4 t . . . . . 0 N--CA 1.495 1.777 0 N-CA-C 103.912 -2.625 . . . . 0.0 103.912 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -68.27 149.43 75.77 Favored 'Trans proline' 0 C--N 1.305 -1.75 0 C-N-CA 122.98 2.453 . . . . 0.0 108.038 170.78 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 1.2 p -141.72 175.02 10.03 Favored 'General case' 0 N--CA 1.495 1.811 0 N-CA-C 115.242 1.571 . . . . 0.0 115.242 -179.755 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.417 HD12 ' HA ' ' A' ' 5' ' ' LEU . 23.5 tp -104.16 150.03 24.72 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 103.682 -2.71 . . . . 0.0 103.682 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . 0.443 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 3.3 m -133.11 -162.51 1.25 Allowed 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 116.299 1.963 . . . . 0.0 116.299 -179.04 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 3.2 p-10 . . . . . 0 N--CA 1.499 1.989 0 O-C-N 126.751 2.532 . . . . 0.0 111.851 -179.967 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 25.0 m . . . . . 0 N--CA 1.502 2.138 0 N-CA-C 112.263 0.468 . . . . 0.0 112.263 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -164.74 179.59 39.34 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 108.945 -1.662 . . . . 0.0 108.945 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 34.3 mm -125.06 149.41 29.62 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.174 0 N-CA-C 108.42 -0.955 . . . . 0.0 108.42 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.664 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 4.5 pp -71.17 148.44 47.34 Favored 'General case' 0 N--CA 1.498 1.946 0 C-N-CA 118.513 -1.275 . . . . 0.0 110.875 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 38.2 m95 -131.4 131.47 43.66 Favored 'General case' 0 N--CA 1.486 1.36 0 N-CA-C 120.389 3.477 . . . . 0.0 120.389 -179.821 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -88.87 49.58 1.81 Allowed 'General case' 0 C--N 1.296 -1.734 1 CA-C-N 106.862 -4.699 . . . . 0.0 112.785 -179.389 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.407 ' CE1' ' HB3' ' A' ' 30' ' ' PRO . 2.2 m-85 -121.21 130.76 24.69 Favored Pre-proline 0 C--N 1.302 -1.468 0 CA-C-O 122.436 1.113 . . . . 0.0 111.3 179.525 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -69.79 -24.28 29.69 Favored 'Trans proline' 0 C--N 1.308 -1.595 0 C-N-CA 124.647 3.565 . . . . 0.0 110.662 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 6.1 p -93.63 15.12 16.97 Favored 'General case' 0 N--CA 1.492 1.642 0 CA-C-N 115.405 -0.816 . . . . 0.0 111.307 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 99.64 -126.01 8.77 Favored Glycine 0 N--CA 1.5 2.901 0 N-CA-C 105.674 -2.97 . . . . 0.0 105.674 -179.88 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.541 ' SG ' ' CA ' ' A' ' 35' ' ' ASN . 35.7 m -86.66 152.24 54.02 Favored Pre-proline 0 C--N 1.304 -1.403 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 179.721 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.758 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 19.9 Cg_endo -73.04 165.83 31.71 Favored 'Trans proline' 0 C--N 1.305 -1.719 0 C-N-CA 122.525 2.15 . . . . 0.0 113.906 173.392 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 5.6 p -51.73 107.42 0.19 Allowed 'General case' 0 C--N 1.298 -1.632 0 CA-C-N 112.341 -2.209 . . . . 0.0 112.247 -179.741 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 115.34 -7.85 20.65 Favored Glycine 0 N--CA 1.498 2.826 0 O-C-N 124.514 1.134 . . . . 0.0 111.737 179.594 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' TRP . . . . . 0.758 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 45.7 m95 -105.76 166.87 10.16 Favored 'General case' 0 C--N 1.304 -1.389 0 N-CA-C 106.143 -1.799 . . . . 0.0 106.143 -179.874 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 54.0 t-80 -147.03 33.82 0.91 Allowed 'General case' 0 N--CA 1.497 1.894 0 C-N-CA 117.337 -1.745 . . . . 0.0 112.884 -179.648 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . 0.541 ' CA ' ' SG ' ' A' ' 29' ' ' CYS . 24.9 t-20 60.44 143.29 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.13 0 N-CA-C 115.187 1.551 . . . . 0.0 115.187 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.876 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 1.7 p -120.99 -41.16 2.56 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-N 114.28 -1.327 . . . . 0.0 108.448 -179.628 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . 0.403 ' HG2' ' H ' ' A' ' 39' ' ' HIS . 77.3 tttt -118.84 116.31 26.23 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 104.708 -2.33 . . . . 0.0 104.708 179.748 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -89.41 8.08 32.62 Favored 'General case' 0 N--CA 1.496 1.827 0 N-CA-C 107.475 -1.306 . . . . 0.0 107.475 179.79 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . 0.403 ' H ' ' HG2' ' A' ' 37' ' ' LYS . 16.2 m-70 -133.04 48.86 2.36 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-N 115.001 -0.999 . . . . 0.0 110.876 -179.708 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 113.41 -165.11 12.01 Favored Glycine 0 N--CA 1.497 2.705 0 O-C-N 124.293 0.995 . . . . 0.0 113.47 179.581 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 15.0 Cg_endo -73.75 -174.01 12.46 Favored 'Cis proline' 0 N--CA 1.497 1.703 0 O-C-N 123.085 1.045 . . . . 0.0 110.933 -5.182 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 6.7 m120 -92.08 -10.68 38.16 Favored 'General case' 0 CA--C 1.484 -1.587 0 N-CA-C 104.579 -2.378 . . . . 0.0 104.579 -179.676 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 33.0 pt -92.04 27.22 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.03 0 C-N-CA 118.204 -1.398 . . . . 0.0 113.689 -179.434 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 116.76 130.85 4.55 Favored Glycine 0 N--CA 1.489 2.215 0 CA-C-N 111.831 -2.44 . . . . 0.0 108.693 -179.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . 0.4 ' NE1' ' O ' ' A' ' 25' ' ' TYR . 8.5 m95 -54.06 131.76 41.36 Favored 'General case' 0 N--CA 1.513 2.704 0 CA-C-O 116.248 -1.834 . . . . 0.0 107.56 -179.56 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' CYS . . . . . 0.876 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 53.3 t -89.44 131.85 35.3 Favored 'General case' 0 N--CA 1.479 0.983 1 N-CA-C 99.333 -4.321 . . . . 0.0 99.333 -179.882 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.459 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 86.2 m -133.74 -173.55 3.27 Favored 'General case' 0 C--N 1.292 -1.9 0 CA-C-N 111.056 -2.793 . . . . 0.0 109.876 -179.166 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.449 ' O ' ' HA ' ' A' ' 33' ' ' TRP . 0.0 OUTLIER -150.48 173.47 14.03 Favored 'General case' 0 C--N 1.297 -1.695 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 179.376 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 3.7 mmpt? . . . . . 0 N--CA 1.502 2.131 0 O-C-N 126.618 2.449 . . . . 0.0 110.874 179.929 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 21.8 t . . . . . 0 N--CA 1.5 2.051 0 N-CA-C 106.686 -1.598 . . . . 0.0 106.686 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -74.47 134.55 18.94 Favored 'Trans proline' 0 C--N 1.306 -1.681 0 C-N-CA 123.048 2.498 . . . . 0.0 117.73 163.819 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -128.82 173.66 10.16 Favored 'General case' 0 N--CA 1.493 1.679 0 N-CA-C 107.589 -1.263 . . . . 0.0 107.589 179.509 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.594 HD23 ' N ' ' A' ' 6' ' ' CYS . 5.4 tt -90.64 147.24 23.43 Favored 'General case' 0 N--CA 1.496 1.866 0 N-CA-C 103.665 -2.717 . . . . 0.0 103.665 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . 0.594 ' N ' HD23 ' A' ' 5' ' ' LEU . 4.4 m -128.34 -171.49 2.47 Favored 'General case' 0 C--N 1.307 -1.271 0 N-CA-C 116.005 1.854 . . . . 0.0 116.005 -179.851 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 34.1 t70 . . . . . 0 N--CA 1.489 1.481 0 CA-C-N 113.196 -1.82 . . . . 0.0 107.575 179.945 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 4.1 t . . . . . 0 N--CA 1.5 2.052 0 CA-C-O 121.505 0.669 . . . . 0.0 110.407 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.516 ' HA3' ' SG ' ' A' ' 6' ' ' CYS . . . -172.48 121.57 0.88 Allowed Glycine 0 N--CA 1.494 2.503 0 N-CA-C 107.065 -2.414 . . . . 0.0 107.065 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.457 ' N ' ' O ' ' A' ' 47' ' ' CYS . 36.3 mm -96.09 137.34 24.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 N-CA-C 104.691 -2.337 . . . . 0.0 104.691 179.736 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.562 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 4.3 pp -65.69 149.33 50.29 Favored 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 117.752 -1.579 . . . . 0.0 107.238 179.812 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.417 ' O ' ' CA ' ' A' ' 44' ' ' GLY . 20.2 m95 -132.17 135.78 46.6 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-O 124.542 2.115 . . . . 0.0 115.882 -179.727 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.1 m-85 -88.91 40.58 0.98 Allowed 'General case' 0 C--N 1.293 -1.849 0 CA-C-N 109.12 -3.673 . . . . 0.0 115.353 -179.383 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.444 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 1.2 m-30 -113.12 120.0 41.24 Favored Pre-proline 0 N--CA 1.487 1.396 0 N-CA-C 107.664 -1.236 . . . . 0.0 107.664 179.713 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -60.93 -21.28 70.53 Favored 'Trans proline' 0 C--N 1.298 -2.091 0 C-N-CA 122.511 2.14 . . . . 0.0 110.414 -170.207 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 4.3 p -97.45 3.67 50.77 Favored 'General case' 0 N--CA 1.491 1.6 0 CA-C-N 114.746 -1.115 . . . . 0.0 113.451 -179.923 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 125.58 -121.86 4.35 Favored Glycine 0 N--CA 1.492 2.38 0 N-CA-C 108.601 -1.8 . . . . 0.0 108.601 179.911 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.55 ' HB3' ' HB2' ' A' ' 33' ' ' TRP . 3.9 m -95.2 158.6 34.51 Favored Pre-proline 0 C--N 1.304 -1.375 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.727 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.3 OUTLIER -79.11 -179.24 5.27 Favored 'Trans proline' 0 C--N 1.312 -1.343 0 C-N-CA 123.242 2.628 . . . . 0.0 114.896 171.033 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 18.4 p -58.41 104.62 0.22 Allowed 'General case' 0 C--N 1.299 -1.591 0 CA-C-N 112.922 -1.944 . . . . 0.0 112.941 -179.587 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 114.15 3.63 22.82 Favored Glycine 0 N--CA 1.501 2.969 0 O-C-N 124.759 1.287 . . . . 0.0 113.561 179.628 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' TRP . . . . . 0.727 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 39.7 m95 -117.75 153.07 34.03 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 107.369 -1.345 . . . . 0.0 107.369 -179.822 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . 0.408 ' O ' ' ND1' ' A' ' 34' ' ' HIS . 36.6 t-80 -137.4 41.5 2.4 Favored 'General case' 0 N--CA 1.5 2.044 0 CA-C-O 122.074 0.94 . . . . 0.0 109.847 -179.496 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . 0.496 ' HA ' ' SG ' ' A' ' 47' ' ' CYS . 24.6 t-20 59.59 156.73 0.03 OUTLIER 'General case' 0 N--CA 1.501 2.089 0 CA-C-O 123.9 1.81 . . . . 0.0 114.286 -179.765 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.778 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -125.66 -52.18 1.58 Allowed 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 104.354 -2.461 . . . . 0.0 104.354 179.725 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . 0.464 ' C ' ' H ' ' A' ' 39' ' ' HIS . 43.7 tttp -118.26 103.98 10.35 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 113.615 -1.63 . . . . 0.0 109.74 179.836 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.44 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -81.82 30.96 0.37 Allowed 'General case' 0 N--CA 1.497 1.902 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 179.573 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . 0.464 ' H ' ' C ' ' A' ' 37' ' ' LYS . 4.5 m-70 -130.49 8.32 4.99 Favored 'General case' 0 N--CA 1.492 1.636 0 CA-C-N 115.53 -0.759 . . . . 0.0 108.957 -179.73 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 128.51 -152.98 19.4 Favored Glycine 0 N--CA 1.496 2.7 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 179.902 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . 0.43 ' HG2' ' O ' ' A' ' 44' ' ' GLY . 26.8 Cg_endo -72.68 -174.61 12.62 Favored 'Cis proline' 0 N--CA 1.508 2.324 0 O-C-N 122.808 0.899 . . . . 0.0 112.586 -2.414 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . 0.446 ' C ' ' H ' ' A' ' 44' ' ' GLY . 17.8 p-10 -91.88 -14.35 29.81 Favored 'General case' 0 CA--C 1.485 -1.533 0 N-CA-C 105.527 -2.027 . . . . 0.0 105.527 -179.654 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 11.0 mt -88.84 30.1 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.341 0 CA-C-N 113.809 -1.541 . . . . 0.0 109.617 -179.405 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.446 ' H ' ' C ' ' A' ' 42' ' ' ASN . . . 114.6 122.18 3.64 Favored Glycine 0 N--CA 1.491 2.347 0 CA-C-N 112.163 -2.289 . . . . 0.0 107.767 -179.853 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . 0.444 ' NE1' ' O ' ' A' ' 25' ' ' TYR . 3.9 m95 -54.68 138.79 40.85 Favored 'General case' 0 N--CA 1.514 2.735 0 CA-C-O 116.795 -1.574 . . . . 0.0 107.946 -179.378 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' CYS . . . . . 0.778 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 13.8 t -88.87 127.4 35.63 Favored 'General case' 0 C--N 1.309 -1.159 0 N-CA-C 102.587 -3.116 . . . . 0.0 102.587 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.496 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 98.0 m -128.9 176.51 7.8 Favored 'General case' 0 CA--C 1.478 -1.8 0 CA-C-N 112.009 -2.36 . . . . 0.0 113.656 -178.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.461 ' HD2' ' HA ' ' A' ' 48' ' ' LYS . 41.1 tptt -150.83 153.08 34.73 Favored 'General case' 0 C--N 1.295 -1.804 0 C-N-CA 118.785 -1.166 . . . . 0.0 109.405 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 7.4 mtpm? . . . . . 0 N--CA 1.5 2.037 0 CA-C-N 111.703 -2.499 . . . . 0.0 110.886 179.775 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 6.3 t . . . . . 0 N--CA 1.5 2.053 0 N-CA-C 106.512 -1.662 . . . . 0.0 106.512 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -79.03 119.86 4.43 Favored 'Trans proline' 0 C--N 1.308 -1.568 0 C-N-CA 122.491 2.127 . . . . 0.0 113.337 160.019 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.453 ' SG ' ' HB3' ' A' ' 22' ' ' LEU . 0.5 OUTLIER -104.59 -171.63 1.96 Allowed 'General case' 0 N--CA 1.495 1.802 0 CA-C-N 114.956 -1.02 . . . . 0.0 110.893 -179.975 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 4.2 tp -98.38 152.29 19.64 Favored 'General case' 0 N--CA 1.497 1.907 0 N-CA-C 104.593 -2.373 . . . . 0.0 104.593 179.838 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . 0.452 ' HB3' ' O ' ' A' ' 36' ' ' CYS . 3.1 m -132.59 -170.63 2.48 Favored 'General case' 0 N--CA 1.485 1.321 0 N-CA-C 115.41 1.633 . . . . 0.0 115.41 -179.62 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 17.2 t70 . . . . . 0 C--N 1.3 -1.583 0 CA-C-N 112.971 -1.922 . . . . 0.0 109.752 -179.922 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 4.5 t . . . . . 0 N--CA 1.502 2.144 0 N-CA-C 113.507 0.929 . . . . 0.0 113.507 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 165.43 -176.3 41.04 Favored Glycine 0 N--CA 1.512 3.738 0 C-N-CA 118.742 -1.694 . . . . 0.0 114.94 179.573 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.405 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 19.3 mm -134.19 149.16 29.97 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.245 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 179.57 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.587 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.5 pp -69.19 146.71 52.19 Favored 'General case' 0 N--CA 1.495 1.794 0 C-N-CA 119.333 -0.947 . . . . 0.0 110.859 179.709 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 37.5 m95 -130.62 130.33 43.83 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 121.374 3.842 . . . . 0.0 121.374 -179.571 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 4.4 m-85 -89.0 49.81 1.85 Allowed 'General case' 0 C--N 1.295 -1.795 1 CA-C-N 108.093 -4.14 . . . . 0.0 112.209 -179.687 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.44 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 2.2 m-85 -122.56 124.56 26.7 Favored Pre-proline 0 N--CA 1.494 1.765 0 N-CA-C 114.144 1.164 . . . . 0.0 114.144 179.876 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -64.16 -20.82 67.63 Favored 'Trans proline' 0 C--N 1.307 -1.641 0 C-N-CA 124.065 3.177 . . . . 0.0 110.935 -177.02 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 5.1 p -94.06 6.9 47.07 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-N 114.576 -1.193 . . . . 0.0 111.207 179.829 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 104.17 -112.52 4.15 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 105.252 -3.139 . . . . 0.0 105.252 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.537 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 13.5 m -96.55 147.96 33.73 Favored Pre-proline 0 C--N 1.305 -1.363 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 179.798 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.73 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 15.2 Cg_endo -74.23 174.67 12.08 Favored 'Trans proline' 0 C--N 1.308 -1.566 0 C-N-CA 122.628 2.219 . . . . 0.0 114.47 174.259 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 12.0 p -53.13 105.65 0.13 Allowed 'General case' 0 C--N 1.299 -1.63 0 CA-C-N 112.469 -2.151 . . . . 0.0 112.568 -179.694 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 111.92 -1.25 27.21 Favored Glycine 0 N--CA 1.503 3.139 0 O-C-N 124.156 0.91 . . . . 0.0 113.814 179.503 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' TRP . . . . . 0.73 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 52.1 m95 -110.45 166.79 10.71 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 108.053 -1.092 . . . . 0.0 108.053 -179.912 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 80.1 t60 -146.98 36.59 0.94 Allowed 'General case' 0 N--CA 1.5 2.03 0 C-N-CA 116.8 -1.96 . . . . 0.0 115.94 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . 0.537 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 0.4 OUTLIER 63.3 137.93 0.02 OUTLIER 'General case' 0 N--CA 1.506 2.326 0 N-CA-C 116.926 2.195 . . . . 0.0 116.926 179.714 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.688 ' SG ' ' HB3' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -118.06 -42.17 2.83 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 105.029 -2.211 . . . . 0.0 105.029 179.71 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . 0.442 ' HD2' ' HA ' ' A' ' 6' ' ' CYS . 57.3 tttt -136.38 120.54 17.79 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 114.824 -1.08 . . . . 0.0 109.544 179.766 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.437 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -97.99 34.21 1.97 Allowed 'General case' 0 N--CA 1.496 1.829 0 N-CA-C 105.505 -2.035 . . . . 0.0 105.505 179.645 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . 0.437 ' ND1' ' C ' ' A' ' 38' ' ' ALA . 3.8 m-70 -133.5 47.92 2.42 Favored 'General case' 0 N--CA 1.495 1.792 0 N-CA-C 106.225 -1.769 . . . . 0.0 106.225 -179.67 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 85.21 -156.61 31.02 Favored Glycine 0 N--CA 1.498 2.779 0 N-CA-C 107.416 -2.274 . . . . 0.0 107.416 -179.749 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 17.6 Cg_endo -72.13 -172.76 9.41 Favored 'Cis proline' 0 N--CA 1.494 1.555 0 CA-C-N 118.612 1.206 . . . . 0.0 112.053 2.5 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 80.2 m-20 -92.32 -15.49 27.3 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 104.647 -2.353 . . . . 0.0 104.647 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 13.5 mt -90.87 29.5 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.21 0 CA-C-N 113.272 -1.786 . . . . 0.0 111.425 -179.255 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 109.07 119.11 4.2 Favored Glycine 0 N--CA 1.491 2.31 0 CA-C-N 112.178 -2.283 . . . . 0.0 111.601 179.853 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . 0.44 ' NE1' ' O ' ' A' ' 25' ' ' TYR . 2.2 m95 -49.44 134.74 18.74 Favored 'General case' 0 N--CA 1.516 2.856 0 CA-C-O 116.231 -1.843 . . . . 0.0 107.449 -179.743 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' CYS . . . . . 0.688 ' HB3' ' SG ' ' A' ' 36' ' ' CYS . 68.5 m -89.45 128.22 35.93 Favored 'General case' 0 N--CA 1.485 1.32 0 N-CA-C 103.689 -2.708 . . . . 0.0 103.689 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.522 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 86.7 m -131.12 -173.49 3.11 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-N 111.955 -2.384 . . . . 0.0 110.314 -179.165 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.417 ' O ' ' HA ' ' A' ' 33' ' ' TRP . 0.0 OUTLIER -151.09 173.7 14.05 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 118.574 -1.25 . . . . 0.0 109.106 179.357 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 95.0 mttt . . . . . 0 C--N 1.292 -1.909 0 O-C-N 126.402 2.314 . . . . 0.0 107.927 179.488 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 9.1 t . . . . . 0 N--CA 1.495 1.81 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.443 ' HA ' ' O ' ' A' ' 20' ' ' GLY . 4.3 Cg_endo -77.2 131.64 11.99 Favored 'Trans proline' 0 N--CA 1.494 1.551 0 C-N-CA 124.067 3.178 . . . . 0.0 114.26 166.916 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -122.17 167.99 12.53 Favored 'General case' 0 N--CA 1.498 1.942 0 CA-C-O 122.602 1.191 . . . . 0.0 114.076 -179.702 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 12.7 tp -79.68 127.34 32.07 Favored 'General case' 0 N--CA 1.493 1.695 0 N-CA-C 106.907 -1.516 . . . . 0.0 106.907 -179.709 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 21.8 m -106.58 -174.11 2.46 Favored 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 118.844 -1.143 . . . . 0.0 112.883 179.65 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 16.3 t70 . . . . . 0 C--N 1.296 -1.727 0 CA-C-N 113.916 -1.493 . . . . 0.0 108.431 -179.778 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 3.2 p . . . . . 0 N--CA 1.488 1.47 0 CA-C-O 120.915 0.388 . . . . 0.0 111.901 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.443 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . 159.33 178.98 33.84 Favored Glycine 0 N--CA 1.499 2.853 0 N-CA-C 108.016 -2.034 . . . . 0.0 108.016 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.474 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 48.6 mm -127.84 145.97 34.24 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.974 0 N-CA-C 106.141 -1.8 . . . . 0.0 106.141 179.736 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.561 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.8 pp -69.67 152.18 45.0 Favored 'General case' 0 N--CA 1.491 1.617 0 C-N-CA 118.257 -1.377 . . . . 0.0 110.115 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.444 ' O ' ' HA3' ' A' ' 44' ' ' GLY . 37.6 m95 -136.41 130.73 33.15 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 118.884 2.92 . . . . 0.0 118.884 179.763 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 6.0 m-85 -89.48 51.47 2.12 Favored 'General case' 0 C--N 1.296 -1.756 1 CA-C-N 107.467 -4.424 . . . . 0.0 111.613 -179.692 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.484 ' CE1' ' HB3' ' A' ' 30' ' ' PRO . 2.4 m-85 -125.07 137.03 28.93 Favored Pre-proline 0 C--N 1.303 -1.414 0 CA-C-O 121.482 0.658 . . . . 0.0 109.613 179.646 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 96.9 Cg_endo -66.95 -30.31 39.72 Favored 'Trans proline' 0 C--N 1.305 -1.75 0 C-N-CA 124.264 3.309 . . . . 0.0 108.636 177.56 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 11.8 p -86.65 31.9 0.67 Allowed 'General case' 0 C--N 1.299 -1.611 0 CA-C-N 113.989 -1.459 . . . . 0.0 109.239 179.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.547 ' HA2' ' CD1' ' A' ' 45' ' ' TRP . . . 76.05 -92.76 0.94 Allowed Glycine 0 N--CA 1.482 1.764 0 N-CA-C 104.399 -3.48 . . . . 0.0 104.399 -179.499 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.568 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 9.4 m -103.75 165.91 12.65 Favored Pre-proline 0 C--N 1.301 -1.515 0 CA-C-N 113.814 -1.193 . . . . 0.0 110.609 -179.849 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.686 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.1 OUTLIER -86.01 167.11 9.64 Favored 'Trans proline' 0 CA--C 1.553 1.472 0 C-N-CA 125.238 3.959 . . . . 0.0 118.336 157.924 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 3.8 m -49.64 109.57 0.29 Allowed 'General case' 0 C--N 1.299 -1.604 0 CA-C-N 111.769 -2.469 . . . . 0.0 112.283 179.845 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 113.46 -6.6 24.66 Favored Glycine 0 N--CA 1.5 2.948 0 CA-C-N 115.218 -0.901 . . . . 0.0 111.901 179.743 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' TRP . . . . . 0.686 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 48.1 m95 -111.51 162.57 14.97 Favored 'General case' 0 N--CA 1.486 1.341 0 N-CA-C 106.321 -1.733 . . . . 0.0 106.321 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . 0.419 ' O ' ' ND1' ' A' ' 34' ' ' HIS . 60.0 t-80 -143.62 34.18 1.29 Allowed 'General case' 0 N--CA 1.498 1.962 0 C-N-CA 118.138 -1.425 . . . . 0.0 113.406 -179.733 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . 0.568 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 3.2 t30 61.76 146.16 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.9 0 N-CA-C 114.375 1.25 . . . . 0.0 114.375 179.916 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.804 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -124.31 -45.74 1.95 Allowed 'General case' 0 N--CA 1.484 1.272 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.039 -179.715 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . 0.53 ' HG2' ' H ' ' A' ' 39' ' ' HIS . 36.0 ttmt -122.01 100.35 6.93 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 105.44 -2.059 . . . . 0.0 105.44 179.431 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -77.55 19.9 0.34 Allowed 'General case' 0 N--CA 1.5 2.034 0 CA-C-N 114.431 -1.259 . . . . 0.0 107.742 179.649 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . 0.53 ' H ' ' HG2' ' A' ' 37' ' ' LYS . 7.4 m-70 -132.75 16.82 4.29 Favored 'General case' 0 N--CA 1.487 1.378 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.476 -179.709 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 149.37 -177.8 27.32 Favored Glycine 0 N--CA 1.501 3.015 0 C-N-CA 119.412 -1.375 . . . . 0.0 111.432 179.695 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . 0.524 ' HD2' ' N ' ' A' ' 46' ' ' CYS . 35.5 Cg_endo -66.25 -171.89 4.45 Favored 'Cis proline' 0 N--CA 1.512 2.592 0 N-CA-C 116.167 1.564 . . . . 0.0 116.167 -4.604 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 16.1 p-10 -92.1 -12.76 32.11 Favored 'General case' 0 N--CA 1.486 1.336 0 N-CA-C 105.505 -2.035 . . . . 0.0 105.505 -179.715 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.43 HG12 ' HB2' ' A' ' 41' ' ' PRO . 12.1 pt -85.81 23.02 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.218 0 O-C-N 124.909 1.38 . . . . 0.0 113.814 -179.49 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.444 ' HA3' ' O ' ' A' ' 23' ' ' TRP . . . 134.63 -116.47 1.61 Allowed Glycine 0 C--N 1.291 -1.962 0 N-CA-C 104.404 -3.478 . . . . 0.0 104.404 -179.906 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . 0.547 ' CD1' ' HA2' ' A' ' 28' ' ' GLY . 1.8 m95 -157.03 151.28 25.09 Favored 'General case' 0 N--CA 1.509 2.501 0 N-CA-C 105.491 -2.04 . . . . 0.0 105.491 -179.891 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' CYS . . . . . 0.804 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 44.5 t -99.06 129.61 45.34 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 102.882 -3.006 . . . . 0.0 102.882 179.864 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.524 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 78.4 m -126.77 -170.7 2.25 Favored 'General case' 0 C--N 1.298 -1.641 0 CA-C-N 113.528 -1.669 . . . . 0.0 109.719 -179.409 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.412 ' H ' ' HD3' ' A' ' 48' ' ' LYS . 0.0 OUTLIER -150.58 172.72 15.06 Favored 'General case' 0 C--N 1.294 -1.822 0 N-CA-C 107.195 -1.409 . . . . 0.0 107.195 179.324 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 84.8 mttt . . . . . 0 N--CA 1.498 1.95 0 O-C-N 126.129 2.143 . . . . 0.0 109.131 179.456 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.408 ' HB ' HD23 ' A' ' 22' ' ' LEU . 11.4 t . . . . . 0 N--CA 1.494 1.766 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_endo -75.81 155.33 39.23 Favored 'Trans proline' 0 N--CA 1.496 1.65 0 C-N-CA 124.024 3.15 . . . . 0.0 112.963 166.717 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.408 ' SG ' ' SG ' ' A' ' 6' ' ' CYS . 9.4 p -132.39 170.78 14.61 Favored 'General case' 0 N--CA 1.499 1.982 0 C-N-CA 119.208 -0.997 . . . . 0.0 108.939 179.574 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 13.9 tp -86.64 81.21 8.32 Favored 'General case' 0 N--CA 1.491 1.624 0 N-CA-C 103.65 -2.722 . . . . 0.0 103.65 179.908 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . 0.408 ' SG ' ' SG ' ' A' ' 4' ' ' CYS . 6.6 m -69.18 170.96 9.1 Favored 'General case' 0 C--N 1.309 -1.188 0 CA-C-O 123.273 1.511 . . . . 0.0 112.375 -179.729 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 7.9 t70 . . . . . 0 N--CA 1.496 1.875 0 CA-C-N 111.07 -2.786 . . . . 0.0 111.301 -179.838 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 48.4 t . . . . . 0 N--CA 1.498 1.935 0 CA-C-O 119.071 -0.49 . . . . 0.0 110.304 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 174.05 -171.83 44.83 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 107.653 -2.179 . . . . 0.0 107.653 -179.882 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 1.2 mp -133.83 153.14 35.9 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.104 0 O-C-N 124.918 1.01 . . . . 0.0 108.553 -179.903 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.621 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.3 pp -71.33 146.34 48.9 Favored 'General case' 0 N--CA 1.499 1.998 0 C-N-CA 120.205 -0.598 . . . . 0.0 111.868 179.812 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.432 ' O ' ' CA ' ' A' ' 44' ' ' GLY . 39.0 m95 -129.08 130.28 46.32 Favored 'General case' 0 N--CA 1.491 1.603 0 N-CA-C 119.512 3.152 . . . . 0.0 119.512 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 3.5 m-85 -88.73 51.38 2.16 Favored 'General case' 0 C--N 1.294 -1.827 1 CA-C-N 107.886 -4.234 . . . . 0.0 113.154 -179.412 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 2.2 m-85 -120.79 142.33 34.21 Favored Pre-proline 0 C--N 1.3 -1.576 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 179.411 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -76.12 -33.16 3.71 Favored 'Trans proline' 0 C--N 1.3 -1.991 0 C-N-CA 125.063 3.842 . . . . 0.0 112.21 172.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 14.1 p -88.61 33.43 0.77 Allowed 'General case' 0 N--CA 1.494 1.735 0 CA-C-O 121.442 0.639 . . . . 0.0 111.083 -179.524 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 76.0 -158.82 50.09 Favored Glycine 0 N--CA 1.495 2.58 0 N-CA-C 105.912 -2.875 . . . . 0.0 105.912 -179.565 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.586 ' SG ' ' CA ' ' A' ' 35' ' ' ASN . 14.0 m -53.06 150.76 9.95 Favored Pre-proline 0 C--N 1.303 -1.441 0 CA-C-N 117.599 0.699 . . . . 0.0 111.941 179.816 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.739 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 4.6 Cg_endo -76.41 159.74 36.01 Favored 'Trans proline' 0 C--N 1.308 -1.566 0 C-N-CA 122.956 2.437 . . . . 0.0 112.043 171.759 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 16.5 t -49.14 129.67 18.13 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-N 113.332 -1.758 . . . . 0.0 109.522 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 97.81 -5.14 61.71 Favored Glycine 0 N--CA 1.496 2.697 0 CA-C-N 112.664 -2.062 . . . . 0.0 111.687 179.762 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' TRP . . . . . 0.739 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 48.1 m95 -111.91 163.77 13.85 Favored 'General case' 0 C--N 1.305 -1.332 0 N-CA-C 106.29 -1.745 . . . . 0.0 106.29 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . 0.401 ' O ' ' ND1' ' A' ' 34' ' ' HIS . 45.5 t-80 -144.24 34.39 1.21 Allowed 'General case' 0 N--CA 1.498 1.974 0 C-N-CA 117.365 -1.734 . . . . 0.0 113.107 -179.818 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . 0.586 ' CA ' ' SG ' ' A' ' 29' ' ' CYS . 23.8 t-20 62.38 144.72 0.02 OUTLIER 'General case' 0 N--CA 1.506 2.333 0 N-CA-C 113.976 1.102 . . . . 0.0 113.976 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.851 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -124.74 -64.9 1.07 Allowed 'General case' 0 C--N 1.306 -1.3 0 N-CA-C 106.672 -1.603 . . . . 0.0 106.672 -179.751 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . 0.593 ' N ' ' SG ' ' A' ' 36' ' ' CYS . 33.1 ttmt -91.05 103.59 16.27 Favored 'General case' 0 C--N 1.302 -1.465 0 CA-C-O 123.567 1.651 . . . . 0.0 107.04 179.704 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.425 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -79.86 24.16 0.41 Allowed 'General case' 0 N--CA 1.495 1.781 0 CA-C-N 113.499 -1.682 . . . . 0.0 107.282 179.489 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . 0.519 ' H ' ' C ' ' A' ' 37' ' ' LYS . 3.3 m-70 -131.85 17.88 4.67 Favored 'General case' 0 N--CA 1.493 1.713 0 N-CA-C 106.966 -1.494 . . . . 0.0 106.966 -179.677 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 111.43 -132.0 10.63 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 25.9 Cg_endo -69.78 -164.06 2.43 Favored 'Cis proline' 0 N--CA 1.503 2.054 0 CA-C-N 117.843 0.821 . . . . 0.0 112.699 1.097 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . 0.409 ' C ' ' H ' ' A' ' 44' ' ' GLY . 22.6 t-20 -92.13 -20.57 21.11 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 106.374 -1.713 . . . . 0.0 106.374 -179.757 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 39.7 pt -86.31 28.33 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 CA-C-N 112.367 -2.197 . . . . 0.0 113.349 -179.104 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.432 ' CA ' ' O ' ' A' ' 23' ' ' TRP . . . 115.03 131.15 4.98 Favored Glycine 0 N--CA 1.484 1.859 0 CA-C-N 111.019 -2.81 . . . . 0.0 109.994 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 14.8 m95 -55.42 130.1 41.26 Favored 'General case' 0 N--CA 1.509 2.484 0 N-CA-C 106.311 -1.737 . . . . 0.0 106.311 -179.657 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' CYS . . . . . 0.851 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 42.7 t -89.15 129.42 35.75 Favored 'General case' 0 C--N 1.31 -1.139 1 N-CA-C 99.341 -4.318 . . . . 0.0 99.341 -179.89 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.539 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 77.8 m -133.93 -175.35 3.81 Favored 'General case' 0 C--N 1.293 -1.888 0 CA-C-N 110.671 -2.968 . . . . 0.0 110.881 -178.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.467 ' O ' ' HA ' ' A' ' 33' ' ' TRP . 0.0 OUTLIER -150.7 172.68 15.19 Favored 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 107.1 -1.445 . . . . 0.0 107.1 179.484 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 54.0 mtpt . . . . . 0 C--N 1.289 -2.032 0 O-C-N 127.248 2.843 . . . . 0.0 109.253 179.697 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 34.0 t . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -82.19 136.15 8.85 Favored 'Trans proline' 0 C--N 1.308 -1.594 0 C-N-CA 124.026 3.151 . . . . 0.0 113.516 162.76 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.403 ' SG ' ' N ' ' A' ' 5' ' ' LEU . 1.8 p -110.45 -156.87 0.6 Allowed 'General case' 0 N--CA 1.504 2.259 0 N-CA-C 107.601 -1.259 . . . . 0.0 107.601 179.778 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.403 ' N ' ' SG ' ' A' ' 4' ' ' CYS . 2.9 tt -118.85 99.97 7.09 Favored 'General case' 0 N--CA 1.503 2.212 0 N-CA-C 101.283 -3.599 . . . . 0.0 101.283 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 2.9 m -78.85 -176.11 4.81 Favored 'General case' 0 C--N 1.308 -1.214 0 N-CA-C 116.424 2.009 . . . . 0.0 116.424 -179.381 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 29.0 t70 . . . . . 0 C--N 1.298 -1.662 0 CA-C-N 112.319 -2.219 . . . . 0.0 109.843 -179.614 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 4.8 m . . . . . 0 N--CA 1.503 2.175 0 N-CA-C 115.385 1.624 . . . . 0.0 115.385 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 167.69 -179.36 41.13 Favored Glycine 0 N--CA 1.502 3.045 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 179.796 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 37.2 mm -132.71 143.94 38.18 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.399 0 O-C-N 124.555 0.797 . . . . 0.0 110.975 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.433 ' O ' HD12 ' A' ' 22' ' ' LEU . 3.9 pp -63.56 154.75 31.63 Favored 'General case' 0 N--CA 1.504 2.244 0 N-CA-C 109.117 -0.697 . . . . 0.0 109.117 179.518 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.552 ' O ' ' HA2' ' A' ' 44' ' ' GLY . 32.4 m95 -134.42 131.4 38.13 Favored 'General case' 0 C--N 1.308 -1.202 0 N-CA-C 118.91 2.93 . . . . 0.0 118.91 -179.694 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -87.57 53.48 2.8 Favored 'General case' 0 C--N 1.291 -1.973 0 CA-C-N 109.316 -3.584 . . . . 0.0 111.796 -179.245 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 2.7 m-85 -125.52 137.06 29.17 Favored Pre-proline 0 C--N 1.306 -1.302 0 CA-C-N 115.052 -0.976 . . . . 0.0 110.352 179.6 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_endo -73.81 -25.43 14.49 Favored 'Trans proline' 0 C--N 1.306 -1.696 1 C-N-CA 125.725 4.283 . . . . 0.0 112.817 177.746 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 5.9 p -95.03 20.66 8.68 Favored 'General case' 0 N--CA 1.493 1.706 0 CA-C-N 115.249 -0.887 . . . . 0.0 111.163 -179.875 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 89.91 -138.27 14.47 Favored Glycine 0 N--CA 1.496 2.687 0 N-CA-C 106.278 -2.729 . . . . 0.0 106.278 -179.817 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.526 ' SG ' ' CA ' ' A' ' 35' ' ' ASN . 29.7 m -69.28 150.05 97.3 Favored Pre-proline 0 C--N 1.305 -1.355 0 CA-C-N 117.496 0.648 . . . . 0.0 109.971 179.889 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.717 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 1.9 Cg_endo -78.31 159.29 29.6 Favored 'Trans proline' 0 C--N 1.31 -1.469 0 C-N-CA 123.207 2.604 . . . . 0.0 112.403 171.198 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 24.1 t -47.96 128.86 14.13 Favored 'General case' 0 C--N 1.305 -1.326 0 CA-C-N 113.168 -1.833 . . . . 0.0 109.3 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 100.51 -8.07 58.3 Favored Glycine 0 N--CA 1.495 2.607 0 CA-C-N 112.628 -2.078 . . . . 0.0 111.421 179.77 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' TRP . . . . . 0.717 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 48.3 m95 -110.29 162.94 14.14 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 106.83 -1.544 . . . . 0.0 106.83 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 78.6 t60 -143.22 29.82 1.44 Allowed 'General case' 0 N--CA 1.499 1.997 0 C-N-CA 118.34 -1.344 . . . . 0.0 113.135 -179.843 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . 0.526 ' CA ' ' SG ' ' A' ' 29' ' ' CYS . 12.1 t-20 62.02 147.13 0.02 OUTLIER 'General case' 0 N--CA 1.505 2.301 0 CA-C-O 123.109 1.433 . . . . 0.0 114.097 -179.79 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.841 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -117.41 -46.91 2.67 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-N 113.341 -1.754 . . . . 0.0 108.003 -179.666 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 19.4 ttpp -132.18 124.77 29.69 Favored 'General case' 0 N--CA 1.497 1.922 0 N-CA-C 107.814 -1.18 . . . . 0.0 107.814 179.43 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -87.13 22.07 2.18 Favored 'General case' 0 N--CA 1.493 1.688 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 179.788 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 16.9 m-70 -131.33 76.72 1.73 Allowed 'General case' 0 N--CA 1.492 1.645 0 CA-C-O 122.243 1.02 . . . . 0.0 108.882 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 68.83 -163.07 50.54 Favored Glycine 0 N--CA 1.492 2.418 0 CA-C-N 113.353 -1.749 . . . . 0.0 109.849 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . 0.446 ' HG2' ' O ' ' A' ' 44' ' ' GLY . 34.1 Cg_endo -71.86 175.14 43.78 Favored 'Cis proline' 0 N--CA 1.495 1.573 0 N-CA-C 107.635 -1.717 . . . . 0.0 107.635 -2.402 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . 0.442 ' C ' ' H ' ' A' ' 44' ' ' GLY . 23.4 m120 -91.53 -10.12 41.86 Favored 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 105.299 -2.112 . . . . 0.0 105.299 -179.484 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 16.1 mt -88.79 28.75 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.225 0 CA-C-N 113.447 -1.706 . . . . 0.0 110.338 -179.438 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.552 ' HA2' ' O ' ' A' ' 23' ' ' TRP . . . 115.98 135.29 5.65 Favored Glycine 0 N--CA 1.486 2.0 0 CA-C-N 111.827 -2.442 . . . . 0.0 112.687 179.789 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . 0.511 ' O ' ' N ' ' A' ' 23' ' ' TRP . 26.3 m95 -62.0 129.39 40.66 Favored 'General case' 0 N--CA 1.501 2.116 0 C-N-CA 120.19 -0.604 . . . . 0.0 111.388 -179.42 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' CYS . . . . . 0.841 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 46.4 t -88.52 114.72 25.43 Favored 'General case' 0 C--N 1.305 -1.359 1 N-CA-C 96.728 -5.286 . . . . 0.0 96.728 179.998 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.532 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 75.1 m -129.89 -176.18 3.84 Favored 'General case' 0 C--N 1.295 -1.768 1 CA-C-N 108.253 -4.067 . . . . 0.0 108.714 -179.407 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.507 ' O ' ' HA ' ' A' ' 33' ' ' TRP . 0.0 OUTLIER -149.97 169.74 20.48 Favored 'General case' 0 C--N 1.294 -1.836 0 C-N-CA 117.614 -1.634 . . . . 0.0 107.698 179.56 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 48.9 mtpt . . . . . 0 C--N 1.29 -2.02 0 O-C-N 127.577 3.048 . . . . 0.0 109.379 179.71 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 61.9 t . . . . . 0 N--CA 1.496 1.84 0 N-CA-C 108.026 -1.101 . . . . 0.0 108.026 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -76.22 158.93 37.27 Favored 'Trans proline' 0 C--N 1.309 -1.54 0 C-N-CA 124.509 3.473 . . . . 0.0 113.405 171.45 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -150.9 164.94 35.12 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 125.48 1.737 . . . . 0.0 108.036 179.614 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.484 HD23 ' N ' ' A' ' 6' ' ' CYS . 9.4 tt -79.38 168.18 19.85 Favored 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 103.404 -2.813 . . . . 0.0 103.404 179.759 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . 0.49 ' HB3' ' C ' ' A' ' 36' ' ' CYS . 3.5 m -140.93 -174.8 4.09 Favored 'General case' 0 C--N 1.302 -1.489 0 N-CA-C 116.662 2.097 . . . . 0.0 116.662 -179.257 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 30.7 t70 . . . . . 0 N--CA 1.492 1.654 0 CA-C-N 112.639 -2.073 . . . . 0.0 107.862 179.943 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 19.7 m . . . . . 0 N--CA 1.502 2.15 0 N-CA-C 112.681 0.623 . . . . 0.0 112.681 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -166.7 -162.46 18.32 Favored Glycine 0 N--CA 1.504 3.195 0 N-CA-C 110.904 -0.878 . . . . 0.0 110.904 -179.863 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 8.1 mm -135.75 146.48 29.59 Favored 'Isoleucine or valine' 0 N--CA 1.515 2.82 0 N-CA-C 113.992 1.108 . . . . 0.0 113.992 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.56 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.6 pp -64.25 151.15 44.41 Favored 'General case' 0 N--CA 1.505 2.317 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 179.17 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.448 ' N ' ' O ' ' A' ' 45' ' ' TRP . 22.3 m95 -133.45 137.41 45.7 Favored 'General case' 0 C--N 1.305 -1.347 0 N-CA-C 116.6 2.074 . . . . 0.0 116.6 -179.656 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -88.47 41.32 1.01 Allowed 'General case' 0 C--N 1.293 -1.87 0 CA-C-N 109.045 -3.707 . . . . 0.0 115.119 -179.408 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -114.67 129.28 25.11 Favored Pre-proline 0 N--CA 1.489 1.52 0 N-CA-C 115.45 1.648 . . . . 0.0 115.45 179.743 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -68.33 -21.53 41.07 Favored 'Trans proline' 0 C--N 1.307 -1.642 0 C-N-CA 123.402 2.734 . . . . 0.0 108.979 -175.106 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -91.32 1.29 57.22 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-N 112.864 -1.971 . . . . 0.0 110.797 179.752 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 107.72 -117.05 5.06 Favored Glycine 0 N--CA 1.498 2.828 0 N-CA-C 105.455 -3.058 . . . . 0.0 105.455 -179.831 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.533 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 10.2 m -93.12 150.23 38.83 Favored Pre-proline 0 C--N 1.305 -1.361 0 N-CA-C 108.404 -0.962 . . . . 0.0 108.404 179.632 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.712 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.5 OUTLIER -76.49 175.53 11.23 Favored 'Trans proline' 0 C--N 1.311 -1.42 0 C-N-CA 123.241 2.627 . . . . 0.0 115.66 176.777 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 16.4 p -50.47 102.88 0.04 OUTLIER 'General case' 0 C--N 1.299 -1.605 0 CA-C-N 112.671 -2.059 . . . . 0.0 112.724 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 112.12 -0.24 26.89 Favored Glycine 0 N--CA 1.503 3.127 0 O-C-N 124.332 1.02 . . . . 0.0 113.61 179.435 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' TRP . . . . . 0.712 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 45.6 m95 -112.3 163.73 14.05 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 107.289 -1.375 . . . . 0.0 107.289 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 73.5 t60 -146.37 37.45 1.02 Allowed 'General case' 0 N--CA 1.501 2.098 0 C-N-CA 118.014 -1.475 . . . . 0.0 114.54 -179.866 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . 0.533 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 23.7 t-20 60.04 149.42 0.02 OUTLIER 'General case' 0 N--CA 1.506 2.338 0 N-CA-C 115.763 1.764 . . . . 0.0 115.763 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.66 ' SG ' ' HB3' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -125.21 -44.91 1.86 Allowed 'General case' 0 C--N 1.303 -1.451 0 CA-C-N 113.52 -1.673 . . . . 0.0 108.067 -179.913 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . 0.46 ' C ' ' H ' ' A' ' 39' ' ' HIS . 36.9 ttmt -124.66 111.13 15.24 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 105.101 -2.185 . . . . 0.0 105.101 179.61 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.436 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -85.01 31.84 0.54 Allowed 'General case' 0 N--CA 1.494 1.749 0 N-CA-C 106.132 -1.803 . . . . 0.0 106.132 179.587 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . 0.46 ' H ' ' C ' ' A' ' 37' ' ' LYS . 4.5 m-70 -132.21 22.28 4.45 Favored 'General case' 0 N--CA 1.497 1.88 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 -179.612 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 107.89 -145.88 16.26 Favored Glycine 0 N--CA 1.494 2.514 0 N-CA-C 109.292 -1.523 . . . . 0.0 109.292 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . 0.659 ' CD ' ' SG ' ' A' ' 46' ' ' CYS . 8.4 Cg_endo -74.97 -173.54 12.5 Favored 'Cis proline' 0 N--CA 1.502 2.011 0 C-N-CA 129.013 0.839 . . . . 0.0 111.36 0.87 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . 0.466 ' C ' ' H ' ' A' ' 44' ' ' GLY . 0.2 OUTLIER -91.9 -8.61 45.9 Favored 'General case' 0 N--CA 1.487 1.385 0 N-CA-C 102.883 -3.006 . . . . 0.0 102.883 179.951 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.488 ' N ' HD12 ' A' ' 43' ' ' ILE . 4.0 mp -90.88 32.45 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 CA-C-O 123.159 1.457 . . . . 0.0 108.245 -179.419 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.466 ' H ' ' C ' ' A' ' 42' ' ' ASN . . . 102.89 127.74 6.19 Favored Glycine 0 N--CA 1.489 2.209 0 CA-C-N 111.88 -2.418 . . . . 0.0 107.094 -179.774 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . 0.448 ' O ' ' N ' ' A' ' 23' ' ' TRP . 6.7 m95 -54.8 135.67 47.32 Favored 'General case' 0 N--CA 1.509 2.485 0 CA-C-O 117.05 -1.452 . . . . 0.0 108.621 -179.519 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' CYS . . . . . 0.66 ' HB3' ' SG ' ' A' ' 36' ' ' CYS . 75.3 m -88.37 122.67 32.13 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 101.885 -3.376 . . . . 0.0 101.885 179.86 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.479 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 75.2 m -128.57 -174.71 3.31 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-N 110.43 -3.077 . . . . 0.0 108.739 -179.495 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.408 ' O ' ' HA ' ' A' ' 33' ' ' TRP . 0.0 OUTLIER -151.36 171.96 16.66 Favored 'General case' 0 C--N 1.299 -1.617 0 N-CA-C 106.684 -1.599 . . . . 0.0 106.684 179.176 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 92.3 mttt . . . . . 0 C--N 1.288 -2.076 0 O-C-N 125.675 1.859 . . . . 0.0 109.437 179.922 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 24.7 t . . . . . 0 N--CA 1.5 2.039 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.405 ' HA ' ' O ' ' A' ' 20' ' ' GLY . 6.9 Cg_endo -79.18 129.65 8.86 Favored 'Trans proline' 0 N--CA 1.491 1.371 0 C-N-CA 123.836 3.024 . . . . 0.0 114.268 165.034 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -119.2 -163.0 0.94 Allowed 'General case' 0 N--CA 1.495 1.822 0 N-CA-C 113.549 0.944 . . . . 0.0 113.549 -179.729 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.473 HD23 ' N ' ' A' ' 6' ' ' CYS . 9.6 tt -111.71 151.68 28.63 Favored 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 104.456 -2.424 . . . . 0.0 104.456 179.848 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . 0.473 ' N ' HD23 ' A' ' 5' ' ' LEU . 5.1 m -140.95 -171.05 3.17 Favored 'General case' 0 N--CA 1.483 1.189 0 N-CA-C 116.224 1.935 . . . . 0.0 116.224 -179.378 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 39.0 t70 . . . . . 0 N--CA 1.49 1.558 0 CA-C-N 112.233 -2.258 . . . . 0.0 108.09 -179.958 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 41.4 t . . . . . 0 N--CA 1.5 2.041 0 CA-C-O 121.124 0.488 . . . . 0.0 110.468 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.517 ' HA2' ' HD3' ' A' ' 48' ' ' LYS . . . -170.99 119.23 0.79 Allowed Glycine 0 N--CA 1.499 2.843 0 CA-C-O 117.979 -1.456 . . . . 0.0 112.32 179.911 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.461 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 37.6 mm -102.71 131.13 51.56 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.312 0 N-CA-C 103.429 -2.804 . . . . 0.0 103.429 179.308 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.595 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 2.1 pp -64.45 158.75 23.05 Favored 'General case' 0 N--CA 1.496 1.85 0 C-N-CA 118.189 -1.404 . . . . 0.0 107.811 179.785 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.48 ' N ' ' O ' ' A' ' 45' ' ' TRP . 19.4 m95 -138.6 135.51 35.02 Favored 'General case' 0 C--N 1.306 -1.324 0 N-CA-C 115.919 1.822 . . . . 0.0 115.919 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -89.06 41.64 1.04 Allowed 'General case' 0 C--N 1.293 -1.878 0 CA-C-N 109.803 -3.362 . . . . 0.0 115.851 -179.611 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.444 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 1.0 OUTLIER -118.34 126.89 26.92 Favored Pre-proline 0 N--CA 1.487 1.379 0 CA-C-O 122.417 1.104 . . . . 0.0 110.225 179.646 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -64.82 -28.71 59.12 Favored 'Trans proline' 0 C--N 1.299 -2.039 0 C-N-CA 122.096 1.864 . . . . 0.0 108.781 -175.237 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 4.6 p -82.36 5.55 19.94 Favored 'General case' 0 N--CA 1.492 1.653 0 CA-C-N 114.661 -1.154 . . . . 0.0 112.52 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 105.79 -128.81 9.52 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 106.032 -2.827 . . . . 0.0 106.032 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.505 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 4.3 m -83.9 145.55 47.04 Favored Pre-proline 0 C--N 1.302 -1.486 0 C-N-CA 120.595 -0.442 . . . . 0.0 110.301 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.693 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 7.0 Cg_endo -75.01 162.27 37.39 Favored 'Trans proline' 0 C--N 1.312 -1.343 0 C-N-CA 123.317 2.678 . . . . 0.0 113.958 176.769 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 18.8 t -45.66 111.94 0.4 Allowed 'General case' 0 N--CA 1.492 1.636 0 CA-C-N 114.362 -1.29 . . . . 0.0 110.205 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 114.14 -8.64 23.0 Favored Glycine 0 N--CA 1.5 2.963 0 CA-C-N 114.573 -1.194 . . . . 0.0 112.93 179.596 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' TRP . . . . . 0.693 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 50.9 m95 -110.76 161.2 16.01 Favored 'General case' 0 N--CA 1.489 1.498 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . 0.429 ' O ' ' ND1' ' A' ' 34' ' ' HIS . 56.5 t-80 -146.83 46.34 1.18 Allowed 'General case' 0 N--CA 1.499 1.978 0 C-N-CA 117.741 -1.584 . . . . 0.0 113.508 -179.812 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . 0.505 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 21.4 t-20 62.64 145.81 0.02 OUTLIER 'General case' 0 N--CA 1.511 2.6 0 N-CA-C 116.418 2.007 . . . . 0.0 116.418 179.846 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.791 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 0.7 OUTLIER -116.29 -43.0 2.98 Favored 'General case' 0 N--CA 1.485 1.28 0 N-CA-C 106.927 -1.509 . . . . 0.0 106.927 179.482 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 8.8 ptpp? -124.31 127.24 47.33 Favored 'General case' 0 N--CA 1.498 1.94 0 N-CA-C 107.406 -1.331 . . . . 0.0 107.406 179.319 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.445 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -77.8 43.14 0.4 Allowed 'General case' 0 N--CA 1.497 1.909 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 179.869 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . 0.445 ' ND1' ' C ' ' A' ' 38' ' ' ALA . 3.5 m-70 -132.05 -81.35 0.51 Allowed 'General case' 0 N--CA 1.498 1.972 0 CA-C-O 119.084 -0.484 . . . . 0.0 110.748 -179.673 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -153.01 -130.38 1.51 Allowed Glycine 0 N--CA 1.509 3.524 0 N-CA-C 109.297 -1.521 . . . . 0.0 109.297 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 0.2 OUTLIER -81.07 -170.17 8.28 Favored 'Cis proline' 0 N--CA 1.5 1.903 0 CA-C-N 120.25 2.025 . . . . 0.0 111.319 -4.178 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 59.6 t30 -92.62 -13.97 28.84 Favored 'General case' 0 N--CA 1.486 1.365 0 N-CA-C 106.094 -1.817 . . . . 0.0 106.094 -179.798 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 37.3 pt -86.6 26.03 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 CA-C-N 113.591 -1.64 . . . . 0.0 113.382 -179.26 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.444 ' HA2' ' O ' ' A' ' 23' ' ' TRP . . . 111.62 119.51 3.84 Favored Glycine 0 N--CA 1.486 2.007 0 CA-C-N 111.602 -2.545 . . . . 0.0 106.875 -179.836 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . 0.48 ' O ' ' N ' ' A' ' 23' ' ' TRP . 20.2 m95 -51.45 133.72 29.44 Favored 'General case' 0 N--CA 1.501 2.095 0 CA-C-N 113.253 -1.473 . . . . 0.0 111.111 -179.432 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' CYS . . . . . 0.791 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 22.8 t -89.26 118.69 29.12 Favored 'General case' 0 C--N 1.305 -1.359 1 N-CA-C 99.746 -4.168 . . . . 0.0 99.746 179.571 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.467 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 86.4 m -126.96 -176.27 3.66 Favored 'General case' 0 CA--C 1.487 -1.443 0 CA-C-N 111.172 -2.74 . . . . 0.0 112.604 -179.357 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.517 ' HD3' ' HA2' ' A' ' 20' ' ' GLY . 34.8 tptt -151.49 157.46 42.33 Favored 'General case' 0 C--N 1.297 -1.697 0 C-N-CA 118.297 -1.361 . . . . 0.0 109.999 -179.821 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 23.8 mttm . . . . . 0 N--CA 1.505 2.298 0 O-C-N 127.039 2.712 . . . . 0.0 110.666 179.646 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 38.9 t . . . . . 0 N--CA 1.494 1.774 0 N-CA-C 103.962 -2.607 . . . . 0.0 103.962 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.429 ' HA ' ' O ' ' A' ' 20' ' ' GLY . 18.6 Cg_endo -72.82 138.13 28.26 Favored 'Trans proline' 0 C--N 1.305 -1.761 0 C-N-CA 122.991 2.461 . . . . 0.0 117.568 163.662 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.556 ' SG ' ' SG ' ' A' ' 6' ' ' CYS . 12.5 p -124.56 159.1 31.4 Favored 'General case' 0 N--CA 1.494 1.766 0 CA-C-N 114.818 -1.083 . . . . 0.0 109.46 179.52 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 10.3 tp -79.7 84.03 5.58 Favored 'General case' 0 N--CA 1.491 1.62 1 N-CA-C 99.612 -4.218 . . . . 0.0 99.612 179.465 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . 0.657 ' SG ' ' HA3' ' A' ' 20' ' ' GLY . 34.7 m -68.41 175.07 3.57 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-O 123.391 1.567 . . . . 0.0 111.567 -179.716 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 12.7 t70 . . . . . 0 C--N 1.294 -1.809 0 CA-C-N 111.498 -2.592 . . . . 0.0 114.506 -179.202 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 12.4 t . . . . . 0 N--CA 1.504 2.274 0 CA-C-O 118.405 -0.807 . . . . 0.0 112.734 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.657 ' HA3' ' SG ' ' A' ' 6' ' ' CYS . . . -162.66 139.09 5.71 Favored Glycine 0 N--CA 1.493 2.467 0 CA-C-O 118.29 -1.283 . . . . 0.0 110.553 -179.785 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.466 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 32.7 mm -102.57 140.69 20.3 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.102 0 N-CA-C 104.268 -2.493 . . . . 0.0 104.268 179.571 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.595 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.6 pp -63.87 146.08 54.65 Favored 'General case' 0 N--CA 1.504 2.238 0 C-N-CA 117.407 -1.717 . . . . 0.0 112.154 179.727 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 40.6 m95 -130.82 131.88 44.9 Favored 'General case' 0 N--CA 1.486 1.327 0 N-CA-C 119.404 3.113 . . . . 0.0 119.404 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -89.39 51.32 2.09 Favored 'General case' 0 C--N 1.301 -1.512 1 CA-C-N 107.895 -4.229 . . . . 0.0 111.334 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.53 ' CE1' ' HB3' ' A' ' 30' ' ' PRO . 2.2 m-85 -125.99 126.37 24.81 Favored Pre-proline 0 N--CA 1.488 1.448 0 CA-C-O 121.588 0.708 . . . . 0.0 111.898 179.834 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -64.13 -19.99 66.79 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 C-N-CA 123.764 2.976 . . . . 0.0 110.286 -178.12 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 10.4 p -88.04 -6.69 57.82 Favored 'General case' 0 N--CA 1.491 1.587 0 CA-C-N 114.004 -1.453 . . . . 0.0 110.933 179.753 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.592 ' HA2' ' CD1' ' A' ' 45' ' ' TRP . . . 114.81 -95.3 0.71 Allowed Glycine 0 N--CA 1.483 1.776 1 N-CA-C 100.932 -4.867 . . . . 0.0 100.932 -179.531 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.541 ' HB3' ' HB2' ' A' ' 33' ' ' TRP . 7.8 m -101.17 164.37 16.15 Favored Pre-proline 0 C--N 1.302 -1.459 0 CA-C-N 114.006 -1.097 . . . . 0.0 108.676 179.768 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.722 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.3 OUTLIER -83.83 167.1 13.05 Favored 'Trans proline' 0 C--N 1.311 -1.412 0 C-N-CA 124.917 3.745 . . . . 0.0 116.177 158.24 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 29.1 t -55.86 126.33 25.22 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-N 113.427 -1.715 . . . . 0.0 109.62 -179.843 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 104.58 -7.12 45.8 Favored Glycine 0 N--CA 1.495 2.628 0 CA-C-N 112.664 -2.062 . . . . 0.0 111.46 179.893 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' TRP . . . . . 0.722 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 49.7 m95 -113.4 152.96 29.36 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 106.335 -1.728 . . . . 0.0 106.335 -179.872 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 64.7 t60 -140.42 44.5 1.86 Allowed 'General case' 0 N--CA 1.493 1.717 0 C-N-CA 119.419 -0.913 . . . . 0.0 109.51 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . 0.571 ' HA ' ' SG ' ' A' ' 47' ' ' CYS . 23.2 t-20 54.74 147.86 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.171 0 CA-C-N 112.951 -1.932 . . . . 0.0 115.428 -179.985 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.676 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 0.8 OUTLIER -119.76 -36.27 3.34 Favored 'General case' 0 C--N 1.309 -1.184 0 N-CA-C 106.632 -1.618 . . . . 0.0 106.632 179.825 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 19.5 ttpt -139.02 122.4 17.16 Favored 'General case' 0 N--CA 1.486 1.336 0 CA-C-O 123.589 1.661 . . . . 0.0 109.98 179.668 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.43 ' O ' ' ND1' ' A' ' 39' ' ' HIS . . . -96.0 21.18 9.03 Favored 'General case' 0 C--N 1.303 -1.419 0 CA-C-N 112.273 -2.239 . . . . 0.0 105.541 179.72 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . 0.43 ' ND1' ' O ' ' A' ' 38' ' ' ALA . 10.7 m-70 -135.72 69.46 1.43 Allowed 'General case' 0 N--CA 1.497 1.895 0 N-CA-C 109.372 -0.603 . . . . 0.0 109.372 -179.719 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 84.08 176.47 51.17 Favored Glycine 0 N--CA 1.502 3.036 0 N-CA-C 106.165 -2.774 . . . . 0.0 106.165 -179.739 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_endo -60.96 169.8 19.37 Favored 'Cis proline' 0 N--CA 1.504 2.089 0 CA-C-N 119.771 1.786 . . . . 0.0 114.434 1.664 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 17.0 t-20 -92.45 -9.08 42.81 Favored 'General case' 0 N--CA 1.484 1.232 0 N-CA-C 104.773 -2.306 . . . . 0.0 104.773 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 17.6 mt -92.7 29.72 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.063 0 CA-C-O 123.059 1.409 . . . . 0.0 109.819 -179.29 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.465 ' C ' ' CD1' ' A' ' 45' ' ' TRP . . . 129.53 -116.58 2.17 Favored Glycine 0 N--CA 1.484 1.84 0 N-CA-C 103.744 -3.742 . . . . 0.0 103.744 -179.772 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . 0.592 ' CD1' ' HA2' ' A' ' 28' ' ' GLY . 3.0 m95 -155.26 -172.07 4.04 Favored 'General case' 0 N--CA 1.507 2.422 0 N-CA-C 104.254 -2.498 . . . . 0.0 104.254 179.853 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' CYS . . . . . 0.676 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 26.2 t -135.75 126.84 27.96 Favored 'General case' 0 N--CA 1.498 1.958 1 N-CA-C 98.985 -4.45 . . . . 0.0 98.985 179.493 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.573 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 70.9 m -131.47 -179.68 5.51 Favored 'General case' 0 CA--C 1.471 -2.061 0 N-CA-C 116.24 1.941 . . . . 0.0 116.24 -178.663 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.567 ' HD3' ' HA2' ' A' ' 20' ' ' GLY . 44.1 tptt -151.04 149.21 29.28 Favored 'General case' 0 C--N 1.297 -1.693 0 C-N-CA 118.716 -1.194 . . . . 0.0 110.672 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . 0.479 ' H ' ' HD2' ' A' ' 48' ' ' LYS . 93.4 mttt . . . . . 0 N--CA 1.494 1.774 0 CA-C-N 112.133 -2.303 . . . . 0.0 108.59 179.317 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 21.4 t . . . . . 0 N--CA 1.497 1.919 0 N-CA-C 106.694 -1.595 . . . . 0.0 106.694 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.419 ' HA ' ' O ' ' A' ' 20' ' ' GLY . 6.9 Cg_endo -77.84 149.76 26.49 Favored 'Trans proline' 0 C--N 1.309 -1.532 0 C-N-CA 122.536 2.157 . . . . 0.0 110.314 169.521 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -138.95 169.43 17.81 Favored 'General case' 0 C--N 1.3 -1.557 0 CA-C-O 121.862 0.839 . . . . 0.0 110.142 179.836 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.413 HD23 ' N ' ' A' ' 6' ' ' CYS . 8.5 tt -91.88 150.52 21.0 Favored 'General case' 0 N--CA 1.492 1.655 0 N-CA-C 102.229 -3.248 . . . . 0.0 102.229 179.647 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . 0.443 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 3.1 m -139.78 -166.46 2.08 Favored 'General case' 0 N--CA 1.493 1.72 0 N-CA-C 113.973 1.101 . . . . 0.0 113.973 -179.519 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . 0.472 ' H ' ' HB3' ' A' ' 37' ' ' LYS . 30.1 t70 . . . . . 0 N--CA 1.496 1.86 0 CA-C-N 112.612 -2.085 . . . . 0.0 108.091 -179.754 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 64.0 p . . . . . 0 N--CA 1.499 1.984 0 N-CA-C 112.904 0.705 . . . . 0.0 112.904 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.419 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -135.45 156.49 22.72 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 108.791 -1.724 . . . . 0.0 108.791 -179.906 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.448 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 44.5 mm -115.56 144.93 22.03 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 N-CA-C 106.098 -1.816 . . . . 0.0 106.098 179.708 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.609 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 4.1 pp -72.69 151.0 42.45 Favored 'General case' 0 N--CA 1.488 1.464 0 C-N-CA 118.438 -1.305 . . . . 0.0 109.041 179.752 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 44.1 m95 -132.31 134.21 44.96 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 117.721 2.489 . . . . 0.0 117.721 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.3 m-85 -89.2 53.13 2.56 Favored 'General case' 0 C--N 1.296 -1.744 1 CA-C-N 107.623 -4.353 . . . . 0.0 109.43 -179.791 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.429 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 2.4 m-85 -126.58 139.2 34.13 Favored Pre-proline 0 C--N 1.306 -1.294 0 CA-C-O 121.671 0.748 . . . . 0.0 111.964 -179.962 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.68 -18.01 37.63 Favored 'Trans proline' 0 C--N 1.305 -1.734 1 C-N-CA 125.415 4.077 . . . . 0.0 110.6 177.161 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 10.7 p -100.26 22.65 11.19 Favored 'General case' 0 C--N 1.299 -1.613 0 CA-C-N 113.334 -1.757 . . . . 0.0 110.886 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.577 ' HA2' ' CD1' ' A' ' 45' ' ' TRP . . . 81.4 -89.98 1.41 Allowed Glycine 0 N--CA 1.484 1.838 1 N-CA-C 102.854 -4.098 . . . . 0.0 102.854 -179.674 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.462 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 24.8 m -98.7 163.57 18.67 Favored Pre-proline 0 C--N 1.302 -1.457 0 CA-C-N 113.719 -1.24 . . . . 0.0 110.996 -179.887 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.696 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.1 OUTLIER -89.05 163.76 5.83 Favored 'Trans proline' 0 CA--C 1.554 1.496 1 C-N-CA 126.701 4.934 . . . . 0.0 117.122 155.785 . . . . . . . . 4 4 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 4.1 m -51.06 111.82 0.62 Allowed 'General case' 0 C--N 1.301 -1.526 0 CA-C-N 112.36 -2.2 . . . . 0.0 114.135 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 113.7 -6.54 24.22 Favored Glycine 0 N--CA 1.506 3.352 0 CA-C-N 115.046 -0.979 . . . . 0.0 112.638 179.68 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' TRP . . . . . 0.696 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 54.7 m95 -106.96 167.17 10.07 Favored 'General case' 0 C--N 1.299 -1.619 0 N-CA-C 106.517 -1.661 . . . . 0.0 106.517 -179.762 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 67.8 t60 -146.96 37.7 0.97 Allowed 'General case' 0 N--CA 1.493 1.69 0 C-N-CA 116.845 -1.942 . . . . 0.0 113.236 179.82 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . 0.499 ' HA ' ' SG ' ' A' ' 47' ' ' CYS . 13.9 t-20 55.88 143.04 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.113 0 N-CA-C 117.484 2.401 . . . . 0.0 117.484 179.556 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.842 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 2.7 p -120.3 -28.37 5.05 Favored 'General case' 0 N--CA 1.486 1.329 0 CA-C-N 115.652 -0.703 . . . . 0.0 111.345 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . 0.472 ' HB3' ' H ' ' A' ' 7' ' ' ASP . 9.5 ptpt -151.05 151.15 31.61 Favored 'General case' 0 N--CA 1.495 1.792 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 179.105 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.449 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -117.0 35.06 4.8 Favored 'General case' 0 N--CA 1.491 1.607 0 N-CA-C 102.388 -3.19 . . . . 0.0 102.388 179.661 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . 0.449 ' ND1' ' C ' ' A' ' 38' ' ' ALA . 4.5 m-70 -128.64 60.31 1.52 Allowed 'General case' 0 N--CA 1.497 1.881 0 N-CA-C 106.943 -1.503 . . . . 0.0 106.943 -179.534 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 74.19 -149.45 40.81 Favored Glycine 0 N--CA 1.496 2.646 0 N-CA-C 104.854 -3.298 . . . . 0.0 104.854 -179.702 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . 0.412 ' HD2' ' C ' ' A' ' 45' ' ' TRP . 42.1 Cg_endo -48.53 176.6 0.39 Allowed 'Cis proline' 0 N--CA 1.504 2.104 0 CA-C-N 119.765 1.783 . . . . 0.0 115.478 -5.499 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.5 m-20 -92.08 -7.77 47.72 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 104.34 -2.467 . . . . 0.0 104.34 -179.719 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 15.0 mt -99.53 22.29 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.85 0 CA-C-O 123.99 1.853 . . . . 0.0 113.006 -179.345 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 133.08 -119.87 2.48 Favored Glycine 0 C--N 1.288 -2.094 0 N-CA-C 104.195 -3.562 . . . . 0.0 104.195 -179.857 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . 0.577 ' CD1' ' HA2' ' A' ' 28' ' ' GLY . 3.9 m95 -152.56 -169.22 3.28 Favored 'General case' 0 N--CA 1.511 2.588 0 N-CA-C 106.923 -1.51 . . . . 0.0 106.923 -179.917 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' CYS . . . . . 0.842 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 43.8 t -139.17 129.4 25.39 Favored 'General case' 0 C--N 1.313 -0.982 0 N-CA-C 101.273 -3.603 . . . . 0.0 101.273 179.13 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.499 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 71.4 m -135.0 -172.13 2.97 Favored 'General case' 0 C--N 1.294 -1.805 0 CA-C-N 111.295 -2.684 . . . . 0.0 108.479 -179.435 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.406 ' N ' ' CD ' ' A' ' 48' ' ' LYS . 0.0 OUTLIER -150.55 173.5 14.03 Favored 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 107.125 -1.435 . . . . 0.0 107.125 179.352 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.499 1.993 0 O-C-N 125.803 1.939 . . . . 0.0 106.681 179.728 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.415 ' HB ' HD23 ' A' ' 22' ' ' LEU . 22.0 t . . . . . 0 N--CA 1.497 1.893 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -72.28 149.65 51.58 Favored 'Trans proline' 0 N--CA 1.494 1.506 0 C-N-CA 124.161 3.24 . . . . 0.0 112.716 167.625 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.595 ' SG ' ' HB3' ' A' ' 22' ' ' LEU . 0.1 OUTLIER -136.88 -176.89 4.51 Favored 'General case' 0 N--CA 1.496 1.844 0 CA-C-N 115.349 -0.842 . . . . 0.0 111.438 179.631 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 6.4 tt -91.15 110.93 22.21 Favored 'General case' 0 N--CA 1.491 1.587 0 C-N-CA 119.428 -0.909 . . . . 0.0 108.829 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . 0.423 ' SG ' ' HA3' ' A' ' 20' ' ' GLY . 7.7 m -88.13 178.42 6.64 Favored 'General case' 0 C--N 1.31 -1.123 0 CA-C-O 123.282 1.515 . . . . 0.0 113.827 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 9.4 t70 . . . . . 0 C--N 1.297 -1.712 0 CA-C-N 111.501 -2.59 . . . . 0.0 110.123 -179.84 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 8.9 t . . . . . 0 N--CA 1.501 2.112 0 CA-C-O 120.901 0.381 . . . . 0.0 111.077 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.423 ' HA3' ' SG ' ' A' ' 6' ' ' CYS . . . -154.4 141.33 8.13 Favored Glycine 0 N--CA 1.496 2.634 0 N-CA-C 110.349 -1.1 . . . . 0.0 110.349 179.987 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.432 ' N ' ' O ' ' A' ' 47' ' ' CYS . 40.8 mm -99.64 138.89 22.61 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.452 0 N-CA-C 107.122 -1.436 . . . . 0.0 107.122 179.767 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.595 ' HB3' ' SG ' ' A' ' 4' ' ' CYS . 1.3 pp -68.97 146.93 52.33 Favored 'General case' 0 N--CA 1.495 1.8 0 C-N-CA 118.925 -1.11 . . . . 0.0 109.155 179.889 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 29.9 m95 -129.06 135.03 48.37 Favored 'General case' 0 C--N 1.307 -1.246 0 N-CA-C 117.882 2.549 . . . . 0.0 117.882 -179.786 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -89.38 49.25 1.72 Allowed 'General case' 0 C--N 1.298 -1.635 1 CA-C-N 108.047 -4.16 . . . . 0.0 113.163 -179.791 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.403 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 2.0 m-85 -122.08 139.3 30.19 Favored Pre-proline 0 C--N 1.301 -1.542 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 179.573 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 13.9 Cg_endo -76.29 -26.3 9.07 Favored 'Trans proline' 0 C--N 1.303 -1.86 0 C-N-CA 125.255 3.97 . . . . 0.0 112.841 174.42 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -88.66 11.94 16.11 Favored 'General case' 0 N--CA 1.494 1.748 0 CA-C-N 114.876 -1.056 . . . . 0.0 113.224 -179.831 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 97.91 -127.2 9.14 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 103.755 -3.738 . . . . 0.0 103.755 -179.722 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.527 ' HB3' ' HB2' ' A' ' 33' ' ' TRP . 8.3 m -85.38 147.04 46.04 Favored Pre-proline 0 C--N 1.303 -1.444 0 CA-C-N 117.716 0.758 . . . . 0.0 110.776 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.698 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 8.5 Cg_endo -75.19 168.28 25.05 Favored 'Trans proline' 0 C--N 1.308 -1.602 0 C-N-CA 123.037 2.491 . . . . 0.0 113.795 176.006 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 2.9 m -45.45 101.45 0.02 OUTLIER 'General case' 0 C--N 1.297 -1.68 0 CA-C-N 112.642 -2.072 . . . . 0.0 113.423 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 116.0 -2.11 21.12 Favored Glycine 0 N--CA 1.507 3.427 0 C-N-CA 120.945 -0.645 . . . . 0.0 114.057 179.63 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' TRP . . . . . 0.698 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 55.4 m95 -111.13 158.29 19.05 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 106.46 -1.682 . . . . 0.0 106.46 -179.851 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 2.0 t-80 -138.54 34.08 2.25 Favored 'General case' 0 N--CA 1.492 1.667 0 C-N-CA 117.615 -1.634 . . . . 0.0 112.507 -179.739 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . 0.507 ' HA ' ' SG ' ' A' ' 29' ' ' CYS . 0.3 OUTLIER 66.4 138.21 0.03 OUTLIER 'General case' 0 N--CA 1.509 2.498 0 N-CA-C 116.566 2.061 . . . . 0.0 116.566 179.734 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.683 ' SG ' ' CB ' ' A' ' 46' ' ' CYS . 0.8 OUTLIER -114.34 -33.37 5.65 Favored 'General case' 0 N--CA 1.484 1.243 0 N-CA-C 104.541 -2.392 . . . . 0.0 104.541 179.485 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 20.7 ptmt -146.4 139.95 25.97 Favored 'General case' 0 N--CA 1.494 1.764 0 CA-C-N 115.481 -0.781 . . . . 0.0 110.069 179.503 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.449 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -112.17 34.81 4.05 Favored 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 103.898 -2.63 . . . . 0.0 103.898 179.833 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . 0.449 ' ND1' ' C ' ' A' ' 38' ' ' ALA . 4.1 m-70 -129.12 57.28 1.65 Allowed 'General case' 0 N--CA 1.499 1.981 0 N-CA-C 107.611 -1.255 . . . . 0.0 107.611 -179.735 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 72.75 -142.04 31.56 Favored Glycine 0 N--CA 1.496 2.695 0 N-CA-C 106.739 -2.544 . . . . 0.0 106.739 -179.656 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . 0.46 ' HG2' ' O ' ' A' ' 44' ' ' GLY . 94.3 Cg_endo -62.34 -169.19 1.42 Allowed 'Cis proline' 0 N--CA 1.496 1.621 0 CA-C-N 118.804 1.302 . . . . 0.0 112.876 -5.065 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 54.2 t30 -93.66 1.53 56.58 Favored 'General case' 0 C--N 1.308 -1.217 0 N-CA-C 105.045 -2.206 . . . . 0.0 105.045 -179.334 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.443 ' N ' HD12 ' A' ' 43' ' ' ILE . 1.1 mp -120.28 37.46 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 O-C-N 125.126 1.516 . . . . 0.0 114.843 -179.008 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.46 ' O ' ' HG2' ' A' ' 41' ' ' PRO . . . 119.59 149.99 8.56 Favored Glycine 0 N--CA 1.485 1.963 0 N-CA-C 106.85 -2.5 . . . . 0.0 106.85 179.932 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . 0.403 ' NE1' ' O ' ' A' ' 25' ' ' TYR . 5.1 m95 -89.38 136.42 33.04 Favored 'General case' 0 N--CA 1.506 2.326 0 CA-C-O 117.175 -1.393 . . . . 0.0 108.329 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' CYS . . . . . 0.683 ' CB ' ' SG ' ' A' ' 36' ' ' CYS . 59.1 m -88.77 127.34 35.6 Favored 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 101.957 -3.349 . . . . 0.0 101.957 179.527 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.569 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 79.7 m -129.81 -174.95 3.45 Favored 'General case' 0 C--N 1.299 -1.601 0 CA-C-N 110.959 -2.837 . . . . 0.0 113.817 -179.243 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.433 ' HD2' ' H ' ' A' ' 49' ' ' LYS . 25.7 tptp -151.6 150.68 30.57 Favored 'General case' 0 C--N 1.295 -1.781 0 C-N-CA 118.57 -1.252 . . . . 0.0 110.26 -179.907 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . 0.433 ' H ' ' HD2' ' A' ' 48' ' ' LYS . 6.0 mtpt . . . . . 0 N--CA 1.499 2.015 0 O-C-N 126.407 2.317 . . . . 0.0 108.422 179.448 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 40.0 t . . . . . 0 N--CA 1.496 1.861 0 N-CA-C 106.863 -1.532 . . . . 0.0 106.863 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -70.66 148.61 59.61 Favored 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 123.533 2.822 . . . . 0.0 111.718 172.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.522 ' SG ' ' HB3' ' A' ' 22' ' ' LEU . 0.8 OUTLIER -146.32 163.3 35.96 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 124.24 0.962 . . . . 0.0 109.724 179.779 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.43 HD23 ' N ' ' A' ' 6' ' ' CYS . 8.9 tt -79.41 150.68 31.25 Favored 'General case' 0 N--CA 1.488 1.446 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 -179.833 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . 0.501 ' HB3' ' HB3' ' A' ' 37' ' ' LYS . 2.5 m -137.83 -145.19 0.19 Allowed 'General case' 0 N--CA 1.491 1.607 0 N-CA-C 116.316 1.969 . . . . 0.0 116.316 -179.663 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . 0.401 ' HB3' ' HA ' ' A' ' 37' ' ' LYS . 18.5 t70 . . . . . 0 N--CA 1.493 1.711 0 N-CA-C 105.941 -1.874 . . . . 0.0 105.941 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 7.3 t . . . . . 0 N--CA 1.498 1.953 0 N-CA-C 107.138 -1.43 . . . . 0.0 107.138 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 170.42 154.67 9.65 Favored Glycine 0 N--CA 1.493 2.448 0 CA-C-N 114.905 -1.043 . . . . 0.0 113.626 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.434 ' N ' ' O ' ' A' ' 47' ' ' CYS . 40.5 mm -116.82 144.77 23.74 Favored 'Isoleucine or valine' 0 N--CA 1.51 2.56 0 N-CA-C 107.639 -1.245 . . . . 0.0 107.639 179.736 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.623 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.8 pp -68.27 151.62 46.65 Favored 'General case' 0 N--CA 1.501 2.123 0 C-N-CA 117.543 -1.663 . . . . 0.0 107.528 179.447 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 22.1 m95 -131.2 140.33 49.87 Favored 'General case' 0 C--N 1.308 -1.198 0 CA-C-O 124.964 2.316 . . . . 0.0 116.985 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.5 m-30 -89.43 35.18 0.81 Allowed 'General case' 0 C--N 1.297 -1.696 1 CA-C-N 107.868 -4.242 . . . . 0.0 115.23 -179.636 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.438 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 1.2 m-30 -111.02 115.17 53.25 Favored Pre-proline 0 C--N 1.301 -1.506 0 N-CA-C 107.036 -1.468 . . . . 0.0 107.036 179.64 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo -61.27 -19.73 65.13 Favored 'Trans proline' 0 C--N 1.299 -2.031 0 C-N-CA 121.007 1.138 . . . . 0.0 109.524 -175.212 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 1.6 p -91.67 1.81 56.9 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 124.396 1.06 . . . . 0.0 112.574 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 121.03 -130.99 8.46 Favored Glycine 0 N--CA 1.497 2.739 0 N-CA-C 108.207 -1.957 . . . . 0.0 108.207 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.617 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 8.4 m -93.36 150.28 38.73 Favored Pre-proline 0 C--N 1.303 -1.441 0 CA-C-N 117.382 0.591 . . . . 0.0 109.868 -179.938 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.72 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.7 OUTLIER -76.13 162.1 34.63 Favored 'Trans proline' 0 C--N 1.309 -1.545 0 C-N-CA 122.515 2.143 . . . . 0.0 113.206 176.079 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 26.4 t -46.14 110.44 0.27 Allowed 'General case' 0 N--CA 1.493 1.692 0 CA-C-N 113.12 -1.855 . . . . 0.0 111.013 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 113.95 -5.57 23.92 Favored Glycine 0 N--CA 1.5 2.936 0 CA-C-N 114.405 -1.27 . . . . 0.0 111.678 179.772 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' TRP . . . . . 0.72 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 35.4 m95 -117.5 152.59 34.74 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 106.992 -1.484 . . . . 0.0 106.992 -179.827 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 55.4 t60 -143.04 42.26 1.54 Allowed 'General case' 0 N--CA 1.496 1.872 0 C-N-CA 117.389 -1.725 . . . . 0.0 112.436 179.866 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . 0.617 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 27.5 t-20 60.63 149.98 0.02 OUTLIER 'General case' 0 N--CA 1.506 2.347 0 N-CA-C 117.947 2.573 . . . . 0.0 117.947 179.742 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.696 ' SG ' ' CB ' ' A' ' 46' ' ' CYS . 13.9 p -115.82 -16.41 11.19 Favored 'General case' 0 N--CA 1.485 1.3 0 CA-C-N 114.352 -1.295 . . . . 0.0 110.983 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . 0.501 ' HB3' ' HB3' ' A' ' 6' ' ' CYS . 15.3 ptmt -144.7 127.04 15.83 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.953 -0.467 . . . . 0.0 111.83 -179.967 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.451 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -80.98 44.29 0.75 Allowed 'General case' 0 N--CA 1.493 1.677 0 N-CA-C 106.606 -1.627 . . . . 0.0 106.606 179.618 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . 0.467 ' H ' ' C ' ' A' ' 37' ' ' LYS . 2.9 m-70 -131.24 -116.6 0.23 Allowed 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 101.53 -3.508 . . . . 0.0 101.53 -179.845 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -126.68 -113.11 1.82 Allowed Glycine 0 N--CA 1.506 3.311 0 N-CA-C 110.782 -0.927 . . . . 0.0 110.782 179.785 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . 0.423 ' HG2' ' O ' ' A' ' 44' ' ' GLY . 83.1 Cg_endo -65.7 -164.77 1.43 Allowed 'Cis proline' 0 N--CA 1.503 2.08 0 N-CA-C 116.316 1.622 . . . . 0.0 116.316 -4.057 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -93.03 -13.91 28.05 Favored 'General case' 0 N--CA 1.486 1.356 0 N-CA-C 106.233 -1.766 . . . . 0.0 106.233 -179.298 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 27.1 pt -103.52 28.76 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.148 0 O-C-N 125.913 2.008 . . . . 0.0 116.234 -179.135 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.423 ' O ' ' HG2' ' A' ' 41' ' ' PRO . . . 129.05 168.36 12.35 Favored Glycine 0 C--N 1.292 -1.892 1 N-CA-C 102.149 -4.38 . . . . 0.0 102.149 -179.973 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . 0.438 ' NE1' ' O ' ' A' ' 25' ' ' TYR . 26.2 m95 -102.9 137.3 41.28 Favored 'General case' 0 C--N 1.281 -2.396 0 N-CA-C 105.259 -2.126 . . . . 0.0 105.259 179.883 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' CYS . . . . . 0.696 ' CB ' ' SG ' ' A' ' 36' ' ' CYS . 98.9 m -90.11 130.12 36.32 Favored 'General case' 0 N--CA 1.478 0.966 1 N-CA-C 100.116 -4.031 . . . . 0.0 100.116 179.509 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.434 ' O ' ' N ' ' A' ' 21' ' ' ILE . 82.1 m -132.92 -170.88 2.54 Favored 'General case' 0 C--N 1.296 -1.754 0 CA-C-N 111.736 -2.483 . . . . 0.0 109.273 -179.305 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.568 ' H ' ' HD3' ' A' ' 48' ' ' LYS . 0.0 OUTLIER -150.55 174.35 13.05 Favored 'General case' 0 C--N 1.295 -1.769 0 O-C-N 124.55 1.156 . . . . 0.0 108.377 179.444 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 29.9 mtpt . . . . . 0 C--N 1.29 -2.006 0 CA-C-O 114.398 -2.715 . . . . 0.0 107.104 179.351 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.403 ' HB ' HD23 ' A' ' 22' ' ' LEU . 22.2 t . . . . . 0 N--CA 1.495 1.806 0 N-CA-C 107.149 -1.426 . . . . 0.0 107.149 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.418 ' HA ' ' HA ' ' A' ' 21' ' ' ILE . 37.5 Cg_endo -71.27 164.69 34.89 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 123.838 3.025 . . . . 0.0 112.439 166.603 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.508 ' SG ' ' HB3' ' A' ' 22' ' ' LEU . 0.1 OUTLIER -148.98 -171.0 3.77 Favored 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 107.205 -1.406 . . . . 0.0 107.205 179.508 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 5.2 tt -104.94 147.58 27.63 Favored 'General case' 0 N--CA 1.495 1.786 0 N-CA-C 103.056 -2.942 . . . . 0.0 103.056 179.792 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . 0.412 ' HA ' ' HE3' ' A' ' 37' ' ' LYS . 3.9 m -122.73 -171.8 2.35 Favored 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 115.056 1.502 . . . . 0.0 115.056 -179.567 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 7.5 t70 . . . . . 0 N--CA 1.49 1.557 0 CA-C-N 112.873 -1.967 . . . . 0.0 108.177 -179.922 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 33.1 t . . . . . 0 N--CA 1.494 1.739 0 CA-C-O 119.058 -0.496 . . . . 0.0 112.102 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -176.14 -161.02 24.54 Favored Glycine 0 N--CA 1.498 2.767 0 C-N-CA 119.171 -1.49 . . . . 0.0 112.031 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.418 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 39.3 mm -132.22 148.58 32.03 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.924 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.52 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 2.9 pp -71.41 144.13 49.89 Favored 'General case' 0 N--CA 1.493 1.709 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 179.595 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 44.1 m95 -126.91 133.61 50.63 Favored 'General case' 0 C--N 1.308 -1.196 0 N-CA-C 118.773 2.879 . . . . 0.0 118.773 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -89.44 51.76 2.19 Favored 'General case' 0 C--N 1.299 -1.629 1 CA-C-N 107.138 -4.574 . . . . 0.0 110.612 -179.83 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.46 ' CE1' ' HB3' ' A' ' 30' ' ' PRO . 2.1 m-85 -124.51 142.54 40.71 Favored Pre-proline 0 C--N 1.304 -1.391 0 CA-C-O 122.468 1.128 . . . . 0.0 110.71 179.739 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 74.7 Cg_endo -68.53 -29.94 29.75 Favored 'Trans proline' 0 C--N 1.304 -1.777 0 C-N-CA 125.075 3.85 . . . . 0.0 108.186 177.936 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 5.1 p -90.36 24.4 2.59 Favored 'General case' 0 C--N 1.301 -1.542 0 CA-C-N 113.726 -1.579 . . . . 0.0 109.269 179.659 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.602 ' HA2' ' CD1' ' A' ' 45' ' ' TRP . . . 81.99 -84.56 1.48 Allowed Glycine 0 N--CA 1.482 1.759 0 N-CA-C 105.005 -3.238 . . . . 0.0 105.005 -179.748 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 9.2 m -100.88 166.96 11.52 Favored Pre-proline 0 C--N 1.307 -1.275 0 CA-C-N 112.649 -1.775 . . . . 0.0 110.851 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.717 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.1 OUTLIER -89.44 167.17 5.21 Favored 'Trans proline' 0 C--N 1.312 -1.355 1 C-N-CA 125.919 4.412 . . . . 0.0 113.763 155.523 . . . . . . . . 4 4 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 18.2 t -60.97 141.37 57.37 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-N 113.784 -1.553 . . . . 0.0 109.181 -179.766 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.06 -2.3 68.74 Favored Glycine 0 N--CA 1.495 2.6 0 CA-C-N 111.675 -2.511 . . . . 0.0 111.551 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' TRP . . . . . 0.717 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 58.7 m95 -111.04 166.52 10.99 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 106.143 -1.799 . . . . 0.0 106.143 -179.743 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . 0.514 ' O ' ' ND1' ' A' ' 34' ' ' HIS . 43.1 t-80 -140.02 31.9 1.98 Allowed 'General case' 0 N--CA 1.496 1.839 0 C-N-CA 118.497 -1.281 . . . . 0.0 112.878 -179.872 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . 0.51 ' HA ' ' SG ' ' A' ' 47' ' ' CYS . 16.7 t-20 59.03 139.66 0.01 OUTLIER 'General case' 0 N--CA 1.511 2.607 0 N-CA-C 114.458 1.281 . . . . 0.0 114.458 -179.934 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.642 ' SG ' ' CB ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -119.43 -41.06 2.73 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.445 -0.784 . . . . 0.0 110.129 -179.725 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . 0.464 ' HG2' ' H ' ' A' ' 39' ' ' HIS . 38.0 ttmt -131.14 138.59 49.54 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 104.696 -2.335 . . . . 0.0 104.696 179.423 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.438 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -117.97 35.63 4.65 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 103.004 -2.962 . . . . 0.0 103.004 179.723 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . 0.464 ' H ' ' HG2' ' A' ' 37' ' ' LYS . 2.7 m-70 -140.09 55.96 1.62 Allowed 'General case' 0 N--CA 1.494 1.769 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 -179.537 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 85.9 -160.55 33.97 Favored Glycine 0 N--CA 1.502 3.049 0 N-CA-C 108.773 -1.731 . . . . 0.0 108.773 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . 0.414 ' HG2' ' O ' ' A' ' 44' ' ' GLY . 68.6 Cg_endo -64.9 -171.0 3.02 Favored 'Cis proline' 0 N--CA 1.507 2.286 0 CA-C-N 118.305 1.053 . . . . 0.0 114.74 -1.551 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 20.9 m120 -92.96 -8.27 43.59 Favored 'General case' 0 N--CA 1.487 1.377 0 N-CA-C 104.616 -2.364 . . . . 0.0 104.616 -179.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 9.9 mm -106.22 32.0 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.961 0 CA-C-O 123.545 1.64 . . . . 0.0 113.782 -178.76 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.414 ' O ' ' HG2' ' A' ' 41' ' ' PRO . . . 124.72 -179.29 16.2 Favored Glycine 0 C--N 1.292 -1.879 1 N-CA-C 102.693 -4.163 . . . . 0.0 102.693 -179.977 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . 0.602 ' CD1' ' HA2' ' A' ' 28' ' ' GLY . 1.2 m95 -119.86 140.65 50.5 Favored 'General case' 0 C--N 1.277 -2.55 0 N-CA-C 103.775 -2.676 . . . . 0.0 103.775 179.709 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' CYS . . . . . 0.642 ' CB ' ' SG ' ' A' ' 36' ' ' CYS . 99.4 m -88.74 133.92 34.08 Favored 'General case' 0 N--CA 1.485 1.298 0 CA-C-N 121.756 2.071 . . . . 0.0 107.34 -179.912 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.516 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 87.3 m -133.71 178.32 7.03 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-N 110.892 -2.867 . . . . 0.0 110.443 -179.233 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.468 ' O ' ' HA ' ' A' ' 33' ' ' TRP . 0.0 OUTLIER -149.27 172.96 14.02 Favored 'General case' 0 C--N 1.304 -1.41 0 C-N-CA 117.525 -1.67 . . . . 0.0 111.757 179.776 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 24.8 mmtm . . . . . 0 N--CA 1.496 1.84 0 O-C-N 127.11 2.756 . . . . 0.0 109.413 179.976 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 13.0 t . . . . . 0 N--CA 1.496 1.85 0 N-CA-C 107.988 -1.115 . . . . 0.0 107.988 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -79.32 135.19 11.83 Favored 'Trans proline' 0 C--N 1.308 -1.559 0 C-N-CA 124.352 3.368 . . . . 0.0 115.001 169.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.44 ' SG ' ' HB3' ' A' ' 22' ' ' LEU . 0.0 OUTLIER -119.46 -178.12 3.53 Favored 'General case' 0 N--CA 1.494 1.772 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.563 179.662 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 6.4 tt -98.5 113.65 25.74 Favored 'General case' 0 N--CA 1.497 1.908 0 N-CA-C 104.962 -2.236 . . . . 0.0 104.962 -179.836 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . 0.403 ' SG ' ' HA3' ' A' ' 20' ' ' GLY . 5.5 m -88.57 -169.01 2.38 Favored 'General case' 0 N--CA 1.487 1.387 0 N-CA-C 119.1 3.0 . . . . 0.0 119.1 -179.179 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 10.8 t0 . . . . . 0 N--CA 1.487 1.394 0 CA-C-N 111.876 -2.42 . . . . 0.0 112.562 -179.655 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 22.8 t . . . . . 0 N--CA 1.499 2.003 0 N-CA-C 112.725 0.639 . . . . 0.0 112.725 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.546 ' HA3' ' SG ' ' A' ' 36' ' ' CYS . . . 174.28 131.53 1.42 Allowed Glycine 0 N--CA 1.48 1.605 0 N-CA-C 108.341 -1.903 . . . . 0.0 108.341 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.493 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 49.7 mm -93.12 132.33 37.64 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.12 0 C-N-CA 116.593 -2.043 . . . . 0.0 105.565 179.851 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.581 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.9 pp -63.0 149.0 46.01 Favored 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 107.276 -1.379 . . . . 0.0 107.276 179.444 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.441 ' CE2' ' HG3' ' A' ' 30' ' ' PRO . 28.5 m95 -129.78 136.83 50.07 Favored 'General case' 0 C--N 1.3 -1.567 0 CA-C-O 124.008 1.861 . . . . 0.0 115.439 -179.812 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -89.11 47.67 1.52 Allowed 'General case' 0 C--N 1.294 -1.845 0 CA-C-N 108.914 -3.766 . . . . 0.0 112.499 -179.809 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 1.1 m-30 -117.33 143.46 32.0 Favored Pre-proline 0 C--N 1.306 -1.322 0 CA-C-O 122.537 1.161 . . . . 0.0 110.362 179.604 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 15.7 Cg_endo -77.19 -35.18 1.82 Allowed 'Trans proline' 0 C--N 1.301 -1.96 0 C-N-CA 123.622 2.881 . . . . 0.0 110.578 175.829 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 10.9 p -89.46 38.77 0.92 Allowed 'General case' 0 N--CA 1.49 1.536 0 CA-C-N 114.61 -1.177 . . . . 0.0 112.38 -179.626 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 73.17 -135.16 20.83 Favored Glycine 0 N--CA 1.5 2.955 0 N-CA-C 108.07 -2.012 . . . . 0.0 108.07 -179.864 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.478 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 15.3 m -72.22 156.18 90.84 Favored Pre-proline 0 C--N 1.304 -1.406 0 CA-C-N 118.793 1.297 . . . . 0.0 111.471 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.726 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.4 OUTLIER -79.71 159.13 24.97 Favored 'Trans proline' 0 C--N 1.307 -1.617 0 C-N-CA 123.281 2.654 . . . . 0.0 111.831 166.597 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 42.0 t -50.07 134.27 22.1 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 113.334 -1.757 . . . . 0.0 109.299 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 95.4 -4.57 67.03 Favored Glycine 0 N--CA 1.498 2.773 0 CA-C-N 112.396 -2.184 . . . . 0.0 111.896 179.835 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' TRP . . . . . 0.726 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 56.4 m95 -112.95 157.2 21.78 Favored 'General case' 0 C--N 1.304 -1.391 0 N-CA-C 105.29 -2.115 . . . . 0.0 105.29 -179.855 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . 0.419 ' O ' ' ND1' ' A' ' 34' ' ' HIS . 65.1 t-80 -140.45 41.49 1.89 Allowed 'General case' 0 C--N 1.299 -1.593 0 C-N-CA 118.291 -1.363 . . . . 0.0 112.084 -179.914 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . 0.478 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 0.2 OUTLIER 63.17 138.37 0.02 OUTLIER 'General case' 0 N--CA 1.505 2.316 0 N-CA-C 115.74 1.755 . . . . 0.0 115.74 179.412 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.608 ' SG ' ' CB ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -114.9 -40.74 3.46 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 105.843 -1.91 . . . . 0.0 105.843 179.775 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . 0.447 ' C ' HD21 ' A' ' 35' ' ' ASN . 21.3 ptmt -138.41 149.32 45.4 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 106.864 -1.532 . . . . 0.0 106.864 179.64 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.452 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -120.0 35.43 4.86 Favored 'General case' 0 C--N 1.293 -1.85 0 N-CA-C 102.506 -3.146 . . . . 0.0 102.506 179.881 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . 0.452 ' ND1' ' C ' ' A' ' 38' ' ' ALA . 3.7 m-70 -127.57 54.9 1.65 Allowed 'General case' 0 N--CA 1.498 1.951 0 N-CA-C 108.404 -0.961 . . . . 0.0 108.404 -179.625 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 74.0 -148.86 40.24 Favored Glycine 0 N--CA 1.496 2.65 0 N-CA-C 105.604 -2.998 . . . . 0.0 105.604 -179.658 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . 0.439 ' HG2' ' O ' ' A' ' 44' ' ' GLY . 51.2 Cg_endo -65.64 -172.63 4.43 Favored 'Cis proline' 0 N--CA 1.501 1.915 0 CA-C-N 119.088 1.444 . . . . 0.0 111.713 -1.4 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 14.3 m120 -93.58 0.52 56.63 Favored 'General case' 0 C--N 1.307 -1.273 0 N-CA-C 104.144 -2.539 . . . . 0.0 104.144 -179.679 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 8.4 mt -116.64 35.02 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 N-CA-C 116.043 1.868 . . . . 0.0 116.043 -178.846 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.439 ' O ' ' HG2' ' A' ' 41' ' ' PRO . . . 119.81 139.76 5.98 Favored Glycine 0 N--CA 1.499 2.846 0 CA-C-N 114.004 -1.453 . . . . 0.0 110.642 179.721 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . 0.416 ' O ' ' N ' ' A' ' 23' ' ' TRP . 6.4 m95 -78.22 129.85 35.59 Favored 'General case' 0 N--CA 1.503 2.194 0 CA-C-O 117.783 -1.103 . . . . 0.0 111.096 -179.267 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' CYS . . . . . 0.608 ' CB ' ' SG ' ' A' ' 36' ' ' CYS . 66.2 m -87.71 122.67 31.66 Favored 'General case' 0 C--N 1.308 -1.204 1 N-CA-C 99.791 -4.152 . . . . 0.0 99.791 179.436 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.56 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 88.8 m -129.18 -178.84 4.81 Favored 'General case' 0 CA--C 1.476 -1.894 0 CA-C-N 109.895 -3.321 . . . . 0.0 111.205 -179.398 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.425 ' HD2' ' H ' ' A' ' 49' ' ' LYS . 24.2 tptp -150.52 152.01 33.53 Favored 'General case' 0 C--N 1.294 -1.846 0 C-N-CA 117.675 -1.61 . . . . 0.0 109.987 -179.84 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . 0.425 ' H ' ' HD2' ' A' ' 48' ' ' LYS . 51.2 mtpt . . . . . 0 N--CA 1.5 2.054 0 O-C-N 126.197 2.186 . . . . 0.0 111.899 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 33.0 t . . . . . 0 N--CA 1.497 1.885 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_endo -77.27 127.77 9.32 Favored 'Trans proline' 0 N--CA 1.493 1.475 0 C-N-CA 124.523 3.482 . . . . 0.0 116.458 170.048 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.526 ' SG ' ' HB3' ' A' ' 22' ' ' LEU . 0.5 OUTLIER -121.08 179.46 4.38 Favored 'General case' 0 C--N 1.301 -1.508 0 CA-C-N 114.624 -1.171 . . . . 0.0 111.13 179.786 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 6.7 tp -91.68 145.98 24.15 Favored 'General case' 0 N--CA 1.491 1.594 0 N-CA-C 104.625 -2.361 . . . . 0.0 104.625 179.874 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . 0.548 ' HA ' ' HD2' ' A' ' 37' ' ' LYS . 6.9 m -119.42 -170.4 1.93 Allowed 'General case' 0 N--CA 1.491 1.583 0 N-CA-C 113.911 1.078 . . . . 0.0 113.911 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 19.8 t70 . . . . . 0 N--CA 1.497 1.887 0 CA-C-N 113.614 -1.63 . . . . 0.0 109.353 179.979 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.498 1.937 0 CA-C-O 122.597 1.189 . . . . 0.0 109.368 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.43 -165.61 18.19 Favored Glycine 0 N--CA 1.502 3.047 0 CA-C-N 114.382 -1.281 . . . . 0.0 111.21 179.804 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.437 HG22 ' O ' ' A' ' 22' ' ' LEU . 28.8 mm -133.88 147.52 30.59 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.265 0 N-CA-C 112.744 0.646 . . . . 0.0 112.744 -179.94 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.588 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 2.8 pp -69.85 152.77 44.16 Favored 'General case' 0 N--CA 1.492 1.644 0 CA-C-N 114.919 -1.037 . . . . 0.0 108.819 179.499 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.678 ' HB2' ' SG ' ' A' ' 29' ' ' CYS . 28.3 m95 -131.93 135.32 46.52 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-O 125.045 2.355 . . . . 0.0 115.986 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.5 m-85 -88.84 54.34 2.98 Favored 'General case' 0 C--N 1.292 -1.892 1 CA-C-N 107.641 -4.345 . . . . 0.0 110.131 -179.669 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.551 ' CE1' ' HB3' ' A' ' 30' ' ' PRO . 2.2 m-85 -123.82 115.88 27.84 Favored Pre-proline 0 N--CA 1.491 1.618 0 CA-C-N 115.497 -0.774 . . . . 0.0 112.656 179.654 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -64.03 -11.85 29.35 Favored 'Trans proline' 0 C--N 1.308 -1.557 0 C-N-CA 123.389 2.726 . . . . 0.0 111.948 -175.412 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 6.6 p -108.93 3.93 22.8 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-N 115.37 -0.832 . . . . 0.0 111.025 179.753 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.4 ' O ' ' CD1' ' A' ' 45' ' ' TRP . . . 126.45 -113.21 1.75 Allowed Glycine 0 N--CA 1.502 3.058 0 N-CA-C 108.727 -1.749 . . . . 0.0 108.727 -179.913 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.678 ' SG ' ' HB2' ' A' ' 23' ' ' TRP . 18.4 m -132.36 156.54 79.98 Favored Pre-proline 0 C--N 1.305 -1.357 0 CA-C-N 117.701 0.75 . . . . 0.0 110.687 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.737 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 9.0 Cg_endo -78.68 162.04 27.39 Favored 'Trans proline' 0 C--N 1.306 -1.68 0 C-N-CA 123.335 2.69 . . . . 0.0 113.323 -167.196 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 22.9 t -51.32 116.43 2.05 Favored 'General case' 0 C--N 1.302 -1.487 0 CA-C-N 113.292 -1.776 . . . . 0.0 110.473 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 115.5 -7.61 20.37 Favored Glycine 0 N--CA 1.499 2.87 0 CA-C-N 113.744 -1.571 . . . . 0.0 111.529 179.761 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' TRP . . . . . 0.737 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 49.9 m95 -109.22 158.94 17.35 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 104.77 -2.307 . . . . 0.0 104.77 -179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 78.3 t60 -138.34 33.04 2.31 Favored 'General case' 0 C--N 1.298 -1.666 0 C-N-CA 118.05 -1.46 . . . . 0.0 114.074 -179.598 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . 0.774 ' HA ' ' SG ' ' A' ' 47' ' ' CYS . 5.1 m-20 57.34 137.35 0.0 OUTLIER 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 116.648 2.092 . . . . 0.0 116.648 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.587 ' SG ' ' HB3' ' A' ' 46' ' ' CYS . 0.6 OUTLIER -112.06 -40.13 4.3 Favored 'General case' 0 N--CA 1.489 1.489 0 CA-C-N 115.015 -0.993 . . . . 0.0 108.931 -179.644 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . 0.548 ' HD2' ' HA ' ' A' ' 6' ' ' CYS . 51.9 tttt -132.87 143.38 49.48 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 107.356 -1.349 . . . . 0.0 107.356 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.441 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -119.47 30.08 7.28 Favored 'General case' 0 N--CA 1.493 1.721 0 N-CA-C 104.772 -2.307 . . . . 0.0 104.772 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . 0.482 ' H ' ' HG2' ' A' ' 37' ' ' LYS . 4.5 m-70 -134.75 62.18 1.65 Allowed 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 107.023 -1.473 . . . . 0.0 107.023 -179.564 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 75.75 -155.94 47.22 Favored Glycine 0 N--CA 1.498 2.798 0 N-CA-C 106.213 -2.755 . . . . 0.0 106.213 -179.728 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_endo -74.09 -169.38 7.0 Favored 'Cis proline' 0 N--CA 1.496 1.669 0 CA-C-N 118.922 1.361 . . . . 0.0 113.923 -0.682 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 10.0 p30 -92.33 -14.66 28.43 Favored 'General case' 0 CA--C 1.486 -1.506 0 N-CA-C 105.992 -1.855 . . . . 0.0 105.992 -179.606 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 31.6 pt -90.28 24.17 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 O-C-N 125.277 1.61 . . . . 0.0 113.978 -179.431 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 114.37 137.79 6.6 Favored Glycine 0 N--CA 1.493 2.472 0 CA-C-N 113.246 -1.797 . . . . 0.0 109.696 -179.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . 0.426 ' O ' ' N ' ' A' ' 23' ' ' TRP . 7.9 m95 -61.53 136.4 58.01 Favored 'General case' 0 N--CA 1.519 3.006 0 CA-C-O 117.317 -1.325 . . . . 0.0 108.421 -179.643 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' CYS . . . . . 0.588 ' HA ' ' HA ' ' A' ' 22' ' ' LEU . 93.0 m -89.9 127.08 35.94 Favored 'General case' 0 N--CA 1.482 1.141 0 CA-C-N 122.26 2.3 . . . . 0.0 105.127 -179.921 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.774 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 93.7 m -136.45 -171.82 3.0 Favored 'General case' 0 C--N 1.3 -1.563 0 CA-C-N 111.327 -2.67 . . . . 0.0 111.005 -179.409 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.538 ' O ' ' HA ' ' A' ' 33' ' ' TRP . 0.0 OUTLIER -151.31 172.29 16.12 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 179.574 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 47.4 mtpt . . . . . 0 C--N 1.291 -1.969 0 O-C-N 126.704 2.503 . . . . 0.0 110.347 179.828 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 29.6 t . . . . . 0 N--CA 1.496 1.852 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -67.27 135.57 37.36 Favored 'Trans proline' 0 N--CA 1.493 1.455 0 C-N-CA 122.333 2.022 . . . . 0.0 110.24 170.051 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -134.06 175.8 9.15 Favored 'General case' 0 N--CA 1.497 1.918 0 CA-C-O 121.563 0.697 . . . . 0.0 112.242 -179.724 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -101.55 141.89 33.74 Favored 'General case' 0 N--CA 1.494 1.732 0 N-CA-C 104.067 -2.568 . . . . 0.0 104.067 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . 0.437 ' HB3' ' C ' ' A' ' 36' ' ' CYS . 1.8 m -113.14 -138.8 0.38 Allowed 'General case' 0 N--CA 1.497 1.892 0 N-CA-C 120.395 3.48 . . . . 0.0 120.395 -178.95 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 . . . . . 0 N--CA 1.507 2.391 0 O-C-N 120.969 -1.082 . . . . 0.0 110.388 -179.828 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 7.1 m . . . . . 0 N--CA 1.5 2.064 0 N-CA-C 115.644 1.72 . . . . 0.0 115.644 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 148.69 -163.69 29.05 Favored Glycine 0 N--CA 1.497 2.743 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.517 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 35.5 mm -135.98 146.42 29.43 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.088 0 CA-C-O 122.487 1.137 . . . . 0.0 109.878 179.852 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.546 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 0.9 OUTLIER -69.69 134.79 49.06 Favored 'General case' 0 C--N 1.297 -1.693 0 CA-C-N 114.654 -1.157 . . . . 0.0 108.625 179.826 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.421 ' CE2' ' HG3' ' A' ' 30' ' ' PRO . 44.5 m95 -124.04 134.18 53.48 Favored 'General case' 0 N--CA 1.484 1.242 0 N-CA-C 118.96 2.948 . . . . 0.0 118.96 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.2 m-30 -88.93 39.58 0.94 Allowed 'General case' 0 C--N 1.296 -1.718 1 CA-C-N 107.366 -4.47 . . . . 0.0 113.064 -179.584 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.42 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 1.2 m-30 -113.07 125.13 30.25 Favored Pre-proline 0 C--N 1.304 -1.402 0 CA-C-O 122.697 1.237 . . . . 0.0 112.271 -179.935 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -66.21 -25.26 50.36 Favored 'Trans proline' 0 C--N 1.302 -1.872 0 C-N-CA 122.507 2.138 . . . . 0.0 108.341 -177.731 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 5.8 p -87.01 5.03 39.44 Favored 'General case' 0 N--CA 1.49 1.536 0 CA-C-N 114.375 -1.284 . . . . 0.0 112.468 179.926 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 110.65 -118.57 5.0 Favored Glycine 0 N--CA 1.498 2.806 0 N-CA-C 106.238 -2.745 . . . . 0.0 106.238 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.51 ' HB3' ' HB2' ' A' ' 33' ' ' TRP . 37.4 m -96.65 153.79 38.65 Favored Pre-proline 0 C--N 1.303 -1.446 0 N-CA-C 106.726 -1.583 . . . . 0.0 106.726 179.735 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.748 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.8 OUTLIER -76.34 169.47 21.89 Favored 'Trans proline' 0 C--N 1.305 -1.726 0 C-N-CA 123.077 2.518 . . . . 0.0 113.829 174.588 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 5.7 m -46.17 103.83 0.04 OUTLIER 'General case' 0 C--N 1.298 -1.633 0 CA-C-N 112.01 -2.359 . . . . 0.0 113.99 -179.854 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 109.11 2.68 31.62 Favored Glycine 0 N--CA 1.501 2.996 0 C-N-CA 120.811 -0.709 . . . . 0.0 114.293 179.481 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' TRP . . . . . 0.748 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 44.7 m95 -110.82 164.81 12.39 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 106.999 -1.482 . . . . 0.0 106.999 -179.954 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 57.7 t-80 -144.76 37.23 1.18 Allowed 'General case' 0 N--CA 1.499 1.992 0 C-N-CA 117.757 -1.577 . . . . 0.0 113.072 -179.722 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . 0.504 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 24.0 t-20 58.43 146.48 0.01 OUTLIER 'General case' 0 N--CA 1.501 2.098 0 CA-C-N 113.248 -1.797 . . . . 0.0 114.673 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.64 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -121.09 -46.67 2.31 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 106.013 -1.847 . . . . 0.0 106.013 179.974 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 13.1 ttmt -107.94 102.08 11.29 Favored 'General case' 0 C--N 1.301 -1.502 0 CA-C-N 113.315 -1.766 . . . . 0.0 108.618 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -83.36 12.28 5.66 Favored 'General case' 0 N--CA 1.496 1.869 0 CA-C-N 113.31 -1.768 . . . . 0.0 107.713 179.511 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 7.4 m-70 -127.22 37.71 4.21 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-N 114.878 -1.055 . . . . 0.0 109.208 -179.667 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 96.23 -149.56 19.35 Favored Glycine 0 N--CA 1.498 2.768 0 CA-C-N 114.538 -1.21 . . . . 0.0 111.267 179.586 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . 0.45 ' HB2' HG12 ' A' ' 43' ' ' ILE . 3.5 Cg_endo -75.5 -173.84 13.2 Favored 'Cis proline' 0 N--CA 1.5 1.861 0 N-CA-C 109.386 -1.044 . . . . 0.0 109.386 1.496 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . 0.476 ' C ' ' H ' ' A' ' 44' ' ' GLY . 56.5 t30 -92.27 -11.97 33.81 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 105.463 -2.051 . . . . 0.0 105.463 -179.783 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.45 HG12 ' HB2' ' A' ' 41' ' ' PRO . 30.5 pt -85.66 28.92 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 CA-C-O 123.302 1.525 . . . . 0.0 112.741 -179.192 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.476 ' H ' ' C ' ' A' ' 42' ' ' ASN . . . 116.98 142.57 7.34 Favored Glycine 0 C--N 1.295 -1.71 0 CA-C-N 110.528 -3.033 . . . . 0.0 106.153 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . 0.42 ' NE1' ' O ' ' A' ' 25' ' ' TYR . 6.9 m95 -77.81 133.77 38.14 Favored 'General case' 0 C--N 1.293 -1.849 0 N-CA-C 104.674 -2.343 . . . . 0.0 104.674 -179.534 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' CYS . . . . . 0.64 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 46.0 t -89.22 129.14 35.84 Favored 'General case' 0 N--CA 1.485 1.318 1 N-CA-C 99.319 -4.326 . . . . 0.0 99.319 179.773 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.524 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 77.3 m -127.88 -170.53 2.25 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-N 113.096 -1.866 . . . . 0.0 110.254 -179.363 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.08 172.3 15.98 Favored 'General case' 0 C--N 1.298 -1.674 0 N-CA-C 107.599 -1.26 . . . . 0.0 107.599 179.311 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 65.3 mttt . . . . . 0 N--CA 1.498 1.961 0 O-C-N 126.267 2.229 . . . . 0.0 108.189 179.267 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 46.8 t . . . . . 0 N--CA 1.499 2.01 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 26.6 Cg_endo -73.11 116.03 4.56 Favored 'Trans proline' 0 C--N 1.308 -1.566 0 C-N-CA 122.877 2.384 . . . . 0.0 114.473 170.664 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.533 ' SG ' ' HB2' ' A' ' 22' ' ' LEU . 0.8 OUTLIER -122.15 163.94 18.65 Favored 'General case' 0 N--CA 1.494 1.774 0 CA-C-N 113.037 -1.892 . . . . 0.0 108.839 -179.799 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.432 HD12 ' HA ' ' A' ' 5' ' ' LEU . 12.2 tp -89.61 174.82 7.54 Favored 'General case' 0 N--CA 1.497 1.886 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 -179.895 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . 0.455 ' HB3' ' C ' ' A' ' 36' ' ' CYS . 1.8 m -135.26 -143.25 0.19 Allowed 'General case' 0 N--CA 1.501 2.097 1 N-CA-C 122.131 4.123 . . . . 0.0 122.131 -178.738 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.497 1.89 0 C-N-CA 118.405 -1.318 . . . . 0.0 108.813 -179.523 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 80.5 p . . . . . 0 N--CA 1.485 1.285 0 CA-C-O 120.987 0.422 . . . . 0.0 111.697 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 153.28 161.58 10.43 Favored Glycine 0 N--CA 1.5 2.926 0 C-N-CA 119.512 -1.328 . . . . 0.0 112.775 179.46 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.458 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 49.1 mm -124.07 137.83 55.75 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.176 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 179.57 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.533 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 34.7 tp -63.99 144.58 56.98 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 179.659 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 42.4 m95 -131.52 134.08 45.75 Favored 'General case' 0 C--N 1.308 -1.236 0 N-CA-C 119.428 3.122 . . . . 0.0 119.428 -179.568 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -88.87 54.45 3.02 Favored 'General case' 0 C--N 1.297 -1.675 1 CA-C-N 108.145 -4.116 . . . . 0.0 108.727 -179.962 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.48 ' CE1' ' HB3' ' A' ' 30' ' ' PRO . 2.4 m-85 -128.73 120.02 20.42 Favored Pre-proline 0 N--CA 1.486 1.368 0 CA-C-N 115.088 -0.96 . . . . 0.0 113.556 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.402 ' HD2' ' HA ' ' A' ' 25' ' ' TYR . 57.3 Cg_endo -67.25 -13.48 39.66 Favored 'Trans proline' 0 C--N 1.309 -1.526 0 C-N-CA 123.793 2.996 . . . . 0.0 110.918 -178.121 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 12.8 p -93.51 -9.23 39.03 Favored 'General case' 0 N--CA 1.491 1.609 0 CA-C-N 114.565 -1.198 . . . . 0.0 110.43 179.81 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.43 ' HA2' ' CD2' ' A' ' 45' ' ' TRP . . . 116.3 -106.96 1.57 Allowed Glycine 0 N--CA 1.482 1.724 1 N-CA-C 102.512 -4.235 . . . . 0.0 102.512 -179.702 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.602 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 16.7 m -99.36 151.66 37.5 Favored Pre-proline 0 C--N 1.301 -1.52 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.678 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.4 OUTLIER -79.46 164.57 23.73 Favored 'Trans proline' 0 C--N 1.306 -1.694 0 C-N-CA 123.005 2.47 . . . . 0.0 114.359 169.831 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 3.1 m -43.93 105.32 0.05 Allowed 'General case' 0 C--N 1.3 -1.581 0 CA-C-N 112.197 -2.274 . . . . 0.0 112.636 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 114.53 -4.12 23.22 Favored Glycine 0 N--CA 1.505 3.26 0 CA-C-N 115.665 -0.698 . . . . 0.0 113.495 179.581 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' TRP . . . . . 0.678 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 49.2 m95 -111.22 166.5 11.04 Favored 'General case' 0 N--CA 1.488 1.43 0 N-CA-C 107.061 -1.459 . . . . 0.0 107.061 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 55.0 t-80 -148.86 40.35 0.89 Allowed 'General case' 0 N--CA 1.505 2.312 0 C-N-CA 117.904 -1.518 . . . . 0.0 114.147 -179.856 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . 0.602 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 1.5 t30 52.36 146.66 0.0 OUTLIER 'General case' 0 N--CA 1.499 1.986 0 CA-C-N 113.001 -1.909 . . . . 0.0 116.073 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.505 ' SG ' ' O ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -119.08 -41.14 2.77 Favored 'General case' 0 C--N 1.306 -1.29 0 CA-C-N 114.582 -1.19 . . . . 0.0 111.336 -179.805 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . 0.514 ' C ' ' H ' ' A' ' 39' ' ' HIS . 44.3 tttm -106.04 106.36 16.83 Favored 'General case' 0 N--CA 1.502 2.136 0 C-N-CA 119.014 -1.074 . . . . 0.0 108.384 179.655 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -65.8 16.66 0.02 OUTLIER 'General case' 0 N--CA 1.505 2.299 0 N-CA-C 113.049 0.759 . . . . 0.0 113.049 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . 0.514 ' H ' ' C ' ' A' ' 37' ' ' LYS . 5.3 m-70 -128.38 -4.84 5.42 Favored 'General case' 0 N--CA 1.494 1.745 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.03 179.947 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 133.97 -119.86 2.36 Favored Glycine 0 N--CA 1.509 3.506 0 C-N-CA 120.685 -0.769 . . . . 0.0 113.086 179.872 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -68.1 -170.82 5.04 Favored 'Cis proline' 0 N--CA 1.504 2.138 0 CA-C-N 118.609 1.205 . . . . 0.0 111.824 -1.669 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 10.0 t-20 -93.72 -5.5 48.3 Favored 'General case' 0 CA--C 1.492 -1.253 0 N-CA-C 106.083 -1.821 . . . . 0.0 106.083 -179.709 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 28.4 mt -94.81 32.14 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.104 0 CA-C-O 123.897 1.808 . . . . 0.0 110.737 -179.005 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 115.96 153.99 10.27 Favored Glycine 0 C--N 1.295 -1.737 1 N-CA-C 101.137 -4.785 . . . . 0.0 101.137 -179.692 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . 0.43 ' CD2' ' HA2' ' A' ' 28' ' ' GLY . 56.4 m95 -86.56 135.37 33.46 Favored 'General case' 0 N--CA 1.505 2.298 0 CA-C-O 116.475 -1.726 . . . . 0.0 108.057 -179.769 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' CYS . . . . . 0.509 ' HA ' ' HA ' ' A' ' 22' ' ' LEU . 59.3 m -92.65 121.18 33.81 Favored 'General case' 0 C--N 1.308 -1.212 1 N-CA-C 96.884 -5.228 . . . . 0.0 96.884 179.763 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.501 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 96.1 m -127.57 -174.57 3.22 Favored 'General case' 0 C--N 1.297 -1.712 0 CA-C-N 112.419 -2.173 . . . . 0.0 108.366 -179.351 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.36 173.14 14.86 Favored 'General case' 0 C--N 1.297 -1.705 0 N-CA-C 106.923 -1.51 . . . . 0.0 106.923 179.32 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 86.8 mttt . . . . . 0 C--N 1.289 -2.049 0 O-C-N 126.255 2.222 . . . . 0.0 106.593 179.337 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 19.4 t . . . . . 0 N--CA 1.492 1.666 0 N-CA-C 106.939 -1.504 . . . . 0.0 106.939 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.47 ' HA ' ' O ' ' A' ' 20' ' ' GLY . 11.0 Cg_endo -77.09 132.95 13.12 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 123.246 2.63 . . . . 0.0 113.147 163.673 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -121.26 177.39 5.18 Favored 'General case' 0 N--CA 1.494 1.734 0 C-N-CA 119.966 -0.694 . . . . 0.0 112.038 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.448 HD23 ' N ' ' A' ' 6' ' ' CYS . 9.4 tt -94.12 150.86 19.94 Favored 'General case' 0 N--CA 1.493 1.687 0 N-CA-C 105.036 -2.209 . . . . 0.0 105.036 179.768 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . 0.481 ' HB3' ' HB2' ' A' ' 37' ' ' LYS . 13.0 m -143.07 -174.85 4.3 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 124.683 1.239 . . . . 0.0 111.739 -179.337 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 9.6 t70 . . . . . 0 N--CA 1.493 1.707 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 179.881 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 5.5 t . . . . . 0 N--CA 1.5 2.074 0 CA-C-O 121.063 0.459 . . . . 0.0 110.079 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.47 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -173.83 -178.01 43.46 Favored Glycine 0 N--CA 1.5 2.904 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.433 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 28.8 mm -134.43 144.11 36.03 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.361 0 N-CA-C 107.072 -1.455 . . . . 0.0 107.072 -179.801 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.504 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.4 pp -66.78 156.62 35.01 Favored 'General case' 0 N--CA 1.491 1.621 0 C-N-CA 118.606 -1.238 . . . . 0.0 108.968 179.715 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.424 ' CE2' ' HG3' ' A' ' 30' ' ' PRO . 35.7 m95 -136.84 134.15 36.63 Favored 'General case' 0 C--N 1.304 -1.371 0 N-CA-C 117.948 2.573 . . . . 0.0 117.948 -179.789 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -89.92 42.49 1.1 Allowed 'General case' 0 C--N 1.296 -1.735 1 CA-C-N 107.784 -4.28 . . . . 0.0 112.411 -179.788 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.445 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 1.3 m-30 -116.3 136.96 23.16 Favored Pre-proline 0 C--N 1.303 -1.418 0 CA-C-O 121.985 0.897 . . . . 0.0 108.749 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -70.02 -17.43 36.39 Favored 'Trans proline' 0 C--N 1.298 -2.082 0 C-N-CA 122.717 2.278 . . . . 0.0 108.607 179.84 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 10.6 p -95.71 23.54 6.1 Favored 'General case' 0 N--CA 1.488 1.445 0 CA-C-N 113.776 -1.556 . . . . 0.0 109.513 179.765 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.611 ' HA2' ' CG ' ' A' ' 45' ' ' TRP . . . 83.13 -94.33 1.76 Allowed Glycine 0 N--CA 1.487 2.053 0 N-CA-C 104.209 -3.556 . . . . 0.0 104.209 -179.677 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.579 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 25.2 m -98.47 165.27 15.47 Favored Pre-proline 0 C--N 1.301 -1.515 0 CA-C-N 113.777 -1.211 . . . . 0.0 110.604 -179.934 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.711 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.1 OUTLIER -88.59 161.48 6.51 Favored 'Trans proline' 0 C--N 1.312 -1.393 1 C-N-CA 125.881 4.387 . . . . 0.0 115.818 156.241 . . . . . . . . 4 4 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 14.0 p -51.55 113.55 1.0 Allowed 'General case' 0 C--N 1.301 -1.512 0 CA-C-N 112.132 -2.303 . . . . 0.0 113.16 -179.758 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 115.94 -6.76 19.7 Favored Glycine 0 N--CA 1.502 3.097 0 O-C-N 124.842 1.339 . . . . 0.0 111.12 179.692 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' TRP . . . . . 0.711 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 42.6 m95 -110.06 173.13 6.47 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 106.156 -1.794 . . . . 0.0 106.156 -179.849 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 77.5 t60 -149.91 29.29 0.74 Allowed 'General case' 0 N--CA 1.496 1.841 0 C-N-CA 117.935 -1.506 . . . . 0.0 112.668 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . 0.588 ' HA ' ' SG ' ' A' ' 47' ' ' CYS . 1.8 t30 62.07 153.35 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.753 0 CA-C-N 114.245 -1.343 . . . . 0.0 111.637 -179.751 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.55 ' SG ' ' HB3' ' A' ' 46' ' ' CYS . 13.9 p -117.68 -39.95 3.08 Favored 'General case' 0 N--CA 1.499 2.024 0 N-CA-C 114.924 1.453 . . . . 0.0 114.924 -179.499 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . 0.481 ' HB2' ' HB3' ' A' ' 6' ' ' CYS . 74.0 tttt -131.4 132.12 44.13 Favored 'General case' 0 N--CA 1.5 2.047 0 N-CA-C 103.532 -2.766 . . . . 0.0 103.532 179.59 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -78.8 22.4 0.37 Allowed 'General case' 0 N--CA 1.495 1.802 0 C-N-CA 117.553 -1.659 . . . . 0.0 107.985 179.716 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . 0.429 ' H ' ' C ' ' A' ' 37' ' ' LYS . 9.5 m-70 -138.79 107.43 5.89 Favored 'General case' 0 N--CA 1.496 1.829 0 N-CA-C 113.713 1.005 . . . . 0.0 113.713 -179.395 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 60.78 -161.93 22.4 Favored Glycine 0 N--CA 1.502 3.08 0 CA-C-N 114.311 -1.313 . . . . 0.0 113.901 179.547 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . 0.45 ' HD2' ' N ' ' A' ' 46' ' ' CYS . 73.0 Cg_endo -55.32 179.93 1.19 Allowed 'Cis proline' 0 N--CA 1.505 2.188 0 C-N-CA 129.362 0.984 . . . . 0.0 114.436 -5.499 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.2 m120 -92.98 -8.25 43.62 Favored 'General case' 0 C--N 1.306 -1.294 0 N-CA-C 104.496 -2.409 . . . . 0.0 104.496 -179.783 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 11.4 mm -100.96 28.86 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.02 0 CA-C-O 123.675 1.703 . . . . 0.0 113.86 -179.008 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 136.01 -131.65 5.81 Favored Glycine 0 N--CA 1.485 1.906 1 N-CA-C 101.762 -4.535 . . . . 0.0 101.762 179.888 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . 0.611 ' CG ' ' HA2' ' A' ' 28' ' ' GLY . 3.0 m95 -153.33 161.29 42.5 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 105.268 -2.123 . . . . 0.0 105.268 179.646 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' CYS . . . . . 0.55 ' HB3' ' SG ' ' A' ' 36' ' ' CYS . 19.3 m -111.54 133.97 53.45 Favored 'General case' 0 N--CA 1.498 1.943 0 CA-C-N 123.037 2.653 . . . . 0.0 104.278 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.588 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 79.0 m -135.12 -173.4 3.31 Favored 'General case' 0 C--N 1.293 -1.865 0 CA-C-N 111.287 -2.688 . . . . 0.0 108.143 -179.399 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -150.6 175.89 11.5 Favored 'General case' 0 C--N 1.294 -1.805 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 179.225 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . 0.473 ' HE3' ' CZ2' ' A' ' 33' ' ' TRP . 22.6 mmtp . . . . . 0 C--N 1.293 -1.861 0 CA-C-O 114.98 -2.438 . . . . 0.0 107.275 179.5 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 45.7 t . . . . . 0 N--CA 1.493 1.699 0 N-CA-C 104.916 -2.253 . . . . 0.0 104.916 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -70.61 135.19 27.85 Favored 'Trans proline' 0 C--N 1.306 -1.659 0 C-N-CA 123.481 2.787 . . . . 0.0 112.132 175.21 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -139.64 174.66 10.28 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 123.968 0.792 . . . . 0.0 111.869 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.523 HD12 ' HA ' ' A' ' 5' ' ' LEU . 13.6 tp -97.8 152.17 19.44 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 102.065 -3.309 . . . . 0.0 102.065 179.766 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . 0.497 ' HB3' ' C ' ' A' ' 36' ' ' CYS . 2.7 m -115.44 -138.08 0.37 Allowed 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 121.007 3.706 . . . . 0.0 121.007 -178.669 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 . . . . . 0 N--CA 1.502 2.163 0 C-N-CA 119.643 -0.823 . . . . 0.0 111.706 -179.699 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 27.3 t . . . . . 0 N--CA 1.5 2.04 0 CA-C-O 118.051 -0.976 . . . . 0.0 113.537 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.457 ' HA2' ' HD3' ' A' ' 48' ' ' LYS . . . -177.33 152.23 11.84 Favored Glycine 0 N--CA 1.501 2.985 0 C-N-CA 119.234 -1.46 . . . . 0.0 111.508 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.502 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 38.8 mm -101.31 137.49 28.79 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.206 0 C-N-CA 117.3 -1.76 . . . . 0.0 106.718 179.623 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' LEU . . . . . 0.53 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 30.8 tp -63.03 136.3 57.74 Favored 'General case' 0 C--N 1.295 -1.786 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 179.821 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 39.5 m95 -127.06 134.94 50.18 Favored 'General case' 0 C--N 1.31 -1.124 0 CA-C-O 125.397 2.522 . . . . 0.0 117.703 -179.848 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -88.73 40.65 0.98 Allowed 'General case' 0 C--N 1.295 -1.767 1 CA-C-N 107.669 -4.332 . . . . 0.0 113.98 -179.539 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.468 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 1.2 m-30 -115.17 122.22 33.68 Favored Pre-proline 0 N--CA 1.489 1.514 0 CA-C-O 122.86 1.314 . . . . 0.0 113.909 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo -63.66 -23.32 69.93 Favored 'Trans proline' 0 C--N 1.301 -1.938 0 C-N-CA 122.268 1.978 . . . . 0.0 108.924 -173.077 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 10.6 p -93.27 8.83 38.74 Favored 'General case' 0 N--CA 1.492 1.635 0 CA-C-N 114.502 -1.227 . . . . 0.0 112.651 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 112.04 -118.63 4.78 Favored Glycine 0 N--CA 1.495 2.62 0 N-CA-C 107.001 -2.439 . . . . 0.0 107.001 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . 0.526 ' HB3' ' HB2' ' A' ' 33' ' ' TRP . 14.8 m -96.21 159.54 31.86 Favored Pre-proline 0 C--N 1.303 -1.444 0 N-CA-C 107.504 -1.295 . . . . 0.0 107.504 179.8 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.723 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 1.6 Cg_endo -78.35 159.56 29.38 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 C-N-CA 122.338 2.025 . . . . 0.0 112.126 169.588 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 27.9 t -49.61 121.97 5.79 Favored 'General case' 0 C--N 1.303 -1.438 0 CA-C-N 113.345 -1.752 . . . . 0.0 108.96 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 109.68 -6.3 31.36 Favored Glycine 0 N--CA 1.498 2.806 0 CA-C-N 113.279 -1.782 . . . . 0.0 111.655 179.673 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' TRP . . . . . 0.723 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 51.0 m95 -113.61 158.12 21.23 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 105.957 -1.868 . . . . 0.0 105.957 -179.938 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 50.6 t-80 -140.13 37.15 1.92 Allowed 'General case' 0 N--CA 1.493 1.7 0 C-N-CA 118.974 -1.09 . . . . 0.0 111.08 -179.774 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . 0.489 ' HA ' ' SG ' ' A' ' 47' ' ' CYS . 22.1 t-20 60.25 152.08 0.02 OUTLIER 'General case' 0 N--CA 1.504 2.225 0 CA-C-N 113.303 -1.772 . . . . 0.0 115.045 179.794 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . 0.548 ' SG ' ' CB ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -125.18 -48.55 1.72 Allowed 'General case' 0 N--CA 1.483 1.219 0 N-CA-C 105.869 -1.9 . . . . 0.0 105.869 -179.972 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 66.2 tttt -113.2 103.1 11.01 Favored 'General case' 0 C--N 1.305 -1.35 0 N-CA-C 105.709 -1.96 . . . . 0.0 105.709 179.719 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.426 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -88.96 18.56 4.76 Favored 'General case' 0 N--CA 1.497 1.885 0 CA-C-N 113.312 -1.767 . . . . 0.0 107.155 179.577 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' HIS . . . . . 0.426 ' ND1' ' C ' ' A' ' 38' ' ' ALA . 7.1 m-70 -129.29 37.37 4.04 Favored 'General case' 0 N--CA 1.489 1.509 0 CA-C-N 114.468 -1.242 . . . . 0.0 109.05 -179.733 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 96.9 -158.32 21.29 Favored Glycine 0 N--CA 1.501 3.009 0 N-CA-C 110.207 -1.157 . . . . 0.0 110.207 179.803 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . 0.461 ' HG2' ' O ' ' A' ' 44' ' ' GLY . 9.2 Cg_endo -74.44 -176.66 18.11 Favored 'Cis proline' 0 N--CA 1.505 2.159 0 CA-C-N 118.914 1.357 . . . . 0.0 110.91 1.448 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 19.4 p-10 -92.32 -11.3 35.49 Favored 'General case' 0 N--CA 1.491 1.578 0 N-CA-C 105.016 -2.216 . . . . 0.0 105.016 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 13.0 mm -88.4 29.05 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.31 0 CA-C-N 113.807 -1.542 . . . . 0.0 110.598 -179.427 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.461 ' O ' ' HG2' ' A' ' 41' ' ' PRO . . . 115.37 130.64 4.81 Favored Glycine 0 N--CA 1.49 2.24 0 CA-C-N 112.414 -2.175 . . . . 0.0 107.853 -179.871 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' TRP . . . . . 0.468 ' NE1' ' O ' ' A' ' 25' ' ' TYR . 2.1 m95 -73.85 134.67 43.34 Favored 'General case' 0 N--CA 1.499 1.98 0 N-CA-C 105.882 -1.896 . . . . 0.0 105.882 -179.434 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' CYS . . . . . 0.548 ' CB ' ' SG ' ' A' ' 36' ' ' CYS . 96.0 m -87.9 128.78 35.36 Favored 'General case' 0 N--CA 1.491 1.62 0 N-CA-C 101.314 -3.587 . . . . 0.0 101.314 179.575 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.503 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 73.7 m -126.71 -176.28 3.65 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-N 113.28 -1.782 . . . . 0.0 113.755 -179.317 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' LYS . . . . . 0.468 ' HD2' ' H ' ' A' ' 49' ' ' LYS . 28.5 tptp -150.76 150.84 31.51 Favored 'General case' 0 C--N 1.292 -1.913 0 CA-C-N 114.931 -1.031 . . . . 0.0 109.817 -179.944 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . 0.468 ' H ' ' HD2' ' A' ' 48' ' ' LYS . 54.1 mtpt . . . . . 0 N--CA 1.501 2.085 0 O-C-N 126.16 2.162 . . . . 0.0 109.666 179.458 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.499 2.849 0 N-CA-C 109.94 -1.264 . . . . 0.0 109.94 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 24.6 t -123.31 142.11 37.78 Favored Pre-proline 0 N--CA 1.497 1.876 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 -179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.412 ' HA ' ' O ' ' A' ' 20' ' ' GLY . 4.9 Cg_endo -81.33 142.13 13.12 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 C-N-CA 123.293 2.662 . . . . 0.0 110.932 164.718 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -137.52 170.03 16.78 Favored 'General case' 0 N--CA 1.495 1.784 0 C-N-CA 119.455 -0.898 . . . . 0.0 111.659 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.534 HD23 ' N ' ' A' ' 6' ' ' CYS . 5.5 tt -85.62 148.05 26.1 Favored 'General case' 0 N--CA 1.495 1.792 0 N-CA-C 106.752 -1.573 . . . . 0.0 106.752 -179.823 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.546 ' HB3' ' C ' ' A' ' 36' ' ' CYS . 2.4 m -127.73 -167.03 1.69 Allowed 'General case' 0 N--CA 1.488 1.443 0 N-CA-C 119.197 3.036 . . . . 0.0 119.197 -179.621 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -74.86 -62.88 1.39 Allowed 'General case' 0 N--CA 1.503 2.199 0 CA-C-N 112.932 -1.94 . . . . 0.0 112.353 -179.762 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 31.9 p -86.48 17.08 4.02 Favored 'General case' 0 N--CA 1.498 1.936 0 C-N-CA 119.254 -0.979 . . . . 0.0 108.66 179.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.48 ' HB2' ' HB2' ' A' ' 6' ' ' CYS . 8.8 t70 -69.41 79.41 0.39 Allowed 'General case' 0 N--CA 1.491 1.623 0 CA-C-O 123.359 1.552 . . . . 0.0 106.985 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -152.01 -81.13 0.03 OUTLIER Glycine 0 N--CA 1.49 2.276 0 CA-C-N 112.294 -2.23 . . . . 0.0 107.863 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_endo -70.79 27.7 0.21 Allowed 'Trans proline' 0 N--CA 1.499 1.851 0 C-N-CA 124.257 3.305 . . . . 0.0 114.45 -176.407 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 75.3 mtt-85 -93.32 153.92 41.47 Favored Pre-proline 0 N--CA 1.497 1.918 0 C-N-CA 119.54 -0.864 . . . . 0.0 112.012 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 7.4 Cg_endo -73.05 -145.7 0.02 OUTLIER 'Trans proline' 0 N--CA 1.503 2.039 0 C-N-CA 125.228 3.952 . . . . 0.0 111.695 -178.397 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 2.7 mpt_? -42.39 136.3 2.4 Favored 'General case' 0 N--CA 1.498 1.928 0 CA-C-O 122.004 0.906 . . . . 0.0 110.439 179.817 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.521 ' O ' ' N ' ' A' ' 17' ' ' THR . . . 96.07 -37.92 3.27 Favored Glycine 0 N--CA 1.498 2.823 0 N-CA-C 109.188 -1.565 . . . . 0.0 109.188 -179.6 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 23.5 t-20 28.95 -64.38 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 117.259 2.318 . . . . 0.0 117.259 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.521 ' N ' ' O ' ' A' ' 15' ' ' GLY . 38.5 p -94.15 7.27 45.86 Favored 'General case' 0 N--CA 1.494 1.726 0 N-CA-C 114.157 1.169 . . . . 0.0 114.157 -179.663 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 31.9 mt -152.1 29.39 0.57 Allowed 'General case' 0 N--CA 1.502 2.139 0 CA-C-N 112.957 -1.929 . . . . 0.0 110.645 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 34.6 m -88.7 43.11 1.12 Allowed 'General case' 0 N--CA 1.505 2.309 0 C-N-CA 119.127 -1.029 . . . . 0.0 113.099 -179.581 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.412 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -157.01 150.43 21.57 Favored Glycine 0 N--CA 1.493 2.46 0 N-CA-C 107.859 -2.096 . . . . 0.0 107.859 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.458 ' N ' ' O ' ' A' ' 47' ' ' CYS . 44.9 mm -113.48 152.99 15.1 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.282 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.528 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 4.2 pp -76.26 151.13 36.87 Favored 'General case' 0 N--CA 1.501 2.077 0 C-N-CA 117.908 -1.517 . . . . 0.0 108.714 179.569 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 30.0 m95 -132.68 130.3 39.92 Favored 'General case' 0 N--CA 1.485 1.288 0 N-CA-C 119.293 3.071 . . . . 0.0 119.293 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -88.28 53.06 2.61 Favored 'General case' 0 C--N 1.295 -1.804 0 CA-C-N 108.569 -3.923 . . . . 0.0 111.377 -179.495 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.462 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 2.3 m-85 -126.14 121.13 23.92 Favored Pre-proline 0 N--CA 1.495 1.784 0 CA-C-N 115.497 -0.774 . . . . 0.0 112.481 179.605 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -64.68 -19.58 64.73 Favored 'Trans proline' 0 C--N 1.307 -1.635 0 C-N-CA 123.941 3.094 . . . . 0.0 111.328 -177.281 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 6.1 p -94.81 11.37 31.78 Favored 'General case' 0 N--CA 1.489 1.507 0 CA-C-N 115.06 -0.973 . . . . 0.0 111.1 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 101.33 -121.83 7.37 Favored Glycine 0 N--CA 1.498 2.77 0 N-CA-C 106.198 -2.761 . . . . 0.0 106.198 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.544 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 24.9 m -89.15 148.88 41.89 Favored Pre-proline 0 C--N 1.305 -1.348 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 179.72 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.723 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 19.5 Cg_endo -74.19 166.92 28.41 Favored 'Trans proline' 0 C--N 1.31 -1.466 0 C-N-CA 122.211 1.941 . . . . 0.0 114.143 172.895 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 9.4 t -53.89 114.52 1.6 Allowed 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 113.989 -1.46 . . . . 0.0 110.285 -179.755 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 113.6 -7.08 24.33 Favored Glycine 0 N--CA 1.5 2.948 0 CA-C-N 113.906 -1.497 . . . . 0.0 112.319 179.549 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' TRP . . . . . 0.723 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 53.7 m95 -110.29 166.24 11.13 Favored 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 106.745 -1.576 . . . . 0.0 106.745 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 51.9 t60 -146.04 29.82 1.07 Allowed 'General case' 0 N--CA 1.503 2.185 0 C-N-CA 117.911 -1.516 . . . . 0.0 113.95 -179.737 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . 0.544 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 23.3 t-20 64.1 152.03 0.04 OUTLIER 'General case' 0 N--CA 1.506 2.335 0 N-CA-C 115.164 1.542 . . . . 0.0 115.164 -179.818 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.717 ' SG ' ' HB3' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -130.16 -45.77 1.12 Allowed 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 113.32 -1.764 . . . . 0.0 107.543 -179.819 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . 0.497 ' C ' ' H ' ' A' ' 39' ' ' HIS . 82.7 tttt -118.57 103.11 9.41 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-O 122.858 1.313 . . . . 0.0 108.837 179.912 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.432 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -81.48 25.25 0.52 Allowed 'General case' 0 N--CA 1.494 1.761 0 N-CA-C 107.181 -1.414 . . . . 0.0 107.181 179.603 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . 0.497 ' H ' ' C ' ' A' ' 37' ' ' LYS . 5.5 m-70 -131.13 10.24 4.91 Favored 'General case' 0 N--CA 1.492 1.636 0 N-CA-C 108.628 -0.878 . . . . 0.0 108.628 -179.727 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 125.43 -142.62 13.91 Favored Glycine 0 N--CA 1.498 2.778 0 N-CA-C 110.168 -1.173 . . . . 0.0 110.168 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.578 ' CD ' ' SG ' ' A' ' 46' ' ' CYS . 85.8 Cg_endo -66.12 -174.66 6.29 Favored 'Cis proline' 0 N--CA 1.5 1.856 0 CA-C-N 118.289 1.045 . . . . 0.0 110.251 -1.872 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 4.1 m-20 -91.7 -8.83 45.9 Favored 'General case' 0 CA--C 1.479 -1.786 0 N-CA-C 105.617 -1.994 . . . . 0.0 105.617 -179.147 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 37.4 mt -95.06 33.33 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.163 0 CA-C-O 123.624 1.678 . . . . 0.0 109.114 -179.495 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.405 ' O ' ' HG2' ' A' ' 41' ' ' PRO . . . 114.06 135.54 6.11 Favored Glycine 0 N--CA 1.485 1.923 0 CA-C-N 111.275 -2.693 . . . . 0.0 107.41 -179.897 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . 0.462 ' NE1' ' O ' ' A' ' 25' ' ' TYR . 6.1 m95 -64.17 134.59 55.12 Favored 'General case' 0 N--CA 1.508 2.454 0 CA-C-O 116.796 -1.573 . . . . 0.0 106.787 -179.544 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' CYS . . . . . 0.717 ' HB3' ' SG ' ' A' ' 36' ' ' CYS . 35.4 m -89.45 124.15 34.23 Favored 'General case' 0 C--N 1.312 -1.063 0 N-CA-C 103.081 -2.933 . . . . 0.0 103.081 179.922 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.538 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 73.4 m -127.4 -169.74 2.1 Favored 'General case' 0 C--N 1.291 -1.972 0 CA-C-N 110.921 -2.854 . . . . 0.0 107.899 -179.533 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.411 ' N ' ' CD ' ' A' ' 48' ' ' LYS . 0.0 OUTLIER -151.67 173.2 14.96 Favored 'General case' 0 C--N 1.292 -1.924 0 N-CA-C 105.175 -2.157 . . . . 0.0 105.175 179.058 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 90.2 mttt . . . . . 0 C--N 1.289 -2.028 0 CA-C-O 114.691 -2.576 . . . . 0.0 106.392 179.524 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 2.545 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 22.4 t -89.36 140.96 28.63 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 103.912 -2.625 . . . . 0.0 103.912 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -68.27 149.43 75.77 Favored 'Trans proline' 0 C--N 1.305 -1.75 0 C-N-CA 122.98 2.453 . . . . 0.0 108.038 170.78 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 1.2 p -141.72 175.02 10.03 Favored 'General case' 0 N--CA 1.495 1.811 0 N-CA-C 115.242 1.571 . . . . 0.0 115.242 -179.755 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.417 HD12 ' HA ' ' A' ' 5' ' ' LEU . 23.5 tp -104.16 150.03 24.72 Favored 'General case' 0 N--CA 1.488 1.471 0 N-CA-C 103.682 -2.71 . . . . 0.0 103.682 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.443 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 3.3 m -133.11 -162.51 1.25 Allowed 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 116.299 1.963 . . . . 0.0 116.299 -179.04 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 3.2 p-10 -25.39 -45.31 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.989 0 O-C-N 126.751 2.532 . . . . 0.0 111.851 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 32.6 t -83.28 48.91 1.46 Allowed 'General case' 0 N--CA 1.502 2.142 0 N-CA-C 106.946 -1.502 . . . . 0.0 106.946 179.775 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -103.48 -71.82 0.72 Allowed 'General case' 0 N--CA 1.491 1.6 0 CA-C-N 113.834 -1.53 . . . . 0.0 108.863 -179.805 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 73.03 169.41 15.0 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 108.126 -1.99 . . . . 0.0 108.126 -179.725 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 14.8 Cg_endo -73.25 17.39 0.42 Allowed 'Trans proline' 0 N--CA 1.495 1.596 0 C-N-CA 124.1 3.2 . . . . 0.0 112.343 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 34.6 ttt180 -130.07 57.63 32.37 Favored Pre-proline 0 N--CA 1.492 1.672 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.443 -179.827 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_endo -72.82 64.18 3.98 Favored 'Trans proline' 0 N--CA 1.499 1.84 0 C-N-CA 124.124 3.216 . . . . 0.0 111.179 -177.42 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 16.5 ptt180 -67.86 146.61 53.49 Favored 'General case' 0 N--CA 1.499 2.004 0 CA-C-N 113.998 -1.455 . . . . 0.0 111.795 -179.713 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 55.69 -11.59 0.01 OUTLIER Glycine 0 N--CA 1.499 2.872 0 N-CA-C 117.13 1.612 . . . . 0.0 117.13 179.748 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 50.1 t30 53.18 79.26 0.12 Allowed 'General case' 0 N--CA 1.508 2.433 0 CA-C-N 119.412 1.606 . . . . 0.0 110.09 -179.854 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 9.0 t -89.06 174.09 8.08 Favored 'General case' 0 N--CA 1.502 2.129 0 C-N-CA 118.493 -1.283 . . . . 0.0 110.437 -179.779 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 48.0 mt -130.36 104.47 7.29 Favored 'General case' 0 N--CA 1.492 1.626 0 CA-C-N 114.125 -1.398 . . . . 0.0 110.255 -179.281 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 25.0 m -114.51 -0.07 13.84 Favored 'General case' 0 N--CA 1.502 2.138 0 C-N-CA 119.766 -0.774 . . . . 0.0 112.263 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -164.74 179.59 39.34 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 108.945 -1.662 . . . . 0.0 108.945 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 34.3 mm -125.06 149.41 29.62 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.174 0 N-CA-C 108.42 -0.955 . . . . 0.0 108.42 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.664 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 4.5 pp -71.17 148.44 47.34 Favored 'General case' 0 N--CA 1.498 1.946 0 C-N-CA 118.513 -1.275 . . . . 0.0 110.875 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 38.2 m95 -131.4 131.47 43.66 Favored 'General case' 0 N--CA 1.486 1.36 0 N-CA-C 120.389 3.477 . . . . 0.0 120.389 -179.821 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -88.87 49.58 1.81 Allowed 'General case' 0 C--N 1.296 -1.734 1 CA-C-N 106.862 -4.699 . . . . 0.0 112.785 -179.389 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.407 ' CE1' ' HB3' ' A' ' 30' ' ' PRO . 2.2 m-85 -121.21 130.76 24.69 Favored Pre-proline 0 C--N 1.302 -1.468 0 CA-C-O 122.436 1.113 . . . . 0.0 111.3 179.525 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -69.79 -24.28 29.69 Favored 'Trans proline' 0 C--N 1.308 -1.595 0 C-N-CA 124.647 3.565 . . . . 0.0 110.662 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 6.1 p -93.63 15.12 16.97 Favored 'General case' 0 N--CA 1.492 1.642 0 CA-C-N 115.405 -0.816 . . . . 0.0 111.307 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 99.64 -126.01 8.77 Favored Glycine 0 N--CA 1.5 2.901 0 N-CA-C 105.674 -2.97 . . . . 0.0 105.674 -179.88 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.541 ' SG ' ' CA ' ' A' ' 35' ' ' ASN . 35.7 m -86.66 152.24 54.02 Favored Pre-proline 0 C--N 1.304 -1.403 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 179.721 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.758 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 19.9 Cg_endo -73.04 165.83 31.71 Favored 'Trans proline' 0 C--N 1.305 -1.719 0 C-N-CA 122.525 2.15 . . . . 0.0 113.906 173.392 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 5.6 p -51.73 107.42 0.19 Allowed 'General case' 0 C--N 1.298 -1.632 0 CA-C-N 112.341 -2.209 . . . . 0.0 112.247 -179.741 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 115.34 -7.85 20.65 Favored Glycine 0 N--CA 1.498 2.826 0 O-C-N 124.514 1.134 . . . . 0.0 111.737 179.594 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' TRP . . . . . 0.758 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 45.7 m95 -105.76 166.87 10.16 Favored 'General case' 0 C--N 1.304 -1.389 0 N-CA-C 106.143 -1.799 . . . . 0.0 106.143 -179.874 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 54.0 t-80 -147.03 33.82 0.91 Allowed 'General case' 0 N--CA 1.497 1.894 0 C-N-CA 117.337 -1.745 . . . . 0.0 112.884 -179.648 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . 0.541 ' CA ' ' SG ' ' A' ' 29' ' ' CYS . 24.9 t-20 60.44 143.29 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.13 0 N-CA-C 115.187 1.551 . . . . 0.0 115.187 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.876 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 1.7 p -120.99 -41.16 2.56 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-N 114.28 -1.327 . . . . 0.0 108.448 -179.628 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . 0.403 ' HG2' ' H ' ' A' ' 39' ' ' HIS . 77.3 tttt -118.84 116.31 26.23 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 104.708 -2.33 . . . . 0.0 104.708 179.748 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -89.41 8.08 32.62 Favored 'General case' 0 N--CA 1.496 1.827 0 N-CA-C 107.475 -1.306 . . . . 0.0 107.475 179.79 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . 0.403 ' H ' ' HG2' ' A' ' 37' ' ' LYS . 16.2 m-70 -133.04 48.86 2.36 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-N 115.001 -0.999 . . . . 0.0 110.876 -179.708 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 113.41 -165.11 12.01 Favored Glycine 0 N--CA 1.497 2.705 0 O-C-N 124.293 0.995 . . . . 0.0 113.47 179.581 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 15.0 Cg_endo -73.75 -174.01 12.46 Favored 'Cis proline' 0 N--CA 1.497 1.703 0 O-C-N 123.085 1.045 . . . . 0.0 110.933 -5.182 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 6.7 m120 -92.08 -10.68 38.16 Favored 'General case' 0 CA--C 1.484 -1.587 0 N-CA-C 104.579 -2.378 . . . . 0.0 104.579 -179.676 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 33.0 pt -92.04 27.22 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.03 0 C-N-CA 118.204 -1.398 . . . . 0.0 113.689 -179.434 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 116.76 130.85 4.55 Favored Glycine 0 N--CA 1.489 2.215 0 CA-C-N 111.831 -2.44 . . . . 0.0 108.693 -179.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . 0.4 ' NE1' ' O ' ' A' ' 25' ' ' TYR . 8.5 m95 -54.06 131.76 41.36 Favored 'General case' 0 N--CA 1.513 2.704 0 CA-C-O 116.248 -1.834 . . . . 0.0 107.56 -179.56 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' CYS . . . . . 0.876 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 53.3 t -89.44 131.85 35.3 Favored 'General case' 0 N--CA 1.479 0.983 1 N-CA-C 99.333 -4.321 . . . . 0.0 99.333 -179.882 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.459 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 86.2 m -133.74 -173.55 3.27 Favored 'General case' 0 C--N 1.292 -1.9 0 CA-C-N 111.056 -2.793 . . . . 0.0 109.876 -179.166 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.449 ' O ' ' HA ' ' A' ' 33' ' ' TRP . 0.0 OUTLIER -150.48 173.47 14.03 Favored 'General case' 0 C--N 1.297 -1.695 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 179.376 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 3.7 mmpt? . . . . . 0 N--CA 1.502 2.131 0 O-C-N 126.618 2.449 . . . . 0.0 110.874 179.929 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 2.74 0 N-CA-C 112.267 -0.333 . . . . 0.0 112.267 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 21.8 t -89.2 150.75 45.58 Favored Pre-proline 0 N--CA 1.5 2.051 0 N-CA-C 106.686 -1.598 . . . . 0.0 106.686 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.534 ' CB ' ' HG ' ' A' ' 18' ' ' LEU . 11.1 Cg_endo -74.47 134.55 18.94 Favored 'Trans proline' 0 C--N 1.306 -1.681 0 C-N-CA 123.048 2.498 . . . . 0.0 117.73 163.819 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -128.82 173.66 10.16 Favored 'General case' 0 N--CA 1.493 1.679 0 N-CA-C 107.589 -1.263 . . . . 0.0 107.589 179.509 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.594 HD23 ' N ' ' A' ' 6' ' ' CYS . 5.4 tt -90.64 147.24 23.43 Favored 'General case' 0 N--CA 1.496 1.866 0 N-CA-C 103.665 -2.717 . . . . 0.0 103.665 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.594 ' N ' HD23 ' A' ' 5' ' ' LEU . 4.4 m -128.34 -171.49 2.47 Favored 'General case' 0 C--N 1.307 -1.271 0 N-CA-C 116.005 1.854 . . . . 0.0 116.005 -179.851 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 34.1 t70 -82.44 -66.76 0.85 Allowed 'General case' 0 N--CA 1.489 1.481 0 CA-C-N 113.196 -1.82 . . . . 0.0 107.575 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 37.9 t -65.1 -7.25 11.43 Favored 'General case' 0 N--CA 1.501 2.095 0 C-N-CA 118.606 -1.238 . . . . 0.0 109.566 179.761 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.561 ' HB2' ' HB2' ' A' ' 6' ' ' CYS . 16.2 t0 -62.76 -23.7 67.34 Favored 'General case' 0 N--CA 1.499 1.979 0 O-C-N 124.358 1.036 . . . . 0.0 108.862 179.699 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 90.06 135.31 5.89 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 107.475 -2.25 . . . . 0.0 107.475 -179.805 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 0.5 OUTLIER -80.1 42.88 1.4 Allowed 'Trans proline' 0 N--CA 1.492 1.412 0 C-N-CA 124.839 3.693 . . . . 0.0 110.509 -171.822 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 1.1 mpt_? -89.97 131.52 38.99 Favored Pre-proline 0 N--CA 1.495 1.801 0 CA-C-N 115.399 -0.819 . . . . 0.0 112.845 -179.698 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -74.44 60.41 4.97 Favored 'Trans proline' 0 N--CA 1.499 1.831 0 C-N-CA 125.049 3.833 . . . . 0.0 112.394 -177.237 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 9.7 mmm180 -93.63 138.02 32.3 Favored 'General case' 0 N--CA 1.499 1.994 0 CA-C-N 113.745 -1.571 . . . . 0.0 109.447 -179.893 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -80.56 4.07 70.6 Favored Glycine 0 N--CA 1.501 3.009 0 C-N-CA 119.53 -1.319 . . . . 0.0 111.946 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 48.5 t30 -147.01 74.44 1.34 Allowed 'General case' 0 N--CA 1.497 1.893 0 N-CA-C 107.453 -1.314 . . . . 0.0 107.453 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 4.0 p -88.72 52.33 2.4 Favored 'General case' 0 C--N 1.298 -1.647 0 CA-C-N 115.158 -0.928 . . . . 0.0 110.693 -179.842 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.534 ' HG ' ' CB ' ' A' ' 3' ' ' PRO . 2.6 tt -73.1 75.7 1.24 Allowed 'General case' 0 N--CA 1.492 1.652 0 N-CA-C 106.133 -1.802 . . . . 0.0 106.133 179.895 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 4.1 t -136.81 23.5 3.09 Favored 'General case' 0 N--CA 1.5 2.052 0 CA-C-N 115.236 -0.893 . . . . 0.0 110.407 -179.704 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.516 ' HA3' ' SG ' ' A' ' 6' ' ' CYS . . . -172.48 121.57 0.88 Allowed Glycine 0 N--CA 1.494 2.503 0 N-CA-C 107.065 -2.414 . . . . 0.0 107.065 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.457 ' N ' ' O ' ' A' ' 47' ' ' CYS . 36.3 mm -96.09 137.34 24.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 N-CA-C 104.691 -2.337 . . . . 0.0 104.691 179.736 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.562 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 4.3 pp -65.69 149.33 50.29 Favored 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 117.752 -1.579 . . . . 0.0 107.238 179.812 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.417 ' O ' ' CA ' ' A' ' 44' ' ' GLY . 20.2 m95 -132.17 135.78 46.6 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-O 124.542 2.115 . . . . 0.0 115.882 -179.727 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.1 m-85 -88.91 40.58 0.98 Allowed 'General case' 0 C--N 1.293 -1.849 0 CA-C-N 109.12 -3.673 . . . . 0.0 115.353 -179.383 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.444 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 1.2 m-30 -113.12 120.0 41.24 Favored Pre-proline 0 N--CA 1.487 1.396 0 N-CA-C 107.664 -1.236 . . . . 0.0 107.664 179.713 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -60.93 -21.28 70.53 Favored 'Trans proline' 0 C--N 1.298 -2.091 0 C-N-CA 122.511 2.14 . . . . 0.0 110.414 -170.207 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 4.3 p -97.45 3.67 50.77 Favored 'General case' 0 N--CA 1.491 1.6 0 CA-C-N 114.746 -1.115 . . . . 0.0 113.451 -179.923 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 125.58 -121.86 4.35 Favored Glycine 0 N--CA 1.492 2.38 0 N-CA-C 108.601 -1.8 . . . . 0.0 108.601 179.911 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.55 ' HB3' ' HB2' ' A' ' 33' ' ' TRP . 3.9 m -95.2 158.6 34.51 Favored Pre-proline 0 C--N 1.304 -1.375 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.727 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.3 OUTLIER -79.11 -179.24 5.27 Favored 'Trans proline' 0 C--N 1.312 -1.343 0 C-N-CA 123.242 2.628 . . . . 0.0 114.896 171.033 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 18.4 p -58.41 104.62 0.22 Allowed 'General case' 0 C--N 1.299 -1.591 0 CA-C-N 112.922 -1.944 . . . . 0.0 112.941 -179.587 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 114.15 3.63 22.82 Favored Glycine 0 N--CA 1.501 2.969 0 O-C-N 124.759 1.287 . . . . 0.0 113.561 179.628 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' TRP . . . . . 0.727 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 39.7 m95 -117.75 153.07 34.03 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 107.369 -1.345 . . . . 0.0 107.369 -179.822 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . 0.408 ' O ' ' ND1' ' A' ' 34' ' ' HIS . 36.6 t-80 -137.4 41.5 2.4 Favored 'General case' 0 N--CA 1.5 2.044 0 CA-C-O 122.074 0.94 . . . . 0.0 109.847 -179.496 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . 0.496 ' HA ' ' SG ' ' A' ' 47' ' ' CYS . 24.6 t-20 59.59 156.73 0.03 OUTLIER 'General case' 0 N--CA 1.501 2.089 0 CA-C-O 123.9 1.81 . . . . 0.0 114.286 -179.765 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.778 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -125.66 -52.18 1.58 Allowed 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 104.354 -2.461 . . . . 0.0 104.354 179.725 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . 0.464 ' C ' ' H ' ' A' ' 39' ' ' HIS . 43.7 tttp -118.26 103.98 10.35 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 113.615 -1.63 . . . . 0.0 109.74 179.836 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.44 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -81.82 30.96 0.37 Allowed 'General case' 0 N--CA 1.497 1.902 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 179.573 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . 0.464 ' H ' ' C ' ' A' ' 37' ' ' LYS . 4.5 m-70 -130.49 8.32 4.99 Favored 'General case' 0 N--CA 1.492 1.636 0 CA-C-N 115.53 -0.759 . . . . 0.0 108.957 -179.73 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 128.51 -152.98 19.4 Favored Glycine 0 N--CA 1.496 2.7 0 N-CA-C 110.295 -1.122 . . . . 0.0 110.295 179.902 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.43 ' HG2' ' O ' ' A' ' 44' ' ' GLY . 26.8 Cg_endo -72.68 -174.61 12.62 Favored 'Cis proline' 0 N--CA 1.508 2.324 0 O-C-N 122.808 0.899 . . . . 0.0 112.586 -2.414 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.446 ' C ' ' H ' ' A' ' 44' ' ' GLY . 17.8 p-10 -91.88 -14.35 29.81 Favored 'General case' 0 CA--C 1.485 -1.533 0 N-CA-C 105.527 -2.027 . . . . 0.0 105.527 -179.654 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 11.0 mt -88.84 30.1 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.341 0 CA-C-N 113.809 -1.541 . . . . 0.0 109.617 -179.405 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.446 ' H ' ' C ' ' A' ' 42' ' ' ASN . . . 114.6 122.18 3.64 Favored Glycine 0 N--CA 1.491 2.347 0 CA-C-N 112.163 -2.289 . . . . 0.0 107.767 -179.853 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . 0.444 ' NE1' ' O ' ' A' ' 25' ' ' TYR . 3.9 m95 -54.68 138.79 40.85 Favored 'General case' 0 N--CA 1.514 2.735 0 CA-C-O 116.795 -1.574 . . . . 0.0 107.946 -179.378 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' CYS . . . . . 0.778 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 13.8 t -88.87 127.4 35.63 Favored 'General case' 0 C--N 1.309 -1.159 0 N-CA-C 102.587 -3.116 . . . . 0.0 102.587 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.496 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 98.0 m -128.9 176.51 7.8 Favored 'General case' 0 CA--C 1.478 -1.8 0 CA-C-N 112.009 -2.36 . . . . 0.0 113.656 -178.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.461 ' HD2' ' HA ' ' A' ' 48' ' ' LYS . 41.1 tptt -150.83 153.08 34.73 Favored 'General case' 0 C--N 1.295 -1.804 0 C-N-CA 118.785 -1.166 . . . . 0.0 109.405 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 7.4 mtpm? . . . . . 0 N--CA 1.5 2.037 0 CA-C-N 111.703 -2.499 . . . . 0.0 110.886 179.775 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 2.691 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 6.3 t -98.12 149.2 35.48 Favored Pre-proline 0 N--CA 1.5 2.053 0 N-CA-C 106.512 -1.662 . . . . 0.0 106.512 179.896 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -79.03 119.86 4.43 Favored 'Trans proline' 0 C--N 1.308 -1.568 0 C-N-CA 122.491 2.127 . . . . 0.0 113.337 160.019 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.453 ' SG ' ' HB3' ' A' ' 22' ' ' LEU . 0.5 OUTLIER -104.59 -171.63 1.96 Allowed 'General case' 0 N--CA 1.495 1.802 0 CA-C-N 114.956 -1.02 . . . . 0.0 110.893 -179.975 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 4.2 tp -98.38 152.29 19.64 Favored 'General case' 0 N--CA 1.497 1.907 0 N-CA-C 104.593 -2.373 . . . . 0.0 104.593 179.838 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.681 ' HB2' ' HB2' ' A' ' 9' ' ' ASP . 3.1 m -132.59 -170.63 2.48 Favored 'General case' 0 N--CA 1.485 1.321 0 N-CA-C 115.41 1.633 . . . . 0.0 115.41 -179.62 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -77.24 -63.93 1.25 Allowed 'General case' 0 C--N 1.3 -1.583 0 CA-C-N 112.971 -1.922 . . . . 0.0 109.752 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 2.4 p -97.46 32.47 2.25 Favored 'General case' 0 C--N 1.296 -1.723 0 CA-C-N 114.969 -1.014 . . . . 0.0 108.824 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.681 ' HB2' ' HB2' ' A' ' 6' ' ' CYS . 2.2 t70 -73.83 64.18 0.94 Allowed 'General case' 0 N--CA 1.496 1.834 0 CA-C-N 114.685 -1.143 . . . . 0.0 110.598 -179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 85.17 157.78 28.57 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 108.044 -2.022 . . . . 0.0 108.044 -179.875 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 8.7 Cg_endo -76.48 26.72 0.42 Allowed 'Trans proline' 0 N--CA 1.496 1.656 0 C-N-CA 124.101 3.201 . . . . 0.0 112.049 169.855 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 34.4 mtp85 -111.18 142.92 27.32 Favored Pre-proline 0 N--CA 1.497 1.884 0 N-CA-C 114.252 1.204 . . . . 0.0 114.252 -179.784 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -72.69 61.6 3.68 Favored 'Trans proline' 0 C--N 1.312 -1.351 0 C-N-CA 124.038 3.159 . . . . 0.0 111.748 170.703 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 14.4 mtm180 60.01 -140.35 0.62 Allowed 'General case' 0 N--CA 1.497 1.915 0 CA-C-N 113.643 -1.617 . . . . 0.0 114.315 179.666 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 85.25 -57.47 4.96 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 22.3 p-10 -156.98 54.38 0.52 Allowed 'General case' 0 N--CA 1.5 2.025 0 CA-C-O 122.369 1.081 . . . . 0.0 109.753 -179.835 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 39.1 p -115.65 90.67 3.39 Favored 'General case' 0 N--CA 1.491 1.587 0 CA-C-N 114.073 -1.422 . . . . 0.0 109.581 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 89.4 mt -118.49 74.08 0.94 Allowed 'General case' 0 N--CA 1.499 1.995 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 -179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 4.5 t -98.71 47.8 0.98 Allowed 'General case' 0 N--CA 1.502 2.144 0 N-CA-C 113.507 0.929 . . . . 0.0 113.507 -179.743 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 165.43 -176.3 41.04 Favored Glycine 0 N--CA 1.512 3.738 0 C-N-CA 118.742 -1.694 . . . . 0.0 114.94 179.573 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.405 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 19.3 mm -134.19 149.16 29.97 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.245 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 179.57 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.587 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.5 pp -69.19 146.71 52.19 Favored 'General case' 0 N--CA 1.495 1.794 0 C-N-CA 119.333 -0.947 . . . . 0.0 110.859 179.709 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 37.5 m95 -130.62 130.33 43.83 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 121.374 3.842 . . . . 0.0 121.374 -179.571 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 4.4 m-85 -89.0 49.81 1.85 Allowed 'General case' 0 C--N 1.295 -1.795 1 CA-C-N 108.093 -4.14 . . . . 0.0 112.209 -179.687 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.44 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 2.2 m-85 -122.56 124.56 26.7 Favored Pre-proline 0 N--CA 1.494 1.765 0 N-CA-C 114.144 1.164 . . . . 0.0 114.144 179.876 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -64.16 -20.82 67.63 Favored 'Trans proline' 0 C--N 1.307 -1.641 0 C-N-CA 124.065 3.177 . . . . 0.0 110.935 -177.02 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 5.1 p -94.06 6.9 47.07 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-N 114.576 -1.193 . . . . 0.0 111.207 179.829 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 104.17 -112.52 4.15 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 105.252 -3.139 . . . . 0.0 105.252 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.537 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 13.5 m -96.55 147.96 33.73 Favored Pre-proline 0 C--N 1.305 -1.363 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 179.798 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.73 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 15.2 Cg_endo -74.23 174.67 12.08 Favored 'Trans proline' 0 C--N 1.308 -1.566 0 C-N-CA 122.628 2.219 . . . . 0.0 114.47 174.259 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 12.0 p -53.13 105.65 0.13 Allowed 'General case' 0 C--N 1.299 -1.63 0 CA-C-N 112.469 -2.151 . . . . 0.0 112.568 -179.694 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 111.92 -1.25 27.21 Favored Glycine 0 N--CA 1.503 3.139 0 O-C-N 124.156 0.91 . . . . 0.0 113.814 179.503 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' TRP . . . . . 0.73 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 52.1 m95 -110.45 166.79 10.71 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 108.053 -1.092 . . . . 0.0 108.053 -179.912 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 80.1 t60 -146.98 36.59 0.94 Allowed 'General case' 0 N--CA 1.5 2.03 0 C-N-CA 116.8 -1.96 . . . . 0.0 115.94 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . 0.537 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 0.4 OUTLIER 63.3 137.93 0.02 OUTLIER 'General case' 0 N--CA 1.506 2.326 0 N-CA-C 116.926 2.195 . . . . 0.0 116.926 179.714 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.688 ' SG ' ' HB3' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -118.06 -42.17 2.83 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 105.029 -2.211 . . . . 0.0 105.029 179.71 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . 0.442 ' HD2' ' HA ' ' A' ' 6' ' ' CYS . 57.3 tttt -136.38 120.54 17.79 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 114.824 -1.08 . . . . 0.0 109.544 179.766 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.437 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -97.99 34.21 1.97 Allowed 'General case' 0 N--CA 1.496 1.829 0 N-CA-C 105.505 -2.035 . . . . 0.0 105.505 179.645 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . 0.437 ' ND1' ' C ' ' A' ' 38' ' ' ALA . 3.8 m-70 -133.5 47.92 2.42 Favored 'General case' 0 N--CA 1.495 1.792 0 N-CA-C 106.225 -1.769 . . . . 0.0 106.225 -179.67 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 85.21 -156.61 31.02 Favored Glycine 0 N--CA 1.498 2.779 0 N-CA-C 107.416 -2.274 . . . . 0.0 107.416 -179.749 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 17.6 Cg_endo -72.13 -172.76 9.41 Favored 'Cis proline' 0 N--CA 1.494 1.555 0 CA-C-N 118.612 1.206 . . . . 0.0 112.053 2.5 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 80.2 m-20 -92.32 -15.49 27.3 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 104.647 -2.353 . . . . 0.0 104.647 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 13.5 mt -90.87 29.5 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.21 0 CA-C-N 113.272 -1.786 . . . . 0.0 111.425 -179.255 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 109.07 119.11 4.2 Favored Glycine 0 N--CA 1.491 2.31 0 CA-C-N 112.178 -2.283 . . . . 0.0 111.601 179.853 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . 0.44 ' NE1' ' O ' ' A' ' 25' ' ' TYR . 2.2 m95 -49.44 134.74 18.74 Favored 'General case' 0 N--CA 1.516 2.856 0 CA-C-O 116.231 -1.843 . . . . 0.0 107.449 -179.743 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' CYS . . . . . 0.688 ' HB3' ' SG ' ' A' ' 36' ' ' CYS . 68.5 m -89.45 128.22 35.93 Favored 'General case' 0 N--CA 1.485 1.32 0 N-CA-C 103.689 -2.708 . . . . 0.0 103.689 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.522 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 86.7 m -131.12 -173.49 3.11 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-N 111.955 -2.384 . . . . 0.0 110.314 -179.165 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.417 ' O ' ' HA ' ' A' ' 33' ' ' TRP . 0.0 OUTLIER -151.09 173.7 14.05 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 118.574 -1.25 . . . . 0.0 109.106 179.357 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 95.0 mttt . . . . . 0 C--N 1.292 -1.909 0 O-C-N 126.402 2.314 . . . . 0.0 107.927 179.488 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 2.507 0 N-CA-C 110.613 -0.995 . . . . 0.0 110.613 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 9.1 t -97.82 142.25 24.27 Favored Pre-proline 0 N--CA 1.495 1.81 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.513 ' HB3' ' HG ' ' A' ' 18' ' ' LEU . 4.3 Cg_endo -77.2 131.64 11.99 Favored 'Trans proline' 0 N--CA 1.494 1.551 0 C-N-CA 124.067 3.178 . . . . 0.0 114.26 166.916 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -122.17 167.99 12.53 Favored 'General case' 0 N--CA 1.498 1.942 0 CA-C-O 122.602 1.191 . . . . 0.0 114.076 -179.702 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 12.7 tp -79.68 127.34 32.07 Favored 'General case' 0 N--CA 1.493 1.695 0 N-CA-C 106.907 -1.516 . . . . 0.0 106.907 -179.709 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.671 ' HB2' ' HB2' ' A' ' 9' ' ' ASP . 21.8 m -106.58 -174.11 2.46 Favored 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 118.844 -1.143 . . . . 0.0 112.883 179.65 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -80.47 -74.92 0.29 Allowed 'General case' 0 C--N 1.296 -1.727 0 CA-C-N 113.916 -1.493 . . . . 0.0 108.431 -179.778 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 1.1 m -46.08 -29.75 1.62 Allowed 'General case' 0 N--CA 1.501 2.076 0 CA-C-N 114.606 -1.179 . . . . 0.0 109.916 179.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.671 ' HB2' ' HB2' ' A' ' 6' ' ' CYS . 45.3 t0 -41.03 -51.48 3.3 Favored 'General case' 0 N--CA 1.494 1.756 0 CA-C-N 111.916 -2.402 . . . . 0.0 111.039 179.814 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 91.89 166.26 39.67 Favored Glycine 0 N--CA 1.501 2.976 0 C-N-CA 119.955 -1.117 . . . . 0.0 113.407 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 0.4 OUTLIER -79.81 40.09 0.92 Allowed 'Trans proline' 0 N--CA 1.502 1.999 1 C-N-CA 125.822 4.348 . . . . 0.0 113.453 -168.227 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.0 mpt_? -113.09 161.57 26.18 Favored Pre-proline 0 N--CA 1.496 1.838 0 CA-C-N 113.671 -1.604 . . . . 0.0 109.607 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 13.7 Cg_endo -75.49 145.32 29.7 Favored 'Trans proline' 0 N--CA 1.493 1.458 0 C-N-CA 124.198 3.265 . . . . 0.0 110.042 166.473 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . 0.472 ' HB3' ' HA ' ' A' ' 18' ' ' LEU . 75.8 mtt85 -67.82 33.67 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.127 0 N-CA-C 114.348 1.24 . . . . 0.0 114.348 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -63.97 23.44 0.09 OUTLIER Glycine 0 N--CA 1.496 2.69 0 N-CA-C 116.231 1.252 . . . . 0.0 116.231 -179.537 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 9.3 m120 -119.58 -84.42 0.66 Allowed 'General case' 0 N--CA 1.493 1.713 0 N-CA-C 106.494 -1.669 . . . . 0.0 106.494 179.653 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 31.9 m -150.52 48.81 0.88 Allowed 'General case' 0 N--CA 1.496 1.859 0 N-CA-C 106.392 -1.707 . . . . 0.0 106.392 179.775 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.513 ' HG ' ' HB3' ' A' ' 3' ' ' PRO . 2.0 mm? 66.67 149.64 0.05 Allowed 'General case' 0 N--CA 1.5 2.028 0 O-C-N 125.152 1.532 . . . . 0.0 109.878 -179.733 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 3.2 p -89.6 -8.16 53.2 Favored 'General case' 0 C--N 1.298 -1.659 0 CA-C-N 115.65 -0.705 . . . . 0.0 111.901 179.806 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.443 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . 159.33 178.98 33.84 Favored Glycine 0 N--CA 1.499 2.853 0 N-CA-C 108.016 -2.034 . . . . 0.0 108.016 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.474 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 48.6 mm -127.84 145.97 34.24 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.974 0 N-CA-C 106.141 -1.8 . . . . 0.0 106.141 179.736 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.561 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.8 pp -69.67 152.18 45.0 Favored 'General case' 0 N--CA 1.491 1.617 0 C-N-CA 118.257 -1.377 . . . . 0.0 110.115 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.444 ' O ' ' HA3' ' A' ' 44' ' ' GLY . 37.6 m95 -136.41 130.73 33.15 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 118.884 2.92 . . . . 0.0 118.884 179.763 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 6.0 m-85 -89.48 51.47 2.12 Favored 'General case' 0 C--N 1.296 -1.756 1 CA-C-N 107.467 -4.424 . . . . 0.0 111.613 -179.692 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.484 ' CE1' ' HB3' ' A' ' 30' ' ' PRO . 2.4 m-85 -125.07 137.03 28.93 Favored Pre-proline 0 C--N 1.303 -1.414 0 CA-C-O 121.482 0.658 . . . . 0.0 109.613 179.646 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 96.9 Cg_endo -66.95 -30.31 39.72 Favored 'Trans proline' 0 C--N 1.305 -1.75 0 C-N-CA 124.264 3.309 . . . . 0.0 108.636 177.56 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 11.8 p -86.65 31.9 0.67 Allowed 'General case' 0 C--N 1.299 -1.611 0 CA-C-N 113.989 -1.459 . . . . 0.0 109.239 179.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.547 ' HA2' ' CD1' ' A' ' 45' ' ' TRP . . . 76.05 -92.76 0.94 Allowed Glycine 0 N--CA 1.482 1.764 0 N-CA-C 104.399 -3.48 . . . . 0.0 104.399 -179.499 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.568 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 9.4 m -103.75 165.91 12.65 Favored Pre-proline 0 C--N 1.301 -1.515 0 CA-C-N 113.814 -1.193 . . . . 0.0 110.609 -179.849 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.686 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.1 OUTLIER -86.01 167.11 9.64 Favored 'Trans proline' 0 CA--C 1.553 1.472 0 C-N-CA 125.238 3.959 . . . . 0.0 118.336 157.924 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 3.8 m -49.64 109.57 0.29 Allowed 'General case' 0 C--N 1.299 -1.604 0 CA-C-N 111.769 -2.469 . . . . 0.0 112.283 179.845 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 113.46 -6.6 24.66 Favored Glycine 0 N--CA 1.5 2.948 0 CA-C-N 115.218 -0.901 . . . . 0.0 111.901 179.743 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' TRP . . . . . 0.686 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 48.1 m95 -111.51 162.57 14.97 Favored 'General case' 0 N--CA 1.486 1.341 0 N-CA-C 106.321 -1.733 . . . . 0.0 106.321 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . 0.419 ' O ' ' ND1' ' A' ' 34' ' ' HIS . 60.0 t-80 -143.62 34.18 1.29 Allowed 'General case' 0 N--CA 1.498 1.962 0 C-N-CA 118.138 -1.425 . . . . 0.0 113.406 -179.733 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . 0.568 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 3.2 t30 61.76 146.16 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.9 0 N-CA-C 114.375 1.25 . . . . 0.0 114.375 179.916 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.804 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -124.31 -45.74 1.95 Allowed 'General case' 0 N--CA 1.484 1.272 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.039 -179.715 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . 0.53 ' HG2' ' H ' ' A' ' 39' ' ' HIS . 36.0 ttmt -122.01 100.35 6.93 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 105.44 -2.059 . . . . 0.0 105.44 179.431 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -77.55 19.9 0.34 Allowed 'General case' 0 N--CA 1.5 2.034 0 CA-C-N 114.431 -1.259 . . . . 0.0 107.742 179.649 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . 0.53 ' H ' ' HG2' ' A' ' 37' ' ' LYS . 7.4 m-70 -132.75 16.82 4.29 Favored 'General case' 0 N--CA 1.487 1.378 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.476 -179.709 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 149.37 -177.8 27.32 Favored Glycine 0 N--CA 1.501 3.015 0 C-N-CA 119.412 -1.375 . . . . 0.0 111.432 179.695 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.524 ' HD2' ' N ' ' A' ' 46' ' ' CYS . 35.5 Cg_endo -66.25 -171.89 4.45 Favored 'Cis proline' 0 N--CA 1.512 2.592 0 N-CA-C 116.167 1.564 . . . . 0.0 116.167 -4.604 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 16.1 p-10 -92.1 -12.76 32.11 Favored 'General case' 0 N--CA 1.486 1.336 0 N-CA-C 105.505 -2.035 . . . . 0.0 105.505 -179.715 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.43 HG12 ' HB2' ' A' ' 41' ' ' PRO . 12.1 pt -85.81 23.02 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.218 0 O-C-N 124.909 1.38 . . . . 0.0 113.814 -179.49 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.444 ' HA3' ' O ' ' A' ' 23' ' ' TRP . . . 134.63 -116.47 1.61 Allowed Glycine 0 C--N 1.291 -1.962 0 N-CA-C 104.404 -3.478 . . . . 0.0 104.404 -179.906 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . 0.547 ' CD1' ' HA2' ' A' ' 28' ' ' GLY . 1.8 m95 -157.03 151.28 25.09 Favored 'General case' 0 N--CA 1.509 2.501 0 N-CA-C 105.491 -2.04 . . . . 0.0 105.491 -179.891 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' CYS . . . . . 0.804 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 44.5 t -99.06 129.61 45.34 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 102.882 -3.006 . . . . 0.0 102.882 179.864 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.524 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 78.4 m -126.77 -170.7 2.25 Favored 'General case' 0 C--N 1.298 -1.641 0 CA-C-N 113.528 -1.669 . . . . 0.0 109.719 -179.409 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.412 ' H ' ' HD3' ' A' ' 48' ' ' LYS . 0.0 OUTLIER -150.58 172.72 15.06 Favored 'General case' 0 C--N 1.294 -1.822 0 N-CA-C 107.195 -1.409 . . . . 0.0 107.195 179.324 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 84.8 mttt . . . . . 0 N--CA 1.498 1.95 0 O-C-N 126.129 2.143 . . . . 0.0 109.131 179.456 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.418 0 N-CA-C 108.913 -1.675 . . . . 0.0 108.913 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.408 ' HB ' HD23 ' A' ' 22' ' ' LEU . 11.4 t -89.56 147.44 37.89 Favored Pre-proline 0 N--CA 1.494 1.766 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 -179.793 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.421 ' HG3' ' HG ' ' A' ' 18' ' ' LEU . 3.9 Cg_endo -75.81 155.33 39.23 Favored 'Trans proline' 0 N--CA 1.496 1.65 0 C-N-CA 124.024 3.15 . . . . 0.0 112.963 166.717 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.408 ' SG ' ' SG ' ' A' ' 6' ' ' CYS . 9.4 p -132.39 170.78 14.61 Favored 'General case' 0 N--CA 1.499 1.982 0 C-N-CA 119.208 -0.997 . . . . 0.0 108.939 179.574 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 13.9 tp -86.64 81.21 8.32 Favored 'General case' 0 N--CA 1.491 1.624 0 N-CA-C 103.65 -2.722 . . . . 0.0 103.65 179.908 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.408 ' SG ' ' SG ' ' A' ' 4' ' ' CYS . 6.6 m -69.18 170.96 9.1 Favored 'General case' 0 C--N 1.309 -1.188 0 CA-C-O 123.273 1.511 . . . . 0.0 112.375 -179.729 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 7.9 t70 -48.05 -46.55 33.52 Favored 'General case' 0 N--CA 1.496 1.875 0 CA-C-N 111.07 -2.786 . . . . 0.0 111.301 -179.838 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 3.9 p -91.14 -6.3 53.8 Favored 'General case' 0 C--N 1.301 -1.532 0 CA-C-N 114.521 -1.218 . . . . 0.0 110.95 179.796 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 10.7 t0 -72.83 80.25 1.15 Allowed 'General case' 0 N--CA 1.491 1.576 0 C-N-CA 118.635 -1.226 . . . . 0.0 110.452 -179.46 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 169.3 -81.65 0.09 OUTLIER Glycine 0 N--CA 1.491 2.359 0 CA-C-N 114.036 -1.438 . . . . 0.0 109.726 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 7.1 Cg_endo -76.37 -4.06 14.59 Favored 'Trans proline' 0 N--CA 1.501 1.956 0 C-N-CA 124.338 3.359 . . . . 0.0 115.099 -172.768 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -106.32 137.78 19.52 Favored Pre-proline 0 C--N 1.294 -1.826 0 CA-C-N 112.893 -1.958 . . . . 0.0 109.314 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -68.52 176.33 5.91 Favored 'Trans proline' 0 N--CA 1.492 1.419 0 C-N-CA 123.866 3.044 . . . . 0.0 110.175 -178.584 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 25.2 mtp85 51.11 19.08 0.64 Allowed 'General case' 0 N--CA 1.493 1.675 0 N-CA-C 113.891 1.071 . . . . 0.0 113.891 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -104.39 -0.89 43.89 Favored Glycine 0 N--CA 1.501 2.97 0 N-CA-C 108.805 -1.718 . . . . 0.0 108.805 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -68.53 -53.86 20.41 Favored 'General case' 0 N--CA 1.488 1.471 0 CA-C-O 122.482 1.134 . . . . 0.0 110.871 -179.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.409 ' O ' ' HB2' ' A' ' 18' ' ' LEU . 7.2 m -88.84 59.28 4.99 Favored 'General case' 0 N--CA 1.495 1.778 0 CA-C-N 115.396 -0.82 . . . . 0.0 109.31 -179.342 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.421 ' HG ' ' HG3' ' A' ' 3' ' ' PRO . 8.9 mp 73.07 125.66 0.04 OUTLIER 'General case' 0 N--CA 1.497 1.909 0 O-C-N 126.246 2.216 . . . . 0.0 108.665 -179.748 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 48.4 t -91.78 -16.18 27.2 Favored 'General case' 0 N--CA 1.498 1.935 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.304 179.821 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 174.05 -171.83 44.83 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 107.653 -2.179 . . . . 0.0 107.653 -179.882 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 1.2 mp -133.83 153.14 35.9 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.104 0 O-C-N 124.918 1.01 . . . . 0.0 108.553 -179.903 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.621 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.3 pp -71.33 146.34 48.9 Favored 'General case' 0 N--CA 1.499 1.998 0 C-N-CA 120.205 -0.598 . . . . 0.0 111.868 179.812 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.432 ' O ' ' CA ' ' A' ' 44' ' ' GLY . 39.0 m95 -129.08 130.28 46.32 Favored 'General case' 0 N--CA 1.491 1.603 0 N-CA-C 119.512 3.152 . . . . 0.0 119.512 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 3.5 m-85 -88.73 51.38 2.16 Favored 'General case' 0 C--N 1.294 -1.827 1 CA-C-N 107.886 -4.234 . . . . 0.0 113.154 -179.412 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 2.2 m-85 -120.79 142.33 34.21 Favored Pre-proline 0 C--N 1.3 -1.576 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 179.411 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -76.12 -33.16 3.71 Favored 'Trans proline' 0 C--N 1.3 -1.991 0 C-N-CA 125.063 3.842 . . . . 0.0 112.21 172.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 14.1 p -88.61 33.43 0.77 Allowed 'General case' 0 N--CA 1.494 1.735 0 CA-C-O 121.442 0.639 . . . . 0.0 111.083 -179.524 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 76.0 -158.82 50.09 Favored Glycine 0 N--CA 1.495 2.58 0 N-CA-C 105.912 -2.875 . . . . 0.0 105.912 -179.565 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.586 ' SG ' ' CA ' ' A' ' 35' ' ' ASN . 14.0 m -53.06 150.76 9.95 Favored Pre-proline 0 C--N 1.303 -1.441 0 CA-C-N 117.599 0.699 . . . . 0.0 111.941 179.816 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.739 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 4.6 Cg_endo -76.41 159.74 36.01 Favored 'Trans proline' 0 C--N 1.308 -1.566 0 C-N-CA 122.956 2.437 . . . . 0.0 112.043 171.759 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 16.5 t -49.14 129.67 18.13 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-N 113.332 -1.758 . . . . 0.0 109.522 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 97.81 -5.14 61.71 Favored Glycine 0 N--CA 1.496 2.697 0 CA-C-N 112.664 -2.062 . . . . 0.0 111.687 179.762 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' TRP . . . . . 0.739 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 48.1 m95 -111.91 163.77 13.85 Favored 'General case' 0 C--N 1.305 -1.332 0 N-CA-C 106.29 -1.745 . . . . 0.0 106.29 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . 0.401 ' O ' ' ND1' ' A' ' 34' ' ' HIS . 45.5 t-80 -144.24 34.39 1.21 Allowed 'General case' 0 N--CA 1.498 1.974 0 C-N-CA 117.365 -1.734 . . . . 0.0 113.107 -179.818 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . 0.586 ' CA ' ' SG ' ' A' ' 29' ' ' CYS . 23.8 t-20 62.38 144.72 0.02 OUTLIER 'General case' 0 N--CA 1.506 2.333 0 N-CA-C 113.976 1.102 . . . . 0.0 113.976 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.851 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -124.74 -64.9 1.07 Allowed 'General case' 0 C--N 1.306 -1.3 0 N-CA-C 106.672 -1.603 . . . . 0.0 106.672 -179.751 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . 0.593 ' N ' ' SG ' ' A' ' 36' ' ' CYS . 33.1 ttmt -91.05 103.59 16.27 Favored 'General case' 0 C--N 1.302 -1.465 0 CA-C-O 123.567 1.651 . . . . 0.0 107.04 179.704 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.425 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -79.86 24.16 0.41 Allowed 'General case' 0 N--CA 1.495 1.781 0 CA-C-N 113.499 -1.682 . . . . 0.0 107.282 179.489 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . 0.519 ' H ' ' C ' ' A' ' 37' ' ' LYS . 3.3 m-70 -131.85 17.88 4.67 Favored 'General case' 0 N--CA 1.493 1.713 0 N-CA-C 106.966 -1.494 . . . . 0.0 106.966 -179.677 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 111.43 -132.0 10.63 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 25.9 Cg_endo -69.78 -164.06 2.43 Favored 'Cis proline' 0 N--CA 1.503 2.054 0 CA-C-N 117.843 0.821 . . . . 0.0 112.699 1.097 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.409 ' C ' ' H ' ' A' ' 44' ' ' GLY . 22.6 t-20 -92.13 -20.57 21.11 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 106.374 -1.713 . . . . 0.0 106.374 -179.757 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 39.7 pt -86.31 28.33 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 CA-C-N 112.367 -2.197 . . . . 0.0 113.349 -179.104 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.432 ' CA ' ' O ' ' A' ' 23' ' ' TRP . . . 115.03 131.15 4.98 Favored Glycine 0 N--CA 1.484 1.859 0 CA-C-N 111.019 -2.81 . . . . 0.0 109.994 179.941 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . . . . . . . . . 14.8 m95 -55.42 130.1 41.26 Favored 'General case' 0 N--CA 1.509 2.484 0 N-CA-C 106.311 -1.737 . . . . 0.0 106.311 -179.657 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' CYS . . . . . 0.851 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 42.7 t -89.15 129.42 35.75 Favored 'General case' 0 C--N 1.31 -1.139 1 N-CA-C 99.341 -4.318 . . . . 0.0 99.341 -179.89 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.539 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 77.8 m -133.93 -175.35 3.81 Favored 'General case' 0 C--N 1.293 -1.888 0 CA-C-N 110.671 -2.968 . . . . 0.0 110.881 -178.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.467 ' O ' ' HA ' ' A' ' 33' ' ' TRP . 0.0 OUTLIER -150.7 172.68 15.19 Favored 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 107.1 -1.445 . . . . 0.0 107.1 179.484 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 54.0 mtpt . . . . . 0 C--N 1.289 -2.032 0 O-C-N 127.248 2.843 . . . . 0.0 109.253 179.697 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.495 2.616 0 N-CA-C 109.005 -1.638 . . . . 0.0 109.005 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 34.0 t -98.78 131.76 25.08 Favored Pre-proline 0 N--CA 1.49 1.565 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -82.19 136.15 8.85 Favored 'Trans proline' 0 C--N 1.308 -1.594 0 C-N-CA 124.026 3.151 . . . . 0.0 113.516 162.76 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.403 ' SG ' ' N ' ' A' ' 5' ' ' LEU . 1.8 p -110.45 -156.87 0.6 Allowed 'General case' 0 N--CA 1.504 2.259 0 N-CA-C 107.601 -1.259 . . . . 0.0 107.601 179.778 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.403 ' N ' ' SG ' ' A' ' 4' ' ' CYS . 2.9 tt -118.85 99.97 7.09 Favored 'General case' 0 N--CA 1.503 2.212 0 N-CA-C 101.283 -3.599 . . . . 0.0 101.283 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.703 ' HB2' ' HB2' ' A' ' 9' ' ' ASP . 2.9 m -78.85 -176.11 4.81 Favored 'General case' 0 C--N 1.308 -1.214 0 N-CA-C 116.424 2.009 . . . . 0.0 116.424 -179.381 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -74.04 -62.33 1.54 Allowed 'General case' 0 C--N 1.298 -1.662 0 CA-C-N 112.319 -2.219 . . . . 0.0 109.843 -179.614 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 1.7 p -89.42 20.23 4.0 Favored 'General case' 0 N--CA 1.493 1.718 0 CA-C-N 114.973 -1.012 . . . . 0.0 108.63 179.709 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.703 ' HB2' ' HB2' ' A' ' 6' ' ' CYS . 2.4 t0 -66.13 -32.58 74.12 Favored 'General case' 0 N--CA 1.494 1.755 0 N-CA-C 106.484 -1.673 . . . . 0.0 106.484 179.748 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 99.37 99.22 2.2 Favored Glycine 0 N--CA 1.486 1.999 0 N-CA-C 103.993 -3.643 . . . . 0.0 103.993 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_endo -78.41 49.18 2.96 Favored 'Trans proline' 0 N--CA 1.495 1.605 0 C-N-CA 124.162 3.241 . . . . 0.0 109.549 -176.351 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 64.7 mtt85 -108.61 163.25 17.4 Favored Pre-proline 0 N--CA 1.496 1.874 0 CA-C-N 113.775 -1.557 . . . . 0.0 111.484 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 13.7 Cg_endo -72.56 49.45 1.47 Allowed 'Trans proline' 0 N--CA 1.5 1.878 0 C-N-CA 124.812 3.675 . . . . 0.0 112.984 176.763 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . 0.472 ' C ' ' H ' ' A' ' 16' ' ' ASN . 0.0 OUTLIER -167.84 122.15 0.96 Allowed 'General case' 0 C--N 1.301 -1.538 0 CA-C-N 113.68 -1.6 . . . . 0.0 112.924 179.974 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.432 ' O ' ' N ' ' A' ' 17' ' ' THR . . . 74.64 -37.33 1.02 Allowed Glycine 0 N--CA 1.498 2.812 0 CA-C-N 114.669 -1.15 . . . . 0.0 112.552 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . 0.472 ' H ' ' C ' ' A' ' 14' ' ' ARG . 66.0 t30 2.74 -47.39 0.0 OUTLIER 'General case' 0 N--CA 1.507 2.417 0 N-CA-C 120.904 3.668 . . . . 0.0 120.904 -179.634 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.432 ' N ' ' O ' ' A' ' 15' ' ' GLY . 26.9 p -121.8 27.58 8.07 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-N 119.341 0.973 . . . . 0.0 112.31 -179.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -136.26 20.73 3.19 Favored 'General case' 0 N--CA 1.497 1.905 0 CA-C-N 114.56 -1.2 . . . . 0.0 110.438 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 4.8 m -89.07 14.51 10.55 Favored 'General case' 0 N--CA 1.503 2.175 0 N-CA-C 115.385 1.624 . . . . 0.0 115.385 -179.335 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 167.69 -179.36 41.13 Favored Glycine 0 N--CA 1.502 3.045 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 179.796 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 37.2 mm -132.71 143.94 38.18 Favored 'Isoleucine or valine' 0 N--CA 1.507 2.399 0 O-C-N 124.555 0.797 . . . . 0.0 110.975 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.433 ' O ' HD12 ' A' ' 22' ' ' LEU . 3.9 pp -63.56 154.75 31.63 Favored 'General case' 0 N--CA 1.504 2.244 0 N-CA-C 109.117 -0.697 . . . . 0.0 109.117 179.518 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.552 ' O ' ' HA2' ' A' ' 44' ' ' GLY . 32.4 m95 -134.42 131.4 38.13 Favored 'General case' 0 C--N 1.308 -1.202 0 N-CA-C 118.91 2.93 . . . . 0.0 118.91 -179.694 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 4.5 m-85 -87.57 53.48 2.8 Favored 'General case' 0 C--N 1.291 -1.973 0 CA-C-N 109.316 -3.584 . . . . 0.0 111.796 -179.245 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 2.7 m-85 -125.52 137.06 29.17 Favored Pre-proline 0 C--N 1.306 -1.302 0 CA-C-N 115.052 -0.976 . . . . 0.0 110.352 179.6 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_endo -73.81 -25.43 14.49 Favored 'Trans proline' 0 C--N 1.306 -1.696 1 C-N-CA 125.725 4.283 . . . . 0.0 112.817 177.746 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 5.9 p -95.03 20.66 8.68 Favored 'General case' 0 N--CA 1.493 1.706 0 CA-C-N 115.249 -0.887 . . . . 0.0 111.163 -179.875 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 89.91 -138.27 14.47 Favored Glycine 0 N--CA 1.496 2.687 0 N-CA-C 106.278 -2.729 . . . . 0.0 106.278 -179.817 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.526 ' SG ' ' CA ' ' A' ' 35' ' ' ASN . 29.7 m -69.28 150.05 97.3 Favored Pre-proline 0 C--N 1.305 -1.355 0 CA-C-N 117.496 0.648 . . . . 0.0 109.971 179.889 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.717 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 1.9 Cg_endo -78.31 159.29 29.6 Favored 'Trans proline' 0 C--N 1.31 -1.469 0 C-N-CA 123.207 2.604 . . . . 0.0 112.403 171.198 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 24.1 t -47.96 128.86 14.13 Favored 'General case' 0 C--N 1.305 -1.326 0 CA-C-N 113.168 -1.833 . . . . 0.0 109.3 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 100.51 -8.07 58.3 Favored Glycine 0 N--CA 1.495 2.607 0 CA-C-N 112.628 -2.078 . . . . 0.0 111.421 179.77 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' TRP . . . . . 0.717 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 48.3 m95 -110.29 162.94 14.14 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 106.83 -1.544 . . . . 0.0 106.83 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 78.6 t60 -143.22 29.82 1.44 Allowed 'General case' 0 N--CA 1.499 1.997 0 C-N-CA 118.34 -1.344 . . . . 0.0 113.135 -179.843 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . 0.526 ' CA ' ' SG ' ' A' ' 29' ' ' CYS . 12.1 t-20 62.02 147.13 0.02 OUTLIER 'General case' 0 N--CA 1.505 2.301 0 CA-C-O 123.109 1.433 . . . . 0.0 114.097 -179.79 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.841 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -117.41 -46.91 2.67 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-N 113.341 -1.754 . . . . 0.0 108.003 -179.666 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 19.4 ttpp -132.18 124.77 29.69 Favored 'General case' 0 N--CA 1.497 1.922 0 N-CA-C 107.814 -1.18 . . . . 0.0 107.814 179.43 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -87.13 22.07 2.18 Favored 'General case' 0 N--CA 1.493 1.688 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 179.788 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 16.9 m-70 -131.33 76.72 1.73 Allowed 'General case' 0 N--CA 1.492 1.645 0 CA-C-O 122.243 1.02 . . . . 0.0 108.882 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 68.83 -163.07 50.54 Favored Glycine 0 N--CA 1.492 2.418 0 CA-C-N 113.353 -1.749 . . . . 0.0 109.849 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.446 ' HG2' ' O ' ' A' ' 44' ' ' GLY . 34.1 Cg_endo -71.86 175.14 43.78 Favored 'Cis proline' 0 N--CA 1.495 1.573 0 N-CA-C 107.635 -1.717 . . . . 0.0 107.635 -2.402 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.442 ' C ' ' H ' ' A' ' 44' ' ' GLY . 23.4 m120 -91.53 -10.12 41.86 Favored 'General case' 0 N--CA 1.488 1.463 0 N-CA-C 105.299 -2.112 . . . . 0.0 105.299 -179.484 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 16.1 mt -88.79 28.75 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.225 0 CA-C-N 113.447 -1.706 . . . . 0.0 110.338 -179.438 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.552 ' HA2' ' O ' ' A' ' 23' ' ' TRP . . . 115.98 135.29 5.65 Favored Glycine 0 N--CA 1.486 2.0 0 CA-C-N 111.827 -2.442 . . . . 0.0 112.687 179.789 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . 0.511 ' O ' ' N ' ' A' ' 23' ' ' TRP . 26.3 m95 -62.0 129.39 40.66 Favored 'General case' 0 N--CA 1.501 2.116 0 C-N-CA 120.19 -0.604 . . . . 0.0 111.388 -179.42 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' CYS . . . . . 0.841 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 46.4 t -88.52 114.72 25.43 Favored 'General case' 0 C--N 1.305 -1.359 1 N-CA-C 96.728 -5.286 . . . . 0.0 96.728 179.998 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.532 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 75.1 m -129.89 -176.18 3.84 Favored 'General case' 0 C--N 1.295 -1.768 1 CA-C-N 108.253 -4.067 . . . . 0.0 108.714 -179.407 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.507 ' O ' ' HA ' ' A' ' 33' ' ' TRP . 0.0 OUTLIER -149.97 169.74 20.48 Favored 'General case' 0 C--N 1.294 -1.836 0 C-N-CA 117.614 -1.634 . . . . 0.0 107.698 179.56 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 48.9 mtpt . . . . . 0 C--N 1.29 -2.02 0 O-C-N 127.577 3.048 . . . . 0.0 109.379 179.71 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.495 2.571 0 N-CA-C 109.053 -1.619 . . . . 0.0 109.053 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 61.9 t -99.73 142.46 24.65 Favored Pre-proline 0 N--CA 1.496 1.84 0 N-CA-C 108.026 -1.101 . . . . 0.0 108.026 -179.903 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -76.22 158.93 37.27 Favored 'Trans proline' 0 C--N 1.309 -1.54 0 C-N-CA 124.509 3.473 . . . . 0.0 113.405 171.45 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -150.9 164.94 35.12 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 125.48 1.737 . . . . 0.0 108.036 179.614 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.484 HD23 ' N ' ' A' ' 6' ' ' CYS . 9.4 tt -79.38 168.18 19.85 Favored 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 103.404 -2.813 . . . . 0.0 103.404 179.759 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.566 ' HB2' ' H ' ' A' ' 9' ' ' ASP . 3.5 m -140.93 -174.8 4.09 Favored 'General case' 0 C--N 1.302 -1.489 0 N-CA-C 116.662 2.097 . . . . 0.0 116.662 -179.257 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -76.74 -31.91 57.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 112.639 -2.073 . . . . 0.0 107.862 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 70.8 p -112.34 -14.77 13.26 Favored 'General case' 0 N--CA 1.496 1.848 0 CA-C-N 115.199 -0.91 . . . . 0.0 112.62 179.646 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.566 ' H ' ' HB2' ' A' ' 6' ' ' CYS . 0.7 OUTLIER -32.51 -39.81 0.04 OUTLIER 'General case' 0 N--CA 1.515 2.804 0 N-CA-C 113.9 1.074 . . . . 0.0 113.9 -179.737 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 140.65 137.52 3.46 Favored Glycine 0 N--CA 1.487 2.055 0 N-CA-C 105.027 -3.229 . . . . 0.0 105.027 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_endo -71.94 24.79 0.25 Allowed 'Trans proline' 0 N--CA 1.497 1.719 0 C-N-CA 124.358 3.372 . . . . 0.0 114.282 -166.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 76.2 mtt180 -109.85 100.36 42.59 Favored Pre-proline 0 N--CA 1.495 1.799 0 C-N-CA 119.849 -0.74 . . . . 0.0 109.546 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_endo -74.4 169.11 23.24 Favored 'Trans proline' 0 N--CA 1.494 1.503 0 C-N-CA 124.09 3.193 . . . . 0.0 111.166 176.39 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 74.8 mtp180 60.46 -169.05 0.16 Allowed 'General case' 0 N--CA 1.494 1.761 0 N-CA-C 108.539 -0.912 . . . . 0.0 108.539 -179.835 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.442 ' O ' ' CB ' ' A' ' 16' ' ' ASN . . . 74.34 -48.91 1.86 Allowed Glycine 0 N--CA 1.5 2.912 0 C-N-CA 119.909 -1.139 . . . . 0.0 113.337 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . 0.442 ' CB ' ' O ' ' A' ' 15' ' ' GLY . 17.1 t-20 98.98 91.53 0.01 OUTLIER 'General case' 0 N--CA 1.511 2.589 0 C-N-CA 126.059 1.744 . . . . 0.0 107.182 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 25.1 p -89.82 160.29 16.57 Favored 'General case' 0 N--CA 1.495 1.8 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.437 -179.843 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 2.0 tt -140.5 70.38 1.36 Allowed 'General case' 0 N--CA 1.501 2.092 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 19.7 m -91.45 -11.91 36.22 Favored 'General case' 0 N--CA 1.502 2.15 0 N-CA-C 112.681 0.623 . . . . 0.0 112.681 179.77 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -166.7 -162.46 18.32 Favored Glycine 0 N--CA 1.504 3.195 0 N-CA-C 110.904 -0.878 . . . . 0.0 110.904 -179.863 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 8.1 mm -135.75 146.48 29.59 Favored 'Isoleucine or valine' 0 N--CA 1.515 2.82 0 N-CA-C 113.992 1.108 . . . . 0.0 113.992 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.56 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.6 pp -64.25 151.15 44.41 Favored 'General case' 0 N--CA 1.505 2.317 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 179.17 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.448 ' N ' ' O ' ' A' ' 45' ' ' TRP . 22.3 m95 -133.45 137.41 45.7 Favored 'General case' 0 C--N 1.305 -1.347 0 N-CA-C 116.6 2.074 . . . . 0.0 116.6 -179.656 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -88.47 41.32 1.01 Allowed 'General case' 0 C--N 1.293 -1.87 0 CA-C-N 109.045 -3.707 . . . . 0.0 115.119 -179.408 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -114.67 129.28 25.11 Favored Pre-proline 0 N--CA 1.489 1.52 0 N-CA-C 115.45 1.648 . . . . 0.0 115.45 179.743 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -68.33 -21.53 41.07 Favored 'Trans proline' 0 C--N 1.307 -1.642 0 C-N-CA 123.402 2.734 . . . . 0.0 108.979 -175.106 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -91.32 1.29 57.22 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-N 112.864 -1.971 . . . . 0.0 110.797 179.752 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 107.72 -117.05 5.06 Favored Glycine 0 N--CA 1.498 2.828 0 N-CA-C 105.455 -3.058 . . . . 0.0 105.455 -179.831 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.533 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 10.2 m -93.12 150.23 38.83 Favored Pre-proline 0 C--N 1.305 -1.361 0 N-CA-C 108.404 -0.962 . . . . 0.0 108.404 179.632 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.712 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.5 OUTLIER -76.49 175.53 11.23 Favored 'Trans proline' 0 C--N 1.311 -1.42 0 C-N-CA 123.241 2.627 . . . . 0.0 115.66 176.777 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 16.4 p -50.47 102.88 0.04 OUTLIER 'General case' 0 C--N 1.299 -1.605 0 CA-C-N 112.671 -2.059 . . . . 0.0 112.724 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 112.12 -0.24 26.89 Favored Glycine 0 N--CA 1.503 3.127 0 O-C-N 124.332 1.02 . . . . 0.0 113.61 179.435 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' TRP . . . . . 0.712 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 45.6 m95 -112.3 163.73 14.05 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 107.289 -1.375 . . . . 0.0 107.289 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 73.5 t60 -146.37 37.45 1.02 Allowed 'General case' 0 N--CA 1.501 2.098 0 C-N-CA 118.014 -1.475 . . . . 0.0 114.54 -179.866 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . 0.533 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 23.7 t-20 60.04 149.42 0.02 OUTLIER 'General case' 0 N--CA 1.506 2.338 0 N-CA-C 115.763 1.764 . . . . 0.0 115.763 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.66 ' SG ' ' HB3' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -125.21 -44.91 1.86 Allowed 'General case' 0 C--N 1.303 -1.451 0 CA-C-N 113.52 -1.673 . . . . 0.0 108.067 -179.913 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . 0.46 ' C ' ' H ' ' A' ' 39' ' ' HIS . 36.9 ttmt -124.66 111.13 15.24 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 105.101 -2.185 . . . . 0.0 105.101 179.61 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.436 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -85.01 31.84 0.54 Allowed 'General case' 0 N--CA 1.494 1.749 0 N-CA-C 106.132 -1.803 . . . . 0.0 106.132 179.587 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . 0.46 ' H ' ' C ' ' A' ' 37' ' ' LYS . 4.5 m-70 -132.21 22.28 4.45 Favored 'General case' 0 N--CA 1.497 1.88 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 -179.612 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 107.89 -145.88 16.26 Favored Glycine 0 N--CA 1.494 2.514 0 N-CA-C 109.292 -1.523 . . . . 0.0 109.292 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.659 ' CD ' ' SG ' ' A' ' 46' ' ' CYS . 8.4 Cg_endo -74.97 -173.54 12.5 Favored 'Cis proline' 0 N--CA 1.502 2.011 0 C-N-CA 129.013 0.839 . . . . 0.0 111.36 0.87 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.466 ' C ' ' H ' ' A' ' 44' ' ' GLY . 0.2 OUTLIER -91.9 -8.61 45.9 Favored 'General case' 0 N--CA 1.487 1.385 0 N-CA-C 102.883 -3.006 . . . . 0.0 102.883 179.951 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.488 ' N ' HD12 ' A' ' 43' ' ' ILE . 4.0 mp -90.88 32.45 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 CA-C-O 123.159 1.457 . . . . 0.0 108.245 -179.419 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.466 ' H ' ' C ' ' A' ' 42' ' ' ASN . . . 102.89 127.74 6.19 Favored Glycine 0 N--CA 1.489 2.209 0 CA-C-N 111.88 -2.418 . . . . 0.0 107.094 -179.774 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . 0.448 ' O ' ' N ' ' A' ' 23' ' ' TRP . 6.7 m95 -54.8 135.67 47.32 Favored 'General case' 0 N--CA 1.509 2.485 0 CA-C-O 117.05 -1.452 . . . . 0.0 108.621 -179.519 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' CYS . . . . . 0.66 ' HB3' ' SG ' ' A' ' 36' ' ' CYS . 75.3 m -88.37 122.67 32.13 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 101.885 -3.376 . . . . 0.0 101.885 179.86 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.479 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 75.2 m -128.57 -174.71 3.31 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-N 110.43 -3.077 . . . . 0.0 108.739 -179.495 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.408 ' O ' ' HA ' ' A' ' 33' ' ' TRP . 0.0 OUTLIER -151.36 171.96 16.66 Favored 'General case' 0 C--N 1.299 -1.617 0 N-CA-C 106.684 -1.599 . . . . 0.0 106.684 179.176 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 92.3 mttt . . . . . 0 C--N 1.288 -2.076 0 O-C-N 125.675 1.859 . . . . 0.0 109.437 179.922 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.5 2.902 0 N-CA-C 110.01 -1.236 . . . . 0.0 110.01 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 24.7 t -96.22 135.61 22.51 Favored Pre-proline 0 N--CA 1.5 2.039 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 179.901 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.434 ' HB2' ' HB3' ' A' ' 18' ' ' LEU . 6.9 Cg_endo -79.18 129.65 8.86 Favored 'Trans proline' 0 N--CA 1.491 1.371 0 C-N-CA 123.836 3.024 . . . . 0.0 114.268 165.034 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -119.2 -163.0 0.94 Allowed 'General case' 0 N--CA 1.495 1.822 0 N-CA-C 113.549 0.944 . . . . 0.0 113.549 -179.729 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.473 HD23 ' N ' ' A' ' 6' ' ' CYS . 9.6 tt -111.71 151.68 28.63 Favored 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 104.456 -2.424 . . . . 0.0 104.456 179.848 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.535 ' HB2' ' HB2' ' A' ' 9' ' ' ASP . 5.1 m -140.95 -171.05 3.17 Favored 'General case' 0 N--CA 1.483 1.189 0 N-CA-C 116.224 1.935 . . . . 0.0 116.224 -179.378 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 39.0 t70 -83.26 -56.67 3.64 Favored 'General case' 0 N--CA 1.49 1.558 0 CA-C-N 112.233 -2.258 . . . . 0.0 108.09 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 34.1 m -76.22 -12.08 60.03 Favored 'General case' 0 N--CA 1.493 1.724 0 C-N-CA 119.425 -0.91 . . . . 0.0 109.592 179.625 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.535 ' HB2' ' HB2' ' A' ' 6' ' ' CYS . 2.5 t70 -52.18 -31.75 33.03 Favored 'General case' 0 N--CA 1.502 2.14 0 CA-C-N 114.622 -1.172 . . . . 0.0 112.115 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 118.72 141.18 6.53 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 107.669 -2.172 . . . . 0.0 107.669 -179.73 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_endo -76.58 37.78 0.58 Allowed 'Trans proline' 0 N--CA 1.498 1.763 1 C-N-CA 125.762 4.308 . . . . 0.0 112.124 -171.136 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 7.4 mtp180 -111.9 81.72 3.69 Favored Pre-proline 0 N--CA 1.491 1.579 0 CA-C-N 115.018 -0.992 . . . . 0.0 110.356 -179.718 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -68.07 154.2 73.14 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.438 2.759 . . . . 0.0 109.187 179.589 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 80.7 mtt180 48.09 15.05 0.06 Allowed 'General case' 0 N--CA 1.501 2.092 0 N-CA-C 114.488 1.292 . . . . 0.0 114.488 -179.744 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -91.59 32.54 5.24 Favored Glycine 0 N--CA 1.498 2.8 0 CA-C-N 114.812 -1.085 . . . . 0.0 111.634 -179.823 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 9.9 t-20 41.55 33.3 0.29 Allowed 'General case' 0 N--CA 1.509 2.485 0 N-CA-C 112.75 0.648 . . . . 0.0 112.75 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 9.1 t -89.71 157.02 18.16 Favored 'General case' 0 N--CA 1.498 1.954 0 C-N-CA 119.36 -0.936 . . . . 0.0 108.955 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.434 ' HB3' ' HB2' ' A' ' 3' ' ' PRO . 85.5 mt -144.91 49.3 1.29 Allowed 'General case' 0 N--CA 1.501 2.116 0 CA-C-O 122.008 0.908 . . . . 0.0 112.512 -179.503 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 41.4 t -88.69 56.6 3.82 Favored 'General case' 0 N--CA 1.5 2.041 0 C-N-CA 118.106 -1.438 . . . . 0.0 110.468 -179.503 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.517 ' HA2' ' HD3' ' A' ' 48' ' ' LYS . . . -170.99 119.23 0.79 Allowed Glycine 0 N--CA 1.499 2.843 0 CA-C-O 117.979 -1.456 . . . . 0.0 112.32 179.911 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.461 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 37.6 mm -102.71 131.13 51.56 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.312 0 N-CA-C 103.429 -2.804 . . . . 0.0 103.429 179.308 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.595 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 2.1 pp -64.45 158.75 23.05 Favored 'General case' 0 N--CA 1.496 1.85 0 C-N-CA 118.189 -1.404 . . . . 0.0 107.811 179.785 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.48 ' N ' ' O ' ' A' ' 45' ' ' TRP . 19.4 m95 -138.6 135.51 35.02 Favored 'General case' 0 C--N 1.306 -1.324 0 N-CA-C 115.919 1.822 . . . . 0.0 115.919 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -89.06 41.64 1.04 Allowed 'General case' 0 C--N 1.293 -1.878 0 CA-C-N 109.803 -3.362 . . . . 0.0 115.851 -179.611 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.444 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 1.0 OUTLIER -118.34 126.89 26.92 Favored Pre-proline 0 N--CA 1.487 1.379 0 CA-C-O 122.417 1.104 . . . . 0.0 110.225 179.646 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -64.82 -28.71 59.12 Favored 'Trans proline' 0 C--N 1.299 -2.039 0 C-N-CA 122.096 1.864 . . . . 0.0 108.781 -175.237 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 4.6 p -82.36 5.55 19.94 Favored 'General case' 0 N--CA 1.492 1.653 0 CA-C-N 114.661 -1.154 . . . . 0.0 112.52 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 105.79 -128.81 9.52 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 106.032 -2.827 . . . . 0.0 106.032 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.505 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 4.3 m -83.9 145.55 47.04 Favored Pre-proline 0 C--N 1.302 -1.486 0 C-N-CA 120.595 -0.442 . . . . 0.0 110.301 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.693 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 7.0 Cg_endo -75.01 162.27 37.39 Favored 'Trans proline' 0 C--N 1.312 -1.343 0 C-N-CA 123.317 2.678 . . . . 0.0 113.958 176.769 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 18.8 t -45.66 111.94 0.4 Allowed 'General case' 0 N--CA 1.492 1.636 0 CA-C-N 114.362 -1.29 . . . . 0.0 110.205 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 114.14 -8.64 23.0 Favored Glycine 0 N--CA 1.5 2.963 0 CA-C-N 114.573 -1.194 . . . . 0.0 112.93 179.596 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' TRP . . . . . 0.693 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 50.9 m95 -110.76 161.2 16.01 Favored 'General case' 0 N--CA 1.489 1.498 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . 0.429 ' O ' ' ND1' ' A' ' 34' ' ' HIS . 56.5 t-80 -146.83 46.34 1.18 Allowed 'General case' 0 N--CA 1.499 1.978 0 C-N-CA 117.741 -1.584 . . . . 0.0 113.508 -179.812 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . 0.505 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 21.4 t-20 62.64 145.81 0.02 OUTLIER 'General case' 0 N--CA 1.511 2.6 0 N-CA-C 116.418 2.007 . . . . 0.0 116.418 179.846 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.791 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 0.7 OUTLIER -116.29 -43.0 2.98 Favored 'General case' 0 N--CA 1.485 1.28 0 N-CA-C 106.927 -1.509 . . . . 0.0 106.927 179.482 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 8.8 ptpp? -124.31 127.24 47.33 Favored 'General case' 0 N--CA 1.498 1.94 0 N-CA-C 107.406 -1.331 . . . . 0.0 107.406 179.319 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.445 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -77.8 43.14 0.4 Allowed 'General case' 0 N--CA 1.497 1.909 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 179.869 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . 0.445 ' ND1' ' C ' ' A' ' 38' ' ' ALA . 3.5 m-70 -132.05 -81.35 0.51 Allowed 'General case' 0 N--CA 1.498 1.972 0 CA-C-O 119.084 -0.484 . . . . 0.0 110.748 -179.673 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -153.01 -130.38 1.51 Allowed Glycine 0 N--CA 1.509 3.524 0 N-CA-C 109.297 -1.521 . . . . 0.0 109.297 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 0.2 OUTLIER -81.07 -170.17 8.28 Favored 'Cis proline' 0 N--CA 1.5 1.903 0 CA-C-N 120.25 2.025 . . . . 0.0 111.319 -4.178 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 59.6 t30 -92.62 -13.97 28.84 Favored 'General case' 0 N--CA 1.486 1.365 0 N-CA-C 106.094 -1.817 . . . . 0.0 106.094 -179.798 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 37.3 pt -86.6 26.03 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 CA-C-N 113.591 -1.64 . . . . 0.0 113.382 -179.26 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.444 ' HA2' ' O ' ' A' ' 23' ' ' TRP . . . 111.62 119.51 3.84 Favored Glycine 0 N--CA 1.486 2.007 0 CA-C-N 111.602 -2.545 . . . . 0.0 106.875 -179.836 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . 0.48 ' O ' ' N ' ' A' ' 23' ' ' TRP . 20.2 m95 -51.45 133.72 29.44 Favored 'General case' 0 N--CA 1.501 2.095 0 CA-C-N 113.253 -1.473 . . . . 0.0 111.111 -179.432 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' CYS . . . . . 0.791 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 22.8 t -89.26 118.69 29.12 Favored 'General case' 0 C--N 1.305 -1.359 1 N-CA-C 99.746 -4.168 . . . . 0.0 99.746 179.571 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.467 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 86.4 m -126.96 -176.27 3.66 Favored 'General case' 0 CA--C 1.487 -1.443 0 CA-C-N 111.172 -2.74 . . . . 0.0 112.604 -179.357 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.517 ' HD3' ' HA2' ' A' ' 20' ' ' GLY . 34.8 tptt -151.49 157.46 42.33 Favored 'General case' 0 C--N 1.297 -1.697 0 C-N-CA 118.297 -1.361 . . . . 0.0 109.999 -179.821 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 23.8 mttm . . . . . 0 N--CA 1.505 2.298 0 O-C-N 127.039 2.712 . . . . 0.0 110.666 179.646 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.466 0 N-CA-C 108.761 -1.736 . . . . 0.0 108.761 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 38.9 t -131.36 153.66 81.7 Favored Pre-proline 0 N--CA 1.494 1.774 0 N-CA-C 103.962 -2.607 . . . . 0.0 103.962 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.446 ' CB ' ' HA ' ' A' ' 18' ' ' LEU . 18.6 Cg_endo -72.82 138.13 28.26 Favored 'Trans proline' 0 C--N 1.305 -1.761 0 C-N-CA 122.991 2.461 . . . . 0.0 117.568 163.662 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.556 ' SG ' ' SG ' ' A' ' 6' ' ' CYS . 12.5 p -124.56 159.1 31.4 Favored 'General case' 0 N--CA 1.494 1.766 0 CA-C-N 114.818 -1.083 . . . . 0.0 109.46 179.52 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 10.3 tp -79.7 84.03 5.58 Favored 'General case' 0 N--CA 1.491 1.62 1 N-CA-C 99.612 -4.218 . . . . 0.0 99.612 179.465 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.657 ' SG ' ' HA3' ' A' ' 20' ' ' GLY . 34.7 m -68.41 175.07 3.57 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-O 123.391 1.567 . . . . 0.0 111.567 -179.716 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 12.7 t70 -49.16 -55.16 13.28 Favored 'General case' 0 C--N 1.294 -1.809 0 CA-C-N 111.498 -2.592 . . . . 0.0 114.506 -179.202 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 27.2 p -90.25 9.2 29.55 Favored 'General case' 0 N--CA 1.499 2.012 0 C-N-CA 118.23 -1.388 . . . . 0.0 108.541 179.784 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.422 ' HB3' ' N ' ' A' ' 6' ' ' CYS . 41.2 t0 -84.81 56.8 4.05 Favored 'General case' 0 N--CA 1.488 1.435 0 N-CA-C 105.791 -1.929 . . . . 0.0 105.791 -179.858 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -95.62 -146.89 21.74 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 104.967 -3.253 . . . . 0.0 104.967 179.836 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 7.2 Cg_endo -77.47 44.85 1.6 Allowed 'Trans proline' 0 C--N 1.311 -1.409 0 C-N-CA 124.586 3.524 . . . . 0.0 109.711 -178.171 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 46.3 mtp180 -89.76 150.23 43.58 Favored Pre-proline 0 C--N 1.297 -1.713 0 CA-C-N 115.311 -0.859 . . . . 0.0 111.147 179.724 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 80.5 Cg_endo -65.09 109.85 1.4 Allowed 'Trans proline' 0 N--CA 1.492 1.401 0 C-N-CA 123.656 2.904 . . . . 0.0 109.747 -178.944 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 9.1 mtp-105 71.99 134.11 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.481 0 O-C-N 125.532 1.77 . . . . 0.0 107.731 -179.81 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 114.59 -24.67 10.96 Favored Glycine 0 N--CA 1.502 3.075 0 C-N-CA 120.267 -0.968 . . . . 0.0 110.853 -179.827 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 29.3 m-80 -40.18 -31.5 0.13 Allowed 'General case' 0 N--CA 1.516 2.874 0 N-CA-C 113.851 1.056 . . . . 0.0 113.851 179.805 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -131.34 27.63 4.75 Favored 'General case' 0 N--CA 1.495 1.791 0 CA-C-N 115.166 -0.925 . . . . 0.0 109.678 -179.796 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.446 ' HA ' ' CB ' ' A' ' 3' ' ' PRO . 0.6 OUTLIER -178.7 39.94 0.0 OUTLIER 'General case' 0 N--CA 1.508 2.466 0 N-CA-C 114.517 1.302 . . . . 0.0 114.517 -179.643 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 12.4 t -89.26 -1.7 58.18 Favored 'General case' 0 N--CA 1.504 2.274 0 C-N-CA 118.956 -1.098 . . . . 0.0 112.734 -179.895 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.657 ' HA3' ' SG ' ' A' ' 6' ' ' CYS . . . -162.66 139.09 5.71 Favored Glycine 0 N--CA 1.493 2.467 0 CA-C-O 118.29 -1.283 . . . . 0.0 110.553 -179.785 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.466 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 32.7 mm -102.57 140.69 20.3 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.102 0 N-CA-C 104.268 -2.493 . . . . 0.0 104.268 179.571 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.595 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.6 pp -63.87 146.08 54.65 Favored 'General case' 0 N--CA 1.504 2.238 0 C-N-CA 117.407 -1.717 . . . . 0.0 112.154 179.727 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 40.6 m95 -130.82 131.88 44.9 Favored 'General case' 0 N--CA 1.486 1.327 0 N-CA-C 119.404 3.113 . . . . 0.0 119.404 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -89.39 51.32 2.09 Favored 'General case' 0 C--N 1.301 -1.512 1 CA-C-N 107.895 -4.229 . . . . 0.0 111.334 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.53 ' CE1' ' HB3' ' A' ' 30' ' ' PRO . 2.2 m-85 -125.99 126.37 24.81 Favored Pre-proline 0 N--CA 1.488 1.448 0 CA-C-O 121.588 0.708 . . . . 0.0 111.898 179.834 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -64.13 -19.99 66.79 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 C-N-CA 123.764 2.976 . . . . 0.0 110.286 -178.12 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 10.4 p -88.04 -6.69 57.82 Favored 'General case' 0 N--CA 1.491 1.587 0 CA-C-N 114.004 -1.453 . . . . 0.0 110.933 179.753 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.592 ' HA2' ' CD1' ' A' ' 45' ' ' TRP . . . 114.81 -95.3 0.71 Allowed Glycine 0 N--CA 1.483 1.776 1 N-CA-C 100.932 -4.867 . . . . 0.0 100.932 -179.531 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.541 ' HB3' ' HB2' ' A' ' 33' ' ' TRP . 7.8 m -101.17 164.37 16.15 Favored Pre-proline 0 C--N 1.302 -1.459 0 CA-C-N 114.006 -1.097 . . . . 0.0 108.676 179.768 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.722 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.3 OUTLIER -83.83 167.1 13.05 Favored 'Trans proline' 0 C--N 1.311 -1.412 0 C-N-CA 124.917 3.745 . . . . 0.0 116.177 158.24 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 29.1 t -55.86 126.33 25.22 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-N 113.427 -1.715 . . . . 0.0 109.62 -179.843 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 104.58 -7.12 45.8 Favored Glycine 0 N--CA 1.495 2.628 0 CA-C-N 112.664 -2.062 . . . . 0.0 111.46 179.893 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' TRP . . . . . 0.722 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 49.7 m95 -113.4 152.96 29.36 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 106.335 -1.728 . . . . 0.0 106.335 -179.872 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 64.7 t60 -140.42 44.5 1.86 Allowed 'General case' 0 N--CA 1.493 1.717 0 C-N-CA 119.419 -0.913 . . . . 0.0 109.51 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . 0.571 ' HA ' ' SG ' ' A' ' 47' ' ' CYS . 23.2 t-20 54.74 147.86 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.171 0 CA-C-N 112.951 -1.932 . . . . 0.0 115.428 -179.985 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.676 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 0.8 OUTLIER -119.76 -36.27 3.34 Favored 'General case' 0 C--N 1.309 -1.184 0 N-CA-C 106.632 -1.618 . . . . 0.0 106.632 179.825 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 19.5 ttpt -139.02 122.4 17.16 Favored 'General case' 0 N--CA 1.486 1.336 0 CA-C-O 123.589 1.661 . . . . 0.0 109.98 179.668 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.43 ' O ' ' ND1' ' A' ' 39' ' ' HIS . . . -96.0 21.18 9.03 Favored 'General case' 0 C--N 1.303 -1.419 0 CA-C-N 112.273 -2.239 . . . . 0.0 105.541 179.72 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . 0.43 ' ND1' ' O ' ' A' ' 38' ' ' ALA . 10.7 m-70 -135.72 69.46 1.43 Allowed 'General case' 0 N--CA 1.497 1.895 0 N-CA-C 109.372 -0.603 . . . . 0.0 109.372 -179.719 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 84.08 176.47 51.17 Favored Glycine 0 N--CA 1.502 3.036 0 N-CA-C 106.165 -2.774 . . . . 0.0 106.165 -179.739 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_endo -60.96 169.8 19.37 Favored 'Cis proline' 0 N--CA 1.504 2.089 0 CA-C-N 119.771 1.786 . . . . 0.0 114.434 1.664 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 17.0 t-20 -92.45 -9.08 42.81 Favored 'General case' 0 N--CA 1.484 1.232 0 N-CA-C 104.773 -2.306 . . . . 0.0 104.773 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 17.6 mt -92.7 29.72 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.063 0 CA-C-O 123.059 1.409 . . . . 0.0 109.819 -179.29 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.465 ' C ' ' CD1' ' A' ' 45' ' ' TRP . . . 129.53 -116.58 2.17 Favored Glycine 0 N--CA 1.484 1.84 0 N-CA-C 103.744 -3.742 . . . . 0.0 103.744 -179.772 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . 0.592 ' CD1' ' HA2' ' A' ' 28' ' ' GLY . 3.0 m95 -155.26 -172.07 4.04 Favored 'General case' 0 N--CA 1.507 2.422 0 N-CA-C 104.254 -2.498 . . . . 0.0 104.254 179.853 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' CYS . . . . . 0.676 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 26.2 t -135.75 126.84 27.96 Favored 'General case' 0 N--CA 1.498 1.958 1 N-CA-C 98.985 -4.45 . . . . 0.0 98.985 179.493 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.573 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 70.9 m -131.47 -179.68 5.51 Favored 'General case' 0 CA--C 1.471 -2.061 0 N-CA-C 116.24 1.941 . . . . 0.0 116.24 -178.663 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.567 ' HD3' ' HA2' ' A' ' 20' ' ' GLY . 44.1 tptt -151.04 149.21 29.28 Favored 'General case' 0 C--N 1.297 -1.693 0 C-N-CA 118.716 -1.194 . . . . 0.0 110.672 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . 0.479 ' H ' ' HD2' ' A' ' 48' ' ' LYS . 93.4 mttt . . . . . 0 N--CA 1.494 1.774 0 CA-C-N 112.133 -2.303 . . . . 0.0 108.59 179.317 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.495 2.576 0 N-CA-C 109.093 -1.603 . . . . 0.0 109.093 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 21.4 t -97.22 147.28 32.72 Favored Pre-proline 0 N--CA 1.497 1.919 0 N-CA-C 106.694 -1.595 . . . . 0.0 106.694 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.419 ' HA ' ' O ' ' A' ' 20' ' ' GLY . 6.9 Cg_endo -77.84 149.76 26.49 Favored 'Trans proline' 0 C--N 1.309 -1.532 0 C-N-CA 122.536 2.157 . . . . 0.0 110.314 169.521 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -138.95 169.43 17.81 Favored 'General case' 0 C--N 1.3 -1.557 0 CA-C-O 121.862 0.839 . . . . 0.0 110.142 179.836 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.413 HD23 ' N ' ' A' ' 6' ' ' CYS . 8.5 tt -91.88 150.52 21.0 Favored 'General case' 0 N--CA 1.492 1.655 0 N-CA-C 102.229 -3.248 . . . . 0.0 102.229 179.647 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.542 ' H ' ' HB3' ' A' ' 9' ' ' ASP . 3.1 m -139.78 -166.46 2.08 Favored 'General case' 0 N--CA 1.493 1.72 0 N-CA-C 113.973 1.101 . . . . 0.0 113.973 -179.519 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . 0.472 ' H ' ' HB3' ' A' ' 37' ' ' LYS . 30.1 t70 -81.19 -59.8 2.52 Favored 'General case' 0 N--CA 1.496 1.86 0 CA-C-N 112.612 -2.085 . . . . 0.0 108.091 -179.754 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 15.2 m -76.51 -13.26 60.1 Favored 'General case' 0 N--CA 1.499 2.002 0 CA-C-N 114.56 -1.2 . . . . 0.0 109.605 179.636 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.542 ' HB3' ' H ' ' A' ' 6' ' ' CYS . 28.7 t70 -65.42 -15.5 62.67 Favored 'General case' 0 N--CA 1.492 1.63 0 CA-C-N 113.655 -1.611 . . . . 0.0 115.18 -179.743 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.447 ' C ' ' H ' ' A' ' 12' ' ' ARG . . . -163.29 70.79 0.21 Allowed Glycine 0 N--CA 1.5 2.957 0 C-N-CA 118.87 -1.633 . . . . 0.0 113.559 -179.659 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_endo -72.43 27.52 0.27 Allowed 'Trans proline' 0 N--CA 1.498 1.784 0 C-N-CA 123.791 2.994 . . . . 0.0 112.276 173.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.447 ' H ' ' C ' ' A' ' 10' ' ' GLY . 19.8 mtp180 -145.36 135.07 11.56 Favored Pre-proline 0 N--CA 1.494 1.77 0 N-CA-C 107.658 -1.238 . . . . 0.0 107.658 -179.841 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 23.2 Cg_endo -73.28 145.04 38.01 Favored 'Trans proline' 0 N--CA 1.49 1.317 0 C-N-CA 123.811 3.007 . . . . 0.0 110.075 -178.773 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 72.8 mtp180 54.11 20.39 2.5 Favored 'General case' 0 N--CA 1.498 1.95 0 CA-C-O 121.994 0.902 . . . . 0.0 111.274 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -70.5 -24.21 76.98 Favored Glycine 0 N--CA 1.493 2.498 0 CA-C-N 114.085 -1.416 . . . . 0.0 112.425 -179.834 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 38.9 m-80 50.41 41.33 24.73 Favored 'General case' 0 N--CA 1.505 2.283 0 CA-C-O 122.15 0.976 . . . . 0.0 111.072 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.3 p -88.97 148.21 23.9 Favored 'General case' 0 C--N 1.301 -1.535 0 CA-C-N 115.47 -0.786 . . . . 0.0 108.987 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 2.0 tt -161.51 91.95 0.86 Allowed 'General case' 0 N--CA 1.499 1.999 0 N-CA-C 106.741 -1.577 . . . . 0.0 106.741 -179.564 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 64.0 p -128.26 31.55 5.02 Favored 'General case' 0 N--CA 1.499 1.984 0 N-CA-C 112.904 0.705 . . . . 0.0 112.904 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.419 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -135.45 156.49 22.72 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 108.791 -1.724 . . . . 0.0 108.791 -179.906 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.448 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 44.5 mm -115.56 144.93 22.03 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 N-CA-C 106.098 -1.816 . . . . 0.0 106.098 179.708 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.609 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 4.1 pp -72.69 151.0 42.45 Favored 'General case' 0 N--CA 1.488 1.464 0 C-N-CA 118.438 -1.305 . . . . 0.0 109.041 179.752 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 44.1 m95 -132.31 134.21 44.96 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 117.721 2.489 . . . . 0.0 117.721 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.3 m-85 -89.2 53.13 2.56 Favored 'General case' 0 C--N 1.296 -1.744 1 CA-C-N 107.623 -4.353 . . . . 0.0 109.43 -179.791 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.429 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 2.4 m-85 -126.58 139.2 34.13 Favored Pre-proline 0 C--N 1.306 -1.294 0 CA-C-O 121.671 0.748 . . . . 0.0 111.964 -179.962 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.68 -18.01 37.63 Favored 'Trans proline' 0 C--N 1.305 -1.734 1 C-N-CA 125.415 4.077 . . . . 0.0 110.6 177.161 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 10.7 p -100.26 22.65 11.19 Favored 'General case' 0 C--N 1.299 -1.613 0 CA-C-N 113.334 -1.757 . . . . 0.0 110.886 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.577 ' HA2' ' CD1' ' A' ' 45' ' ' TRP . . . 81.4 -89.98 1.41 Allowed Glycine 0 N--CA 1.484 1.838 1 N-CA-C 102.854 -4.098 . . . . 0.0 102.854 -179.674 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.462 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 24.8 m -98.7 163.57 18.67 Favored Pre-proline 0 C--N 1.302 -1.457 0 CA-C-N 113.719 -1.24 . . . . 0.0 110.996 -179.887 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.696 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.1 OUTLIER -89.05 163.76 5.83 Favored 'Trans proline' 0 CA--C 1.554 1.496 1 C-N-CA 126.701 4.934 . . . . 0.0 117.122 155.785 . . . . . . . . 4 4 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 4.1 m -51.06 111.82 0.62 Allowed 'General case' 0 C--N 1.301 -1.526 0 CA-C-N 112.36 -2.2 . . . . 0.0 114.135 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 113.7 -6.54 24.22 Favored Glycine 0 N--CA 1.506 3.352 0 CA-C-N 115.046 -0.979 . . . . 0.0 112.638 179.68 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' TRP . . . . . 0.696 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 54.7 m95 -106.96 167.17 10.07 Favored 'General case' 0 C--N 1.299 -1.619 0 N-CA-C 106.517 -1.661 . . . . 0.0 106.517 -179.762 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 67.8 t60 -146.96 37.7 0.97 Allowed 'General case' 0 N--CA 1.493 1.69 0 C-N-CA 116.845 -1.942 . . . . 0.0 113.236 179.82 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . 0.499 ' HA ' ' SG ' ' A' ' 47' ' ' CYS . 13.9 t-20 55.88 143.04 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.113 0 N-CA-C 117.484 2.401 . . . . 0.0 117.484 179.556 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.842 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 2.7 p -120.3 -28.37 5.05 Favored 'General case' 0 N--CA 1.486 1.329 0 CA-C-N 115.652 -0.703 . . . . 0.0 111.345 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . 0.472 ' HB3' ' H ' ' A' ' 7' ' ' ASP . 9.5 ptpt -151.05 151.15 31.61 Favored 'General case' 0 N--CA 1.495 1.792 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 179.105 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.449 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -117.0 35.06 4.8 Favored 'General case' 0 N--CA 1.491 1.607 0 N-CA-C 102.388 -3.19 . . . . 0.0 102.388 179.661 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . 0.449 ' ND1' ' C ' ' A' ' 38' ' ' ALA . 4.5 m-70 -128.64 60.31 1.52 Allowed 'General case' 0 N--CA 1.497 1.881 0 N-CA-C 106.943 -1.503 . . . . 0.0 106.943 -179.534 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 74.19 -149.45 40.81 Favored Glycine 0 N--CA 1.496 2.646 0 N-CA-C 104.854 -3.298 . . . . 0.0 104.854 -179.702 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.412 ' HD2' ' C ' ' A' ' 45' ' ' TRP . 42.1 Cg_endo -48.53 176.6 0.39 Allowed 'Cis proline' 0 N--CA 1.504 2.104 0 CA-C-N 119.765 1.783 . . . . 0.0 115.478 -5.499 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.5 m-20 -92.08 -7.77 47.72 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 104.34 -2.467 . . . . 0.0 104.34 -179.719 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 15.0 mt -99.53 22.29 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.85 0 CA-C-O 123.99 1.853 . . . . 0.0 113.006 -179.345 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 133.08 -119.87 2.48 Favored Glycine 0 C--N 1.288 -2.094 0 N-CA-C 104.195 -3.562 . . . . 0.0 104.195 -179.857 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . 0.577 ' CD1' ' HA2' ' A' ' 28' ' ' GLY . 3.9 m95 -152.56 -169.22 3.28 Favored 'General case' 0 N--CA 1.511 2.588 0 N-CA-C 106.923 -1.51 . . . . 0.0 106.923 -179.917 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' CYS . . . . . 0.842 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 43.8 t -139.17 129.4 25.39 Favored 'General case' 0 C--N 1.313 -0.982 0 N-CA-C 101.273 -3.603 . . . . 0.0 101.273 179.13 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.499 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 71.4 m -135.0 -172.13 2.97 Favored 'General case' 0 C--N 1.294 -1.805 0 CA-C-N 111.295 -2.684 . . . . 0.0 108.479 -179.435 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.406 ' N ' ' CD ' ' A' ' 48' ' ' LYS . 0.0 OUTLIER -150.55 173.5 14.03 Favored 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 107.125 -1.435 . . . . 0.0 107.125 179.352 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.499 1.993 0 O-C-N 125.803 1.939 . . . . 0.0 106.681 179.728 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 2.725 0 N-CA-C 108.914 -1.674 . . . . 0.0 108.914 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.415 ' HB ' HD23 ' A' ' 22' ' ' LEU . 22.0 t -94.74 146.13 30.85 Favored Pre-proline 0 N--CA 1.497 1.893 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 -179.926 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -72.28 149.65 51.58 Favored 'Trans proline' 0 N--CA 1.494 1.506 0 C-N-CA 124.161 3.24 . . . . 0.0 112.716 167.625 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.595 ' SG ' ' HB3' ' A' ' 22' ' ' LEU . 0.1 OUTLIER -136.88 -176.89 4.51 Favored 'General case' 0 N--CA 1.496 1.844 0 CA-C-N 115.349 -0.842 . . . . 0.0 111.438 179.631 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 6.4 tt -91.15 110.93 22.21 Favored 'General case' 0 N--CA 1.491 1.587 0 C-N-CA 119.428 -0.909 . . . . 0.0 108.829 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.423 ' SG ' ' HA3' ' A' ' 20' ' ' GLY . 7.7 m -88.13 178.42 6.64 Favored 'General case' 0 C--N 1.31 -1.123 0 CA-C-O 123.282 1.515 . . . . 0.0 113.827 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -55.36 -65.73 0.54 Allowed 'General case' 0 C--N 1.297 -1.712 0 CA-C-N 111.501 -2.59 . . . . 0.0 110.123 -179.84 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 65.1 m -80.69 26.55 0.4 Allowed 'General case' 0 N--CA 1.498 1.947 0 C-N-CA 118.971 -1.092 . . . . 0.0 109.381 179.804 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -94.79 -3.0 49.84 Favored 'General case' 0 N--CA 1.495 1.819 0 C-N-CA 119.341 -0.943 . . . . 0.0 113.536 -179.554 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -39.52 -55.41 2.61 Favored Glycine 0 N--CA 1.506 3.336 0 N-CA-C 115.049 0.78 . . . . 0.0 115.049 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_endo -75.34 11.0 1.64 Allowed 'Trans proline' 0 N--CA 1.5 1.872 0 C-N-CA 123.501 2.801 . . . . 0.0 113.903 179.721 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.433 ' HB3' HG21 ' A' ' 17' ' ' THR . 51.9 mtt85 -135.93 70.68 63.82 Favored Pre-proline 0 N--CA 1.492 1.67 0 CA-C-N 114.635 -1.166 . . . . 0.0 112.133 -179.768 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_endo -74.78 -147.78 0.03 OUTLIER 'Trans proline' 0 N--CA 1.493 1.471 0 C-N-CA 124.785 3.656 . . . . 0.0 111.495 178.915 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 6.3 ptp180 -62.66 -161.1 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.044 0 CA-C-N 115.7 -0.682 . . . . 0.0 112.016 -179.886 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 86.16 31.52 19.71 Favored Glycine 0 N--CA 1.5 2.943 0 C-N-CA 120.0 -1.095 . . . . 0.0 111.213 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 1.7 t30 61.89 52.23 3.49 Favored 'General case' 0 N--CA 1.506 2.348 0 CA-C-O 122.788 1.28 . . . . 0.0 109.663 179.913 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.433 HG21 ' HB3' ' A' ' 12' ' ' ARG . 23.3 m -98.86 121.75 41.22 Favored 'General case' 0 N--CA 1.495 1.811 0 CA-C-N 114.074 -1.421 . . . . 0.0 110.528 -179.897 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 7.4 mp -117.95 85.87 2.42 Favored 'General case' 0 N--CA 1.504 2.244 0 CA-C-O 122.36 1.076 . . . . 0.0 111.191 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 8.9 t -90.11 -29.12 18.52 Favored 'General case' 0 N--CA 1.501 2.112 0 CA-C-N 113.374 -1.739 . . . . 0.0 111.077 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.423 ' HA3' ' SG ' ' A' ' 6' ' ' CYS . . . -154.4 141.33 8.13 Favored Glycine 0 N--CA 1.496 2.634 0 N-CA-C 110.349 -1.1 . . . . 0.0 110.349 179.987 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.432 ' N ' ' O ' ' A' ' 47' ' ' CYS . 40.8 mm -99.64 138.89 22.61 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.452 0 N-CA-C 107.122 -1.436 . . . . 0.0 107.122 179.767 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.595 ' HB3' ' SG ' ' A' ' 4' ' ' CYS . 1.3 pp -68.97 146.93 52.33 Favored 'General case' 0 N--CA 1.495 1.8 0 C-N-CA 118.925 -1.11 . . . . 0.0 109.155 179.889 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 29.9 m95 -129.06 135.03 48.37 Favored 'General case' 0 C--N 1.307 -1.246 0 N-CA-C 117.882 2.549 . . . . 0.0 117.882 -179.786 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -89.38 49.25 1.72 Allowed 'General case' 0 C--N 1.298 -1.635 1 CA-C-N 108.047 -4.16 . . . . 0.0 113.163 -179.791 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.403 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 2.0 m-85 -122.08 139.3 30.19 Favored Pre-proline 0 C--N 1.301 -1.542 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 179.573 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 13.9 Cg_endo -76.29 -26.3 9.07 Favored 'Trans proline' 0 C--N 1.303 -1.86 0 C-N-CA 125.255 3.97 . . . . 0.0 112.841 174.42 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -88.66 11.94 16.11 Favored 'General case' 0 N--CA 1.494 1.748 0 CA-C-N 114.876 -1.056 . . . . 0.0 113.224 -179.831 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 97.91 -127.2 9.14 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 103.755 -3.738 . . . . 0.0 103.755 -179.722 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.527 ' HB3' ' HB2' ' A' ' 33' ' ' TRP . 8.3 m -85.38 147.04 46.04 Favored Pre-proline 0 C--N 1.303 -1.444 0 CA-C-N 117.716 0.758 . . . . 0.0 110.776 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.698 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 8.5 Cg_endo -75.19 168.28 25.05 Favored 'Trans proline' 0 C--N 1.308 -1.602 0 C-N-CA 123.037 2.491 . . . . 0.0 113.795 176.006 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 2.9 m -45.45 101.45 0.02 OUTLIER 'General case' 0 C--N 1.297 -1.68 0 CA-C-N 112.642 -2.072 . . . . 0.0 113.423 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 116.0 -2.11 21.12 Favored Glycine 0 N--CA 1.507 3.427 0 C-N-CA 120.945 -0.645 . . . . 0.0 114.057 179.63 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' TRP . . . . . 0.698 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 55.4 m95 -111.13 158.29 19.05 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 106.46 -1.682 . . . . 0.0 106.46 -179.851 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 2.0 t-80 -138.54 34.08 2.25 Favored 'General case' 0 N--CA 1.492 1.667 0 C-N-CA 117.615 -1.634 . . . . 0.0 112.507 -179.739 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . 0.507 ' HA ' ' SG ' ' A' ' 29' ' ' CYS . 0.3 OUTLIER 66.4 138.21 0.03 OUTLIER 'General case' 0 N--CA 1.509 2.498 0 N-CA-C 116.566 2.061 . . . . 0.0 116.566 179.734 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.683 ' SG ' ' CB ' ' A' ' 46' ' ' CYS . 0.8 OUTLIER -114.34 -33.37 5.65 Favored 'General case' 0 N--CA 1.484 1.243 0 N-CA-C 104.541 -2.392 . . . . 0.0 104.541 179.485 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 20.7 ptmt -146.4 139.95 25.97 Favored 'General case' 0 N--CA 1.494 1.764 0 CA-C-N 115.481 -0.781 . . . . 0.0 110.069 179.503 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.449 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -112.17 34.81 4.05 Favored 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 103.898 -2.63 . . . . 0.0 103.898 179.833 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . 0.449 ' ND1' ' C ' ' A' ' 38' ' ' ALA . 4.1 m-70 -129.12 57.28 1.65 Allowed 'General case' 0 N--CA 1.499 1.981 0 N-CA-C 107.611 -1.255 . . . . 0.0 107.611 -179.735 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 72.75 -142.04 31.56 Favored Glycine 0 N--CA 1.496 2.695 0 N-CA-C 106.739 -2.544 . . . . 0.0 106.739 -179.656 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.46 ' HG2' ' O ' ' A' ' 44' ' ' GLY . 94.3 Cg_endo -62.34 -169.19 1.42 Allowed 'Cis proline' 0 N--CA 1.496 1.621 0 CA-C-N 118.804 1.302 . . . . 0.0 112.876 -5.065 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 54.2 t30 -93.66 1.53 56.58 Favored 'General case' 0 C--N 1.308 -1.217 0 N-CA-C 105.045 -2.206 . . . . 0.0 105.045 -179.334 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.443 ' N ' HD12 ' A' ' 43' ' ' ILE . 1.1 mp -120.28 37.46 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 O-C-N 125.126 1.516 . . . . 0.0 114.843 -179.008 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.46 ' O ' ' HG2' ' A' ' 41' ' ' PRO . . . 119.59 149.99 8.56 Favored Glycine 0 N--CA 1.485 1.963 0 N-CA-C 106.85 -2.5 . . . . 0.0 106.85 179.932 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . 0.403 ' NE1' ' O ' ' A' ' 25' ' ' TYR . 5.1 m95 -89.38 136.42 33.04 Favored 'General case' 0 N--CA 1.506 2.326 0 CA-C-O 117.175 -1.393 . . . . 0.0 108.329 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' CYS . . . . . 0.683 ' CB ' ' SG ' ' A' ' 36' ' ' CYS . 59.1 m -88.77 127.34 35.6 Favored 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 101.957 -3.349 . . . . 0.0 101.957 179.527 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.569 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 79.7 m -129.81 -174.95 3.45 Favored 'General case' 0 C--N 1.299 -1.601 0 CA-C-N 110.959 -2.837 . . . . 0.0 113.817 -179.243 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.433 ' HD2' ' H ' ' A' ' 49' ' ' LYS . 25.7 tptp -151.6 150.68 30.57 Favored 'General case' 0 C--N 1.295 -1.781 0 C-N-CA 118.57 -1.252 . . . . 0.0 110.26 -179.907 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . 0.433 ' H ' ' HD2' ' A' ' 48' ' ' LYS . 6.0 mtpt . . . . . 0 N--CA 1.499 2.015 0 O-C-N 126.407 2.317 . . . . 0.0 108.422 179.448 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 2.673 0 N-CA-C 108.968 -1.653 . . . . 0.0 108.968 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 40.0 t -98.23 140.86 22.15 Favored Pre-proline 0 N--CA 1.496 1.861 0 N-CA-C 106.863 -1.532 . . . . 0.0 106.863 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -70.66 148.61 59.61 Favored 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 123.533 2.822 . . . . 0.0 111.718 172.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.522 ' SG ' ' HB3' ' A' ' 22' ' ' LEU . 0.8 OUTLIER -146.32 163.3 35.96 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 124.24 0.962 . . . . 0.0 109.724 179.779 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.43 HD23 ' N ' ' A' ' 6' ' ' CYS . 8.9 tt -79.41 150.68 31.25 Favored 'General case' 0 N--CA 1.488 1.446 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 -179.833 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.573 ' SG ' ' HB2' ' A' ' 9' ' ' ASP . 2.5 m -137.83 -145.19 0.19 Allowed 'General case' 0 N--CA 1.491 1.607 0 N-CA-C 116.316 1.969 . . . . 0.0 116.316 -179.663 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . 0.401 ' HB3' ' HA ' ' A' ' 37' ' ' LYS . 18.5 t70 -106.15 -59.02 1.84 Allowed 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 105.941 -1.874 . . . . 0.0 105.941 179.891 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 2.7 m -90.97 12.57 19.22 Favored 'General case' 0 N--CA 1.497 1.917 0 CA-C-N 114.164 -1.38 . . . . 0.0 108.508 179.668 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.573 ' HB2' ' SG ' ' A' ' 6' ' ' CYS . 5.0 t0 -66.21 72.24 0.07 Allowed 'General case' 0 N--CA 1.487 1.39 0 CA-C-N 115.013 -0.994 . . . . 0.0 111.49 -179.91 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.42 ' HA3' ' HB2' ' A' ' 16' ' ' ASN . . . 120.88 80.9 0.61 Allowed Glycine 0 N--CA 1.495 2.589 0 C-N-CA 120.242 -0.98 . . . . 0.0 112.979 179.827 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 7.4 Cg_endo -74.99 35.99 0.43 Allowed 'Trans proline' 0 N--CA 1.503 2.031 1 C-N-CA 125.336 4.024 . . . . 0.0 112.528 177.999 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 76.3 mtt85 -144.11 168.32 12.88 Favored Pre-proline 0 N--CA 1.49 1.567 0 N-CA-C 107.525 -1.287 . . . . 0.0 107.525 -179.87 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 16.4 Cg_endo -72.58 -170.53 0.6 Allowed 'Trans proline' 0 N--CA 1.493 1.456 0 C-N-CA 123.666 2.911 . . . . 0.0 113.188 169.633 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 16.0 ptt85 -16.62 109.99 0.02 OUTLIER 'General case' 0 N--CA 1.502 2.125 0 N-CA-C 117.433 2.383 . . . . 0.0 117.433 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 119.81 -21.6 8.95 Favored Glycine 0 N--CA 1.505 3.24 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . 0.42 ' HB2' ' HA3' ' A' ' 10' ' ' GLY . 15.9 p-10 -61.34 72.46 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.466 0 CA-C-O 122.996 1.379 . . . . 0.0 111.408 -179.922 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 7.5 p -138.76 169.69 17.33 Favored 'General case' 0 C--N 1.295 -1.774 0 N-CA-C 106.02 -1.844 . . . . 0.0 106.02 179.605 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 20.2 tp 49.45 56.82 7.25 Favored 'General case' 0 N--CA 1.509 2.495 0 CA-C-O 123.142 1.449 . . . . 0.0 110.224 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 7.3 t -121.25 43.43 2.81 Favored 'General case' 0 N--CA 1.498 1.953 0 CA-C-N 113.993 -1.458 . . . . 0.0 107.138 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 170.42 154.67 9.65 Favored Glycine 0 N--CA 1.493 2.448 0 CA-C-N 114.905 -1.043 . . . . 0.0 113.626 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.434 ' N ' ' O ' ' A' ' 47' ' ' CYS . 40.5 mm -116.82 144.77 23.74 Favored 'Isoleucine or valine' 0 N--CA 1.51 2.56 0 N-CA-C 107.639 -1.245 . . . . 0.0 107.639 179.736 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.623 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.8 pp -68.27 151.62 46.65 Favored 'General case' 0 N--CA 1.501 2.123 0 C-N-CA 117.543 -1.663 . . . . 0.0 107.528 179.447 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 22.1 m95 -131.2 140.33 49.87 Favored 'General case' 0 C--N 1.308 -1.198 0 CA-C-O 124.964 2.316 . . . . 0.0 116.985 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.5 m-30 -89.43 35.18 0.81 Allowed 'General case' 0 C--N 1.297 -1.696 1 CA-C-N 107.868 -4.242 . . . . 0.0 115.23 -179.636 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.438 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 1.2 m-30 -111.02 115.17 53.25 Favored Pre-proline 0 C--N 1.301 -1.506 0 N-CA-C 107.036 -1.468 . . . . 0.0 107.036 179.64 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo -61.27 -19.73 65.13 Favored 'Trans proline' 0 C--N 1.299 -2.031 0 C-N-CA 121.007 1.138 . . . . 0.0 109.524 -175.212 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 1.6 p -91.67 1.81 56.9 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 124.396 1.06 . . . . 0.0 112.574 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 121.03 -130.99 8.46 Favored Glycine 0 N--CA 1.497 2.739 0 N-CA-C 108.207 -1.957 . . . . 0.0 108.207 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.617 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 8.4 m -93.36 150.28 38.73 Favored Pre-proline 0 C--N 1.303 -1.441 0 CA-C-N 117.382 0.591 . . . . 0.0 109.868 -179.938 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.72 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.7 OUTLIER -76.13 162.1 34.63 Favored 'Trans proline' 0 C--N 1.309 -1.545 0 C-N-CA 122.515 2.143 . . . . 0.0 113.206 176.079 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 26.4 t -46.14 110.44 0.27 Allowed 'General case' 0 N--CA 1.493 1.692 0 CA-C-N 113.12 -1.855 . . . . 0.0 111.013 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 113.95 -5.57 23.92 Favored Glycine 0 N--CA 1.5 2.936 0 CA-C-N 114.405 -1.27 . . . . 0.0 111.678 179.772 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' TRP . . . . . 0.72 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 35.4 m95 -117.5 152.59 34.74 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 106.992 -1.484 . . . . 0.0 106.992 -179.827 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 55.4 t60 -143.04 42.26 1.54 Allowed 'General case' 0 N--CA 1.496 1.872 0 C-N-CA 117.389 -1.725 . . . . 0.0 112.436 179.866 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . 0.617 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 27.5 t-20 60.63 149.98 0.02 OUTLIER 'General case' 0 N--CA 1.506 2.347 0 N-CA-C 117.947 2.573 . . . . 0.0 117.947 179.742 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.696 ' SG ' ' CB ' ' A' ' 46' ' ' CYS . 13.9 p -115.82 -16.41 11.19 Favored 'General case' 0 N--CA 1.485 1.3 0 CA-C-N 114.352 -1.295 . . . . 0.0 110.983 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . 0.501 ' HB3' ' HB3' ' A' ' 6' ' ' CYS . 15.3 ptmt -144.7 127.04 15.83 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.953 -0.467 . . . . 0.0 111.83 -179.967 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.451 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -80.98 44.29 0.75 Allowed 'General case' 0 N--CA 1.493 1.677 0 N-CA-C 106.606 -1.627 . . . . 0.0 106.606 179.618 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . 0.467 ' H ' ' C ' ' A' ' 37' ' ' LYS . 2.9 m-70 -131.24 -116.6 0.23 Allowed 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 101.53 -3.508 . . . . 0.0 101.53 -179.845 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -126.68 -113.11 1.82 Allowed Glycine 0 N--CA 1.506 3.311 0 N-CA-C 110.782 -0.927 . . . . 0.0 110.782 179.785 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.423 ' HG2' ' O ' ' A' ' 44' ' ' GLY . 83.1 Cg_endo -65.7 -164.77 1.43 Allowed 'Cis proline' 0 N--CA 1.503 2.08 0 N-CA-C 116.316 1.622 . . . . 0.0 116.316 -4.057 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -93.03 -13.91 28.05 Favored 'General case' 0 N--CA 1.486 1.356 0 N-CA-C 106.233 -1.766 . . . . 0.0 106.233 -179.298 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 27.1 pt -103.52 28.76 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.148 0 O-C-N 125.913 2.008 . . . . 0.0 116.234 -179.135 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.423 ' O ' ' HG2' ' A' ' 41' ' ' PRO . . . 129.05 168.36 12.35 Favored Glycine 0 C--N 1.292 -1.892 1 N-CA-C 102.149 -4.38 . . . . 0.0 102.149 -179.973 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . 0.438 ' NE1' ' O ' ' A' ' 25' ' ' TYR . 26.2 m95 -102.9 137.3 41.28 Favored 'General case' 0 C--N 1.281 -2.396 0 N-CA-C 105.259 -2.126 . . . . 0.0 105.259 179.883 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' CYS . . . . . 0.696 ' CB ' ' SG ' ' A' ' 36' ' ' CYS . 98.9 m -90.11 130.12 36.32 Favored 'General case' 0 N--CA 1.478 0.966 1 N-CA-C 100.116 -4.031 . . . . 0.0 100.116 179.509 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.434 ' O ' ' N ' ' A' ' 21' ' ' ILE . 82.1 m -132.92 -170.88 2.54 Favored 'General case' 0 C--N 1.296 -1.754 0 CA-C-N 111.736 -2.483 . . . . 0.0 109.273 -179.305 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.568 ' H ' ' HD3' ' A' ' 48' ' ' LYS . 0.0 OUTLIER -150.55 174.35 13.05 Favored 'General case' 0 C--N 1.295 -1.769 0 O-C-N 124.55 1.156 . . . . 0.0 108.377 179.444 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 29.9 mtpt . . . . . 0 C--N 1.29 -2.006 0 CA-C-O 114.398 -2.715 . . . . 0.0 107.104 179.351 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 2.721 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.403 ' HB ' HD23 ' A' ' 22' ' ' LEU . 22.2 t -99.99 140.44 21.52 Favored Pre-proline 0 N--CA 1.495 1.806 0 N-CA-C 107.149 -1.426 . . . . 0.0 107.149 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.418 ' HA ' ' HA ' ' A' ' 21' ' ' ILE . 37.5 Cg_endo -71.27 164.69 34.89 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 123.838 3.025 . . . . 0.0 112.439 166.603 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.508 ' SG ' ' HB3' ' A' ' 22' ' ' LEU . 0.1 OUTLIER -148.98 -171.0 3.77 Favored 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 107.205 -1.406 . . . . 0.0 107.205 179.508 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 5.2 tt -104.94 147.58 27.63 Favored 'General case' 0 N--CA 1.495 1.786 0 N-CA-C 103.056 -2.942 . . . . 0.0 103.056 179.792 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.584 ' HB2' ' HB2' ' A' ' 9' ' ' ASP . 3.9 m -122.73 -171.8 2.35 Favored 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 115.056 1.502 . . . . 0.0 115.056 -179.567 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 7.5 t70 -67.45 -76.26 0.09 Allowed 'General case' 0 N--CA 1.49 1.557 0 CA-C-N 112.873 -1.967 . . . . 0.0 108.177 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 50.3 m -85.25 50.34 1.93 Allowed 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 107.648 -1.241 . . . . 0.0 107.648 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.584 ' HB2' ' HB2' ' A' ' 6' ' ' CYS . 14.9 t0 -102.18 126.0 49.03 Favored 'General case' 0 N--CA 1.489 1.479 0 CA-C-N 114.851 -1.068 . . . . 0.0 112.886 -179.658 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.613 ' H ' ' HD2' ' A' ' 11' ' ' PRO . . . -111.75 -51.28 0.57 Allowed Glycine 0 N--CA 1.503 3.135 0 CA-C-N 112.915 -1.948 . . . . 0.0 112.665 179.655 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.613 ' HD2' ' H ' ' A' ' 10' ' ' GLY . 10.0 Cg_endo -82.54 70.34 6.96 Favored 'Trans proline' 0 N--CA 1.488 1.179 0 C-N-CA 125.289 3.993 . . . . 0.0 103.303 174.537 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 13.1 mtt85 -87.62 156.13 53.31 Favored Pre-proline 0 C--N 1.293 -1.878 0 CA-C-N 110.297 -3.138 . . . . 0.0 111.623 -179.694 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 85.1 Cg_endo -62.47 135.62 54.43 Favored 'Trans proline' 0 N--CA 1.489 1.261 0 C-N-CA 123.744 2.963 . . . . 0.0 109.551 175.985 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 80.5 mtm180 87.45 109.85 0.04 OUTLIER 'General case' 0 N--CA 1.485 1.297 0 O-C-N 126.123 2.139 . . . . 0.0 106.771 -179.632 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 94.42 -16.87 60.15 Favored Glycine 0 N--CA 1.496 2.684 0 C-N-CA 120.083 -1.056 . . . . 0.0 111.382 -179.956 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 18.8 t-20 -149.43 -117.97 0.05 Allowed 'General case' 0 N--CA 1.498 1.934 0 C-N-CA 118.749 -1.18 . . . . 0.0 113.114 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.1 m -126.97 -144.73 0.3 Allowed 'General case' 0 N--CA 1.495 1.813 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 -179.362 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -131.23 137.99 49.15 Favored 'General case' 0 N--CA 1.494 1.729 0 N-CA-C 106.715 -1.587 . . . . 0.0 106.715 179.631 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 33.1 t -89.66 -13.66 36.53 Favored 'General case' 0 N--CA 1.494 1.739 0 CA-C-N 115.196 -0.911 . . . . 0.0 112.102 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -176.14 -161.02 24.54 Favored Glycine 0 N--CA 1.498 2.767 0 C-N-CA 119.171 -1.49 . . . . 0.0 112.031 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.418 ' HA ' ' HA ' ' A' ' 3' ' ' PRO . 39.3 mm -132.22 148.58 32.03 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.924 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 -179.949 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.52 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 2.9 pp -71.41 144.13 49.89 Favored 'General case' 0 N--CA 1.493 1.709 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 179.595 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 44.1 m95 -126.91 133.61 50.63 Favored 'General case' 0 C--N 1.308 -1.196 0 N-CA-C 118.773 2.879 . . . . 0.0 118.773 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -89.44 51.76 2.19 Favored 'General case' 0 C--N 1.299 -1.629 1 CA-C-N 107.138 -4.574 . . . . 0.0 110.612 -179.83 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.46 ' CE1' ' HB3' ' A' ' 30' ' ' PRO . 2.1 m-85 -124.51 142.54 40.71 Favored Pre-proline 0 C--N 1.304 -1.391 0 CA-C-O 122.468 1.128 . . . . 0.0 110.71 179.739 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 74.7 Cg_endo -68.53 -29.94 29.75 Favored 'Trans proline' 0 C--N 1.304 -1.777 0 C-N-CA 125.075 3.85 . . . . 0.0 108.186 177.936 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 5.1 p -90.36 24.4 2.59 Favored 'General case' 0 C--N 1.301 -1.542 0 CA-C-N 113.726 -1.579 . . . . 0.0 109.269 179.659 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.602 ' HA2' ' CD1' ' A' ' 45' ' ' TRP . . . 81.99 -84.56 1.48 Allowed Glycine 0 N--CA 1.482 1.759 0 N-CA-C 105.005 -3.238 . . . . 0.0 105.005 -179.748 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 9.2 m -100.88 166.96 11.52 Favored Pre-proline 0 C--N 1.307 -1.275 0 CA-C-N 112.649 -1.775 . . . . 0.0 110.851 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.717 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.1 OUTLIER -89.44 167.17 5.21 Favored 'Trans proline' 0 C--N 1.312 -1.355 1 C-N-CA 125.919 4.412 . . . . 0.0 113.763 155.523 . . . . . . . . 4 4 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 18.2 t -60.97 141.37 57.37 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-N 113.784 -1.553 . . . . 0.0 109.181 -179.766 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 94.06 -2.3 68.74 Favored Glycine 0 N--CA 1.495 2.6 0 CA-C-N 111.675 -2.511 . . . . 0.0 111.551 -179.919 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' TRP . . . . . 0.717 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 58.7 m95 -111.04 166.52 10.99 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 106.143 -1.799 . . . . 0.0 106.143 -179.743 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . 0.514 ' O ' ' ND1' ' A' ' 34' ' ' HIS . 43.1 t-80 -140.02 31.9 1.98 Allowed 'General case' 0 N--CA 1.496 1.839 0 C-N-CA 118.497 -1.281 . . . . 0.0 112.878 -179.872 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . 0.51 ' HA ' ' SG ' ' A' ' 47' ' ' CYS . 16.7 t-20 59.03 139.66 0.01 OUTLIER 'General case' 0 N--CA 1.511 2.607 0 N-CA-C 114.458 1.281 . . . . 0.0 114.458 -179.934 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.642 ' SG ' ' CB ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -119.43 -41.06 2.73 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.445 -0.784 . . . . 0.0 110.129 -179.725 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . 0.464 ' HG2' ' H ' ' A' ' 39' ' ' HIS . 38.0 ttmt -131.14 138.59 49.54 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 104.696 -2.335 . . . . 0.0 104.696 179.423 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.438 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -117.97 35.63 4.65 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 103.004 -2.962 . . . . 0.0 103.004 179.723 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . 0.464 ' H ' ' HG2' ' A' ' 37' ' ' LYS . 2.7 m-70 -140.09 55.96 1.62 Allowed 'General case' 0 N--CA 1.494 1.769 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 -179.537 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 85.9 -160.55 33.97 Favored Glycine 0 N--CA 1.502 3.049 0 N-CA-C 108.773 -1.731 . . . . 0.0 108.773 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.414 ' HG2' ' O ' ' A' ' 44' ' ' GLY . 68.6 Cg_endo -64.9 -171.0 3.02 Favored 'Cis proline' 0 N--CA 1.507 2.286 0 CA-C-N 118.305 1.053 . . . . 0.0 114.74 -1.551 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 20.9 m120 -92.96 -8.27 43.59 Favored 'General case' 0 N--CA 1.487 1.377 0 N-CA-C 104.616 -2.364 . . . . 0.0 104.616 -179.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 9.9 mm -106.22 32.0 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.961 0 CA-C-O 123.545 1.64 . . . . 0.0 113.782 -178.76 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.414 ' O ' ' HG2' ' A' ' 41' ' ' PRO . . . 124.72 -179.29 16.2 Favored Glycine 0 C--N 1.292 -1.879 1 N-CA-C 102.693 -4.163 . . . . 0.0 102.693 -179.977 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . 0.602 ' CD1' ' HA2' ' A' ' 28' ' ' GLY . 1.2 m95 -119.86 140.65 50.5 Favored 'General case' 0 C--N 1.277 -2.55 0 N-CA-C 103.775 -2.676 . . . . 0.0 103.775 179.709 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' CYS . . . . . 0.642 ' CB ' ' SG ' ' A' ' 36' ' ' CYS . 99.4 m -88.74 133.92 34.08 Favored 'General case' 0 N--CA 1.485 1.298 0 CA-C-N 121.756 2.071 . . . . 0.0 107.34 -179.912 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.516 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 87.3 m -133.71 178.32 7.03 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-N 110.892 -2.867 . . . . 0.0 110.443 -179.233 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.468 ' O ' ' HA ' ' A' ' 33' ' ' TRP . 0.0 OUTLIER -149.27 172.96 14.02 Favored 'General case' 0 C--N 1.304 -1.41 0 C-N-CA 117.525 -1.67 . . . . 0.0 111.757 179.776 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 24.8 mmtm . . . . . 0 N--CA 1.496 1.84 0 O-C-N 127.11 2.756 . . . . 0.0 109.413 179.976 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 2.693 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 13.0 t -96.11 141.88 23.77 Favored Pre-proline 0 N--CA 1.496 1.85 0 N-CA-C 107.988 -1.115 . . . . 0.0 107.988 -179.867 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.401 ' CB ' ' HG ' ' A' ' 18' ' ' LEU . 1.7 Cg_endo -79.32 135.19 11.83 Favored 'Trans proline' 0 C--N 1.308 -1.559 0 C-N-CA 124.352 3.368 . . . . 0.0 115.001 169.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.44 ' SG ' ' HB3' ' A' ' 22' ' ' LEU . 0.0 OUTLIER -119.46 -178.12 3.53 Favored 'General case' 0 N--CA 1.494 1.772 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.563 179.662 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 6.4 tt -98.5 113.65 25.74 Favored 'General case' 0 N--CA 1.497 1.908 0 N-CA-C 104.962 -2.236 . . . . 0.0 104.962 -179.836 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.44 ' HB2' ' HB2' ' A' ' 9' ' ' ASP . 5.5 m -88.57 -169.01 2.38 Favored 'General case' 0 N--CA 1.487 1.387 0 N-CA-C 119.1 3.0 . . . . 0.0 119.1 -179.179 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 10.8 t0 -66.0 -83.66 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.394 0 CA-C-N 111.876 -2.42 . . . . 0.0 112.562 -179.655 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 1.4 m -55.33 -20.95 13.07 Favored 'General case' 0 N--CA 1.498 1.97 0 CA-C-O 121.53 0.681 . . . . 0.0 110.928 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.44 ' HB2' ' HB2' ' A' ' 6' ' ' CYS . 45.2 t0 -46.69 -62.04 1.56 Allowed 'General case' 0 C--N 1.303 -1.443 0 CA-C-N 112.571 -2.104 . . . . 0.0 114.681 -179.912 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 52.76 -144.62 21.71 Favored Glycine 0 N--CA 1.498 2.793 0 N-CA-C 108.139 -1.984 . . . . 0.0 108.139 -179.514 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER -83.75 19.14 1.4 Allowed 'Trans proline' 0 N--CA 1.494 1.514 0 C-N-CA 123.984 3.123 . . . . 0.0 113.092 170.8 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 93.6 mtt-85 -132.28 80.28 63.95 Favored Pre-proline 0 N--CA 1.502 2.175 0 N-CA-C 114.52 1.304 . . . . 0.0 114.52 -179.692 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -68.06 143.59 60.43 Favored 'Trans proline' 0 N--CA 1.5 1.863 0 C-N-CA 124.667 3.578 . . . . 0.0 110.575 171.027 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 74.6 mtm180 -101.26 105.23 16.3 Favored 'General case' 0 N--CA 1.499 2.005 0 CA-C-O 122.163 0.983 . . . . 0.0 112.255 -179.848 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 129.17 37.0 0.4 Allowed Glycine 0 N--CA 1.499 2.891 0 N-CA-C 109.31 -1.516 . . . . 0.0 109.31 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 35.9 m-80 77.02 -48.42 0.53 Allowed 'General case' 0 N--CA 1.509 2.499 0 C-N-CA 124.393 1.077 . . . . 0.0 108.954 -179.842 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 7.8 t -150.33 -176.28 5.41 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 106.643 -1.614 . . . . 0.0 106.643 179.786 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.401 ' HG ' ' CB ' ' A' ' 3' ' ' PRO . 4.7 mp 63.53 136.54 0.02 OUTLIER 'General case' 0 N--CA 1.507 2.4 0 O-C-N 125.114 1.509 . . . . 0.0 111.087 -179.546 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 22.8 t -129.91 -10.48 4.35 Favored 'General case' 0 N--CA 1.499 2.003 0 C-N-CA 118.436 -1.305 . . . . 0.0 112.725 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.546 ' HA3' ' SG ' ' A' ' 36' ' ' CYS . . . 174.28 131.53 1.42 Allowed Glycine 0 N--CA 1.48 1.605 0 N-CA-C 108.341 -1.903 . . . . 0.0 108.341 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.493 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 49.7 mm -93.12 132.33 37.64 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.12 0 C-N-CA 116.593 -2.043 . . . . 0.0 105.565 179.851 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.581 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.9 pp -63.0 149.0 46.01 Favored 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 107.276 -1.379 . . . . 0.0 107.276 179.444 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.441 ' CE2' ' HG3' ' A' ' 30' ' ' PRO . 28.5 m95 -129.78 136.83 50.07 Favored 'General case' 0 C--N 1.3 -1.567 0 CA-C-O 124.008 1.861 . . . . 0.0 115.439 -179.812 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -89.11 47.67 1.52 Allowed 'General case' 0 C--N 1.294 -1.845 0 CA-C-N 108.914 -3.766 . . . . 0.0 112.499 -179.809 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 1.1 m-30 -117.33 143.46 32.0 Favored Pre-proline 0 C--N 1.306 -1.322 0 CA-C-O 122.537 1.161 . . . . 0.0 110.362 179.604 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 15.7 Cg_endo -77.19 -35.18 1.82 Allowed 'Trans proline' 0 C--N 1.301 -1.96 0 C-N-CA 123.622 2.881 . . . . 0.0 110.578 175.829 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 10.9 p -89.46 38.77 0.92 Allowed 'General case' 0 N--CA 1.49 1.536 0 CA-C-N 114.61 -1.177 . . . . 0.0 112.38 -179.626 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 73.17 -135.16 20.83 Favored Glycine 0 N--CA 1.5 2.955 0 N-CA-C 108.07 -2.012 . . . . 0.0 108.07 -179.864 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.478 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 15.3 m -72.22 156.18 90.84 Favored Pre-proline 0 C--N 1.304 -1.406 0 CA-C-N 118.793 1.297 . . . . 0.0 111.471 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.726 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.4 OUTLIER -79.71 159.13 24.97 Favored 'Trans proline' 0 C--N 1.307 -1.617 0 C-N-CA 123.281 2.654 . . . . 0.0 111.831 166.597 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 42.0 t -50.07 134.27 22.1 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 113.334 -1.757 . . . . 0.0 109.299 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 95.4 -4.57 67.03 Favored Glycine 0 N--CA 1.498 2.773 0 CA-C-N 112.396 -2.184 . . . . 0.0 111.896 179.835 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' TRP . . . . . 0.726 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 56.4 m95 -112.95 157.2 21.78 Favored 'General case' 0 C--N 1.304 -1.391 0 N-CA-C 105.29 -2.115 . . . . 0.0 105.29 -179.855 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . 0.419 ' O ' ' ND1' ' A' ' 34' ' ' HIS . 65.1 t-80 -140.45 41.49 1.89 Allowed 'General case' 0 C--N 1.299 -1.593 0 C-N-CA 118.291 -1.363 . . . . 0.0 112.084 -179.914 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . 0.478 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 0.2 OUTLIER 63.17 138.37 0.02 OUTLIER 'General case' 0 N--CA 1.505 2.316 0 N-CA-C 115.74 1.755 . . . . 0.0 115.74 179.412 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.608 ' SG ' ' CB ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -114.9 -40.74 3.46 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 105.843 -1.91 . . . . 0.0 105.843 179.775 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . 0.447 ' C ' HD21 ' A' ' 35' ' ' ASN . 21.3 ptmt -138.41 149.32 45.4 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 106.864 -1.532 . . . . 0.0 106.864 179.64 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.452 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -120.0 35.43 4.86 Favored 'General case' 0 C--N 1.293 -1.85 0 N-CA-C 102.506 -3.146 . . . . 0.0 102.506 179.881 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . 0.452 ' ND1' ' C ' ' A' ' 38' ' ' ALA . 3.7 m-70 -127.57 54.9 1.65 Allowed 'General case' 0 N--CA 1.498 1.951 0 N-CA-C 108.404 -0.961 . . . . 0.0 108.404 -179.625 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 74.0 -148.86 40.24 Favored Glycine 0 N--CA 1.496 2.65 0 N-CA-C 105.604 -2.998 . . . . 0.0 105.604 -179.658 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.439 ' HG2' ' O ' ' A' ' 44' ' ' GLY . 51.2 Cg_endo -65.64 -172.63 4.43 Favored 'Cis proline' 0 N--CA 1.501 1.915 0 CA-C-N 119.088 1.444 . . . . 0.0 111.713 -1.4 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 14.3 m120 -93.58 0.52 56.63 Favored 'General case' 0 C--N 1.307 -1.273 0 N-CA-C 104.144 -2.539 . . . . 0.0 104.144 -179.679 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 8.4 mt -116.64 35.02 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 N-CA-C 116.043 1.868 . . . . 0.0 116.043 -178.846 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.439 ' O ' ' HG2' ' A' ' 41' ' ' PRO . . . 119.81 139.76 5.98 Favored Glycine 0 N--CA 1.499 2.846 0 CA-C-N 114.004 -1.453 . . . . 0.0 110.642 179.721 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . 0.416 ' O ' ' N ' ' A' ' 23' ' ' TRP . 6.4 m95 -78.22 129.85 35.59 Favored 'General case' 0 N--CA 1.503 2.194 0 CA-C-O 117.783 -1.103 . . . . 0.0 111.096 -179.267 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' CYS . . . . . 0.608 ' CB ' ' SG ' ' A' ' 36' ' ' CYS . 66.2 m -87.71 122.67 31.66 Favored 'General case' 0 C--N 1.308 -1.204 1 N-CA-C 99.791 -4.152 . . . . 0.0 99.791 179.436 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.56 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 88.8 m -129.18 -178.84 4.81 Favored 'General case' 0 CA--C 1.476 -1.894 0 CA-C-N 109.895 -3.321 . . . . 0.0 111.205 -179.398 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.425 ' HD2' ' H ' ' A' ' 49' ' ' LYS . 24.2 tptp -150.52 152.01 33.53 Favored 'General case' 0 C--N 1.294 -1.846 0 C-N-CA 117.675 -1.61 . . . . 0.0 109.987 -179.84 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . 0.425 ' H ' ' HD2' ' A' ' 48' ' ' LYS . 51.2 mtpt . . . . . 0 N--CA 1.5 2.054 0 O-C-N 126.197 2.186 . . . . 0.0 111.899 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.495 2.585 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 33.0 t -97.25 135.59 21.8 Favored Pre-proline 0 N--CA 1.497 1.885 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.5 ' HB2' ' HA ' ' A' ' 18' ' ' LEU . 3.0 Cg_endo -77.27 127.77 9.32 Favored 'Trans proline' 0 N--CA 1.493 1.475 0 C-N-CA 124.523 3.482 . . . . 0.0 116.458 170.048 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.526 ' SG ' ' HB3' ' A' ' 22' ' ' LEU . 0.5 OUTLIER -121.08 179.46 4.38 Favored 'General case' 0 C--N 1.301 -1.508 0 CA-C-N 114.624 -1.171 . . . . 0.0 111.13 179.786 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 6.7 tp -91.68 145.98 24.15 Favored 'General case' 0 N--CA 1.491 1.594 0 N-CA-C 104.625 -2.361 . . . . 0.0 104.625 179.874 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.613 ' HB2' ' HB2' ' A' ' 9' ' ' ASP . 6.9 m -119.42 -170.4 1.93 Allowed 'General case' 0 N--CA 1.491 1.583 0 N-CA-C 113.911 1.078 . . . . 0.0 113.911 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -86.74 -50.46 6.74 Favored 'General case' 0 N--CA 1.497 1.887 0 CA-C-N 113.614 -1.63 . . . . 0.0 109.353 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -67.21 -32.23 73.14 Favored 'General case' 0 N--CA 1.492 1.664 0 CA-C-N 111.881 -2.418 . . . . 0.0 107.157 179.668 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.613 ' HB2' ' HB2' ' A' ' 6' ' ' CYS . 63.1 t0 -49.43 -69.71 0.11 Allowed 'General case' 0 N--CA 1.497 1.878 0 CA-C-N 112.052 -2.34 . . . . 0.0 109.326 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 63.53 165.7 0.75 Allowed Glycine 0 N--CA 1.488 2.137 0 CA-C-N 113.261 -1.79 . . . . 0.0 111.572 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_endo -79.23 39.04 0.77 Allowed 'Trans proline' 0 C--N 1.308 -1.603 0 C-N-CA 123.882 3.055 . . . . 0.0 110.149 175.559 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.0 mpt_? -89.51 158.97 45.0 Favored Pre-proline 0 N--CA 1.493 1.717 0 CA-C-N 115.462 -0.79 . . . . 0.0 112.578 -179.607 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -72.67 58.93 3.3 Favored 'Trans proline' 0 N--CA 1.495 1.562 0 C-N-CA 124.424 3.416 . . . . 0.0 112.132 174.537 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -173.77 116.9 0.25 Allowed 'General case' 0 N--CA 1.493 1.721 0 CA-C-N 113.683 -1.599 . . . . 0.0 110.424 179.873 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 54.7 32.19 54.09 Favored Glycine 0 N--CA 1.504 3.202 0 N-CA-C 110.187 -1.165 . . . . 0.0 110.187 -179.909 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 -60.59 -44.53 96.13 Favored 'General case' 0 N--CA 1.503 2.188 0 CA-C-O 121.982 0.896 . . . . 0.0 109.819 -179.793 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.0 t -104.19 155.47 18.69 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 104.487 -2.412 . . . . 0.0 104.487 179.807 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.5 ' HA ' ' HB2' ' A' ' 3' ' ' PRO . 2.3 tt 38.51 66.6 0.49 Allowed 'General case' 0 N--CA 1.499 2.012 0 O-C-N 125.11 1.506 . . . . 0.0 108.911 -179.52 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -88.66 52.98 2.57 Favored 'General case' 0 N--CA 1.498 1.937 0 CA-C-N 113.781 -1.554 . . . . 0.0 109.368 -179.339 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 101.43 -165.61 18.19 Favored Glycine 0 N--CA 1.502 3.047 0 CA-C-N 114.382 -1.281 . . . . 0.0 111.21 179.804 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.437 HG22 ' O ' ' A' ' 22' ' ' LEU . 28.8 mm -133.88 147.52 30.59 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.265 0 N-CA-C 112.744 0.646 . . . . 0.0 112.744 -179.94 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.588 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 2.8 pp -69.85 152.77 44.16 Favored 'General case' 0 N--CA 1.492 1.644 0 CA-C-N 114.919 -1.037 . . . . 0.0 108.819 179.499 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.678 ' HB2' ' SG ' ' A' ' 29' ' ' CYS . 28.3 m95 -131.93 135.32 46.52 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-O 125.045 2.355 . . . . 0.0 115.986 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.5 m-85 -88.84 54.34 2.98 Favored 'General case' 0 C--N 1.292 -1.892 1 CA-C-N 107.641 -4.345 . . . . 0.0 110.131 -179.669 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.551 ' CE1' ' HB3' ' A' ' 30' ' ' PRO . 2.2 m-85 -123.82 115.88 27.84 Favored Pre-proline 0 N--CA 1.491 1.618 0 CA-C-N 115.497 -0.774 . . . . 0.0 112.656 179.654 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -64.03 -11.85 29.35 Favored 'Trans proline' 0 C--N 1.308 -1.557 0 C-N-CA 123.389 2.726 . . . . 0.0 111.948 -175.412 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 6.6 p -108.93 3.93 22.8 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-N 115.37 -0.832 . . . . 0.0 111.025 179.753 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.4 ' O ' ' CD1' ' A' ' 45' ' ' TRP . . . 126.45 -113.21 1.75 Allowed Glycine 0 N--CA 1.502 3.058 0 N-CA-C 108.727 -1.749 . . . . 0.0 108.727 -179.913 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.678 ' SG ' ' HB2' ' A' ' 23' ' ' TRP . 18.4 m -132.36 156.54 79.98 Favored Pre-proline 0 C--N 1.305 -1.357 0 CA-C-N 117.701 0.75 . . . . 0.0 110.687 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.737 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 9.0 Cg_endo -78.68 162.04 27.39 Favored 'Trans proline' 0 C--N 1.306 -1.68 0 C-N-CA 123.335 2.69 . . . . 0.0 113.323 -167.196 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 22.9 t -51.32 116.43 2.05 Favored 'General case' 0 C--N 1.302 -1.487 0 CA-C-N 113.292 -1.776 . . . . 0.0 110.473 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 115.5 -7.61 20.37 Favored Glycine 0 N--CA 1.499 2.87 0 CA-C-N 113.744 -1.571 . . . . 0.0 111.529 179.761 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' TRP . . . . . 0.737 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 49.9 m95 -109.22 158.94 17.35 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 104.77 -2.307 . . . . 0.0 104.77 -179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 78.3 t60 -138.34 33.04 2.31 Favored 'General case' 0 C--N 1.298 -1.666 0 C-N-CA 118.05 -1.46 . . . . 0.0 114.074 -179.598 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . 0.774 ' HA ' ' SG ' ' A' ' 47' ' ' CYS . 5.1 m-20 57.34 137.35 0.0 OUTLIER 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 116.648 2.092 . . . . 0.0 116.648 -179.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.587 ' SG ' ' HB3' ' A' ' 46' ' ' CYS . 0.6 OUTLIER -112.06 -40.13 4.3 Favored 'General case' 0 N--CA 1.489 1.489 0 CA-C-N 115.015 -0.993 . . . . 0.0 108.931 -179.644 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . 0.548 ' HD2' ' HA ' ' A' ' 6' ' ' CYS . 51.9 tttt -132.87 143.38 49.48 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 107.356 -1.349 . . . . 0.0 107.356 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.441 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -119.47 30.08 7.28 Favored 'General case' 0 N--CA 1.493 1.721 0 N-CA-C 104.772 -2.307 . . . . 0.0 104.772 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . 0.482 ' H ' ' HG2' ' A' ' 37' ' ' LYS . 4.5 m-70 -134.75 62.18 1.65 Allowed 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 107.023 -1.473 . . . . 0.0 107.023 -179.564 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 75.75 -155.94 47.22 Favored Glycine 0 N--CA 1.498 2.798 0 N-CA-C 106.213 -2.755 . . . . 0.0 106.213 -179.728 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_endo -74.09 -169.38 7.0 Favored 'Cis proline' 0 N--CA 1.496 1.669 0 CA-C-N 118.922 1.361 . . . . 0.0 113.923 -0.682 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 10.0 p30 -92.33 -14.66 28.43 Favored 'General case' 0 CA--C 1.486 -1.506 0 N-CA-C 105.992 -1.855 . . . . 0.0 105.992 -179.606 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 31.6 pt -90.28 24.17 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 O-C-N 125.277 1.61 . . . . 0.0 113.978 -179.431 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 114.37 137.79 6.6 Favored Glycine 0 N--CA 1.493 2.472 0 CA-C-N 113.246 -1.797 . . . . 0.0 109.696 -179.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . 0.426 ' O ' ' N ' ' A' ' 23' ' ' TRP . 7.9 m95 -61.53 136.4 58.01 Favored 'General case' 0 N--CA 1.519 3.006 0 CA-C-O 117.317 -1.325 . . . . 0.0 108.421 -179.643 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' CYS . . . . . 0.588 ' HA ' ' HA ' ' A' ' 22' ' ' LEU . 93.0 m -89.9 127.08 35.94 Favored 'General case' 0 N--CA 1.482 1.141 0 CA-C-N 122.26 2.3 . . . . 0.0 105.127 -179.921 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.774 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 93.7 m -136.45 -171.82 3.0 Favored 'General case' 0 C--N 1.3 -1.563 0 CA-C-N 111.327 -2.67 . . . . 0.0 111.005 -179.409 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.538 ' O ' ' HA ' ' A' ' 33' ' ' TRP . 0.0 OUTLIER -151.31 172.29 16.12 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 179.574 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 47.4 mtpt . . . . . 0 C--N 1.291 -1.969 0 O-C-N 126.704 2.503 . . . . 0.0 110.347 179.828 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 2.656 0 N-CA-C 109.314 -1.514 . . . . 0.0 109.314 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 29.6 t -89.57 137.34 28.84 Favored Pre-proline 0 N--CA 1.496 1.852 0 C-N-CA 118.779 -1.168 . . . . 0.0 109.407 -179.78 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -67.27 135.57 37.36 Favored 'Trans proline' 0 N--CA 1.493 1.455 0 C-N-CA 122.333 2.022 . . . . 0.0 110.24 170.051 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -134.06 175.8 9.15 Favored 'General case' 0 N--CA 1.497 1.918 0 CA-C-O 121.563 0.697 . . . . 0.0 112.242 -179.724 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -101.55 141.89 33.74 Favored 'General case' 0 N--CA 1.494 1.732 0 N-CA-C 104.067 -2.568 . . . . 0.0 104.067 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.437 ' HB3' ' C ' ' A' ' 36' ' ' CYS . 1.8 m -113.14 -138.8 0.38 Allowed 'General case' 0 N--CA 1.497 1.892 0 N-CA-C 120.395 3.48 . . . . 0.0 120.395 -178.95 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -60.39 -15.79 29.47 Favored 'General case' 0 N--CA 1.507 2.391 0 O-C-N 120.969 -1.082 . . . . 0.0 110.388 -179.828 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 31.7 t -92.81 9.28 35.9 Favored 'General case' 0 N--CA 1.503 2.194 0 N-CA-C 107.383 -1.34 . . . . 0.0 107.383 179.347 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.402 ' CB ' ' O ' ' A' ' 6' ' ' CYS . 19.1 t70 -81.02 79.2 7.74 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 106.802 -1.555 . . . . 0.0 106.802 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.4 ' C ' ' H ' ' A' ' 12' ' ' ARG . . . -73.27 -157.25 4.15 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 106.755 -2.538 . . . . 0.0 106.755 179.62 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 17.6 Cg_endo -75.36 41.35 0.77 Allowed 'Trans proline' 0 N--CA 1.497 1.697 0 C-N-CA 124.502 3.468 . . . . 0.0 110.448 179.332 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.4 ' H ' ' C ' ' A' ' 10' ' ' GLY . 7.9 ttt85 -122.09 135.53 25.48 Favored Pre-proline 0 C--N 1.304 -1.375 0 N-CA-C 106.953 -1.499 . . . . 0.0 106.953 -179.854 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -62.25 154.94 59.78 Favored 'Trans proline' 0 C--N 1.311 -1.418 0 C-N-CA 123.323 2.682 . . . . 0.0 115.113 -177.104 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 35.1 ptt180 -70.26 149.33 47.55 Favored 'General case' 0 N--CA 1.489 1.51 0 CA-C-N 111.648 -2.524 . . . . 0.0 108.595 179.849 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 102.88 -30.62 10.04 Favored Glycine 0 N--CA 1.498 2.806 0 N-CA-C 109.619 -1.392 . . . . 0.0 109.619 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 15.4 m-20 -45.26 -41.91 9.04 Favored 'General case' 0 N--CA 1.502 2.152 0 CA-C-O 121.611 0.72 . . . . 0.0 112.378 179.835 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 6.9 t -150.29 153.89 36.94 Favored 'General case' 0 N--CA 1.49 1.563 0 N-CA-C 107.268 -1.382 . . . . 0.0 107.268 179.814 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 34.7 mt -106.98 91.08 3.51 Favored 'General case' 0 N--CA 1.496 1.867 0 N-CA-C 105.075 -2.195 . . . . 0.0 105.075 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 7.1 m -90.16 21.95 3.52 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 115.644 1.72 . . . . 0.0 115.644 -179.571 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 148.69 -163.69 29.05 Favored Glycine 0 N--CA 1.497 2.743 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.517 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 35.5 mm -135.98 146.42 29.43 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.088 0 CA-C-O 122.487 1.137 . . . . 0.0 109.878 179.852 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.546 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 0.9 OUTLIER -69.69 134.79 49.06 Favored 'General case' 0 C--N 1.297 -1.693 0 CA-C-N 114.654 -1.157 . . . . 0.0 108.625 179.826 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.421 ' CE2' ' HG3' ' A' ' 30' ' ' PRO . 44.5 m95 -124.04 134.18 53.48 Favored 'General case' 0 N--CA 1.484 1.242 0 N-CA-C 118.96 2.948 . . . . 0.0 118.96 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 2.2 m-30 -88.93 39.58 0.94 Allowed 'General case' 0 C--N 1.296 -1.718 1 CA-C-N 107.366 -4.47 . . . . 0.0 113.064 -179.584 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.42 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 1.2 m-30 -113.07 125.13 30.25 Favored Pre-proline 0 C--N 1.304 -1.402 0 CA-C-O 122.697 1.237 . . . . 0.0 112.271 -179.935 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -66.21 -25.26 50.36 Favored 'Trans proline' 0 C--N 1.302 -1.872 0 C-N-CA 122.507 2.138 . . . . 0.0 108.341 -177.731 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 5.8 p -87.01 5.03 39.44 Favored 'General case' 0 N--CA 1.49 1.536 0 CA-C-N 114.375 -1.284 . . . . 0.0 112.468 179.926 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 110.65 -118.57 5.0 Favored Glycine 0 N--CA 1.498 2.806 0 N-CA-C 106.238 -2.745 . . . . 0.0 106.238 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.51 ' HB3' ' HB2' ' A' ' 33' ' ' TRP . 37.4 m -96.65 153.79 38.65 Favored Pre-proline 0 C--N 1.303 -1.446 0 N-CA-C 106.726 -1.583 . . . . 0.0 106.726 179.735 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.748 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.8 OUTLIER -76.34 169.47 21.89 Favored 'Trans proline' 0 C--N 1.305 -1.726 0 C-N-CA 123.077 2.518 . . . . 0.0 113.829 174.588 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 5.7 m -46.17 103.83 0.04 OUTLIER 'General case' 0 C--N 1.298 -1.633 0 CA-C-N 112.01 -2.359 . . . . 0.0 113.99 -179.854 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 109.11 2.68 31.62 Favored Glycine 0 N--CA 1.501 2.996 0 C-N-CA 120.811 -0.709 . . . . 0.0 114.293 179.481 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' TRP . . . . . 0.748 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 44.7 m95 -110.82 164.81 12.39 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 106.999 -1.482 . . . . 0.0 106.999 -179.954 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 57.7 t-80 -144.76 37.23 1.18 Allowed 'General case' 0 N--CA 1.499 1.992 0 C-N-CA 117.757 -1.577 . . . . 0.0 113.072 -179.722 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . 0.504 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 24.0 t-20 58.43 146.48 0.01 OUTLIER 'General case' 0 N--CA 1.501 2.098 0 CA-C-N 113.248 -1.797 . . . . 0.0 114.673 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.64 ' SG ' ' SG ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -121.09 -46.67 2.31 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 106.013 -1.847 . . . . 0.0 106.013 179.974 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 13.1 ttmt -107.94 102.08 11.29 Favored 'General case' 0 C--N 1.301 -1.502 0 CA-C-N 113.315 -1.766 . . . . 0.0 108.618 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -83.36 12.28 5.66 Favored 'General case' 0 N--CA 1.496 1.869 0 CA-C-N 113.31 -1.768 . . . . 0.0 107.713 179.511 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . . . . . . . . . 7.4 m-70 -127.22 37.71 4.21 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-N 114.878 -1.055 . . . . 0.0 109.208 -179.667 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 96.23 -149.56 19.35 Favored Glycine 0 N--CA 1.498 2.768 0 CA-C-N 114.538 -1.21 . . . . 0.0 111.267 179.586 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.45 ' HB2' HG12 ' A' ' 43' ' ' ILE . 3.5 Cg_endo -75.5 -173.84 13.2 Favored 'Cis proline' 0 N--CA 1.5 1.861 0 N-CA-C 109.386 -1.044 . . . . 0.0 109.386 1.496 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.476 ' C ' ' H ' ' A' ' 44' ' ' GLY . 56.5 t30 -92.27 -11.97 33.81 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 105.463 -2.051 . . . . 0.0 105.463 -179.783 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.45 HG12 ' HB2' ' A' ' 41' ' ' PRO . 30.5 pt -85.66 28.92 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 CA-C-O 123.302 1.525 . . . . 0.0 112.741 -179.192 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.476 ' H ' ' C ' ' A' ' 42' ' ' ASN . . . 116.98 142.57 7.34 Favored Glycine 0 C--N 1.295 -1.71 0 CA-C-N 110.528 -3.033 . . . . 0.0 106.153 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . 0.42 ' NE1' ' O ' ' A' ' 25' ' ' TYR . 6.9 m95 -77.81 133.77 38.14 Favored 'General case' 0 C--N 1.293 -1.849 0 N-CA-C 104.674 -2.343 . . . . 0.0 104.674 -179.534 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' CYS . . . . . 0.64 ' SG ' ' SG ' ' A' ' 36' ' ' CYS . 46.0 t -89.22 129.14 35.84 Favored 'General case' 0 N--CA 1.485 1.318 1 N-CA-C 99.319 -4.326 . . . . 0.0 99.319 179.773 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.524 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 77.3 m -127.88 -170.53 2.25 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-N 113.096 -1.866 . . . . 0.0 110.254 -179.363 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.08 172.3 15.98 Favored 'General case' 0 C--N 1.298 -1.674 0 N-CA-C 107.599 -1.26 . . . . 0.0 107.599 179.311 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 65.3 mttt . . . . . 0 N--CA 1.498 1.961 0 O-C-N 126.267 2.229 . . . . 0.0 108.189 179.267 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.498 2.831 0 N-CA-C 109.993 -1.243 . . . . 0.0 109.993 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 46.8 t -112.98 134.94 21.69 Favored Pre-proline 0 N--CA 1.499 2.01 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.401 ' HB2' ' HB3' ' A' ' 18' ' ' LEU . 26.6 Cg_endo -73.11 116.03 4.56 Favored 'Trans proline' 0 C--N 1.308 -1.566 0 C-N-CA 122.877 2.384 . . . . 0.0 114.473 170.664 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.533 ' SG ' ' HB2' ' A' ' 22' ' ' LEU . 0.8 OUTLIER -122.15 163.94 18.65 Favored 'General case' 0 N--CA 1.494 1.774 0 CA-C-N 113.037 -1.892 . . . . 0.0 108.839 -179.799 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.432 HD12 ' HA ' ' A' ' 5' ' ' LEU . 12.2 tp -89.61 174.82 7.54 Favored 'General case' 0 N--CA 1.497 1.886 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 -179.895 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.455 ' HB3' ' C ' ' A' ' 36' ' ' CYS . 1.8 m -135.26 -143.25 0.19 Allowed 'General case' 0 N--CA 1.501 2.097 1 N-CA-C 122.131 4.123 . . . . 0.0 122.131 -178.738 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -56.55 -31.63 64.36 Favored 'General case' 0 N--CA 1.497 1.89 0 C-N-CA 118.405 -1.318 . . . . 0.0 108.813 -179.523 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 24.9 m -80.42 13.93 2.23 Favored 'General case' 0 N--CA 1.497 1.888 0 C-N-CA 119.469 -0.892 . . . . 0.0 110.246 179.689 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.416 ' HB3' ' O ' ' A' ' 6' ' ' CYS . 5.6 t0 -75.06 63.85 1.3 Allowed 'General case' 0 N--CA 1.502 2.166 0 CA-C-O 121.928 0.87 . . . . 0.0 109.13 179.845 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -148.43 -169.82 15.7 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 107.401 -2.28 . . . . 0.0 107.401 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_endo -76.24 34.23 0.43 Allowed 'Trans proline' 0 N--CA 1.499 1.834 1 C-N-CA 125.434 4.089 . . . . 0.0 114.789 -162.779 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 29.7 mtp180 -119.3 122.94 29.07 Favored Pre-proline 0 N--CA 1.498 1.942 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.068 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 17.4 Cg_endo -72.08 60.22 3.07 Favored 'Trans proline' 0 N--CA 1.501 1.919 0 C-N-CA 123.742 2.961 . . . . 0.0 114.472 -174.859 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . 0.4 ' C ' ' H ' ' A' ' 16' ' ' ASN . 86.5 mtt-85 -147.13 136.87 23.03 Favored 'General case' 0 N--CA 1.489 1.498 0 CA-C-N 113.882 -1.508 . . . . 0.0 107.951 179.991 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.405 ' O ' ' N ' ' A' ' 17' ' ' THR . . . 76.35 -39.38 1.45 Allowed Glycine 0 N--CA 1.499 2.842 0 C-N-CA 120.789 -0.72 . . . . 0.0 111.945 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . 0.592 HD22 ' N ' ' A' ' 17' ' ' THR . 0.5 OUTLIER -22.53 -41.2 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.333 0 N-CA-C 117.696 2.48 . . . . 0.0 117.696 -179.807 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.592 ' N ' HD22 ' A' ' 16' ' ' ASN . 0.7 OUTLIER -96.14 99.97 11.66 Favored 'General case' 0 C--N 1.297 -1.687 0 N-CA-C 114.286 1.217 . . . . 0.0 114.286 -179.463 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.401 ' HB3' ' HB2' ' A' ' 3' ' ' PRO . 25.8 mt 31.77 55.26 0.3 Allowed 'General case' 0 N--CA 1.502 2.146 0 N-CA-C 116.014 1.857 . . . . 0.0 116.014 179.399 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 80.5 p -89.06 57.63 4.19 Favored 'General case' 0 C--N 1.3 -1.544 0 C-N-CA 119.896 -0.722 . . . . 0.0 111.697 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 153.28 161.58 10.43 Favored Glycine 0 N--CA 1.5 2.926 0 C-N-CA 119.512 -1.328 . . . . 0.0 112.775 179.46 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.458 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 49.1 mm -124.07 137.83 55.75 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.176 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 179.57 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.533 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 34.7 tp -63.99 144.58 56.98 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 179.659 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 42.4 m95 -131.52 134.08 45.75 Favored 'General case' 0 C--N 1.308 -1.236 0 N-CA-C 119.428 3.122 . . . . 0.0 119.428 -179.568 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -88.87 54.45 3.02 Favored 'General case' 0 C--N 1.297 -1.675 1 CA-C-N 108.145 -4.116 . . . . 0.0 108.727 -179.962 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.48 ' CE1' ' HB3' ' A' ' 30' ' ' PRO . 2.4 m-85 -128.73 120.02 20.42 Favored Pre-proline 0 N--CA 1.486 1.368 0 CA-C-N 115.088 -0.96 . . . . 0.0 113.556 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.402 ' HD2' ' HA ' ' A' ' 25' ' ' TYR . 57.3 Cg_endo -67.25 -13.48 39.66 Favored 'Trans proline' 0 C--N 1.309 -1.526 0 C-N-CA 123.793 2.996 . . . . 0.0 110.918 -178.121 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 12.8 p -93.51 -9.23 39.03 Favored 'General case' 0 N--CA 1.491 1.609 0 CA-C-N 114.565 -1.198 . . . . 0.0 110.43 179.81 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.43 ' HA2' ' CD2' ' A' ' 45' ' ' TRP . . . 116.3 -106.96 1.57 Allowed Glycine 0 N--CA 1.482 1.724 1 N-CA-C 102.512 -4.235 . . . . 0.0 102.512 -179.702 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.602 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 16.7 m -99.36 151.66 37.5 Favored Pre-proline 0 C--N 1.301 -1.52 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.678 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.4 OUTLIER -79.46 164.57 23.73 Favored 'Trans proline' 0 C--N 1.306 -1.694 0 C-N-CA 123.005 2.47 . . . . 0.0 114.359 169.831 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 3.1 m -43.93 105.32 0.05 Allowed 'General case' 0 C--N 1.3 -1.581 0 CA-C-N 112.197 -2.274 . . . . 0.0 112.636 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 114.53 -4.12 23.22 Favored Glycine 0 N--CA 1.505 3.26 0 CA-C-N 115.665 -0.698 . . . . 0.0 113.495 179.581 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' TRP . . . . . 0.678 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 49.2 m95 -111.22 166.5 11.04 Favored 'General case' 0 N--CA 1.488 1.43 0 N-CA-C 107.061 -1.459 . . . . 0.0 107.061 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 55.0 t-80 -148.86 40.35 0.89 Allowed 'General case' 0 N--CA 1.505 2.312 0 C-N-CA 117.904 -1.518 . . . . 0.0 114.147 -179.856 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . 0.602 ' N ' ' SG ' ' A' ' 29' ' ' CYS . 1.5 t30 52.36 146.66 0.0 OUTLIER 'General case' 0 N--CA 1.499 1.986 0 CA-C-N 113.001 -1.909 . . . . 0.0 116.073 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.505 ' SG ' ' O ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -119.08 -41.14 2.77 Favored 'General case' 0 C--N 1.306 -1.29 0 CA-C-N 114.582 -1.19 . . . . 0.0 111.336 -179.805 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . 0.514 ' C ' ' H ' ' A' ' 39' ' ' HIS . 44.3 tttm -106.04 106.36 16.83 Favored 'General case' 0 N--CA 1.502 2.136 0 C-N-CA 119.014 -1.074 . . . . 0.0 108.384 179.655 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -65.8 16.66 0.02 OUTLIER 'General case' 0 N--CA 1.505 2.299 0 N-CA-C 113.049 0.759 . . . . 0.0 113.049 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . 0.514 ' H ' ' C ' ' A' ' 37' ' ' LYS . 5.3 m-70 -128.38 -4.84 5.42 Favored 'General case' 0 N--CA 1.494 1.745 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.03 179.947 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 133.97 -119.86 2.36 Favored Glycine 0 N--CA 1.509 3.506 0 C-N-CA 120.685 -0.769 . . . . 0.0 113.086 179.872 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -68.1 -170.82 5.04 Favored 'Cis proline' 0 N--CA 1.504 2.138 0 CA-C-N 118.609 1.205 . . . . 0.0 111.824 -1.669 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 10.0 t-20 -93.72 -5.5 48.3 Favored 'General case' 0 CA--C 1.492 -1.253 0 N-CA-C 106.083 -1.821 . . . . 0.0 106.083 -179.709 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 28.4 mt -94.81 32.14 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.104 0 CA-C-O 123.897 1.808 . . . . 0.0 110.737 -179.005 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 115.96 153.99 10.27 Favored Glycine 0 C--N 1.295 -1.737 1 N-CA-C 101.137 -4.785 . . . . 0.0 101.137 -179.692 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . 0.43 ' CD2' ' HA2' ' A' ' 28' ' ' GLY . 56.4 m95 -86.56 135.37 33.46 Favored 'General case' 0 N--CA 1.505 2.298 0 CA-C-O 116.475 -1.726 . . . . 0.0 108.057 -179.769 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' CYS . . . . . 0.509 ' HA ' ' HA ' ' A' ' 22' ' ' LEU . 59.3 m -92.65 121.18 33.81 Favored 'General case' 0 C--N 1.308 -1.212 1 N-CA-C 96.884 -5.228 . . . . 0.0 96.884 179.763 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.501 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 96.1 m -127.57 -174.57 3.22 Favored 'General case' 0 C--N 1.297 -1.712 0 CA-C-N 112.419 -2.173 . . . . 0.0 108.366 -179.351 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.36 173.14 14.86 Favored 'General case' 0 C--N 1.297 -1.705 0 N-CA-C 106.923 -1.51 . . . . 0.0 106.923 179.32 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 86.8 mttt . . . . . 0 C--N 1.289 -2.049 0 O-C-N 126.255 2.222 . . . . 0.0 106.593 179.337 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.495 2.576 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 19.4 t -89.92 141.11 27.88 Favored Pre-proline 0 N--CA 1.492 1.666 0 N-CA-C 106.939 -1.504 . . . . 0.0 106.939 -179.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.47 ' HA ' ' O ' ' A' ' 20' ' ' GLY . 11.0 Cg_endo -77.09 132.95 13.12 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 C-N-CA 123.246 2.63 . . . . 0.0 113.147 163.673 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -121.26 177.39 5.18 Favored 'General case' 0 N--CA 1.494 1.734 0 C-N-CA 119.966 -0.694 . . . . 0.0 112.038 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.448 HD23 ' N ' ' A' ' 6' ' ' CYS . 9.4 tt -94.12 150.86 19.94 Favored 'General case' 0 N--CA 1.493 1.687 0 N-CA-C 105.036 -2.209 . . . . 0.0 105.036 179.768 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.5 ' HB2' ' HB2' ' A' ' 9' ' ' ASP . 13.0 m -143.07 -174.85 4.3 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 124.683 1.239 . . . . 0.0 111.739 -179.337 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -78.24 -45.01 24.02 Favored 'General case' 0 N--CA 1.493 1.707 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 179.881 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 63.6 m -109.39 33.55 4.26 Favored 'General case' 0 N--CA 1.494 1.733 0 N-CA-C 106.72 -1.585 . . . . 0.0 106.72 179.705 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.5 ' HB2' ' HB2' ' A' ' 6' ' ' CYS . 0.8 OUTLIER -69.98 78.89 0.48 Allowed 'General case' 0 N--CA 1.501 2.107 0 CA-C-O 121.747 0.784 . . . . 0.0 112.109 -179.94 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 58.18 63.38 5.3 Favored Glycine 0 N--CA 1.504 3.205 0 CA-C-N 114.246 -1.343 . . . . 0.0 112.929 179.653 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 14.5 Cg_endo -71.19 25.86 0.22 Allowed 'Trans proline' 0 N--CA 1.503 2.037 1 C-N-CA 125.493 4.129 . . . . 0.0 115.224 -166.581 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.423 ' HD2' ' NH1' ' A' ' 14' ' ' ARG . 13.8 mtt-85 -140.76 162.07 50.79 Favored Pre-proline 0 N--CA 1.49 1.554 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 179.819 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_endo -67.86 64.01 0.93 Allowed 'Trans proline' 0 N--CA 1.497 1.729 0 C-N-CA 124.001 3.134 . . . . 0.0 113.765 -179.523 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . 0.48 ' C ' ' H ' ' A' ' 16' ' ' ASN . 47.7 mtm180 -137.47 136.19 37.51 Favored 'General case' 0 N--CA 1.493 1.702 0 N-CA-C 103.3 -2.852 . . . . 0.0 103.3 179.736 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.422 ' O ' ' HB2' ' A' ' 16' ' ' ASN . . . 77.58 -34.14 1.6 Allowed Glycine 0 N--CA 1.508 3.459 0 C-N-CA 120.155 -1.021 . . . . 0.0 110.874 -179.817 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . 0.48 ' H ' ' C ' ' A' ' 14' ' ' ARG . 1.2 m-80 81.46 -56.6 0.27 Allowed 'General case' 0 N--CA 1.505 2.298 0 C-N-CA 125.929 1.692 . . . . 0.0 106.626 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 86.6 m -151.0 155.92 40.07 Favored 'General case' 0 N--CA 1.497 1.918 0 N-CA-C 105.593 -2.002 . . . . 0.0 105.593 179.593 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 47.1 mt 71.68 111.79 0.06 Allowed 'General case' 0 N--CA 1.511 2.613 0 O-C-N 124.596 1.185 . . . . 0.0 110.593 179.874 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 5.5 t -144.64 32.27 1.17 Allowed 'General case' 0 N--CA 1.5 2.074 0 C-N-CA 120.019 -0.672 . . . . 0.0 110.079 -179.902 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.47 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -173.83 -178.01 43.46 Favored Glycine 0 N--CA 1.5 2.904 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.433 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 28.8 mm -134.43 144.11 36.03 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.361 0 N-CA-C 107.072 -1.455 . . . . 0.0 107.072 -179.801 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.504 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 3.4 pp -66.78 156.62 35.01 Favored 'General case' 0 N--CA 1.491 1.621 0 C-N-CA 118.606 -1.238 . . . . 0.0 108.968 179.715 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.424 ' CE2' ' HG3' ' A' ' 30' ' ' PRO . 35.7 m95 -136.84 134.15 36.63 Favored 'General case' 0 C--N 1.304 -1.371 0 N-CA-C 117.948 2.573 . . . . 0.0 117.948 -179.789 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -89.92 42.49 1.1 Allowed 'General case' 0 C--N 1.296 -1.735 1 CA-C-N 107.784 -4.28 . . . . 0.0 112.411 -179.788 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.445 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 1.3 m-30 -116.3 136.96 23.16 Favored Pre-proline 0 C--N 1.303 -1.418 0 CA-C-O 121.985 0.897 . . . . 0.0 108.749 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -70.02 -17.43 36.39 Favored 'Trans proline' 0 C--N 1.298 -2.082 0 C-N-CA 122.717 2.278 . . . . 0.0 108.607 179.84 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 10.6 p -95.71 23.54 6.1 Favored 'General case' 0 N--CA 1.488 1.445 0 CA-C-N 113.776 -1.556 . . . . 0.0 109.513 179.765 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.611 ' HA2' ' CG ' ' A' ' 45' ' ' TRP . . . 83.13 -94.33 1.76 Allowed Glycine 0 N--CA 1.487 2.053 0 N-CA-C 104.209 -3.556 . . . . 0.0 104.209 -179.677 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.579 ' SG ' ' N ' ' A' ' 35' ' ' ASN . 25.2 m -98.47 165.27 15.47 Favored Pre-proline 0 C--N 1.301 -1.515 0 CA-C-N 113.777 -1.211 . . . . 0.0 110.604 -179.934 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.711 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 0.1 OUTLIER -88.59 161.48 6.51 Favored 'Trans proline' 0 C--N 1.312 -1.393 1 C-N-CA 125.881 4.387 . . . . 0.0 115.818 156.241 . . . . . . . . 4 4 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 14.0 p -51.55 113.55 1.0 Allowed 'General case' 0 C--N 1.301 -1.512 0 CA-C-N 112.132 -2.303 . . . . 0.0 113.16 -179.758 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 115.94 -6.76 19.7 Favored Glycine 0 N--CA 1.502 3.097 0 O-C-N 124.842 1.339 . . . . 0.0 111.12 179.692 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' TRP . . . . . 0.711 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 42.6 m95 -110.06 173.13 6.47 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 106.156 -1.794 . . . . 0.0 106.156 -179.849 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 77.5 t60 -149.91 29.29 0.74 Allowed 'General case' 0 N--CA 1.496 1.841 0 C-N-CA 117.935 -1.506 . . . . 0.0 112.668 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . 0.588 ' HA ' ' SG ' ' A' ' 47' ' ' CYS . 1.8 t30 62.07 153.35 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.753 0 CA-C-N 114.245 -1.343 . . . . 0.0 111.637 -179.751 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.55 ' SG ' ' HB3' ' A' ' 46' ' ' CYS . 13.9 p -117.68 -39.95 3.08 Favored 'General case' 0 N--CA 1.499 2.024 0 N-CA-C 114.924 1.453 . . . . 0.0 114.924 -179.499 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . 0.481 ' HB2' ' HB3' ' A' ' 6' ' ' CYS . 74.0 tttt -131.4 132.12 44.13 Favored 'General case' 0 N--CA 1.5 2.047 0 N-CA-C 103.532 -2.766 . . . . 0.0 103.532 179.59 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -78.8 22.4 0.37 Allowed 'General case' 0 N--CA 1.495 1.802 0 C-N-CA 117.553 -1.659 . . . . 0.0 107.985 179.716 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . 0.429 ' H ' ' C ' ' A' ' 37' ' ' LYS . 9.5 m-70 -138.79 107.43 5.89 Favored 'General case' 0 N--CA 1.496 1.829 0 N-CA-C 113.713 1.005 . . . . 0.0 113.713 -179.395 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 60.78 -161.93 22.4 Favored Glycine 0 N--CA 1.502 3.08 0 CA-C-N 114.311 -1.313 . . . . 0.0 113.901 179.547 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.45 ' HD2' ' N ' ' A' ' 46' ' ' CYS . 73.0 Cg_endo -55.32 179.93 1.19 Allowed 'Cis proline' 0 N--CA 1.505 2.188 0 C-N-CA 129.362 0.984 . . . . 0.0 114.436 -5.499 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.2 m120 -92.98 -8.25 43.62 Favored 'General case' 0 C--N 1.306 -1.294 0 N-CA-C 104.496 -2.409 . . . . 0.0 104.496 -179.783 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 11.4 mm -100.96 28.86 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.02 0 CA-C-O 123.675 1.703 . . . . 0.0 113.86 -179.008 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 136.01 -131.65 5.81 Favored Glycine 0 N--CA 1.485 1.906 1 N-CA-C 101.762 -4.535 . . . . 0.0 101.762 179.888 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . 0.611 ' CG ' ' HA2' ' A' ' 28' ' ' GLY . 3.0 m95 -153.33 161.29 42.5 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 105.268 -2.123 . . . . 0.0 105.268 179.646 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' CYS . . . . . 0.55 ' HB3' ' SG ' ' A' ' 36' ' ' CYS . 19.3 m -111.54 133.97 53.45 Favored 'General case' 0 N--CA 1.498 1.943 0 CA-C-N 123.037 2.653 . . . . 0.0 104.278 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.588 ' SG ' ' HA ' ' A' ' 35' ' ' ASN . 79.0 m -135.12 -173.4 3.31 Favored 'General case' 0 C--N 1.293 -1.865 0 CA-C-N 111.287 -2.688 . . . . 0.0 108.143 -179.399 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -150.6 175.89 11.5 Favored 'General case' 0 C--N 1.294 -1.805 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 179.225 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . 0.473 ' HE3' ' CZ2' ' A' ' 33' ' ' TRP . 22.6 mmtp . . . . . 0 C--N 1.293 -1.861 0 CA-C-O 114.98 -2.438 . . . . 0.0 107.275 179.5 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 2.733 0 N-CA-C 110.46 -1.056 . . . . 0.0 110.46 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 45.7 t -112.58 135.61 21.52 Favored Pre-proline 0 N--CA 1.493 1.699 0 N-CA-C 104.916 -2.253 . . . . 0.0 104.916 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -70.61 135.19 27.85 Favored 'Trans proline' 0 C--N 1.306 -1.659 0 C-N-CA 123.481 2.787 . . . . 0.0 112.132 175.21 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -139.64 174.66 10.28 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 123.968 0.792 . . . . 0.0 111.869 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.523 HD12 ' HA ' ' A' ' 5' ' ' LEU . 13.6 tp -97.8 152.17 19.44 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 102.065 -3.309 . . . . 0.0 102.065 179.766 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.497 ' HB3' ' C ' ' A' ' 36' ' ' CYS . 2.7 m -115.44 -138.08 0.37 Allowed 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 121.007 3.706 . . . . 0.0 121.007 -178.669 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -52.34 -25.08 8.77 Favored 'General case' 0 N--CA 1.502 2.163 0 C-N-CA 119.643 -0.823 . . . . 0.0 111.706 -179.699 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 12.6 t -94.75 19.62 9.79 Favored 'General case' 0 N--CA 1.499 2.015 0 CA-C-O 121.752 0.786 . . . . 0.0 109.336 179.762 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -75.8 75.16 2.75 Favored 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 107.591 -1.263 . . . . 0.0 107.591 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -157.83 -84.52 0.05 OUTLIER Glycine 0 N--CA 1.489 2.22 0 CA-C-N 112.716 -2.038 . . . . 0.0 108.955 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_endo -76.17 37.85 0.56 Allowed 'Trans proline' 0 N--CA 1.5 1.911 1 C-N-CA 125.748 4.298 . . . . 0.0 112.512 -167.562 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 1.4 tpt180 -121.85 132.54 24.22 Favored Pre-proline 0 N--CA 1.495 1.799 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 -179.711 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -77.48 -166.87 0.42 Allowed 'Trans proline' 0 C--N 1.314 -1.243 0 C-N-CA 123.735 2.957 . . . . 0.0 111.499 176.888 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 54.7 mtt180 -74.57 158.09 34.32 Favored 'General case' 0 N--CA 1.494 1.77 0 N-CA-C 107.927 -1.138 . . . . 0.0 107.927 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 148.63 -44.17 0.77 Allowed Glycine 0 N--CA 1.498 2.804 0 N-CA-C 108.76 -1.736 . . . . 0.0 108.76 179.861 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 8.3 t-20 75.13 85.29 0.1 Allowed 'General case' 0 N--CA 1.501 2.098 0 CA-C-N 113.686 -1.257 . . . . 0.0 109.343 179.917 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.3 m -94.08 120.77 34.8 Favored 'General case' 0 N--CA 1.494 1.761 0 CA-C-N 113.76 -1.564 . . . . 0.0 109.195 -179.845 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 2.4 mp -66.26 88.34 0.12 Allowed 'General case' 0 N--CA 1.499 1.986 0 CA-C-O 121.391 0.615 . . . . 0.0 110.944 179.793 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 27.3 t -90.25 -16.82 28.6 Favored 'General case' 0 N--CA 1.5 2.04 0 CA-C-O 118.051 -0.976 . . . . 0.0 113.537 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.457 ' HA2' ' HD3' ' A' ' 48' ' ' LYS . . . -177.33 152.23 11.84 Favored Glycine 0 N--CA 1.501 2.985 0 C-N-CA 119.234 -1.46 . . . . 0.0 111.508 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.502 ' HB ' ' CZ3' ' A' ' 33' ' ' TRP . 38.8 mm -101.31 137.49 28.79 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.206 0 C-N-CA 117.3 -1.76 . . . . 0.0 106.718 179.623 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.53 ' HA ' ' HA ' ' A' ' 46' ' ' CYS . 30.8 tp -63.03 136.3 57.74 Favored 'General case' 0 C--N 1.295 -1.786 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 179.821 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 39.5 m95 -127.06 134.94 50.18 Favored 'General case' 0 C--N 1.31 -1.124 0 CA-C-O 125.397 2.522 . . . . 0.0 117.703 -179.848 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -88.73 40.65 0.98 Allowed 'General case' 0 C--N 1.295 -1.767 1 CA-C-N 107.669 -4.332 . . . . 0.0 113.98 -179.539 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.468 ' O ' ' NE1' ' A' ' 45' ' ' TRP . 1.2 m-30 -115.17 122.22 33.68 Favored Pre-proline 0 N--CA 1.489 1.514 0 CA-C-O 122.86 1.314 . . . . 0.0 113.909 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo -63.66 -23.32 69.93 Favored 'Trans proline' 0 C--N 1.301 -1.938 0 C-N-CA 122.268 1.978 . . . . 0.0 108.924 -173.077 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 10.6 p -93.27 8.83 38.74 Favored 'General case' 0 N--CA 1.492 1.635 0 CA-C-N 114.502 -1.227 . . . . 0.0 112.651 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 112.04 -118.63 4.78 Favored Glycine 0 N--CA 1.495 2.62 0 N-CA-C 107.001 -2.439 . . . . 0.0 107.001 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . 0.526 ' HB3' ' HB2' ' A' ' 33' ' ' TRP . 14.8 m -96.21 159.54 31.86 Favored Pre-proline 0 C--N 1.303 -1.444 0 N-CA-C 107.504 -1.295 . . . . 0.0 107.504 179.8 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.723 ' HG2' ' CD1' ' A' ' 33' ' ' TRP . 1.6 Cg_endo -78.35 159.56 29.38 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 C-N-CA 122.338 2.025 . . . . 0.0 112.126 169.588 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 27.9 t -49.61 121.97 5.79 Favored 'General case' 0 C--N 1.303 -1.438 0 CA-C-N 113.345 -1.752 . . . . 0.0 108.96 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 109.68 -6.3 31.36 Favored Glycine 0 N--CA 1.498 2.806 0 CA-C-N 113.279 -1.782 . . . . 0.0 111.655 179.673 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' TRP . . . . . 0.723 ' CD1' ' HG2' ' A' ' 30' ' ' PRO . 51.0 m95 -113.61 158.12 21.23 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 105.957 -1.868 . . . . 0.0 105.957 -179.938 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 50.6 t-80 -140.13 37.15 1.92 Allowed 'General case' 0 N--CA 1.493 1.7 0 C-N-CA 118.974 -1.09 . . . . 0.0 111.08 -179.774 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . 0.489 ' HA ' ' SG ' ' A' ' 47' ' ' CYS . 22.1 t-20 60.25 152.08 0.02 OUTLIER 'General case' 0 N--CA 1.504 2.225 0 CA-C-N 113.303 -1.772 . . . . 0.0 115.045 179.794 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . 0.548 ' SG ' ' CB ' ' A' ' 46' ' ' CYS . 0.5 OUTLIER -125.18 -48.55 1.72 Allowed 'General case' 0 N--CA 1.483 1.219 0 N-CA-C 105.869 -1.9 . . . . 0.0 105.869 -179.972 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 66.2 tttt -113.2 103.1 11.01 Favored 'General case' 0 C--N 1.305 -1.35 0 N-CA-C 105.709 -1.96 . . . . 0.0 105.709 179.719 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.426 ' C ' ' ND1' ' A' ' 39' ' ' HIS . . . -88.96 18.56 4.76 Favored 'General case' 0 N--CA 1.497 1.885 0 CA-C-N 113.312 -1.767 . . . . 0.0 107.155 179.577 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' HIS . . . . . 0.426 ' ND1' ' C ' ' A' ' 38' ' ' ALA . 7.1 m-70 -129.29 37.37 4.04 Favored 'General case' 0 N--CA 1.489 1.509 0 CA-C-N 114.468 -1.242 . . . . 0.0 109.05 -179.733 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 96.9 -158.32 21.29 Favored Glycine 0 N--CA 1.501 3.009 0 N-CA-C 110.207 -1.157 . . . . 0.0 110.207 179.803 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.461 ' HG2' ' O ' ' A' ' 44' ' ' GLY . 9.2 Cg_endo -74.44 -176.66 18.11 Favored 'Cis proline' 0 N--CA 1.505 2.159 0 CA-C-N 118.914 1.357 . . . . 0.0 110.91 1.448 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 19.4 p-10 -92.32 -11.3 35.49 Favored 'General case' 0 N--CA 1.491 1.578 0 N-CA-C 105.016 -2.216 . . . . 0.0 105.016 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 13.0 mm -88.4 29.05 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.31 0 CA-C-N 113.807 -1.542 . . . . 0.0 110.598 -179.427 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.461 ' O ' ' HG2' ' A' ' 41' ' ' PRO . . . 115.37 130.64 4.81 Favored Glycine 0 N--CA 1.49 2.24 0 CA-C-N 112.414 -2.175 . . . . 0.0 107.853 -179.871 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' TRP . . . . . 0.468 ' NE1' ' O ' ' A' ' 25' ' ' TYR . 2.1 m95 -73.85 134.67 43.34 Favored 'General case' 0 N--CA 1.499 1.98 0 N-CA-C 105.882 -1.896 . . . . 0.0 105.882 -179.434 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' CYS . . . . . 0.548 ' CB ' ' SG ' ' A' ' 36' ' ' CYS . 96.0 m -87.9 128.78 35.36 Favored 'General case' 0 N--CA 1.491 1.62 0 N-CA-C 101.314 -3.587 . . . . 0.0 101.314 179.575 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.503 ' HA ' ' N ' ' A' ' 36' ' ' CYS . 73.7 m -126.71 -176.28 3.65 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-N 113.28 -1.782 . . . . 0.0 113.755 -179.317 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' LYS . . . . . 0.468 ' HD2' ' H ' ' A' ' 49' ' ' LYS . 28.5 tptp -150.76 150.84 31.51 Favored 'General case' 0 C--N 1.292 -1.913 0 CA-C-N 114.931 -1.031 . . . . 0.0 109.817 -179.944 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . 0.468 ' H ' ' HD2' ' A' ' 48' ' ' LYS . 54.1 mtpt . . . . . 0 N--CA 1.501 2.085 0 O-C-N 126.16 2.162 . . . . 0.0 109.666 179.458 . . . . . . . . 1 1 . 1 stop_ save_